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Influence of mtrarenal cyclosporin A deposits on acute rejection
reaction in renal transplants. A. Montes Puerta, M. Bustos de Abajo,
M. T. Medina Cano, N. Navarro MartInez, P. Lardelli Claret, D.
Aguilar Peña, J. Aneiros Cachaza, T. Caballero Morales, and R.
Garcia Del Moral, Department of Pathology, University Hospital, and
Department of Nefrology, Virgen de las Nieves Hospital, Granada,
Spain. The diagnosis of rejection in post-transplant renal biopsy is
currently based on analysis of leucocyte subsets in histological sections
of frozen tissue. Although fluctuations in serum levels of cyclosporin A
(C5A) may influence the triggering of acute rejection crises, no relation-
ship has yet been established between intrarenal drug concentrations
and the type of leucocyte subset that causes histological lesions. This
comparative immunohistochemical study examines glomerulointersti-
tial infiltrates in 40 post-transplant renal biopsies with acute transplant
dysfunction (mAb recognizing CD4S, CD3, CD4, CD8, CDI6, CD25,
CD57, UCHL-l, L-26 and macrophages) in relation with intrarenal CsA
deposits, studied by the alkaline phosphatase method with an anti-CsA
mAb (provided by Sandoz Pharma SAE). Biopsies were divided into
two groups (with and without visible CsA deposits), and infiltrate cells
were quantified as the mean number of leukocytes per glomerulus and
mm2 of interstice. The results were analyzed with Student's 1-test,
Mann-Whitney tests, Kruskal-Wallis tests and ANOVA. The main
findings were: (1) At the glomerular level, although infiltration was more
severe in the group of biopsies with raised intrarenal CsA, there was no
significant difference between the two groups of patients (13.4 1.5 vs.
8.4 2.8 and 3.1 0.7 vs. 1.6 0.6 cells/glomerulus for CD45- and
CD8-positive cells, respectively); (2) At the interstitial level, biopsies
lacking intrarenal CsA deposits showed greater infiltration by CD4-
positive cells (2222 383 vs. 1252 153 cells/mm2, Student's t-test)
and CD57-positive cells (NK cells) (239 70 vs. 54 13 cells/mm2,
Student's 1-test) than samples with many CsA deposits. We conclude
that in situ determination of CsA defines two types of renal transplant
rejection: (a) predominantly interstitial, coursing with low intrarenal
drug levels, in which CD4-positive and NK cells predominate, and (b)
rejection characterized by large intrarenal CsA deposits, with larger
amounts of glomerular inflammatory cells, and a tendency for macro-
phages and CD8-positive cells to predominate.
Comparative study of three techniques for the detection of cytomega-
lovirus in the urine of kidney transplant patients. D. Ferrer, P. Sanchez
Perez, L.M. Pallardó, M. Gobernado, B. Acosta, J. Sanchez Plumed,
E. Orero, and J.M. Cruz, Services of Microbiology and Nephrology,
Hospital La Fe, Valencia, Spain. Objective: The purpose of the study
was to know the usefulness of three techniques for the detection of
CMV in the urine of kidney transplant patients: viral isolation in
conventional cell culture (CC), identification of CMV early antigens in
shell-vial culture (SV), and detection of viral DNA by means of the
polymerase chain reaction assay (PCR). Material and methods: Urine
samples obtained from 60 renal transplant patients were processed.
Samples were collected every fortnight during the first three months
after transplantation, and every month subsequently, until the sixth
month. A whole of 419 samples was cultured both by CC and SV.
Seventy samples were also processed for the PCR. Results: CMV was
detected in 115 (27.4%) of the 419 samples cultured: in IS the diagnosis
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was made only by SV, in 52 only by CC, and in 48 by both methods. In
29 out of the 100 cases detected by CC, CMV was not isolated until the
third week, and in 22 until the 30 days of culture. Of the 70 samples
processed by the three methods, 12 (17.1%) were positive by SV, 15
(21.4%) by CC, and 25 (35.7%) by PCR. Conclusions: (1) CC is a more
sensitive method for the detection of CMV in urine (85.4 vs. 54.7%);
nevertheless, with SV the diagnosis can be obtained earlier, so both
techniques should be used simultaneously. (2) PCR is the most sensitive
and useful method for the early detection of CMV in urine.
Higher prevalence of antibodies against hepatitis C virus (HCV) in
patients on hemodialysis (lID). J.A. Rodriguez, R. Roca, A. Pelegn, M.
Buti, R. Jardi, J. Bartolomé, J. Fort, J. Camps, R. Esteban, A. Olmos,
and L, Piera, Services of Nephrology, Hepathology and Biochemistry,
Hospital General Vail d'Hebrón, Centro de NefrologIa "Virgen de
Montserrat," Barcelona, Spain. To study the prevalence and charac-
teristics of HCV infection, we tested the level of antibodies anti-HCV in
244 dialysis patients. We studied the following variables: age, sex, time
on dialysis, blood transfusion, and kidney transplant background.
Anti-HCV antibodies were first tested by (ELISA) first-generation test,
and later by an (ELISA) second-generation test (Abbott Laboratories).
Results: The first ELISA test for anti-HCV antibodies gave positive
results in 56 patients (22.9%), while the second ELISA assay was
positive in 72 patients (30%). No significant differences for the age, sex,
type of nephropathy or with the time on dialysis were observed.
Nevertheless, valuable differences were found when we took into
account the ALT levels (15% vs. 2%, P < 0.01) and the blood
transfusion background (85% vs. 63%, P> 0.01) and kidney transplant.
We conclude that HD patients are a risk population to be infected by
HCV. HCV hepatitis has been underestimated using first generation
ELISA assay. While the high prevalence of HCV hepatitis is unrelated
to the type of nephropathy as well as from the time on dialysis, there
seems to be a close relationship with the blood transfusion and kidney
transplant background.
Intravenous versus subcutaneous administration of recombinant hu-
man erythropoietln (rHuEpo) in pre-dialysis children. M. Navarro, A.
Alonso, I. Muñoz, M. Gonzalez, and C.G. Meseguer, Renal Unit
Children's Hospital La Paz, Madrid, Spain. Anemic predialysis chil-
dren treated with rHuEpo, either intravenous (iv.) or subcutaneous
(s.c.) were evaluated. Twenty-two children (14 M, 8 F), aged 6.8 5.5
years with estimated glomerular filtration (EGF) of 14.8 5.5 mI/rn/I .73
and Hb of 8.6 1.15 g/dl have been included in the study. Eleven
received i.v. rHuEpo, initial dose of 150 U/Kg/once a week by a nurse,
and 11 received s.c. rHuEpo, 100 U/Kg/w in one or two divided doses,
by a family member. RHuEpo dose was increased to achieve a target
Hb of 11 to 12 g/dl. After 3 months of treatment, Hb rose from 8 I to
10.5 I g/dl (P < 0.001) in the i.v. group, and from 9 0.08 to 10.94
I g/dl (P < 0.001) in the s.c. group. After six months of treatment S.C.
patients maintained target Hb with a lower rHuEpo dose than i.v.
patients (154 8 vs. 260 62 U/Kg/w, P < 0.01). Significant decrease
of ferritine was similar in both groups (P < 0.05). All patients were on
oral iron supplement, since ferritine was under 100 ng/ml. Renal
functionremainedstable(i.v.: 12 3.6to 11.9± 3.9m1/m/1,73;s.c.: 17
6 to IS 6 ml/m/l .73). Pre-riluEpo hypertension was present in
1402
Abstracts 1403
three s.c. and four i.v. children, but during treatment two of the i.v.
group developed hypertension (17%) and none did in the s.c. group.
Significant increase in T calcium and Ca was present in the i.v. group
(10.1 Ito 11.1 12 mgldl and 1.27 0.09 to 1.35 0.09 mmollliter,P < 0.01). There was a linear correlation between TCa and rHuEpo
dose (r = 0.32, P < 0.01). No major side effects were found. A similar
increase of appetite, liveliness and activity was present in both groups.
We conclude that rHuEpo increases Hb to target levels, given either
i.v. or s.c. Maintaining rHuEpo dose was lower for the s.c. group (P <
0.01), resulting in cost reduction and the advantage of family adminis-
tration. i.v. route increases serum calcium in relationship with rHuEpo
dose and may have a higher risk of developing hypertension.
Berger's Disease (BD): Clinical histological correlation. Experience in
22 patients. RU. Garcia, R.S. Espinosa, R. Venegas, et a!, Faculty of
Medicine, Universidad de Valparaiso, Chile. In order to establish a
clinical histological (CH) correlation (C) in BD our casuistic was
revised. Twenty-two patients (P) were analyzed [8 F and 14 M, average
age 31 years (7—60)] who were carriers of BD according to WHO. C was
based on the following parameters (Pm): (A) Proteinuria (Pi, mg/dl),
plasma creatinine (Ci, mg/dl, Pi/Ci, P/C), diastolic arterial pressure
(PAi), during the diagnosis; the average arterial pressure (PAx) and the
decrease of renal function (RF, nICi > I .5) in the first year of follow-up
(1A). (B) BD was classified in: GI, Gil, Gill, GIV and GV; subdividing
Gill in: GILL (+), GILL (++) and Gill (-1-++), grouping them for the
analysis of C in 2: GIll (+ +) or less and GIlL (+ + +)or more. Of the 22
P, 7 (32%) went to dialysis D before two years (, 14 m). The remaining
ones have maintained their RF during the follow-up ( 38 m; 3—112 m).
The P of the first group showed histology H Gill (+ + +) or above. In
the second group, they all presented Gill (++) or lower. The Pm that
appeared better C with H were: (1) Higher creatinine in the first year/Ci
(n/Ci) < 1.5, with a predictive value of negativity (VP—) of 92.9% and
a predictive value of positivity (VP+) of 83.3%, and (2) Ci (<1.5),
(VP—) of 76.9%. The association (A) of Pi (<2) + Ci improves C: (VP—)
87.5%; C which is still better with A P/C (<2) + Ci, where (VP—)
reaches 88.8% and (VP+) is 100%. With A P/C + Ci + PAi or Pi ÷ Ci
+ PAi, (VP—) and (VP+) reached 100%. The Pm which C with D were
Pi + Ci and P/C + Ci with (VP—) 100% and 80% and (VP+) of 75% and
100%, respectively. To summarize: (I) There is a good C CH in BD. (2)
The analysis of Ci + P/C, or P/C + Ci + PAi and of RF in IA (n/Ci)
allows us to determine H. (3) Pi ÷ Ci and P/C + Ci was C with the
entrance of P into D.
Cyclosporine and probucol: Description of a pharmacokinetic interac-
tion. P. Sanchez Perez, J. Sanchez Plumed, 1. Beneyto, E. Orero, C.
Gallego, J.L. Gorriz, F. Ros, and L.M. PallardO, Services of Nephrol-
ogy and Pharmacy, Hospital La Fe, Valencia, Spain. After an initial
observation that the levels of cyclosporine (CsA) decreased in renal
transplant patients having started treatment with probucol (P) as an
hypolipemiant drug, a pharmacokinetic trial was designed to establish
whether or not an interference between both drugs occurred. Ten renal
transplant patients were selected. They were having P (500 mg/day) for
at least eight weeks. The changes in the levels of CsA after adminis-
tration of P were studied, through a procedure entailing the determina-
tion of monoclonal CsA, and CsA and metabolites both in whole blood
and in plasma by the fluorescence polarization immunoassay (TDX,
Abbott). The determinations were carried out at weekly intervals during
five weeks, while the patients continued treatment with P. Later, after
having stopped the drug for one month, the study was repeated under
identical conditions. The duration of the trial was 15 weeks. A signifi-
cant increase in the levels of CsA, CsA and metabolites in total blood or
plasma was observed after stopping P. We conclude that the joint
administration of P and CsA results in a reduction of the CsA levels in
renal transplant patients. The mechanism of this interference is un-
known.
Markers of cytomegalovirus (CMV) infection in renal transplant pa-
tients. D. Ferrer, P. Sanchez Perez, B. Acosta, L.M. Pallardó, J.
Sanchez Plumed, E. Orero, J. Garcia, J. Crespo, and J.M. Cruz,
Services of Microbiology and Nephrology, Hospital La Fe, Valencia,
Spain. A prospective study in a population of 60 recipients of kidney
transplants was performed during one year, in order to evaluate the
usefulness of the markers of active infection and their relationship with
the development of symptomatic disease. The microbiologic study
consisted of the investigation of urinary excretion of the virus by means
of conventional cell culture and short cell culture in shell vial and the
detection of specific antibodies by ELISA. Serum and urine samples
were collected every fortnight during the first three months post-
transplant and every month subsequently, until the sixth month. The
frequency of primary infection was 80% and of secondary infection
75.4%, diagnosed by the isolation of CMV in the urine of 41 patients
(68.3%) and/or detection of 1gM antibodies in 31 patients (51.6%). The
maximum urinary excretion rate was observed during the second month
post-transplant. In 70.7% of the patients the excretion of the virus was
maintained for a month or longer. LgM antibodies appeared more
frequently when urinary excretion of the virus was prolonged (72.4 vs.
50%), but this was not associated with the development of symptoms.
CMV disease was present in 26.6% of the patients with active infection.
Urinary excretion of the virus and/or the 1gM response was present
when symptoms started in the majority of cases (83.3%). Both markers
appeared at an earlier stage in the group of patients with CMV disease
compared to the patients with asymptomatic infection. We consider
that the periodic determination of the markers of CMV infection during
the first months post-transplant can be useful for the detection of
patients at risk of CMV disease and for a rapid diagnosis when
symptoms appear.
Treatment with 1,25-(OH)2 vitamin D3 modifies cellular immune
response in patients with chronic renal failure (CRF). A. Ferreira, M.C.
Saraiva, E. Arranhado, A.P. Font, MA. Santos, F. Nolasco, and A.
Coelho, S. de Nefrologia, H. Curry Cabra! and Lab. Endocrinologia
IPOFG, Lisboa, Portugal. Despite being well-recognized, the impair-
ment of cell immune response in renal failure patients has an unknown
origin. These patients also have a reduced 1.25-(OH)2 vit. D3 renal
synthesis, resulting in decreased circulating levels of this hormone.
Recently this hormone has been shown to interfere with in vitro
monocyte-macrophage and lymphocyte function, and may have an
important role in the immune response. In this study we analyzed the
cellular immune response of six chronic renal failure patients before and
a after a two month course of oral I .25-(OH)2 vit. D3 (0.25 pg/day). The
six patients had a mean age of 67 years 7.7, and all had a creatinine
clearance lower than 25 mI/mm (mean 16.1 5.4mI/mm). None of them
was on hemodialysis. One patient had polycystic renal disease, one
analgesic nephropathy, and four hypertensive nephroangiosclerosis.
None of the patients had a past history of asthma or atopic disease,
evidence of recent infection, or received recent vaccination or immu-
nosuppression therapy. Patients were studied before treatment with
I .25-D3 (TO), and after one and two months of treatment (TI and T2,
respectively). In each assessment a multiple antigen skin test was
performed (tuberculin PPD and Multitest CMI, Institut Mérieux), and
circulating levels of Interleukin 2 receptor levels (p 55) and I.23-D3
determined, as well as the T cell populations (CD3, CD4, CD8, CD25,
DR, CD4SRaCD4, CD45RoCD4). Before treatment (TO), the mean
result of the multiple skin test was 6.6mm (representing the sum of each
antigen's response), no patient showing a response above 10.5 mm.
After two months treatment, the mean total skin test increased to 26.3
mm (P = 0.03, rank sum test). Circulating interleukin 2 receptor levels
also increased from 8330 pg/mI before treatment, to 9268 pg/mI at two
months (P = 0.03). Renal function and plasma total calcium did not
changed significantly during the two month period. There was also no
change in the already reduced 1 .25-D3 levels, or significant modifica-
tions in T cell populations. In conclusion, treatment with l.25-D3
improved the decreased response to multiple skin antigen test, as well
as increasing the levels of circulating interleukin 2 receptor in renal
failure patients. The impaired cell immune response in these patients
may thus be related to their well-known changes in I .25-D3 synthesis.
Variations on insertion technique of swan neck catheters for CAPD. J.
Arrieta, J.J. de los Mozos, and E. Olivar, Hospital Ntra Sra de
Aranzazu, San Sebastian, Spain. Bedside insertion of swan neck
catheters by a nephrologist has the advantage of using a standard
technique that is difficult to achieve when we rely on a surgical team for
the CAPD catheter insertion. We have modified the classic technique
(Tenckhoff trocar and guide wire) using the paramedial site through
rectus muscle and a medial skin exit. The angle of bend between cuffs
is closer than recommended by the manufacturer, and we put the bend
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deeper than usual, over the rectus fascia. The internal cuff was placed
in an oblique position into the rectus, within a longitudinal incision of
the fascia. We did not use purse string or internal sutures. Insertion is
done without either the prefluing of the abdomen or antibiotic prophi-
laxy. The procedure lasts about 15 minutes and hospital admission is
not necessary. After insertion and a 500 ml permeability test, we use an
"absolute dry" break-in period of 10 to 15 days. In the last 24 months
we have inserted 35 catheters in 31 patients (X = 51 years, 4 diabetics).
Nine had a previous catheter. Only two patients had poor drainage due
to tip migration; one was corrected by peritoneoscopy and in the other
the catheter was removed. None had solution leak after the break-in
period, or tunnel infection in the three months alter insertion. One
patient had a persistent infection of exit site without peritonitis. Five
patients had peritonitis unrelated to the catheter in the three months
after insertion. Compared to a previous period in our hospital, these
results are much better than obtained with surgical insertion.
Effects of the decrease of magnesium (MG) concentration In the
dialyzed fluid on the erythrocyte MG, plasmatic parathohormone (PTH)
and bony matrix. R.O. Garcia, R. Espinosa, H. Opazo, G. Silva, eta!,
A Nef Hospital, Faculty of Medicine, Universidad de Valparaiso,
Chile. It has been demonstrated that renal patients on chronic hemodi-
alysis (HD) have normal plasma levels of MG but high MG erythrocyte
concentrations (MGEC). Experimental studies have associated MGEC
with bone concentrations of this catedn, thus suggesting a pathogenic
function of MG on renal osteodystrophy. A reduction in the MG
concentration of dialyzed fluid (from 0.5 to 0.25 mmol/liter) was done,
to study the variation of the concentrations of plasmatic MG (PMG) and
its relations with PTH, calcium (Ca), phosphorus (P), alkaline phos-
phatase (AP) and bony matrix applied to II patients under study. They
underwent HD standard technique during six months. In this period,
their biochemical parameters were controlled, and a bone biopsy and a
sample for PTH plasma level were taken. Then, MG was reduced in the
dialyzed fluid to 0.25 mmollliter for two months, repeating bone biopsy
and PTH. The biochemical parameters were, before and after the
change of MG in the dialyzed fluid: Ca: 9.1 0.8, 8.4 0.7 mg/dl (P <
0.05); P: 6.0 1.4, 5.5 1.9 mg/dl (NS), AP: 102 113, 122 167
U/liter (NS); PTH: 2.0 0.9, 2.3 0.8 nglml; MGEC: 2.4 0.6, 2.6
0.3 mmol/liter (P = 0.08); PMG: 1.3 0.3, 0.8 0.2 mmol/liter (P <
0.001). Bony matrix analysis did not reveal any difference between both
bone biopsies. It is concluded that: (I) The reduction of MG in the
dialyzed fluid of the HD patient does not produce any change in the
bony matrix. (2) A decrease of PMG but with no modification of MGEC
was observed. The role of MGEC as an indicator of bone MG and the
function that it may have in osteomalasia has been discussed.
Intermittent peritoneal dialysis (IPD) versus hemodialysis (lID) in the
diabetic patient: A comparative study. R.O. Garcia, G. Silva, and
R.N.M. Gomez, A Nef Hospital, Faculty of Medicine, Universidad de
Valparaiso, Chile. The usefulness of IPD in the treatment of the
diabetic patient has previously been demonstrated, assigning its possi-
ble advantages over HD. A comparison between these two dialytic
modes was done, from a clinical, nutritional and laboratory point of
view. Twenty patients were included in the protocol (3 F and 17 M) who
were divided into three groups: (A) Those treated with IPD (N = 14);
(B) Those treated with HD (N = 12); and (C) Those treated with both
techniques, in consecutive periods (N = 6). Outstanding items of the
results: (I) Systolic arterial pressure at the beginning and end of the
proceedings was: 164 and 151 mm Hg (P <0.05); 147 and 140mm Hg (NS)
in groups A and B, respectively. Diastolic pressure 91 and 89mm Hg (NS)
and 85 and 83 mm Hg, respectively (NS). The decrease of arterial
pressure during the proceedings was similar in both groups. (2) The
weight loss was 3.8 0.8 and 2.5 0.5 kg/session in IPD and HD,
respectively (P < 0.0005). (3) The episodes of intolerance were 7 x l0
and 38 x lO epi/patfproceed, for IPD and HD (P < 0.001), with
different numbers of hypotensions, episodes of cramp and vomiting, (4)
The number of hospitalizations/pat/month and infections was lower
than in group B (P < 0.05 and P < 0.005). The total number of
complications was similar. (5) Plasmatic calcium (P < 0.005), albumin
(P < 0.05) and alkaline phosphatase (P < 0.01) were lower in group A.(6) Index weight/height was lower in group A (P < 0.05). (7) The
actuariales surviving curves of both dialytic methods were similar. We
conclude that both dialysis techniques are adequate for the diabetic
patient, with a low index of complications. IPD is better tolerated than
HD, but some nutritional parameters of the patients seem to be lower
with this technique.
1gM mesanglal proliferative glomerulonephritis. Clinical and Immuno-
histochenilcal differential analysis with minimal change and immunoneg-
ative mesangial proliferative glomerulonephrltls. M. Gómez Morales, F.
0' Valle Ravassa, M. Andájar Sanchez, C. Ramirez Tortosa, A. Montes
Puerta, A. Navas Parejo, S. Cerezo Morales, and R. Garcia del Moral,
Department of Pathology, University Hospital, and Department of
Nephrology, Virgen de las Nieves Hospital, Granada, Spain. 1gM
mesangial proliferative glomerulonephritis 1gM (IgMMPGN) shows
diffuse proliferation of mesangial cells and capillomesangial binding of
1gM, associated clinically with complete nephrotic syndrome (NS) or
persistent proteinuna. Its possibie relation with minimal change gb-
merulopathy (MCGN) and NS-associated immunonegative mesangial
proliferative glomerulonephritis (I-MPGN) is currently under debate.
We compared cinicopathological feature differences in therapeutic
response and glomerulo-interstitial leucocyte subsets in renal biopsies
from 19 patients with MCGN, 18 patients with IgMMPGN, and 10
patients with I-MPGN. An extensive panel of mAbs (CD45, CD3, CD4,
CD8, CD1 lb, CDI5, L-26, UCHL-l and anti-macrophage mAb) was
used in the immunohistological study of frozen sections with the
alkaline phosphatase method. The results were expressed as the mean
number of immunostained cells per glomerulus and mm2 of interstitium.
The main findings were: (1) Therapeutic response was significantly
different (comparison of percentages, P < 0.05) between all three
histological types, with good response in MCGN, moderate response in
I-MPGN, and poor response in IgMMPGN. (2) With regard to glomer-
ular inflammatory infiltrate, more macrophages were present in 1gM-
MPGN than in controls and the other two histological groups analyzed
(Student's (-test P < 0.01). (3) Interstitial inflammatory infiltrate was
patent in all histological types analyzed, and was especially marked in
IgMMPGN (ANOVA, P < 0.05). (4) In IgMMPGN, but not in MCGN
or I-MPGN, initial proteinuria was markedly dependent on glomerular
inflammatory infiltrate by nonspecific immune cells (macrophages and
granulocytes) and B and T lymphocytes (multiple correlation r2 = 0.97,
P < 0.01). We conclude that IgMMPGN displays a notable degree of
glomerular and interstitial infiltrate, and has a less favorable course than
MPGN or Ig-MPGN. Proteinuria in these patients is essentially related
with the deposition of a circulating factor that might trigger this
phenomenon.
Relationship between the expression of GP-170 and intrarenal deposits
of CsA, in 40 human post-transplant biopsies and in the MDCK cell line,
from kidney proximal tubule. D. Aguilar Pena, M. GOmez Morales, M.
Andtijar Sanchez, F. 0' Valle Ravassa, M. AguilarPefla, M.I. Quesada
Vazquez, J.L. Lopez Hidalgo, M.A. Lucena Robles, J.L. Santos Perez,
A. Montes Puerta, and R. Garcia Del Moral, Department of Pathology,
University Hospital, Granada, Spain. Sensitivity to CsA seems to be
related to the functional activity of GP-170, a transmembrane glyco-
protein present in normal secretory epithelia, which acts as a drug efflux
pump, removing toxic compounds from the cell, and consuming two
molecules of ATP. In order to test this affirmation and to evaluate the
relationship between expression of GP-170, CsA accumulation and
morphologic signs of nephrotoxicity, we have determined the intrarenal
presence of CsA and GP-170 in parallel, in 32 post-transplant biopsies
by immunostaining with MoAbs against both substances; 19 cases
showed signs of CsA nephrotoxicity. Immunohistochemical studies
were performed using the APAAP technique. The expression of GP-l70
in MDCK cell line from dog kidney was also studied by FACS in basal
conditions, and of GP-l70 and CsA after seven days of culture in MEM
plus 0.5 and 1 Ag/ml of CsA. Results showed a considerable overlapping
between the curves of GP-170 and CsA in all renal biopsies (Spearman's
correlation test: r = 0.44; P < 0.05). When considering only cases
without histological signs of CsA nephrotoxicity, the increase in the
CsA deposits was accompanied by a peak in the GP-170 expression,
more intense than in the whole series (r = 0.70, P < 0.01, Spearman
test). On the contrary, when considering only cases with toxic tubu-
lopathy the relationship was much lower (r = 0.40, P < 0.1, Spearman
test). CsA renal deposits did not correlate with CsA serum levels. In
MDCK cell line the expression of GP-l70 increased from 40 to 80%
positive cells after seven days of CsA exposition. Moreover, the
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fluorescence intensity was much higher than in controls (P < 0.05,
Student's 1-test), suggesting that the number of GP-170 molecules per
cell was higher. We conclude that: (I) CsA induces overexpression of
GP-170 as a mechanism of detoxification on kidney proximal tubule
cells. (2) The weaker association between GP-l70 overexpression and
intrarenal deposits of CsA, in patients who develop CsA nephrotoxic-
ity, suggests that these cases may have some deficiency in this normal
response, retaining excessive amounts of CsA.
Severe hyperparathyroidism with basal hypercalceinia in hemodialysis
patients. Treatment with intravenous calcitriol. G. de Arriba, M.D.
Jarillo, F. Garcia-Martin, A. Liébana, and M. Sanchez, Hospital
General Universiiario de Guadalajara, Spain. Intravenous calcitriol,
based on its capacity to suppress PTH secretion, has been used in the
treatment of secondary hyperparathyroidism in hemodialysis patients.
Our aim was to evaluate the efficacy of intravenous calcitriol in patients
with severe secondary hyperparathyroidism (diagnosed by bone bi-
opsy) and basal hypercalcemia. We studied three patients with a mean
age of 54 19.6 years old (27—73) on hemodialysis for 93 41.4
months. We used Calcitriol i.v. (I jig after each hemodialysis session),
with reduction of the dose if serum total calcium was greater than II
mg/dl. Modification of serum calcium, phosphorus, alkaline phos-
phatase and FFHI were analyzed after eight weeks of treatment.
Calcium in the dialysate was 3 mEq/liter. Basal total serum calcium was
10.8 0.3 mg/dl, phosphorus 4.7 0.8 mg/dl, and alkaline phosphatase
741 590 lU/liter. After treatment, serum calcium was reduced by 3%
and alkaline phosphatase by 5%, but phosphorus had increased 22%
(even with an increase of chelating drugs). Basal PTHi was 783 458
pg/mI, and after treatment an increase of 0.5% was observed. Although
our experience is limited, these results suggest that hemodialysis
patients with severe secondary hyperparathyroidism and basal hyper-
calcemia did not respond to a short-term course of intravenous calcitriol
at the doses utilized. In this group of patients other therapeutic
alternatives should be considered.
Reactive perforating collagenosis associated with end-stage renal dis-
ease. M.D. Jarillo, P. Jaén, F. Garcia-Martin, J. Cuevas, G. de Arriba,
and M. Sanchez, Hospital General Universitario de Guadalajara,
Spain. Cutaneous abnormalities and generalized pruritus are frequent in
uremic patients. Reactive perforating dermatoses (RPD) are character-
ized by hyperkeratotic papules with transepidermal elimination of
degenerated material, including collagen or elastic fibers. Classically
related with diabetes mellitus, in uremic patients their knowledge is
rare. Our aim was to analyze their incidence in uremic patients on
hemodialysis. We studied 88 uremic patients on periodic hemodialysis,
mean age 57 14 years (range 20—81) and they were on hemodialysis for
49 35 months. Six patients (7%, 4 male 2 females, mean age 53 12
years) had skin biopsy specimens of RPC, clinically characterized by
intense pruritus and localized in the legs. The etiology of chronic renal
failure was chronic interstitial nephropathies (3), amyloidosis (I), and
diabetes mellitus (I); the mean time on hemodialysis 53 12 months.
Two patients have severe hyperparathyroidism, and no correlation was
found with serum levels of Ca, P. PTH or beta2-microglobulin. The
cutaneous lesions persist between six months to two years, despite
topical treatment. In summary, reactive perforating collagenosis is
frequent in uremic patients on hemodialysis, and severe pruritus is its
clinical manifestation. The etiology is unknown, but it is suggested that
a transcutaneous elimination of hemodialysis-related foreign material
exists.
Prevalence of antibodies for hepatitis C virus (anti-HCV) and control
on patients undergoing hemodialysis (HD). MA. Acosta, MS. Chaves,
andS.E. Prudkin, Centro de Enfermedades Renales and Hemodialysis,
Parana-Entre Rios, Republica Argentina. Hepatitis C virus is a well-
known risk factor in HD units due to frequent parenteral contact with
blood transfusions (BT). In Argentina the prevalence in HD of anti-
HCV averages from 55% to 70% of BT. In May 1991 our HD unit
checked lgG anti-HCV in all patients, using first generation anti-HCV-
EIA kits, just imported into the country. A resulting 19.5% of the
patients were reactive, and they were isolated in common rooms. Six
months later (Nov. 1991), a more sensitive control was made, using an
anti-HCV-EIA, second generation kit, plus a third generation one,
which diminishes false positive results. Some 30.6% of the patients
turned out positive. There were antecedents of BT in only five of the
eleven new cases; they were confined to true isolation in a special room.
Considering that new kits shorten the exposure period to three months,
all the 94 patients in the unit were controlled in February 1992 with an
anti-HCV-EIA kit, third generation. The weakly reactive patients
underwent an LIA confirming test; 27.6% of them were reactive. The
group of reactive patients consisted of 16 men and 10 women; average
age was 48.5 9.6 years; time on HD was 4.7 2.3 years, and there
were BT antecedents in 69.2% and a rise of TGO-TGP in 73%. The
non-reactive group was composed of 42 men and 26 women; the
average age was 48.1 5.9 years; the time on HD was 2.39 0.8 years;
there were BT antecedents in 27.9% and a rise of TGO-TGP in a 7.35%.
There was no statistically significant difference (P < 0.01) between the
two groups as related to age or sex; it did show one for a P < 0.01
related to time on HD, transfusion antecedents and rise of TGO-TGP.
It is evident that exposure to BT is the main reason for HCV in HD, but
staff and equipment are also a means of transmission, as seen between
May and November 1991; the use of a more sensitive kit is also to be
noted. Our relatively low prevalence of anti-HCV is to be attributed to:
(I) adequate water treatment, filter reprocessing and equipment sani-
tizing according to AAMI rules (avoidance of contaminants such as Al,
Cu, Cl, formol, etc.) as anemia causes (BT antecedents in a 37.3% of the
94 patients under control); (2) true isolation of reactive patients by
special care; (3) anti-HCV checkup at the start of HD treatment and
then every three months with the latest generation kit, plus a confirming
test for weakly reactive patients.
Hispanoamerica, racial heterogeneity, racial mixture and cadaver
kidney graft survival. S. Arce, Y. Trujillo, F. Ramos, S. Perez, H.O.
Rojas, and 0. Suarez. It has been reported by some authors from
developed countries that cadaver kidney transplantations performed
between White race individuals have a better clinical outcome than
those performed between donor and recipients belonging to different
races. Hispanoamerica is well distinguished by its racial heterogeneity
and a predominant tendency toward racial mixture. The Cuban popu-
lation is composed of approximately 55% Whites, 5% Negroes and 45%
racial mixed, and this last group continuously increases to grow. In this
paper we analyzed 895 first cadaver kidney grafts; therapy with
azathiopnne and corticosteroids was employed in all of them. The
results, taking into account the race of donor and recipients, are as
follows:
Race
don rec
No. of
cases 3 M 6 M 12 M 24 M 36 M 48 M 60 M
M N 104 78 62 58 54 47 46 44
B M 36 83 63 57 54 44 40 37
W B 89 80 62 53 39 31 31 31
W W 318 72 58 49 42 38 34 32
W M 132 75 62 48 38 30 25 20
M M 80 71 57 47 36 30 27 27
B W 58 74 53 46 38 29 29 26
B B 28 57 39 32 32 32 32 26
M B 50 54 38 28 26 23 23 23
Abbreviations are: W, White; B, Black; M, Mulatto.
When the actuarial graft survival curve of transplants was performed
between White individuals (318) is compared with that obtained in other
racial combinations as a whole (577), there are no statistically signifi-
cant differences (P = 0.05). We conclude that first cadaver kidney
grafts, performed between White individuals, do not have a better
clinical outcome in comparison with those obtained in the rest of the
possible racial combinations in an Hispanoamencan country, such as
Cuba, characterized for its racial heterogeneity and racial mixture.
Clinical utility of genetic markers in autosomal dominant polycystic
kidney disease (ADPKD). S. Aguado, E. Gómez, E. Gago, M. Gorostidi,
P. Escalada, C. Lopez Larrea, M.J. Menéndez, J. Alvarez Grande, and
H. Covadonga, Oviedo. Whereas clinical utility of genetic markers of
ADPKD is clearly established in genetic counseling, its use is more
questioned in other clinical fields. We studied the contribution of these
techniques to diagnosis of ecographically unaffected gene carriers and
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towards detection of clinical complications of ADPKD. Genetic studies
with DNA probes were offered to 42 ADPKD families regularly
reviewed in our hospital. A minimum of six family members with at
least two of them with classical disease including ecographically detect-
able renal cysts, was required for performance of genetic studies.
Twenty-eight families, due to the insufficient number of members
available for study or to their unwillingness to participate, were not
suitable for genetic studies. Within the 14 families genetically studied,
13 were linked to chromosome 16 (ADPKD type 1) and the 14th was
heterogenetic (non-linked disease). Within the remaining 13 families
with informative genetic studies, a total of 121 at risk members were
studied, 81 of whom (66.9%) proved to be genetic carriers. Seventy-five
out of 81 (92.6%) patients were conventionally diagnosed with eco-
graphical studies. Six out of 81(7.4%) genetic carriers did not have
renal cysts when genetically characterized. Within the group of patients
conventionally diagnosed, the mean age at ecographical diagnosis was
34 12 years, whereas that of genetically diagnosed patients was 17
7 (P < 0.025). All clinical, biochemical and radiologic studies performed
in this last group were completely normal. In conclusion: (1) A high
percentage of ADPKD (type 1) families are unsuitable for the perfor-
mance of genetic studies. (2) Within ADPKDI families, genetic markers
detect a significant percentage (7.4%) of ecographically unaffected
patients. (3) While identification of these genetic carriers (eco — and gen
+) is very useful for genetic counseling, it has not demonstrated any
clinical utility in detection of ADPKD complications.
Glomerulopathies following renal transplants: A morphological analy-
sis. MOnica Patricia Revelo and Eduardo A/yes Bambirra, Pathology
Department, School of Medicine, Federal University of Minas Gerais,
Belo Horizonte, Brazil. The real incidence of glomerulopathies follow-
ing renal transplants is not completely established and it varies accord-
ing to several factors. However, glomerulopathies are becoming more
frequent day after day as a cause of renal allogralt failure. A retrospec-
tive (1980—1989) and prospective (1990—1991) study was performed
using 529 allograft biopsies out of 3413 renal biopsies. The specimens
were sent from diverse hospitals in Belo Horizonte as well as from rural
city hospitals in Minas Gerais in order to find out: (a) incidence of
allograft biopsy among the total series of the renal pathology service;
(b) frequency of glomerulopathies following transplant, and (c) the most
frequent morphological patterns of glomerular lesions. Light micros-
copy and direct immunofluorescence were used in the present study. It
was observed that allograft biopsies represent 18.92% of the renal
pathology series. Sixty-five percent of the allograft specimens showed
glomerular changes which were classified as: sclerosing (27.8%); pro-
liferative (13.9%); mixed (34.4%) and non-proliferative (13.9%). Gb-
merular lesions were more frequent among transplants aging more than
one year (35.86), and they were associated with chronic rejection.
There was a lack of clinical data that could lead us to a more specific
diagnosis of the glomerular lesions. We conclude that a systematic
analysis of albograft biopsies makes it possible to follow-up the patient
as well as identify the morphological features of the lesions and its
course. The analysis of our series demonstrated that the incidence of
allograft biopsies increased during the period of the study and that
glomerulopathies following renal allograft were frequent. it is also clear
that the increasing number in allograft biopsies shows that it is a very
safe and reliable procedure when monitoring these patients.
Diffuse mesangial sclerosis: Morphological analysis of seven cases.
MOnica Patricia Revelo, Eduardo Alves Bambirra, Rosa M. Viero, and
Marcelo F. Franco, Pathology Department, School of Medicine, Fed-
eral University of Minas Gerais, Belo Horizonte; Medical School of
Botucatu, UNESP, São Paulo, Brazil. Diffuse mesangial sclerosis
(DMS) is an occasional cause of nephrotic syndrome in the first year of
life. It shows marked proteinuria and a rapid and progressive loss of
renal function leading to fatal renal failure before the patient reaches
three years of age. Histologic lesions are very specific and can be
identified through biopsy. This disease must be diagnosed as early as
possible since its development and prognosis are unfavorable. Seven
new cases of EMD are reported, all of them showing quick loss of renal
function. One patient died and two cases were observed in one family.
A clinical summary of the cases is observed in Table 1.
Table I. Clinical signs and evolution of patients with DMS
Cases Age Sex
Clinical
data Evolution
1 2 months
-
F oliguria from birth,
nephrosis
renal failure
2 2 years 6 months F congenital
nephrotic
syndrome
renal failure
death
3 1 year M nephrotic syndrome renal failure
4 9 months M nephrotic syndrome renal failure
5 8 months M oligoamnion,
peritonite
renal failure
6 9 months M nephrotic syndrome death
7 2 years F nephrosis renal failure
pulmonar
hemorrhage
Light microscopy, immunofluorescence and transmission electron mi-
croscopy were used in the morphological analysis. We conclude that
although DMS is not a frequent disease, it should be part of the
differential diagnosis when dealing with congenital nephrotic syndrome.
Renal biopsy in lupus nephropathy—A 12-year study. Maria Valèria
Correia Pereira, Monica Patricia Revelo, and Eduardo Alves Barn-
birra, Departamento de Anatomia Patolôgica and Medicina Legal da
Universidad Federal de Minas Gerais, Belo Horizonte, Brazil. The
renal biopsy is an important element in the evaluation of renal involve-
ment in systemic lupus erythematosus (SLE). It allows the diagnosis of
the histologic lesions, as well as the definition of the therapeutic choices
and the follow-up of individual cases. In a retrospective study, we have
analyzed 285 renal biopsies from patients with SLE that were submitted
to the Department of Pathology, School of Medicine, Federal Univer-
sity of Minas Gerais, Belo Horizonte, Brazil, from 1980 to 199!. The
biopsies came from different hospitals of Belo Horizonte and many
other regions of Minas Gerais. The histopathologic study was per-
formed using light and immunofluorescence microscopy. We have
observed a progressive increase in the total number of renal biopsies
and also in those from patients with SLE. There was no increase in the
relation between total renal biopsies and renal biopsies in patients with
SLE, as it is shown in the graphic below.
The results show that renal biopsy is important in the follow-up of
patients, and also demonstrate that there isn't a protocol for renal
biopsies in patients with SLE in our region.
Study of lipid metabolism in chronic hemodlalysis patients. M. Solari,
A.M. Linchenco, H. Viñuela, J. Scrigna, A. Lotero, R. Feuli, H,
Coletti, and H. Pugliessi, Department of Nephrology and Central
Laboratory, Hospital Italiano, Rosario, Argentina. A group of 32
patients undergoing chronic hemodialysis was studied with the aim of
establishing the basal lipid pattern and its evolution with time. Choles-
terol (C), triglyceride (TG), uric acid, HDL cholesterol (CHDL),
lipidogram (LG), apo A1 and ape B were measured. The Castelli
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atherogenic index was calculated: l = C/CHDL, which is expressed
according to different degrees of penetration pointing out the fact that
the higher the grade, the greater the risk. G corresponds to I:
>4.5—5.5; G2 corresponds to 1 > 5.5—6.5; 03 corresponds to I: >6.5.
With apo A1 and apo B values, we determined the risk index 12: apo
A2/apo B. Sixty-two percent of patients had a normal lipid profile and
34.4% corresponded to Fredrikson Type IV which was the most
frequently encountered disorder. Of all patients studied, 43.75% had
CHDL values below 40 mg/dl and 28.1% of these were in the group
considered as "normal" according to Fredrikson's classification. Apo
A1 and apo B exhibited normal values in 97% and 87.5% of the
population, respectively. The highest index as atherogenic marker
proved to be that of Castelli (Ii) with a 40.6% incidence above the
maximum accepted value of 4.5, from which 28.1% corresponded to G1;
3.1% to 02 and 9.4% to G3. No significant differences in the variables
studied were found between the first and the last controls. Our
conclusion is that Fredrickson Type IV in the most frequently found
lipid pattern, having observed neither variations with time nor an
increase in the atherogenic risk index due to dialysis, per se.
Impact of hepatitis C virus in a population of patients undergoing
chronic hemodialysis. AM. Linchenco, H. Coletti, J. Scrigna, M.
Baquio, H. Vifluela, A. Lotero, and R. Feuli, Department of Nephrol-
ogy and Central Laboratory, Hospital Italiano, Rosario, Argentina.
The aim of this study was to search for the presence, risk factors and
clinical significance of hepatitis C virus antibody (HCV) in a population
of patients undergoing chronic hemodialysis (CHD). The presence of
the HCV antibody in 44 patients was determined by the use of second
generation enzymoimmunoassay method (ELISA). Twenty-seven out
of the 44 patients (61.36%) were seropositive, and no significant
differences were observed between both groups based on sex and age.
Patients who were found to be anti-HCV positive were the ones who
received a greater number of transfusions and who had stayed in CHD
for a longer period of time, compared with seronegative patients, the
difference being statistically significant with P < 0.05 and P < 0.01,
respectively. Clinical data and laboratory tests performed during the 12
months prior to the anti-HCV test were retrospectively analyzed. Only
four of the seropositive patients (14.8%) showed liver abnormalities
based on the significant increase of enzymes with or without clinical
symptoms. Six out of the 44 patients underwent renal transplantation
(Tx), and four of them were seropositive. Seven months after Tx, one
of them developed jaundice; a liver needle biopsy was performed and
the result is discussed. The different alternatives related to this high
percentage of positive sera results are reviewed, and it is concluded that
the longer the time on chronic hemodialysis and the greater the number
of blood transfusions, the more significant the relationship of positive
sera to anti-HCV.
Clinical significance of anti-N-like antibodies. H. Coletti, AM.
Linchenco, H. Vinuela, A. Lotero, and R. Feuli, Department of
Nephrology, Hospital Italiano, Rosario, Argentina. MNSs erythrocyte
system antigens are found to be associated to glycophorins A and B red
cell (RC) basal membranes. Howel and Perkins (1971) showed the
presence of an N-specific antibody in a group of patients undergoing
chronic hemodialysis (CHD). It is postulated that this antibody (anti-
N-like) would appear as a response to the action of formaldehyde
solutions habitually used to resterilize dialysis filters. There was a
search for the presence of anti-N-like antibodies in 23 out of 50 patients
suffering from end-stage renal disease (ESRD) in chronic hemodialysis
whose treatment period ranged from five to 67 months. Capillary
dialyzers resterilized in 2% formaldehyde solutions were used. It was
evidenced that 20 patients (87%) were immunized. They were classified
according to the ABO, Rh system and its anti-N-like antibodies
simultaneously titered with native and formolated RCMN. Afterwards,
filter sterilization was performed with 2% iodated povidone. A signifi-
cant decrease in transfusion requirement was recorded during the six
months after having changed the sterilization method. As to anti-N-like
antibody, its activity decreased in some cases, its level was steady in
others, and it totally disappeared in a patient six months after renal
transplantation (Tx). The anti N-like antibodies behave as a cold
agglutinine reactive in saline producing immunohemolysis. There might
be a severe complication associated during renal Tx when the donor's
kidney is cooled to a similar or lower temperature to which the antibody
is able to agglutinate receptor erythrocytes. Additionally, its presence
impairs the anemic condition of a patient in chronic hemodialysis,
therefore not being able to achieve the expected results when adminis-
tering human recombinant erythropoietin (EPO). It is concluded that it
is necessary to look for the presence of anti-N-like antibodies in
hemodialyzed patients, especially in potential Tx receptors in whom
filters are resterilized with formaldehyde. In case these antibodies were
detected, the method of sterilization should be immediately changed.
Prevalence of dyslipidemias in treated essential hypertension, according
to White and Black races. Helga Maria Mazzarolo-Cruz, and Jenner
Cruz, Nephrology Division, University of São Paulo, Brazil. Serum
lipid levels were evaluated in 131 Whites (31 males, 100 females, 60
1 SEM years) and in 60 Blacks (15 males, 45 females, 53 1 years) with
treated essential hypertension. The hypertension duration was similar
in both races (12.6 0.8 and 12.6 1 years), but its onset was earlier
in the Blacks (40.5 5.2 vs. 47.5 1.2 years). Obesity (BMI> 30) was
frequent in White and Black females (30% and 35.7%). To define
abnormal serum lipids, the used values were: LDL-cholesterol 160
mg/dl; HDL-cholesterol < 35 mg/dl; triglycerides ' 200 mgldl; LDL/
HDL 4.5. The total prevalence of dyslipidemias was higher in Whites
than in Blacks (65.7% vs. 48.3%, P < 0.05), occurring qualitative
differences by races: (a) Mixed hyperlipidemia was more prevalent in
Whites than in Blacks (12.2% vs. 1.7%, P < 0.025) as well isolated
hypertnglyceridemia (6.9% vs. 3.3%). Thus, the prevalence of hyper-
triglyceridemic dyslipidemias was higher in Whites (19.1% vs. 5%, P <
0.001); (b) Abnormal ratio LDL/HDL prevalence was higher in Whites(39.5% vs. 16.7%, P < 0.001); (c) The prevalences of hyper-LDL-
cholesterolemia and of hypo-HDL-cholesterolemia were similar in
Whites and Blacks (38.2% vs. 30%, and 22% vs. 20%). (d) Hypertri-
glyceridemic dyslipidemias were more frequent in obese White females
than in obese Black ones (33.3% vs. 12.5%). Excluding abnormal values
of serum lipids, similar mean levels of LDL, HDL and LDL/HDL were
found in both races, being respectively 133 2 and 129 4 mgldl; 47
1 and 48 2 mg/dl; 3.2 0.1 and 3.2 0.1. However, the mean
normal triglyceridemia was lower in Blacks than in Whites (105 5 vs.
120 3 mg/dl, P <0.025). Conclusions: (I) White hypertensives showed
higher prevalence of dyslipidemias, particularly the hypereriglyceri-
demic phenotypes. (2) The mean normal triglyceridemia was lower in
Black hypertensives. This finding could be attributable to racial differ-
ences.
Hypertension in 1,000 students from Great São Paulo, Brazil. Denise
Maria Maior Simonatto, Marilia de Deus Dias, Rosana Luz Machado,
and Jenner Cruz, Hugo Abensur, Nephrology Division, University of
Mogi das Cruzes, São Paulo, Brazil. A sample of 1,000 students (450
males, 550 females, 6—18 years old), predominantly Caucasians (83.7%),
from Great São Paulo Elementary Schools, Brazil, was classified in four
age groups: 6—9, 10—12, 13—15 and 16—18 years of age, to study the
prevalence of hypertension among them. Blood pressure levels were
correlated with family history of hypertension, age, sex, race, weight
and height. The pressure was taken three times, in the left arm, in sitting
and standing positions. The first and fourth Korotkoff sounds defined
systolic and diastolic pressures, and the values were adjusted by the
table of Maxwell et al. Only three obese children were included. We
concluded that until nine years old blood pressure was similar in both
sexes. As girls grow up earlier than boys, their blood pressures rise
first. After 16 years, mean blood pressure is higher in males than in
females: 126 4 mm Hg (sEM)/76 3 vs. 115 2/74 2. The
prevalences of systolic and diastolic hypertension were greater in
students with a family history of hypertension (12.2% and 13.8%,
respectively) than in those without it (4.7% and 3.8%). Students relating
familial hypertension showed higher levels of blood pressure than those
who denied it. However, the difference was only significant in the age
group over 16 years: 125 5/82 4 vs. 116 3/72 2 mm Hg. The
prevalence of high blood pressure levels was greater in male Negroes
(10%) than in Caucasians, mulattoes and Orientals (7.7%, 7.0% and
4.3%, respectively). Among the 1,000 students investigated, the prev-
alence of high blood pressure, either systolic or diastolic, was the same,
corresponding to 6.9%, not necessarily in the same individuals.
Lisinopril effects on proteinuria (P), microalbuminuria (mA) and blood
pressure (BP) in various glomerulopathies. A. Wassermann, C. Braccal-
enti, M. Scappicchio, and 0. Mompo, Sección Nefrologia, Hospital
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Municipal de Vte. Lopez, Florida, Argentina. Former assays with
lisinopril show no effect on proteinuria; however, most recently signif-
icant reduction was observed, without renal function modification. We
treated 16 patients with proteinuna due to: focal and segmental glomer-
ulosclerosis (2), obesity (1), diabetic nephropathy with (P) (8), and
diabetic nephropathy with (mA) (5). Blood pressure was elevated in
nine and normal in seven patients. Serum creatinine was under 1.2
mg/dl in 10, between 1.2 and 2 mg/dl in three, and greater in three
patients. Initial dose was 10 mg (one sixteen year old patient with FSG
received 5 mg); lisinopril dose was incremented to 20 or 30 mg if (P),
(mA) or hypertension persisted. After 4.25 1.25 months (range 1—17)
total remission of(P) or (mA) was observed in six patients, reduction in
seven and increase in two (one of them confirmed nonfulfillment of the
treatment). Blood pressure rested constant in normotensive patients,
but decreased in hypertensive ones (pre- 164/93 mm Hg; post- 144/84
mm Hg). Serum creatinine increased in four patients, but they didn't
require treatment discontinuation. Kalemia remained constant. One
patient was discontinued because of a nonproductive cough related to
the drug. Conclusion: These results suggest that lisinopril decreased (P)
and (mA) in various glomerulopathies with or without hypertension.
Serum creatinine showed little modification and hypertension went to
normal. Long-term lisinopril effect on progression of renal lesion
remains to be demonstrated.
Screening for microalbuminuria (mA) and proteinuria (P) in diabetic
patients. A. Wassermann, M. Scappicchio, C. Braccalenti, 0. Mompo,
R. Schultz, and A. Elbert, Hospital Vicente Lopez Fundacion Cenha,
Florida, Argentina. Even though (P) is accepted as a diabetic nephrop-
athy marker, certain controversies remain about the prognostic value of
(mA). Microalbuminuria is probably related to nephropathy in insulin
dependent diabetes (I.D.D.), and to cardiovascular death rate in non-
insulin dependent diabetes (N.I.D.D.). We evaluated 104 consecutive
patients attending for routine external examination. Urine was collected
during night rest, after a high-protein dinner. Determination of (mA) by
immunoturbidimetric assay (Urin Pak, R), quantitative (P) and serum
creatinine were done in all patients. Results are shown in the table:
I.D.D.
N = 30
A
g/min Normotensive Hypertensive Total
Age <20 n=8 6 14
years % = 27 20 47
37.2 14.9
Sex
20—200 8
27
3
10
II
37
F = 19 M = 11
Time from diagnosis
>200 1
3
4
13
5
17
months 17 13 30
169.6 118.9 57 43
N.I.D.D. A
N = 74 g/min Normotensive Hypertensive Total
Age <20 33 22 55
years 45 30 74
51.4 11.1
Sex
20—200 5
7
6
8
Il
15
F = 38 M = 36
Time from diagnosis
>200 2
3
6
8
8
11
months 40 34 74
123.5 98.0 54 46
Time from diagnosis correlated positively with (mA) in I.D.D. but not
in N.I.D.D. (r = 0.85 vs. 0.06). I.D.D. patients showed greater
prevalence of (mA) for normo- and hypertensives. Proteinuria showed
similar distribution; however, nine patients presenting pathologic range
of (mA) should be undetected only if performing quantitative (P)
analysis. Microalbuminuria should be routinely determined to detect
and prevent diabetic nephropathy.
Effect of calcitriol treatment on osteocalcin levels in chronic hemodial-
ysis patients. A.L. Negri, C.E. Bogado, E.E. Fradinger, and J.R.
Zanchetta, Instituto de Investigaciones Metabolicas, Buenos Aires,
Argentina. Serum osteocalcin (BGP) concentration is a biochemical
marker of bone turnover, probably reflecting osteoblastic function. In
hemodialysis patients a relationship between serum BGP levels and
histomorphometric parameters of bone formation has been observed.
The effect of calcitriol on serum BGP levels in these patients has been
poorly studied and remains controversial. Thus, we decided to assess
the evolution of serum BGP levels and its relationship with other
biochemical bone parameters in hemodialysis patients under two dif-
ferent forms of calcitriol treatment. Thirteen patients with secondary
hyperparathyroidism (intact PTH >200 pg/ml), undergoing chronic
hemodialysis (mean time 86.3 months) were scheduled to receive
calcitrioi either in oral pulses (OP group, 4 sg, first and third hemodi-
alysis of the week, N = 7) or intravenously (i.v. group 1—2 zg/
hemodialysis, N = 6) for 12 weeks. Serum BGP, intact PTH (IPTH),
total alkaline phosphatase (AP) and bone AP isoenzyme (BAP) were
determined in all patients at the beginning (I) and at the end (I) of the
study. Results are expressed as mean SEM. A significant fail in serum
BGP levels was observed in both groups (OP i: 33.9 2.3, f: 18.7 2.9
ng/ml, P < 0.001; i.v. i: 39.2 3.2, f: 16.9 2.0, P < 0.01), while no
significant changes in AP and BAP could be demonstrated. A significant
decrease in IPTH was observed in i.v. (i: 537.1 121.6, f: 263.7 108.8
pg/mI, P < 0.01), but not in OP (i: 555.3 139, f: 350.4 127.4 pg/mi,P = NS). However, taking all patients as a whole, a significant linear
correlation was found between the percentage of change in IPTH and
BGP serum levels during treatment (r = 0.87, P < 0.001). Our results
show that short-term calcitriol treatment (either OP or i.v.), decreases
serum BGP but not AP or BAP levels, and that these changes in BGP
correlate with those of IP'FH, probably reflecting changes in bone
turnover. Thus, BGP serum level seems a sensitive marker of bone
remodeling in hemodialysis patients under calcitriol treatment.
Comparative study of three ways of administration of calcitriol to
patients with secondary hyperparathyroidism in chronic hemodlalysis.
A.L. Negri, G.E. Bogado, E.E. Fradinger, A. Zucchini, A. Locatelli, A.
Cusumano, A. Wasserman, L. Levy, M. Norbis, A. Garlevaro, M.R.
Achranowicz, and J.R. Zanchetta, Instituto de Investigaciones Meta-
bolicas and Cooperative Group for the Study of Vitamin D3 in Dialysis,
Buenos Aires, Argentina. Bone lesions produced by secondary hyper-
parathyroidism (2HPT) are one of the most frequent complications in
patients with end-stage renal failure undergoing chronic hemodialysis.
Results of several clinical trials indicate the efficacy of calcitriol in
treating this form of renal osteodystrophy. There are different ways of
administration of this drug, but there are few studies comparing their
efficacy and tolerance. Twenty-seven patients in chronic hemodialysis
(90 45.8 months) with 2HPT (baseline intact PTH > 200 pg/mI) were
studied. They were dialyzed four hours per session, three times per
week, using hollow-fiber dializers. Dialysate calcium concentration was
3 mEq/liter. Patients were randomized to receive calcitriol on an oral
daily basis (OD 0.5 sg, N = 6), in oral pulses (OP 4 sg, 1st and 3rd
hemodialysis of the week, N = 12), and intravenously (i.v. 1—2
sg/hemodialysis, N 9) for 12 weeks. Total serum calcium and
phosphorus were measured previous to each dialysis. Baseline (i) and
final (1) values were obtained for intact PTH (IPTH Allegro, Nichols
Inst.), BGP, Alkaline Phosphatase (AP), and its bone isoenzyme (BAP).
Results of the patients that completed the three weeks of treatment are
expressed as mean SEM. There were no significant differences in
baseline laboratory data among the three groups. There were no
changes in serum calcium during treatment except for one episode of
hypercalcemia in OP. but a significant rise in serum phosphate was
observed in OD (i: 5.44 0.65, f: 6.96 0.74 mg%) and OP (i: 5.53
0.43, f: 7,06 0.84 mg%) groups despite the use of phosphate binders.
A significant decrease in IPTH levels was observed in iv. (i: 537.1
121.6, f: 263.7 108.9,P < 0.002), but not in OD (i: 506 95.6, f: 395.4
107.2, P = NS) and OP (i: 555.3 139.4, f: 350.4 127.4, P = NS)
groups. Our results show that, in the short-term, i.v. administration of
calcitriol was more effective in reducing intact FF11 levels than the
other forms of administration.
Factors predicting renal and patient survival in primary amyloidosis
(AL). f.M. Campisiol, D.B. Bernard, M.S. Siskind, A.S. Cohen, JJ.
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Anderson, and M. Skinner (Introduction by L.L. Revert), Boston
University School of Medicine, Boston, Massachusetts, USA. Renal
involvement in AL is well-recognized. Risk factors associated with
progression to ESRD have not been established. We evaluated clinical
markers of renal disease present at diagnosis of AL that might predict
the later development of ESRD. All 140 patients with AL seen in our
CRC over a six year period were included. The median survival of the
entire group was 17 5.5 months. At initial visit, 69 patients had > 2
g/day proteinuria, and 37 had creatinine> 1.5 mg/dl, and 2 1/22 patients
who eventually required dialysis had initial proteinuria of> 2 g/day.
Only six of these had an initial creatinine of> 1.5 mg/dl. The presence
or absence of—M—protein or the type of light chain did not predict
progressive renal failure. The initial median proteinuria of patients
eventually requiring dialysis was 10.5 g/day (0.5—38) versus 3.7 g/day
(0—26) for those not requiring dialysis. The 22 patients who required
dialysis had a median survival of 31 3 months versus 14 7 months
in patients never dialyzed (P < 0.005). Median survival from diagnosis
of ESRD was 17 12 months. Median survival of patients with > 2
g/day proteinuria not reaching ESRD was 17.5 3.7 months. We
conclude that in AL: (a) Progression to ESRD occurs predominantly in
patients with proteinuria > 2 g/day; (b) The development of heavy
proteinuria or ESRD does not necessarily predict a poor survival; and
(C) Renal replacement therapy for ESRD is clearly mandatory.
In vitro synthesis of 132-microglobulin: Role of hemodialysis, dialysis
membranes, diatysis-amyloidosis and lymphokines. J.M. Campisto!, R.
Mo/ma, D. Bernard, R. Rodriguez, E. Mirapeix, J. Muñoz-Gomez, and
L.L. Revert, Hospital Clinic, University of Barcelona, Spain; Boston
University School of Medicine, Boston, Massachusetts, USA. Dialysis-
Amyloidosis (A/32M) is a well-recognized chronic complication in
long-term dialysis patients, whose pathogenesis remains unknown,
although /32-microglobulin (/32-M) has a central role as the amy-
loidogenic protein. To investigate the factors responsible for the in vitro
/32-M synthesis, we studied /32-M production by lymphocyte cultures
obtained from dialysis patients and grown under different circum-
stances and compared the results with a control group of subjects with
normal renal function. We were unable to demonstrate any influence on
the in vitro /32-M synthesis rate by the presence of chronic renal failure,
the hemodialysis treatment, the type of the dialysis membrane used or
the clinical presence of A132M. Rather, dialysis membranes, sterilized
with ethylene oxide and 8 rays added to the lymphocyte cultures,
exerted a strong dose-dependent inhibitory effect on 132-M synthesis,
and the addition to the lymphocyte cultures of normal rabbit serum
markedly stimulated /32-M synthesis. In summary, peripheral blood
lymphocytes from uremic patients from a normal in vitro J32-M synthe-
sis and the direct interaction between lymphocytes and dialysis mem-
branes during hemodialysis are unlikely to contribute to /32-M synthesis
observed during hemodialysis.
Immunochemical demonstration of plasma proteinase inhibitors in
/32-microglobulin amyloid deposits (A/32M). f.M. Campistol, T. Shira-
hama, C. Abraham, M. Sole, D. Bernard, A.S. Cohen, andM. Skinner,
Boston University School of Medicine, Boston, MA; Hospital Clinic,
University of Barcelona, Barcelona, Spain. A/32M represents a fre-
quent complication in long-term dialysis patients. Although the patho-
genetic mechanism has yet to be fully understood, it is known that
amyloid fibrils usually consist of intact molecules of /32-M. Plasma
proteinase inhibitors (PPI) have been involved in the amyloidogenesis
process, especially since the identification of a1-antichymotrypsin in
the /3-protein amyloid deposits of Alzheimer's disease. We immuno-
chemically evaluated the presence and distribution of several PPIs
(a1-proteinase inhibitor, a1-antichymotrypsin, antithrombin III, a-
macroglobulin and tissue inhibitor metalloproteinase) and amyloid P
component in A/32M deposits in osteoarticular and visceral tissues from
dialysis patients with A132M. All but one (anti-al-antichymotrypsin) of
the PPI antibodies tested were demonstrated, and showed varying
degrees of positive reaction against A/32M deposits. The biochemical
analysis (SDS-PAGE and Western blot analysis) of the solubilized
f32M-amyloid fibrils confirmed the results of the immunohistochemical
study, demonstrating positive reactions with the antibodies directed
against all of the tested PPls. In summary, PPIs could play an important
role in the pathogenesis of AP2M by their association with proteolytic
components favoring /32-M fibrillogenesis.
Polyvlnylpyrrolidone in dialyzer sterilization. A 14 year experience. R.
Abelardo and M.D. Martin, Centro Nefrologico Integral, Wilde, PCIA
de BS.AS. Argentina. This is the experience gathered from March 1978
until January 1992 in the treatment of ninety patients suffering from
chronic renal failure, with a total of 75,830 hemodialyses in which PVPI
was used for the sterilization of dialyzers, and not formaldehyde 5%.
The study began in 1977, when PVPI appeared in Argentina, with the
aim of avoiding the unwanted side effects caused by formaldehyde,
such as irritating gas in the eyes and lungs, chemical flevitis in
arterial-venous by-pass, choking and hemolysis derived from the acci-
dental passage of formaldehyde into the blood stream, and production
of antierythrocitary antibodies with an important decrease in hema-
tocrits. The following are the points studied: toxicity in the long and the
short run, no affectation of dialyzer components, lack of caustic effects
on arterial-venous by-pass, bactericidal, fungicidal, sporicidal, and
viricidal action, relation with septic processes, no air rarefaction and
prevention of infection spreading. This is the summary of the findings
explained in seven provious papers about 14 years of unparalleled
experience, which proved the haig antiseptic efficiency, the complete
lack of toxicity—either acute or chronic—the absence of side effects,
the lack of anti-erythrocytary antibody formation with a higher re-
sponse to erythropoietin and the alternative of using PVPI for material
and equipment disinfection.
Vesicoureteric reflux (VUR) and severity of renal scarring in familial
and non-familial affected patients. M. Navarro, L. Espinosa, L. Muñoz,
and E. Izquierdo, Children's Hospital La Paz, Madrid, Spain. Renal
scarring, severity of reflux, urinary tract infection (UTI), hypertension
and renal insufficiency were evaluated in 27 familial cases and 466
non-proven familial patients, all affected by vesicoureteric reflux. Renal
scarring has been evaluated by echography and 990 Tc-DMSA scanning.
Reflux by x-ray cystography and estimated glomerular filtration was
calculated by the height (Swartz).
Familial 27 Non-familial 466
Patient results
Age of diagnosis years 2.69 2.16
UTI 23 (85%) 355 (76%)
Bilateral VUR 20 (74%) 260 (56%)
Renal scarring 20 (74%) 139 (30%)
Bilateral 15 (74%) 52 (37%)
Mean follow-up years 9.3 5.6
UTI/child/year 0.35 0.22
Febril 74% 46%
CRF 5 (18%) 33 (7%)
EGF ml/m/I.73 32 14 48 8
ESRD 3 (60%) 2 (6%)
Hypertension 3 (11%) 31(7%)
Renal units results
Refluxing kidney 47 726
Grading 1II—IV 34 (72%) 310 (43%)
Scarred kidneys 31 (66%) 191(26%)
Diffuse_— 21 (68%) 132 (70%)
Bilateral and severe reflux were more frequent in familial patients. The
total number of scarring kidneys was also 2.5 times more frequent. The
incidence of scarring in both kidneys was twice that in familial patients.
CRF occurred 2.6 times more often in the familial members, and
showed a risk of developing ESRD 10 times more often. We conclude
that in children with a proven family history of VUR, risk factors for
progressive reflux nephropathy are increased.
Determination of glomerular filtration 8GF9, by 51 Cr-EDTA, creati-
nine clearance (Ccr) and estimated glomerular filtration (EGF) in chil-
dren with normal renal function (NRF) and chronic renal failure (CRF).
M. Navarro, A. Alonso, N. Sanchez, G.D. Lasa, Pediatric Nephrology
and Nuclear Medicine, Hospital La Paz, Madrid, Spain. We compared
the results of GF measured by 51 Cr-EDTA, Ccr and EGF in 21 children
with NRF and 54 with CRF of varying severity. The 21 children with
NRF aged 11.8 4.8 years were used as control group. The 54 children
on CRF aged 11.9 4.9 years had OF ranging from 6 to 79 ml/m/l.73
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measured by 51 Cr-EDTA. The structural damage was due to refiux
nephropathy in 38 and posterior uretheral valves plus refiux in 16. The
51 Cr-EDTA clearance was determined by a multiple sample method.
Ccr with 24 hour urine collection and EGF with serum creatinine and
height (Swartz) were as follows:
Control = 21 CRF = 54
51 Cr-EDTA mI/m/I.73 110 30 39 l9&
Ccr mI/rn/i .73 123 37 55 29
EGFmI/m/1.73 119 30 61 31
Ratio C/51 Cr-EDTA 1.1 1.4
Ratio EGF/5l Cr-EDTA 1.08 1.56
Results are means SD. a p < 0.001.
There was no significant difference between the three methods in the
control group, but either C. or EGF overestimated true GFR signifi-
cantly in CRF (P < 0.001). OF in CRF was analyzed as the severity of
renal failure. The results were as follows:
GRF in mIIm/l.73/means SD 79—49 39—20 <20
51 Cr-EDTA
Cr
EGF
Ratio Ccr/51 Cr-EDTA
Ratio EGF/5l Cr-EDTA
4 13b
15b9b
1.34
1.5
22 7'
28 6ab
346b
1.27
1.54
12 515 6
15±4
1.25
1.25
a P < oo5 b <0.001
EGF and C. overestimated significantly true OF (51 Cr-EDTA) in mild
and moderate CRF (P < 0.001; P < 0.05). Neither Cr nor GFR
overestimated significantly true OF (51 Cr-EDTA), in children with
NRF or severe CRF. This study illustrates the difficulties of measuring
GFR in children with structural damage and mild to moderate degree of
CRF.
Reflux nephropathy: Study of 27 familIes. M. Navarro, L. Espinosa,
L. Muñoz, and C. Sanchez-Villegas, Children's Hospital La Paz,
Madrid, Spain. Between 1979 and 1991, 56 families have been investi-
gated for vesicoureteric refiux (VUR) and/or refiux nephropathy. Twen-
ty-seven families with two or more affected members have been
selected for the study. There were 101 family members investigated, (27
propositus, 41 siblings, 33 parents). Nine families (33%) had more than
two members affected, and two siblings were twins. Renal scarring has
been evaluated by echography and 99° Tc-DMSA scanning. X-ray
cystography was done in 27 propositus, 34 of 41 siblings, and two of 33
parents.
27 Propositus 41 Siblings 33 Parents
Patient results
Age of study years 2.7 2.4 5,8 4.5 38 5.5
SexM/F 11/16 22/19 19/20
UTI 23 (85%) 17 (41%) 4 (11%)
VUR 27 (110%) 22 (65%) 0
bilateral 20 (74%) 11(50%) —
Renal scarring 20 (74%) 17 (41%) 7 (21%)
bilateral 15 (75%) 7 (41%) 4 (57%)
CRF 5 (18%) 2 (5%) 3 (9%)
*EGF/ml/m/l73 32 14 58 26 36 32
ESRD 3(60%) 0 1 (33%)
Hypertension 3 (11%) 1(2%) ?
Renal units results
Refiuxing renal units 47 (87%) 33 (49%) —
Grading III—IV 34 (72%) 18 (55%) —
Scarring renal units 31(57%) 24 (29%) 9 (14%)
Focal 10 (32%) 11(46%) 3 (33%)
Diffuse 21(68%) 13 (54%) 6 (67%)
U Estimated Glomerular Filtration (Swartz).
40% of the 101 members investigated were affected, and 10% were in
CRF or renal replacement therapy. There were eight families with
members in CRF, two with two members, and six with one. Family
members on CRF were 100% males in the offspring population and 67%
of parents. HLA investigation did not show any specific haplotype. We
conclude that familial cases with reflux have a high incidence of severe
reflux, renal scarring and bilateral diffuse kidney damage. In this study,
33% of the families had one or more members on CRF, mainly male
patients.
Chronic hemodialysis and hepatitis C (HC): Cooperative study in the
south of Portugal. A. Sousa, P.L. Neves, M.J. Xavier, I. Bernardo, V.
Santos, J. Aniceto, and J.P. Amorim, Hospital de Evora and Hospital
de Faro, Portugal. Hepatitis C is endemic in hemodialysis units. The
published data on its prevalence are disparate. The prevalence of
anti-HC antibodies (HCAb) (2nd generation enzyme immunoassay,
Abbott) in the 307 patients of four units in the South of Portugal was
38.8%, with a wide variation between units (19.5—69%). We compared
the two groups of patients (I, HCAb+; II, HCAb—):
N
Mean age
years
Time on HDU
months
No.
transfusions'
1 119 57.9 56.5° 4d
II 188 60.5 397°
a mean; b median; C P = 0.001; d P = 0.02
The presence of HCAb was associated with an increase (twice normal)
in AST and ALT levels (P = 0.001). Our results suggest the probable
co-existence of two modes of HC virus transmission: vertical (blood
transfusions) and horizontal (time on hemodialysis and center effect).
Anti-hepatitis C antibodies (HCAb) and chronic hemodialysis (HD):
Horizontal transmission of the virus? Pedro Leao Neves and Jodo P.
Amorim, Servico de Nefrologia, Faro, Portugal. Hepatitis C (HC) is
endemic in hemodialysis units, and its mode of transmission has not
been clearly defined. In this study we included 133 patients of a
hemodialysis unit (M = 61, F = 72; mean age = 58.2 years). The
prevalence of HCAb was 20.3% (2nd generation enzyme, Abbott). We
compared the HCAb+ (Group I) and the HCAb— (Group II) patients:
N
Sex
M/F
Mean age
years
Time on HD
months
No.
transfusions
I 27 13/14 52.9 56.7a 4.1
II 106 48/58 59.5 32.3a 3.5
a P = 0.01
Between July 1991 and March 1992, eight patients became HCAb+.
The positivation was related with the fact that these patients were
dialyzed next to previously positive patients (P = 0.02). HCAb+ was
related with an increase in ALT, AST and GGT levels (P = 0.001).
Summary: (I) Relation between HCAb and Time on HD. (2) Associa-
tion between HCAb positivation and neighboring positive patients. Our
results suggest that HC virus has a horizontal transmission among HD
unit patients.
Cholera and IRA at the IPSS ilillospital, Chimbote, Peril 1991. Julio
Arteaga Alcantara and Diana Cossio Flores, Nephrology Service,
Department of Medicine, IPSS Hospital iii Chimbote, Perd. In Chim-
bote City, the first cases of cholera were detected during an epidemic in
Perd; our hospital had 4,472 cases during the entire year, especially in
February and March. IRA diagnosis was made from a clinical point of
view using urea and blood creatinine as the only resources. For the
treatment, hemodialysis and catheter vigo #14 were used as an output.
We report for IRA a number of 9.6 thousand which represents 1% (43
cases) from the total of patients; 53,5% (23 cases) had oliguria; 41.9 (18
cases) had well-kept diuresis, and 4.6% (2 cases) had anuna. 76.7% (33
cases) needed dialysis, with an average of 4 dialyses per patient; 69.7
(23 cases) recovered renal function, and 30.3% (10 cases) died due to
IRA complications. The Etareo group was between 50 and 60 years old,
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with a less significant number of the male sex. We conclude that the
factor which most predisposes IRA factor in cholera is age (50—60
years). The oliguric type of IRA was the most encountered, and sepsis
was the diagnosis factor which was the most relevant for diseased
patients.
Relative deficit of endogenous EPO in anemia secondary to acute renal
failure (ARF). V. FernOndez, M. Campbell, P. liscoff, H. Beresán, P.
Rendo, J. Bidegaray, L. Marangunich, M. Gig/jo, E. Arrizurrieta, and
C. Bozzini, Hospital Pte. PerOn-IDIM-School of Dentistry, UBA, Bio
Sidus S.A., Buenos Aires, Argentina. Considering a trial performed
upon rats with induced acute nephrotoxicity (human metahemoglobin
125 mg/kg i.v. injection) where a dramatic decrease of plasmatic EPO
levels was observed (from 19 mU/mI to 7.5 mU/mi) together with the
impairment of renal function, a clinical trial was designed in anemic
patients due to acute renal failure; endogenous EPO levels were dosed
by RIA with the following results: N = 7 (6 and 1); age : 36.5 years
(18—58): six patients had to undergo hemodialysis, HD/patient: 7.1;
ARF etiology: septic abortion: 3; incompatible transfusion: 2; acute
pyelonephritis: 1; dehydration secondary to gastroenteritis: I. The
results were as follows:
Hematocrit
%
Creatinine
mg%
EPO
mU/mi
(Basal) TO 25.6 6.3 6.6 4.2 17.4 3.0
Tl5 25.3 4,6 3.8 2.6 26.2 175b
T30 30.5 3.9 1.9 1.3 26.9 11.1
a EPO normal value by RIA: 10—30 mU/mI.
b Without outlayer 19.1 2.8 mU/mi.
Conclusion: The relative deficit of endogenous EPO constitutes one of
the causes of anemia secondary to ARF. According to the results
obtained, we consider that clinical trials should be conducted using
recombinant human erythropoietin to assess its efficiency in correcting
anemia secondary to ARF.
Clinical trial with BHK.derived recombinant human erythropoietin
(rHuEPO) in anemic pediatric patients due to chronic renal failure
(CRF). L. Biscigniano, P. Rendo, A. D,az, M. Rubinstein, M. Costa, L.
Marangunich, A. Turconi, J.C. Sanchez Avalos, and M. Criscuolo,
Serv. Nefrol. Htal. Garrahan; Bio Sidus S.A.; Lab. Anal. Clin. H.
Garrahan; Serv. Hematol. Htal. J. de San Martin, Buenos Aires,
Argentina. The efficiency of rHuEPO in anemia secondary to RCF and
the effect of the correction there upon physical aptitude, intellectual
capacity, growth, nutrition and hemorheological changes were evalu-
ated. Doses of 25 U/kg i.v. or s.c. route three times weekly were
administered and were increased according to the response obtained.
Results were evaluated in three groups. Group A: 16 patients on chronic
hemodialysis (CHD); follow-up (FU) 210 days, basal hemoglobin (Hb0)
6.4 1.1; Hb210 10.0 1.7 g%; basal reticulocyte production rate
(RPRO) 0.31 0.18; RPR2IO 0.93 0.60; basal ferritin (F0) 726 287;
F210 438 395 (P < 0.05). Group B: eight patients undergoing
continuous ambulatory peritoneal dialysis (CAPD); FU 120 days; Hb0
6.8 0.8 Hb120 8.5 1.0; RPR0 0.26 0.09; RPR120 0.34 0.21; F0 344
369; F120 376 278 (P < 0.05). Group C: six predialysis (PD) patients
FU 90 days; Hb0 6.6 0.9; Hb 9.6 1.9; RPR0 0.31 0.17; 1PR90
0.84 0.71 F11 841 1208; F 71 35 (P < 0.05). In group A,
transfusion requirements ceased after 120 days. Groups B and C were
not transfused during FU Antibodies to rHuEPO dosed by ninth month
of treatment in group A were negative. Side effects: Group A: 9/16
flu-like syndrome; 6/16 myalgia; 4/16 exacerbation of arterial hyperten-
sion; 3/16 seizures (one child with history of seizures; one child due to
arterial hypertension and one due to post-dialytic syndrome). Group B:
2/8 rise of arterial hypertension. Group C: 2/6 rise of arterial hyperten-
sion. Results of the second endpoint will be presented at the meeting.
Conclusion: rHuEPO proved efficient in treating anemia secondary to
RCF in the three surveyed groups.
Reversal by indomethacin (IMT) of renal effects of dopamine (DM).
Probable relationship between dopaminergic and prostaglandin system in
anesthetized aipha-adrenergic blocked dogs. N.L. Yeyati and G. Alten-
berg, Hospital Esc. Gral. José de San Martin Universidad de Buenos
Aires, Buenos Aires, Argentina. In previous work we demonstrated that
DM in subjects with normal renal function provoked renal vasodilation
and increased sodium and free water excretion. These effects of DM are
reversed by IMT. We postulate that DM could stimulate PGs synthesis
and these autacoids could agonistically modulate the renal effects of
DM. In the present study LMT administration reversed the renal effects
of DM in alpha-adrenergic blocked anesthetized dogs, supporting our
hypotheses. The results are shown in the table.
Control DM DM+IMT
V mI/mm 0.94 0.24 2.26 0.34a 1.43 Ø,33a
UNaV p.Eq/min 105 39 222 44 140 3o
Uosm mOsm/kg 447 99 309 85 378 136
C1., mi/mm 33 4 41 3 28 3
C13Hipp. mi/mm 69 9 89 9 63 9
MBPmm Hg 140 7 156 2 152 2
a p = 5%
Intravenous (i.v.) 1-alpha hydroxyvitamin D3 (laD3) in hemodialysis
patients with severe hyperparathyroidism (HPTH). A. Vila Lobos, J.
Ca/ado, F. Remédio, A. Ramos, J. Bispo, and F. Ribeiro, Clinica de
Doencas Renais, Lisboa, Portugal. Active vitamin D3 metabolites
promote HPTH control and have been described to be more effective to
induce chemical parathyroidectomy when given intravenously. To
assess that issue we made a prospective study in 10 patients: eight were
male, and the mean age was 42 (24—61) years; they were dialyzed for
106.2 (51—147) months and HPTH resistant to oral calcitriol (0.25—0.75
jig/day). Patients with a total serum calcium greater than 11.0 mg/dl,
serum phosphorus greater than 6.5 mg/dl, and a desferoxamine stimu-
lation test with an increment greater than 100 pg/liter were excluded.
I nD3 was given intravenously three times a week at the end of each
dialysis treatment for 12 weeks with increasing doses (1.0 up to 4.0 sg),
keeping calcium dialysis bath at 3.5 mEqlliter. Pre- and post-dialysis
serum total calcium, phosphorus and alkaline phosphatase were mea-
sured weekly and serum aluminum and C-Pl'H were measured
monthly. Only PTH variation between the first and the twelfth week
had statistical significance (P = 0.015), when the laD3 dose was 4.0 jg
(C-P'I'H: week 1 = 759.1; week 4 = 684.6; week 8 = 579.3; week 12 =
533.1 pg/mI). We also found that six weeks and 12 weeks after laD3
interruption, PTH was respectively 611.5 and 792.6 pg/mI, though
patients were on oral calcitriol. Conclusions: (1) i.v. laD3 was appar-
ently effective in HPTH control. (2) The laD3 beneficial effect lasted
only during its administration. This study suggests that i.v. I aD3 given
for longer periods and/or greater doses may be effective in chemical
parathyroidectomy.
Silent myocardial ischemia (SMI) in hemodialysis (HD). Prevalence and
associated factors. J. Lacueva, C. Gonzalez, F. Palacios, R. Enriquez,
J. Cabezuelo, A. Gal/ego, A. Reyes, and M.D. Arenas, Nephroiogy
Section and Critical Care Unit, Elche General Hospital, Elche, Spain.
Silent myocardial ischemia (SMI) seems to be of similar clinical
significance to symptomatic myocardial ischemia. However, there is
scarce information about the prevalence and the factors associated with
SM! in hemodialysis (HD). We prospectively studied SMI by holter
recording (2448 Elatec recorder) on 43 patients with end-stage renal
disease (22 male and 21 female, mean age of 53 17 years) during their
usual session of HD. Dialysate buffer was acetate in 31 cases and
bicarbonate in 12. Eight (18.6%) out of 43 patients underwent SM!
during HD. Total time of SM! ranged between eight and 168 minutes,
and it was not symptomatic in any case. SMI was associated with a
lower hemoglobin (8.17 1.39 vs. 9.52 1.65 g/dl, P < 0.05) and older
age (68 12 vs. 50 17 years, P < 0.05). No relationship was found
between SM! and other factors, such as: renal failure etiology, gender,
time on dialysis, past history of ischemic heart disease, left ventricular
hypertrophy on ECG, hypertension, smoking, obesity or hyperlipemia.
We compared the effect of changing dialysate buffer in five of our
patients with SMI. In four of them, we noted SMI in acetate mode as
well as in bicarbonate mode. However, total length of SM! was longer
in acetate mode (98 68 vs. 13 14 minutes, P < 0.05). We can
conclude that SM! has a high prevalence in HD. Age and degree of
anemia were statistically associated with its appearance. Bicarbonate as
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the base in dialysis fluid doesn't suppress SM!, but ischemic episodes
were shorter in bicarbonate HD than in acetate HD.
Peritoneal dialysate IgG concentration in continuous ambulatory pen-
toneal dialysis patients: Clinical significance. F. Teixeira Sousa, Edgar
Almeida, Antonio Sousa, M. Ana Portugal, and M. Martins Prata,
Nephrology Unit, Biochimic Laboratory, H. Santa Maria, Lisbon,
Portugal. Several authors reported increasing evidence of the perito-
neal dialysate IgG (IgGD) in the immunological mechanisms of local
defense accomplished by the peritoneal macrophages. Positive corre-
lations between !gGD and opsonic activity of the peritoneal cells have
been described. Two determinations of IgGD, separated by four to six
months, using nephelometry, were done in the peritoneal effluent of 20
patients (9 men, 11 women, mean age 45.9 17.0 years) on CAPD more
than four months. Overnight peritoneal fluids (8.4 1.3 hours) were
used for this purpose. Incidence of pentonites (IP) was 1.5/patient year.
Mean value for IgGD was 14.5 9.1 mg/dl and no significant differences
were found between the two determinations, although in 12 patients
(60%) a variation of 20% or more was seen. No correlation was found
between !gGD and age (r = 0.36), time of dialysis (r = 0.19),and serum
albumin (r = 0.38), whereas a positive correlation was found with serum
IgG (r 0.53; P < 0.02), dialysate albumin (r = 0.82; P < 0.001) and IP(r = 0.48; P < 0.04). The IgGD was significantly higher in the patients
with IP >1/year than with IP <1/year (20.0 11.0vs. 11.6 6.7 mg/dl;
P <0.05). Great variations between two determinations in IgGD was seen
which means that many factors contribute to this difference. The lowest
levels of IgG in peritoneal fluid don't correlate with the incidence of
peritonitis, not permitting the separation of patients at high risk for
peritonitis, and suggesting a multifactorial mechanism of these infections.
Nutritional assessment of continuous ambulatory peritoneal dialysis
patients (CAPD). F. Teixeira Sousa, Isabel Castro, AntOnio Sousa,
Edgar Almeida, and M. Martins Prata, Nephrology Unit, H. Santa
Maria, Lisbon, Portugal. Some factors account for protein calorie
malnutrition in CAPD patients, such as infections, protein loss in
dialysis fluid, and inadequate calorie protein intake. The calorie protein
supplementation (CPS) in normal diets can improve the nutritional
status (NS) in these patients. In a cohort of 12 patients, of whom seven
were diabetics, mean age 51 17.1 years, on CAPD from eight to 74
months, we evaluated the NS performing dietary inquiry, dietary
protein intake (DPI), using the urea kinetic model and a nutritional
index based on eight parameters: corporal mass index (CMI), triceps
skinfold thickness (TSF), mid-arm circumference (MAC), mid-arm
muscle circumference (MAMC), serum albumin and transferrin (ALB,
TF), total lymphocyte count, and clinical examination. We followed
these patients during a period of five to 15 months, correcting the NS
with CPS. There was a significant increase in: CMI (22.3 2.0 vs. 23
2.3; P < 0.02), ALB (3.5 0.4 vs. 3.8 0.4g/dl; P < 0.02), TF (265.5
25.1 vs. 280.5 19 mg/dl; P <0.03), and creatinine (6.3 2.9 vs. 7.5
2.7 mg/dl; P < 0.05). Comparing the diabetic with the non-diabetic
group, no differences were seen in the NS. The most significant
correlations between nutritional index and anthropometric measure-
ments were: CM! (r =
—0.78; P < 0.02), MAC (r —0.75; P < 0.03)
and MAMC (r =
—0.74; P < 0.05). A good correlation between DPI
estimated by dietary inquiry and by urea kinetic was found (r 0.63; P
<0.03). The NS of the diabetic and non-diabetic patients on CAPD is
similar; the calorie protein supplementation in normal diet can improve
the NS, and dietary inquiry seems to be a good and simple method to
assess dietary protein intake,
Rapid control of acute hyperkalemia with nebulized salbutamol. Fun-
daciOn de Nefrologla Buenos Aires, Buenos Aires, Argentina. Fifteen
patients on chronic hemodialysis received twenty-two treatments with
20 mg nebulized salbutamol (4 ml of 0.6 g% in 4 ml of saline) to control
an episode of acute hyperkalemia (6.58 0.14range: 5.7—7.9 mEq/liter)
and as a previous step before dialysis. Plasma potassium concentration
at 20, 40, 60, 90 and 180 minutes post-salbutamol were: 5.85 0.21,
5.58 0.21, 5.48 0.27, 5.46 0.17 and 5.57 0.34 mEq/liter,
respectively. The decrease of plasma potassium was significant at 40
minutes and maximal at 90 minutes: 1.12 0.10 mEq/liter, and
persisted for at least three hours (in 3 patients up to 6 hours). No
correlation was found between the grade of hyperkalemia and the
magnitude of plasma potassium decrease after therapy. The systolic and
diastolic blood pressure decreased significantly at 60 and 80 minutes
post-treatment: 134 6.45vs. 119 6.79and 74 4.12vs. 64.66 3.88
mm Hg (P < 0.02 and P < 0.001). The heart rate and respiratory
frequency increased significantly at 60 to 80 and 20 minutes, respec-
tively (90 4.45 vs. 113 4.55 beats/mm and 19.57 0.98vs. 23.42
1.24 resp/min; P < 0.001). The secondary effects of the administration
of the drug, such as sinus tachycardia, fine tremor and anxiety in
patients 6, 4 and 1, respectively, were moderate and well tolerated. It is
concluded that, due to its technical feasibility, promptness of action,
duration of hypokalemic effect, few side effects and repeatability,
nebulized salbutamol can be considered as a first choice in the treat-
ment of acute hyperkalemia.
Acquired cystic kidney disease in hemodlalysis patients. C. Mendoza,
M. Villanueva Meyer, I. Castle, V. Santivañez, and C. Battilana,
Instituto Peruano de InvestigaciOn Cientifica Aplicada—IPICA, Centro
de Didlisis Santa Maria Reyna, Centro de DiOlisis San Borja, Lima,
PerO. The acquired cystic kidney disease (ACKD) has been reported
frequently in patients suffering from chronic renal failure (CRF),
particularly in patients in a dialysis program. We report the results
through ecosonographic evaluation obtained in a study performed in 20
patients (13 male, 7 female) with chronic renal failure in a regular
hemodialysis program. From the total population, we identify seven
cases with ACKD (35%), four male and three female. Bilateral cysts in
six patients (85%) and unilateral in one patient (15%). Ten cysts were
reported in four patients (57%). With respect to time in the hemodialysis
program, we observed that the four patients with more than 10 years in
the program complained of ACKD, which represents 100% for this
group: two patients in the group between six and 10 years in hemodi-
alysis (50%), and one patient in the group between 0 to 5 years in HD
(8.3%). There was no relation between the cause of CRF and the
incidence of ACKD, and there was no statistical significance between
the mean hemoglobin in the group with ERQA (7.62 g/dl) and control
(6.32 g/dl). All patients were asymptomatic. We concluded that the
incidence of ACKD increases in relation with the time in the hemodi-
alysis program, producing in some cases important complications, and
also that ultrasound study is a good auxiliary diagnostic method. Due to
these facts, we recommend the performing of periodic studies to
evaluate ACKD in hemodialysis units.
Improvement of the quality of life of hemodialysis patients treated with
erythropoletln (EPO). A controlled study. F. Moreno, F. Valderrdbano,
F.J. Aracil, and R. Perez, Hospital PrIncipe de Aslurias and H.
Gregorio MaranOn, Madrid, Spain. In order to evaluate a possible
improvement of the QL of patients treated with EPO, we prospectively
studied a group of 57 stable patients on hemodialysis who were about to
begin treatment with EPO, and followed their progress at three and six
months. The QL was measured using the "Karnofsky performance
scale" and the "sickness impact profile" (SIP). A control group of 29
hemodialysis patients, none of whom required EPO, was simulta-
neously studied. In the EPO group the mean hematocrit increased from
21% to 29%, and in the control group remained stable throughout the
study (30%). In the group treated with EPO a significant improvement
was observed on the Karnofsky Scale as well as in physical and
psychosocial dimensions and in the overall score for the SIP.
Karnofsky
scale
SIP
Physical
dimension
Psychosocial
dimension
Overall score
for SIP
EPO patients:
Initial 68.4 (1.8) 15.35 (1.85) 19.07 (1.89) 19.84 (1.65)
3rd month 78.6 (1.6) 11.27 (1,59) 12.17 (1.34) 14.77 (1.38)
6th month 81.0 (1.5) 9.56 (1.44) 10.85 (1.29) 13.48 (1.22)
Controls:
Initial 79.6 (2.6) 11.56 (2.42) 15.97 (3.02) 16.60(2.37)
3rd month 77.2 (2.7) 10.51 (2.51) 14.07 (2.71) 14.95 (2.23)
6th month 76.8 (2.6) 10,64 (2.49) 14.28 (2.86) 15.14 (2.18)
Mean sE; (SIP: lower score => better QL).
ANOVA for repeated measures: EPO: P < 0.0001 for all within
factors
Controls: P = NS for all within factors
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It can be concluded that treatment of anemia with EPO significantly
improved the QL of hemodialysis patients. This effect was not observed
in the control group.
Improvement of the quality of life (QL) of elderly patients on hemodi-
alysis (HD) treated with erythropoietin (EPO). F. Moreno, F. Valderrd-
bano, F.J. Aracil, and R. Perez, Hospital PrIncipe de Asturias and H.
Gregorio Maranón, Madrid, Spain. The aim of this study was to assess
if EPO improves the indicators of QL in elderly patients on HD in the
same way it does in young patients. A group of 57 stable patients on HD
commencing treatment with EPO was studied. The QL was evaluated
using the questionnaire sickness impact profile" (SIP) and the "Kar-
nofsky performance scale", before EPO treatment and after three and
six months. No diabetic patients or patients with associated invalid
pathologies were included. The patients were divided into two groups:
Al Age <60 years (N = 34; time on HD: 3.4 yr.; mean age: 38 yr.); B/
age 60 years (N = 23; time on HD: 2 yr.; mean age: 67 yr.) The
indicators of QL prior to treatment were worse in the group of elderly
patients, and this difference continued throughout the study. In both
groups the indicators of QL improves in a parallel way during the study.
No relation was found between belonging to an age group and the
changes in the indicators of QL. Results are shown in the table (mean
and SE).
Age
group
SIP
Physical
Karnofsky dimension
Psychosocial
dimension
Overall
score SIP
Hct.
%
60 Basal
6th month
<60 Basal
6th month
61(1.5) 26.5 (2.4)
75 (2.5) 18.6 (2.4)
73 (2.5) 7.8 (1.7)
85 (1.5) 3.4 (0.7)
23.1 (2.6)
13.3 (2.2)
16.3 (2.5)
9.2 (1.5)
27.7 (2.1)
20.0 (1.8)
14,5 (1.9)
9.1 (1.2)
21(0.5)
28 (0.6)
22 (0.4)
30(0.5)
ANOVA 2x2, for repeated measures: Between age groups ap <
0.0001, b P < 0.001. Basall6th month: P <0.0001 for all EPO patients.
Interaction Age/QL indicators: P = NS.
Increments in scores (6th month, Basal)
60 yr. 14.3 (2) —7.9 (2.3) —9.8 (2.7) —7.7 (2.0)
<60 yr. 11.5 (2) —4.4 (1.4) —7.1 (1.7) —5.4 (1.2)
ANOVA: P = NS between age groups.(SIP: lower score = >better QL)
In conclusion, we did not find that age was a determining factor in the
improvement of the parameters of QL in patients on HD treated with
EPO. Elderly patients show an improvement in the indicators of QL
similar to that found in younger patients, thereby fully justifying the use
of EPO in this age group.
Blood pressure behavior in patients on chronic hemodialysis (CH)
treated with subcutaneous and endovenous (e.v.) erythropoietin (EPO).
L. Amaya, C. Alberto Bone/li, N. Perez, A. Chamorro, Z. Olmos, P.
Brusco, J. Velazquez, N. Guitian, and I. Castro, Central Military
Hospital, Bs.As., Argentina. Eighteen patients on CH (10 women and 8
men, 18—68, average age about 46.3 years, with 62.3 months, 2—146, of
average dialysis time) were included in this task. For this they had to
have: Hto. <25% with or without symptomatology; Hto. >25% with
symptomatology; and transfusional requirement. We excluded those
with: Hta not controlled; hyperparathyroidism not controlled; acute
bleeding; and infection in activity. To get ferric levels >80 mgldl, those
patients who needed it took FE orally. From the 18 patients, five had
previously high pressure who received medical treatment. Three high
pressure patients did not suffer any change in their blood pressure. The
anti-high pressure doses had to be adjusted in the other two patients,
maintaining them with normal blood pressure. One of these two patients
received e.v. treatment and the other received s.c. treatment. In
conclusion, in our experience the EPO treatment did not increase the
blood pressure in people with previously normal blood pressure. There
was an increase of blood pressure in two of the five patients with
previously high pressure, which could be managed with an increase of
the medication, making the numerical character stable. We couldn't
evaluate the differences in the blood pressure behavior between the
patients who received EPO, s.c. and e.v.
Erythropoietin (EPO) endovenous versus subcutaneous to patients on
chronic hemodialysis (Cli). L. Amaya, C. Alberto Bone/li, N. Perez, A.
Chamorro, Z. Olmos, P. Brusco, J. Velazquez, N. Guitian, and I.
Castro, Central Military Hospital, Bs.As., Argentina. Eighteen patients
on CH, 10 women and eight men of about 46.3 years old (18—68) average
age with 62.3 months (2—146) of average dialysis time were included in
this task. For this they had to have: Hto <25% with or without
symptomatology; Hto >25% with symptomatology; and transfusional
requirement. We excluded those with: Hta. not controlled; hyperpara-
thyroidism not controlled; acute bleeding; and infection in activity. To
get ferric levels >80 mg/dl, those patients who needed it took FE orally.
The target was to get a Hto. 30% and Hb of 10.5 g % (±0.5 g %). Seven
patients (6 men and 1 woman) were treated with EPO in doses
subcutaneous of 30 U/Kg. The rest of the II patients (2 men and 9
women) received 50 U/Kg endovenous post-dialysis. They were eval-
uated after six weeks without any modification in the initial doses. Six
of the seven patients who received subcutaneous EPO answered from
the 11 patients who received endovenous EPO, getting an Hto of 30%
(±3). In conclusion, patients treated with subcutaneous and en-
dovenous EPO presented the desired answer with an increase of Hto
and Hb to cyphers arranged before. A similar answer can be observed
in both groups, one of them receiving S.C. less doses.
Recombinant human erythropoietin (rHuEPO) free of albumin, efficacy
and tolerance in patients with chronic renal failure (CRF) on hemodialysis
(HD). M. Alvarez Quiroga, A. Locate//i, R. Barone, L. De Benedetti,
and M. Gomez, Nefrology Service-C/in/ca Olivos, Buenos Aires, Ar-
gentina. The efficacy and tolerance of rHuEPO, free of albumin, was
evaluated in patients with anemia secondary to CRF in HD. Twenty
patients were selected and received the drug three times a week; ten,
intravenously (iv.), five subcutaneously (s.c.), and five alternatively.
The follow-up performed during eight months was divided into two
periods: correction period (CP) with gradual increase of the dose until
reaching the target hematocrit (TH), not exceeding 200 U/Kg body
weight (UKbw), and maintenance period (MP) with the minimal dose
necessary to maintain the reached values. The TH was individual for
each patient: greater than 10 volumes %, referred to the initial hema-
tocrit (IH) and not higher than 35%. Three patients of the s.c. group
were excluded from the study in CP, two because they presented
another anemia etiology (myeloma, medullary fibrosis), and one due to
his own decision. The remaining seventeen reached the TH. The
following data are shown:
Route IH TH FHb M. Dose pa Dose MP
i.v. lOp 21.2 + 2.1 32.3 + 1.9 29.7 + 1.7 88 + 104.11 48 + 30.11
s.c. 2p 20 28.5 32.5 80 40
i.v. s.c. 23.2 + 3.3 34 + 1.2 31.8 + 3.4 60 + 69.64 42 + 24.94
sp
a maximum dose CP; ' FH, final hematocrit. Abbreviation is: p,
patient
Five patients did not show adverse effects (AE); in the other twelve
these AE were observed: post-HD fever (3), headache (4), influenza-
like syndrome (2), pruritus (1), diarrhea (1), arterial hypertension (7),
hyperkalemia (1), seizures (2), thrombosis of the central retinal artery
(1). It is concluded that rHuEPO is effective in correcting renal anemia
using the i.v. and s.c. routes. All the patients present a sensation of
physical comfort and a better tolerance of exercise. The severe AE
would be related to a high dose or a quick rise of the hematocnt, and
consequently both situations should be avoided.
Glomerular filtration rate (GFR) during intra-arterial renal infusion of
amino acids (AA) and glucagon in healthy humans. C. Maggiora Edu-
ardo, C. Salvidea Julio, and A. Agost Carreno César, Nephrology and
Radiology Services, Sanatorio Mitre, Buenos Aires, Argentina. Like
protein intake, endovenous infusion of AA induces an increase in GFR,
perhaps due to direct effect of AA or of L-arginine (nitric oxide) on
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glomerular hemodynamics. Glucagon presumably modulates these di-
rect effects. Six volunteers, potential related donors for renal trans-
plant, were studied just prior to renal arteriography. A catheter was
placed in each renal artery proximally, guided by radioscopy without
administering contrast medium. Alter bilateral infusion, GFR was
measured by continuous infusion with DTPA-Tc99, collecting urine by
vesical catheter, during eight consecutive 30-minute periods. Infusion
for each artery consisted of two control periods with saline solution (0.5
mI/min/! .73 m2), followed by three periods with AA plus glucagon (2
ng/kg/min), a dose which mimics peak post-prandial physiological
arterial levels.
Subject group
Control period
(2—30 mm
periods)
Exp. period A
(3—30 win
periods)
Exp. period B
(3—30 mm
periods)
Control Saline Saline Saline
group (N = 2) 91.7 5.7 92.7 3.7 90.5 3.5
Experimental Saline 10% AA 10% AA + Glucagon
group (N = 4) 99.7 4.2 96.2 2.4 92.9 4.5
All values expressed as means SE (mI/mm/I .73 ma).
Repeated ANOVA measurement; P = 0.5 (NS).
Bilateral proximal renal intra-arterial infusion of the AA including
L-arginine and of AA plus glucagon fails to increase GFR in healthy
humans. GFR increase by endovenous AA infusion hardly seems
attributable to their direct effect on the kidneys, but rather mediated by
extrarenal factors other than glucagon.
Over 10 years survival—Renal transplantation in Argentina. C. Agost
Carreno, Consejo Argentino de Trasplante Renal S.A.N., Buenos
Aires, Argentina. During 1991, a survey was made in order to study the
development of renal transplantation with graft survival higher than 10
years. The results of this survey revealed that 30% of the centers (9/30)
have patients bearing this characteristic. Reports were given about 100
grafts: 89 of which were recipients of living related donor kidneys and
11 of cadaveric ones. Ninety-six patients were transplanted once; only
four recipients were transplanted twice, and due to the two grafts they
outlived 10 years. It was not possible to make actuarial survival rates
due to the fact that it was unlikely to estimate the figures regarding
transplants performed every year before 1980 as a consequence of the
lack of registry reports. The older recipient was transplanted 22 years
ago; 60% of the patients aged between 30 and 40 years were grafted;
children aged under 10 were not grafted, and patients over 50 years of
age represented 1%. Almost 70% of the patients were male. More than
50% of the grafted patients suffered from a primary glomerulopathy.
The typification was carried out according to the HLA (A-B for living
and cadaveric donors); DR was not made. The complete death rate
regarding all the patients who outlived 10 years amounts to 12%. Causes
of death were due to vascular diseases (50%), neoplasia (25%), and
infection (25%). The maintenance immunosuppression consists of Aza-
thioprine and corticosteroid dosages. An analysis on disorders is
carried out.
Results of renal transplantation In Argentina. A national survey
(1984—1990). C. Agost Carreño, Consejo Argentino de Trasplante
Renal, S.A.N., Buenos Aires, Argentina. Since 1984, 93% of the renal
transplant centers have brought about a report on renal transplantations
that have already been performed. Up to 1990, 1530 grafts were made;
60% of them were performed with kidneys obtained from L.R.D,, and
the remaining 40% were carried out with cadaver donor kidneys.
Depending upon the years considered, four to nine transplantations
P.M.P. per year have been performed. The age of 50% of this group of
people ranges from 30 to 40 years. No more than 10% of the aforemen-
tioned group is composed of people younger than 10 years old or older
than 50. Sixty percent belonging to said group were male. More than
35% of the etiologies of R.F. were due to primary glomerulopathy, 23%
thereof were of uncertain etiology. Type I diabetes represented 2.3%
Hemodialysis was the prior substitutive therapy in 97% of the cases; 2%
were treated with C.A.P.D., and the remaining 1% were not dialyzed.
As regards blood transfusions, 90% of the patients were transfused
before transplantation, but only 22% were transfused in order to seek
the "transfusion effect." In the past several years, transplant centers
have tried to avoid transfusions. Throughout the course of these seven
years, actuarial survival for 902 patients who have received kidneys
from living related donors is 86% and graft survival is 70%. For 627
cadaver graft recipients, patient survival has been 81%, and graft
survival has been 42%. The most frequent cause of death was infection
(60%), and graft loss was, in most cases, due to chronic rejection. Graft
loss as a consequence of recurrences of the primary disease or due to
technical failure occurred only in a few cases.
Urolithiasis in children: Metabolic study and follow-up. M.G.M.G.
Penido, J.S.S.D. Diniz, M.L.S.F. Moreira, J.M.P. Silva, and E.M.
Lima, Unidade de Nefrologia Pedidtrica, Ay. Alfredo Baleno, Belo
Horizonte, Brazil. Fifty-five children (31 male, 24 female) with renal
stones have been studied during the mean period of four years and
divided in three groups according to age: group A, 11 children (20%)
aged 0 to 7 years; group B, 24 children (44%) aged 7 to 12 yrs; group C,
20 children (36%), older than 12 years. Each patient had normal renal
function (blood creatintne 0.8 mg%) and none was hypertensive. Each
patient was studied according to the same protocol which included the
following investigations: plain abdominal x-ray, abdominal ultrasound,
oral calcium loading test, two fasting morning venous blood samples
assayed for full blood count, electrolytes, urea, creatinine, calcium,
phosphorus, alkaline phosphatase, parathyroid hormone. Three 24 hour
urine samples were collected for measurement of the following param-
eters: creatinine calcium, phosphorus, uric acid, citrate, oxalate, mag-
nesium, cyclic adenosive 3'S' monophosphate (cAMP). Stream urine
was analyzed to determine the pH and culture. The diagnosis of
idiopathic hypercalciuria was made in 39 patients (7 1%) based on the
findings of a urinary 24 hour calcium excretion higher than 4mg/kg body
weight. Renal hypercalciuria predominated in this group of children
(56%) compared to absorptive hypercalciuria (26%). In 44% of the
patients the hypercalciuria was associated with uric acid hyperexcre-
tion. A family history of urolithiasis was present in 31(56%) children.
Twenty-five patients (45%) presented abdominal pain and hematuria,
and classic renal colic was reported in 14 children (25%). Urinary tract
infection was present in 22 (40%) children. We have observed that the
specific treatment was associated with a good outcome in 62% of the
patients.
Double-lwnen catheter: Alternative in patients with difficult vascular
access for hemodialysis. M. Medina Chavez, J. Calderon C., and L.
Carrillo C., Nephorogy Service Hospital E. Rebagliati M. fF55, Lima,
Perd. We report our experience in double-lumen catheters (D.L.C.).
Six hundred thirty-nine patients were evaluated in a year from July 1990
to July 1991 in the Department of Hemodialysis. Twenty-seven of these
needed D.L.C. We used 12 and 15 cm catheters and used the
Seldinger's technique. The veins used were preferably those of the
neck. Different brands of D.L.C. were used, but "Cook" were the ones
used most. We report that 27/639 needed D.L.C., out of which there
were 14 women (14/27, 52%) and 13 men (13/27, 48%). The average age
was 45. Among the causes of placement of D.L.C. were harmed veins
16/27 (59%), diabetics 7/27 (26%), children 4/27 (15%). The average
duration is analyzed according to heparinization (1.000 IU in 10cc NaCl
6 days; 5.000 on the venous side; 2.500 IU on the arterial side = 15
days; 5.000 IU on both venous and arterial sides = 44 days). The total
number of placed D.L.C. was 84. The frequency of boardings was:
angie jugular right subclavian 38/84 (45%), V.S.C.I. sub boarding 16/84
(18%) right internal jugular vein previous boarding 14/84 (17%). The
principal reason for removal in the retrospective study is obstruction on
both arterial and venous sides 26/54 (48%); in the prospective study the
arterial obstruction is 8/30 (27%), fever 7/30 (23%), removed by itself
6/30 (20%). ConclusIons: (I) D.L.C. is an excellent alternative in
patients with troublesome vascular access. (2) It makes HD duration for
longer periods of time. (3) We recommend hepannization with 5.000 IU
on both arterial and venous sides. (4) To avoid obstruction or fever, this
should be handled as asepticly as possible.
Allergic reactions in hemodlalysls. M. Medina Chavez, L. Carrillo C.,
Nephrology Service Hospital, E. Rebagliati M., Lima, Peru. We report
incidence and the fiuxogram in A.R.}1. patients. Between January 1987
and July 1991, 1.783 patients were tested in the Hemodialysis Depart-
ment; we applied the protocol of diagnosis and treatment in patients
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showing signs ofA.R.H. A.R.H. was found in 16/1783 patients (1%, the
average in hemodialysis when A.R.H. appears in 595 days. The clinical
features presented by the sixteen patients were pruritus, pulsatile
migraine hypotension during the first hours on hemodialysis, and
cosinophilia, and then in lesser degree bronchospasm, leukopenia,
urticaria, angioneurotic edema, laryngeal edema, arrest. We did not find
retroesternal pain or fever. Among the discovered cases there were
first-use dialyzers (ethylene oxide 3/16 (18.75%). When there is over
one usage the causes are: formaldehyde 8/16 (50%), amprolene 3/16
(18.75%), and cuprophane 2/16 (12.50%). Conclusions: Our 1% inci-
dence does not reflect the realistic figures for the country, but it can give
us an idea of the magnitude and also the danger of not recognizing it.
The common clinical features are pruritus and pulsatile migraine.
Formaldehyde does definitely take the first place as a sensitizer agent,
followed by ethylene oxide and amprolene, and then cuprophane.
Treatment of pruritus with membrane stabilizer of mastocites (ketotif-
eno). M. Medina Chavez, A. Vidalon F., Nephorology Service Hospital
E. Rebagliati M. IPSS, Lima, Perá. Pruritus is an unpleasant accom-
paniment to IRC. It is treated in several ways, not always obtaining the
desired results. We propose this new treatment: Material and methods:
We tested and applied the protocol of treatment to 31 patients with
pruritus: days 2, 4, 8, 10, 12, 16 and the month were controlled, and the
therapeutic response was evaluated during this period. Fairly good (F),
is considered when the patient can sleep. Good (G), when the patient
can sleep and the disappearance of scabs from scratching. Very Good
(VG), was stated above and the reporting of the patient not having
pruritus any longer. Findings: Out of the 31 patients that were treated,
6/31 (20%) "F" 8/31 (26%) "G", 17/31 (51%) VG. When adding VG, we
had 80% success in the treatment, besides we could make sure that
when the treatment was cancelled, pruritus came in a month with the
same intensity or higher. An important finding is the improvement of
appetite and sleep. Conclusions: (1) Ketotifeno is a good alternative in
patients with pruritus. (2) The action of Ketotifeno would be explained
due to the presence of mastocites in the dermo-epidermal union shown
in the late years by skin biopsy. (3) If there is not any therapeutic
response in fifteen days, even if this is continued, there is no improve-
ment. (4) The recommended dose is I mg/l2 hours, orally. (5) In those
that we can find therapeutic response there is also improvement of
sleepiness and appetite. (6) We do not recommend that this be taken as
the only medication, since it can be associated with other medications
suitable for pruritus.
Physiopathology of the lipid metabolism and other alterations in the
nephrotic syndrome under two diets of different protein content. A
prospective and randomized cross-over study. P. Abaigar, G. Torres, J.
Santos, M. Casas, M.L. Carrasco, A. Vazquez, R. De Toro, S.
Pascual, Hospital G. Yague, Burgos, Spain. A 19 patient group with
nephrotic syndrome was studied, They were submitted to a prospec-
tive, random and cross-over study with two types of diets of different
protein content (0.8 and 1.6 g of protein/kg/day). Each diet lasted six
months. Clinical and biochemical controls were made every two
months. Lipid metabolism: The cholesterol total had a correlation
coefficient with the cholesterol L.D.L. (r = 0,95, P 0.000), with the
apoprotein B (r = 0.89, P = 0.000), C. albumin (r = 0.79, P = 0.000) and
with albumin (r =
—0.67, P = 0.000). When multiple regression was
made only the albumin and the C. albumin entered on the model
(Multiple r = 0.89, P = 0.000). The tryglycerides only depended on the
C. albumin (Multiple r = 0.72, P = 0.000). The cholesterol L.D.L. had
a correlation coefficient of 0.76 with the C. albumin, albumin (—0.76),
albuminuria (0.61), proteinuria (0.67), and apolipoprotein B (0.80, P =
0.000); when we analyzed these data with multiple regression, we
observed that the first variable was the C. albumin (M.R. = 0.76, P =
0.002) and the second the albumin (M.R. = 0.82, P = 0.000). The apo
B had correlation coefficient with the C. albumin (r = 0.71), albumin (r
= —0.68), albuminuria (0.54), and proteinuria (0.52). Applying multiple
regression the variations of the apo B depended on the C. albumin
(M.R. = 0.71, P = 0.000). Other biochemical alterations were the
albumin and albuminuria (r = —0.46). With multiple regression only the
C. albumin entered on the model (M.R. = 0.73, P = 0.000). We
appreciated a correlation coefficient of 0.81 (P 0.000) between the
plasma urea and the volume %; if we made multiple regression between
volume % (dep.) and the other variables, the urea was the first variable
of the model (M.R. = 0.59, P = 0.000). In the nephrotic syndrome the
alterations from lipid metabolism depend and are mainly related to the
albumin clearance. This may depend on permeability glomerular alter-
ations. The modifications of plasmatic urea through the control of diet
proteins can be useful in order to control the polyuria.
Influence of dietary protein content and enzymatic inhibitors of anglo-
tensin on nephrotic syndrome. A prospective and randomized cross-over
study. P. Abaigar, G. Torres, M.L. Carrasco, A. VOzquez, R. De Toro,
J. Santos, S. Pascual, Hospital Gral Yague, Burgos, Spain. The
present study was undertaken to evaluate the variations of several
factors in a group of 19 patients with nephrotic syndrome exposed to
two kinds of protein diets 0.8 g/kglday and 1.6 g/kg/day. Each diet lasted
for a period of six months. Captopril (25 g) was given in the last two
months of each period. A washed-out period of two months, with free
diet, was established between both dietetic treatments. Biochemical,
clinical and anthropometric measurements were every two months.
Basal 2 months
Diet 0.8 g/protein/kg/day
Factor IX% 149.7 III 195.7 66
Fibnnog. g% 4.1 1.4 3.7 1.1
Cholesterol g% 311 110 283.9 79,7a
Apolipo. B g% 203.3 65 183.7 49.8
Un. prot. g/24 hr 6.5 2.9 6.3 3.4
Un. alb. g/24 hr 3.9 1.8 4.06 2.5
Albüminag% 3.1 0.79 3.2 0.63
Musc. Mass. kg 23 6.4 22.1 6.06a
Plas. cr. pgs% 1.69 0.68 1.79 0.67
Diet 1.6 glprotein/kg/day
Prot. cat. rate pg/kg/day 1.16 0.59 1.41 0,15b
Plas. urea gr% 65 26.8 71 36.7
Un. Cr. p.g/24hr
Un. urea g/24 hr
1069 361
18.8 5.8
1186 359b
23 4,gb
Sys A.P. mm Hg 130 15.8 136 21.5a
Plas Cr. g% 1.4 0.59 1.5 0.81
4 months 6 months
Diet 0.8 g/protein/kg/day
Factor IX % 205 l15 180 92
Fibninóg. g% 4.1 1.3 3.5 1.1
Cholesterol g% 287,6 9l.4a 271 90,7b
Apolipo. B g% 179.7 59 172.5 98.7a
Un. prot. g/24 hr 5.5 2.8 4.4 2.3a
Uri. alb. g/24 hr 3.6 0.9" 2.6 1,5b
AlbUmina g% 3.6 09" 3.4 0.89"
Musc. Mass. kg 20.2 6.9 21.8 5.4"
Plas. cr. ags% 1.85 0.78 1.89 0.7a
Diet 1.6 g/protein/kg/day
Prot. cat. rate pg/kg/day
Plas. urea pgr%
1.38 0.18"
80
1.43 043b
83 42b
Uni.Cr.p.g/24hr 1169± 326 l319±356a
Un. urea g/24 hr 23.6 5.2" 25.4 82b
Sys A.P. mm Hg 143 15.8 135 16.5
Plas Cr. g% 1.7 1.03 1.6 1.18
a P < 0.05; b p < 0.01
Patients with nephrotic syndrome can be treated with 0.8 g/prot/kg/day
because the total cholesterol, apolipoprotein B, proteinunia, and albu-
minunia decreased and the p. albumin increased. However, the nutri-
tional state must be checked in order to avoid malnutrition. We did not
observe any effect of captopril under both diets.
Plasma volume changes on hemodialysis (HD), hemodiafiltration (HDF)
and paired filtration dialysis (PFD) with isotonic and hypertonic solutions.
J. Santos, G. Torres, M.L. Carrasco, A. Vázquez, P. Abaigar, S.
Pascual, and R. Toro, Hospital General Yague, Burgos, Spain. We
selected eight patients from our program who were treated with HD,
HDF, and PFD with isotonic and hypertonic solutions for a week (six
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kinds of different dialysis). A week of wash-out, with conventional HD,
was established among each technique. The hypertonicity on HD was
reached by changing the dialysate from 178 mEq/liter of Na to 135
mEq/liter of Na each 45 minutes. A solution with 220 mEq/liter of Na
was the plasma volume difference in intradialytic or interdialytic
periods.
Plasma vol Isotonic Hypertonic P
HD intra 8.32 3.79% 4.47 1.65% 0.017
HD inter 12.31 1.90% 5.12 1.83% 0.015
HDF intra 8.51 3.89% 4.90 1.83% 0.06
HDF inter 12.78 0.55% 2.04 0.15% 0.03
PFD intra 6.27 5.7% 5.71 2.38% NS
HDF inter 17.94 10.82% 2.13 2.40% 0.06
The hypertonicity in HD, as in HDF or PFD, better preserved the
plasma volume in the interdialysis period because of the filling of the
intracellular space. The hypertonicity, on HD and HDF, decreased the
intradialytic change of the plasma volume. We suggest hypertonic
dialysis in order to improve the comfort on dialysis. Also this does not
bring overload of interdialysis plasma volume.
Effect of recombinant human erythropoietin on functional capacity in
patients with renal failure and chronic hemodialysls. N. Marigliano, R.
Hidalgo Ottolenghi, R. Fernández de Soria, R. Fernández, J.R. Go-
mez-Martino, and A. Covarsi, Division of Nephrology, DivisiOn of
Cardiology, General Hospital, Caceres, Spain. The purpose of this
study was to assess the effect of the hemoglobin increase on the
exercise capacity in patients with renal failure on chronic hemodialysis
under recombinant human erythropoietin (rHuEPO) treatment. Eight
patients (age 52 15) were studied, and each patient exercised on a
treadmill system with the used of the BRUCE modified protocol
(limited by symptoms). Exercise testing was done before the adminis-
tration of rHuEPO (ET 1) and repeated after six months 18 days of
treatment (ET 2). The rises in hemoglobin and hematocrit were statis-
tically significant 6.7 I vs. 9.0 1.6and 20 3 vs. 28 5 (P <0.01).
Heart rate V02
MAX
Time
(mm)MAX REC %
ETI 131± 16 100± 14 75±10 24.5±8 11±3
ET2 150± 13 88± 13 89± 7 39± 12 15±3
Abbreviations are: MAX, maximal; REC, recovery; %, percentage of
the expected maximal heart rate; MAX V02, maximal oxygen con-
sumption; MIN, minute. a P < 0.05; b p < 0.01
There was no statistical difference in systolic blood pressure; the
diastolic blood pressure showed a tendency to mild hypertensive
response with maximal exercise: 80 5 vs. 88 7 (P < 0.05). We
conclude that after rHuEPO treatment a better tolerance to exercise is
reached with a rise in the main parameters of functional capacity.
Plasma exchange (PE) and monoclonal antibodies (OKT3) In the
treatment of acute vascular rejection. M.C. Prados, A. Franco, M.P.
Perdiguero, J. Contreras, J. Olivares, Department of Nephrology,
Hospital of Alicante, Alicante, Spain. Acute transplant endovasculitis
is a sign of vascular rejection (VR) and bad prognosis. VR is presum-
ably mediated by humoral factors with a significant cellular activation,
both of which could be treated by PE and OKT3. We have retrospec-
tively studied 146 consecutive kidney transplants. Immunosuppression
was achieved with prednisone, azathioprine and cyclosporin A. Eight
recipients had acute rejection with histological lesions of acute endo-
vasculitis. Five of them (group I) were treated with PF and OKT3 (5
mg/24 hr) for ten consecutive days. PF was performed for six alternate
days with a cellulose diacetate filter, removing 2000 cc plasma/session.
The other three patients (group II) received pulse therapy of i.v.
metilprednisolone, 1 g/24 hr on three consecutive days. Group I: One
patient lost his graft due to this burst while under treatment. At the
present time, the other patients maintain good renal function (Cr P <
2.5 mg/dl) at 8, 17, 19 and 20 months post-transplant. Only one of them
had a severe CMV infection which resolved with gancyclovir therapy.
Group II: All patients needed to re-initiate dialysis after acute rejection.
We think that treatment with PE and OKT3 could be useful in cases of
rejection with acute endovasculitis lesions.
A new technique for percutaneous renal biopsy. Joaquim Bordalo, F.
Carvalho, Marques da Costa, Service of Nephrology, Hospital Curry
Cabral, Lisbon, Portugal. Percutaneous renal biopsy (PRB) has be-
come one of the fundamental diagnostic techniques in nephrology.
Though relatively safe, it is not without risks. We report our experience
with a new PBR method since November 1991. The method combines
the use of an automated biopsy device (Biopsy System, Bard), dispos-
able biopsy needles 14 G x 16 cm (17 mm specimen notch), and a 3.5
MHz linear ultrasound biopsy probe (BP) attached to the ultrasound
scanner (Siemens Sonoline SL1). The needle is passed through the BP
and advanced to the capsule under ultrasound guidance. Activation
causes the obturator to advance 23 mm into the kidney, followed
immediately by the cannula. In 102 patients, age 13 to 79, mean
creatinine 3.2 (0.4—11.4), 99/102 (97.0%) had specimens adequate for
tissue diagnosis. For each biopsy a mean of 1.8 needle passes was
required. An average of 18 glomeruli (range 3—46) was seen per biopsy.
In three biopsies no renal tissue was obtained, while in one core
pancreas was obtained (high left kidney). There were only minor
complications: 5/102 had gross hematuria; 4/102 had perinephric hem-
orrhage, detected by ultrasound; 0/102 had significant drop in Hct,
nephrectomy or death. The new method is simple, providing accurate
localization of the kidney, direct visualization of the biopsy, reduction
of intrarenal needle dwell time, minor complications, and results in a
very high success rate.
Continuous arteriovenous hemofiltration in acute renal failure post-
cardiovascular surgery. S. Nicolai, E. Conci, J. Neubuerger, F. Zelaya,
G. Boccardo, Instituto Modelo de Cardiologia, Cordoba, Argentina.
Patients with acute renal failure (ARF) immediately following cardio-
vascular surgery (CVS) are hemodynamically unstable, have ventricu-
lar failure, fluid overload and hypotension. These patients respond
poorly to conventional hemodialysis treatment, and peritoneal dialysis
is contraindicated. We evaluated 16 patients with ARF post-CVS with
continuous arteriovenous hemofiltration (CAVH), with a mean blood
pressure of 64 8.2 mm Hg and diastolic pulmonary pressure of 21
6.7mm Hg. Femoral artery andvein were used for vascular access in 14
patients, radial artery and subclavian vein in one patient and Scribner
shunt in one patient. Amikon 20 hemofilters were connected directly to
the arterial and venous cannulation with a modified 75 cm hemodialysis
tubing. The ultrafiltration was performed spontaneously withoutpumps
and was collected in a standard urine bag. Heparinization was done by
infusion pumps to maintain a KPTF double the control value. Mean
treatment duration was 41 36hours; mean output treatment was 7.22
26 mllmin. The pre-treatment values were: urea 1.32 0.51 g/liter,
creatinine 4.36 1.17 mg%, and potassium 4.88 0.61 mEq/liter, and
post-treatment: urea 1.28 0.42gfliter, creatinine 4.28 1.14mg% and
potassium 4.77 0.67 mEq/liter. We observed good hemodynamic
tolerance for the procedure, allowing infusion of drugs, blood and
parenteral nutrition. The only complication observed was filter coagu-
lation in four patients (25%) that required a new one. Eight patients
(50%) recovered renal function in the hemodynamically stable group.
One patient in this group died of ventricular fibrillation (VF). The other
eight patients (50%) never recovered renal function. They were more
unstable hemodynamically and all of them died: two patients from
sepsis, two from VF, and four patients from cardiogenic shock. The
immediate mortality of CAVH was 56.2%. Conclusion: In our experi-
ence CAVH seems to be a useful method of treatment in patients with
ARF post-C VS.
Renovascular hypertension—Incidence——Treatment. S. Nicolai, A.
Sampaolesi, G. Pacheco, G. Boccardo, Instit uto Modelo de Cardiolo-
gia, Cordoba, Argentina. Renovascular Hypertension (RVH) is one of
the most frequent causes of secondary hypertension (HT). The inci-
dence is between 1 to 20% of all HT. We performed selective renal
artenography in 194 hypertensive patients with a systolic blood pres-
sure of 201 20mm Hg, diastolic blood pressure of 109 13mm Hg,
and mean age of 57 13. In this group, 60 patients (30.4%) were found
to have RVH. The stenosis was classified according to arteriographic
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appearance and clinical history as being due to atheromatosis in 46
patients (76.6%) and fibromuscular dysplasia in 14 patients (23.4%).
Nine patients (19.6%) with atheromatosis and five patients (36%) with
fibrodysplasia had bilateral disease. If the stenosis was at least 75% of
the arterial luminal diameter and the transtenotic gradient >20 mm Hg
percutaneous transluminal renal angioplasty (PTRA) was performed.
This was done in 30 patients with atheromatosis and in 13 patients with
fibrodysplasia. PTRA was technically successful in 100% of fibromus-
cular dysplasia and in 89% of unilateral and 85.7% of bilateral athero-
matosis. The blood pressure was reduced to normal or improved in
100% of the fibrodysplasia group, in 70% of unilateral and in 50% of
bilateral atheromatosis. Immediate complications were seen in five
patients (11.6%) and only in the atheromatous group. They were: mild
dissection of renal artery two patients (4.6%), acute renal failure one
patient (2.3%) and unsuccessful PTRA two patients (4.6%). The aver-
age follow-up period was 15 months (range 6—24). Recurrent stenoses
was seen in eight patients (32%) with atheromatous disease and one
patient with fibrodysplasia. PTRA was repeated in all. In this group,
recurrence was seen in four patients (50%) with atheromatous lesions.
Conclusions: (I) Incidence of RVH in our hypertensive patient popula-
tion was 30.5%. (2) The lesions were 76.6% atheromatosis, and 23.4%
fibromuscular dysplasia. (3) PTRA could be considered the first line of
treatment due to the low morbidity and no mortality in the RVH due to
atheromatous lesion. (4) PTRA is the best choice of treatment in RVH
due to fibromuscular dysplasia. (5) The incidence of re-stenosis in
patients with atheromatosis is 32% and the re-stenosis about 50%.
Progression of chronic renal failure (CRF) in children depending on
etiology and protein diet. M. Vazquez Martul, J.L. EcUa, M. Ramirez,
J.L. Garcia. Servicio Nefrologla, Hospital Niño Jesás, Madrid, Spain.
To analyze the influence of a causal disease and the protein ingestion in
the evolution of CRF in 27 children with GFR lower than 80 mI/mini
1.73, we made a prospective study of 1.5 years. Eighteen were boys
(66,6%) and nine were girls (33.3%) aged 7.9 4.03 years. CRF was
secondary of the following diseases: 20 uropathies (74%), one glomer-
ulonephritis (3.75%), four hereditary nephropathies (14.8%) and two
metabolic nephropathies (7.4%). A group of patients was on a protein
diet less than 1.5 g/kg/day and others on a diet equal to or higher than
1.5 gikg/day. Renal function, biochemistry hematologic, somatometric
and diet control were carried out at 0, 6, 12, 18 months. No one patient
had hypertension (HT) in the beginning and three developed HT during
evolution. HPT was found in four children in the initial study and it
developed in 19 during evolution. GFR was higher, equal to 40
mlImin/l.73 m2 in 17 patients (63%) and less than 40 in 10 (37%).
Progression of CFR evaluated by 1/Cr was lower (P < 0.01) in
uropathies (0.74 0.25) than in hereditary nephropathies. In 18% of
uropathies risk factors existed (infection, surgery), but they didn't
affect evolution rate. CFR appeared to show a faster decline in those
patients with high protein diet (P < 0.001). An inverse correlation was
found between cholesterol and RF progression (P < 0.05; r = 0.23). At
starting, nine patients (33.3%) had a stature less than or equal to 1 so,
and correlation was found between evolutary GFR and height (P <
0.05; r = 0.50). Conclusions: In this series, etiology has had influence in
progression of renal insufficiency being lower in uropathies. A higher
protein ingestion has been associated to a faster CFR progression. High
cholesterol levels were associated to a lower GFR.
Study of secondary hyperparathyroidism (IIPT) in chronic renal failure
(CRF) during childhood. M. Vázquez Martul, M. Ramirez, J.L. Ecjja,
M. Martino, J.L. Garcia, Servicio de Nefrologia, Hospital Nino Jesus,
Madrid, Spain. In order to evaluate HPT in CRF, a prospective
protocol was applied during 1.5 years to a group of 27 patients aged 7.15
3.86 years. Blood, urea, creatinine, glomerular filtrate rate (GFR),
ions, acid-base balance, PTH, alkaline phosphatase, calcium, phos-
phate and magnesium were done each trimester. Dietetic evaluations
were also done. Left hand, knee and ankle evaluations were carried out
each semester by X-ray. During this period, high PTH levels (>50
pg/mI, intact mol) were found in 19 patients (70%), while eight patients
(30%) had normal PTH values. Conventional radiographic (X-ray) study
was diagnostic only in one case of HPT. The following parameters
(mean I SD) were analyzed in these two groups.
HPT No HPT Significance
PTH pg/mI >50 50
GFR ml/min/1.73 42.7 24 51 22 P < 0.05
Ca2 mm/liter 0.92 0.26 0.99 0.17 NS
Ph mg/dl 4.9 0.43 4.03 0.47 P < 0.05
Alkaline phosphatase 284 95.8 250 197.75 NS
NaHCO3 21 3.07 23 2.68 P < 0.05
Pr Kg/dia 1.80 0.98 1.45 0.51 P <0.05
Pr%RDA 159±37 130±40 P<0.l
Vit 1,25(OH)2D ng/k 20.82 14.2 10.45 8.3 P < 0.1
CO3Ca mg/kg 23.2 12.3 22.7 16.5 NS
Thirteen episodes of hypercalcemia were found in seven children,
having no relation to Vitamin D doses. Conclusions: HTP was more
frequent and had a better correlation in those cases with GFR less than
40 ml/minil .73 m2. Metabolic acidosis and phosphate blood levels were
seen to be associated in HPT. A high protein diet could be a detrimental
factor. Neither alkaline phosphatase nor conventional radiographic
study has been of diagnostic value in HTP.
Importance of the delta of volume in the estimation of generation of
urea and catabolic protein rate. S.A. Konig and J.H. Flores, Sanatorio
Allende, Cordoba, Argentina. The difference in the catabolic protein
rate (TCP) was evaluated, starting from the different formulae (F) of
generation (OR) of urea (UR) and the direct estimation of the TCP used
in the Cooperative National Study of Dialysis (ECND). We intended to
introduce the difference of volume (V), between the weight (PE) of
leaving dialysis (D) and the PE of entrance to the next. This value, delta
of volume (DV), was added to V post-D, upon which the V of
distribution (Dis) of urea pre-Dis was more real. The V of Dis of UR is
calculated in two ways: (I) % corporal PE (V%); (2) by the F of Watson
(Vest). The F of 0 are divided according to the V of Dis: (1) with V%:
A (with V only), Cl (product (x) of concentrations (c) times pre- and
post-V and C2 (x) of C times with addition of DV; (2) with Vest: B (with
V only), Dl (x) of C times pre- and post-V and D2 (x) of C times V with
addition of DV. (I) with V%: a,Cl,C2; (2) with Vest: B,Dl,D2. One
hundred fifty determinations were carried out in 36 patients, with Pc
59.2 kg, DV of 3.11 1.04, CPT (average concentration in time of urea)
109 29.9, KT/V0.83 0.35. For all of them the F of G and CPT were
carried out, and the % of variation (PV) with 0D2 and TCP D2, and it
was related CPT and TCP according to the F. Or: A 9.3, B 9.3, Cl 10.2,
C2 10.9, Dl 9.31, D2 10.9. TCP: A 1.1, B 1.13, Cl 1.19, C2 1.27, Dl
1.13, D2 1.32. NCDS 1.51. Significant differences (DS) were shown
between the formulae that considered two volumes and the formulae of
generation of urea with volume only, a DS was noticed between those
which considered or not the delta of volume. The TCP ECND presented
DS with every formula, that overvalued it, The C2 and D2 formulae did
not show DS. DS were noticed in the CPT/TCP relation; the percentage
probability of morbidity overvalued the V% formulae and underesti-
mated the TCP ECND. The use of DV introduces DS, and allows a
better handling of the patients on HD.
Incidence of the bounce of urea in the dialysis adjusting parameters.
S.A. Konig, CONICOR, Cordoba, Argentina. The incidence of the
bounce of urea (RE) in the different parameters of categorization of
dialysis based on kinetics models of urea is evaluated here. This
evaluation was carried out independently of the fact that the bounce
phenomenon belongs to dialysis conducted catabolism or to transcellu-
lar imbalance. For this evaluation the following parameters were
considered: percentage of reduction of urea (PRU); Kt/V (kinetic
model); average concentration in time of urea (CPT); urea (UR);
generation (OR); and catabolic protein rate (TCP). Based on data of 150
determinations, 36 patients with an average weight of 69.2 kg DV of
3.11 1.04, all the determinations were carried out considering bounce
values of urea that varied between 2.5 and 35%. The following were the
average values without considering bounce of urea: PRU 45%; CPT 109
29.9 mg%; Kt/V 0.83 0.35; UR OR 9.27 3.59 mg/mm; TCP 1.08
0.38 g/kg/day. The following were the percentage ranks of variation
noticed: PRU reductions from 2.55 to 35%; Kt/V decrease from 2.18 to
29.6%; CPT decrease from 1.18 to 9.93; UR GR reduction from 1.44 to
20.23%. To consider the bounce of urea determines modifications of
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different magnitudes in the parameters, the difference responding to the
handling of the post-dialysis value in the corresponding formula. The
greatest variation was observed in PRU and in the Kt/V, decreasing the
modification in the case of the CPT to one-third in absolute values. It is
necessary to consider the bounce of urea, even more, if hemodialysis of
high efficiency is carried out, since the modification this introduces in
the different parameters may not be balanced, even when a Kt/V greater
than I is prescribed.
Influence of non-immunological factors in the results of 100 cyclospo-
tine-treated cadaveric renal transplants. Cecilia Grahovac, Pablo Mar-
sari, Graciela Boccardo, Henry Paladini, Manuel Goyanes, Javier de
Arteaga, and Federico Garzón, Programa de Transplanter Renales,
Hospital Privado, COrdoba, Argentina. Donor and recipient age, recip-
ient diabetes, time on the waiting list, long distance organ sharing, cold
ischemia time, incidence and severity of acute tubular necrosis have
been reported to influence patient and graft survival in cadaveric renal
transplantation. We analyzed those factors in a series of 100 consecu-
tive cadaveric renal allografts immunosuppressed with steroids and
cyclosporine. Kidneys were implanted into HLA best matched recipi-
ents with emphasis on loci B and Dr compatibilities. One year patient
and graft survival was 87% and 75%, including highly sensitized
patients and second transplants. Recipient age was seven to 65 years,
and only those older than 60 (N = 6) had a clearly lower survival rate
at first year (50%). Donor age was less than I to 62 years; poor graft
survival was seen with donors less than two years of age, but no
relationship was found between donor age and graft survival. Seventy-
five percent of the kidneys were harvested locally, the rest coming from
distant cities or from abroad, but this factor showed no influence on
results. Seven of the recipients were diabetics and only three of them
had a functioning graft at one year post-transplantation. Cold ischemia
time was less than 24 hours in 28 kidneys that had a 65% incidence of
acute tubular necrosis and one-year graft survival of 83%. Forty
kidneys were implanted with a cold ischemia time of 24 to 35 hours and
had 83% incidence of acute tubular necrosis and one year first graft
survival of 73%. Acute tubular necrosis developed in 100% of 20
transplants within 37 to 48 hours of cold ischemia time and had 90% one
year graft survival. Twelve kidneys implanted with more than 48 hours
of cold ischemia time had 100% incidence of acute tubular necrosis and
80% one year first graft survival. One year first transplant and graft
survival for the entire series, excluding recipients older than 60 and
diabetics, were 89 and 81%. We conclude that in this series long
distance organ sharing, long periods on the waiting list and prolonged
cold ischemia time have no impact on one year survival. Poor results
were found with donors less than two years of age and with recipients
older than 60 years and diabetics.
Effects of oral protein load on the urinary excretion of lithogenic
substances. Pablo Massari, Gabriela Garay, Nilda Garces, and Rose-
marie Holtz, Servicio de Nefrologia, Hospital Privado de COrdoba,
Córdoba, Argentina. It has been previously shown that chronic protein
feeding increases the urinary excretion of some constituents of urinary
calculi. To evaluate the acute response to an oral protein load, we
investigated 10 normal subjects (N) and 10 renal stone former patients
with hypercalciuria (HC) before and after an oral protein load of 1 g/k
as cooked beef under water diuresis, analyzing blood and urinary
samples for creatinine, calcium, phosphorus, sodium, urate, sulphate
and oxalate. The HC group showed higher basal excretion of calcium
and FE Na. Sulphate excretion rate and clearance were not different
from N. After the protein meal, creatinine clearance increased by 28%
in N and 13% in HC (P < 0.005) and the calcium excretion per 100 ml
of Ccr increased significantly more in HC (N: 1.18 to 2.61; HC: 1.89 to
3.80; P < 0.05). Serum creatinine was augmented by 15% in the HC
group. Both groups showed similar increment in the excretion rate and
clearance of urate (90%). There were no changes in oxalate excretion
from the basal rate in both groups. These results suggest that an oral
protein load induces an acute increase in the excretion of urate and
calcium and that hypercalciuric stone former patients show a rather
different response to this maneuver than normal controls.
A study of renal acidification capacity In patients with lithiasis in the
absence of distal renal tubular acidosis. J. Chahin, V.G. Nieto, A.
Torres, E. Gallego, M. Muros, C. Leon, and J.G. Perez, Nephrology
Service, Nuestra Sra. de la Candelaria Hospital, Santa Cruz de
Tenerife, Spain. It has been reported that certain patients with hyper-
calciuria and lithiasis may, in time, evolve towards distal renal tubular
acidosis. In a group of patients with lithiasis and unimpaired capacity to
reduce pH satisfactorily in the acidification test, we wanted to establish
whether or not defects in the excretion of hydrogen ions could be found.
Patients and methods: In a sample of 35 patients with lithiasis, we
analyzed minimum urinary pH, citrate excretion index (CITIE) and the
formation of titrable acid (TA) and Ammonium (Am) in the urine of
minimum pH, after ammonium chloride overloading. Twenty-eight of
these patients with idiopathic hypercalciuria (Group IH) and seven from
other causes (Group OC) had adequately reduced urinary pH to below
5.35, both with ammonium chloride and with furosemide. The results
were compared with 10 healthy controls (Group C). Results: TA
elimination was significantly lower for groups IH (29.6 11.7; pEq/
min/I.73 m2) and OC (25.5 8.31; P < 0.05) than for group C (44.9
10.6). Am elimination was significantly reduced only in group IH (51.9
18.8 Eq/mi&l.73 m2; P < 0.05) as compared to group C (66.7
21.3). No differences of minimum pH were observed. In both groups we
found reduced TA and Am formation among patients whose CitIE was
lower than 0.4 mg/l00 ml GFR as compared to those with higher CitIE
values, Conclusion: In patients with lithiasis, whatever the cause, a
certain acidification capacity defect can be observed, even with ade-
quate urinary pH. This defect appears to be related to some factor
characteristic of the lithiasis, as well as hypercalciuria.
Antibodies against hepatitis C virus in hemodialysis and hospital
personnel. J. Chahin, E. Gallego, M.L. Mendez, V.G. Nieto, and J.
Garcia, Nephrology Service, Nuestra Sra. de Ia Candelaria Hospital,
Santa Cruz de Tenerife, Spain. We determined the number of antibod-
ies against the hepatitis C virus (ACC) among 52 PH patients and
hospital personnel (PS) (N = 21) on two occasions in eight months, in
order to know the incidence and evolution. The analytic methods used
were the enzymoimmunoanalysis and second generation Western blot
confirmation test. Results: We observed that there was no incidence of
ACC in the personnel group as compared to 34.6% in the PH group.
Duration time on hemodialysis was longer for the PH positives (P <
0.001). We found no correlation between ACC and number of transfu-
sions, but there was between this number and elevated post-transfusion
transaminase (TRS; P < 0.05). Elevated TRS appeared more often as
moderate peaks (less than twice the normal range) in the PH positive
group than in the negative (P < 0.05), without there being persistent
alterations in any particular case. There was no new positivity in the
second determination of ACC, and two PH patients even became
negative. We observed that the PH with ACC corresponded to those
transfused prior to June 28, 1990, on which date we began the
determination of ACC in our blood bank, despite the fact that there do
not exist any differences in the TRN before and after this date. We also
observed a significantly greater need for erythropoietin among the PH
with positive ACC than the negatives (P < 0.05). Conclusions: (1) The
determination of ACC in donor blood has had a definite impact on
reducing the incidence of hepatitis C. (2) Current procedures of dialysis,
without recourse to drastic measures of machine isolation, are reason-
able. (3) There is an increase for the need of erythropoietin in PH and
ACC.
Enterococcus bacteremla and endocarditis in two hemodlalysis centers.
Juan Nm Ferrari, Alvaro Quintana, Alejandro Opertti, Luis Patrone,
Ricardo Cuña, Nelson Acosta, Teresa Lacuesta, and Walter Pedreira,
Centro Regional de Asistencia Nefrologica Integral, and Departa-
mento de Bacteriologia, Facultad de Medicina, Montevideo, Uruguay.
In an eight month period, II cases of En:erococcusfaecium bacteremia
observed in two hemodialysis centers were managed by similar criteria
by the same medical staff. This problem group represented the 29.7% of
the treated dialysis population. Of them three developed aortic and one
mitral valve localization. Cross infection and contamination of treated
water and dialysis systems were investigated and discarded. Re-use and
disinfection procedures were also studied and modified without achiev-
ing epidemic control. Intestinal flora was investigated and an inverse
ratio between enterococcus sp./Gram-negative bacilus (E/GNB) was
found in the 0.53 of studied patients. The predominant isolated Entero-
coccus species was E.faecium. The problem group was compared with
the rest of dialysis population in a three month period before the
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infectious episode and 0.75 of them received antibiotics (ATB) of which
0.62 of them more than one. Only 0.50 of the other patients received
ATB and all of them only one. The most frequent ATB employed in the
problem group were ciprofloxacine and cotrimoxazol, while in the rest
were ampicilin and amoxicilin. Patients with intestinal flora alteration
were treated with vancomicin 500 mg/day orally, with normalization of
the E/GNB in all of them. ATB plans were changed favoring the use of
ampicilin or cefradine. After 12 months of follow-up from when these
measures were taken, no more bacteriemias were observed. We believe
from these findings that the original focus of bacteremia was probably
entenc and that use of determinated ATB favored intestinal flora
alteration.
Hyperlipidemia in uremics on maintenance hemodialysis and their
treatment with gemfibrozil. Juan Nm Ferrari, Clara Schcolnik, and
Miriam Angona, Nephrology Service and Central Clinical Laboratory,
Armed Forces Central Hospital, Montevideo, Uruguay. Hyperlipid-
emia is a frequent factor in uremia and in dialysis patients, and some
authors point out that it can be an important factor of accelerated
atherosclerosis. We prospectively evaluated 19 uremics on mainte-
nance hemodialysis (HD) with determinations of plasma cholesterol
(C), plasma triglycerides (TG), HDL-Cholesterol (HDLC), and calcu-
lated no-HDL-Cholesterol (noHDL-C) and risk factor C/HDLC. Re-
suits were compared with the ones of blood donors from the same
hospital (Schcolnik, 1985), taken out as normal reference range. In the
HD group we found that 79% had elevated TO, 42% had low HDLC and
53% had increased risk factor C/HDLC. Of them 47% were type IV and
21% type Lib. From that group, 10 hyperlipidemic patients were treated
with gemfibrozil, 600 mg/day, and six of them had a 17 month period of
follow-up. Their previous renal diet was not changed. We found a
significant decrease (P < 0,05) of TO, up to 30% of the initial value, and
an equally significant increase of HDLC up to 53% of initial value,
without changes of the total cholesterol. These tendencies were kept
during the 17 month follow-up (variance analysis P < 0.05). Enzymes,
including CPK, were always within a normal range. We believe that
gemfibrozil modulates hyperlipidemia in this group of high cardiovas-
cular risk patients, without main colateral effects and without need of an
even more restricted diet, already difficult for many patients to accept.
Central adiposity and total obesity: Assessing cardiovascular risk in
essential hypertension (EH). R. Mann, M. Gorostidi, F. Fernández-
Vega, P. Escalada, S. Aguado, J. Alvarez-Grande, Hypertension Unit,
Department of Nephrology, Covadonga Hospital, Oviedo, Spain. With
the aim of characterizing two different anthropometric variables in the
assessment of cardiovascular risk in EH, we performed a cross sec-
tional observational study of 336 patients with WHO Ito III grade EH
(181 M, 155 F). Body mass index (BMI) and waist/hip-circumference
ratio (WHR) were determined and patients were classified as having
obesity or upper body obesity when these parameters were above the
50th percentile (29 kg/m2 and 0.94, respectively). Correlations with
cardiovascular complications (stroke, ischemic heart disease, conges-
tive heart failure, peripheral arteriopathy), nephrosclerosis (creatinine
 1.5 mg/dl), metabolic disturbances (total and HDL-cholesterol, tri-
glycerides, glucose) and mean blood pressure levels were analyzed.
Total cardiovascular events correlated negatively with BMI (P < 0.001)
and positively with WHR (P < 0.01). The quintiles of BMI and WHR
showed a positive correlation with the lipid profile (P < 0.01). Creati-
nine (P < 0.05), glucose (P < 0.001) and smoking habits (P < 0.001)
were correlated positively with WHR but not with BMI. Mean blood
pressure levels were similar in all groups. In conclusion, WHR is an
anthropometric parameter more closely associated with cardiovascular
risk than BMI in patients with EH.
Non-insulin dependent diabetes mellitus associated hypertension
(NIDDM-H): Comparison with essential hypertension (EH). R. Mann,
M. Gorostidi, E. Gonzalez, F. Fernandez-Vega, E. Gómez, and J.
Alvarez-Grande, Hypertension Unit, Department of Nephrology, Co-
vadonga Hospital, Oviedo, Spain. The objective of the study was to
characterize the vascular morbidity and the metabolic disorders of
NIDDM-H. We performed a cross sectional observation of 119 cases
with NIDDM-H in an outpatient clinic, the controls being 628 WHO Ito
Ill grade EH patients seen in the same period of time. We analyzed
systolic, diastolic and mean blood pressure levels, smoking habits,
body mass index (BMI), lipid profiles (total and HDL-cholesterol and
triglycerides), cardiovascular complications (stroke, ischemic heart
disease, left ventricular hypertrophy, peripheral arteriopathy) and
presence of renal disease. Both groups were similar in mean blood
pressure levels, sex, percentage of smokers, and left ventricular hyper-
trophy prevalence. Cases were older than controls (58.2 10.9 vs. 50.1
12.9 years, P < 0.001). BMI was higher in the NIDDM-H group (29.6
4.7 vs. 28.8 4.9, P < 0.005) as well as total cholesterol (6.1 1.2
vs. 5.9 1.2 mmol/liter, P < 0.05) and triglyceride levels (2.0 1.2 vs.
1.5 0.9 mmol/liter, P < 0.001); meanwhile, HDL-cholesterol was
lower (1.2 0.4 vs. 1.3 0.4 mmol/liter, P < 0.01). Creatinine levels
 1.5 mg/dl and proteinuria 0.5 g/day prevalences were also higher (54
vs. 25 and 48 vs. 10%, respectively, P < 0.001). Cardiovascular
complications were also more frequent in the case group (P < 0.001)
except for stroke, whose prevalence was similar. In conclusion, pa-
tients with NIDDM-H have a worse metabolic profile and higher risk for
vascular complications and renal failure than EH ones with similar
degrees of blood pressure control.
Gene transfer into the mammalian kidney: First steps towards renal
gene therapy. Ricardo J. Bosch, Adrian S. Woolf, and Leon G. Fine,
Division of Nephrology, UCLA, Cal,fornia, USA, and Department of
Medicine, Rayne Institute, UCMSM, London, England, United King-
dom. If new genes could be introduced into the adult kidney, then novel
gene products could be used for "renal gene therapy." We have used a
replication-defective retrovirus, Psi 2 BAG, to transduce /3-gaiactosi-
dase (lac-z) and neomycin resistance (neo-r) reporter genes into the
adult rat kidney. Retrovirus integrated into replicating cells and there-
fore tubular cell division was induced by a dose of folic acid (i.p. 240
mg/k). This drug causes a rapidly reversible episode of renal insuffi-
ciency. At the time of maximal cell division (2 days post-folate) virus or
control serum was injected directly into the kidney. One to seven weeks
afterwards kidneys were harvested. DNA was extracted and analyzed
by polymerase chain reaction (PCR) to amplify a 559 base pairs proviral
sequence which spans the lac-z and neo-r genes. Frozen sections were
stained with X-Gal to identify /3-gal activity. Using PCR, the provirus
was identified in virus-injected but not in control rat kidneys. Histology
demonstrated positive cells confined to the proximal tubules of infected
rats. No positive staining was seen in mock infected kidneys. In a total
of 15 active experiments, PCR and /3-gal histology was positive in eight
animals. Further studies should attempt to establish the long-term gene
expression of transduced gene products which are secreted into the
urine or the renal interstitium.
Twelve years of chronic hemodialysis (CHD) in Chile: 1980—1991. H.
Poblete Badal, Renal Unit Carlos Van Buren Hospital, University of
Valparaiso School of Medicine, Valparaiso, Chile. To know the devel-
opment of CHD in Chile, we performed, with the support of the Chilean
Society of Nephrology, annual investigations, between 1980—I 991, with
the participation of all Chilean CHD centers.
Results 1980
Total population of Chile
thousands
Pop Metropolitan region %
Pop Fifth region %
Pop other regions %
Patients in CHD totals
Pt CHD/million pop
Pt CHD metropolitan region %
Pt CHD fifth region %
Pt CHD other regions %
Pt CHD in hospitals %
Pt CHD in EHC %
Pt CHD at home %
II .200
Abbreviations are: pop, population; pt, patient(s); EHC, extrahospi-
talary centers.
Up to August 31, 1991 a total of 65 CHD centers attended in 23 cities:
29 units in hospitals, 36 in EHC. Thirty dialysis centers were in
Santiago (the capital city). We obtained other data of the CHD pop: age,
1991
13.300
39
II
50
1979
149
64.0
12.5
23.5
37.0
62.8
0.2
39
II
50
143
12.7
67.8
25.2
7.0
77.6
8.4
14.0
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sex, basal nephropathy, HIV and HbAg positive patients, and rehabil-
itation and mortality rates. In addition, data on dialysis techniques,
reutilization of dialysis materials and availability of drugs were ob-
tained. Conclusions: (1) Between 1980—1991, a substantial increase in
patient CHD/million population occurred. (2) The predominance of
CHD was unequal in the capital city and nearby fifth region. (3) The
number of patients who attended hospitals decreased, and an increase
in patients who attended EHC was observed. (4) Home CHD practi-
cally disappeared.
Localization of endopeptidases with kinase activity through the rat
nephron. D.E. Casarini, M. Boim, M.A. Cenedeze, R.C.R. Stella, and
N. Schor, Disciplina de Nefrologia, Departamento de Medicina, Es-
cola Paulista de Medicina, São Paulo, Brasil. In a previous work, we
isolated from human urine, endopeptidases able to inactivate bradyki-
nm (Argl-Pro2-Pro3-Gly4-PheS-Ser6-Pro7-Phe8-Arg9) as prolyl-endo-
peptidase that hydrolyzes the Pro3-G1y4 bound, serino-proteinases,
that hydrolyzes the Phe5-Ser6 and an enzyme similar to E.C.24. 11 that
hydrolyzes Gly4-PheS and Pro7-Phe8. In order to localize them in the
kidney, the tubular fluid was collected from different portions of the
nephron though micropuncture techniques and incubation with BK.
The hydrolysis products were separated by reverse phase in high
performance liquid chromatography, using an RP 18 column and
acetonitrile gradient from 5 to 35% of 0.1% of fosforic acid. Endopep-
tidases that hydrolyze the peptide bound Pro3-G1y4 and G1y4-Phe5 in
the Bk molecule were found at the distal-distal portion of the nephron.
Detected in the distal-proximal portion were endopeptidases that hy-
drolyze the peptide bound Phe5-Ser6, G1y4-Phe5 and Pro3-Gly4. Ob-
serving the presence of endopeptidases at the distal nephron could be
physiologically important, since in this segment were found low molec-
ular weight kininogen and kallikrein, being then, the action site of kinin.
These enzymes could be involved in the hydrolysis of kinins produced
in this portion.
Renovascular hypertensive patients (RVHP): Purification and charac-
terization of angiotensin converting enzyme (ACE) from urine of patients
treated and untreated with diuretic. R.H. Costa, D.E. Casarini, F.L.
Plavinik, J.E. Portela, 0. Marson, and K.B. Alves, Quimica Organica
e Disciplina de Nefrologia, Escola Paulista de Medicina, São Paulo,
SP, Brasil. It was previously verified that after ion exchange chroma-
tography of urine from essential mild hypertensive patients, without
diuretic, two enzymes with angiotensin converting activity were eluted
in phosphate buffer, 0.7 and 1.25 mS with molecular weight of 88 and 61
KDa, respectively. Otherwise, with diuretic, only the enzyme with 88
KDa was eluted, at 0.7 mS. The aim of this work was to make a similar
study with renovascular hypertensive patients (RVHP) treated and
untreated with clortalidone. A pool of urine from 29 RVHP without
diuretic and another one from 10 RVHP with diuretic were submitted to
DEAE-cellulose chromatography in 0.02 M phosphate buffer, pH 7.0.
With a linear gradient from 0.02 M to 0.5 M, pH 7.0 of the same buffer,
two enzymes from urine of treated RVHP were eluted (0.7 and 1.25 mS)
with the same molecular weight of 88 KDa, in 0.7 mS. The enzymes
were totally inhibited by ions Co2, Mn2, EDTA and captopril were in
the mrt range. The control group presented a chromatographic profile
similar to that found for treated patients. The appearance of a low
molecular weight enzyme can be one of the facts that collaborates with
the maintenance of the hypertensive state.
Cyclo-oxygenase and lipo-oxygenase inhibItion In gestational hyperten-
sion. J.C. Fraire and M.C. Fama, Hospital Italiano, Cordoba, Argen-
tina. It has been suggested that pre-eclampsia may result from an
imbalance of either cyclo-oxygenase or lipo-oxygenase products or
both. We evaluated the outcome of pregnancy after combined therapy
with aspirin (ASA) and lysine clonixinate (L.Cl), a lipo-oxygenase
inhibitor, in 14 pregnant women at high risk for pre-eclampsia. Nine
were chronic hypertensives and four of them had had previous pre-
eclampsia and fetal death. The remaining five patients had transient
(gestational) hypertension. Five patients began therapy between the
14th and 20th week with ASA 100 mg/qd and L.Cl. 250 mg/qd. Nine
started treatment after the 20th week with equal ASA dose but with 375
mg/qd of L.Cl. Results: Thirteen pregnancies reached normal term and
delivered normal babies with the following APGARD: seven had scores
7 to 8; three had scores of 8, and three had scores between 8 and 9. One
baby was born at 33 weeks with an APGARD of 7, progressed to 9 in
five minutes and had humidified oxygen for 48 hours. His weight was
1710 g. Placentas were evaluated by ultrasound, according to the
Grannun and Hobbing classffication. Six placentas were type I, 3 were
type I-Il, 3 were type II and 2 were type 11-111. We conclude that
combined therapy with ASA and L.Cl in pregnant patients at high risk
for pre-eclampsia is probably safe for both mother and fetus.
Cholera and acute renal failure: Valoratlon of the renal injury.
Treatment and mortality at Rebagliaty Hospital, IPSS, Lima, Perd. M.
Camacho Bonilla, Division of Nephrology, Rebagliati Hospital, IPSS,
Lima, Perd. With the purpose of measuring renal damage, determining
mortality and evaluating the treatment used during the cholera epi-
demic, we analyzed 3,000 cholera patients during the first 14 weeks of
the outbreak (Febr-91); we detected 150 patients with acute renal failure
(ARF). All showed a predisposing factor, a precipitating factor and
urinary sediment and its histological correlation. It was found that the
incidence of ARF in cholera patients was 5%, and the majority of the
patients were over 60 years of age, making age the major predisposing
factor. Arterial hypotension was found to be a precipitating factor in
75% of these cases. The length of the oligunc period of one day was
found in most of the patients. Pathological sediment was characterized
by: low grade proteinuria, microhematuria, and cast were present in
23%, which was early and fast. Renal biopsy showed: tubular necrosis
and interstitial nephritis, Immunofluorescence was negative. Only 10%
of the patients with ARF required hemodialysis. From a total of the
patients with ARF, the mortality registered was only 2%. In conclusion,
the renal injury resulting from hemodynamic changes in only a small
number of the ARF patients showed: tubular necrosis and interstitial
nephritis. Pathological urinary sediment of small duration has nothing
to do with the severity or prognosis of ARF. The medical treatment
resolved most of the cases. Hemodialysis was required in 5/1000
patients. Mortality by ARF is 2%; nevertheless, in patients on hemo-
dialysis, mortality increased 10 times in relation with severe hydroelec-
trolytic damage and the age of the patients.
Percutaneous biopsy of the transplanted kidney. Technique and com-
plications. M. Camacho, A. Valdez, L. Quiroa, F. Bardales, P. Men-
dez, N. Seminario, Gisela Pimentel, and C. Liendo, Servicio de
Nefrologia, Hospital Edgardo Rebagliati Martins, IPSS, Lima, Perd.
The purpose of the present is to show the complications following the
percutaneous biopsy of the transplanted kidney. One hundred forty-six
percutaneous biopsies were done on the transplanted kidney of 146
patients. No limit was placed on the number of biopsies performed on
one kidney; 41% were re-biopsied and the highest number was five. The
renal biopsy was done in case of doubt of the diagnosis (renal reject,
acute renal failure, glomerulopathy and cyclosporine toxicity). The
percutaneous biopsy of the transplanted kidney was introduced into the
Rebagliati Hospital in September 1985 by one of the authors (MCB),
who used the Via Silverman needle according to the Murphy technique
(palpation method); ultrasonography was used in the 5%. The creatinine
levels ranged between 0.7 zg% to 4.3 pg%. The patients who had levels
of urea above of 100 sg% were dialyzed previously. No biopsy was
performed before the patient's blood pressure was adequately con-
trolled (>160 100 mm Hg). Renal tissue samples were obtained in
95.4%. Macroscopic hematuria lasting <24 hours was seen in three
biopsies (2.1%), and prolonged hematuria lasting >24 hours was seen in
nine biopsies (6.1%). Hematuria lasted seven days in one patient. One
patient needed a blood transfusion and surgery. Transient anuria due to
clot obstruction of the ureter was seen in two patients; one of them
showed stenosis of the ureter. None of these complications led to loss
of the transplanted kidney. It is suggested that the freedom from serious
complications is related to the safety of the technique and the precau-
tions applied to preparations of the patient.
Cadaver Kidney Transplantation's National Organization: Is it Impos-
sible for the Third World in general and Hispanoamerica In particular?
The Cuban experience. Sergio Arce, Francis Ramos, Yolanda Trujillo,
Omar Sudrez, Sonia Perez, and Maria J. Nunez, Institute of Nephrol-
ogy, Habana, Cuba. Taking into account the twenty years Cuba's
experience in kidney transplantation, we analyzed 1164 first cadaver
kidney transplants. The first 898 were performed with a regional
transplant organization (east, west and center) and the rest of the 266
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transplants with a national organization, and a national coordinator
center. The kidneys were harvested upon immunological and clinical
basis (ABO group, cross match, level of preformed anti-HLA antibod-
ies, HLA A and B compatibility and clinical priorities of receptors). For
this proposal, an appropriate computer program was prepared. Imuran
and steroids were employed as basic therapy. When the results were
obtained, those of the regional organization, were compared with those
of the national organization; a difference of 10% was observed in graft
survival (49% vs. 59%) at one year of transplantation. Also, the more
compatible HLA A and B cases (3—4 compatibilities) in which the graft
survival reached 66%, at one year, were only 18 in the 898 transplants
performed with a regional organization in 17 years, and of 28 in the 266
transplants performed in only two years with a national organization
(only one national waiting list). We conclude that in Third World
countries in general, and Hispanoamerica in particular (which had
reached a low in their socioeconomical and public health conditions),
cadaver kidney transplantation could be performed in an organized way
with satisfactory results.
Intravenous (i.v.) Fe-gluconate therapy in iron deficient patients on
chronic hemodialysis (HD). V. Peral, A. Rogada, P. Vidau, R. Tome, C.
Rodriguez, and J. Herrera, Servicio de Nefrologia, Hospital Genera!
de Asturias, Oviedo, Spain. Patients on chronic HD have an abnormal
iron balance, usually an iron deficiency, and in such patients continuous
oral iron is commonly prescribed. To determine their iron status, serum
ferritin (SF) transferrin saturation (TS) and serum Fe were determined
in 60 patients on chronic HD. We considered iron deficiency when SF
was below 120 ng/ml and TS below 18%. Twenty-four of these patients
(40%) had iron deficiency; their ages ranged from 18 to 75 years and
they had been on HD for 6 + 4.84 years. All but four (who had oral
intolerance) were taking oral ferrous sulphate 105—2 10 mg of elemental
iron daily, and five had been on EPO therapy for 2 years. These 24
patients received i.v. Fe-gluconate 125 mg of elemental iron at the end
of each dialysis session for eight successive sessions, a week and two
months after SF, TS and serum Fe were measured again. A marked
increase of SF was observed after the administration, from 49.68 19
to 316.54 171 (P < 0.001), but its serum concentration decreased
significantly at two months. Although the increase was still significant,
increase of Hb, Hto and TS was found too; the other parameters were
unchanged:
Parameters Pre- 2 months P
SF 49.68 19.21 135.86 89.28 <0.001
TS 23.04 13.81 31 12.20 <0.05
Hb 8.22 1.62 9.38 2.19 <0.01
Hto 23.3 5.91 29.54 6.51 <0.01
We conclude that SF is the most reliable index of iron state, Prophy-
lactic treatment with oral iron, average 150 mg of elemental iron daily
was inadequate in 40% of these patients. There was a positive response
after i.v. iron therapy, and no side effects were found. Oral iron is not
always enough to correct iron deficiency in HD patients, and supple-
mental i.v. iron may need to be periodically administered. Iron status
should be frequently monitored in these patients to maintain a good iron
balance.
Renal protection in radiation nephritis (RN). L. Juncos, H. Cejas, S.
Baigorria, and J.C. Cornejo, Instituto Privado Especialidades Médi-
cas, COrdoba, Argentina. Renal failure in RN could result from tissue
ionization, arterial or glomerular hypertension, or compensatory hyper-
trophy. We studied the effects of a low protein diet (LP) and enalapril
(E), 50 mg/liter in drinking water, on renal function and structure of
uninephrectomized rats with radiated remnant kidney. Baseline serum
and urine electrolytes, systolic blood pressure (SBP), serum creatinine
(Scr), Clearance (Car), UNa+ -i-V, UK+V and UproteinV were not differ-
ent between control (C) (N = 6), E (N = 6) and LP (N = 6) rats.
Week
C
E
LP
0 16
84 4.8 l24 9.3
79 4.0 78 4.1
85 5.8 123 5.5
0 16
6.0 1.1 15.la 7.6
54 1.1 6.9 1.1
6.9 0.9 7.7 0.8
Scr
mg/dl
Cpr
mg/min/100 g
Week
C
E
LP
0 16
0.5 0.02 0.9* 0.06
0.5 0.04 0.6 0.06
0.5 0.01 0.9 0.1
0 16
0.73 0.12 0.25a 0.06
0.88 0.12 0.80 0.09
0.88 0.2 0.48a 1.10
Values are means I 5EM. a p < 0.05 vs. week 0 (ANOVA).
At 16 weeks, mean PRA (ng/ml/hr) were: C 7.0 1.2; E 13.2 2.5 (P
<0.05) and LP 12.5 0.9 (P < 0.05). Glomerular sclerosis index: (0 to
4+)C 3.4 0.1; E 2.7 0.7(P <0.05); LP2.8 0.2(P <0.05). Renal
volume (ml): C 0.45 0.02; E: 0.32 0.02 (P < 0.05); LP 0, 41 0.02
(NS). E improved all parameters. LP did not prevent hypertension or
renal hypertrophy and was less effective in protecting the kidney.
Value of the intrarenal pressure determination (IRP) in the manage.
ment of renal failure after kidney transplantation. C. Rodriguez, A.
Pinto, C.L. Milanes, V. Allende, R. Diaz, C. Stempel, V. Paz-Martinez,
andJ.R. Weisinger, Centro Nacional de Didlisis y Transplante (MSAS)
and Division of Nephrology, Hospital Universitario de Caracas, Ven-
ezuela. Previous studies have demonstrated that the IRP could repre-
sent a useful method in the discrimination of post-transplant renal
failure. In order to assess the sensitivity and specificity of this method,
we measured the IRP using a fine needle according to the Salaman's
technique, on days 3 and 7 after the renal transplant, and before renal
biopsies indicated for differential diagnosis of acute rejection (AR),
cyclosporine toxicity (CyT) or acute tubular necrosis (ATN). We
performed 246 determinations in 28 patients. The normal values during
days 3 and 7 were 21.4 1.32mm Hg. AR increased the IRP to 41.3
9.5 mm Hg (N = 47, P < 0.001). In patients with ATN the IRP did not
change significantly (22.6 1.9 mm Hg, N = 26, NS), but in the CyT
group there was a slight increase (28.0 3.3 mm Hg, N = 9, P = 0.04).
The sensitivity (Sens), specificity (Spec) and positive or negative
predictive values (PV) were calculated using the renal biopsy as the
standard.
Sens Spec PV+ PV=
AR 92.9% 86.8% 72% 97%
ATN 96.0% 100% 96% 99%
CyT 100% 83.3% 100% 80%
These results suggest that the IRP represents a useful technique in the
management of the acute renal dysfunction in the renal transplant
recipient.
Comparison of bone mineral content in hypercalciuric and normal
children. L. Garcia, A. Bercowsky, N. Caviedes, B. Barilla, Y. Car-
dona, R. Martinis, E. BellorIn-Font, V. Paz Martinez, and J.R.
Weisinger, Divisions of Nephrology and Endocrinology, Hospital Pe-
diOtrico "Ellas Toro" and Hospital Universitario de Caracas, Venezu-
ela. Hypercalciuria (H) appears to be another factor in the appearance
of low bone mass in the adult population, probably secondary to a
persistently negative calcium balance. In order to study the effect of H
during early stages, we determined trabecular, cortical and total bone
mineral content in 21 hypercalciuric children with a mean age of 9.33
2.08 years, urinary calcium (Ca) excretion of 4.73 0.94 mg/kg/day,
and fasting fractional excretion of Ca (FeCa) of 0.29 0.16. We
compared these results with those obtained in a group of nine normal
children (C) with similar age (9.31 2.39 years), size and sex distribu-
tion (urinary Ca 1.16 0.52 mg/Kg/day, P <0.001, and FeCa of 0.056
0.032, P < 0.001). The results of the bone mineral content as
determined with dual photon absorptiometry in the lumbar spine
SBP
mm Hg
rotein
mgfIOO giday
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(Lumbar), femoral neck (neck), Ward's triangle (Ward) and total bone
mineral (TBM) expressed in g/cm2 were:
Lumbar Neck Ward TBM
C (N = 9) 0.65 0.04 0.75 0.11 0.82 0.12 0.87 0.12
H (N = 21) 0.55 0.09
P<0.03
0.68 0.11
NS
0.77 0.13
NS
0.83 0.08
NS
These results suggest that hypercalciuric children when compared to
similar controls tend to have lower trabecular with conservation of
cortical bone mineral content.
Outcome of renal transplant in Uruguay. L. Rodriguez Juanicó, F.
Gonzalez Martinez, S. Orihuela, L. Curi, L. Garcia Guido, 0. Balboa,
Montevideo, Uruguay. In our country, there is a transplant legislation
since 1971, forbidding non-related living donors (LD) and requiring the
explicit consent for cadaveric donors (CD). Uruguay has a population
of 3 million inhabitants (M.i.); since 1969, we have performed 235
transplants, 83% from cadaveric donors. In 1989, 11.8 renal transplants!
M.i. were made, among the highest number in South America. Since
then the number of transplants has decreased, to 81M.i. in 1991. There
are 215 patients (19% of dialyzed patients) on the waiting list (WL), with
an average waiting time of 26 22months. The mean time on WL was
19 months and the mean time on dialysis 38 24 months for these
patients. Average age was 36 13 years (range 7 to 64); 63% were
males. For cadaveric donors, in 94% two or less matchings were found
in HLA A and B. Causes of death for CD were trauma (55%), meningeal
hemorrhage (26%) and cranial bullet wound (11%). Warm ischemia was
4 4 minutes and cold 23.5 6 hours, despite the small area of the
country. Immediate recovery of diuresis in the postoperatory period
was present in 68% of the cases; only 42% were associated with
immediate functional recovery. Now alive with functioning graft, 61%;
on dialysis, 28% and dead 11%.
Years of survival
1 3 5 7 9
All patients 92 88 86 82 82%
All grafts 78 66 60 51 45%
LD patients 94 94 94 94 %
LD grafts 78 74 63 63 %
CD patients 92 86 84 78 %
CDgrafts 78 64 58 46 %
There were no significant differences in CD graft according to matching
(possibly because this was low, 94% had two or less matches in HLA A
and B, average 1.6). Neither did we find differences according to age of
the recipient, warm or cold ischemia. Actuarial graft survival was
significantly lower in the following groups: women, ABO group A, and
those treated with Azathioprine and corticosteroids. This last group
includes patients until 1988, as survival improved progressively with
time and different immunosuppressive protocols. Allograft survival in
patients under 20 years of age was smaller; however, difference with
other age groups was not significant. Although there exists an adequate
legal and organization frame, transplantation rate is low and falling in
the last years. It is still necessary to implement actions to optimize the
results, to detect possible donors and sensitize the population towards
positive consent of the donation.
Decrease of the Incidence of allergic pathology In the patients on
hemodialysis. A. Liébana Canada, P. Gonzalez Delgado, E. Martinez
Benavides, C. Sanchez Perales, C. Perez Miranda, M.C. Ruiz Olmos,
M.J. Garcia Corals, and V. Perez Banasco, Nephrology, Allergy and
Laboratory Services, General Hospital "Ciudad de Jaén," Jaén,
Spain. Introduction: It is known that there exists a situation of immu-
nity tolerance in chronic uremia which conditions a higher incidence of
infections, tumors, immunologic response altered in the presence of
viral infections, and anergia in retarded cutaneous hypersensitivity
tests, having studied these aspects basically. The aim of this present
study is the analysis of immediate hypersensitivity, based on the
observation of a lower incidence of allergic manifestations in the
patients on dialysis. Methodology: The incidence of respiratory and
cutaneous allergic symptomatology was analyzed by means of directed
questionnaire, by 110 patients on hemodialysis. They all had a cutane-
ous sensitization test to 10 common antigens, with a determination of
total IgE and specific RAST to the positive. The results are compared
with the ones obtained from a control group of 36 people, on whom the
same determinations were made. Results: (I) The incidence of respira-
tory allergic manifestations is remarkably lower in the group of patients
on hemodialysis than in the control group, with a statistic significance of
P = 0.01 for rhinitis and P = 0.001 for bronchial asthma, the incidence
of urticaria not being significant. (2) The incidence of positivity in the
cutaneous tests was noticeably higher in the control group than in the
patients on dialysis (P = 0.01), with the positivity to the olive tree
allergen the most frequent in them. (3) There was no statistically
significant difference observed with the levels of total IgE. Conclusions:
The patients on hemodialysis presented a lower incidence of allergic
symptomatology and a decreased response to the cutaneous sensitiza-
tion tests as an expression, not only of an alteration of the cellular
immunity, but also of the humoral immunity.
Osmolar gap as evaluation of safety of mannitol use in hemodialysis
(1W). A. Santana, C. Oliveira, M. Bruges, E. Gomes, P. Ponce, and
J.D. Barata, Nephrology Department, Santa Cruz Hospital, Lisbon,
Portugal. Our purpose was to study plasma osmolality alterations,
induced by prophylactic doses of mannitol, and its removal during HD
sessions. Methods: A prospective, controlled study with 10 patients,
age x 50 (22.72) years, HD time x 25 (2.88) months. All patients did a
standard HD session, with a 1.3 m2 surface area cuprophane dialyzer,
blood flow 200 mI/mm, four hours, dialysis solution: Na = 138
mEq/liter, K = 2 mEq/liter, no dextrose, acetate 38 mEq!liter 20%
mannitol I g/kg was infused during the first hour. Five out of the 10
patients (control group), did a second HD session without mannitol
(control). BUN, glycemia, Na, K and osmolarity (osm) were sequen-
tially measured in plasma and dialysis effluent solution at 0, 1, 2, 3 and
4 hours of HD. Osmolar gap was defined as the difference between
measured and calculated osm (calculated osm = 2 x [Na ÷ K1 +
glycemiall8 + ureal5.6). Results: Plasma osm was similar in the two
groups at the end of the session (mannitol x 299.5 + 9.5 control x 300
+ 9.7). In the mannitol group plasma osm and osmolar gap rose at the
first hour and decreased at the second to values similar to the control
group (P < 0.05). In the control group osm decreased throughout the
session.
Osm
Gap 0 hr 1 hr 2 hr 3 hr 4 hr
Mannitol 5.2 7.3 23.5 7.9 9.0 5.5 5.9 6.0 2.9 5.0
Control 3.6 3.7 3.2 6.3 5.9 10.9 2.6 7.9 3.4 10.7
Conclusions: Mannitol infusion raises plasma osm, contributing to the
osmolar gap. After the second hour of HD osmolar gap was similar in
the two groups, suggesting that mannitol is removed in the first two
hours.
Respiratory infection in renal transplantation, A. Santana, A, Gaspar,
J.M. Figueira, T. Marques, D. Machado, and J. Simoes, Nephrology
and Microbiology Departments, Santa Cruz Hospital, Lisbon, Portu-
gal. Respiratory infection (RI) is an important prognostic factor of renal
transplantation outcome. Purpose: To retrospectively identify etiology
and describe the clinical course of RI among renal transplant recipients.
PatIents: 130 consecutively renal cadaver transplanted patients, 94
male, 36 female, age x 42.6 years, with a post-transplantation follow-up
period of 28.6 21.3 months, were evaluated for occurrence, etiology,
prognostic factors and evolution of hospital and community acquired
RI. Results: 54 patients had 81 respiratory infection episodes; 76
patients did not have this complication.
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Hospital
acquired
Community
acquired
Patients 40.7% 59.3%
Previous anti-rejection 88% 48% P 0.000
treatment
Etiologic agent 65% 44% P = NS
identification
Fever 90% 60% P = 0.01
Pneumonia 94% 60% P = 0.004
Multi-systemic 39% 19% P = 0.05
involvement
Transplant failure 18% 17% P NS
Mortality 12% 6% P = NS
Conclusions: Both hospital and community RI influence the overall
success of renal transplantation, In our series anti-rejection therapy was
an important predisposing factor of pneumonia.
Anemia evolution after renal transplantation (RT). A. Gaspar, A.
Santana, A. Bataiha Reis, E. Correia, D. Machado, and J. Si,nöes,
Nephrology and Clinical Pathology Departments, Santa Cruz Hospital,
Lisbon, Portugal. Purpose: To study the influence of previous admin-
istration of erythropoietin (EPO) in the evolution of anemia after RT.
Methods: Prospective study in 21 consecutively renal cadaver trans-
planted patients, 11 previously treated with EPO (group A), and 10
without this therapy (group B). Age, hemodialysis duration, renal
failure etiology, hematologic values and immunosuppression protocol
had no statistically significant differences in the two groups. Hemoglo-
bin (HB), creatinine, ferritine, transferrine and erythropoietin blood
levels (blood EPO) were sequentially measured for six months. Results:
RT day 30 days
A B A B
HB
10.5 10.8 P = NS 10.5 8.5 P = 0.009
Creatinineb
9.9 9.8 P = NS 2.7 2.3 P = NS
1.7 3.7 1.5 1.0
Blood EPO
44 18.2 P = NS 25.6 26.7 P = NS
43 9,9 12.2 25.8
90 days 180 days
A B A B
HB
12.2 10.8 P = NS 13.7 11.8 P = NS
Creatinineb
1.7 1.6 P=NS 1.7 1.7 P=NS
0.5 0.5 0.6 0.8
Blood EPO
33.5 21.5 P = NS 23.9 17.2 P = NS
21.1 13.6 19.8 8.6
a g/dl; b mg/dl
Erythrocytosis occurred in the following six months in two patients,
one in each group. Conclusions: The anemia correction was slower in
patients previously on EPO. There was no correlation between EPO
blood levels and Hb or creatinine.
Contamination of dialysate and backtransport: Key factors for therapy
quality in dialysis. J. Vienken, V. Daum, and R. Bambauer, Institute of
Medical Membrane Applications, Akzo Faser AG, Wuppertal, Ger-
many. With the increasing use of highly permeable dialysis membranes,
dialysate contamination with endotoxins and their possible backtrans-
port to the patient's blood may play an important role in therapy
quality. Dialysate quality: We studied water and dialysate quality in 30
German and 51 Midwestern American dialysis centers. Bacteria from
the Pseudomonas strain were found in dialysate samples of 90% of the
German and American centers. In parallel, in 60% of the dialysis
centers endotoxin contamination was higher than permitted by the
AAMI standard. Samples from dialysate showed a higher contamina-
tion than samples from RO-water in all cases. Backtransport: Back-
transport in dialyzers from the dialysate to the blood side follows two
mechanisms: backdiffusion and backfiltration. Backfiltration is ob-
served only with highly permeable membranes, as dialysate pressure
exceeds that of blood. Theoretical and experimental data prove that 1.5
liters of water are filtered into the blood stream if membranes with a
UF-factor of 40 (for example PSu-F60) are used. Furthermore, as
endotoxins also exist as fragments with molecular weights as small as
800 fragments, they are able to pass dialysis membranes by diffusion.
Consequences: Backtransport of possibly contaminated dialysate into
the patient's blood stream cannot be avoided with any membrane.
High-flux membranes are less effective barriers for endotoxins than
low-flux membranes. To reduce the risk of backtransport the use of
membranes with a moderate UF is recommended.
Antibodies against hepatitis C virus (AbHCV): Prevalence, incidence
and transmission of the virus in a hemodialysis (lID) unit. J. Pinto dos
Santos, J. Piairo, C. Mil-Homens, H. Vizella, A. Nogueira, and J.
Barbas, Centro de Hemodidlise do Lumiar, Lab Imunonuclear, Lisbon,
Portugal. From January 1991 to January 1992, 96 chrome HD patients
(57 M and 39 F; age 60.781 12.17 years; time on HD 59.562 36.977
months) were followed up with monthly AbHCV determinations using
a second generation ELISA test. All the patients and staff members
were negative for HBsAg and HIV I-I! throughout the study, and the
staff has also remained negative for AbHCV. ELISA test was initially
validated with a RIBA HCV Sia Prototype showing 100% sensitivity
and 96.3% specificity. Prevalence of HCV positive patients was 14.6%
at the beginning and 36.5% at the end of the study. The incidence of
positive seroconversion was 25.6%. Among the 14 initially HCV
positive patients there was no negative seroconversion. Concerning a
past history of blood transfusions or the number of transfused units
throughout the study, no differences were found between the group of
patients who seroconverted (N = 21) and the group who remained
seronegative (N = 61). Difference was not found in the number of
treatments using the same dialysis "infected" machines. Time on HD
was significantly longer in patients who have had positive seroconver-
sion (P < 0.00001). There was a significantly increased risk of positive
seroconversion in seronegative patients dialyzed in contiguous position
to HCV positive patients (P = 0.0114; relative risk = 3.2). These facts
strongly suggest a horizontal transmission of HCV.
Prognostic meaning of proteinuria in kidney transplants. C. Videla, J.
Vega, and H. Borja, Nephrology Department Fricke Hospital, Viña del
Mar, Chile. The purpose of this study was to determine the prognostic
value of proteinuria in patients with renal transplants under immuno-
suppression therapy. We prospectively studied 82 patients who under-
went renal transplant from April 1981 to November 1990. Nineteen
patients were excluded by incomplete data or loss of follow-up.
Persistent proteinuria was defined as a value greater than 0.5 g/day for
a period longer than six months. Thirty-four patients developed pro-
teinuria due to chronic rejection (55.5%), transplant glomerulopathy
(7.4%), or acute rejection (25.9%). Recurrent glomerulonephritis of the
graft was less common. In 87% of patients proteinuria was present
during the first three years following renal transplantation. Actuarial
survival was different between patients with or without proteinuria after
two years (72.9% vs. 100%, P < 0.02), three years (61.4 vs. 100%, P <
0.001), five years (40.9% vs. 100%, P < 0.001). Similarly, renal function
was worse at first year of follow-up (serum creatinine 2.01 I vs. 0.96
0.29 mg/dI, P <0.0001) and at five years (3.27 1.23 vs. 0.95 0.29,P < 0.0005). Acute rejection episodes were more common in patients
with proteinuna (77.5% vs. 3.4%, P < 0.0001). The velocity of renal
function inpairment was similar in patients with chronic rejection and
those with glomerulonephritis. In conclusion, patients with renal trans-
plantation who developed proteinuria have a worse prognosis, regard-
less of the cause of proteinuria.
1424 Abstracts
Application of a community nephrology program in Cuba. J. Valdivia,
M. Almaguer, I. Sollet, A. Garcia, 0. Benitez, and R. Garcia, Cuba.
Since 1984 a program of prevention and integral care of chronic renal
failure (CRF) has been developed in Cienfuegos province, Cuba (pop.
326383). The program is focused on early diagnosis of CRF through the
periodic analysis of serum creatinine of people in risk groups (those
with either renal diseases, hypertension, or diabetic history), and the
control of risk factors to attenuate progression and health education at
primary care level. Ofthe627 cases with CRF under study in thepeiiod
of 1984-1991, 383 remainalive, 175 are dead, and the rest of them had
been transplanted or left the program because they moved to other
places. The accumulated prevalence (x 100,000 inhabitants) has been of
30 in 1984, 50 in 1987, 104 in 1990 and 117 in 1991. The progressive
increase can be explained by the active search for CRF patients in the
whole population. The distribution by stage of the glomerular filtration
rate (GFR) shows an increasing trend at early stages. In 1984 at stage I
(70—50 mI/mm) there were no patients, at stage 11(49—30 mI/mm) 37.6%,
at stage III (29—10 mI/mm) 48.6%, and at stage IV below (10 mI/mm)
12.8% of patients. In 1991, at stage I there were 11.3% of patients, at
stage II 65%, at stage III 6.6% and at stage IV 17.1%. The 75% of
patients fell in stages I and II. The four first causes of CRF are:
Malignant nephroangioesclerosis 22%, diabetic nephropathy 20.2%,
obstructive uropathy, 0.4% and chronic glomerulonephritis 6.4%.
Epidemiology of adult polycystic kidney disease (APKD) in Galicia.
Impact of the renal replacement therapy. Nephropathies Register of the
Community of Galicia, Spain. The objective of this retrospective study
is to describe the prevalence, incidence and survival of the patients with
APKD in the community of Galicia, Spain (population of 2.7 million
persons) during the last two decades, as well as the repercussion of the
renal replacement therapy on the survival rate. Data of a total of 515
patients were obtained from_all the nephrology units of Galicia. The age
at diagnosis was 46 15 (X SD) years. The ratio males/females was
48/52 (%). There was a positive family history in 63% of the patients.
The time period of follow-up was 6 5.6 (X SD) years. The incidence
rate (new cases per year per million persons) increased from two at the
beginning of the seventies decade to 14 at present. The prevalence at
December 1991 was of 1 in 8132 individuals. The estimation of patient
survival was performed by the method of Kaplan and Meier. The
expected 50% patient survival was of 29 years from diagnosis. A total of
81 deaths (16%) was registered. Cerebro-vascular accident was the
main cause of death (20%). A comparative study between 202 patients
(39%, group I) who required renal replacement therapy (62 of them
were transplanted) and 301 patients (58%, group 2) without renal
replacement therapy was carried out. The expected 50% patient sur-
vival from diagnosis was significantly lower in group 1(21 years) versus
group 2 (32 years, P < 0.01), and the death rate average was signifi-
cantly higher in group 1 (28%) vs. group 2 (8%, P < 0.05). There were
no significant differences in relation to sex or age at diagnosis. Conclu-
sions: APKD was mainly diagnosed in the fifth decade of life; its annual
incidence increased progressively; less than half of the patients required
dialysis; the expected long-term patient survival was satisfactory;
mortality was higher in the group of patients who required renal
replacement therapy.
Cyclosporine monotherapy (MT) versus trIple therapy (TT) In steady
state renal transplant patients; Cardiovascular risk factors. (Multicentric
study). M. Arias, P. Pereira, J.J. Plaza, A. Sanz Guajardo, and J.A.
Zubimendi, Hospital Valdecilla, Cantabria; Hospital V. Del Rocio,
Sevilla; Fundacion Jimenez Diaz, Madrid; Hospital La Paz, Madrid,
Spain. Introduction: Immunosuppressor drugs enhance some side ef-
fects that influence graft and patient survival, mainly infection and
cardiovascular risk factors. The results of a prospective, randomized
and multicentric study, comparing cyclosporin (CsA) MT versus TI' in
steady state first transplant recipients are described. Patients and
methods: After 90 days under TT, 74 patients (age 42.9 13, 19—62
years) were randomized according to 10 risk factors: donor and
receptor age, diabetes, dialysis treatment, living or cadaveric donor,
serum creatinine, proteinuna, number of antihypertensive drugs, acute
rejection episodes and days of CsA discontinuation. Thirty-seven
patients kept TI' treatment and 37 changed to CsA MT. During one
year, renal function and immunosuppressor side effects were evaluated
quarterly. Results: CsA MT was stopped in 24.3% (9/37) patients due to
elevation of creatinine levels or after an acute rejection episode. Renal
function was similar in both groups (P = NS). In TI' patients, higher
levels of serum glucose (P < 0.05), cholesterol (P < 0.01) and
triglicerides (P < 0.05) were observed after the sixth or ninth month,
associated with a significant weight gain (TI' = 8.1 kg; MT = 1.2 kg; P
<0.01). Number and severity of acute rejection episodes after the third
month were similar. A higher incidence of infections was shown in TI'
(P < 0.05). Frequency and severity of hypertension and number of
antihypertensive drugs show no statistical differences between groups.
Conclusion: CsA MT is a therapeutic chance, with similar results to TI'
treatment, in steady state renal transplant patients of a wide range of
age, with favorable effects on cardiovascular risk factors.
Idiopathic membranous nephropathy in Chile: A cooperative study of
82 patIents. J.C. Flores, S. Mezzano, A. Jara, H. Rosenberg, E. Lorca,
and E. Roessler, Hospital Militar, Santiago; Universidad Austral,
Valdivia; Hospital Universidad Catolica, Santiago; Hospital FACH,
Santiago; Hospital del Salvador, Santiago, Chile. We have reviewed
the clinical course and long-term prognosis of 82 patients (50 males, 32
females), mainly adults, with idiopathic membranous nephropathy seen
between 1961 and 1989 at several renal units in Chile. Seventy-nine
patients (96%) presented with nephrotic syndrome. Follow-up ranged
from five months to 20 years (mean 5.2 years); 31 patients (38%) were
followed for a period longer than five years. Sixty percent of patients
received immunosuppressive treatment at some stage during the
course. During the follow-up, 33 patients (40%) developed some degree
of renal progression, with renal death in 22 (27%); among the patients
who went into terminal renal failure, while 12 showed early progres-
sion, within three years after diagnosis, three did a late progression,
after 15 years. Twenty-five (76%) out of 33 patients who progressed
followed a course with persistent and refractory nephrotic syndrome.
Among 49 patients (60%) who ended the follow-up with normal renal
function, half (25) went into complete remission early after diagnosis (19
remitted before 3 years), and the other half (24) showed persistent
proteinuria, but only in six within the nephrotic range. Older age, male
sex and initial renal insufficiency were onset features associated with a
more unfavorable outcome. Patients who were given therapy did better.
There was no correlation between histologic stage and outcome.
Actuarial survival at five and 10 years was 74% and 63%, respectively
(there were no survival criteria was renal and patient death). Six
patients died during follow up, three in uremia and three for cardiovas-
cular reasons.
Acute renal failure (ARF) in fertile aged women. E. Wainer, C.
Campos, M. Ferndndez, D. Pisciotano, and C. Vitale, Hospital Nacio-
nal "A. Posadas," Haedo, Argentina. It has been stated that incidence
of ARF in pregnant women has dramatically decreased in industrialized
countries due to the virtual disappearance of septic abortion and better
prenatal care. On the other hand, hospital acquired ARF implies poor
prognosis, and despite widespread use of hemodialysis mortality is
persistently high. Causes of ARF in our country are different to those
reported in industrialized countries due to the existence of illegal
abortions. We retrospectively analyzed 106 women, aged between 15
and 45 years, presenting ARF that required dialysis between 1978 and
1991. In order to compare clinical presentation and mortality of ARF in
women of similar age, patients were grouped in three causative cate-
gories of ARF: Group 1: septic abortion (S.A.), included 57 patients
that had evidences of abortive maneuvers during the first trimester and
were admitted to the hospital due to overt ARF and hemolysis; Group
2: obstetric patients (O.P.), included 14 patients who developed ARF
during late pregnancy; and Group 3: hospital acquired ARF (H.A.),
included 35 women who developed ARF during hospitalization due to
medical or surgical causes. Table 1 summarizes our findings (mean SD).
S.A. O.P. H.A.
(N = 57) (N = l4) (N 35)
Age years 29.2 5.8 34,2 5.0 35.7 8.3a
BUN ing/dI 91.4 44.2 72.8 26.2 121.7 85.4a
Serum K mEq/liter 4.04 1.03 4.75 .96 4.64 l.13a
Oliguria days
Mortality
11.0 9.7
12/57 (21%)
11.5 13.6
5/14 (35.7%)
12.3 11.1
22/35 (626%)b
a Anova P < 0.02; ' Chi square P < 0.001
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We conclude that: (1) Septic abortion is the single most frequent cause
of ARF in this group of patients. (2) Despite low mortality when
compared with the other two groups, S.A. causes almost 30% of deaths.
(3) Serum potassium is significantly lower in the S.A. group. (4) H.A.
ARF implies poor prognosis, and mortality in this group is similar to
that reported by others.
Autosomal dominant polycystic kidney disease (ADPKD): Clinical
survey in 70 gene carriers. Edgar Almeida, J.G. Silva, J.R. Pinto, I.
Távora, S. Almeida, J. Lavinha, M.M. Prata, Nephrology and Radi-
ology Departments, Santa Maria Hospital, Laboratory of Human
Genetics INSA, Lisbon, Portugal. Neomutation rate for ADPKD is
estimated at 6.5 to 10 x i0-. Accordingly, diagnosis of ADPKD
depends on demonstration of dominant transmission of renal cyst in
kindreds. Seventy-one kindreds, including 170 individuals, were pro-
spectively screened by renal echography. In 34 kindreds (70 patients),
diagnosis was established according to Bear, that is, bilateral involve-
ment with at least three cysts. Renal failure (RF) was defined as
creatinine clearances <or = to 80 mllmin. In 21 patients, mean age 23.6
(7-60) at the diagnosis, of whom 17 were asymptomatic, renal ultra-
sonography was performed as part of kindred screening. In 53 symp-
tomatic patients, mean age at the diagnosis was 31.2 (8—56), and mean
time from symptoms to diagnosis was 7.4 years (0—38). The most
frequent clinical presentations were HT (15/53) and renal colic (12/53).
Prevalence of HT and RF increases with age and is 75% at 38 years for
both. Seventy-five percent of 42 screened patients had hepatic cysts.
We suggest that the differences between this and other cohorts (higher
prevalence of HT, RF and hepatic cysts) may be consequent to our rigid
inclusion criteria, and that other cohorts may have included patients
with cysts but without ADPKD.
Can the response to hepatitis B vaccination predict post-transfusion
immunization in hemodialysis patients? J. Perez, L. Marzo, C. Santam-
aria, C. Peralta, M.J. Bello, A. Garbayo, A. Sanjuan, and J.A.
Gutierrez, Servicios Nefrologia y Hematologia, Hospital "Miguel
Servet," Zaragoza, Spain. Vaccination against Hepatitis B (HB) is
routinely done in patients with chronic renal failure at the beginning of
hemodialysis treatment. If the level of anti-HBs antibodies was able to
predict the post-transfusional cytotoxic antibodies synthesis, we could
identify in this way a group of high immunological risks ("responder
patients") for renal transplantation. We have retrospectively studied a
group of 42 patients. All of them had received an adequate vaccination
strategy against HB virus and three blood transfusions as part of our
pretransplant protocol. The determination of anti-HBs antibody level
was done after every dose of vaccine. Cytotoxic antibodies were
measured two weeks after every blood transfusion. The statistical
analysis of the results included McNemar test and Student's (-test.
After the first cycle of vaccine, 25 of the 42 patients (60.9%) became
anti-HBs (+), but only 35.7% (15 of 42) showed cytotoxic antibodies (P
0.05). After the booster dose 36 of the 42 patients (85.7%) were
anti-HBs (+), but, again, only 24 of the 42 patients (57.1%; P = 0.01)
showed cytotoxic antibodies at the end of the three transfusions. We
have not found significant differences in relation to age, sex, number of
doses of vaccine or renal disease etiology, when compared to anti-HBs
(+) and anti-HBs (—)patients. In the anti-HEs (+) group we did not find
significant differences in age, sex, number of doses of vaccine or
etiology of renal disease when compared to patients who developed
cytotoxic antibodies with those who did not. We did find a statistically
significant difference when we studied the number of blood transfu-
sions: 15.7 units in the (+) group versus 5.6 units in the (—) cytotoxic
antibodies group (P = 0.005). Conclusions: In our experience the level
of response to hepatitis B vaccination does not identify that group of
patients who are prone to develop cytotoxic antibodies after blood
transfusions, since vaccination sensitizes between 7.4% and 49.7%
more than transfusions.
Prophylaxis of cytomegalovirus infection with hyperimmune globulin in
renal transplant patients. P. Sdnchez Perez, L.M. PallardO, J. Sanchez
Plumed, J. Garcia, E. Orero, I. Beneylo, J.M. Cruz, Service of
Nephrology, Hospital Ia Fe, Valencia, Spain. Cytomegalovirus (CMV)
infection is a major cause of morbidity and mortality in renal transplant
patients, mainly in those severely immunocompromised, such as occurs
after treatment with antilymphocyte preparations, and after primary
infection. We have studied the effect of passive immunization with
CMV hyperimmune globulin (HG) in 18 recipients of kidney allografts
considered to be at risk of developing CMV disease: Group A: seven
CMV antibody-negative patients, recipients of a kidney from CMV
antibody-positive donors; Group B: eleven patients which received
OKT3 monoclonal antibody, associated to cyclosporine for prevention
or treatment of acute rejection (five and six patients, respectively). The
protocol consisted of the administration of a dose of HG (Cytotect,
Biotest Pharma) every three weeks for three consecutive months. The
diagnosis of CMV infection was made by isolation of the virus in urine,
seroconversion and/or a fourfold increase in anti-CMV antibody titers.
Fever, leukopenia, respiratory symptoms, hepatitis and gastrointestinal
symptoms were considered CMV disease when infection was docu-
mented. Results:
Culture+ 1gM IgG Infection Symptoms
GroupA(7) 4 6 3 6 3
GroupB(ll) 8 4 3 8 5
None of the patients required hospitalization or specific antiviral
therapy. Our results suggest that in renal transplant patients at high risk
for CMV disease, HG therapy can effectively prevent the appearance of
symptoms or attenuate the severity of the disease.
Acute pancreatitis in renal transplant recipients. A. Sanjuan, J. Paul,
C. Santamaria, L.M. Lou, C. Peralta, J. Perez, and J.A. Gutierrez,
Servicio Nefrologia, Hospital "Miguel Servet," Zaragoza, Spain. A
high incidence of acute pancreatitis (A.P.) has been described after
renal transplantation. There are several etiological factors that make
this complication more frequent than what is observed in the general
population or in renal patients undergoing hemodialysis treatment. We
report our experience about the incidence and clinical outcome of A.P.
in a renal transplantation population of 125 who received a graft
between 1986 and 1991 at our institution. All the patients were treated
with an immunosuppression protocol including cyclosporin A (CsA)
and prednisone. Five cases (3 males, aged 49, 57, 58; and 2 females aged
42 and 48) were diagnosed with A.P. Before the renal transplantation no
previous history of cholelithiasis, hypercalcemia, dyslipemia or alcohol
abuse was observed in any case. After transplantation three patients
showed cholelithiasis, one mild hypercalcemia and two patients had no
predisponent factors. CsA levels were in the therapeutic range without
hepatotoxicity or nephrotoxicity signs. Four cases had a favorable
outcome with conservative medical management. The fifth patient died
because a refractary shock developed in a recurrent bout of A.P. two
months after the initial episode. Conclusions: (I) There was an unex-
pected high incidence of A.P. in our study. (2) The A.P. post-renal
transplantation has a high morbidity/mortality similar to that reported in
the other series. (3) We think patients under CsA therapy have a
tendency to develop cholelithiasis. This could promote the A.P. epi-
sodes.
Progressive Impairment of graft function: Results after switching to
triple therapy (cyclosporine + prednisone + azathioprine). J. Paul, L.M.
Lou, C. Santamaria, C. Peralta, M.J. Bello, L. Pastor, L. Plaza, and
J.A. Gutierrez, Servicio de Nefrologia y Anatomia Patologica, Hospi-
tal "Miguel Servet," Zaragoza, Spain. A group of patients presented,
early or late in the course of transplantation, a progressive impairment
of graft function. We present our experience with 27 of these patients
initially treated with cyclosponne (CsA) + prednisone (PDN) who were
switched to a protocol including CsA + PDN + azathioprine (AZA).
The CsA dose was gradually reduced as AZA was added (at a dose of
1—2 mg/kg/day). The patients were divided in two groups: Group I (N =
19): with data of chronic CsA nephrotoxicity. Group II (N = 8): with
criteria of chronic rejection. The switching was done at a mean time of
12.1 months after transplantation. Renal biopsy was obtained in 22
patients (82%). Twelve months after adding AZA the renal function was
re-evaluated: Group I: there was an improvement in 15 patients
(78.9%); three patients (15.8%) remained stable and one patient (5.3%)
showed a decrease in the graft function. Group II: only three patients
(37.5%) improved their renal function; four patients (50%) remained
stable and one patient (12.5%) worsened. So, globally, the renal
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function showed an improvement in 18 patients (66.7%), remained
stable in seven patients (25.9%) and worsened in two patients (7.4%).
We have seen no clinical complications and have observed no rejection
episodes or graft losses. Conclusions: The switching from CsA + PDN
to CsA + PDN + AZA can ameliorate the clinical course of these
patients who show a progressive impairment of renal function after
renal transplantation. (The best results have been seen in the group of
CsA nephrotoxicity).
Clinical course and prognosis of focal segmental glomerulosclerosis In
children. Reinaldo Martinelli, Alice Setsuko Okumura, Edilson Brito,
and Heonir Rocha, Federal University of Bahia, Medical School,
Salvador-Bahia, Brazil. In order to analyze the clinical course and
prognosis of focal segmental glomerulosclerosis (FSGS), 23 children (11
male and 12 female) with a mean age of 6.35 3.18 years, were studied.
All the children had a previous diagnosis of steroid-resistant nephrotic
syndrome. At the initial evaluation three children presented with
systemic hypertension, four with renal failure, and three with both
conditions. The four patients treated with steroids (second trial) re-
mained unresponsive to the treatment, and of the 19 patients treated
with steroids and cyclophosphamide, eight experienced complete re-
mission of proteinuria, three a partial remission of proteinuna, while in
eight these there was no response. The clinical course was polycyclic in
10 patients (all treated with steroid and cyclophosphamide), persistent
non-nephrotic proteinuria in six patients (2 treated with steroids) and
persistent nephrotic syndrome in seven. At the final evaluation (fol-
low-up = 73.5 63.3 months) two patients had hypertension and four
developed hypertension and renal insufficiency (advanced in 1). A
correlation between clinical course and/or to therapy and loss of renal
function was not observed. Although it was a selected group of patients
it is possible to conclude: (I) "Malignant" FSGS is infrequent in our
center; (2) The prognosis of FSGS in children is reserved—it is a slowly
evolving disease; (3) There is no correlation between the clinical course
and prognosis; (4) Long-term, randomized studies are necessary to
better define the influence of therapy on the renal function in FSGS.
Renal failure in tetanus: Possible role of rhabdomyolysis. Reinaldo
Martinelli, Cdcia M. Matos, and Heonir Rocha, Federal University of
Bahia, Medical School, Salvador-Bahia, Brazil. Acute renal failure is
not a frequent complication in tetanus. The intense muscular work
resulting in rhabdomyolysis, the profuse sweating, hyperactivity of the
sympathetic nervous system and metabolic disturbance that accompany
tetanus, may cause renal failure. To study the frequency and examine
the role of rhabdomyolysis in acute renal failure, 18 adult patients with
the diagnosis of generalized tetanus consecutively admitted to the
hospital were prospectively studied. Of these, 14 were male and 4 were
female with a mean age of 31.8 2.0 years. Except for mild proteinuria
(<3.5 g/day) recorded in nine patients, the urinalyses were unremark-
able. Serum creatinine < 1.4 mg/dl was recorded in 39% of the patients,
abnormal levels of CPK in 85% and myoglobin 120 igIliter in 39%.
Oliguria was documented in one patient and none required dialysis
therapy. The clinical course of recovery, although four patients died
during the hospitalization (unrelated to renal failure). No correlation
between renal failure and myoglobin and/or CPK levels was found. It is
concluded that acute renal failure is not infrequent in tetanus; usually it
is non-oliguric, mild and transient and not related to the severity of the
tetanus or to serum levels of myoglobin and/or CPK.
Clinical course of schistosomal mansoni glomerulopathy: Factors that
could influence the progression. Reinaldo Martinelli, Luiz José C.
Pereira, Antonio Carlos B. Noblat, and Heonir Rocha, Federal Uni-
versity of Bahia, Medical School, Salvador-Bahia, Brasil. Glomerular
involvement has been very well demonstrated in hepatosplenic schis-
tosomiasis mansoni, in clinical and in experimental studies. In order to
analyze the clinical course and factors that could influence the progres-
sion of the glomerular disease, 36 hepatosplenic patients with mesan-
giocapillary glomerulonephritis (MCGN = 21) and focal segmental
glomerulosclerosis (FSGS = 15)were studied. The mean follow-up was
seven years. The initial presentations were similar in both groups and
not different from patients with the idiopathic forms of these glomeru-
lopathies. The clinical course was of progression: at the end of the study
24/36 had renal failure. Renal insufficiency and/or arterial hypertension
at time of the diagnosis of renal disease and persistent nephrotic
syndrome were associated with progression towards renal failure; the
immunosuppressive and anti-parasitic treatments did not influence the
clinical course. It is concluded that the glomerulopathy associated with
hepatosplenic schistosomiasis mansoni is progression, resistant to
immunosuppressive therapy, evolving independently of the presence or
absence of the parasite.
The influence of cyclophosphamide in the clinical course of focal
segmental glomerulosclerosis (FSGS) in adults. Reinaldo Martinelli, and
Heonir Rocha, Federal University of Bahia, Medical School, Salvador-
Bahia, Brazil. The use of cyclophosphamide in the treatment of FSGS
in adults has been a matter of controversy. To examine the influence of
cyclophosphamide in the clinical course and prognosis of FSGS in
adults, 36 patients (22 males and 14 females) with a mean age of 28.0
13.5 years were studied. At the time of the diagnosis two patients had
systemic hypertension, seven renal insufficiency, and 10 hypertension
and renal insufficiency. Of them, 13 patients were treated with steroids
and cyclophosphamide. The clinical response to therapy was desig-
nated as good (complete remission of proteinuria) in two patients
treated with steroids, partial in five and absent in six. Among the
patients treated with steroids plus cyclophosphamide, it was good in
five, partial in three and absent in four patients. The clinical course was
of persistence of nephrotic syndrome in 7/13 patients treated with
steroids, 3/13 treated with steroids + cyclophosphamide and 6/11
patients treated symptomatically. Persistent non-nephrotic proteinuria
was recorded in 2/13 patients treated with steroids, 2/12 treated with
steroid + cyclophosphamide and 2/11 untreated patients. A polycydic
course of nephrotic syndrome was observed in 4/13 treated with
steroids, 7/12 treated with steroids and cyclophosphamide and in 1/Il
untreated. At the end of the follow-up (52.8 months) seven patients
treated with steroids, four treated with steroid + cyclophosphamide
and four untreated patients had renal failure. Although uncontrolled,
the present study suggests cyclophosphamide may have a beneficial
influence on the clinical course and prognosis of FSGS in adults.
Percutaneous translumlnal angioplasty in renovascular hypertension,
f.M. Galceran, A. Martinez-Amenos, H. Rama, X. Sarrias, J. Alsina,
and X. Montana, Servicios de Nefrologla y Radiologla, Ciudad Sani-
taria de Bellvitge, Universidad de Barcelona, Barcelona, Spain. Per-
cutaneous transluminal angioplasty (PTA) is nowadays the treatment of
choice for the majority of cases of renovascular hypertension. This
technique has, however, a certain risk of complications and the lesions
can also reproduce. We present the results of 86 patients with renovas-
cular hypertension who underwent PTA in our hospital between 1981
and 1991. The inclusion criterion was hypertension with a renal artery
stenosis greater than 50% without considering functional tests. The
etiology of the stenoses was atheromatous (N = 49) and dysplasic (N =
37). The ostium was involved in 29 cases. Stenosis was unilateral in 53
cases, bilateral in 19 and affected a solitary functioning kidney in 14
cases. The percentage of technically satisfactory PTA was 90.6% (N =
78). In six patients bilateral PTA was performed in the same procedure.
There were few complications, mainly hematomas in the puncture site.
There was a significant improvement of blood pressure immediately
after PTA and also at the end of the follow-up (mean 24 months). Four
patients progressed to end-stage renal failure and two patients died of
causes unrelated to PTA. Re-stenosis developed in 11 cases (12.7%)
between six months and four years after PTA, nine of them underwent
a second PTA. We conclude that PTA is an effective treatment for
renovascular hypertension, with low risk of complications even in the
case of a solitary functioning kidney or bilateral stenosis, it is cheaper
than a surgical procedure and, in case of re-stenosis, it can be re-tried
without further complications.
Percutaneous angioplasty of the renal artery in patients with a solitary
functioning kidney. f.M. Galcerdn, A. MartInez-Amenós, H. Rama, X.
Sarrias, J. Montana, and J. Alsina, Servicios de Nefrologla y Radio-
logla, Ciudad Sanitaria de Bellvitge, Hospitalet de Llobregat, Barce-
lona, Spain. Patients with renal artery stenosis of a solitary functioning
kidney (SFK) constitute a special group of risks among renovascular
hypertensive patients, not only because of the severity of their hyper-
tension but for the incidence of renal failure as well, which, in most of
the cases, can progress rapidly. The practice of percutaneous arterial
angioplasty (PTA) in these cases has been sometimes considered
relatively contraindicated because of its potential complications (throm-
bosis, arterial wall rupture). The surgical treatment, however, has a
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high risk that rises progressively with the level of renal failure. We
present the results of 14 patients (9 men, 5 women, age 55 15) with
renal artery stenosis and a SFK that underwent PTA in our hospital
during the period 1981—1991. There were 11 cases of atheroma and three
cases of dysplasia. PTA was technically satisfactory in 12 cases (85.7%)
obtaining a significative improvement of systolic blood pressure (SBP,P = 0.004) and diastolic blood pressure (DBP, P = 0.0013) with less
antihypertensive treatment. There were no complications except for
one case of transient worsening of renal function due to contrast
nephrotoxicity. At one year of follow-up the patients evaluated (N = 6)
still were showing lower levels of DBP although the low number doesn't
allow the taking of statistical conclusions. The re-stenosis percentage
was 16.6% (N = 2). By now, the patients have an average follow-up of
35 30 months with lower levels of SBP and DBP. Except for two
cases who progressed to end-stage renal failure, the rest of them show
maintenance of their levels of renal function. The two cases in whom
PTA was not satisfactory underwent renal autotransplantation with
success.
Cell-mediated lympholysis in renal transplants (CML). Maria del
Carmen Samaniego, Maria Cristina Liorente de Carlin, and Cristina
Aguirre, Instituto de Investigaciones Medicas Aifredo Lanari, Fac.de
Medicina de Ia Universidad de Buenos Aires, Argentina. Recipient (R)
capacity to originate T cytotoxic (Tc) lymphocytes directed against the
aloantigens of HLA hemocompatible donors (D) and HLA incompatible
controls (C) was evaluated using the CML test, in order to relate them
to the immunosuppressor treatments and post-transplantation time.
Nineteen kidney transplant recipients (R, 3 from cadaver and 16 related
living donors) were studied. Ten R were treated with cyclosporine
(CsA, 3.5 mg/kg/day), anti-lymphocyte globulin (ALG) and prednisone
(0.5 mg/kg/day). Nine R were treated with azathioprine (AZ, 2 mg/kg!
day) and prednisone (1 mg/kg/day). Three R were studied during the
first, second, third and fourth year post-transplantation. Ligthbody's
and col. technic were performed. The results were expressed in percent
(%) of 51 Cr liberation. CML in AZ immunosuppressed R were
performed in a length of time including two months to nine years
post-transplantation; the results were a specific D hyporesponse: 15.3 +
1.8% (N = 9) and a conserved response against C: 76.82 + 3.2% (N =
9). No significant differences were found. A group of R followed with
CsA was studied 3 to 14 months post-transplantation. CML against D
were: 3.14 + 0.8% (N = 7); CML against C were: 34.25 + 2.54% (N =
10). Three R were studied along four years post-transplantation. During
the first year CML were 3.6%, 2.6% and 3.5%; second year 3.2%, 3.6%,
2.3%; third year 3.8%, 2.5% and 1.7%; and the fourth year 7% and 9%.
The responses against their unrelated controls were first year: 31%,
31% and 28%; second year 48%, 56% and 37%; third year 63%, 78% and
53%; fourth year 65% and 61%. Our results indicate that GAL-CyA
combination initially produces an unspecific hyporesponse, as mea-
sured by the CML technique, progressing with time towards an specific
donor hyporesponse similar to that found in AZ immunosuppressed R.
Effects of immunosuppression with azathioprine and steroids on hepa-
titis B (HVB) replication in renal transplant (TxR) recipients. J. Vila, J.
Genesca, R. JardI, M. Campins, A. Segarra, R. Roca, L. Capdevila, C.
Cantarell, and L. Piera, Nephrology Unit and Liver Unit, Hospital
General Vail Hebron, Barcelona, Spain. The aim of this work was to
study the influence of immunosuppression with azathioprine and ste-
roids (AZA.S) on HVB replication. Between 1973 and 1985, 173 kidney
transplants were performed using cadaveric grafts. Twenty of these
patients were HVB carriers before transplant. HVB infection markers
were determined before and after TxR on these 20 HVB carriers.
AgHBs, AgHBe/Ac anti-HBe, and AC anti-HBc were analyzed by
RIA(ABBOT), and HVB-DNA was analyzed by a modification of
Scotto Tecknic. Results were evaluated using Fischer and Mann-
Whitney U test. Statistically significant differences were observed
among the following: HVB-DNA were positive(+) in seven pre-TxR
and in IS post-TxR patients, that is, and an increase in the number of
HVB-DNA + post-TxR patients (P = 0.032). The median count of
HVB-DNA levels were 67 and 126 g/ml pre- and post-TxR, respec-
tively, indicating higher median HVB-DNA values post-TxR (P =
0.004). Conclusion: The greatest number of the HVB-DNA + patients
post-TxR and the highest HVB-DNA median count level suggest that
immunosuppression linked to TxR (AZA and S) facilitate HVB repli-
cation.
Therapeutic immunoadsorption in Goodpasture's syndrome. F. Mo-
reso, R. Poveda, R. Garcia-Osuna, S. Gil-Vernet, L. Carreras, f.M.
Griño, and J. Aisina, Servei de Nefrologia, Hospital Universitari de
Belivitge, Barcelona, Spain. The introduction of plasma exchange (PE)
associated with steroids and cyclophosphamide has allowed a better
prognosis of the Goodpasture's disease, mainly of the pulmonary
involvement. Renal disease can improve if this therapy is started before
the development of extensive crescentic lesions and severe renal
failure. Therapeutic immunoadsorption (IA) could achieve better re-
sults than PE therapy, attending its higher specificity in removing
immunoglobulins and its higher amount of treated plasma. We report
two cases of anti-GBM disease with pulmonary and renal involvement
in which IA was performed. Case I is a 27 year old man who was
admitted with hemoptisis and dispnea due to pulmonary bleeding. Pa02
and diffusing lung capacity of carbon monoxide (DLCO) was seriously
impaired. Serum RIA for anti-GBM antibodies titer was 24% (N <
10%). Serum creatinine was normal. Hematuria was present. Renal
biopsy showed linear parietal lgG and C3 staining in glomeruli. Light
microscopy was normal. IA was started in an alternate day schedule.
Four procedures (29 liters of plasma) were performed. Oral prednisone
(F, I mg/k/day) and cyclophosphamide (CF, 1.5 mg/k/day) were added.
Dramatic decrease in serum anti-GBM titer was observed. Rx, Pa02
and DLCO normalized after the third procedure. Nine months later the
patient remains under oral P and CF therapy being symptom free.
Microscopic hematuria persists. Case 2 is a 28 year old man who was
referred from another hospital having a clinical and semiologic pulmo-
nary disease similar to case 1. Serum anti-GBM titer was 33%. Serum
creatinine was rapidly reaching 350 mol/liter. After admission, renal
biopsy was performed showing extensive crescentic GN. IF was
consistent with anti-GBM disease. PE and oral P and CF were started
with no pulmonary or renal response after three daily procedures (9
liters of exchanged plasma). Anuria was then established. IA was
initiated in an alternate day regimen. Five procedures (39 liters of
plasma) were performed. Alveolar bleeding disappeared, but no re-
sponse was obtained in renal disease. IA has been more effective than
PE in resolving lung involvement of Goodpasture's syndrome. Progres-
sion of renal disease might stop if early IA was applied, when no
extensive crescentic GN was present on renal biopsy.
Reflection of the selection criteria of the patients advised to CAPD
treatment. S. Y. Thrahim, M.G. Lima, i.E. Oliveira, and H.P. Athayde,
Grupo de Assisténcia Médica Nefrologica, Rio de Janeiro, Brasil. The
authors studied 39 patients advised to CAPD treatment and established
a selection criteria based on the individual analysis of each case. Eight
patients were excluded from the proceedings for clinical and or emo-
tional reasons. The remaining 31 patients were divided into five groups
according to the responsibility of the method. CAPD treatment is
indicated by some authors for end-stage renal failure in old people,
diabetics, patients with vascular access and cardiovascular problems,
but we question these parameters because they exclude the patient's
biopsychosocial complexity and the family nucleus. The necessary
conditions for the CAPD execution by the patients, by the family and by
other people were determined and it established a psychosocial assis-
tance consisting of individual attention to the patient, to the family and
discussion with the involved staff. We concluded that the staff must
consider the individual clinical and psychological aspects of the patients
and the structural conditions of their familiar nucleus. It is important to
singularize that CAPD is an ideal treatment when it is assumed by the
own patient.
Clearance overestimation, in dialytic prescription, when based on blood
flow: Recirculation as a correction factor. S. Colaco, M. Leal, H.
Estiheiro, and J.D. Barata, Sociedade Portuguesa de Diáiise, SPD,
Amadora, Portugal. Urea (U) clearance (K) is an important variable in
the assessment of dialysis adequacy. The instantaneous method
(INST), based on blood flow (QB), is the most used because of its
simplicity. We have done a prospective study to compare UK deter-
mined with the INST method and global (GLOB) clearance of urea.
Studies were performed on 13 patients (nine male, four female; aged
56.8 9.7 years; time on dialysis 37.7 23.5 months). A polysulfone
capillary dialyzer (Hemofiow F6, Fresenius) was used in 23 hemodial-
ysis (HD) sessions. UK was calculated at I hour of HD with ultrafil-
tration (UF) = 0, according to the formula: K = QB (A — V)/A (A =
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arterial; V = venous); determination of GLOB K was based on total
collection of dialysis effluent (E), according to the formula K = VE
CE/(CO + CI + C4) :3 (V = volume; c = concentration; 0 = start; I =
1st hr, 4 = 4th hr). Student's t-test and linear regression were used for
statistical analysis. Results: INST K and GLOB K values were,
respectively: 179.74 + 19.89 and 153.57 24.40; there was a good
correlation between them (r = 0.74P < 0.001). INST K was superior to
GLOB K in 20%. In II HD treatments recirculation (R) was calculated
and INST K was pondered to R (Kp) according to the formula: Kp = K
(1 — R)/l — R. (1 — K/QB). In this group Kp was identical to GLOB K,
179.29 20.99 (P = NS) with correlation r = 0.9. ConclusIons: The
instantaneous method for determination of UK overestimates GLOB
K. Ponderation to R approaches INST K to GLOB K.
Protective effect of superoxide dismutase liposomed in an experimental
renal warm ischemia model. D. Seron, J. Torras, A.M. Castelao, M.
Carrera, R. Cases, F. Moreso, P. Puig Parellada, P. Gonzalez, J.
Alsina, and f.M. Grino, Nephrology and Pathology Services, Hospital
of Belivilge, Pharmacology Department, Faculty of Medicine, Univer-
sity of Barcelona, Barcelona, Spain. Improvement of acute renal warm
ischemic injury has been shown by superoxide dismutase (SOD), a
potent scavenger of superoxide radicals, when administered just prior
to reperfusion. Inclusion of SOD in liposomes (lipo-SOD) prolongs
SOD half-life (SOD: 6 mm; lipo-SOD: 4 hrs). The protective effect of
lipo-SOD in a bilateral renal warm ischemic model of 60 minutes was
studied. Sixty male Wistar rats were included in seven groups: Or. I,
isovolumetric saline serum (N = 10); Gr. 2, isovolumetric liposome (N
= 7); Gr. 3, SOD pre-ischemia (N = 8); Or. 4, SOD pre-reperfusion (N
= 10); Gr. 5, lipo-SOD pre-ischemia (N = 9); Gr. 6, lipo-SOD
pre-reperfusion (N = 9); Gr. 7, lipo-SOD 1 hour pre-ischemia (N = 7).
SOD and lipo-SOD were administered EV at 20 mg/kg body wt. Weight,
diuresis, creatinine per 100 g body wt (smol/liter) (Cr1100 g) and
creatinine clearance per 100 g body wt (d/min) (CrCI/lOO g) were
determined on days 0, 1, 2 and 7. At 15 minutes post-reperfusion and at
seven days post-surgery, kidneys were processed for conventional
histology. Comparisons between groups were made using an ANOVA.
Renal function on day 0 and kidney histology at 15 minutes post-
reperfusion were not different between groups (P = NS). One rat from
Or. I died due to uremia. Results are shown in the table:
Cr/1 00 g CQJ100 g
HistologyDay 2 Day 7 Day 2 Day 7
Group 1 76.8 23.0 22.3 3.3 113 27 217 40 7.4 1.2
Group 2 83.3 23.2 21.2 1.3 79 24 148 18 12.9 1.2
Group 3 125.8 29.9 19.2 0.7 81 27 312 37 10.3 1.2
Group 4 58.5 6.5 18.9 0.9 193 30 441 44 9.5 1.0
GroupS 42.1 7.6 22.9 1.3 166 31 297 15 7.6 1.6
Group 6 31.3 4.6 20.5 1.3 236 38 308 19 4.6 0.9
Group 7 78.6 23.7
P = 0.045
24.9 1.9
P = 0.044
227 81
P = 0.028
292 25
P = 0.0001
7.1 1.3
P = 0.0007
We conclude that inclusion of SOD in liposomes does not reduce its
protective effect when administered pre-reperfusion and on the con-
trary, this is potentiated when it is administered pre-ischemia.
Effects of sodium overload and unilateral nephrectomy upon nephrop-
athy and hypertension in diabetic rats. R.A .M. Cadaval, L.J.E. Portela,
F.L. Plavnik, D. Bossolan, M.D.A. Lima, A.B. Ribeiro, and 0.
Kohlmann Jr, Nephrology Division, Escola Paulista de Medicina, São
Paulo, Brazil. We studied in male diabetic Wistar rats (diabetes mellitus
induced by streptozotocin, 60 mg/kg/i.v.) the effects of salt overload
(saline 1% to drink, SALT) associated or not to left nephrectomy (NEP)
(groups: DM+SALT+NEP, N = 8; and DM+SALT, N = 12, respec-
tively) upon development and progression of elevated blood pressure
levels and diabetic nephropathy. As control groups we studied diabetic
rats receiving tap water to drink submitted or not to left nephrectomy
(groups: DM+NEP, N = 12 and DM, N = 9, respectively). All animals
were followed for 18 weeks and had tail arterial pressure (mm Hg) and
albuminuria (mg/24 hr) determined every two weeks and inulin clear-
ance (mI/mm) measured at week 18. Results are mean SEM.
Group
Tail artena! pressure
Baseline 6 weeks 12 weeks 18 weeks
DM+SALT 114 2.2 170 22ab 169 l3.8a 172
DM+SALT+ 114 1.2 148 6gd 184 3.8w' 194 15'
NEP
DM+NEP 116 2.4 152 8.7a 168 3.6a 164 3.tr
DM 119 1.5 148 8.6a 161 44a 157 2.5
Albuminuria
DM+SALT 0.1 0.0 0.3 0.3 0.4 0.2 1.3 14ab
DM+SALT+ 0.1 0.1 10. 8.0 15.0 12 79.0 59
NEP
DM+NEP 0.1 0.0 1.1 l.3 2.9 37ftC 6.3
DM 0.1 0.0 0.4 0.2 0.7 0.5 0.6 o.4
Inulin clearance
DM+SALT = DM+SALT+ DM+NEP DM = 0.32
0.66 NEP = 014d = 0.55
a P < 0.05 vs. baseline; b P < 0.05 vs. DM; c p < 0.05 vs. DM and
DM+SALT; d p < 0.05 vs. remainders.-
Conclusion: Development and progression of hypertension and ne-
phropathy in diabetic rats are enhanced by sodium overload and
unilateral nephrectomy.
Enzymatic profile analysis in malignant hypertension. L. Portela, J.E.
Plavnik, and F.L. Saragoca, M.A.S. Nephrology Department, Escola
Paulista de Medicina, São Paulo, Brasil. Malignant hypertension is a
clinical condition of the hypertensive disease that has become a rare
disease in developed countries, but not so rare in undeveloped coun-
tries. The hallmarks of malignant hypertension are diastolic blood
pressure greater than 130 mm Hg, grade III and IV retinal changes in
the classification of Keith et al, and vascular damage to different organs
such as heart and kidney. The most important clinical findings in
malignant hypertension are the retinal changes and a medical history
which may reveal symptoms of a severe hypertensive disease, usually
referred as headaches, weight loss, abdominal pain and scotomas. In
order to identify the enzymatic profile changes due to malignant
hypertension, 63 patients were studied and blood samples were ob-
tained for SOOT, SGTP, LHD, CPK, CK-MB and amylase. Patients
were classified into seven groups: normotensives (NT, N = 10);
essential hypertensives with normal renal function (EHN, N = 10);
malignant hypertensives with normal renal function (MHN, N = 6);
malignant hypertensives with end-stage renal failure (MHESRF, N =
8); malignant hypertensives with renal failure (MHRF, N = 11);
normotensive with end-stage renal failure (NTESRF, N = 9); essential
hypertensives with end-stage renal failure (EHESRF, n+ 10). Patients
with renal failure were not in a dialysis program. Our data show that
SOOT, SGPT, CPK, CK-MB and LDH did not change during the
malignant period. The mean values for amylase were statistically
significant for: MHN (138.5 12.4), MHESRF (182.3 32.4), MHRF
(198.4 29.5) when compared with control groups, NT (94.3 29.1),
EHN (108.7 29.4), NTESRF (64.7 13.7) and EHESRF (68.1
29.2), P < 0.0001. These data suggest that the vascular damage found in
malignant hypertension may cause an alteration in serum amylase and
are not related with renal function. This alteration could be a marker in
this situation.
Effects of phosphorus on the development of hyperparathyroldism In
rats with moderate renal failure. f. Bover, M. Rodriguez, A J. Felsen-
feld, M.E. Martinez, L. Machado, P. Trinidad, and F. Liach, Wads-
worth VA Medical Center and UCLA, Los Angeles, Cal(fornia, USA. It
is well known that a high phosphorus diet (HPD) exacerbates the
secondary hyperparathyroidism (HP'!') of renal failure. The deleterious
effect of phosphorus (P) could be mediated by decreased calcitriol
(CTR) levels or by a decreased calcemic response to parathyroid
hormone (PTH). The purpose of this study was to evaluate if a HPD
affects the development of hyperparathyroidism independent of CTR.
Methods: Normal rats [N, Creatinine (Cr) <0.3 mg/dl] and rats with
moderate renal failure (MRF, Cr 0.4—0.6 mgldl) were fed a 0.6% P
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(MPD) or 1.2% P (HPD). After 15 days, the MRF group received a
subcutaneous infusion of P1'H (Aizet miniosmotic pump) for 48 hours to
evaluate the calcemic response. Results (mean standard error):
N 0.6%P N 1.2%P MRF 0.6%P MRF 1.2%P
Cr 0.24 0.01 0.25 0.01 0.51 0.Ola 0.51 0.OIC
Calcium 9.58 0.07 9.95 0.06 9.79 0.08 9.64 0.12C
P 8.1 0.2 7.7 0.2 8.0 0.2 9.1 0.3
PTH 43 3 48 2 74 4 142 16bc
CTR 122 12 193 l5 68 6 139 l0
AMPc 57±4 73÷4a
Calcium post-PTH 18.6 0.6 12.1 0.6C
Cr, Calcium and P = mg/dl; PTH and CTR pg/mi; cAMP (cyclic
AMP) = pmol/min.
P < 0.05; a vs. N 0.6%P, ' v. MRF 0.6P, vs. N 1.2%P.
In moderate real failure, the HPD: (1) increased PTH levels indepen-
dent of CTR, and (2) blunted the calcemic response to PTH. However,
the MPD did not prevent the development of HPT in moderate renal
failure. CTR levels were higher in rats receiving a HPD than a MPD.
Conclusions: (I) In moderate renal failure, a HPD exacerbates HPT
because of a decreased calcemic response to PTH. (2) The effect of
PTH and calcium on calcitnol production might override the inhibitory
effect of phosphorus. (3) The low calcitriol levels may be responsible for
the HPT observed on a moderate P diet.
Lovastatin therapy in patients with hyperlipidemia and nephrotic protein-
uria. R. Poveda, R. GarcIa-Osuna, F. Moreso, L. Carreras, andJ. Alsina,
Servei de Nefrologla, Hospital Universitari de Bellvitge, Barcelona,
Spain. Hyperlipidemia associated with nephrotic syndrome is considered
secondary to renal disease. Moreover, increased serum cholesterol has
been reported among the factors that can contribute to the progression of
renal disease to glomerulosclerosis and renal failure. In the present study
we have investigated the results of lovastatin therapy in patients presenting
hyperlipidemia and nephrotic proteinuria, their effects on lipid serum
profile and the evolution of renal disease after treatment, namely GFR and
urinary protein excretion. Fourteen non-diabetic patients not receiving
steroid therapy were included in the study. Twelve were males and two
females, aged 35 to 69 (mean 52) and whose diagnosis determined by renal
biopsy were: focal glomerulosclerosis (9), membranous nephropathy (3),
IgA nephropathy (1) and amyloidosis (1). Mean GFR was 68 42 mI/mm
and mean proteinuria was 5.3 2.3 g/day. After a three month period of
low-cholesterol diet, the patients received lovastatin 20 mg/twice daily
during a mean period of nine months (range 5—15). Lovastatin reduced
total cholesterol by 27%, from 8.2 1 to 5.9 2.7 mMol/liter (P < 0.05),
LDL-chol by 30%, from 5.9 0.8 to 4.1 0.8 mmol/liter (P < 0.05) and
Apoprotein B by 26% from 1.4 0.2 to I 0.2 g/liter (P < 0.05). A slight
decrease was seen in HDL-chol by 6% from 1.2 0.2 to 1.1 0.1
mmollliter) (P = 0.04),but with an increase in HDUtotal chol by 28% from
0.14 0.04 to 0.18 0.03 (P = 0.02). VLDL-chol, Apoprotein A-I and
triglycerides were unchanged. No secondary effects were observed. GFR
and proteinuria did not change during follow-up. Treatment with lovastatin
is safe and effective in nephrotic patients. Further studies are required in
order to assess if long-term therapy can influence the progression of renal
disease.
Effects of Isradipine on arterial blood pressure, renal hemodynamic and
function. I.B.A. Silva, V.G.A. Fagundes, A. V.B. Duane, and E.A.
Francischetti, Rio de Janeiro State University, Rio de Janeiro, Brazil.
We studied the arterial blood pressure, renal hemodynamic and func-
tion in 15 patients with mild to moderate essential hypertension, 37 to 67
years old, taking isradipine (I), 2.5 mg b.i.d., during two months
compared with placebo (P), during two weeks. Renal evaluations were
carried out three hours after the morning dose of P or!. GFR and ERPF
were measured by clearances of creatinine and hippuran. Proximal
(PRNa) and distal (DRNa) reabsorptions of sodium were assessed by
lithium clearance (CL,). Renal vascular resistance (RVR) and filtration
fraction (FF) were obtained by standard formulae. Plasma renin activity
(PRA) and serum aldosterone (Aldo) were determined by radioimmu-
noassay. Twelve patients were analyzed statistically.
Group I (7 patients) Group 2 (5 patients)
Placebo Isradipine Placebo Isradipine
MAP 118.0 2.5 105.8 2.6a 116.0 2.9 101.2 3.la
ERPF 478.9 25.7 642.2 61.6C 573.4 70.2 499.5 64.3
GFR 127.4 8.7 105.4 6.l 110.8 2.2 119.0 2.6
RVR 114.3 9.7 104.3 lO.4C 122.0 12.8 124.0 16.0
FF 26.8 2.0 16.8 11b 20.3 2.8 25.4 3.8
CL, 22.8 1.3 32.5 33C 22.5 1.4 35.1 2.6C
CNa 2.9 0.2 2.9 0.3 2.5 0.3 3.0 0.4
PRNa 14.5 1.0 10.1 0.7a 12.3 1.3 11.7 0.6
DRNa 2.7 0.1 4.1 0.4C 2.7 0.2 4.5 0.4C
PRA 1.6 0.4 2.1 0.4 1.1 0.4 1.1 0.3
Aldo 124.7 17.7 140.7 26.9 168.8 21.7 139.4 26.7
Values are mean SEM. a P < 0.001;b P < 0.01; C P < 0.05.
Isradipine controlled the blood pressure, avoided the hyperfiltration
and maintained the sodium homeostases mainly in hypertensive pa-
tients that modulated their renal response, probably dilating afferent
and efferent glomerular vasculature.
Vasculitis and renal compromise. L. Montenegro, J. Gambino, C.
Aguirre, and A. Zucchini, Instituto de Investigaciones Medicas Alfredo
Lanari, UBA, Buenos Aires, Argentina. The common features of
systemic vasculitis in the kidney frequently have patterns of necrotizing
glomerulonephritis. During the past 10 years, 18 patients with a clinical
diagnosis of systemic vasculitis underwent a renal biopsy when they
presented altered urinary sediments (proteinuria superior to 2 g/24 hrs;
cylindruria or microhematuria) and/or plasmatic creatinine 2 mg% or
more (10 were women and eight men, with 38 years as an average age,
16 to 64). The clinical diagnoses were: Henoch Schönlein purpura (3);
Wegener's granulomatosis (3); systemic vasculitis (4); Goodpasture's
syndrome (5); cryoglobulinemia (2); and Behcet's disease (1). At the
moment of the renal biopsy the following elements were considered:
clinical manifestations, renal function, renal histology, and response to
corticoidal and immunosuppressing treatments (Azathioprine, Cyclo-
phospamide) in 16 patients. The renal biopsy was carried out within a
variable lapse of time as from the start of the clinical manifestation: in
15 patients within five months and in three patients after 12 months.
Histology showed: FNGN (11); extracapilar GN (2), focal and glomer-
ulosclerosis (3) diffuse proliferative GN (1), membrane proliferative ON
(1). Anti-GMB were positive in three patients. No granulomas were
found in the biopsis of the patients with Wegener's glomerulomatosis,
one of which was ANCA+. The clinical outcome was irregular: out of
four patients with a rapidly evolutive form, three died due to septic and
hemorrhagic complications within a four to six month period; four
patients could not be followed, and of the remaining 10, four entered
CH HD within an average of 45.5 months (I to 96) and six are under
control (36 to 120 months) with a stable renal function. Conclusion: The
renal pattern in our patients was severe, with a greater incidence of
FNGN. The rapidly evolutive forms with crescents had the poorest
prognosis. The treatment with immunosuppression and corticoid ther-
apy was satisfactory for the control of the clinical manifestations and
the preservation of the renal function.
Hepatitis C virus antibodies (anti.HVC) and cytomegalovirus (anti-
CMV 1gM) In patients on hemodialysis (lID) and after kidney transplan-
tation (TX). A. Zucchini, C. Aguirre, G. Benchetrit, V. Vazquez, and
M. Virginillo, Instituto de Investigaciones Medicas Alfredo Lanari,
U.B.A., Buenos Aires, Argentina. There is a high incidence of hepatic
diseases in patients on HD, and the most common cause is viral
infections. With the vaccination and epidemiologic rules, the hepatitis B
virus and other viral infections have decreased considerably. Serum
samples were investigated for anti-HVC and anti-CMV (measured by
immunoassay) from two groups of patients: Group I: 24 patients on HD,
11 males and 13 females, 17 to 66 years old (mean, 43.5) and mean time
on HD of 43.3 months (3 to 109). Group II: 27 renal TX recipient
patients, 17 males and 10 females, 22 to 57 years old (mean: 36.4) and
mean post-TX time of 53.6 months (2 to 144). All of them, but one, had
received immunosuppressive treatment with CsA. In the group I were
isolated anti-HVC(+) in 12 patients and five of them were further
anti-CMV IgM(+). Among them were three patients with HBsAg(+)
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who became seronegative during the last year. All of them were
transfused in a number of 2 to 57 and presented transitory increments of
transaminases in the last 12 months (except 2 of them with normal levels
at the survery time), without clinical signs of liver disease. In the group
II there were three patients with anti-HVC(+) and 14 anti-CMVIgM(+);
all of them were transfused in the prior-TX period and they were
seropositive in an average post-TX time of 100 months. One died due to
A.R.D.S. with the highest levels for anti-CMV. Liver biopsy was
performed in nine patients (7 on HD and 2 TX). Conclusions: The
incidence of anti-H VC(+) in our patients on HD was 66.6%; they were
related to time on HD and number of units of blood transfused. All the
patients with anti-HVC(+) developed chronic hepatitis in the biopsy. In
the TX group, the incidence of anti-HVC(+) was lower than group I
(11.1%), with a high incidence of anti-CMV(+), 51%, although related
with the immunosuppressive treatment. The three patients with anti-
HVC(+) were the ones who received more transfusions during the HD
period.
500 consecutive cases of acute renal failure (ARF) in a universitary
hospital. A. Zucchini, C. Aguirre, R. Martin, andJ. Firmat, Inst it uto de
Investigaciones Medicas Alfredo Lanari, U.B.A., Buenos Aires, Argen-
tina. From December 1977 to December 1991 there was an admission of
500 patients with ARF at the IDIM. The etiologies were divided into
three groups: (A) medical causes; (B) post-surgical, and (C) gyneco-
obstetrical. Group A: 261 patients (124 women, 137 men, average age
43.7, 14—83), 89 of which died (34%). The highest mortality was due to
hemodynamic shock (53%) and sepsis (37%). Group B: 70 patients (33
women, 46 men, average age 39.9, 15—84), 32 of whom died (39%). The
lighest mortality was due to biliar tract surgery (72.8%). Group C: 161
patients, 134 of whom died (3 1%). The highest mortalities were due to
Mondor syndrome, (37%) and hysterectomy (44%). Of the 27 patients
with a different obstetrical cause, eight died (30%) and of the remaining
19, three developed a CRF due to a cortical renal necrosis, confirmed
by biopsy. Out of 359 patients who survived the ARF episode, 64 did
not recover their renal function (39 among them had renal failure
antecedents, creatinine superior to 2 mg%) and two patients with
diagnosis through biopsy of acute tubular necrosis did not recover renal
function either. Conclusions: The global mortality of this series was
31%, ARF post-biliar tract surgery and due to sepsis can be held as the
most severe. Recovery of renal function, leaving aside the patients with
previous renal failure was 93%. Infectious complications were present
in 88% of the patients who died.
Study of lymphocyte populations (LP) in hemodialysis patients (HP)
treated with recombinant erythropoietin (rHuEPO). J.A. Rodriguez, I.
Caragol, R. Roca, A. Pelegrl, T. Espanol, J. Fort, A. Olmos, and L.
Piera, Services of Nephrology and Immunology, Hospital General Vail
d'Hebrón, Centro de Nefrologla Virgen de Montserrat, Barcelona,
Spain. In order to assess the effects of rHuEPO treatment on LP, a
prospective study of 15 HP was carried out. We studied seven males
and eight females with a mean age of 55.6(28—77) years pre-dialysis with
subcutaneous rHuEPO, the initial dose being 20 U/Kg. Tests were done
before and after three and six months of therapy. Moabs staining and
flowcytometer enumeration of the following LP was done: T lympho-
cytes (TL) (CD3), BL (CD19), T helper (CD4), T suppressor (CD8), NK
cells (CD3,CD16,CD56), NK like (CD3,CD16,CD56) and activated TL
(CD3DR). In vitro proliferative response to PHA mitogen and cutane-
ous tests were carried out in order to study T cell function. PRA (panel
reactive antibodies) were also measured. Results: Six months after
initiating treatment with rHuEPO, a significant increase in the following
LP was found: NK (66 72 vs. 293 209), NK like (15 17 vs. 139
activated LT(21 l7vs. 147± 123), and BL(151 101 vs. 221
147). No differences were found in the rest of LP studied in the level
of anti-HLA antibodies response or cutaneous tests with rHuEPO
treatment.
Increased Immunization after hepatitis B vaccination in patients under
treatment with rHuEPO. J.A. Rodriguez, R. Roca, A. PelegrI, M. Buti,
R. JardI, J. Bartolomé, J. Fort, J. Camps, R. Esteban, A. Olmos, and
L. Piera, Services of Nephrology and Immunology, Hospital General
Vail d'Hebrón, Ceniro de Nefrologla Virgen de Montserrat, Barcelona,
Spain. Beside the known action of rHuEPO on erythropoiesis, alter-
ations of the immune system related to the treatment with rHuEPO
have been described. The aim of our study is to analyze the effects of
rHuEPO treatment on the response to hepatitis B vaccination. Methods:
We studied 45 patients (27 males and 18 females) with a mean age of
57.98 13.4 years who had been dialyzed for an average of 45.7 30.5
months. The anti-HBs antibody titers were tested one year later alter
three doses of 20 tg. HB-DNA recombinant vaccine was given at 0, 1
and 2 months. Twenty-three patients (Group I) were in treatment with
rHuEPO; the other 22 patients (group II) had never received such
treatment. Results: Twelve patients of group I (52.2%) and only five
patients of group II (22.7%) became immunized, showing titers of
antibodies anti-HBs greater than 10 mIU/ml (P < 0.05). Six patients
from group I and only one from group II showed titers of antibodies
greater than 100 mIU/ml. Neither significant differences on age, gender,
duration of dialysis nor on the hematocrit levels previous to vaccination
were found between the 17 patients who became immunized and the 28
who did not. Nevertheless, a significant difference in response to
hepatitis B immunization was found between patients of group 1(70.6%)
and group 11(39.2%). Conclusion: Treatment with rHuEPO carries an
increased response after HB vaccination, suggesting that rHuEPO not
only corrects anemia but can also improve immunosuppressed status of
uremic patients.
Valuation upon the route of administration or rHuEPO in hemodialysis
patients (HP). A. PelegrI, R. Roca, J.A. Rodriguez, J. Fort, A. Mayol,
and J. Camps, Centro de NefrologIa 'Virgen de Montserrat," Barce-
lona, Spain. A prospective study was carried out in 35 HP in order to
evaluate the response to rHuEPO treatment given subcutaneously (s.c.)
in comparison with intravenous therapy (i.v.). During 12 months, 19
patients (Group I, Il males and 8 females with a mean age of 46.6 years)
were treated i.v., while 16 patients (Group II, 8 females and 8 males,
with a mean age of 62 years) were treated s.c. An initial dose of 40 U per
Kg alter dialysis was given to the former and 20 U per Kg before
dialysis was given to the latter. These dosages were doubled at six
weeks of treatment and later on each four weeks until the hematocrit
(Hct) reached the level of 30%. Later on a dose adjustment was done to
maintain such Hct. We evaluate the dosage, time elapsed to correct the
anemia, mean dose given for dialysis session, as well as the untoward
effects. Results: Before treatment, no significant differences were found
between the levels of Hct 18.4 2.6 and femtine (Fr) 150.8 176 of
Group I patients and the levels of Hct 19.5 1.48 and Fr 328.4 308
of Group II patients. Patients of Group I needed a mean of 3.36 months
to reach the desired Hct, while patients of Group II nedeed a mean of
4.18 months. The total dose of rHuEPO given for anemia correction
period was 880 399 U/Kg in the former and 581 310 U/Kg in the
latter (P < 0.05). The monthly Hct values were not different in both
groups, except in the fourth month. The mean dose given during the 12
months was 48 26.5 U/kg/dialysis in Group I and 32.4 17.1
U/Kg/dialysis in Group II (P < 0.001). Before starting the treatment,
47.3% of patients of Group I and 50% of patients of Group II had
hypertension. In 31.5% of the former and 31.2% of the latter a
developing or worsening hypertension was seen. Two patients of the
S.C. group suffered local hematoma. Conclusions: (1) With our sched-
uled dosage, the anemia was much faster corrected with intravenous
administration. (2) Lower doses of rHuEPO were needed when we used
subcutaneous administration. (3) No differences in hypertension side
effects were seen in both types of treatment.
Acute renal failure and sepsis. J. Vega, H. Borja, and C. Videla,
Hospital G. Fricke, Universidad de Valpara(so, Chile. Acute renal
failure (ARF) is common in sepsis. Since ARF is usually non-oliguric
and hypercatabolic, it might be expected that the severity of azotemia
and metabolic acidosis be higher, and the incidence of hyponatremia
and hyperkalemia, lesser. This prospective study attempted to deter-
mine whether septic ARE differentiates from non-septic ARF regarding
prognosis and evolution. We have investigated 132 (10%) of 1321
consecutive patients admitted to an ICU, who developed ARF. Sixty-
nine (52%) patients had septic ARE and 63 had (48%) non-septic ARF.
When comparing patients with septic and non-septic ARF, there were
no differences in the interval between ARF diagnosis and ICU admis-
sion (2 vs. 2 days), urine volume (1606 vs. 1765 ml), degree of azotemia
(BUN 85 vs. 82 mg/dl; creatinine 5.3 vs. 5.2 mg/dI), incidence of
hypercatabolism (10 vs. 19%) and hyperkalemia (19 vs. 24%). Signifi-
cant differences were only seen in the incidence of hyponatremia (52 vs.
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30%, P < 0.02) and metabolic acidosis (51 vs. 28%, P < 0.01). A similar
percentage of patients in both groups underwent dialysis and received
dopamine and furosemide at the onset of ARF. Mortality was higher in
septic ARF (60 vs. 36%, P < 0.002). Conclusions: (I) Hypercatabolic
and non-oliguric ARF had a similar incidence among septic and
non-septic ARF patients. (2) Metabolic acidosis and hyponatremia had
a higher incidence in septic ARF. (3) Mortality is higher in septic ARF.
(4) In both groups respiratory failure which required mechanical venti-
lation was associated with a worse prognosis.
Acute renal failure during pregnancy. J. Vega, M. Wiegand, C.
Videla, and H. Borja, Hospital G. Fricke Universidad de ValparaIso,
Chile. In the past, most of the acute renal failure (ARF) occurring
during pregnancy was due to septic abortion or severe hemorrhage. At
present, this is no longer seen. The purpose of this study was to clarify
the etiology, behavior and prognosis of ARF during pregnancy. We
prospectively studied 2794 patients who were admitted to our ICU.
From these, 311 (11.1%) developed ARF. Thirty (9.6%) of them were
pregnant women. The etiology of ARF was pre-eclampsia in 13 pa-
tients, septic abortion in six, and others causes in the remaining 11.
Thirty-three percent of ARF were oliguric. Oliguria was longer and the
severity of azotemia was higher in ARF due to septic abortion. Sixty-six
percent of patients developed hyponatremia, 30% metabolic acidosis,
20% hyperkalemia, and 43% of patients required mechanical ventila-
tion. Ninety percent of patients developed thrombocytopenia and 73%
hyperbilirubinemia, and 50% required dialysis. In one-half of patients
renal function recovered while in the hospital, 33% of patients were
discharged with some degree of renal impairment, and 17% died. During
follow-up seven of 10 patients who had renal impairment normalized
renal function and three went into chronic renal failure. Conclusions: (1)
ARF during pregnancy has a low incidence. (2) Pre-eclampsia is the
main cause of ARF in pregnancy. (3) Renal function usually recovers.
(4) Mortality is around 20%.
Oculo-renal syndrome without ANCA. J. Vega, R. Espinoza, H.
Borja, and C. Videla, Hospital G. Fricke, Universidad de Valparalso,
Chile. Nephropathies due to multisystem diseases may be associated
with ophthalmic pathology, such as episcleritis and orbitary pseudotu-
mor. These are, occasionally, the main clinical features which allow the
diagnosis and prompt treatment of a crescentic glomerulonephritis. We
herein report three patients whose diseases began with inflammatory
ophthalmopathy associated with absent ANCA and (—) immunofluo-
rescence on renal biopsy (BpR). Case I. Female, 68 years old. in
February 1991 she had left eye episcleritis which did not recover using
local steroids. Her creatinine (Cr) was 0.7 mg/dl, ESR 77 mm/hr and
hematuria(+). In April 1991, Cr 3.2 mg/dl, Cr clearance 15 mI/mm. BpR
showed 30% of glomeruli with crescents, necrotic loops and granulo-
mas. Treatment with prednisone and cyclophosphamide was begun.
Two month later Cr was 1.2 mg/dl, and ESR 7 mm/hr. Case II. Female,
33 years old in April 1990 she had left eye episcleritis which did not
recover with antiinflammatory drugs and local steroids. In December
1990 a CT scan showed a left orbitary pseudotumor. Cr was 0.9 mg/dl,
Cr clearance 75 mI/mm, and hematuria(+). BpR showed 36% of
glomeruli with crescents and vasculitis in one artery. Prednisone and
cyclophosphamide were begun. In July 1991, Cr was 0.5 mg/dl, Cr
clearance 165 mllmin, and hematuria(—). Case III. Female, 62 years old
April 1991, right eye episcleritis. Cr increase from 3.6 to 6.3 mg/dl in
seven days. BpR showed 60% of glomeruli with necrosis and 50% with
crescents. Prednisone and Cyclophosphamide were begun. Two
months later Cr 1.2 mg/dl, ESR 8 mm/hr. Conclusions: (1) Ophthalmic
inflammation may precede or be the only sign of a multisystem disease
able to lead to a rapidly progressive glomerulonephritis. (2) Its rapid
diagnosis can prevent the development of renal failure or cure it, if
already present, using immunosuppression. (3) Antineutrophil cytoplas-
matic antibodies may be absent in this oculo-renal inflammatory syn-
drome secondary to a systemic vasculitis.
Primary glomerulophaties. A clinical pathological study. Ch. Pedro
Méndez, M. Ca,nacho, and C. Asato, Servicio de Nefrologla, Hospital
National Edgardo Rebagliati Martins, Instituto Peruano de Seguridad
Social, Lima, Perd. From a total of 617 renal biopsies performed in our
service (HERM) from 1982 through 1992, clinical hitories and renal
biopsies from 114 patients undergoing primary glomerulopathies (GP)
were taken: the average age was 39 years and the masculine sex
predominated (55%). Histologically, the incidence was: membranous
proliferative (GNMP) 32%, focal and segmentary sclerosis (GNFyS)
25%, membranous (MGN) 19%, mesangial (GNMs) 12%, minimal
lesions (LMGN) 8%, and rapidly progressive 4%. Swelling and patho-
logical urinary sediment were present in 100% of the patients. Hema-
tuna, nephrotic syndrome and arterial hypertension were observed at
70%, 73% and 85%, respectively in patients with GNMP. Nephrotic
syndrome and arterial hypertension were present at 64% and 63% in
those with EF and SGN. Diverse grades of renal insufficiency at the
moment of diagnosis were present: 55% in MPGN, 69% in EF and
SON, 27 in MGN, and in MPGN 16% of sclerosed glomeruli (GE) and
71% of chronic interstitial nephritis (CIN), IgG 51%, 1gM 76%, IgA 22%
and C3 71% in capillary bundles. The most frequent in messangium was
1gM (44%) In EF and SON: 5% GE, 65% CIN, IgG 25%, 1gM 67%, IgA
17%, and C3 50%. In MGN: 6% GE, 65% CIN, IgG 74%, 1gM 89%, IgA
26% and C3 60% in capillary bundles in messangial 1gM was the most
frequent (27%). Biopsies of LMGN were optically normal and with no
deposits at immunofluorescence. From this investigation we conclude
that MPGN is the most frequent variety in our environment with the
major incidence occurring in young adults (43%). The clinical features
at the moment of diagnosis varied according to the renal histological
picture. The percentage by scierosed glomeruli and the concomitance of
chronical intersticial nephritis reveal the antiquity of the renal lesion
and make evident the too late diagnosis of glomerulopathies.
Renal amyloidosis. Cli. Pedro Méndez, F. Juan Fajardo, and M.
Camacho, Servicio de Nefrologla, Hospital Nacional Edgardo Reba-
gliati Martins, Instituto Peruano de Seguridad Social, Lima, Perá.
From a total of about 617 renal biopsies performed in our Service, thirty
of them (5%) corresponded to renal amyloidosis. Twenty-five patients
were analyzed. Nineteen cases (72%) were classified as secondary
amyloidosis. Ten cases were classified as TBC in lungs, three as
rheumatoid arthritis, (R.A.), three as spondylitis ankylosing, two as
multiple myeloma, and one case as systemic lupus erythematosus
(SLE). Ages of occurrence fluctuated between 30 to 85 years (average
40), with male predominance of 68%; time between the primary disease
and diagnosis of amyloidosis varied between 8 and 55 years for the
groups of patients with TBC, and from 9 to 20 years for carriers of R.A.
All the patients presented proteinuria at the beginning, twelve of them
debuted with nephrotic syndrome, and 45% were found with diverse
CR1 and ATH. Seven of the 19 patients initiated a periodic hemodialysis
program after 3 or 4 years of follow-up. A group of 5 patients was
catalogued as primary amyloidosis. A third group of our series is
confirmed by the two cases on inherited familial amyloidosis. The first
case (familial Mediterranean fever) was a girl who initiated the sickness
at 5 years with intermittent fever, then recurrent serositis; at 6 years she
developed nephrotic syndrome, and at age 12 started hemodialysis. The
second case (Muckle Wells Syndrome) was a male patient with recur-
rent urticana from birth; when he was 15 he developed severe neuro-
sensorial hipoacusia and infertility. When he was 50 he developed
nephrotic syndrome, and began hemodialysis at age 64. Colchicina was
used as a treatment with no solution to primary and secondary
amyloidosis. In one of the cases of inherited familial amyloidosis
(FMF), colchicina was effective in reducing the fever crisis. The renal
transplant was performed in two patients (secondary amyloidosis to
TBC) and the follow-up for two and four years is successful. The causes
of amyloidosis in our series are the same as the reports in national
literature, except for the two cases of inherited familial amyloidosis that
we include in our presentation.
Rehabilitation of patients on hemodialysls. Cli. Pedro Méndez, Slier.
may Aronés, L. Carrillo, P. Castro, and W. Chavarry, Servicio de
Nefrologla, Hospital Nacional Edgardo Rebagliati Martins, Instituto
Peruano de Seguridad Social, Lima, Perd. One hundred eighty evolu-
tions of patients on hemodialysis were studied (ERMNH) to determine
the index of corporal mass, maintenance of the habitual activity, and
the degree of rehabilitation according to Wetzels. The permanence of
hemodialysis in these series varies from 10 months to 15 years, thinning
out by 82% in less time than five years. The age fluctuated between five
and 33 years, 15.8% aged less than 18 years. We considered Grade I as
rehabilitation grade (01-rh) if the patient worked at his capability and
didn't need care. Grade LI (GIL-rh) was considered if the patient was
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disabled from working but required no major care. Grade III (Gill-rh)
was for disabled patients who required care. These three grades were
considered as categories A, B and C, according to the presence of
symptoms and dependence. Our results show: GI-rh, 44.97%; GIA,
26.98%; GIB, 13.23%; GIC 4.7%; GIl-rh, 25.39%; GIIA, 52%; GlIB,
14.8%; GIIC, 1.06%; GIll-rh, 29.63%; GIIIA, 18.52%; GIIIB, 10.58%;
GIIIC, 0.53%. The index of corporal mass (CMI) is obtained by dividing
the dry weight by the stature elevated to the square. The CMI was
determined in 174 patients. A CMI between 22—25 was considered
normal; less than that was considered to be malnutrition. The group
examined revealed CMI normal in 46 patients (73.56%). These, in turn,
were grouped into 46 patients (23.39%) with mild malnutrition and 55
patients (29.10%) with serious malnutrition. One hundred and one
patients (53.4%) from the group studied abandoned their daily activi-
ties. Seventy-seven from them (40.75), stayed disabled, and the 24
remaining (12.7%) changed to simplier activities. An adequate rehabil-
itation permits the patients to recover their family and social lives with
an adequate quality of life. Our results show that 45.5% (GIIBC +
GIIIABC) of the series compared to the 42.3% of patients who showed
mild to severe malnutrition and with the 40% couldn't keep their normal
activities.
Criteria on choice about the receptacles of renal transplantation.
Comparison of two methodologies. Ch. Pedro Méndez, and A. VidalOn,
Servicio de Nefrologla, Hospital National Edgardo Rebagliati Martins,
Instituto Peruano de Seguridad Social, Lima, Perd. One of the most
important criteria for deciding about a renal transplant is the disposition
of elements which may lead to successful experiences. This becomes
dramatically necessary when the transplantation program doesn't have
a large enough quantity of organs. Therefore, it's very important to rank
the patients according to priority. It's necessary to select the patients
objectively. There is a great need for these criteria to be well-defined.
Concerning this issue, we have qualified the risk factors in 192 patients
from the hemodialysis program of the Edgardo Rebagliati Martins
national hospital using the Toledo-Pereyra's score which qualifies with
different grades, the different clinical situations with the probabilities of
these risk factors happening in patients with renal failure. These are
categorized in grades: Grade I, low risk (0.60); Grade II, a higher risk
(0.60—0.90); Grade III, very high risk (0.90—1.10); and Grade IV,
extremely high risk. More than 1.1% in this group were patients
excluded who were older than sixty, diabetics, hyper-respondants,
patients with breathing, cardiovascular, hepatic, urologic or neurologic
severe pathology, as well as collagen's disease. The results according to
Toledo-Pereyra were: Grade I: 104 patients; Grade II: 67 patients;
Grade III: 15 patients; Grade IV: 6 patients. Results with habitual
criteria considered 103 patients as not eligible to be transplanted, while
89 were in conditions for being transplanted. This quantity is signifi-
cantly inferior to the total with a minimal risk (Grade I 104 patients),
and therefore they are prone to a successful transplant. We propose that
other groups state the same comparison and this could compel us to
make efforts to standardize the criteria for selection as a step toward a
successful organization of the National Program on Renal Transplants.
Prevalence of hepatitis B and C in hemodialysis and renal transplan-
tation programs. C/i. Pedro Méndez, A. Vidalón, and A. ColichOn,
Service of Nephrology, National Hospital "Edgardo Rebagliati Mar-
tins," Peruvian Institute of National Security, Lima, Perd. The pres-
ence of hepatitis B and C is great in patients who have been previously
transfused. There is scarce information to this effect in our country. We
aimed studied infection through HBV, HCV and measured the immu-
nologic answer to the anti-HBV vaccine in the non-reactive group. One
hundred and eight patients on hemodialysis, 39 renal transplants, and 18
personnel who worked in the hemodialysis center were studied. We
used clinical sheets and immunoenzymatic tests from third generation
(Abbot Labul) to detect silken markers anti-HCV, FIBsAg positive;
HBsAb, HBcAb and a researching on hepatic profile. Thirty-two
non-reactive people were injected with anti-recombining HBV-DNA
vaccine: 14 from hemodialysis, 11 from renal transplant, and 7 para-
medic personnel. One hundred percent of the patients had had blood
transfusions and 26% of them had a history ofjaundice. HBV and HCV
were detected at 69% and 38% in those on HD (18% were HBsAg
carriers), 82% and 81% from renal transplant (21% were HB5Ag
carriers) and in 99% and 6% from personnel (11% HBsAg positive),
respectively. The calculation of risk on post-transfusional hepatitis was
89% being predominant in transplants from those who had jaundice;
90% were positive to HBV and 11% to HCV. The vaccine responsive-
ness was 100% in paramedic personnel, fair in those on hemodialysis
(75%), and poor in those from transplants (25%). Conclusions: The
prevalence of HBV and HCV is high in the group studied: 75% and
45%, respectively. The risk of developing post-transfusional hepatitis is
elevated: 89% being high risk renal transplant. There was a great
number of HBsAg carriers: 21% in those from transplants, 18% on
hemodialysis, and 11% in the paramedic group. The antecedent of
jaundice was more related to hepatitis B (89%) than to hepatitis C
(11%). Viral infections, post-transfusional responsiveness has a hyper-
endemic prevalence in our studied population, and the immune protec-
tor for HBV was poor. The intent of this investigation was to motivate
a prevention, promotion and follow-up of patients and paramedical
personnel at risk of acquiring hepatitis in post-transfusional programs.
Reversal by indomethacin (IMT) of renal effects of dopamine (DM).
Probable relationship between dopaminergic and prostaglandin system In
anesthetized alpha-adrenergic blocked dogs. N.L. Yeyati, and G. Altem-
berg. The aim of this study was to investigate the possible involvement
of prostaglandin hormones (PGS) on the renal effects of DM. For this
purpose, five dogs (15—20 kg) were anesthetized with 30 mg kg of
pentobarbital and a-adrenergic activity block with phenoxibenzamine(POB) 1 mg kg. One hour after, inulin and 'I Hipuran dissolved in
normal saline were infused at a rate of 1 ml min'. After 50 minutes
equilibration, blood and urine were collected every 30 minutes for
control periods. Thereafter, 6 izg kg . min of DM were infused i.v.
at a rate of 0.3 ml min'. Ten minutes later blood and urine were
collected every 15 minutes for four periods. Twenty minutes after, 3 to
4 periods lasting 20 minutes were established. Urine was collected from
a catheter placed in the left ureter, blood pressure was monitorized
from a catheter inserted in an aorta through a catheter in the femoral
vein. Inulin, gamma activity of 'I Hippuran, osmolality and Na were
determined in all samples. Results are shown in the following table and
the statistically significance of the effects was evaluated by the two-
sided Student's t-test of pair differences where I = mean SE.
Control DM DM + IMT
V mI/mm 0.94 0.24 2.26 0.34a 1.43 0.33a
UNaV jsEq/min 105 39 222 44 140 30
Uom mOsm/kg 447 99 309 85 378 136
C1 mI/mm 33.5 4.1 41 34 28 2.7a
''i
mi/mm
69.5 9.3 89.5 93 63.2 8.8a
MBP mm Hg 140 7 156 2 152 2
a p <5%
In conclusion, inhibition of renal PGS synthesis by IMT partially
reverses the renal effects of DM. It may be postulated that DM
stimulates PGS synthesis which could act synergistically on the renal
effects. Apparently, this is the case with others substances such
acethylcholine, bradikinin and clonidine.
Hepatitis C virus in hemodialysis: Evaluation of seroconversion and
serologic methods. F. Fernández Mora, E. Sudrez, R. Ortega, A.
Jimeno, M.S. Garrido, C. Suarez, and J. Gonzalez, Nephrology Unit,
Gasiroenterology Section, Clinical Laboratory, General Hospital,
Huelva, Spain. Objectives: To know the seroconversion to anti-HCV in
a hemodialysis unit and to evaluate the serologic methods to detect
anti-HCV. Material and methods: 131 patients on HD (84 M, 47 F) were
studied. The mean age was 55.1 1.1 years (17—80); the length of time
on HD was 52 3.5 months (3—174), and they had received 16.1 1.7
blood unit transfusions (0—128). Anti-HCV was detected by ELISA-Ist
(E-1) and ELISA-2nd generation (E-2, ORTHO) in July 1991. Fifty-
three patients that were ELISA-2 (+) were evaluated by RIBA 2nd
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generation (CHIRON). In 106 patients of the total group of 131 an
ELISA-l test had been performed in July 1991; the remaining 25
patients were admitted to the HD program during the study period.
Seroconversion was considered in those patients which were ELISA-1
(—) in July 1990 and ELISA-1 (+) one year later. Results: (1) Serocon-
version: from the group of patients tested in July 1990 with ELISA-1, 32
were anti-HCV (+) and 74 were anti-HCV (—). Ten patients who were
E-1 negative in July 1990 were positive in June 1991, with a serocon-
version rate of 13.5%. Seven of those 10 patients had been transfused
with blood anti-HCV (—) during the study period and three had received
the last transfusion 8, 8 and 13 months prior to the study. (2) Serologic
HCV markers in July 1991:
N % RIBA(+) RIBAIND RIBA(-)
E-l(+)/E-2(+) 42 (32) 36/38 2/38 0/38
E-l(—)/E-2(+) 15 (11.5) 8/15 7/15 0/15
E-l(—)/E-2(—) 74 (56.5) — —
RIBA was undetermined in 9 patients: C22-3 was detected in 7 patients
and C33-c in 2 patients. Conclusions: (I) The seroconversion rate during
the period July 1990 to July 1991 was 13.5% in our series, without
observing a clear relation with blood unit transfusions. These dates
suggest the existence of other factors in the transmission of HCV. (2)
There is a high agreement between ELISA 1st and 2nd generation and
a higher sensibility with ELISA 2nd generation, that increases anti-
HCV 11.5%. (3) The high positivity of RIBA 2nd generation in patients
ELISA 2nd (+) confirms the validity of the last method as diagnostic for
HCV.
Hepatitis C virus in hemodlalysis: A clinical study. F. Fernández
Mora, R. Ortega, E. Suárez, A. Jimeno, F. Fernández Girón, A.
Dominguez, and J.M. Onaindla, Nephrology Unit, Gastroenterology
Section, Clinical Laboratory, General Hospital, Huelva, Spain. To
study the relation between elevations of serum ALT and serum AST
and hepatitis C virus, 127 patients (83 M, 44 F) on hemodialysis (HD)
were studied. All of them were HBsAg negative, the mean age was 55.3
1.2 years (17—80), the length of time on HD treatment 51.1 3.5
months (3—174), and they had received 16,1 1.8 blood unit transfu-
sions (0—128). From the admission into the HD program serum ALT,
AST, bilirubin and alkaline phosphatase measurements were performed
twice monthly. All patients had normal serum ALT when HD was
started. Acute hepatitis (AH) was diagnosed when ALT was> 5 times
the normal level, remaining elevated for at least one month. Acute
hepatitis non-A non-B was considered if there was not serologic
evidence for HBV, HAy, CMV or EB virus infection after exclusion of
drugs and other causes of ALT elevation. Acute hepatitis was consid-
ered resolved if ALT was normal one year later, and chronic hepatitis
considered to be resolved when serum ALT was transitorily or persis-
tently elevated after AH. A transitory increase of serum ALT was
considered if ALT > 1.5 normal levels in some non-consecutive
analysis. Anti-HCV with ELISA 2nd generation (ORTHO) was per-
formed at the moment of the study. Results: Anti-HCV (+) prevalence
was 43.3%. Serum ALT was normal in 115 patients (90.5%) at the
moment of the study. The evolution of serum ALT during HD treatment
was as follows:
Serum
ALT N % anti-HCV + % anti-HCV —
Normal 76 (59.8) 10(13.1) 66 (86.9)
T. increase 19 (14.9) 13 (68.4) 6 (31.6)
A. hepatitis 32 (25.2) 32 (100) 0
All acute hepatitis was non-A non-B, and 15 (46.8%) became chronic.
With chi-square a statistical relation (P < 0.001) was found between
alterations of serum ALT (either transitory or acute) and the presence
of anti-HCV. Conclusions: (I) In our series, every patient which showed
AH now has anti-HCV (+). This suggests that virus C is the principally
responsible for AH in HD. (2) The evolution of patients with AH and
anti-HCV (+) is chronic in at least 46.8% of them. (3) The prevalence of
anti-HCV (+) in patients with continuous normal ALT is 13.3%, and it
requires further study.
Renal protection in radiation nephritis (RN). L. Juncos, H. Cejas, S.
Baigorria, and J.C. Cornejo, Instituto Privado Especialidades Médi-
cas, COrdoba, Argentina. Renal failure in RN could result from tissue
ionization, arterial or glomerular hypertension, or compensatory hyper-
trophy. We studied the effects of a low protein diet (LP) and enalapril
(E, 50 mg/liter in drinking water) on renal function and structure of
uninephrectomized rats with radiated remnant kidney. Baseline serum
and urine electrolytes, systolic blood pressure (SBP), serum creatinine
(SCr), clearance (Cc,), UNa+ +V, UK+V and UI,ro,flV were not different
between control (C) (N = 6), E (N = 6), and LP (N = 6) rats.
SBP mm Hg UproteinV mg/IOO g/day
WeekO 16 0 16
C 84 4.8 124 9•3a
E 79 4.0 78 4.1
LP 85 5.8 123 55
6.0 1.1 15.1 7.6a
5.4 1.1 6.9 1.1
6.9 0.9 7.7 0.8
Se,. mg/dl C ,ng/min/100 g
0 16 0 16
0.5 0.02 0.9 0.06a
0.5 0.04 0.6 0.06
0.5 0.01 0.9 o.la
0.73 0.12 0.25 0.06a
0.88 0.12 0.80 0.09
0.88 0.2 0.48 l.l0a
Values are Means SEM. a p < 0.05 vs. week 0 (ANOVA).
At week 16, mean PRA (ng/ml/hr) were: C, 7.0 1.2; E, 13.2 2.5 (P
<0.05) and LP, 12.5 0.9 (P < 0.05). Glomerular sclerosis index: (0 to
4+) C, 3.4 0.1; E, 2.7 0.7 (P < 0.05); LP, 2.8 0.2 (P < 0.05).
Renal volume (ml): C, 0.45 0.02; E, 0.32 0.02 (P < 0.05); LP, 0.41
0.02 (NS). E improved all parameters. LP did not prevent hyperten-
sion or renal hypertrophy and was less effective in protecting the
kidney.
Cyclo-oxygenase and lipo-oxygenase inhibition in gestational hyperten-
sion. J.C. Fraire, and M.C. Fama, Hospital italiano, COrdoba, Argen-
tina. It has been suggested that pre-eclampsia may result from an
imbalance of either cyclo-oxygenase or lipo-oxygenase products or
both. We evaluated the outcome of pregnancy after combined therapy
with aspirin (ASA) and lysine clonixinate (L.Cl, a lipo-oxygenase
inhibitor) in 14 pregnant women at high risk for pre-eclampsia. Nine
were chronic hypertensives and 4 of them had had previous pre-
eclampsia and fetal death. The remaining 5 patients had transient
(gestational) hypertension. Five patients began therapy between the
14th and 20th week with ASA 100 mg/qd and L.Cl.250 mg/qd. Nine
started treatment after the 20th week with equal ASA dose but with 375
mg/gd of L.C1. Results: Thirteen pregnancies reached normal term and
delivered normal babies with the following APGARD: 7 had scores 7 to
8; 3 had scores of 8, and 3 had scores between 8 and 9. One baby was
born at 33 weeks with an APGARD of 7, progressed to 9 in 5 minutes
and had humidified oxygen for 48 hours. His weight was 1710 g.
Placentas were evaluated by ultrasound, according to the Grannun and
Hobbing classification. Six placentas were type I, 3 were type I-Il, 3
were type II, and 2 were type It-Ill. We conclude that combined
therapy with ASA and L.C1 in pregnant patients at high risk for
pre-eclampsia is probably safe for both mother and fetus.
Evolution of the serum levels of erythropoietin in kidney transplants.
M. Fernandez-Lucas, R. Marcén, J.J. Villafruela, J.L. Teruel, L.
Orcifino, P. Serrano, C. Gámez, and J. Ortuño, Hospital "Ramon y
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Cajal," Madrid, Spain. The two main processes in the development of
anemia in end-stage renal disease are the failure in the synthesis and the
alteration on the response of endogenous erythropoietin (eEPO). Cor-
rection of anemia in the immediate post-transplantation period and its
relation to eEPO levels are studied in the present work. We have
determined the levels of EPO in 36 patients on a regular basis between
the surgery for renal transplant and two months of post-transplant.
They were on treatment with cyclosporin A at standard doses. Group I
(22 patients) received recombinant human erythropoietin (rHuEPO)
within the hemodialysis period. Group 11(14 patients) did not receive
EPO substitution therapy, Taking the groups together, we observed a
decrease of EPO levels until the tenth day of post-transplant, and this
results in a parallel decrease of hemoglobin levels. Thereafter, a
progressive rise appears in both parameters. In Group 1, there is a sharp
decline of EPO levels in the first two days. There are also lower values
of hemoglobin than in Group II at two months post-transplant. In Group
II, we observed a rise in the EPO levels in the immediate post-surgery
period. The function of the graft did not modify the EPO leves in the
two groups. Conclusions: Our study suggests that eEPO levels in the
immediate post-transplant period depend on the therapy with rHuEPO
during hemodialysis. Patients without previous rHuEPO substitution
therapy have an initial rise of the eEPO synthesis and a prompt
recovery of the anemia. The therapy with rHuEPO annuls this initial
increase.
Use of protein/creatinine index (PRO/CRE) to assess protelnurla. M.
Rivera, J. Navarro, C. Quereda, N. Gallego, G. Garcia Otero, A.
Gonzalo, and J. Ortuño, Hospital Ramón y Cajal, Madrid, Spain.
Measurement of 24 hour urine protein excretion has a number of
disadvantages, mainly in old and very ill patients. On the other hand,
patient compliance is always in doubt and collection errors can occur.
On the contrary, spot samples have many advantages. One hundred
sixteen spot urine samples were collected from 20 patients (II male and
9 female) with stable renal function. Their mean C. was 66 mI/mm/I .73
m2 (range 2—128). Urine protein excretion was expressed in: g/liter,
mg/mm, mg/kg/day and mg/m2/hr. Correlation among those expressions
of proteinuna and PRO/CRE was obtained. We found that: (I) There is
an excellent correlation among the different forms of proteinuna
expression (r = 0.99). (2) There is a linear correlation among the above
mentioned expressions of proteinuria and PRO/CRE index (r = 0.79),
mainly in patients with Ccr >30 (r = 0.97). However, PRO/CRE index
was not realiable when Cr was <30 (r = 0.56). Finally, a PRO/CRE
index> 2.26 expresses a nephrotic range proteinuria and a PRO/CRE <
0.82 a non-significant proteinuria. Conclusion: PRO/CRE index is a
useful and reliable test in that it replaces 24 hour protein excretion,
except in patients with end-stage renal failure.
Cimetidine-aided creatinine clearance as a marker of glomerular
filtration in renal transplantation. P. Serrano, R. Marcén, L. Orofino, J.
Sabater, M. Mitjavilla, M. Fernández, J.L. Teruel, and I. Ortuño,
Departments of Nephrology and Nuclear Medicine, Hospital Ramón y
Cajal, Madrid, Spain. Creatinine clearance (Ccr) is not an accurate
marker of glomerular filtration rate (GFR) in renal transplant patients.
The overestimation of GFR by C. could be due to the hypersecretion
of creatinine by injured tubules. In 21 stable renal transplant patients on
cyclosporine, with serum creatinine (Sr) between 1.0 and 4.3 mg/dl
(mean 1.9 0.8 mg/dl), GFR was evaluated by clearances of 51Cr-
EDTA (Cr-EDTA) and/or inulin (C1), and by before and after
cimetidine administration (400 mg four times daily for two days). Ce,.
overestimates GFR measured by Cr-EDTA and/or C1,, (56 21 mI/mm
vs. 36 13 mI/mm; P < 0.01). S. rose after cimetidine from 1.9 0.8
mg/dl to 2.4 0.8 mg/dl; P < 0.001. The mean ratios of C. to CrEDTA
or C were 1.6 0.4 before cimetidine and 1.1 0.3 after cimetidine
(P < 0.001). Similar findings were obtained in 7 renal transplant patients
on azathioprine. In all cases Sr returned to pre-cimetidine values after
drug withdrawal. No side effects were observed. Our results confirm
that Ccr overestimates GFR in renal transplant patients. The cimetidine
administration improves the accuracy and precision of Ccr, avoiding
other expensive and inconvenient techniques such as Cr-EDTA or
inulin clearances.
Effectiveness of the prophylaxis in the recurrent urinary infection. Use
of an index. Norma Garrote, Laura Sarasino, and Susana Angeleri,
Renal Section, Departament of Medicine, Julio A. Méndez Hospital,
Bs.As., Argentina. Antimicrobial prophylaxis (P) of recurrent urinary
tract infection (UTI) is a recourse used over the last years in order to
suppress or lessen the reinfection. Since 1980 we have been using it in
patient carriers of recurrent UTI receiving no other treatment. We have
committed ourselves to assess and show mathematically the outcomes,
through an index of reinfection, as well as the subsequent answer in
patients in which the interruption of the prophylaxis was possible.
Twenty-eight patients have undergone prophylaxis with more than 3
recurrences in 6 months or 4 in a year; six of them had normal
urography; the 22 remaining patients have shown one or more renal or
urological abnormalities. The antimicrobial agents used were tn-
methoprim-sulfamethoxazole (TMP-SMZ) (80—400 mg), nitrofurantoin
(NF) 100 mg, cephalexin (CF) 500 mg, and norfioxacin (N) 200 mg. The
length of the tgatment was not less than 6 months, the maximum being
142 months (X 22). In order to determine the effectiveness of the
prophylaxis, an index of reinfection was established, connecting the
number of UTI with the following time related to six months.
N of UTI x 6 months
Index of reinfection =
following time
This index was applied to previous prophylaxis and intraprophylaxis on
each one of the patients. Average of the indexes was determined: the
previous was 4.34 and we have observed a decrease of the same to 0.34
(P < 0.001) intraprophylaxis. In order to assess the answer to the
different antimicrobial agents, the same index was applied, being 0.75
with TMP-SMZ, 0.28 with NF, 0.17 with CF and 0.00 with N. In 17
patients the prophylaxis was interrupted with a subsequent following of
7 to 81 months (X 17). The index of reinfection subsequent to the
prophylaxis on these patients showed a significant reduction with
regard to the previous one. We conclude that: prophylaxis is effective
during its administration and after it has been interrupted to achieve the
suppression or decrease of reinfection on patient carriers of recurrent
UTI. The efficiency of prophylaxis can be mathematically measurable.
Cephalexin and nitrofurantoin were the most effective antimicrobial
agents in our sample. We have not had experience with norfioxacin for
periods longer than 8 months.
Treatment of anemia with erythropoletln In uremic patients not yet on
dialysis. Sergio Kaplan, Ismael Habib, Roxana Valette, and Dora
Salas, Universidad Nac. de Tucumán, Cendial Tucumdn, Argentina.
Objectives: to determine the safety and efficacy of recombinant human
erythropoietin (rHuEPO) in the treatment of anemia in patients with
chronic renal failure not yet on dialysis. Patients: rHuEPO was given to
10 ambulatory patients with chronic renal failure (CRF), with creatinine
clearance lower than 30 mI/minim2; serum creatinine (SCr) higher than 3
mg/dl and anemia with hematocrite lower than 30%, for a follow-up
period of 4 months. Method: rHuEPO was given subcutaneously, with
initial doses of 40 U/kg three times a week. The target hematocrit range
was 35% in women and 40% in men. Doses were adjusted monthly and
they varied in each patient. Maintenance doses were 20—30 U/kg 3 times
a week (in two patients once a week). Measurements: hematocnit,
hemoglobin, iron stores, reticulocytes, and transfusion needs were
measured, and patients were asked about their quality of life. Renal
function and careful arterial pressure control were measured. Results:
Htc increased significantly from 27% before treatment to 36% in 4
months (P = 0.0001) in 100% of the patients, just as hemoglobin.
Reticulocytes increased from 1.1 to 3.2% (P = 0.0002). Four patients
previously hypertensive increased diastolic BP needing correction of
hypertension. Renal function valued by C. and the reciprocal of the
Sr over time did not show impairment in our patients; correction of
anemia was related to an evident improvement of the patients, increase
of their energy level and their quality of life. No patient needed
transfusions during treatment and no side effects were observed.
Conclusion: rHuEPO is efficient, safe, it does not impair renal function
and it does not increase BP significantly on predialysis patients.
Treatment of refractary nephrotic syndrome with cyclosporin A.
Sergio Kaplan, Roxana Valette, and Ismael Habib, Universidad Na-
cional de Tucumán, Cendial Tucumdn, Argentina. Objectives: to eval-
uate the effect of cyclosporin A (CsA) in patients with refractary
nephrotic syndrome (RNS) who did not respond to the treatment with
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prednisone and cyclophosphamide. Patients: Twelve patients with RNS
were classified according to the histology in minimal change disease
(MCD) (N = 2) membranous nephropathy (N = 4); focal and segmental
glomeruloscierosis (FSGE) (N = 3); and mesangioproliferative GN
(MPGN) (N = 3). Methods: CsA was given for 12 months at doses 5
mg/k/day. The doses were modified according to cyclosporinemia (RIA
using monoclonal antibodies) in order to maintain 100 ng/ml values. At
the same time prednisone was given. Measurements: to evaluate re-
sponse and tolerance to treatment, 24 hour proteinuria, plasma albumin
and renal function were studied. According to the answer they were
classified as complete remission (CR): proteinuria (Pr) inferior to 0.5
g/24 hrs; partial remission (PR): Pr inferior to 3 g/24 hrs; and no
response (NR): no change in proteinuria and persistence of NS. Results:
MCD: CR in 2/2 patients (100%); membranous nephropathy: CR in 1/4;
Pr diminished from 6.8 3.3 to 2.1 0.40 g/24 hrs; serum creatinine
(Scr) increased from 1.1 0.3 to 1.30 0.7 mg/dl. MPGN: CR in 1/3
patients; PR in 2/3 patients; Pr diminished from 5.3 2.8 to 2.5 0.34
g/24 hrs. FSGE: CR no patients; PR: 2/3 patients; NR: 1/3; Pr
diminished from 8.6 4.2 to 3.1 2 g/24 hrs and Scr increased from 1.9
1.1 to 2.6 2.3 mg/dl. Conclusion: administration of CsA improves
clinical development and seems to be effective in RNS. In MCD it
represents an efficient alternative therapy. In other glomerulopathies it
improves clinical development, allowing for partial remissions, with
few toxic effects due to low dose administered.
Presentation of renal osteodystrophy in uremic diabetic patients.
R.M.A. Moysés, A.M. Misael, G.M.F. Reis, S.C. Teixeira, L.M. Reis,
M.M. Marcondes, and V. Jorgeui, LIM 25 and LIM 26, Facultad de
Medicina USP, Av. Dr. Ama/do, São Paulo, Brazil. Diabetes mellitus
(DM) is a disease associated with an extensive list of complications,
involving most systems of the organism, including bone. Diabetic
patients with normal renal function frequently show osteopenia, and
uremic diabetics seldom have secondary hyperparathyroidism, that is
generally seen in uremic patients without DM. We compared the
clinical, biochemical and histomorphometric findings in two groups of
patients (group I = 13 diabetic patients; group 2 = 11 non-diabetic),
with the same age and time on dialysis. We studied these 24 patients
with chronic renal failure in the dialysis program, who presented signs
and symptoms of renal osteodystrophy (muscular and/or bone pain) and
with bone biopsy. We didn't see any difference in age (51.6 13.1 X
52.0 11.8) and time on dialysis (29.4 21.7 x 28.8 17.7 months).
Serum concentrations of calcium and phosphorus were similar in the
two groups, but alkaline phosphatase was lower in group 1. In this
group, the bone histology disclosed: 9 patients with adynamic bone
disease (AD), 2 with osteitis fibrosa (OF), and 2 with osteomalacia
(OM). In group 2 we found 3 AD, 4 OF 3 OM and 1 case of mixed
uremic osteodystrophy. Group I had trabecular volume (21.5 8.5 x
28.2 6.5%; P <0.05), osteoid volume (7.2 10.1 x 19.2 2.02%; P
< 0.05), osteoblastic surface (1.9 2.5 x 8.9 7.6%; P < 0.001),
osteoclastic surface (1.3 2.3 x 4.0 3.3%; P <0.01) and medullar
fibrosis (0.6 1.1 x 2.9 2.5%; P < 0.01) significantly lower than
group 2. Group I had also trabecular surface recovered by aluminum
greater than group 2 (25.9 30.7 x 11.1 26.2%; P < 0.05). In
summary, this study suggests that diabetic patients have a greater
incidence of adynamic bone disease and of aluminum intoxication.
Renal transplantation in children. C.D. Garcia, A. U/mann, L.
Deboni, E. Keitel, A.E. Bittar, G. Cantisani, S.P. Vito/a, E. Guerra,
M.L. Zanotelli, J.C. Goldani, A.E. Silveira, and V.D. Garcia, Servicio
Nefrologia Santa Casa de Porto Alegre, RS, Brazil. With the purpose
of discussing the specific problem of renal transplantation in children,
we reviewed our experience. From May 1977 to April 1992, 407
transplants were performed, 50 (12.3%) of them in 44 children between
2 and 15 years old. The mean age was 11.3 (SD = 3.3); weight varied
from 8 to 46 kg, and 66.8% of these children were female. The most
frequent causes of end-stage renal disease were: glomerulonephritis
(27.3%), obstructive uropathy (25%), and reflux nephropathy (15.9%).
Seven children were submitted to transplantation without previous
dialysis (14%). Cadaver donors were used in 11 cases (22%), living
related donors in 32 (64%), and non-related or distant relatives in 7
(14%). The immunosuppression therapy used until 1986 was azathaio-
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prime and prednisone, and after this year, cyclosporine was added.
OKT3 was used in the treatment of cortic-resistant acute rejection (6
cases). The survival of the patient and of the allograft, in the first
transplant with living donor, in the first year was, respectively, 94.9%
and 82.7%. After a mean follow-up of 26.16 months (±22.81), twenty-
one grafts were lost in twenty children, 6 due to acute rejection, 11 due
to chronic rejection. Two patients died with functioning allografts (lip
carcinoma and pen-renal bleeding), and 2 grafts were lost in the
pre-operatory period (I renal artery thrombosis and 1 patient died due
to ventricular fibrillation). Eleven children with obstructive uropathy
were transplanted, and 5 of them needed urological surgery before
transplantation. Four adolescents lost 5 allografts because of non-
compliance. We concluded that there are certain peculiarities to trans-
plantation in children, like technical difficulties owing to the size of the
children, the greater frequency of obstructive uropathy as the underly-
ing pathology, and non-compliance to treatment, especially in adoles-
cents.
Renal transplantation without previous transfusion in haploidentical
patients. E. Keitel, A. Bittar, A.P. Si/va, F. Gon calves, J.C. Goldani,
and V.D. Garcia, Nephrology Service of Santa Casa de Misericórdia of
Porto Alegre, RS, Brazil. From January 1990 to the present date we
performed 46 renal transplants with haploidentical related living do-
nors. Seventeen patients (group I) had no previous transfusion and
received prophylactic immunosuppression with triple therapy
(Csa+Aza+Pred). Twenty-nine patients that had been transfused pre-
transplantation were randomized into two groups to receive or not to
receive cyclosporine. Eighteen patients received triple therapy (group
II) and eleven patients received only azathioprine and prednisone
(group III). The number of acute rejection episodes and the graft
survival were analyzed at six months. All groups were matched in age,
sex and race. Group II had less acute rejection episodes (0.66 0.48)
than group 1(1.23 0.75) and group III (1.36 0.67). The graft survival
rate was similar among the 3 groups (I: 100%; II: 94.4%; III: 90.9%).
One patient in each group (II and III) died with a functioning graft due
to sepsis. In this preliminary study, even though the patients with no
transfusion pre-transpiantation (group I) had more episodes of acute
rejection than patients that did receive blood transfusion and were
taking cyclosporine (group II), both groups had the same graft survival
at six months. There was no significant difference between group I and
III in episodes of acute rejection or in graft survival. We believe that if
cyclosporine is going to be part of immunosuppression protocol,
deliberate blood transfusion pre-transpiantation is not necessary.
Outpatient clinic of pediatric nephrology: 2537 referrals from 1988 to
1991. C.D. Garcia, A. Uhlmann, P.A. Pires, A.C. Ribeiro, S.M. Meira,
A. Rocha, C. Renk, M. Ortiz, R. Sal/es, and V.D. Garcia, Pediatric
Nephrology ISCMPA, Porto Alegre, RS, Brazil. To provide a picture of
children's referrals to an outpatient clinic of pediatric nephrology in a
General Hospital, we analyzed the number, the reasons for referral, and
the renal diagnosis over a 42 month period. Between June 18, 1988 and
December 31, 1991, 2537 pediatric patients were referred to pediatric
nephrology, outpatient clinic for evaluation and treatment of renal
disorders. More than 40% of patients were under 2 years of age, and
32% between 3 and 6 years old. Females accounted for 61% of the
referrals. The most common reason for referral was urinary tract
infection (UTI) 1446(57%), followed by miccional disorders as enuresis
175 (6.9%), glomerulopathies 147 (5.9%), and abnormal urinalysis
including hematuria 122 (4.9%). From 427 children referred for urinary
tract infection, who completed all the protocol investigation (US, VCU
and DMSA), 88 (20.7%) had vesicoureteral reflux and 38 (8.9%) had
other urinary tract anomalies, and 301 (70.4%) had normal urinary
tracts. During this period 42 patients with ESRD were followed: 50%
had urological anomalies including reflux nephropathy and obstructive
uropathy, 23.9% had glomerulonephntis, and 14.3% had hereditary
familial nephropathy. We conclude that the majority (55%) was less
than 6 years old and the most frequent renal diseases found were: UTI,
vesicoureteral refiux, and glomerulopathies.
Renal transplantation in Cochabamba. J.P. Barrenechea, A. Sauma,
R.5. Arze, G. Urenda, J. Patiño, and R. Claure, Centro Medico
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Quirurgico Boliviano Belga, Caja Petrolera de Salud, Cochabamba,
Bolivia. We present our initial experience with 15 grafts on 15 patients
at the second city in Bolivia. In 1980 the first transplant took place, and
since 1987 the other 14 were performed at a private institution and the
National Health Service. All donors were living, but 3 were unrelated.
They were aged 18—63 years, mean 37 years. The primary diseases
were: glomerular 9, tubulointerstitjal 4, and in 2 unknown. Eight
patients were on IPD and the others on HD and/or IPD. Eleven patients
were blood group 0, and HLA typing was performed locally in the last
6 cases showing a one-haplotype match for A, B and DR antigens.
Donor nephrectomy took place trough a median laparotomy in 6.
Kidneys were flushed with a Collins-type solution prepared locally.
Arterial anastomosis was termino-terminal in 9. Ureteral implantation
was according to Gregoir's. Warm ischemia time was 1—10 minutes and
cold ischemia 20—150 minutes. Urine output occurred immediately in
14. Immunosuppression was comprised of prednisone and azathioprine
in all plus CsA in only one. Complications occurring at one institution
were: acute rejection 2, arterial thrombosis and wound infection 2,
sepsis, ureteral leak and lymphocele 1. Late complications were hyper-
tension 7, chronic rejection 2 and policitemia 1. Two patients died from
sepsis and one died following an embolic bowel necrosis. Thirteen
patients were fully rehabilitated. Our program is expanding due to close
cooperation among the medical staff and the ability to perform cross-
matching and HLA typing locally. The rehabilitation achieved is
satisfactory, cost-effective and superior to any other form of replace-
ment therapy.
Hypertension in pregnancy (HT-P) at public hospitals (PH) and na-
tional health service (NHS). R.S. Arze, E. Alarcon, and W. Salinas,
Hospital Materno Infantil German Urquidi and Caja Nacional de
Salud, Cochabamba, Bolivia. HT-P is an important cause of morbidity
and mortality for both mother and fetus. The consequences depend on
medical care and follow-up before term and after delivery. In order to
compare the clinical significance of HT-P in PH and NHS, we analyzed
the records of 371 patients admitted since 1982. We looked at age,
number of pregnancies, follow-up before delivery, past medical history,
maternal and fetal events. The prevalence of HT-P was 0.58%, mean BP
148/105, age 16—49 years (mean 29), and multiple pregnancies in 62%. In
PH, 84% had no clinical follow-up before delivery and in 92% no
relevant past medical history was recorded among NHS patients: 17%
had documented renal disorders, 12% had previous hypertension, and
3% were diabetic. Maternal complications were minimal at NHS, while
at PH 13% had eclamptic seizures, 11% were oliguric, 8% comatous,
and 5% jaundiced. Fetal complications were similar, but at PH 25% of
the fetuses died. Management comprised anti-hypertensive drugs (56%
PH vs. 8% NHS), anticonvulsants (80% PH vs. 2% NHS), induction of
pregnancy (40% PH vs. 78% NHS), and Caesarean section (60% PH vs.
22% NHS). Blood pressure came back to normal in 81%. Maternal
death at PH was 15%. We conclude that prevalence of HT-P, age and
multiple pregnancies were similar in both hospitals. At NHS we found
better information on past medical history and follow-up before deliv-
ery, minimal maternal complications, and no deaths, while at PH
maternal complications and deaths, and fetal deaths were higher despite
a more aggressive approach to delivery.
Acute renal failure at Centro Medico Quirurgico Boliviano Belga. R.S.
Arze and J. Ramirez, Centro Medico Quirdrgico Boliviano Belga,
Cochabamba, Bolivia. In order to know the incidence, main risk
factors, concomitant organ failures, clinical course and management of
acute renal failure at our institution, we analyzed prospectively 41 cases
between June 1989—1991. The annual incidence was 13.6 cases. Maid
female ratio was 1:1. The ages were 18—85 years, with 54% older than
60. Medical/surgical ARF ratio was 1.3:1, with a clear predominance of
prerenal and renal causes. There was oliguric ARF in 76% and at
discovery severe (s-creat > 3 mg/dl, BUN > 100 mg/dl) in 59%. The
main risk factors were: severe tissue hypoxia due to concomitant
circulatory and/or respiratory failure in 67%, aminoglycosides in 30%,
and exposure to non-steroidal anti-inflammatory agents in 16%. All
patients had other associated organ failures, including 61% with heart
disease and 43% with respiratory disease. Forty-four percent required
dopamine as a pharmacological support for the circulation, and 15%
required intra-aortic balloon contrapulsation in order to improve a low
cardiac output. Twenty-five percent required dialysis. Overall mortality
was 50%, 70% being in those with three organ failures and 90% in those
with four organs in failure. We conclude that ARF in the hospital setting
is frequent among elderly patients, with other organs diseased, increas-
ing the mortality with an increasing number of organs in failure, despite
pharmacological, hemodynamic and dialytic support.
Use of percentage reduction of urea In adequate hemodlalysis (lID).
Dres. Dominga Jiménez Guzmdn, Jesds Romero LOpez, Alejandro
Trevino-Becerra, Manuel Torres-Zamora, Delfina Reyes de los S.
Specialties Hospital, National Medical Center, "XXI Century,"
I.M.S.S., Mexico, D.F., Mexico. The urea percentage reduction (UPR)
is a method which allows for the performance of the kinetic model of
urea in an easier way than Gotch's and Sargent's original formulae, but
with the same efficiency and reliability. Objective: To measure the
quantity of dialysis determined by the UPR method, and compare with
Ks/V in ten HD stable patients, without complications. Materials and
methods: Blood samples were obtained to determine pre- and post-HD,
BUN and creatinine obtained Ks/V from UPR with the following
formula:
K1N = 0.23 x UPR — 02.84
The statistic analysis was done with the Student's 1-test and correlation
coefficient. Results: Pre- and post-HD BUN values were 82 22 and 29
10 mg%, respectively (P = 0.005; creatinine pre-HD was 10 3 mg%
and post-HD 4.6 1.2 (P = 0.005). The Ks/V obtained was 1.18 0.22
and by (UPR) 1.16 0.20, without a significant difference (p 0.16)
and positive correlation coefficient was found between two methods
(r+0.98 with P = 0.001). Conclusions: Ks/V values obtained by PRU
were similar to those obtained by the traditional method. A positive
correlation was found, highly significant between these methods, which
allows us to conclude that the PRU is a simple and effective method to
carry out calculations of kinetic urea in hemodialysis patients. (K =
urea depuration of HD filter; = time in timutes in HD; V = volume
distribution of urea).
Slow progression of chronic renal failure through uric acid and serum
phosphorouS. Alejandro Treviño-Becerra, Catalina Palomares, Jesás
Romero, Pedro Trinidad, and Dominga Jiménez, Nephrology Depart-
ment, Specialties Hospital National Medical Center "XX! Century,"
I.M.S.S. Mexico City, Mexico. We have shown that patients with mild
chronic renal failure, taking an isocaloric diet low in proteins, contain-
ing 1 mg purines, 10 mg phosphorous kg/body wt for four weeks, and
alternated with a purine-free diet for 4 weeks, an increase in glomerular
filtration (GF) is obtained, decreases in blood urea (U) and uric acid
(UA) occur, and the progression of chronic renal failure is delayed foi
long periods. In this study we show a group of S patients (41 years X
age) with different renal pathology, who received therapy during 54 to
77 months. Also, uric acid by phosphorous product was obtained; it is
considered by using an index of nutrition and progression in uremia.
Results are as follows:
Urea Uric acid P
Ce,. Produce
mI/mm mg% UAxP
Initial 24.2 6.8 85.8 19.9 5.3 1.6 3.7 0.0 19.4 7.8
Final 22.4 11.6 82.8 31.1 4.8 2.3 3.2 0.6 15.9 8.9
This treatment is effective for more than 6 years in delaying the fall of
GF. Patients are asymptomatic, have good nutrition and normal blood
pressure and keep in good health. Furthermore, it is feasible that urates
and phosphorous avoid damaging remnant renal tissue. It is concluded
that a diet low in purines alternated without purines, with high doses of
allopurinol, decreases uric acid, preserves residual renal function, and
product AU xP can be considered a uremic index which measures
progression and nutrition.
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Implantation of Tenckboff catheter (C) by percutaneous method: An
eighteen-month experience. Jesds Romero Lopez, Alejandro Treviño-
Becerra, Valentin Fuentes, and Manuel Torres-Zatnora, Specialties
Hospital, National Medical Center "XXI Century," I.M.S.S. Mexico
City, Mexico. Our experience was analyzed in which we implanted the
Tenckhoff catheter first by percutaneous method (implanted directly,
31c), and then by using a copper wire. The study consisted of 98 C,
implanted in 94 patients with a successful initial function of 89 (95.9%)
and late dysfunction of 25 (25.5%), due primarily to migration and
obstruction by omentum; all the dysfunctioning C required surgical
replacement with the exception of 4 that were withdrawn and replaced
by percutaneous method. When comparing the initial function of the C,
the first 31 with the remaining 38 in relation to the use of the copper wire
to implant the C, it was found that without a wire, initially 19.3%
dysfunctioned with copper wire 4.4% (P <0.000!). The effect that the
direction of the subcutaneous tunnel had on the dysfunction was
evaluated and it was found that with the horizontal tunnel it was 48.7%,
while with the vertical or oblique tunnel the late dysfunction was
reduced to 12% (P < 0.001). Laceration of intestine or omentum was
seen in five cases (5%), but mortality was zero. The application of the
C by percutaneous method with copper wire and subcutaneous vertical
or oblique tunner is a useful technique, and good results are obtained
for the long term without complications.
Isolation and characterization of plasmic compounds of low molecular
weight In hemodlalysis (HD). M.C. Martin Mateo, J. de Ia Rosa, J.
Bustamante, and V. Perez Diaz, Departamento de Bioquimica de Ia
Facultad de ciencias y Servicio de NefrologIa del Hospital Universi-
tario, Valladolid, Spain. In spite of the numerous studies which have
been performed to isolate and characterize the "middle molecules"
(MM) in uremia, at present their chemical structure is still not clear.
Our investigation is directed towards the isolation and posterior study
of the chemical structure of MM. In 10 patients undergoing hemodial-
ysis (HD) with polyacrilonitrile membrane, the MM were isolated both
before and after HD by molecular exclusion chromatography with
Sephadex G-lS. The peaks were lyophilized and passed through DEAE
Sephadex A-25 ionic interchange chromatography. The fractions eluted
by such chromatography were submitted to infrared spectroscopy
(Cignns Spectrophotometro 100 in BrK pills) and to a nuclear magnetic
resonance of Hi and Cl3. The presence of MM was verified in the
patients on HD, descending after HD treatment. By means of mass
spectroscopy (Hewlett-Packard GcfMS Mass Spectro), the existence of
two well-defined peaks at 220 and 222 Daltons was found. The results
obtained through infrared spectroscopy indicate the existence of vibra-
tions corresponding to carboxylic and terminal aminic groups, which
are not of a peptide nature given their placement in this spectrum.
Induction of, free oxygen radicals (FOR) by metals in hemodialysis
(ND). M.C. Martin Mateo, C. Nieto, J. Bustamante, A. De Paual, J.
Nunez, A. Mendiluce, and F. Dapena, Departamento de Bioquimica,
Facultad de Ciencias, Valladolid Servicio de NefrologIa, Hospital
Universitario, Valladolid, Spain. The induction of free oxygen radicals
(FOR) by metals, such as mercury, copper, lead and cadmium, has been
studied thoroughly. We have studied the effect of copper (Cu) and its
inhibition by cistein in vitro in red blood cells of patients on HD. Two
groups were studied: 10 healthy individuals and 10 patients on HD
before and after HD, treating the blood cells with different concentra-
tions of Cu and cistein. The percentages of oxyhemoglobin (OxyHb),
desoxyhemoglobin (desoxyHb), methemoglobin (metHb) and malonil-
dialdehyde acid (MDA) were determined in vitro for both groups. An
increase in the percentage of hemolysis and MDA with respect to the
control group has been found, being higher after HD thus indicating a
production of FOR through HD. The percentage of hemolysis of the
blood cells is raised when incubated with Cu and lowered when cistein
is added, a fact which reveals the inhibiting effect of cistein on
hemolysis.
Angiotensin converting enzyme (ACE) and hemodialysis (ND). A.
Mendiluce, J. Nuñez, R. Bustamante, C. Rubio, N.S. Jabari, M.
Arranz, F. Dapena, and J. Bustamante, Servicio de Nefrologia, Hos-
pital Universitario, Valladolid, Spain. The angiotensin converting
enzyme (ACE) is located on the surface of the pulmonary vascular
endothelium. Thoraxic or mechanical stimulation of this endothelium
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produces a plasmatic elevation of ACE levels. During HD a decrease in
oxygen tension takes place; this hypoxia is secondary to the pulmonary
dysfunction produced by the activation of the complement and the
trapping of leukocytes in the vascular bed of the lung. The objective of
this study was to determine the ACE plasma levels in relation to the
effects of HD on pulmonary stimulation and variations of plasma
volume. A control group of 5 healthy individuals with ACE levels of
29.6 16.4U/liter were studied, as well as a group of hypertensive HD
patients (5 men and 6 women, with an average age of 53.3 19.6 years)
who were dialyzed with a membrane of 1 m2, for 4 hours 3 times a week.
ACE levels were determined before and after HD by a colorimetric
enzymatic method, obtaining the following values: before HD, 47.16
22.7 U/liter and after HD, 50.1 23.9 U/liter; the elevation is significant
with P < 0.1. In 2 patients who presented a residual diuresis of I liter,
the values decreased. There was a significant elevation (P < 0.05)
between the control group and ACE levels following HD, as well as
between ACE levels after HD and plasma volume losses produced by
the HD. In conclusion, ACE levels rise with HD, being related not only
to the bioincompatibility of the membrane, but also to the plasma
volume lost during the HD.
Acute phase reactans C3a and 132 microgiobulin (132m) in hemodialysis(HD). R. Bustamante, C. Rublo, J. Bustamante, N.S. Jabaiy, A.
Mendiluce, J. Nunez, A. Palencia, F. Dapena, and M. Arranz, Servicio
de NefrologIa, Hospital Universitario, Valladolid, Spain. The bioin-
compatibility of HD membranes is a stimulus for the formation of
proteins of the acute phase of inflammation, which can elevate the
levels of 132m levels both in serum and in poorly perfused tissues. We
have studied the interrelations of acute phase reactans, such as granu-
locyte elastase and fibronectin, with both 132m as well as the C3a
complement fraction in 65 patients undergoing HD. Cuprophane mem-
branes were used for dialysis in 35 patients, EVAL in 10, and polysul-
fone in 10. Samples were taken at 0, 5, 30, 120 and 240 minutes of HD.
The 4 groups were dialyzed with their respective membranes for over 6
months, for 4 hours 3 times a week. The membrane surface was 1 m2.
Granulocyte elastase and f32m were determined by immunoenzyme
assay, fibronectin by nephelometry, and C3a radial immunodiffusion. In
the cuprophane group a significant correlation was found between 13m,
elastase, and C3a, but not with fibronectin. There was a correlation
between C3a and fibronectin in the EVAL group, while a correlation
between f32m and elastase with C3a appeared in the PAN group. The
group using polysulfone showed a correlation between /32m and elas-
tase, and between fibronectin and C3a with leukocytes. These findings
support the existence of a stimulus of the acute phase reactants as well
as for C3a on the liberation of m in HD.
Prednisone plus clorambucil treatment of membranous glomerulone-
phritis (GN) with progressive renal insufficiency. A. Araque, M. Praga,
A. Mazuecos, A. Andrès, J.R. Mosquera, T. Ortuño, andi.L. Rodicio,
Hospital 12 de Octubre, Madrid, Spain. Although many cases of
idiopathic membranous GN present spontaneous remissions, the ap-
pearance of progressive renal insufficiency has an ominous prognostic
significance. We have treated 4 male patients with membranous GN and
deteriorating renal function with a treatment protocol of prednisone (I
mg/kg/day first month; 0.5 mg/kg/day second month; 0.5 mg/kg/alter-
nate days for another four months) and clorambucil (0.1—0.2 mg/kg/day)
for six months. Their ages oscillated between 25 and 67 years (x 37
19). All of them presented nephrotic syndrome, with proteinuria 9.3—20
g/24 hr (x 14.3 5) at the start of treatment, serum creatimne 1.8—2.5
mg/dl (x 2.2 0.3) and creatinine clearance 32—51 mI/mm (x 42 9).
Renal biopsies, performed 2—34 months before (10 IS) showed
membranous GN stage II in 3 cases and stage III in the remaining. After
the treatment, renal function had normalized in 3 cases and improved in
I. Two patients presented complete remission (proteinuria <0.2 g/24
hr), one patient partial remission (proteinuria <3.5 g/24 hr), and the
remaining persisted with nephrotic-range proteinuria, but with a reduc-
tion higher than 50% of initial value and disappearance of hypoalbu-
minemia. The favorable effects of treatment on renal function and
proteinuria were apparent after the second month of treatment. Fol-
low-up after the end of the treatment has been 12—29 months (19 8):
renal function remained stable, last creatinine being 0.8-1.6 mg/dl (1.2
0.3), creatinine clearance 52—87 mI/mm (72 16) and proteinuria
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0—5.7 g/24 hr (2.2 2.7). We have compared these four cases with 19
other patients with membranous ON and progressive renal insufficiency
who did not receive immunosuppressive treatment: none of them
presented spontaneous remission, and renal function continued to
deteriorate in all but I. At the end of follow-up, 9 cases had started
dialysis and the serum creatinines of those remaining were 1.8—7.2
mg/dl (3.6 1.5). In conclusion, treatment with prednisone plus
clorambucil in oral administration for six months can stop the progres-
sion to terminal renal insufficiency in patients with membranous ON
and deteriorating renal function.
Long-term evolution of idiopathic non-treated membranous glomeru-
lonephritls (GN). A. Mazuecos, M. Praga, A. Araque, E. Hernandez, R.
Sanchez, J.M. Morales, and J.L. Rodicio, Hospital 12 de Octubre,
Madrid, Spain. The indication of immunosuppressive treatments in
idiopathic membranous ON is a subject of considerable debate. We
have analyzed the evolution of 46 patients with membranous ON who
did not receive treatment (30 males, 16 females) aged 12—81 years (x
47.6 17.7). The duration of follow-up was 60 40 months. Clinical
presentation was nephrotic syndrome with normal renal function in 39
cases (84%), non-nephrotic proteinuria with normal renal function in 4
(8.6%), and nephrotic syndrome with renal insufficiency (serum creat-
mine > 1.7 mg/dl) in 3 (6.5%). At the end of follow-up 26 patients
(56.5%) (Group 1) had normal renal function: twelve of them (46.1%)
were in complete remission (proteinuria <0.5 g/24 hr), 11(42.3%) in
partial remission (proteinuria < 3.5 g/24 hr with a reduction higher than
50% of initial values), and 3 (11.5%) maintained stable proteinuria. The
onset of the remissions oscillated between 12 and 48 months after the
diagnosis (x 28 12), and only 2 cases presented relapses in the
follow-up. The remaining 20 patients (43.5%) (Group II) developed
renal insufficiency, progressive in all the cases but 1. Nine of the Group
II patients were on chronic dialysis at the end of follow-up and the 11
remaining had a serum creatinine of 3.5 1.5 mg/dl. With the exception
of two patients, the onset of renal insufficiency was observed within the
first 30 months after the diagnosis. There were significant differences
between both Groups in age (Group I 42,5 16 years; Group II 55.2
18; P < 0.05), initial mean arterial pressure (95 9.8mm Hg vs. 102
12; P < 0.05) and initial serum creatinine (0.9 0.2 mg/dl vs. 1.4 I;
P < 0.05), but not in the histological stage or in the initial proteinuria.
Fifty percent of males and 31% of females developed renal insuffi-
ciency, but without statistical significance. In conclusion: (1) A clear
dual evolution can be observed in the spontaneous long-term evolution
of membranous ON, with half of the patients reaching spontaneous
remissions, whereas almost all of the remaining patients developed
progressive renal insufficiency; (2) Both ways of evolution, to sponta-
neous remissions or to renal impairment were defined within the first 3
years of evolution in the great majority of cases; (3) Given the high
number of spontaneous remissions, we think that immunosuppressive
treatments should be restricted to those patients that develop renal
insufficiency.
Echographic study of parathyroid glands in patients on chronic hemo-
dialysis. R. Sanchez, A. Ramos, M. Praga, C. Campo, f.M. Alcazar,
and F. Granados, Hospital 12 de Octubre, Madrid, Spain. The recent
introduction of intravenous calcitriol in the treatment of secondary
hyperparathyroidism of patients on chronic hemodialysis has permitted
a non-surgical approach to advanced cases of this complication. Mea-
surements of parathyroid gland volume could offer another estimation
of the effectiveness of this treatment. Modern ecographic techniques
allow the measurement of enlarged glands, whereas normal non-
hypertrophic glands are not visible. We have performed an echographic
study (Toshiba echography-7.5 mHz) of the parathyroid glands in 23
hemodialysis patients (13 females, 10 males). All of them presented
elevated levels of circulating parathyroid hormone (P'FH); an assay for
intact PTH molecule (normal value less than 60 pg/mI) was employed.
The number of patients with visible parathyroid glands on ecography
was 17 (73.9%). In 7 of them there was 1 visible gland, in 3 patients 2
glands, in 4 patients 3 glands, and in 3 patients 4 visible glands. By
tridimensional measurements, the total volume of parathyroid tissue
was calculated; it oscillated between 13 and 5580 mm3 (x 1163 1770).
Patients were divided in three Groups, according to their P'FH levels:
Group I (N = 6) with PTH 60—240 pg/mI; Group II (N = 8); 240—600
pg/nI, and Group III (N = 9), PTH higher than 600 pg/ml. The
parathyroid volume in Group I was 242 359 mm3, in Group II 611
1036 mm3, and in Group III 2267 2299 mm3, with a statistically
significant difference between Groups I and II and Group III (P < 0.05).
In addition, a significant positive correlation between the parathyroid
volume and PTH levels was found (r = 0.59, P> 0.01). In six patients,
a second study was performed after 3—6 months on intravenous cal-
citriol therapy. In spite of marked decreases in PTH levels, the
parathyroid volume had not changed in four of them; the remaining two
cases showed a clear diminution of enlarged glands, In conclusion,
echographic studies of parathyroid glands in dialysis patients allow a
precise evaluation of enlarged glands; their volume is positively corre-
lated with PTH levels, although rapid decreases of PTH with i.v.
calcitriol treatment is not accompanied by gland volume modifications
in the short-term evolution.
HMGCoA reductase inhibitors in the treatment of hyperlipidemia of
type II diabetes mellitus associated with diabetic nephropathy. A.M.
Castelao, M.T. Gonzalez, C. Vinzia, M.J. Castineiras, and J. Alsina,
Hospital de Bellvitge Princeps d'Espanya," University of Barcelona,
Barcelona, Spain. Cardiovascular mortality in diabetes mellitus (DM) is
very frequently associated with hypercholesterolemia, especially in
non-insulin dependent patients (Type II DM). We have studied 12
patients with T II DM and diabetic nephropathy (DN), diabetic retinop-
athy and proteinuria. Mean age of DM diagnostic was 39.6 II years.
DN was discovered at 53 11 years. All the patients suffered
hypertension and received concomitant treatment with captopril. Un-
der 6 months of cholesterol restricted diet, total cholesterol persisted
above 6.7 mmol/liter (N < 5.2 mmol/liter), starting lovastatin (20
mg/day). The evolution was as follows:
Before
After 6
months P
P1. urea mmol/liter 14.4 5 14.8 6 NS
P1. creatinine pjnol/liter 159 43 159 48 NS
P1. glucose mmol/liter 11.4 4.7 10.7 5.9 NS
Glycosylated AIc Hb % 11.6 1.7 11.9 1.6 NS
GFRCr-EDTA,ml/min 49± 11 43.5± 10 NS
Proteinuriag/day 3.13 2.2 3.78 2.8 NS
Total chol. mmol/liter 8.33 1 6.15 0.83 0.01
Tryglicerides mmol/liter 2.48 1 3.05 1.9 NS
HDL-chol mmol/liter 1.3 0.4 1.18 0.39 NS
LDL-chol mmol/liter 6.1 0.4 4.08 1.5 0.05
Apolipoprot. Al g/liter 1.46 0.3 1.5 0.37 NS
Apolipoprot. B g/liter 1.83 0.1 1.4 0.35 0.05
Lovastatin was well-tolerated with no side effects after 6 to 12 months
of treatment (average 11 months). In three patients the dose was
increased to 30 mg/day. Proteinuria did not change in spite of the
decrease in total chol. In conclusion, lovastatin reduced cholesterol
levels in T II DM, at the expense of total cholesterol, LDL-cholesterol
and apolipoprotein B. Factors like obesity and poor observance of diet
are probably responsible for the inadequate control of hypercholester-
olemia in these patients.
HMGCoA reductase inhibitors lovastatin and simvastatln in the treat-
ment of hypercholesterolemia after renal transplantation under cyclospo-
nfl A immunosuppression. A.M. Castelao, J.M. Grinó, S. Gil Vernet, E.
Andrés, D. Serón, M.J. Castineiras, M. Roca, and J. Alsina, Hospital
de Bellvitge Princeps d'Espanya, University of Barcelona, Barcelona,
Spain. Hypercholesterolemia (hyperchol) after renal transplantation(RT) is a frequent cause of morbidity and mortality. We have studied
the effect of the new HMGCoA reductase inhibitors (HMGCOARI) in
our patients with persistent hyperchol above 6.5 mmol/liter after 3
months of lipidic diet restriction. All the patients were under cyclospo-
rin A (CsA) and prednisone (PNS) immunosuppression. Fifty-one
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patients (34 males, 16 females, 16 to 65 years old, average 43.9 10.9
years), under CsA and PNS immunosuppression, received lovastatin
(20 mg/day) or simvastatin (10 mg/day). There were 26 patients in the
first group and 25 in the second one. Age, HLA matching, plasma
creatinine, proteinuria, T Chol, tn, HDL, LDL, VLDL, apolipoprotein
Al (apo Al), apo B, GFR (Cr-EDTA) and RPF (1-121-hippurate) were
not different between both groups before treatment. No changes in CsA
whole blood levels were seen. The effects of HMGCoARI on lipidic
parameters are shown in the table:
Lovastatin Simvastatin
Before 12 months P Before 12 months P
T.chol. 7.9 1 5.79 0.7 0.0001 7.5 0.8 5.91 0.7 0.0001
mmol/
liter
Triglyc 2.1 0.9 1.54 0.4 NS 1.67 0.4 1.47 0.6 NS
mmol/
liter
HDL 1.3 0.6 1.62 0.3 NS 1.56 0.2 1.34 0.2 NS
mmoll
liter
HDL2 0.5 0.3 0.54 0.4 NS 0.6 0.3 0.36 0.2 NS
mmol/
liter
HDL3 0.8 0.3 0.99 0.4 NS 0.9 0.3 1.37 0.2 NS
mmol/
liter
LDL 5.3 0.8 3.88 0.6 0.001 4.4 1 3.57 0.7 0.01
mmol/
liter
Lovastatin Simvastatin
Before 12 months P Before 12 months P
VLDL 0.9 0.7 0.37 0.2 NS 1.0 0.7 0.46 0.1 NS
mmol/
liter
Apo Al 1.4 0.5 1.62 0.2 NS 1.4 0.2 1.63 0.2 0.03
g/liter
Apo B 1.2 0.1 0.91 0.2 0.001 1.07 0.2 0.93 0.3 NS
g/liter
No significant changes were seen in GFR or RPF after treatment.
Lovastatin was stopped in 3 patients due to myalgia and/or increase in
alanin.amino.transferase (ALT). We stopped simvastatin only in one
patient due to ALT increase. The side effects were reversible after
stopping the treatment. In conclusion, both HMGCoARI were able to
reduce significantly total cholesterol, LDL chol. and apolipoprotein B
with no severe side effects. No interference on CsA was observed at
moderate HMGCoARI dosage.
Incidence and evolution of transplant glomerulopathy. A.M. Castelao,
F. Moreso, M. Carrera, J.M. Griñó, D. Serón, R. Casas, andJ. Alsina,
Departments of Nephrology and Pathology, Hospital de Bellvilge
PrInceps d'Espanya, University of Barcelona, Barcelona, Spain.
Transplant glomerulopathy (TGP) emerges as an important cause of
proteinunia and late renal failure after transplantation (RT). From June
1980 to December 1991, 22 out of 600 patients (3.6%) with RT were
diagnosed with TOP, based on clinical and pathological data. There
were 15 males, 7 females, from 16 to 57 years old (average 33.8 12
years). Immunosuppression included azathiopnine (Aza) and pred-
nisone (PNS) in 7 patients, cyclosporin A (CsA) and PNS in 5,
ALG-CsA-PNS in 6, and OKT3-CsA-PNS in 4 patients. In 2 cases TOP
was diagnosed in a routine biopsy. In the other patients graft biopsy was
performed due to proteinuria above 1 g/day (11) and/or impaired graft
function (11). At the time of biopsy plasma creatinine was 306 108
smol/liter, and proteinuria 4 3.2g/day, rising to nephrotic range in 13
patients. Fifteen patients lost their graft 56 31 months after RT (7 in
aza-PNS group, 4 CsA-PNS, 3 ALG-CsA-PNS, 1 OKT3-CsA-PNS).
The other 7 patients have functioning grafts (plasma creatinine 294
165 &mol/liter) with proteinunia 1.6 I g/clay, 46 15 months after RI.
One patient died due to pneumonia and sepsis with a functioning graft.
In conclusion, in our experience TGP is associated with nephrotic
proteinunia and a rapid decline of graft function, with a poor long-term
prognosis for the graft, independent of the kind of immunosuppression.
Long-term renal function of kidneys transplanted from non-heart beating
cadaver donors. A.M. Castelao, J.M. Grinó, C. Gonzalez, S. Gil Vernet, E.
Andrés, D. Serón, J. Torras, J.M. Galcerdn, J. Bover, E. Franco, and I.
Alsina, Hospital de Bellvitge Princeps d'Espanya, University of Barce-
lona, Barcelona, Spain, Due to the shortage of organs to maintain active
kidney transplant programs, an alternative was initiated years ago in order
to take advantage of the kidneys from NHBCD, in spite of the high risk of
acute tubular necrosis (ATN), especially under cyclosporin A (CsA)
treatment. Our study examines long-term renal function of kidneys trans-
planted from March 1985 to December 1991, comparing the results of two
groups of patients (0-I, recipients from NHBCD, N = 24), versus a
control group of randomly selected recipients of a kidney from heart-
beating CD (0-11, HBCD, N = 48). Immunosuppression included pred-
nisone (PNS) plus azathioprine (N = 3) or CsA (alone in 6 patients or in
combination with a short-course of ALO in 12 patients or with OKT3 in 3
patients) in G-I. In 0-Il, patients were treated with PNS plus CsA (alone
in 21 patients, or combined with ALG in 19 patients or with OKT in 8
patients). Both groups were similar in age, HLA matching and cold
ischemia time.
0-I G-II P
ATN 65% 13% 0.001
Length of oliguna days 9.5 4.5 5.4 6 d 0.01
Dialysis treatments 6.5 4 3 3.8 0.001
Acute rejection 7 p (29%) 14 p (29%) NS
episodes
Plasma creatinine junol/ 188 104 147 36 0.03
liter 1 year
Plasma creatinine 155 45 165 92 NS
3 years
Plasma creatinine 164 61 166 118 NS
6 years
Graft survival I year 83% 86% NS
Graft survival 3 years 75% 84% NS
Graft survival 6 years 73% 68% NS
Patient survival 96% 98% NS
1 year
Patient survival 92% 96% NS
3 years
Patient survival 92% 96% NS
6 years
In summary: (I) The incidence of ATN still remains higher in the
recipients of NHBCD, but has decreased from 87 to 65%, instead of
CsA immunosuppression. (2) The incidence of primary non-functioning
grafts is maintained in 8.7%. (3) The length of oligunia and dialysis is
higher in the NHBCD group. (4) Graft and patient survival were not
different in both groups. In conclusion, NHBCD continues to be a good
alternative to help maintain an active transplant program, in view of the
excellent long-term function results.
Calcium antagonists (verapamil) versus ACEI (enalapril) In the treat-
ment of hypertension of kidney transplanted patients under cyclosporin A
and predrnsone immunosuppression. A randomized study. A.M. Caste-
lao, J.M. GriñO, J.M. Gakerán, E. Andrés, S. Gil Verne:, D. SerOn,
A .M. Amenós, and J. Alsina, Hospital de Brellvitge "Princeps
d'Espanya," University of Barcelona, Barcelona, Spain. Hypertension
(y) is one of the most frequent events after renal transplantation (RT),
attributed in many cases to cyclosporin A (CsA) and prednisone (PNS)
immunosuppression. We have studied 48 patients presenting Fly after
RT, all of them treated with CsA and PNS. The patients were randomly
allocated to receive oral SR verapamil (initial dose 240 mg/day, 0-1) or
enalapnil (initial dose 5 mg/day, G-II). A digital sustraction angiography
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was performed in order to discard the presence of renal artery estenosis
prior to enalapril therapy. The characteristics of both groups are
described as follows:
Verapamil, G-I P
N of patients 24 —
Age 43 8.6 NS
Gender 14 m, 10 f —
Six month dosage 280 104 mg/day —
Before 6 months
Systolic BP mm Hg 173 16 160 33 0.05
Diastolic BP mm Hg 104 75 91 13 0.03
Plasma creatinine 202 91 195 100 NS
i.unol/liter
GFR Cr-ED TA, 41 27 48 29 NS
mi/mm
CsA levels
m.s.RIA, ng/ml 181 81 214 111 0.05
P1 K mmol/liter 4.4 0.9 4.4 0.4 0.009
Hematocrit % 41 7.5 43 6 0.02
Proteinuna g/day 0.9 0.8 1.26 1.2 NS
Enalapril, G-II P
N of patients 24 —
Age 41 9.7 NS
Gender 15 m, 9 f —
Six month dosage 5.6 2.9 mg/day —
Before 6 months
Systolic BP mm Hg 163 16 139 17 0.05
Diastolic BP mm Hg 99 9.2 86 12 0.03
Plasma creatinine pinol/liter 167 48 167 45 NS
GFR Cr-ED TA, mI/mm 47 15 46 16 NS
CsA levels m.s. RIA, ng/ml 143 36 132 54 0.05
P1 K mmol/Iiter 4.4 0.4 4.8 0.8 0.009
Hematocrit % 43 6 38 8 0.02
Proteinuria glday 2.02 2.4 1.4 1.8 NS
Verapamil was withdrawn in 5 patients due to tachycardia (2), heart
failure (1), and good Hy control (2). In 16 patients CsA blood levels
rose, allowing CsA dosage to decrease. Enalapnl was stopped in 1
patient due to cough, inducing mild K increase and hematocrit de-
crease. In conclusion, both protocols were efficient in controlling Hy,
side effects being relatively more frequent in the verapamil group, but
allowing us to reduce CsA dosage. The possible renoprotective effect of
both verapamil and enalapril requires controlled long-term studies, due
to the many different factors involved in Hy after RT.
Ceftrlaxone-doxaclllin versus aztreonam-cioxacillin in the prophylaxis
of urinary infections after renal transplantation (RT). A randomized
study. A.M. Casteiao, J.M. Grinó, J. Torras, E. Andrés, S. Gil Vernet,
C. Gonzalez, D. SerOn, F. Moreso, P. Ferrer, N. Serraliach, and J.
Alsina, Hospital de Belivilge Princeps d'Espanya, University of Barce-
lona, Barcelona, Spain. Urinary infection (UI) is very frequent after
RT. In our previous experience UI due to Pseudomona aeruginosa and
E. coli obliged us to change the prophylactic use of antibiotics after RT,
in order to decrease the incidence of UI. Between January 1990 and
October 1991, one hundred patients who received a RT in our hospital
were randomized to receive cloxacilline (CXC) and ceftriaxone (CFT)
or aztreonam (AZT) as follows: G-I: I g CFT + I g CXC before RT,
followed by CFT (1 g/day) + CXC (I g/6 hr), for 4 days. C-il: I g AZT
+ I g CXC before RT, followed by AZT (I g/d) + CXC (1 g/6 hr) for 4
days, There were no differences between groups regarding age, gender,
HLA mismatches, cold and warm ischemia time or immunosuppression
(CsA-ALG-PNS or CsA-OKT3-PNS). We analyzed IU incidence
within the first 3 months after RT:
G-I G-II pa
Patients 50 50 —
Plasma creatinine 150 53 148 78 NS
pnol/liter
IU episodes 37 in 22 patients 31 in 19 pat. NS
Onset of IU day 23 21 23 22 —
Grampositive 27 22 NS
Gramnegative 8 8 NS
Fungal UI 2 1 —
Other infections 5 (pneumonia
4, CMV I)
2 (wound and
drainage I.)
a Student's t-test.
The most frequent gram-positive UI were due to streptococcus f. (21
episodes in each group) and staphylococcus (5 episodes in 0-I). The
most frequent gram-negative IU was related to E. coli (3 episodes in
each group). Neither patient died nor was urinary sepsis produced in
the period studied. In conclusion, both prophylactic protocols have
decreased the incidence of UI, but the increase of UI due to strepto-
coccus will need a new prophylactic approach.
Renal transplantation before starting dialysis. A.M. Casteiao, f.M.
Grind, E. Andrés, S. GilVernet, D. SerOn, M.T. Gonzalez, J.M.
Galcerán, F. Moreso, and I. Alsina, Nefrology Department, Hospital
de Bellvilge "Princeps d'Espanya," University of Barcelona, Barce-
lona, Spain. From 1984, sixteen patients (G-I), 8 males and 8 females,
34.8 16 years old, with advanced renal failure but not yet on a chronic
dialysis program (plasma creatinine 620 170 smol/liter, Creat,,,.,nc 11.4
6 mI/mm), received a cadaveric kidney transplant (RT). We com-
pared their evolution with a selective randomized group (0-I!) taken
from the other recipient to the same donor or the recipient from the
previous donor. C-Il was composed by 12 males and 4 females, 38.8
9 years old, who had previously been on chronic dialysis.
C-I G-II
Prior blood 10 p (62.5%) 13 p (81%)
transfusions
PRA<30% 16p l6p
SecondRT 4p 2p
Combined I I
liver+ kidney T
HLA A+B 1.08 0.75 1.07 0.88
identities
DR identities 1.08 0.64 1.35 0.6
Immunosuppression 4 aza, 1 CsA, 1
CsA+aza
6 CsA+ALG, 4
CsA+OKT3
3 aza, 3 CsA
4 CsA+ALG, 6
CsA+OKT3
ATN-hemodialysis 1 (0 HD) 6 (12 7 HD)
Acute rejection 50% (8 patients) 37.5% (6 pat.)
Follow-up 36 22 months 37 29 months
Graft losses 5 (2 Cr R, 1 AR,
2 deaths with
functioning
grafts)
4 (2 AR, 1 renal
vein thrombosis,
I transplant GP)
Current creatinine 100 18 smol/
liter
163 75 iimol/liter
Actuarial graft 100% 1 year, 88% 1 year, 73%
survival 84% 3 years 3 yearsa
Actuarial patient 100% 1 year, 87.5% I year, 87.5%
survival 94% 3 years 3 years
Infections
Urine 3 (in 2 patients) 13 (in 8 patients)
CMV 1 1
Pneumonia — I
Sepsis — 1
a p = NS, Kaplan Meyer, log rank test.
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In conclusion, the patients receiving a renal transplant before starting
dialysis present a lower acute tubular necrosis incidence and urinary
infections than those transplanted alter entering chronic dialysis. In
addition there are economic advantages to this procedure.
Lipid abnormalities in transplantation: Comparison with uremia and
hemodialysis. L. Sanchez, E. Martin, I. UsOn, F. Tornero, and R.
Peces, Division of Nephrology, Hospital Central de Asturias, Oviedo,
and Hospital Virgen De La Luz, Cuenca, Spain. We assessed all the
patients who received a cadaver renal transplant in Hospital Central de
Asturias between 1982 and 1988, with a graft survival of at least 6
months. Serum cholesterol (CHOL) and triglyceride (TG) levels were
considered during the periods of chronic renal failure (CRF), hemodi-
alysis (HD), and renal transplant (RT). There were 70 patients, 41 males
and 29 females, aged 16—58 years (X = 39.6years). They received HD
during 3—131 months (X = 26.5 months). In 62 patients, the first
allograft, the second in 7 and the third in 1. 15 of them were followed
during 6 months, and 55 during 1 year. The treatment included
predmsone (P), azathioprine (AZA), and cyclosporine (CsA) in 39
patients, and P and AZA in 31. Hypertriglyceridemia (TO higher than
160 mg/dl) was observed in 43% during CRF, 60% in HD and 28% in RT
with a survival of at least 12 months. Hypercholesterolemia (CHOL
higher than 240 mg/dl) appeared in 24% during CRF, 5% in HD, and
41% in transplant recipients. In RT treated with CsA, the serum total
CHOL values were higher than in the group treated with AZA (243.9
7.7 vs. 220.9 6.8, P < 0.05). We didn't observed any influence of CsA
on triglicerides. There were no significant differences in CHOL and TO
levels between the RT who received diuretics (thiazide or furosemide)
and the RT who didn't. Conclusions: (1) Hypertriglyceridemia is the
main abnormality in uremia and hemodialysis. (2) Hypercholesterol-
emia is a frequent problem in TR. (3) Cyclosporine is involved in the
etiology of hypercholesterolemia post-transplant.
Estimation of hemoglobIn and hematocrit post-hemodialysis in the
treatment of anemia with recombinant human erythropoietin (rHuEPO).
E. Martin, L. Sanchez, F. Tornero, J. Usón, and J. Va!, Division of
Nephrology and Unit of Hematology, Hospital Virgen de Ia Luz,
Cuenca, Spain. The aim of the modifications in rHuEPO dosage in the
treatment of anemia in hemodialysis (HD) patients is to provide the best
hemoglobin (Hb) and hematocrit (Htc) levels without adverse effects.
Assays are usually performed in the blood obtained pre-HD in the first
session of the week. These results can be influenced by the weight gain
of the patient, leading to underestimation of Hb and Htc, with the risk
of producing polyglobulia post-HD and side effects (hypertension,
thrombosis). To determine the importance of these changes, and to
obtain an easy way of quantification, we have analyzed Hb and Htc
levels pre- and post-HD during one HD session, in 44 patients (23 males
and 21 females), with average dry weight of 61.3 11.7 kg (41.8—84).
The differences in Hb and Htc levels were, respectively, 1.1 0.9g/dl
(—0.5—4.5) and 2.9 2.8% (—1.9—13.1), with mean weight gain during
one HD session of 2.3 1 kg (0.2—4.8). To evaluate the differences
between Hb and Htc levels pre- and post-HD as related to the weight
variation (dif. weight), we propose these linear regression equations:
dif. Hb = 0.18823 + 0.39998 x dif. weight, r = 0.44126, P <0.01.
dif. Htc = — 0.4263 + 1.432 x dif. weight, r = 0.50543, P < 0.001.
We conclude that to provide an adequate rHuEPO dosage administra-
tion, we must bear in mind the changes that could induce the hemodi-
lution due to the weight gain. These changes could be reduced consid-
ering Hb and Htc post-HD levels or using the equations that we propose
in our study.
Acute renal failure (ARF) in obstetrics—A retrospective study In 5
years. P. Cisalpina, 0. Lima, Horacio Falcão, Cilnica de Rim Art /icia!
São Joao de Meriti, Rio de Janeiro, Brasil. We followed 15 patients
with ARF related to pregnancy during 5 years. The median age was 32
years old (20 to 40), and 47% were primiparas. The etiology inS (33.3%)
cases was secondary to premature detachment of the placenta, in 4
cases was pre-eclampsia (26.6%), in three cases septic abortion, post-
partum hemorrhage in 2 cases (13.3%), and one case secondary to
hemorrhage postcesarian section (6.6%). As to the nephrologic diagno-
sis, acute tubular necrosis was responsible in 10 (66.6%) of the cases.
The median duration of time of the ARF was 11 (eleven) days, and 80%
were oligoanuric and 20% polyuric. Of the patients studied, 8 required
dialysis (53.3%), (6 HD and 2 PD), and the remaining 7 were treated
conservatively and recovered renal function. Two patients in the
dialysis group died (13%). The seriously ill patients were associated
with septic shock and hemorrhagic phenomenon. In one patient renal
insufficiency became chronic. The major incidence of ARF occurred in
the third trimester of pregnancy (11 patients) while the others were in
the first trimester. Only 3 patients had complete antenatal care. Our
conclusion is to call attention to the necessity of good antenatal care
during all periods of pregnancy. This monthly follow-up is rather
difficult in third world countries. The most severe cases of ARF were
associated with sepsis. Early dialysis in the infected group is manda-
tory.
T cell clones isolated from experimental lupus nephritis demonstrate
that the renal involvement of systemic lupus erythematosus (SLE) is
organ-specific. C. Diaz-Gallo and V.E. Rubin Kelley, Renal Division,
Brigham and Women's Hospital, Harvard Medical School, Boston,
Massachusetts, USA. The participation of autoreactive T cell infiltrates
in the pathogenesis of organ-specific autoimmune nephritis has been
well-described. However, the contribution of nephro-specific autoreac-
tive T cells to the development of nephritis in the context of systemic
autoimmune diseases is not known. We used an experimental model of
SLE (MRL/lpr mouse) to investigate the existence of autoreactive and
organ-specific T cells in systemic autoimmune diseases. We isolated
and cloned T cells that infiltrate the renal interstitium of nephritic mice.
The results demonstrated that all 6 kidney-infiltrating (KI) T cell clones
isolated expressed the same phenotype (CD3+, TCR a//3+, CD4—,
CD8—, B220+) which is characteristic of the abnormal T cell popula-
tion known to proliferate in these animals. All clones were autoreactive
and organ-specific, proliferating against renal tissue: renal tubular
epithelial cells (4.2 0.4 cpm x 10-) and mesangial cells (2.5 0.2
cpm x l0-), but not to non-renal tissues: liver (I 0.1 cpm x l0-) or
spleen (0.9 0.1 cpm x l0) (P < 0.05). All clones were capable of
inducing class II (2% to 40%) and intercellular adhesion molecule
(ICAM-l) (48% to 70%) on tubular epithelial cells. In addition, all KI T
cell clones have transcripts of cytokines involved in the immune
response (TNF-a, TGF-13, IL-4). In conclusion, the isolation of nephro-
specific KI T cell clones in murine lupus nephritis demonstrates that
renal involvement in systemic autoimmune diseases may be organ-
specific. The capacity of KI T cells to induce class II and ICAM-1 on
tubular epithelial cells indicates that KI T cells directly participate in
the immune response. The study of the renal antigen(s) that initiate this
immune reaction may contribute to the development of therapeutic
strategies to prevent renal injury in SLE.
IFN-y-activation of renal tubular epithelial cells diminishes the auto-
immune response in experimental lupus nephritls. C. Diaz-Gallo and
V.E. Rubin Kelley, Renal Division, Brigham and Women's Hospital,
Harvard Medical School, Boston, Massachusetts, USA. Activation
[that is, expression of MHC class II and intercellular adhesion mole-
cule-I (ICAM-1)] of renal parenchymal cells is an early event in
autoimmune nephritis. It is not known, however, whether activation is
a primary event or is secondary to the autoimmune injury. Recent
studies demonstrated that although activation of antigen-presenting
cells is required to induce T cell proliferation, activation of epitheliai
cells renders hapten-specific clones antigen-specific unresponsive. In
the present study we investigate whether activated renal tubular epi-
thelial cells (TECs) modified the autoimmune response. In an expen-
mental model of lupus nephritis (MRL/lpr mouse) we isolated TECs and
kidney-infiltrating (KI) T cell clones. These KI T cell clones were
autoreactive and proliferated exclusively to renal tubular and mesangial
cells. TECs were stimulated with IFN-y and class II and ICAM-l
induction was assessed by flow cytometry. T cell proliferation against
IFN-'y.activated TECs was decreased compared to the proliferation
against unstimulated TECs (2.2 0.1 cpm x lO vs. 4.3 0.4 cpm xl0; P < 0.05). Glutaraldehyde fixation did not alter the ability of
activated TECs to reduce proliferation, indicting that this decrease in
proliferation is not due to secreted factors. Trypan blue staining
demonstrated that T cells in culture with activated TECs remain viable.
In conclusion, IFN-y activation of TECs induces in vitro an inhibition
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of T cell autoreactivity. Alterations of this regulatory mechanism in vivo
may cause the progression of autoimmune injury.
Expression of the intercellular adhesion molecule-i (ICAM-1) in nor-
mal human kidney. P. Arrizabalaga, A. Torras, E. Mirapeix, P. Engel,
C. Serra, and L. Revert, Nephrology Service, Immunology Laboratory,
Hospital Clinic, Barcelona, Spain. Mononuclear leukocytes (T cells
and macrophages) are histological features in glomerulonephritis. They
act in immune cellular interactions recognizing the ICAM- I, a ligand for
CDt l/CD18 (or LFA-l). ICAM-1 expression is induced by inflamma-
tory cytokines on the surface of endothelial and epithelial cells. Our aim
was to know the possible expression and distribution of ICAM-l
antigen in the normal human kidney. Material and methods: We
obtained and used a monoclonal antibody (MA): RM3.A5 (CD54)
directed against ICAM-l with avidin-biotin-peroxidase technique on 10
normal renal biopsies. Tonsil sections were used as positive control.
Same tissues incubated with MA to non-ICAM-1, ascitic fluid of NS1
myeloma line or without MA were used as negative control. Results: A
constant immunohistochemical staining pattern for ICAM- I antigen
was observed in all specimens. We observed heavy positive stain in the
glomerular and peritubular capillaries, and in the endothelium of
medium or large vessels. Parietal epithelium of Bowman's capsule
showed ICAM-l antigens occasionally. No stain was present in tubular
epithelium. Conclusions: In the normal human kidney, endothelial and
glomerular parietal epithelial cells express ICAM-l antigens. The
observation suggests that these cells might play a role in possible local
immune interactions.
Low urinary citrate excretion relative to calcium in idiopathic calcium
stone formers. M.A.P. Rebelo, J.A.G. Leite, and N.C. Aradjo, Division
of Nephrology, Hospital Universitdrio Pedro Ernesto, Universidade do
Estado do Rio de Janeiro, FAPERJ, Rio de Janeiro, Brazil. Citrate has
been identified as a naturally occurring inhibitor of calcium oxalate/
calcium phosphate crystallization due to its property to form soluble
complexes with calcium. We measured urinary citrate and calcium in 45
non-hypercalciuric non-hypocitraturic calcium stone formers (SF) and
16 healthy subjects (HS) in order to assess the urinary citrate/calcium
ratio. Normocalciuria was defined as less than 4 mg/kg/day and nor-
mocitraturia as more than 320 mg/day. No significant statistical differ-
ences were observed between normals (HS) and stone formers (SF)
except for urinary citrate and citrate/calcium ratios, which were lower
in later studies (see Table below). The findings suggest that despite
normocalciuria and normocitraturia, the calcium stone formers have a
higher risk of calcium salts supersaturation, due to a low urinary
citrate/calcium ratio.
UCit UCa .UCit/UCa
mg/mg
Age
years Nmg/24 hr
HS
M 655.2 (432.0) 149.5 (50.0) 4.99 (4.19) 27.6 (3.62) 08
F 670.5 (310.1) 132.2 (66.3) 6.31 (4.11) 38.2 (9.63) 08
B 662.8 (363.3) 140.8 (57.4) 5.65 (4.07) 32.9 (8.91) 16
SF
M 486.7 (171.4) 149.9 (40.8) 3.42 (1.35) 39.3 (13.4) 24
F 513.3 (167.0) 126.0 (29.7) 4.07 (1.95) 38.4 (11.5) 21
B 499.1 (168.0)a 138.7 (37.6) 3.72 (l.67)a 38.9(12.4) 45
Abbreviations are: M, male; F, female; B, both; Standard deviation
figures are in parentheses.
a P < 0.05 HS(B) vs. SF(B)
Recurrence in renal lithiasis. N.C. Aradjo, and M.A.P. Rebelo,
Division of Nephrology, Hospital Universitário Pedro Ernesto, Univer-
sidade do Estado do Rio de Janeiro, FAPERJ, Rio de Janeiro, Brazil.
The stone recurrence rate (RR) was calculated by dividing the number
of stones formed by the total time-interval disease (Ti-D), in 106
patients (57 women), who formed at least two stones. The mean age and
Ti-D were 39.9 and 7.34 years, respectively. The patients were rear-
ranged according to hypercalciuria, hyperuricosuria, none or infection
stone. The mean RR was 1.37 stones/patient year. Age, sex, etiology
and metabolic abnormalities in idiopathic lithiasis had no statistically
significant effect on RR. On the other hand the Ti-D had a striking
influence on RR: patients with a short time-interval disease (<4 years)
had a higher RR than patients with a longer one—2.59 (2.58) versus 0.69
(0.61) stone/patient year; P < 0.05. Indeed it was observed that RR
suffers a progressive decline until 10 years of disease. It was concluded
that: (a) RR assessment in patients with a Ti-D shorter than 4 years has
a false high value; (b) RR suffers a progressive decline with the duration
of the disease that stabilizes at 10 years and remains constant for a
period longer than 20 years.
Ti-D Age RR N
<4 36.6 2.60 (2.58) 38
4—5 39.9 0.96 (0.52) 16
6—7 35.6 0.89 (0.96) 12
8—9 46.8 0.72 (0.53) 09
10—11 41.8 0.40 (0.27) 09
12—13 43.0 0.37 (0.13) 05
14—15 46.8 0.60 (0.41) 07
19—27 43.5 0.46 (0.42) 10
Standard deviation figures are in parentheses
Low hypocitraturla incidence among calcium stone formers without
renal calculi. N.C. Aradjo, J.A.G. Leite, and M.A.P. Rebelo, Division
of Nephrology, Hospital Universitdrio Pedro Ernesto, Universidade do
Estado do Rio de Janeiro, Rio de Janeiro, Brasil. The natural course of
calcium urolithiasis is likely to be morbid and chronic and does not
wane with age, and the chance of calcium oxalate/calcium phosphate to
be expelled is low as 1 in 3 and 1 in 5, respectively. Patients with
roentgenographic evidence of stone at the begin of treatment have a
higher recurrence rate than those stone-free. Urine citrate plays an
important role as a preventing factor against stone formation in the
urinary tract, and hypocitraturia is a common physiologic disturbance
in calcium urolithiasis. These facts prompt us to evaluate urinary citrate
excretion in patients classified according to the presence (28 patients) or
absence (19 patients) of renal calcification. All the subjects were
investigated while on their usual dietary habits. Citrate was determined
by an enzymatic method using citrate lyase. Hypocitraturia was defined
as less than 320 mg/day. Stone-free patients had a significant higher
citrate excretion than patients with roentgenographic evidence of stone
[455.3 (158.7) vs. 340.5 (179.6) mg/24 hr; P < 0.051 and a lower
incidence of hypocitraturia (5.3% vs. 46.4%; P <0.005). Moreover, just
one stone-free patient had hypocitraturia. The results suggest that in
patients with renal calcification the urine citrate assessment is manda-
tory and the disease activity is higher due to a lower urinary inhibitory
effect secondary to a decreased citrate excretion. (Standard deviation
figures are in parentheses).
New method for the CAPD prescription. M.G. Lima, N.B. Pinho, J.E.
Oliveira, H.P. Athayde, R.B. Mendes, and L.C. Perefra. The new
method establishes a relationship between prescription of dialysis and
protein catabolism rate excluding the anabolic fraction that is not
dialyzed. The results were compared to the Brendan and the Prakash
methods. The protein catabolism rate was calculated by the drained
volume (ml) x BUN (mg%) X 6.25/actual weight and the drained
volume was calculated by the protein catabolic rate X actual weight X
6.25/BUN 0.42 mg/mI. The three methods were employed in 11 patients
in a CAPD program evaluating the dialysis index (DI), the prescription
of the BUN for the methods, the residual clearance (Kru) and the actual
BUN. All the patients were in the PET range from lower to higher
levels. The protein intake was between 1.12 0.23, the caloric intake
was between 29.4 4.99, and the protein catabolism rate was between
0.36—0.15 g/kg/day. The dialysis index obtained in our method shows in
a precise form the necessity of changing the amount of required therapy
only in three patients. The others methods didn't reach the real goal to
be attained in these patients. The proposed method allows a more
precise prescription of the patients in a CAPD program considering the
patient's nutritional state and maintaining them in a positive or neutral
nitrogen balance.
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Hemodialysis by double lumen catheter—Evaluation by urea kinetics
study. N.B. Pinho, M.G. Lima, J.E. Oliveira, H.P. Athayde, L.C.
Pereira, and R.B. Mendes. The urea kinetics model was determined in
11 patients with end-stage renal failure at the beginning of their dialysis
therapy with double lumen catheter as vascular access. The K,IV,
(clearance x time/volume), its adjustment and the protein catabolism
rate (PCR) were calculated. In the selection of the dialysis parameters
the residual renal clearance of urea, the volume of urea distribution and
the protein catabolism rate were considered. Seven patients were in the
ideal Ks/V. Four patients had modifications in the dialysis times or in
the dialysis membrane surface according to the PCR and the ideal Ks/V.
The high blood recirculation rate in dialysis therapy using double lumen
catheter is well known, but it is possible to equate the hemodialysis
obtaining an ideal Ks/V similar to chronic dialysis therapy. The dialysis
time, the pump flow, the dialyzer membrane clearance and the protein
catabolism rate are important for the settlement of the Kr/V.
Primary cultures of rabbit proximal tubule cells as an in vitro model for
studying the role of renal growth regulating factors. C. Penaranda, C.
GarcIa-Canton, A. GarcIa-Ocana, and P. Esbrit, Laboratorio de la
Unidad MetabOlica, Fundación Jiménez DIaz, Madrid, Spain. We have
established a primary culture of rabbit proximal tubule cells (PTC) to
evaluate the mitogenic effect of growth factors involved in the control of
renal cell proliferation, in normal and pathologic conditions. We used
kidneys from male New Zealand albino rabbits (1.-I .5 kg body wt).
Renal cortex slices were digested with 0.6 mg/mI collagenase in Hank's
solution for 30 minutes in a 5% CO2 incubator at 37°C. The resulting
tubule suspension was filtered through a tea strainer and centrifuged
with 45% isotonic Percoll at 20,000 g for 30 minutes. Then, the 4th band
from the top was resuspended in DME:Ham's Fl2 (1:1) containing 20
mM Hepes-NaHCO3 and antibiotics, pH 7.4, supplemented with 5
tg/ml insulin, 5 gIml transferrin, 5 X 10 M hydrocortisone and 1%
heat-inactivated fetal bovine serum. This medium was changed every
2—3 days until cell confluence (8—10 days). The P1'C were characterized
by: microscopic examination, enzymatic analysis, cAMP response to
parathormone (PTH) 1—34, PTH-related peptide 1—34 and vasopressin,
and sodium-dependent glucose transport. The first and second subcul-
tures of these cells were used as primary culture cells. Agonist
mitogenicity was assessed by (3H) thymidine incorporation to serum-
depleted PTC, for 20 hours. Our results show that EGF is the most
potent mitogen among those studied, within lO_7_lO_b0 M. TGFI3 at 5
ng/ml inhibits this effect of EGF. IGF-I at l08 M induces an additive
effect to that of EGF. Partially purified extracts of 7 days-uninephrec-
tomized plasma from renal donors, displayed renotropic activity in
PTC.
Role of plasma exchange in the early treatment of Guillain-Barré
syndrome. I. Berdud, A. Martin-Malo, J. Gomez, M.A. Alvarez De
Lara, D. Del Castillo, S. TallOn, D. Perez, E. Bescansa, and P. Aljama,
Servicios de Nefrologla y Neurologla, Hospital Universitario • Reina
Sofia," COrdoba, Spain. Guillain-Barr syndrome (G-B), is a common
cause of acute flaccid paralysis in previously healthy individuals.
Frequently, the disease runs a serious course and, at times, evolves into
a fulminant disease. Until recently, the treatment of G-B has been
limited to supportive measures including mechanical ventilation. How-
ever, in the last few years, some reports have suggested that plasma
exchange (PE) is helpful in the management of G-B. The aim of this
study was to evaluate, prospectively, the potential benefit of PE in
patients with G-B. The study was not randomized due to ethical
reasons. Seven patients with G-B were studied. The mean age of the
patients was 49.14 16.7 years, 3 were men and 4 women. The
diagnosis was based on three criteria: (1) motor impairment measured
by a score from Ito V; (2) analysis of spinal fluid, (3) electromyogram.
The presentation of the disease was acute in five cases and subacute in
two. Treatment with PE was initiated within 24—48 hours of the hospital
admission. Our PE protocol included a total of 6 sessions performed
every 48 hours using 2 liters exchange (albumin in normal saline) per
session. At the end of the treatment, clinical symptoms disappeared in
5 patients (motor score V/V), and in the other two clinical symptoms
improved (from IN to III-IV/V). None of the patients required mechan-
ical ventilation or admission to ICU. Complication included fever in
three cases and deep vein thrombosis in one case, all attributable to
canalization of femoral vein needed to perform PE. In conclusion, PE
appears to be effective in the treatment of G-B, at least when adminis-
tered early (24—48 hrs) in the course of the disease, mechanical
ventilation was avoided in all of our patients. Thus, PE is a good
alternative to other therapeutic modalities including administration of
gammaglobulin.
Diabetes mellitus and transient impaired glucose tolerance following
renal transplantation. José Guerra, Ana M° Correia, A. Gomes da
Costa, M° José Sampaio, José Lopes, Fernanda Rêgo, NIdia ZOzimo,
and J. Rodrgues Pena, Unidade de Transplantacao Renal da Cruz
Vermelha Portuguesa, Lisboa, Portugal. The incidence of post-trans-
plant diabetes mellitus (PTDM) and transient impaired glucose toler-
ance (PTIGT) was analyzed in 498 renal allograft patients from June
1980 through June 1991. They were all nondiabetic and had received
either azathioprine and prednisolone (Group I, 150 patients) or cyclo-
sporin A, prednisolone and occasionally azathioprine (Group II, 348
patients) as maintenance immunosuppression. Mean follow-up varied
from 5.7 years for Group Ito 2.7 years for Group II. Age beyond forty
years and the male sex were associated with increased risk for VFDM.
Patients from Group H developed PTDM more rapidly than those from
Group 1(3.3 months vs. 32.4 months), despite having received lower
cumulative steroid dosage at 45 days post-transplantation. The inci-
dence of PTDM was similar for two groups (7.3% vs. 8.3%) but the
number of patients developing PTDM and PTIGT related to parenteral
methyiprednisolone during acute rejection episodes was significantly
greater in Group II. These results suggest that cyclosporine may act as
a diabetogenic agent, either by interaction with steroid therapy or by an
additional effect causing PTIGT or an earlier development of PTDM.
Steroid replacement by azathioprine in renal allograft recipients on
double therapy with cyclosporin A. José Guerra, NIdia ZOzimo, José
Lopes, Fernanda Régo, Ana M° Correia, M° José Sampaio, A. Gomes
da Costa, and J. Rodrigues Pena, Unidade de Transplantaçao Renal
da Cruz Vermelha Portuguesa, Lisboa, Portugal. From March 1990
through January 1992, twenty-four renal transplant recipients on ther-
apy with cyclosporin A plus prednisolone and presenting serious steroid
side effects, were subjected to progressive prednisolone tapering while
azathioprine was added at I mg/kg/day and increased to 1.5 mg/kg/day.
The study began within 2.5 + 1.5 years (1—6) after renal transplantation.
Twelve patients were males sex and twelve were women. Mean age at
the beginning of the study was 40 ÷ 14 years (10—57). Weight gain
between renal transplantation and the entry in the trial ranged from 68.7
+ 15 kg to 84 + 12.4 kg (P < 0.05). Mter a mean follow-up period of
14.2 + 4.5 months (7—22), 2 patients had experienced acute rejection
episodes on the second and tenth month which reverted completely.
Serum cholesterol levels were lowered from 238 + 36 mg/dl to 1% + 34
mg/dl (P < 0.05), and there was a slight decrease in triglycerides, not
statistically significant. Overall weight reduction ranged 8% of the initial
weight. It was possible to lower antihypertensive therapy in 4 patients
and oral hypoglycemic agents in 4 NIDDM patients. Cataracts did not
evolve in 2 cases. Cyclosporin A and azathioprine appear to be a safe
immunosuppression therapy, with obvious advantages for those more
susceptible to adverse steroid side effects.
Perforating dermatitis In hemodialysis patients. Response to treatment.
H. Altman, M.L. Gomez, G. Santoro, and E. Wainer, Hospital Nacio-
nat Profesor A. Posadas, Haedo, Argentina. Perforating dermatitis are
rare diseases in the general population. In a previous paper, we
established that their incidence in hemodialysis patients was 13.6% out
of 88 patients in the study, which makes it relatively frequent. The
purpose of this study was to update that group of patients and to
characterize their response to local treatment. Thirteen patients were
studied, 5 women and 8 men with a mean age of 43.7 11.7 years and
a mean stay on dialysis of 37.1 27.1 months. These patients were not
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different from the general population of hemodialyzed patients regard-
ing age, sex, time on dialysis, pre-dialysis urea levels, calcium, phos-
phorus, or serum alkaline phosphatase. Eight of those patients had
folliculitis, I had reactive perforating collagenosis, 2 kyrle, and 2
nodular prurigo + perforating folliculitis. Six patients received photo-
therapy, and 5 local therapy without phototherapy. Eight showed relief
of symptoms (pruritus) and 7 experienced partial or total improvement
of lesions. We concluded that local therapy with corticosteroids,
peroxides, urea, antraline, and phototherapy is beneficial for the
treatment of these patients.
Does "white coat" hypertension (fiT) disappear in chronic patients? J.
Herrera, V. Peral, P. Vidau, A. Garcia, and F.J.B. Quiros, Hospital
General de Asturias, Nephrology Department, Oviedo, Spain. Ambu-
latory blood pressure monitoring (ABPM) improves the diagnosis of
HT, avoiding among others the "white coat" HT. We should hope that
the daily relations between doctors and patients could cancel alarm
reaction. Casual blood pressure (CBP) was taken in 34 renal transplant
recipients (Tx), 24 men and 10 women (mean age 45.5 13 years) with
normal renal function, before Tx and one year later; a 24 hour ABPM
was done at that time. A mercury sphygmomanometer was used by the
nurse and a Spacelabs 90202 monitor for ambulatory. Hypotensive
drugs were discontinued fifteen days before monitoring. Before trans-
plants all patients had HT using CBP criteria (Tx Al). One year later 17
patients still had HT using CBP criteria (Tx A2) and only 11 of them
(32.5%) had HT following ABPM criteria (Tx A3).
Group N patients Systolic BP Diastolic BP
Tx Al 34 (100%) 157.3 13.9 101.2 6.9
Tx A2 17 (50%) 146.0 19 91.5 15
Tx A3 11(32.5%) 156.8 15.5 93.4 11
HT was defind for CBP following the JNC and WHO directions (1988)
and the Weber's directions (1988) for ABPM. ABPM improves the
diagnosis of HT in patients with renal transplant with normal renal
function, these chronic patients keep showing "white coat" HT (alarm
reaction).
Ambulatory blood pressure monitoring (ABPM). A better diagnostic
procedure of hypertension (lIT) in hemodialysis (HI)). J. Herrera, C.
Rodriguez, P. Vidau, A. Garcia, and J.F.B. Quirôs, Hospital General
de Asturias, Nephrology Department, Oviedo, Spain. The "white
coat" HT causes an increase in diagnostic mistakes. The daily relation
between doctors and patients should reduce this phenomenon, and
ABPM improves the diagnosis of HT. Casual blood pressure (CBP) was
taken with a mercury sphygmomanometer in 44 patients (27 men, 17
women, mean age 47 15 years) before starting treatment with HD.
One year after the program, all of them were studied with ABPM 24
hours during a short period interdialysis, with a monitor SPACELABS
90202. Hypotensive drugs were discontinued fifteen day before the
registry. Before HD all patients had HT according CBP criteria (HD
Al). One year later 27 patients had HT following CBP criteria (HD A2)
and only 15 of them (34%) had HT following ABPM criteria (HD A3).
Group N patients Systolic BP Diastolic BP
HD 44 (100%) 159.7 15.3 103 8.2
Al
HD 27 (61.3%) 151.6 23 92 16.2
A2
HD 15 (34%) 158.8 15.5 93.4 11
A3
(Systolic and diastolic blood pressure (BP) in mm Hg).
We followed the JNC and WHO criteria (1988) for CBP, and the
Weber's criteria (1988) for ABPM. ABPM improves the diagnosis of HT
in chronic patients on HD, who keeps presenting this phenomenon of
"white coat" HT.
Clinical results of renal transplantation: Fifteen years experience in one
center. A. Mocarquer, J. Morales, I. Galleguillos, J. Pefaur, E. James,
P. Salinas, and J. Aguiló, Hospital Barros Luco-Trudeau, Facultad de
Medicina, Universidad de Chile, Santiago, Chile. The long-term clini-
cal results of renal transplantation are usually based on multi-center
experience, without description of the graft function at the end of the
observation period. We investigated the patient and graft survival with
actuarial methods in all the 378 renal transplants performed in our
hospital between 1976 and 1991. We also evaluated the level of renal
function and the blood pressure at the end of the observation period.
There were 263 living related (LR) and 115 cadaveric kidney recipients
(Cad). Two hundred and eighty-nine patients were treated with pred-
nisone and azathioprine (P+A). Sixty-eight patients received pred-
nisone, azathioprine and cyclosporine (P+A+C). Twenty-one were
treated with prednisone and cyclosporine for one year (P+C) and then
switched to P+A. The % actuarial patient and graft survivals are shown
in the following table:
Patients Graft
Cad Total LR CadTotal LR
lyear 93 96
5 years 88 90
10 years 85 88
87 83
82 63
78 50
90 68
67 54
55 38
The next table shows % actuarial
immunosuppressive protocols:
graft survival under the different
Total LR Cad
P P+A P+ P+
-I-A +C C A P+A P++C C P+ P+A P+A +C C
1 year 82 92 81 89
5 years 62 73 67 67
96 89
78 67
61 88 33
49 71 —
At the time of this study, plasma creatinine concentration (Pcr) at 5 and
10 years in all functioning grafts, was 1.54 0.84mg/dl and 1.41 0.45
mg/dl, respectively. Seventy-one per cent of the grafts had a 1Cr less
than 1.5 mg/dl and 90% less than 2.5 mg/dl. The average blood pressure
at 5 and 10 years was 130/82 and 128/82 mm Hg, respectively. We
concluded that around 50% of the recipients have their grafts function-
ing at 10 years. Better results are obtained with living related donors
and with patients treated with P+A+C. The majority of patients with
functioning grafts have a normal blood pressure and good Cr-
Ischemlc Ileitis non-occlusive In hemodialysis patients. M. Ramirez de
Arellano, X. Cuevas, M. Chiner, M. Fulquet, A. Garceran, J. Sala, and
J. Armengol, Departments of Nephrology and Surgery, Hospital de
Terrassa, Barcelona, Spain. Acute mesenteric ischemia non-occlusive
is a rare complication in patients on chronic hemodialysis. We present
studies of 2 male patients of 79 and 59 years old with chronic renal
failure on hemodialysis for 4 years and 1 year, respectively. The first
patient was a diabetic type II non-insulin dependent with arterial
pressure of around 100 mm Hg and with frequent moments of hypoten-
sion during the dialysis session. The second patient suffered from
polycystic disease with severe periferical vasculopathy and vascular
calcification visible on X-Ray. The clinical pattern of both patients was
acute abdominal pain during the 12 hours following hemodialysis,
during which nothing unusual occurred. The pain was located in the
right iliac fossa with no signs of peritoneal irritation, apirexia, normal
blood pressure, metabolic acidosis and leukocytosis. A laparotomic
exploration was done revealing a segmentary ischemia of the terminal
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ileon with normal mesenteric vascularization confirmed by the histo-
logical examination. As the most important physiopathological mecha-
nism, we would emphasize the progressive atherosclerosis preventing
the normal colateral circulation in ischemic anatomic area. Conclusion:
The non-occlusive ischemia ileitis must be considered within the
differential diagnosis of acute abdominal pain in patients on hemodial-
ysis.
Hepatic histopathology of patients in hemodialysis HVC+. M. Fulquet,
X. Cuevas, M. Chiner, M. Ramirez de Arellano, F. Vallribera, J. Sala,
J. Armen go!, and I. Roig, Departments of Nephrology and Surgery,
Hospital de Terrassa, Barcelona, Spain. Forty to sixty percent of
patients with antibodies against the C virus can evolve a chronic
hepatopathy confirmed histologically. Patients on HD are in the high
risk groups, especially those who will receive renal transplants (hepa-
topathy is one of the principle causes of death). The aim of this study
was to know the prevalence of HVC+ carriers on HD and the hepatic
histology of those who also have an increase of hepatic enzymes.
Material and methods: Sixty-nine patients on HD, 36 males and 33
females, were put into two groups—carriers and non-carriers of
HVC+—according to the ELISA II technique. The HVC— group
contained 49 patients, average age 61(26—84) and time on HD 3.06 years
(0.2—10). The HVC+ group was of 20 patients, average age 51 (22—84)
and time on HD of 5.9 (0.8—16) years. The HVC was determined by
ELISA generation I and II and confirmed by Riba 4. Hepatic enzymes
were analyzed every 3 months. A hepatic biopsy by laparoscope was
done in those HVC+ patients who showed high hepatic enzyme levels
during 6 months. The HVC+ patients were not isolated. Results: Of
patients on HD, 28.3% were HVC+ carriers; 8.1% of HVC— patients
have an increase of hepatic enzymes against 85% of the HVC+ group,
and 90% of HVC+ patients had received transfusions. Preliminary
results of hepatic histologic biopsies show 2 chronic active hepatitis, 2
hemosiderosis and 1 chronic alcoholic hepatopathy. Conclusions: (I)
Patients on HD present a high prevalence of HVC+. (2) Transfusions
are the principal methods of transmission. (3) Special measures of
isolation of HVC+ patients do not seem to be indicated. (4) The HVC+
patients have a high incidence of hepatic enzyme increase.
Is the higher percentage of adynamic form of Insulin-dependent dia-
betic patients compared with non-diabetic uremic patients caused by
aluminum? X. Cuevas, J. Aubia, S. Serrano, L.L. Marinoso, J. Bosch,
and M. Fulquet, Department of Nephrology, Hospital de Terrassa,
Hospital Esperanca, and Hospital del Mar, Barcelona, Spain. Andress
found a higher value of accumulation of aluminum in the trabecular
surface of diabetics on dialysis (DM-D) than uremic non-diabetics (U).
This would be due to the lower bone remodeling and the higher
accumulation of body aluminum. Our goal was to study whether
trabecular surface covered by aluminum (AL S/BS) is different between
the DM-D and the U, and whether the aluminum deposits on the bone
of diabetics is a consequence or a cause of the low bone remodeling and
especially the adynamic form. Material and methods: We compared the
AL S/BS of 40 DM-D with 33 U and 10 DM in pre-dialysis. The static
histomorphometric bone study was available for 40 DM-D, 33 U and for
10 DM in pre-dialysis and dynamic parameters were available for 23
DM-D, 17 U and 10DM in pre-dialysis. We determined the biochemical
and hormonal: Ca, P, FA, Mg, P'FH-c, calcitonine, and DM patients
also BGP and I ,25(Ok{)2D3. Results: (1) The AL S/BS was negative in
the DM in pre-dialysis, 3.54% for the DM-D and 3.11% for the U. There
were no significant differences between the last two groups. (2) The DM
had a lower bone remodeling and a higher proportion of adynamic form
[similar in pre- (40%) and post- (30.4%) dialysis] than the U (17.6%).
Conclusions: (1) The DM on dialysis did not show a higher accumulation
of aluminum on the trabecular surface than the non-diabetic U. (2) The
low bone remodeling in the DM does not imply a higher accumulation
of aluminum. (3) The higher percentage of adynamic form is not only
due to the presence of aluminum.
Histomorphometric bone pattern of insulin-dependent diabetics on
dialysis (DM-I) defined in the pre-dialysis stage. X. Cuevas, J. Aubia, J.
Bosch, S. Serrano, L.L. Mariñoso, M. Ramirez de Arellano, and M.
Rios, Department of Nephrology, Hospital de Terrassa, Hospital
Esperança, and Hospital del Mar, University Central Bioestadistica,
Barcelona, Spain. Our objective was to describe and compare histo-
morphometric results and calcium-phosphate metabolism of DM-I
during the stage of pre- and post-dialysis. Material and methods: The
DM-I on dialysis (DM-D) group of 40 patients with average age of 54
14 years (22 males and 18 females, 14 are DM type I and 24 type II). In
all patients we had histomorphometric bone for static parameters and in
23 of 40 patients also for dynamic. The pre-dialysis group (DM-tR) of 17
had average age of 62 13 years (17 males and 10 females); 14 are DM-I
and 3 DM-II. The renal function expressed in creatinine (p) =2.37
mg/dl. For 10 of 17 patients we had histomorphometric bone for static
and dynamic parameters. Both groups were tested for: Ca, F, FA, Mg,
FFH-c, l.25(OH)2D3, BGP, calcitonine (Ct). Results: (I) Ca, P, FA,
I .25(OH)2D3 and BGP show no differences between the two groups. (2)
The DM-D showed significantly higher values than the DM-IR in Mg
(3.12 0.1 vs. 2.7 0.14; P = 0.02), PTH-c (1.59 0.17 vs. 0.81
0.27; P = 0.01) and Ct (187 21 vs. 109 26; P = 0.02). (3) There were
no differences in all static and dynamic parameters of the histomorpho-
metric bone. Conclusions: (1) The histomorphometric bone patterns of
the DM-I on dialysis are predefined in pre-dialysis stage. (2) The
metabolic changes of calcium-phosphate cannot be related to morpho-
metric bone results.
Urinary sodiumlcreatinlne relation in patients with nephrolithiasis by
hypercalciuria. A.F.C. Dias, S.A. Agreste, and S.R. Ferreira Filho,
Servico de Nefrologia da Universidade Federal de Uberldndia, Uber-
ldndia, MG, Brasil. In certain segments of the nephron, calcium and
sodium tubular reabsorptions are associated. This correlation Ca /
Na could explain, in part, the rise of nephrolithiasis in patients with an
excessive dietary intake of sodium. The aim of the present work was to
evaluate the urinary sodium/creatinine relation, in patients with neph-
rolithiasis by renal and absorptive hypercalciuria, in order to find the
possible existing differences between these metabolic disturbances. We
used the oral calcium load test in two groups: Group A: (N = 14),
patients with nephrolithiasis by absorptive hypercalciuria, with 31.29
3.98 years old (X sEM); Group B: (N = 24), patients with nephroli-
thiasis by renal hypercalciuria, with 38.25 2.58 years old (X SEM).
Both groups had previous histories of repetition renal lithiasis and
absence of other associated systemic diseases. After an initial period
of two hours, followed by a previous night of fasting, 1.0 g of
calcium/rn2 of corporal surface was given orally, and after three hours
the possible alterations on urinary sodium were observed. The results
are in Table 1:
Table 1. Urinary sodium/creatinine relation before and after oral
calcium load test
Before After
HCaR (N = 24)
HCaAb (N = 14)
3.22 0.36
1.97 0.22
P<0.05
2.86 0.26
2.81 0,29
NS
NS
P < 0.05
Abbreviations are: HCaR: renal hypercalciuria; HCaAb: absorptive
hypercalciuria; NS: not significant.
When compared to the group with absorptive hypercalciuria, our data
show a high index of the urinary sodium/creatinine relation on the
pre-test phase, of the group with renal hypercalciuria. After excessive
oral ingestion of calcium there is an alteration of these results, which
makes patients with absorptive hypercalciuria increase the index of
urinary sodium/creatinine relation, to the level of that one found in
patients with renal hypercalciuria.
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Metabolic study in patients with lower limb paraplegia. A.F.C. Dias,
L.F.B. Nunes, M.C. Teixeira, S.A. Agreste, and S.R. Ferreira Filho,
Serviço de Nefrologia da Universidade Federal de Uberldndia, Uber.
lândia, M.G, Brasil. We used the oral calcium load test in seven
patients with lower limb paraplegia. We verified a high incidence of
metabolic alterations, of which prevailed the renal hypercalciuria.
HCaAb 14.3%
HUr —
HCaR 28.6%
Cystinuria —
HCaR + HUr + renal tubular acidosis 14.3%
HCaR + cystinuria 14.3%
N.M.A. 28.6%
Abbreviations are: HCaAb: absorptive hypercalciuria; HUr: hyper-
uricosuric; HCaR: renal hypercalciuria; N.M.A.: no metabolic alter-
ations.
Serum Urinary
calcium calcium! Intestinal
mg% creatinine absorption
Patients Before After Before After index Diagnosis
V.B.B. 9.5 8.2 0.09 0.21 2.3 HCaAb
J.B.C. 10.2 12.1 0.25 0.43 1.7 HCaR + HUr ÷
renal tubular
acidosis
J.S. 8.6 9.8 0.09 0.07 0.8 N.M.A.
W.N. 10.7 10.6 0.06 0.14 2.4 N.M.A.
W.S.S. 9.8 10.2 0.20 0.19 1.0 HCaR
J.F.M. 9.9 10.2 0.18 0.47 2.6 HCaR
J.A.A. 10.0 10.5 0.36 0,19 0.5 HCaR + cystinuria
X 9.8 10.2 0.18 0.24 1.6
SEM 0.25 0.44 0.04 0.06 0.32
Table 3. 24 hour urine dosages, of calcium, uric acid, magnesium
and phosphorusa
Patients
Calcium Uric acid Magnesium Phosphorus
mg/24 hr mg124 hr mg/24 hr mg/24 hr
V.B.B. 142.2 367.2 61.2 459.0
J.B.C. 165.2 696.2 106.2 1439.0
J.S. 119.0 323.0 64.5 206.0
W.N. 78.0 405.0 75.0 593.6
W.S.S. 77.8 472.6 41.7 540.0
J.F.M. 90.0 552.0 56.8 570.0
J.A.A. 295.0 574.0 115.0 530.4
X 138.2 484.3 74.3 619.7
SEM 28.99 49.69 10.13 145.22
a It was considered the maximum value, in at least 2 samples of urine
of 24 hours.
As the tendency observed in this preliminary data is still maintained,
the outstanding changes on Ca ' urinary excretion may be related to a
bone demineralization, once these patients present lower limb immo-
bility. The presence of urinary calculi, in the bladder, of 4 patients, was
also noted. These calculi may result from repetition urinary infections,
common pathology to this group of patients, associated to the metabolic
alterations that were found.
Microalbuminurla and physical exercise in healthy young subjects.
J.R.P. Tasso, S.R. Ferreira Filho, and J.C.B. Lucas, Servico de
Nefrologia da Universidade Federal de Uberlándia, Uberlándia, MG,
Brasil. In healthy subjects microalbuminuria (MCA) has been associ-
ated with pathologic changes in coronary and vascular vessels. It has
been used as a predictive sign of these diseases without relation to the
others risk factors, such as: hypertension, cigarette smoking and
obesity. However, there are studies that relate blood pressure and
MCA in normal subjects, although the possible association between
blood pressure and MCA during physical exercise hasn't been well-
established. The objective of this study was to make normal subjectives
undergo a maximum exercise test on a bicycle ergometer, relating levels of
blood pressure and MCA before and after exercise. The group consisted of
14 normal volunteers between ages 18 and 23 (mean age 21.3 0.3 years,
mean blood pressure 87.4 2.1 mm Hg). There were 12 men and 2
women. Subjects underwent an exercise test on a cycle ergometer with
progressive increases in the workload imposed and observation of the
blood pressure and heart rate. When each volunteer reached physical
exhaustion the cycling was stopped. Samples of urine and blood were
collected before and after 3 hours of maximum exercise test on a cycle
ergometer. Urinary albumin excretion larger than 20 g/min was consid-
ered as MCA. Radioimmunoassay (RIA) kits (DPC, Los Angeles, Califor-
nia, USA) were utilized to determine the MCA. The results of MCA before
and after the maximum exercise test are in Table 1.
Table 1. Excretion of microalbuminuria (MCA) and hemodynamic
variables before and after maximum exercise test on a bicycle
ergometer
MCA MHR MSBP MDBP MMBP
pg/min beats/mm mm Hg
Before 4.8 0.7 73.8 2.5 120 3.7 69.6 1.9 87.4 2.1
During! 27.5 6.9a 144.7 2.8a 176.4 6 73.5 6 107.8 2.8a
after
D.E.
mm
MWR
Watts
DP
mm Hg beats/mm
— — 8.827 425
38.5 34 178.5 l5 25.601 l097
Abbreviations are: MCA, microalbuminuria; MHR, maximum heart
rate; MSBP, maximum systolic blood pressure; BDBP, maximum
diastolic blood pressure; MMBP, maximum mean blood pressure; DE,
duration of exercise; MWR, maximum workload reached; DP, double
product.
a maximum exercise test on a cycle ergometer; P < 0.005
Table 2. Correlation between assessment of (MCA) found after
physical exercise and several variables measured
MSBP : r = 0.12 (NS)
MDBP : r = 0.21 (NS)
MCAX MMBP
MWR
DE
:
:
:
r = 0.10 (NS)
r = 0.17 (NS)
r = 0.19 (NS)
Our data confirm MCA in the urine due to intense physical exercises;
however, this increase in the urinary albumin excretion did not corre-
late significantly with any variables that had been studied: maximum
systolic blood pressure, maximum diastolic blood pressure, maximum
mean blood pressure, maximum workload developed and duration of
exercise. On the other hand, for the determination of the MCA it is
advisable to collect the material with the patient in relative resting state.
Arterial hypertension in aged patients: Systemic hemodynamic varia-
tions induced by body position. F.M. Pereira, M. Viviane, and S.R.
Ferreira Filho, Servico de Nefrologia do Universidade Federal de
Uberldndia, Uberldndia, MG Brasil. The knowledge of the hemody-
namic alterations induced by the different positions of the body in
hypertense patients may be a great help concerning to the hypotensor
drugs used in these persons. The aim of this study was to determine the
alterations of the cardiac index (C.1), systolic index (S.I), systolic
arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial
pressure (MAP), heart rate (HR) and total periferic resistance (TPR), in
aged normo- and hypertense patients, and normal volunteers, when
these individuals change from supine to ortostatic positions. The aged
Table 1. Metabolic alterations on patients with lower limb paraplegia
(N = 7)
Table 2. Oral calcium load test
NS is not significant
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group was divided into 4 subgroups according to the systemic blood
pressure levels: group 1: presenting 9 normal volunteers, 66 3.6 years
(X SE), with SAP < 140 mm Hg and DAP < 90 mm Hg; group 2: N
= 10, 71 7.8 years, SAP between 140 and 160 mm Hg and DAP < 90
mmHg; group 3: N = 9, 71 6.1 years SAP> 160 mm Hg and DAP
<90mm Hg; group 4: N= 9, 66 5.3 years, SAP> 160mm Hg and
DAP> 90 mm Hg. These groups were compared among themselves and
also with young volunteers (group J: N = 10, 22 2.! years, SAP < 140
mm Hg, DAP <90 mm Hg). After a period of 30 minute rest in supine
position (SI) the integrants of each group remained in ortostatic position
for at least 5 minutes (OR), and then returned to supine position (SI!).
The hemodynamic measures were taken at the end of SI, at the first and
after the fifth minutes in ortostatism and in SI!. For these evaluations
we used a non-invasive method (Thoraxic Bio Impedance, Bo Med.
Instruments). The results showed that group 1 had hemodynamic
behavior similar to group J. The relation between the HR variations and
MAP variations (heart rate gain, HRG) in these patients were of +2.7
and +5.2 respectively, considering the modifications occurred between
SI and OR after the fifth minute. The percentual reductions which
occurred with systolic index from SI to OR were of 22% (Gl) and of
33% (GJ) and again in HR of 19% (GI) and 29% (GJ). (Table 1)
Table 1. Hemodynamic modifications noted in postural alteration
from supine to ortostatic—comparisons between the young group and
the aged group
HRG TPR CI SI MAP HR
Gj +5.2 +21% —14% —33% +4.5% +29%
01 +2.7 +14% —7% —22% +5.5% +19%
02 +1.6 +13% —1% —10% +4.7% +11%
G3 +0.6 +6% —2% —10% +7.0% +6%
G4 +1.7 +5% —6% —15% +3.3% +11%
Our figures, despite the preliminaries, showed that the aged group with
different levels of systemic arterial pressure has distinct hemodynamic
behaviors when they pass to ortostatic position, and the group with
more similarity to the young group is the normotensive aged group.
Systemic hemodynamic response to food intake in normal subjects.
M.A. Nery, S.R. Ferreira Filho, S.A. Agreste, S. Watanabe, Servico de
Nefrologia da Universidade Federal de Uberlôndia, Uberldndia, MG,
Brash. The digestive process can occur with systemic pressure level
reduction, due to the release of several vasodilation feature hormones
during digestion. Invasive methods employed to evaluate hemodynamic
variables make difficult the study of alimentation-induced alterations.
Thoracic Bloimpedancy (NCCO-3 Bomed Instruments-Ca) provides
evaluation of systemic hemodynamic events, after a meal, through a
non-invasive manner. Two groups of volunteers were studied: group A,
N = 11, 22 0.8 mean age (X SE), who received a meal of 700 kcal
(38% carbohydrates, 19% proteins and 43% fats) in the morning, after
one night of fasting; group B, N = 10, 22 0.5 mean age, who received
650 ml of water in the morning, after one night of fasting. Cardiac index
(CI), stroke volume index (SVi), heart rate (HR), mean arterial pressure
(MAP) and systemic vascular resistance index (SVR1) were determined
during a period of fasting (F), 5, 15, 30,45 and 60 minutes after ingestion
of meal or water. Results are demonstrated in the table:
Group F S mm 15 mm 30 mm 45 mm 60 mm
CI A 3.6 4.0 45 47° 4.6° 4.4°
ml/min in2 B 3.2 3.0° 3.0° 3.0 3.0° 3.1
SVi A 56 57 65° 70° 68° 63°
mi/beat m2 B 49 49 49 5! 49 49
HR A 64 69 71 68 68 71°
bpm B 65 61° 60 60° 59° 63
MAP A 88 93 87° 88° 87 88°
mm Hg B 84 87 86 86 86° 85
SVRi A 2040 1961 1612° 1553° 1608° 1636°
dyn sec cm5 B 2187 2468° 2461* 2427° 2432° 2334°
a P < 0.05 vs. F
The results demonstrate a significant cardiac index increase after the
intake of a meal, due to elevations in stroke volume index and heart
rate. There was concomitant systemic vascular resistance index reduction.
These alterations were not observed after ingestion of water. Alimenta-
tion-induced modifications should be considered, especially when hypo-
tensive medications were prescribed after meals, since additional effects
could exacerbate the related hemodynamic alterations.
Systemic hemodynamic response to food Intake in normotensive and
hypertensive elderly patients. S. Watanabe, S.R. Ferreira Filho, S.A.
Agresge, Servico de Nefrologia da Universidade Federal de Uberldn-
dia, Uberldndia, MG, Brasil. This study evaluates the cardiac output
(CO), stroke volume (SV), heart rate (HR), mean arterial pressure
(MAP), and systemic vascular resistance (SVR) in normotensive (group
A) and hypertensive (group B) elderly patients. Group A: N = 10, 9
males and 1 female, 70.2 1.8 mean age (X SE) and arterial blood
pressure < 160 x 95 mm Hg at rest. Group B: N = 10, 8 males and 2
females, 72.3 1.6 mean age and arterial blood pressure > 160 x 95
mm Hg at rest. Group A received a standard meal of 700 kcal (subgroup
A1, N 10) and 650 ml of water (subgroup A2, N 9) after one night
of fasting. Group B was studied identically with food (subgroup B1, N
= 10) andwater (subgroup B2, N = 9) ingestion. CO. SV, HR, MAP and
SVR were evaluated during a period of fasting (F), 5, 15, 30, 45 and 60
minutes after intake of meal or water. These variables were obtained by
non-invasive methods: Thoracic Bioimpedancy (NCCO-3 Bomed In-
struments, Ca monitor) and Dixtal 2710 (Doppler) automatic arterial
blood pressure monitor. Results are demonstrated in Tables I and 2.
Table 1. Hemodynamic alterations after food (A1) and water (A2)
ingestion in normotensive elderly patients
Group F 5 mm 15 mm 30 mm 45 mm 60 mm
CO
liter/mm
SV
mi/beat
HR
bpm
MAP
mmHg
SVR
dyn - sec
a P < 0.0
A1 3.7
A2 3.7
A1 57
A2 55
A1 66
A2 66
A1 104
A2 106
A1 2499
A2 2673
5 versus F
4.5°
3.5°
63°
55
71°
65
107
109°
2211°
2914°
49
3.5
69°
55
70°
63°
102
111°
1993°
2925°
4.8°
3.4°
67°
55
71
63°
103
112°
2021°
3008°
4.5°
3.5°
64°
54
69°
64
103
112°
2167°
3033°
44*
3.6
62°
55
70°
67
101
116°
2101°
2986°
Table 2. Hemodynamic alterations after food (B4) and water (B2)
ingestion in hypertensive elderly patients
Group F 5 mm 15 mm 30 mm 45 mm 60 mm
CO B1 3.6 4.la 4.6° 4.6° 4.6a 4.3
liter/mm B2 3.6 3.4 3.3° 3.2° 3.3 3.6
SV B1 64 67 73° 74° 74 70°
mi/beat B2 67 62 61° 60° 60° 62°
HR B1 59 64 65° 64* 64° 64*
bpm B2 56 57 56 54 57 59
MAP B1 117 121 111 109° 111° 109°
mm Hg B2 116 122 122 123 126° 122
SVR B1 2735 2446° 2049° 2036° 2087° 2145°
dyn-sec
°P < 0.05
B2 2811
versus F
2956° 3029 3145 3225° 2980
—
The results demonstrate a significant cardiac output increase in normo-
tensive and hypertensive patients only after food intake, from alter-
ations on stroke volume and heart rate. After ingestion of water, there
was a significant decrease on this variable in both groups. Mean arterial
pressure reduction only happened in the hypertensive group who
received a standard meal. The knowledge of these alterations can
contribute to the therapeutic management in order to avoid extra
hypotensive effects on elderly patients with high blood pressure levels.
Cyclo-oxygenase and llpo-oxygenase Inhibition in gestational hyperten-
sion. J.C. Fraire and M.C. Fama, Hospital Itaiiano, Córdoba, Argen-
tina. It has been suggested that pre-eclampsia may result from an
imbalance of either cyclo-oxygenase or lipo-oxygenase products, or
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both. We evaluated the outcome of pregnancy after combined therapy
with aspirin (ASA) and lysine clonixinate (L.C1), a lipo-oxygenase
inhibitor, in 14 pregnant women at high risk for pre-eclampsia. Nine
were chronic hypertensives and 4 of them had had previous pre-
eclampsia and fetal death. The remaining 5 patients had transient
(gestational) hypertension. Five patients began therapy between the
14th and 20th week with ASA 100 mg q.d. and L.C1. 250 mg q.d. Nine
started treatment after the 20th week with equal ASA dose but with 375
mg q.d. of L.Cl. Results: Thirteen pregnancies reached normal term and
delivered normal babies with the following APGARD: 7 had scores 7 to
8, 3 had scores of 8, and 3 had scores between 8 and 9. One baby was
born at 33 weeks with an APGARD of 7, progressed to 9 in 5 minutes
and had humidified oxygen for 48 hours. His weight was 1710 g.
Placentas were evaluated by ultrasound, according to the Grannun and
Hobbing classification. Six placentas were type I, 3 were type I-lI, 3
were type II, and 2 were type Il-Ill. We conclude that combined
therapy with ASA and L.Cl in pregnant patients at high risk for
pre-eclampsia is probably safe for both mother and fetus.
Renal protection in radiation nephritis (RN). L. Juncos, H. Cejas, S.
Baigorria, and J.C. Cornejo, Instituto Privado Especialidades Médi-
cas, COrdoba, Argentina. Renal failure in RN could result from tissue
ionization, arterial or glomerular hypertension, or compensatory hyper-
trophy. We studied the effects of a low protein diet (LP) and enalapril
(E) 50 mg/liter in drinking water, on renal function and structure of
uninephrectomized rats with radiated remnant kidney. Baseline serum
and urine electrolytes, systolic blood pressure (SBP), serum creatinine
(Se,), clearance creatinine (Ce.), UNa+ + V, UK*V and UDroteinV were not
different between control (C) (N = 6), E (N = 6) and LP (N = 6) rats.
SBP
mm Hg
UproteinV
mg/100 glday
0 weeks 16 weeks 0 weeks 16 weeks
C
E
LP
84 4.8
79 4.0
85 5.8
124 93
78 4.1
123 558
6.0 1.1 15.1 7.6a
5.4 1.1 6.9 1.1
6.9 0.9 7.7 0.8
Sr
mg/dl
Cpr
mg/minIIOO g
0 weeks 16 weeks 0 weeks 16 weeks
C
E
LP
0.5 0.02
0.5 0.04
0.5 0.01
0.9 0.06k
0.6 0.06
0.9 o.Ia
0.73 0.12 0.25 o.06
0.88 0.12 0.80 0.09
0.88 0.2 0.48 1.lOa
Values are Means I SEM. a p < 0.05 vs. wk. 0 (ANOVA).
At 16 weeks mean PRA (ng/mllhr) were: C, 7.0 1.2; E, 13.2 2.5 (P
<0.05) and LP 12.5 0.9 (P < 0.05). Glomerular sclerosis index: (0 to
4+) C, 3.4 0.1; E, 2.7 0.7 (P < 0.05); LP, 2.8 0.2 (P < 0.05).
Renal volume (ml): C, 0.45 0.02; E, 0.32 0.02 (P < 0.05); LP, 0.41
0.02 (NS). E improved all parameters. LP did not prevent hypertension or
renal hypertrophy and was less effective in protecting the kidney.
Antibodies against hepatitis C virus (AbHCV): prevalence, Incidence
and transmission of the virus in a hemodlalysis (lID) unit. J. Pinto dos
Santos, J. Piairo, C. Mil-Homens, H. Vizella, A. Nogueira, and J.
Barbas, Centro de Hemodiálise do Lumiar, Lab Imunonuclear, Lisbon,
Portugal. From January 1991 to January 1992, 96 chronic HD patients
(57 M and 39 F; age 60.781 12.17 years; time on HD 59.562 36,977
months) were followed-up with monthly AbHCV determinations using
a 2nd generation ELISA test. All the patients and staff members have
been negative for HBsAg and HIV I-li throughout the study, and the
staff has also remained negative for AbHCV. ELISA test was initially
validated with a RIBA HCV Sia Prototype showing 100% sensitivity
and 96.3% specificity. Prevalence of HCV positive patients was 14.6%
at the, beginning and 36.5% at the end of the study. The incidence of
positive seroconversion was 25.6%. Among the 14 initially HCV
positive patients there was no negative seroconversion. Concerning a
past history of blood transfusions or the number of transfused units
throughout the study, no differences were found between the group of
patients who has seroconverted (N = 21) and the group who has
remained seronegative (N = 61). Difference was neither found in the
number of treatments using the same dialysis "infected" machines.
Time on HD was significantly longer in patients who have had positive
seroconversion (P < 0.00001). There was a significantly increased risk
of positive seroconversion in seronegative patients dialyzed in contig-
uous position to HCV positive patients (P = 0.0114; relative risk = 3.2).
These facts strongly suggest a horizontal transmission of HCV.
Viral hepatitis and hepatic dysfunction. Analysis of a HBsAg+ hemo.
dialysis population. J. Graca Silva, J.M. Frazao, C. Oliveira, C. Pires,
and F. Carrera, Centro Medico Nacional, Lisbon, Portugal. We
studied the serology of hepatitis B and C virus and tried to correlate it
with the presence of hepatic dysfunction [aminotransferases above
normal in the 6 months that preceded the study, in 35 patients (mean age
50.8 + 13.0 years, mean time on hemodialysis 97.5 + 58.8 months)]. All
but 3 were HBsAg+ for more than 6 months and none had clinical or
biochemical evidence of hepatic failure. In a cross sectional study we
analyzed the serology of HBV (HBsAg, anti-HBs, HBeAg, anti-HBe,
anti-HBc and DNA polymerase) and BCV (Anti-HCV). In the 6 months
previous to the study 24 patients had elevated aminotransferases and 11
had consistently normal hepatic function. In addition 2 patients were
HBeAg+, 27 anti-HBe+, 6 DNA Polimerase+ and 24 anti-HCV+.
Anti-
Hepatic function
HCV
+ — +
DNA
—
HB
+
eAg
—
HBe
+ —
Normal 6 5 2 9 2 9 8 3
Abnormal 18 6 4 20 0 24 19 5
Conclusions: (1) We did not find any correlation between the existence
of HBV viral replication markers and increased aminotransferases. (2)
DNA polymerase while having a negative correlation with anti-HBe did
not, however, have a positive correlation with HBeAg. (3) The exis-
tence of anti-HCV has no correlation with hepatic dysfunction in this
population.
One year evolution of anti-HCV antibody in a hemodlalysis population.
J. Graca Silva, C. Oliveira, J.M. Frazão, C. Pires, and F. Carrera,
Centro Medico Nacional, Lisbon, Portugal. We studied a population of
151 patients on chronic hemodialysis, all HB5Ag negative, in order to
identify the prevalence and evolution during one year of the anti-HCV
antibody and its correlation with NANB hepatitis. Monthly ALT/AST
were evaluated from the beginning of the patient's HD, and anti-HVC
(Ortho HCV antibody) every 3 months over the year of 1990. When
patients had at least 2 consecutive months of the elevated ALT/AST
without an identifiable cause of liver injury (virus, toxic substances,
alcohol, drugs), we classified them as having NANB hepatitis. We
identified 85 patients with NANB hepatitis, 57 of them with biochemical
criteria of chronic hepatic disease. During the year in analysis, of the 72
patients anti-HCV+ at the beginning of the study, 64 remained positive.
Of the 79 initially anti-HCV negative, 63 remained negative. In 24
patients we observed fluctuations of anti-HCV serology without a
definite correlation with hepatic function.
Without NANBH With NANBH
Anti-HCV +
Anti-HCV-iate 8
Conclusions: (1) The majority of our population did not change their
anti-HCV titers during the year studied. (2) The persistence of stable
titers of anti-HCV correlates with the existence/absence of NANB
hepatitis. (; P =0.05) (3) Patients with biochemical criteria of chronic
hepatic disease have a stronger correlation with anti-HCV. (k; =
0.001).
Captoprii test and renin determination as a chailenge test, as a
diagnostic procedure, and its predictive value in renovascular hyperten-
sion (RVH). J. Alfonzo, T. NotO, F. Izquierdo, R. Fraxedas, and H.
Bayarre, Instituto de Nefrologla y CIMEQ, La Habana, Cuba. To
examine the efficiency of captopril test (CT) and plasma renin activity
(PRA) in peripheral and renal veins as a diagnostic procedure, and to
detennine its predictive value, we studied 456 hypertensive patients
between September 1986 to May 1991. In 162 subjects a complete
screening test for RVH was performed (CT, captopril stimulated
23
55
41
28
16
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peripheral renin measurements, 99m TcDMSA before and after capto-
pril administration and DSA). RVH due to artery stenosis (AS) and with
unilateral renal parenquimatoses disease (URPD) with increased renin
production by ipsilateral kidney were identified. From a total of 162
patients, 53.1% were female and 46,9% male, and 62.2% were White
subjects. Clinical features found associated with RVH were: ateroma-
tous disease (69.2%), kidney asymmetry (65.2%), severe and refractory
hypertension (53.2%). CT (+) test in 44.5% (70.8% with Sr < 120
mmollliter and 29%> 120 mmol/liter). In RVH the CT was (+) in 48.8%
and in essential hypertension (EH) CT (—) in 90.6% (sensitivity 85.4%,
specificity 61.2%). High PRA was found in 46.6% (56.2% with RVH)
and close normal range in 80%ofEH patients (5 = 71% and Esp 67.6%).
A correlation between CT and PRA was found (P < 0.05). The most
predictive curability renin ratio value in RVH was renal vein renin ratio
(83.8%). RVH was diagnosed in 79 patients (48.7%) [31 (19.1%)
unilateral; 15 (9.2%) bilateral and 33 (20.3%) URPD]. PTA was per-
formed with satisfactory results in 13 cases and 21 had surgical
revascularjzatjon procedures (2 autotransplant) or nephrectomy. In
97.05 of the cases a better pressure response (cure or improvement) to
intervention therapy was found.
Ozone as a contrast medium for digital substraction renal angiography
in the study of hypertensive patients. J. Alfonzo, C. Ugarte, I. Banasco,
and J. GarcIa, Instituto de Nefrologia y Centro de Investigaciones
Medico QuirOrgicas, La Habaña, Cuba. Radiological images of the
aorta and the renal arteries are essential for the follow-up of potential
renovascular hypertensive patients. The goal of this paper is to present
the result of the evaluation of ozone, a radiological contrast medium,
with intra-arterial digital substraction renal angiography (DSA) in a
group of hypertensive patients in whom allergic reactions to iodine
contrast media had been reported. After femoral catheterization
(Seldinger technique), an intra-aortic catheter was placed at L-2 level.
Twenty ml of 33 tg/1iter of ozone was injected by hand with a crystal
syringe and DSA (Angiotrom CMP, Siemens) was performed in 12
patients. We were able to obtain clear images of abdominal aorta and
renal arteries with few and transitory side effects that guide us to
identify 3 cases of renal stenosis similar to those obtained by iodine
contrast medium. Follow-up studies of renal function were unchanged
in the whole group of studied patients, The quality of the images, low
cost, and absence of major complications in short as well as long
follow-up make this technique useful in patients in whom iodine
contrast medium could be dangerous.
Hypertension and unilateral small kidney. Study of 78 moderate and
severe hypertensive patients. J. Alfonzo, B. Montero, C. Ugarte, J.
Banasco, R. Fraxedas, H. Bayarre, A. Caste!!, andJ. Garcia, Instituto
de NefrologIa y CIMEQ, La Habaña, Cuba. The goal of this paper is to
evaluate the role of a small unilateral kidney in the pathophysiology of
hypertension in adult hypertensive patients with renal asymmetry.
Seventy-eight (6.5%) cases from 1200 diagnosed as having arterial
hypertension showed one asymmetric sized kidney in a plain abdominal
film or in ultrasound renal study, and were classified by size reduction
into 3 groups: Group I (m = 17) less than 15%: Group II (m = 18)
15—50%; and Group III (m = 43) more than 50%. Captopril test (CT),
peripheral renin activity (PRA) before and 90 minutes after 50 mg
captopril administration, renal vein renin activity (RVRA), 99m
TcDMSA gammagraphy before and after captopril and DSA were
performed in all cases. The RK was affected in 46.6% cases and LK in
53.9%. CT was positive in 46.1% in Group land 66.6% in Group II and
Ill. PRA showed in normal range of 58.8% in Group I and increased in
Group 11(88.8%) and in Group III (83.7%). Renovascular hypertension
(RVH) was diagnosed in 59 (75%) cases: 26 (33%) renal artery stenosis
and 33 (42%) unilateral parenquimatous disease. No relation was found
between the asymmetric unilateral kidney and hypertension in 19(25%)
patients, and we called it non-renvascular hypertension (NRVH).
Seven cases were treated by PTA (2 cured and 5 improved); 13 cases
had surgical revascularization or nephrectomy (4 cured and 9 im-
proved), and 56 patients were pharmacologically treated (54 controle
and 2 without control). In general, 20 (33%) of all RVH cases were
cured or improved with interventional procedures. We conclude that
both hypertension and renal unilateral kidney may be present and not
causally related, especially when renal asymmetry is not prominent
(Group 1) and an increase in renin production by ipsilateral kidney can't
be demonstrated. With combined studies and appropriate choice of
treatment, good results in hypertension control can be obtained.
Densitometry and histomorphometry in 19 patients with renal trans-
plant after being on peritoneal dialysis. J. Tamayo, A. Mondragon, E.
Altamirano, M. Renbolth, F. Chessal, and F. Velazquez, Fundacion
Medica Sur, Hospital Moce!, Mexico City, Centro Medico del Potosi,
San Luis Pozosi, Mexico. Renal Insufficiency is always associated with
renal osteodystrophy (RO); glucocorticoid (G) administration is also
associated with secondary osteoporosis (SO). After the renal trans-
plant, the bone metabolic disease is under the influence of RO and/orG.
This transversal study analyzed the bone density (BD) according to the
DXA technic (Hologic QRD 1000 W) in 19 patients who had renal
transplant after being on continuous ambulatory peritoneal dialysis
(CAPD) between 5 and 30 months: we studied 9 females, average age
30.8 years (range 19—54) and 10 males, average age 31.4 years (range
18—44). This study was performed between 3 and 43 months after the
renal transplant (average 22.6 months), and the creatinine clearance
was 61.5 15.2 ml/minll.73 m2 (27.3—86.77). Fourteen patients had low
BD and were classified according to the DXA of the lumbar spine in
group a, with two or more standard deviations below the average for the
young adult, (6 patients). In group b we detected 8 patients and they had
less than two standard deviations. The rest of the patients, five of them
(group C) had normal or high BD. Histomorphometry was done in 6
patients: one of group a, four of group b and one of group c.
Osteomalacia was detected in five of them and one had aplastic bone
disease. None of the patients had aluminum or iron in the mineralization
front; we always found a fluorescent tetracicline band. The data
suggest: (a) BD is low in 73% of renal transplant recipients; (b) there is
no relationship with the creatinine clearance or the time elapsed after
the renal transplant; (c) osteomalacia was found in 5 of the 6 bone
biopsies performed. These findings may reflect persistent RO or the
influence of the G on the vitamin D metabolism.
Continuous and ambulatory peritoneal dialysis (CAPD) in patients with
diabetic nephropathy (ON). C. Chavez, L. Jose, F. Chessal, A. Perea, J.
Isordia, A. Navarro, E. Costa, and L. Llamazares, Nephro!ogy,
Endocrinology, Surgery and Nursing Department, Centro Medico del
Potosi; Rena! Lab, School of Medicine, San Luis Potosi, Mexico. A
significant number of patients with chronic renal failure (CRF) were
seen in Centro Medico del Potosi and were included in the CAPD
program. This is a retrospective study of 86 patients included in the
CAPD-DN program, who had Tenckhoff catheter placement between
January 1982 and December 1991, because of CRF. Of the 86 patients
included, 32 had DN (37.2%), only 25 of the 32 patients were included.
Five patients had diabetes mellitus type I. Sixteen patients were male.
The average age was 39.2 years and 60.1 years for the DM type II
group. All the patients were diabetics for more than 15 years. The
average observation time was 16 months (range 3—.48 months). The
Tenckhoff catheter worked fine during the observation period. There
was improvement of CRF laboratory values. The retinopathy, neurop-
athy and angiopathy did not progress in 10, 12 and 19 of the patients
described, respectively. Only 6 patients did not require blood transfu-
sion. Peritonitis was the most frequent complication causing the death
of two patients and the loss of six catheters. The mortality was 48%.
Three of the living patients had renal transplants and three more are
waiting for the same procedure to be done. We feel that DN was the
leading cause of CRF in this group of patients. The high mortality and
extrarenal complications of DM were secondary to delayed CAPD. We
proposed an early inclusion in the CAPD program and a multidisci-
plinary approach to improve the quality of life before the renal
transplant.
Body composition (BC) evaluation in patients with chronic renal failure
on maintenance hemodlalysis (H). José Maria Basaluzzo, Rodolfo Gini-
ger, José Maria Sanfilippo, Susana Esperanza, Cristina Vallvé and
Daniel E. Lopez, Centro de Nefrologla y DiOlisis (CENEDI), Buenos
Aires, Argentina. BC was studied in 41 patients (19 male and 22 female,
age 49 17), on H for 3.92 2.81 years. Pre-dialysis water excess was
evaluated by calculating the residual mass (RM) (pre-dialysis body
weight of fat, skeletal, muscular and visceral body masses weight). BC
was determined by the anthropometric fractionation of body mass
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method reported by Drinkwater and Ross. Energetic store was calcu-
lated as fat mass (kg)/skeletal mass (kg) (normal range 0.85—I .47) and
protein store as muscular mass (kg)/skeletal mass (kg) (normal range
2.15—2.72).
Results N
Energetic
store
% N
Protein
store
%
Normal 20 48.7 20 48.7
Decreased: (a) moderate 11 26.8 13 31.7
(b) severe 4 9.7 6 14.6
Increased: (a) moderate 2 4.8 1 2.4
(b) severe 4 9.7 1 2.4
RM was 4.13 2.26 kg before H, with a reduction in body weight of
2.21 1.10 kg at the end of the procedure. No significant relationship
was found between energetic and protein stores with time on dialysis,
age, RM and associated diseases. It was concluded that half of the
patients on H showed energetic and protein malnutrition, which seems
to be independent of the time elapsed since the beginning of the H
treatment. Besides, calculation of the RM is an adequate approach to
estimate water excess at the initiation of the dialysis session, contrib-
uting to program a correct ultrafiltration.
Spontaneous decrease of polymorphonuclear cells (PMN) in patients
with chronic renal failure and hemodialyzed patients. MarIa Ilvento,
AgusrIn Quevedo, Hector Estravez, Roberto Diez, Maria Estevez, and
Luisa Sen, National Academy of Medicine, Buenos Aires, Argentina.
The aim of the study was to evaluate polymorphonuclear cell (PMN)
chemotaxis from patients with chronic renal failure and the effect of
hemodialysis. We studied 29 patients with chronic renal diseases of
whom 19 were on hemodialysis. The chemoattractant used was
N-formyl-methionyl-leycyl-phenylalanine. The random migration of
PMN from hemodialyzed patients was lower than that of normal
controls (N = 16, P = 0.01) or the group of patients without hemodi-
alysis (P = 0.05); no difference was found between this last group and
normal controls. Although the migration indices (MI) of the non-
hemodialyzed group and the hemodialyzed one were similar, both
groups differed from controls (P = 0.01). In conclusion, hemodialysis
mainly affects PMN random migration, while chronic renal failure and
hemodialysis are responsible for the impaired directed migration in-
duced by the chemoattractant.
Grey level granulometry: A new method to quantify interstitial chronic
renal damage. D. Serón, M.F. Colomé-Serra, F. Moreso, L. Carreras,
R. Poveda, A.M. Castelao, J.M. GriCó, J. Alsina, J. Serra, Servicio
NefrologIa Hospital de Bellvitge, Barcelona, Spain, and Ecole des
Mines, Fontainebleau, France. Interstitial surface (IS) is a quantitative
measure of chronic interstitial renal damage that correlates with gb-
merular filtration rate (GFR) at the time of biopsy and prognosis of renal
disease. IS is measured with a point-counting technique or with a light
pen. These morphometric methods are very time consuming and
depend to a certain extent on the skills of the observer. The aim of the
present study is to apply mathematical morphology techniques in order
to quantify interstitial chronic renal damage. The rationale for this
approach is that renal interstitium can be viewed as a texture, and for
this reason interstitial changes could be quantified with grey level
granulometry, Fifty-nine fields at 200 x magnification from 14 renal
biopsies with different degrees of chronic renal damage were stained
with silver methenamine and digitalized at 256 x 256 pixels on a
hexagonal raster. In each field, IS was measured with a point-counting
technique and a 108 point graticule. Visilog 3.6 software was used for
image analysis. The opening and closing functions of the spectral grey
level granulometry with a structuring element of increasing size nH = 1,
2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 24 was calculated for a nonnal
kidney, a kidney with moderate IgA disease, and a kidney with severe
IgA disease. The result of this experiment showed that only the opening
function clearly discriminated between different stages of chronic renal
damage. Interstitial texture disappeared from opening 1 to opening 6.
Tubular lumen disappeared from opening 8 to opening 24. A second
experiment was performed in which granulometric function from open-
ing Ito 6 was calculated in all studied fields. The result obtained in each
step of granulometry positively correlated with interstitial surface, and
the best correlation coefficient was obtained with the second step of the
opening function (r = 0.77, P = 0.0001). We conclude that grey level
granulometry constitutes a new approach to objectively and quickly
quantify interstitial chronic renal damage.
Characterization and kinetics of the interstitial cell infiltrate in early
gentamicln (G) nephrotoxlcity. Carlos A. Vaamonde and Victoriano
Pardo, Departments of Medicine and Pathology, VA Medical Center
and University of Miami School of Medicine, Miami, Florida, USA. We
studied the interstitial cell infiltrate induced by 0 administration in an
inbred rat strain to determine its nature and functional significance.
Lewis rats were injected s.c. with 60 mg/kg body wtJday of G for 8 days
and sacrificed at baseline, 4 hours, 2 hours, 1, 2, 8, and 14 days.
Matched rats injected with Ringer's were controls (C). Cryostat sec-
tions were stained by the APAAP immunoperoxidase technique with 10
monoclonal antibodies to rat lympho-hematopoietic antigens, and vi-
mentin (V). By days I and 2 there was a significant increase in 0-treated
rats of Ia+, LCA+, and W3/25+ (T helper) interstitial cells. This
pattern was replaced by an Ia+, LCA+, ED2+, and 0X42+ infiltrate,
probably representing macrophages. T suppressor cells (0X8+) in-
creased on day 8, as W3/25 cells were decreasing. Sparse proximal
tubular cells were V+ only in G rats at day 8 corresponding to focal
areas of tubular necrosis and regeneration. After 24 and 48 hours of G,
there were no changes in serum creatinine despite high renal cortical 0.
By day 8 creatinine clearance in 0 decreased from 1.1 0.1 (SE)
ml/min/lOO g body wt to 0.2 0.1 (P < 0.0001), whereas in C it
remained unchanged. High gentamicin concentrations in the renal
cortex were associated with early (24 hr) interstitial inflammation in the
absence of functional or morphologic features of tubular injury. These
changes may play a role in the pathogenesis of G nephrotoxicity.
Renal transplantation in Latin America: Attempts to develop a Latin
American transplant registry. E.A. Santiago-Delpin. Since 1970 statis-
tics on organ transplantation have been kept with increasing care in
Latin America. Most recently, registries have been developed in
several of the more mature and larger programs. Polls, telephone
interviews and questionnaires in the last two years have resulted in the
gradual formation of a database consisting essentially of tally-counts or
enumerations of the organ transplants performed in Latin America to
date. Almost all Latin countries in this hemisphere have provided data,
including Mexico in North America; Cuba, Dominican Republic and
Puerto Rico in the Caribbean; Guatemala, El Salvador, Honduras,
CostaRica and Panama in Central America; and Colombia, Venezuela,
Brazil, Ecuador, Peni, Bolivia, Argentina, Uruguay, Paraguay and
Chile in South America. A total of 23,830 kidney transplants have been
performed in the region, with higher volume countries being Brazil
(almost half of this amount), Mexico, Argentina, Cuba, Chile, Colombia
and Venezuela. In addition the region has performed 430 heart trans-
plants, 215 liver transplants, 27 pancreas transplants, 24 kidney-pan-
creas, 22 lung transplants, and 7 heart-lung transplants. Immunosup-
pression protocols and published results appear to be similar to those in
larger European and North American registries. Tropical and unusual
infections are reported occasionally, the most important pathogens
causing morbidity in Latin American being viruses (Cytomegalovirus),
bacteria (E. Coli, Klebsiella) and parasites (Pneumocystis cannii and
Amoebas). There are a number of initiatives from national and interna-
tional Latin American societies to develop more formal continued data
retrieval and monitoring in order to develop formal registries.
Soclo-ethical aspects of the treatment of renal Insufficiency in America.
Limited economic resources force governments and societies through-
out America to establish access and exclusion criteria for dialysis and
transplant services. The process requires that the ethical principles of
equal distribution, well-being of the majority, availability of resources
and non-discrimination because of sex, race, religion, politics, social
and economic status be taken in consideration. These principles should
challenge the nephrology community in America to assume the initia-
tive in this area together with bioethicists. The last word as to the
rationing of services should come from the society itself, after an
adequate consensus has been achieved. The participation of dialysis
and transplant patients is vital in that process. All strategies towards
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this purpose recommended by the First Conference on Consensus over
Chronic Renal Insufficiency, Dialysis and Transplant held in Caracas,
Venezuela (May, 1988) under the auspices of the Pan American Health
Organization should be implemented.
Primary glomerulonephritis: Clinical and pathological study. Gina
Solis, Elizabeth Escudero, Carmen Asato, Adolfo Villar, Rodolfo
Zavala, and AbdIas Hurtado, Section of Nephrology, Hospital Nacio-
nal Arzobispo Loayza, Section of Pathology, Hospital Guillermo Alm-
enara, Lima, Perá. A clinical and pathological study of primary
glomerulonephritis (ON) was performed in our hospital between June
1984 and December 1990. The history and renal biopsy (Bx) of 70
patients, 60 female and 10 male, with mean age of 33.9 years, were
examined. The most frequent symptom was edema, and 34.69% had
arterial hypertension (HT). The urinary sediment was pathologic in
100% Without a characteristic pattern in either GN (21% had a positive
urine culture), massive proteinuna in 78.57%, hypoalbuminemia in
88%, anemia in 78.78%. Twenty-two (31.42%) had renal failure (RF).
The occurrence of each GN was: membrano-proliferative (MP) 33
(47.14%), membranous (M) 14 (20%), focal and segmental escierosis
(FSS) 11 (15.71%), mesangial (Ms) 6 (8.57%), minimal glomerular
changes (MGC) 5 (7.14%), and crescentic (Cr) ON 1 (1.42%). Sixty-
seven patients had immunofluorescence study (IF). In the MP-GN
group, 15.6% had scierosed glomeruli and 63.63% interstitial nephritis
(IN), IgG: 72%, 1gM: 81%, IgA: 45%, and C3: 78% in capillary loops, in
mesangium 1gM was most frequent (45.45%). In M-GN, 8.14% had
sclerosed glomeruli, 50% IN, IgG: 86.7%, 1gM: 71%, IgA: 50% and C3:
85% in capillary loops. In FSS, 12% had sclerosed glomeruli, 36% IN,
1gM and C3 were found only in IF. In Ms-GN there were no scierosed
glomeruli and 33% had IN; 1gM were found in 66% in capillary loops
and in mesangium. In Cr-ON all glomeruli had cellular crescents and C3
was found in the vascular endothelium. The MGC-GN Bx were
optically normal without deposition in IF. We concluded that the
MP-GN is the most frequent primary GN in our patients in adult
population. The primary GN presents as nephrotic syndrome in most
patients and often with HT, RF and IN.
Furosemide and oligurlc (0) acute renal failure (ARF) in cholera.
AbdIas Hurtado, Elizabeth Escudero, Juana Celis, Maria Hurtado,
Gina Solis, Boris Medina, and Jaime Urcia, Section of Nephrology
"Hospital Nacional Arzobispo Loayza," Lima, Perd. We evaluated
100 patients with cholera and ARF, during an epidemic outbreak
between February and May 1991, who attended the Hospital Arzobispo
Loayza. Fifty patients were O-ARF, and the response to furosemide in
these patients was evaluated in a retrospective study, analyzing the
clinical evolution and the requirements of hemodialysis (HD). A rever-
sion of the oliguria in 41 patients was achieved by administering
furosemide in an average dose of 312 200 mg/day. However, 15
patients required HD. Nine patients were unresponsive to furosemide
and required HD. There were no age-related differences between
non-HD and HD patients (54.11 12.1 vs. 56.86 13 years). The
duration of the disease was shorter in non-HD patients (4.33 4.37 vs.
5.0 2.6 days); also, the maximal serum creatinine rate was lower in
non-HD patients (7.3 2.5 vs. 9.8 2.0 mg/dl, P < 0.01). The
furosemide average dose was 204 188 in non-HD vs. 420 233
mg/day in HD patients (P < 0.001). Six patients who belonged to the
HD group died (P < 0.05). In our experience it was evident that the use
of furosemide achieved a high percentage of reversion in O-ARF, the
non-HD patients required a lower dose than HD patients. We suggest
that furosemide administered in an average dose of 200 mg/day deter-
mines the group of patients with a lesser degree of renal impairment.
Tubule interstitial disease (Tm): Clinical pathological study. Elizabeth
Escudero, Abdias Hurtado, Carmen Asato, and Rodolfo Zavala, Sec-
tion of Nephrology, H.G.N. "Arzobispo Loayza," Section of Pathol-
ogy, Hospital Guillermo Almenara lrigoyen, Lima, Peru. We evaluated
the history and renal biopsy (lix) of 24 female patients with TID
between 1984 and 1989. Seventy-five percent of the cases were second-
ary to infections: sepsis in acute pyelonefrittis (PNF) 10; septic abortion
3; sepsis in pleural empyema 2; tuberculosis (TBC) 2; brucella 1. Of the
cases, 16.4% were drug-induced (diclofenac, ibuprofen, oxacilin, rifam-
picin). One case was related to the home distilling of alcoholic bever-
ages (H-DAB). The clinical settings were acute renal failure (ARF) 20
(83.3%); reactivated chronic renal failure (CRF) I; significant protein-
uria 11; nephrotic syndrome 2 (TBC and PNF with pre-eclampsia);
eosinophiluria 3. Fever and pathological sediment were found in 100%.
Renal Bx: In TID related to infections we observed acute tubular
necrosis (ATN) 55.5%; mononuclear infiltrate (MN) 94.4%; polymor-
phonuclear infiltrate (PMN) 50%. Granulomas and caseum necrosis
were found in TBC. In drug-induced TID, 75% showed ATN, 100%
MN, 25% PMN and 50% eosinophil infiltrate. PTS with H-DAB showed
ATN, MN and eosinophil infiltrate. Patients with CRF showed MN
infiltrate, signs of ATN, fibrosis and moderate atrophy. Twenty-five
percent of patients with TID had mild mesangial hyperplasia. Immuno-
fluorescence evaluation was practiced in 87.5% of patients, being
positive in 66.6% in capillary loops and vascular endothelium with a
granular pattern; only one case showed interstitial deposits. We con-
cluded that ARF is a common way of presentation for TID, with
infectious diseases being the first cause. MN infiltrate and ATN are the
predominant histological lesions.
Low urinary citrate excretion relative to calcium in idiopathic calcium
stone formers. M.A.P. Rebelo, J.A.G. Leite, andN.C. Aradjo, Division
of Nephrology, Hospital Universitdrio Pedro Ernesto, Universidade do
Estado do Rio de Janeiro, Rio de Janeiro, Brazil. Citrate has been
identified as a naturally occurring inhibitor of calcium oxalate/calcium
phosphate crystallization due to its properties to form soluble com-
plexes with calcium. We measured urinary citrate and calcium in 45
non-hypercalciuric non-hypocitraturic calcium stone formers (SF) and
16 healthy subjects (HS) in order to assess the urinary citrate/calcium
ratio. Normocalciuria was defined as less than 4 mg/kg/day and nor-
mocitraturia as more than 320 mg/day. No significant statistical differ-
ence was observed between normals (HS) and stone formers (SF)
except for urinary citrate and citrate/calcium ratio which were lower in
later. The findings suggest that despite normocalciuria and normocitra-
turia the calcium stone formers have a higher risk to calcium salts
supersaturation, due to a low urinary citrate/calcium ratio.
Uj1
mg/24 hr
Uca
mg/24 hr
Ujt/Uca
mg/mg
Age
years N
HS
M 655.2 432.0 149.5 50.0 4.99 4.19 27.6 3.62 08
F 670.5 310.1 132.2 66.3 6.31 4.11 38.2 9.63 08
B 662.8 363.3 140.8 57.4 5.65 4.07 32.9 8.91 16
SF
M 486.7 171.4 149.9 40.8 3.42 1.35 39.3 13.4 24
F 513.3 167.0 126.0 29.7 4.07 1.95 38.4 11.5 21
B 499.1 l68.Oa 138.7 37.6 3.72 l.67a 38.9 12.4 45
Abbreviations are: M, male; F, female; B, both.
a P < 0.05 HS(B) vs. SF(B)
Recurrence in renal lithiasis. N.C. Arafljo and M.A.P. Rebelo,
Division of Nephrology, Hospital Universitdrio Pedro Ernesto, Univer-
sidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. The stone
recurrence rate (RR) was calculated by dividing the number of stones
formed by the total time-interval disease (Ti-D), in 106 patients (57
women), who formed at least two stones. The mean age and Ti-D were
39.9 and 7.34 years, respectively. The patients were rearranged accord-
ing to hypercalciuria, hyperuricosuria, no stones or infection. The mean
RR was 1.37 stones/patient year. Age, sex, etiology and metabolic
abnormalities in idiopathic lithiasis had no statistically significant effect
on RR. On the other hand, the Ti-D had a striking influence on RR:
patients with a short time-interval disease (<4 years) had a higher RR
than patients with a longer one (2.59 2.58 vs. 0.69 0.61 stones/
patient year; P < 0.05). Indeed it was observed that RR suffers a
progressive decline until 10 years of disease. It was concluded that: (a)
RR assessment in patients with a Ti-D shorter than 4 years has a false
high value; (b) RR suffers a progressive decline with the duration of the
disease that stabilizes at 10 years and remains constant for a period
longer than 20 years.
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Ti-D Age RR N
<4 36.6 2.60 2.58 38
4—5 39.9 0.96 0.52 16
6—7 35.6 0.89 0.96 12
8—9 46.8 0.72 0.53 09
10—11 41.8 0.40 0.27 09
12—13 43.0 0.37 0.13 05
14—15 46.8 0.60 0.41 07
19—27 43.5 0.46 0.42 10
Long-term evolution of patients treated with vitamin D3 i.v. C. Sanz
Moreno, E. Baamonde, J. Hernandez, J.M. Garrancho, J. Fernandez,
D. Sanz Guajardo, and J. Bogella, Nephrology Service, Puerta de
Hierro Hospital, Madrid, Spain. Vitamin D3 i.v. is an effective treat-
ment to control severe hyperparathyroidism resistant to other thera-
peutics. However, the short experience with this kind of therapeutic
sets up a lot of questions about the period of time of administration and
the long-term possibility to change to oral vitamin D3. Eighteen months
ago we began the treatment with 2 rg of vitamin D i.v., 3 times/week in
12 patients of our hemodialysis program with severe hyperparathyroid-
ism. Only in 6 cases have we been able to follow the total evolution
during this period of time. One patient died due to causes unconnected
with the treatment. Another was transferred to another hemodialysis
center. Three patients received kidney grafts while they were being
treated with vitamin D i.v. One patient was submitted to parathyroid-
ectomy since he didn't respond to the treatment. In 3 of the 6 remaining
cases treatment was suspended 10 months later since their iP'FH values
were normal; one of them still values almost normal (iP'FH 80.3 pg/mI)
receiving oral vitamin D (0.25 pg/day); in spite of the fact that today the
other 2 aren't receiving vitamin D, but only calcium carbonate, after 8
months the iPTH value is normal (79 9 pg/mI). Three patients still
continue to receive vitamin D i.v. because when we tried to change to
oral vitamin D, the iPl'H increased. After the 18 months of treatment
the iPTH value passed from 581.6 119.9 pg/mI to 189.7 67.2 pg/mI.
In conclusion, parathyroid glands show a large variability response. It's
important to keep in mind the 2 cases that are today controlled without
using any vitamin D compound; this could perhaps be explained by the
gland calcium change of sensitivity alter being treated with vitamin D
i.v.
Peritonitis caused by fungus of the Candida type in peritoneal dialysis.
L. Perez Burner, E. Fernandez Ruiz, P. Lopez Alvarez, J.M. Diaz
Sampelayo, and J. Rodriguez Hernandez, Medical Science Institute of
Villa Clara, Division of Nephrology, Provincial Hospital, Santa Clara,
Villa Clara, Cuba. The peritoneal fungal infections cause difficulty in
selecting the most effective and least risky therapy. We analyzed our
scheme of treatment, complications and evolution of these patients.
Material and methods: 224 patients from July 1989 to October 1991
(including both months) were treated by intermittent peritoneal dialysis
with two cuff Tenckhoff catheter. Thus, for the diagnosis of fungal
peritonitis, the presence of clinical signs of intrabdominal sepsis,
cellulate of peritoneal liquid effluent elevated over 100 cells X cubic
millimeters, levaduriform cells in the direct gram in two or more times
and the presence of two or more positive cultures for fungus were
analyzed. Results: 8 patients had episodes of peritonitis by Candida, and
the evolution was bad in the majority of the patients. All of them had a
history previous bacterial peritonitis treated with cephalosporine and
aminoglucosid. The complications were frequent and the loss of the
peritoneal membrane for dialysis occurred in six patients. Mortality was
not high as compared with the data of other authors. Conclusions: Ways
of immediate diagnosis as well as an effective therapy are main goals for
this septic complication of peritoneal dialysis. The effectiveness of the
systemic amphotericyn B associated with local intraperitoneal Micon-
azole together with total parenteral nutrition, hemodialytic support,
local use of heparin and removing the intraperitoneal catheter are
measures to analyze patients suffering from peritonitis by Candida
during peritoneal dialysis.
Membrane plasmapheresis and continuous peritoneal dialysis in treat-
ment of patients suffering from secondary multiorgan failure to leptospi-
rosis. L. Perez Burnes, E. Fernandez Ruiz, P. Lopez Alvarez, and I.
Rodriguez Hernandez, Medical Sciences Institute of Villa Clara, Divi-
sion of Nephrology, Provincial Hospital Santa Clara, Villa Clara,
Cuba. Icterohemorragiae leptospirosis is a disease which is relatively
frequent in our country; some patients during its evolution develop
multivisceral disorders that require intensive interdisciplinary treat-
ment. We have used plasmapheresis in combination with continuous
peritoneal dialysis within the context of intensive support in the critical
patient having multiorgan failure. The results obtained are satisfactory,
causing us to state a new therapeutic choice. Materials and methods: Six
patients suffering from secondary multivisceral failure due to leptospi-
rosis were assisted by the nephrological service from July 1990 to
January 1992 (including both years). Membrane plasmapheresis and
continuous peritoneal dialysis were used. The affected organs, compli-
cations and their evolutions after this combination extractive therapy
were analyzed. Results: A clinical improvement was evident alter three
sessions of plasmapheresis with fresh frozen plasma reinlusion and
separation of 150% of plasmatic volume and 72 hours of continuous
peritoneal dialysis; in this way we obtained a clinical and analytical
improvement within the stated parameters for the diagnosis of the
visceral failure. There were no diseases in the series. Conclusions: The
combination of the depurative methods in patients who are seriously
affected by multivisceral failure secondary to leptospirosis must be
analyzed within the context of intensive care as immediately as possi-
ble. Although it is a small sample, the few complications and the
absence of mortality in such a situation needs further intensive discus-
sion and analysis.
Vascular access for hemodialysis. Two years experience. F.J. Vazquez
Roque, L. Perez Burnes, D. Rivero Valeron, E. Fernandez Ruiz, N.
Portal Benitez, and R. Martinez Mondeja, Medical Science Institute of
Villa Clara, Division of Nephrology, Provincial Hospital Santa Clara,
Villa Clara, Cuba. The lives of the patients suffering from end-stage
renal disease depend on the precise vascular access which permits the
connection between the patient and the hemodialysis machine. It is our
intention to convey the importance of the vascular access for the
hemodialysis procedure which may determine for the patient with renal
failure the difference between life and death. Material and methods: The
clinical charts of 77 patients, in whom 94 vascular accesses were
performed, were studied. The patients were grouped taking into ac-
count age, sex, localization and type of anastomosis. The evolution of
the vascular access related mainly either to the presence or not of
immediate thrill and was analyzed, as well as the complications
depending on the type and in relation to the time of the procedure.
Results: Vascular access was frequent in patients between 30 to 39 years
old (32.4%) with predominance in the series in favor of males, 46
patients (59.7%). The arteriovenous fistula in the upper limbs together
with lateral terminal anastomosis in the forearm region were the most
frequent. The 72% of the fistulas performed were functioning, as well as
those which showed immediate thrill (92%). Conclusions: The presence
of the immediate thrill alter the performance of the arteriovenous fistula
is very suggestive of a good function later. The most frequent compli-
cation found was thrombosis. The preoperatory physiotherapy with
dilation of the venous system associated with anti-aggregation of
platelet, the use of papaverine, heparin and transoperatory dilation with
the fine plastic tube make up a group of factors that together with
accurate surgical technique are essential for the development and
adequate maturity of the artenovenous fistula.
Acute renal failure in 138 patients: Clinical analysis. E. Fernandez
Ruiz, L. Perez Burnes, P. Lopez Alvarez, f.M. Diaz Sampelayo, R.
Martinez Mondeja, and J. Rodriguez Hernandez, Medical Science
Institute of Villa Clara, Division of Nephrology, Provincial Hospital
Santa Clara, Villa Clara, Cuba. Our country is a developing country
with an adequate health system, which has changed the evolution and
incidence of several diseases. Acute renal failure is not an exception,
and we have studied the etiology, complications and evolution of this
frequent syndrome in our hospital system. Material and methods: From
July 1988 to July 1991 (including both years), 138 patients suffering from
acute renal failure were diagnosed (77 women and 61 men). The
diagnosis was reached by the clinical antecedents of the patients and
diagnostical urinary index among other lab parameters. Results: The
most frequent causes of the syndrome were both clinical or surgical
sepsis, associated with the use of antibiotics, and hypovolemia caused
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by acute hemorrhage or volumen contraction alter vomiting, intestinal
loss or burning. One hundred one patients had the oliguric form and 37
patients no oliguric variable. The most frequent complications in this
group were cardiac failure and respiratory or systemic sepsis. The
mortality was 61.6%, mainly burn and surgical patients. The group
between 55 to 65 years old and the over 65 year old group had a high
mortality. Conclusion: The causes of acute renal failure in our city are
not different from those of other industrialized countries. The surgical
group and the older group had the highest mortality with no relation to
the depurative treatment.
Hemoperfusion in acute exogenous intoxlcations. E. Fernandez Ruiz,
L. Perez Burnes, P. Lopez Alvarez, J.M. Diaz Sampelayo, R. Martinez
Mondeja, and J. Rodriguez Hernandez, Medical Sciences Institute of
Villa Clara, Division of Nephrology, Provincial Hospital Santa Clara,
Villa Clara, Cuba. Acute intoxications are difficult problems for the
physicians and a therapeutic possibility is the use of one or more
depurative methods, which could be very important in some patients.
The hemoperfusion which was introduced in our city around the end of
1986 means a new therapeutic choice for some of these patients.
Material and methods: Forty-eight patients were analyzed; they re-
ceived hemoperfusion with activated charcoal to treat acute exogenous
intoxications from November 1986 to December 1991. We stated the
causes of the intoxication. There were complications and a later
evolution after this method of treatment. Results: The main causes of
the exogenous intoxication were sedative drugs, sedative drugs +
tricyclic, phosphated organs, and polypharmacy; the complications
resulting from the methods were only few and easily handled, and the
mortality was 24%. We should understand that in spite of the present
controversy, our results in the evolution of intoxicated patients by
tricyclic therapy are in favor of the use of this technique. Conclusions:
The hemoperfusion with activated charcoal is a method that can be used
in intoxicated patients due to a rapid recuperation of vital function,
improved outcomes, and decreased complications in relation to coma
and mechanic ventilation.
Could aluminium change the immune response? Carmen Tzanno-
Martins, Luis S. Azevedo, Marcia Tanji, Ana Cristina Silva, Marcello
Marcondes, Emil Sabbaga, Vanda Jorgetti, and Alberto J.S. Duarte,
University São Paulo Medical School, São Paulo, Brazil. Aluminium
(Al) intoxication is common in chronic renal failure patients. Recently,
some papers have reported a possible immunosuppressor role of Al.
Successful renal transplantations with few rejection episodes have been
associated with dialysis encephalopathy and with high tissue levels of
this metal. There is also a report concerning a great susceptibility to
infection in Al-intoxicated patients. The objective of this paper was to
evaluate possible immunosuppressive properties of Al analyzing in vitro
proliferative response of lymphocytes from normal animals and from
animals with chronic renal failure, intoxicated or not with Al. Isogenic
Lewis rats (RT") were used and divided into 4 groups: Ia normal
control, lb normal renal function Al intoxicated, ha chronic renal
failure and lib chronic renal failure Al intoxicated. Chronic renal failure
was obtained by subtotal nephrectomy. Two weeks later blood urea
was measured to ensure renal failure and Al intoxication was started.
Daily intraperitoneal injections of a 0.25 M AICI3 solution were used
during 4 weeks until accumulative dose of 30 mg/animal was achieved.
Controls received saline. Bone histochemistry as well as Al quantifica-
tion in bones were performed. Rat spleen cells (4 x io cells/well) were
delivered to a 96 well plate containing Concanavalin-A 5 g/ml and 10
tg/ml. Blastogenesis was evaluated by tntiated tymidine incorporation
alter 72 hours of incubation. Groups II had high urea levels (P < 0.01).
Groups lb and hIb had high Al tissue concentration and Al histochem-
istry was strongly positive. Blastogenesis occurred in four groups but
with different levels of response (P <0.001). Animals from group lb and
lib showed less intense blastogenesis when compared to the others
groups at the 2 concentrations of Concanavalin-A (P < 0.001). Group
ha showed an impaired response in relation to group ha. These results
suggest that Al could play some role in immune response in renal
patients.
Body composition (BC) evaluation in patients with chronic renal failure
on maintenance hemodlalysis (H). José Maria Basaluzzo, Rodolfo Gini-
ger, José Maria Sanfilippo, Susana Esperanza, Cristina Vallvé and
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Daniel E. LOpez, Centro de NefrologIa y DiOlisis (CENEDI), Buenos
Aires, Argentina. BC was studied in 41 patients, 19 male and 22 female,
aged 49 17 years, on H for 3.92 2.81 years. Pre-dialysis water
excess was evaluated by calculating the residual mass (RM) (pre-
dialysis body wt— of fat, skeletal, muscular and visceral body masses
weight). BC was determined by the anthropometric fractionation of
body mass method reported by Drinkwater and Ross. Energetic store
was calculated as fat mass (kg)/skeletal mass (kg) (normal range
0.85—1.47) and protein store as muscular mass (kg)/skeletal mass (kg)
(normal range 2.15—2.72).
Results N
Energetic
store % N
Protein
store %
Normal 20 48.7 20 48.7
Decreased: (a) moderate 11 26.8 13 31.7
(b) severe 4 9.7 6 14.6
Increased: (a) moderate 2 4.8 1 2.4
(b) severe 4 9.7 1 2.4
RM was 4.13 2.26 kg before H, with a reduction in body weight of
2.21 1.10 kg at the end of the procedure. No significant relationship
was found between energetic and protein stores with time on dialysis,
age, RM and associated diseases. It was concluded that half of the
patients on H showed energetic and protein malnutrition, which seems
to be independent of the time elapsed since the beginning of the H
treatment. Besides, calculation of the RM is an adequate approach to
estimate water excess at the initiation of the dialysis session, contrib-
uting to program a correct ultrafiltration.
Cardiovascular morbidity in hypertension patients related to the body
mass index (BMI). J. Soler Amigo for Fundacio Per l'Estudi de Ia
Hipertensio arterial dels Hospitals Comarcals de Catalunya
(FEHTACC), Manresa, Spain. This communication pertains to the
studies of exploitation of our hypertension patient register. It corre-
sponds to 1902 patients registered until April 1992. More than 25% of
patients have been studied for three years. The relation between obesity
and arterial hypertension has been known for years. The aim of this
communication is to evaluate the BMI influence on the appearance of
new cardiovascular events in hypertension patients. To this effect we
have studied: (1) Weight evolution during the research; (2) The pres-
ence or absence and concentration of risk factors in BMI function; and
(3) The appearance of new cardiovascular events after 3 years of
research. Results: We have observed three groups of patients: one in
which patients have gained weight, another in which patients have lost
weight, and another in which patients have maintained their BMI in
relation to the entry register. These groups were kept constant during
the study and there were close to 30% of hypertension patients in each
one. Only 5% of the patients reflected significant weight loss. Between
25 to 30% of the patients in each group didn't show related risk factors,
and the presence of risk factors by percentage and number is similar in
all the groups, except a little more prevalence of diabetes and dislipemia
in the groups with high BMI. The number of cardiovascular events
don't show significant differences in our hypertension patients after 3
years of study, and the number of patients without new events after 3
years fluctuated between 75—82% (Mantel-Cox 6.144 for 3 degrees of
freedom P = 0.1048). Conclusions: (I) The patients with high BMI show
neither a high concentration nor high number of risk factors. (2) After 3
years of research, the hypertension patients don't show a great number
of cardiovascular events in relation to high BMI.
Effects of HMG-CoA reductase inhibitor (lovastatin) in hypercholester-
olemic patients on dialysis. J. Grande Villoria, H. Diaz Molina, and A.
Gonzalez Lopez, Hospital' Virgen de Ia Concha," Zamora, Spain. in
patients with chronic renal failure (CRF) there is a discussion about
whether cardiovascular disease is accelerated or not. The decrease of
total serum cholesterol (T-C) and LDL-cholesterol (LDL-C) may di-
minish the risk of atherosclerosis. The contribution of hypertriglyceri-
demia (HTG) to coronary disease does is not demonstrated. We studied
ten patients with CRF on hemodialysis displaying moderate hypercho-
lesterolemia and HTG. Lovastatin was administered in doses of 20
mg/day over a period of six months. After this period T-C was reduced
1454 Abstracts
from 217.1 27.5 to 164 22.3 (P <0.001). The LDL-C was reduced
from 135.6 27.2to89.9 26 (P < 0.01), and apolipoprotein B (ApoB)
from 131.4 24 to 84.9 23.2 (P < 0.001). The serum concentrations
of HDL-cholesterol, VLDL-cholesterol, triglycerides and phospholip-
ids were not altered in these patients. In the control group there are
fourteen hemodialysis patients with like datas of T-C and triglycerides.
After six months of control, insignificant differences were found in the
analytic parameters (T-C, LDL-C, HDL-C, VLDLC, phospholipids
and Apo Al). We evaluated in monthly intervals: alkaline phosphatase,
alanine aminotransferase, asparte aminotransferase, gamma-glutamyl
transpeptidase, serum lactic dehydrogenase, serum creatinine kinase,
total proteins and albumin. No significant differences in both groups
occurred. The HMG-CoA reductase inhibitor (lovastatin) reduced the
T-C, LDL-C and Apo B in hypercholesterolemic patients with CRF on
hemodialysis. The lovastatin didn't modify triglyceride levels. After six
months there were no differences between control and lovastatin treated
patients with respect to liver enzymes and other side effects. More
research is needed to define effects of this drug on patients on dialysis.
Treatment with OKT3 of pediatric renal transplants with acute rejec-
tion resistant to high doses of methyiprednisone. M. Monteverde, A.
Turconi, N. Delgado, J. PeRaloza, L. Bisignano, andM. Diaz, Hospital
de Pediatria J.P. Garraham, Buenos Aires, Argentina. Monoclonal
antibodies such as OKT3 have been used in the treatment of renal
transplants with acute rejection resistant to high doses of methylpred-
nisone. We decided to evaluate its efficacy and the incidence of
infections in a pediatric renal transplant population. Five male and five
female patients, with a mean age of 9.2 years (age range 4—16 years)
received OKT3 5 mg/day during 10 to 14 days after having an acute
rejection resistant to methylprednisone. Eight patients had a positive
response with a decrease in mean serum creatinine from of 3.4 mg%
pre-treatment to 1.4 post-treatment (P < 0.01). Side effects associated
with the administration of the antibodies were transient and easy to
manage. Five patients had CMV infections (1 with donor CMV+, I with
receptor CMV+, I with CMV+ in donor and receptor and 2 donor
CMV— with receptor unknown). All of them were treated with gancy-
clovir with a positive outcome, including a girl with a severe respiratory
infection that required mechanical ventilation. Four patients had acute
uncomplicated bacterial infections that responded promptly to antibi-
otic treatment. We conclude that OKT3 is safe and effective in treating
acute rejections to methylprednisolone. Effective treatment of infec-
tious complications due to cytomegalovirus is now possible with
gancyclovir.
Conversion enzyme inhibitors (CEI) and low protein diet (LPD) in
diabetic nephropathy. A. Fraga, E. Oddo, M. Franchino, A. Nesse, and
E. Arrizurieta, Instituto de Investigaciones Medicas Alfredo Lanari,
Medical School, University ofBuenos Aires, Buenos Aires, Argentina.
The influence of CEI and LPD on the progression of the incipient and
overt diabetic nephropathy was compared. After a control period of 9.4
to 13.7 months, 7 insulin-dependent diabetic (IDD) patients were
randomly assigned to two treatment modalities: LPD (0.6 g/k/day, N =
4) or CEI (10 mg/day, N = 3) for 9 months. During the control period,
mean values of plasma creatinine; creatinine, inulin and PAH clear-
ances (Cr, C1,,, CPAH) were: 1.5 0.75 mg/dl (0.88—3.13); 75 28.1
(33—117), 62 28.4 (22—11), and 297 108.6 (127—417) mllmin,
respectively. Proteinuria (0.65—4.84 g/day) and microalbuminuria (>30
mg/day) were observed in 4 and 3 patients, respectively. Mean fasting
and non-fasting plasma glucose values were 1.46 0.47 and 2.2 0.44
mg/dl, respectively. Mean fructosamine and HbAlc values were: 456
108.5 prnol/liter and 11.26 1.29%, respectively. Mean arterial blood
pressure was 137/79 mm Hg. On LPD, plasma creatinine and CPAH rose
20 and 10% respectively, while C. and C1,, dropped 16 and 8%,
respectively. There were no changes in protein excretion, mean arterial
blood pressure, plasma lipids, plasma glucose, fructosamine or HbAlc.
On CEI, rose 40% (P < 0.01). No other changes were observed.
Renal function was better preserved in patients on CEI treatment than
in those on LPD.
Chronic adaptation to potassium (K) loading and kallikrein-kinin
system (KKS). D. Veron, E. Oddo, D. Tufaro, R. Martin, and E.
Arrizurieta, Inst it uto de Investigaciones Medicas "A. Lanari," Buenos
Aires, Argentina. Chronic K intake modifies renal tubular and colonic
transport inducing hyperaldosteronism. The increase in mineralocorti-
coid activity may be related with changes in the KKS. To study the
influence of the KKS upon the chronic adaptation to K loading the
potential difference (PD in mV) and short circuit current (Isc in uAmp)
before and after amiloride, and the KKS activity by the kallikrein
excretion (UK, nkat/day) basal and experimental in the distal colon of
control (C), K adapted (K) and control (C-Apr) and K adapted (K-Apr)
treated with intraperitoneal aprotinin (Kallikrein inhibitor) were mea-
sured. The results are shown in the table:
Group
Pre-
PD
Amiloride
Isc Post-PD
Amiloride
Isc
U
Basal
K
Exp
C —5.1
+1,4
30.6
4-5.5
—3.96
+1.3
23.1
+4.4
58.8
+11
57
+6.5
K —19.6
+2.1
169.9
+17.4
—2.6
+0.2
21.2
+2.9
61.8
+6.4
105.6
+18.3
C-Apr —8.3
+1.9
40.6
+5.3
—5.8
+1.2
32.9
+6.8
58,9
+6.8
6
+2.9
K-Apr —10.9
+1.8
76.7
+10
—4.4
+1.5
27.1
+7.8
57.5
+12
4.6
+1.3
UK is increased in K adapted rats. The inhibition of the KKS by
aprotinin blunted the adaptation phenomenon, as is demonstrated by
the changes in electrical parameters.
Long-term effect of early uninephrectomy (uNx) and protein intake
upon remnant kidney D. Tufaro, A. Tufro, C. Alvarez, E. Arrizurieta,
Inst it uto de Investigaciones Medicas "Alfredo Lanari," Buenos Aires,
Argentina. Although it is well-known that a critical reduction of renal
mass and high protein intake induce renal damage, the long-term effect
of uNx upon the remnant kidney remains to be elucidated. Male Wistar
rats were uNx when five days old and placed, after weaning, on a diet
containing 20 or 40% protein. Sham operated rats were used as controls
(C). After 365 days renal function, kidney and body wt, mean arterial
blood pressure and kidney morphology were evaluated. The results
obtained were the following:
Group
Body
wt
Kidney
wt
C1,, CPAB
mI/mm FF
BP
mm Hg
C 20% 435
+65
1.21
+0.15
2.25
+0.26
6.92
+0.92
0.33
+0.01
124
+3.4
C40% 456
+16
1.40
+0.92
2.51
+0.30
7.51
+1.19
0.34
+0.02
113
+2.9
uNx2O% 3%
+29
2.l0a
+0.20
l.15
+0.26
4.59
+0.99
0.25
+0.01
l47
+7.5
uNx 40% 404
+52
2.39a
+0.38
1.66
+0.29
6.04
+0.97
0.28
+0.03
140
+7.3
Both groups of uNx rats showed kidneys with focal and segmental
glomerulosclerosis of similar degrees. Kidneys of C rats were normal.
Early uNx induced late focal and segmental glomerulosclerosis not
dependent on protein intake.
Effect of calcitriol treatment on osteocalcin levels in chronic hemodlal-
ysis patients. A .L. Negri, C.E. Bogado, E.E. Fradinger, and JR.
Zanchetta, Instituto de Investigaciones Metabolicas, Buenos Aires,
Argentina. Serum osteocalcin (BGP) concentration is a biochemical
marker of bone turnover, probably reflecting osteoblastic function. In
hemodialysis patients a relationship between serum BGP levels and
histomorphometric parameters of bone formation has been observed.
The effect of calcitriol administration on serum BGP levels in chronic
hemodialysis patients has been poorly studied and remains controver-
sial. The aim of this study was to assess the evolution of BGP serum
levels and the relationship between BGP and other biochemical bone
parameters in hemodialysis patients under two different forms of
calcitriol treatment. Twelve patients with secondary hyperparathyroid-
ism (intact PTH >200 pg/ml), undergoing chronic hemodialysis (mean
time 86.3 months) were scheduled to receive calcitriol either in oral
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pulses (o.p. group, 4 g, 1st and 3rd hemodialysis of the week, N = 6)
or intravenously (i.v. group 1—2 pg/hemodialysis, N = 6) for 12 weeks.
Serum BGP, intact FF11 (iPTH), total alkaline phosphatase (AP) and
bone AP isoenzyme (BAP) were determined in all patients every two
weeks. Results are expressed as mean SEM. An early increase, but a
subsequently significant fall in serum BGP levels was observed in both
groups (o.p. initial: 33.9 2.3, final: 18.7 2.9 ng/ml, P < 0.001; i.v.
initial: 39.2 3.2, final: 16.9 2.0, P < 0.01), while no significant
changes in AP and BAP could be demonstrated. A significant decrease
in iPTH was observed in i.v. (initial: 537.1 263.7, final: 263.7 108.8
pg/mi, P < 0.01), but not in o.p. (initial: 555.3 139.7, final: 350.4
127.4, NS). However, taking all patients as a whole group, a significant
correlation between BGP and IPTH changes (r = 0.65, P < 0.05) was
obtained. Our results show that in short-term calcitriol treatment (either
o.p. or i.v.), (a) serum BGP, but not AP or BAP levels decrease; and (b)
BGP changes correlate with those of IPTH probably reflecting changes
in bone turnover. Thus, BGP seems to be a sensitive marker of bone
remodeling in hemodialysis patients under calcitnoi treatment. Further
studies are necessary to elucidate the meaning of the early increase in
BGP levels induced by calcitriol administration.
A comparative study of three forms of caicitriol administration in
chronic hemodialysis patients. A.L. Negri, C.E. Bogado, E.E.
Fradinger, and J.R. Zanchetta, Instituto de Invesligaciones Metabol-
icas, Buenos Aires, Argentina. The results of several clinical trials
indicate the efficacy of calcitriol in treating patients with symptomatic
secondary hyperparathyroidism (2HTP). There are different ways of
administration of this drug to these patients, but there are few studies
comparing their efficacy and tolerance. Twenty-seven patients on
chronic hemodialysis (90 45.8 months) with 2HPT (baseline intact
PTH >200 pg/mI) were studied. Patients were randomized to receive
calcitriol on an oral daily basis (OD, 0.5 pg/day; N = 6), in oral pulses(o.p. 4 sg, 1st and 3rd hemodialysis of the week; N = 12) and
intravenously (i.v., 1—2 ig/hemodialysis; N 9) for 12 weeks. During
the follow-up period, total serum calcium and phosphate in each
hemodialysis session and mid-region P'FH (MMPTH) every two weeks
were measured. Baseline and final intact PTH (iFFH) (Allegro, Nichols
Inst.) were also determined. Results are expressed as mean SEM.
There were no significant differences in baseline laboratory data among
the three groups. Initial serum calcium values were normal and serum
phosphate below 6 mg% in the three groups. Serum calcium remained
without significant changes during treatment, but a significant rise in
serum phosphate was observed in OD (initial 5.44 0.65, final 6.%
0.74) and o.p. (initial 5.53 0.43, final 7.06 0.84 mg%) groups,
despite phosphate binder administration. A significant decrease in
serum iPTH levels was observed in i.v. group (initial 537.1 121.6,
final 263.78 108.9, P <0.002), but not in OD (initial 506.7 95.6, final
395.4 107.2, NS) and o.p. (initial 555.3 139.4, final 350.41 127.4,
NS) groups. Three patients in o.p. left the study because of intolerance
(I gastrointestinal; 2 severe pruritus). Our results show that, in the
short-term, intravenous administration of calcitriol was more effective
in reducing intact PTH levels, and o.p. was the worst tolerated.
Acute renal in Malarie Falciparum. C. Tilac, Division of Nephrology,
University of Oriente, School of Medicine, Bolivar City, Venezuela.
Because of geographic determinants in the Boilvar State, and bordering
Brazil, we observed increases in Malane cases between 1983 and 1988.
We therefore conducted a prospective study in those patients who came
to the University Hospital "Rufz y Pdez" (Bollvar City) with clinical
and laboratory findings of acute tubular necrosis. Between 1983 and
1988 we followed-up thirty-two cases (31 adult patients and one
newborn 25 days old, 28 males and four females). The mean age of the
patients was 26 (range: 14—44). Plasmodium falciparum in repeated
blood smears was reported in all the cases: 53% of these had anuria and
47% had normal diuresis. Laboratory findings were as follows: All the
patients had proteinuria, hypostenuria and hematuria; 24 hour urinary
protein was in a range of 270—500 mg. Only five patients had nephrotic
range. Low ranges in CH5O-C3 and C4 were also reported. Renal
samples were obtained in 10 patients, six by renal biopsy and four by
necropsy. The most notable finding at light and electronic microscopy
was severe tubulo-interstitial nephritis without glomerular lesion. Thir-
teen patients (40.62%) went to dialysis therapy (either peritoneal or
hemodialysis). Of those, 4 patients died (30.76%) and 9 had satisfactory
outcome (69.23%). Our study leads us to conclude that: (a) In our state,
Malane Falciparum is a frequent etiology of renal acute failure. (b) In
our patients the renal lesion was predominantly tubulo-interstitial. (c)
Probable immunological bases in the affected systems etiology. (d)
Dialysis therapy was beneficial. (e) Poor outcome (cerebral, renal, GI
system complications) in those patients with delayed therapy (more
than six days). (f) They should be treated immediately.
Acute renal failure due to African honey bee (Apis Meilifera Adanso-
nil). C. Tilac and L. Sanchez, Nephrology and Pathology DivisiOn,
Department of Medicine, University of Oriente, BolIvar City, Venezu-
ela. In 1956 the Brazilian government brought honeybees (Apis Mel-
lifera Adansonii) from South Africa in order to improve honey produc-
tion. A small group of these bees escaped and grew into a big migratory
population. They crossed the Amazon and came to Venezuela, where
they have killed between 30—50 people in the last four years. In this
report we describe 4 patients (3 male, 1 female) with ages between
34—65 years (mean 45 years) who attended the Nephrology Division
because of bee stings by African honey bees. Their main symptom was
acute renal failure. Clinical manifestations were as follows: (a) Anuria,
inflammatory edema, GI bleeding and high blood pressure. (b) Elevated
BUN, hyperkalemia, hypocalcemia, leukocytosis and anemia. (C) Renal
histology finding was tubulo-interstitial nephritis. We also described the
venom compounds: enzymes, low molecular weight agents and toxic
polypeptides. There is a close relationship between clinical and labo-
ratory findings and venom compounds. We conclude that African honey
bee stings should be included as etiology of acute renal failure. We also
believe that renal failure etiology is an anaphylatic reaction due to this
type of aggressive honey bee.
Urolithiasis in children: Metabolic study and follow-up. M.G.M.G.
Penido, J.S.S.D. Diniz, M.L.S.F. Moreira, and J.M.P. Silva, Lima,
Peru. Fifty-five children (31 males, 24 females) with renal stones have
been studied during the mean period of 4 years, divided into 3 groups
according to age: group A, 11 children (20%) aged 0—7 years; group B,
24 children (44%) aged 7—12 years; group C, 20 children (36%) older
than 12 years. Each patient had normal renal function (blood creatinine
0.8 mg% and none was hypertensive. Each patient was studied accord-
ing to the same protocol which included the following investigations:
plain abdominal X-ray; abdominal ultrasound; oral calcium loading test;
2 fasting morning venous blood samples assayed for full blood count,
electrolytes, urea, creatinine, calcium, phosphorus, alkaline phos-
phatase, parathyroid hormone. Three 24 hour urine samples were
collected for measurement of the following parameters: creatinine
calcium, phosphorus, uric acid, citrate, oxalate, magnesium, cyclic
adenosine 3'S' monophosphate (CAMP). Stream urine was analyzed to
determine the pH and cultures. The diagnosis of idiopathic hypercalci-
uria was made in 39 patients (71%) based on the findings of a urinary 24
hour calcium excretion higher than 4 mg/kg body weight. Renal
hypercalciuria predominated in this group of children (56%) compared
to absorptive hypercalciuria (26%). In 44% of the patients the hyper-
calciuria was associated with uric acid hyperexcretion. A family history
of urolithiasis was present in 31(56%) children, and 25 patients (45%)
presented abdominal pain and hematuria and classic renal colic was
reported in 14 children (25%). Urinary tract infection was present in 22
(40%) children.
Effects of nifedipine on carbohydrate metabolism disorders in chrome
renal failure. P.L. Santa Cruz, M. de LeOn; G. LeOn, L.M. Garcia, and
M.E. Rangel, "Manuel Ascunce Domenech" Teaching Provincial
Hospital, Camagaey, Cuba. Disorders of carbohydrates in chronic
renal failure (CRF) are commonly known. With the aim to assess the
possible influence of the calcium entry blocker, nifedipine (Nf), on such
disorders, a group of 16 patients (11 men and 5 women) with CRF due
to primary nephropathy were studied. The serum creatinine ranged
from 220 and 530 mol/liter and glomerular filtration rate (GFR) was
between 15 and 40 mI/mm x 1.73 m2 b.s. The sample was randomly
divided into two groups and a double-blind selection was also used. All
the patients were initially given an oral glucose overload which was
repeated at the end of study. Blood sampling was carried out (at fast
time, 30, 60, 120 and 180 mm) alter the glucose intake in order to
determine the glucose and insulin levels. A group of 8 patients was
given Nf (30 mg/day per os) during 14 days and the rest received
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placebo administered in the same way. The Nf group showed a
significant reduction of the glucose level at 60, 120 and 180 minutes and
a marked decrease of insulin from the very beginning of the test was
also observed. It was concluded that patients in the Nf group improved
their glucose intolerance and hyperinsulinemia after a two-week course
of Nf therapy.
Renal function and occult morbidity due to chronic renal failure (CFR)
in elderly people. P.L. Santa Cruz, N. Bonet, P. Abril, M.E. Rangel,
and M.D. Canfuch, "Manuel Ascunce Domenech" Teaching Provin-
cial Hospital, Camaguey, Cuba. Kidneys are said to be the most
susceptible organs to disorders caused by aging, thus increasing the risk
of various kidney diseases. To study the renal function in elderly
patients, 478 persons (60 years or over) 369 men (77.2%) and 109
women (22.8%) admitted to different nursing homes in the province of
CamagUey, Cuba assisted by means of a family doctor subsystem were
studied. In all of them different variables such as age, body weight,
race, serum creatinine using the Jaff-Folin methods, and glomerular
filtration rate (GFR) estimated according to Crockroft and Gault equa-
tion were assessed. Normal levels of serum creatinine and GFR were
established according to sex and age, being statistically checked (using
the Kolmogorov-Smirnov test and the simple and multiple regression
analysis). To decide whether suspicious or conspicuous CRF, the
percentiles 10 and 5 of the GFR were calculated in addition to 90 and 95
percentiles of the serum creatinine with the previous conversion of the
latter to normal log. In both sexes, the normal serum creatinine was
established on the highest value 1.6 mgldl (141 smol/liter), while GFR
varied by sex and age, being lower in women and decreasing signifi-
cantly (P < 0.01) in both sexes with age. Twenty-three cases (14 men
and 9 women) were detected as having CRF (4.81%) who were
previously undiagnosed and 8 male patients (2.17%) who were consid-
ered as having suspicious CRF. These results may substantiate the
criterion that elderly persons per se are at risk of suffering from a
chronic renal function disease.
Vitamin B6—Piridoxine——and alterations of carbohydrates in chronic
renal failure (CRF). Possible effects. P.L. Santa Cruz, J.R. Do,ninguez,
M.E. Range!, and B. Carrasco, "Manuel Ascunce Domenech" Teach-
ing Provincial Hospital, Camagdey, Cuba. In order to assess the
possible action of vitamin B6 on carbohydrate disorders in uremia, a
controlled clinical trial was carried out in 28 patients with CRF (serum
creatinine range between 353 and 707 tzmolJliter and creatinine clear-
ance range 10 and 25 mI/mm x 1.73 m2 b.s.) who had a manifest
intolerance to carbohydrates with hyperinsulinemia and a paradoxical
increase of the growth hormone concomitant, evidenced during an oral
overload of glucose (GT1'). Half of the randomly selected patients were
treated with 150 mg/day of vitamin B6 per Os in addition to 100 mg by
intramuscular route tn-weekly during 12 weeks. Alter this period, the
GTT and hormone measurements in treated and nontreated patients
were repeated. The second measurement showed in the treated group
(but not in the second one), a marked recovery of carbohydrate
tolerance with a significant improvement of hypennsulinemia (P < 0.05)
and a decrease of GH levels, although the latter's response was still
paradoxical. It was concluded that vitamin B6 apparently exerts a
beneficial influence on carbohydrate disorders and the resistance to
insulin observed in CRF.
Risk factors for chronic renal failure (CRF). Study of a population
assisted by family doctors. P.L. Santa Craz, I. Pereira, M.E. Rangel, J.
Collot, and P. Abril, "Manuel Ascunce Domenech" Teaching Provin-
cial Hospital, Camagdey, Cuba. A sample of 12,238 people over 15
years living in an area of Camaguey City was studied to find the main
risk factors of CRF. All the patients were assisted by family doctors
who obtained their written consent and surveys. There were 5711 men
and 6527 women under study. A total of 5582 (45.6%) patients showed
one or more of the risk factors considered in the investigation, being
more frequent the risk factors according to age (P < 0.001). The main
risk factors found were: high blood pressure (25.6%), obesity (10.9%),
chronic intake of analgesics (9.8%), repeated urinary infection (7.3%),
diabetes mellitus (5%), and kidney stones (2.4%). Out of those persons
with some of the risk factors present, 38 were diagnosed as having CRF,
that is, the morbidity rate in this group was 687 x 100,000 being
significantly higher (P < 0.001) than the estimated rate for the general
population (335 x 100,000).
Behavior of blood sugar, insulin and growth hormone (GH) after oral
glucose overload test (GTT) in patients with mild and moderate chronic
renal failure (CRF). P.L. Santa Cruz, M. de LeOn, M. Castilla, M.E.
Rangel, G. LeOn, and B. Carrasco, "Manuel Ascunce Domenech"
Teaching Provincial Hospital, Camaguey, Cuba. Eighteen patients
diagnosed with mild chronic renal failure (serum creatinine range
between 133 and 176 mol/1iter and GFR range between 41—70 mI/mm
x 1.73 m2 b.s.) and 20 patients with moderate CRF (serum creatinine
range between 177 and 354 molI1iter and GFR range between 25—40
mI/mm x 1.73 m2 b.s.) were studied to identify the carbohydrate
disorders in CRF. All of them had CRF due to a primary kidney disease.
Twenty-five healthy volunteers were considered as the control group. A
GTF was done in all patients and together with the measurement of
blood sugar levels (fast, 60, 120 and 180 mm), insulin and growth
hormone were also measured. Glucose was measured by enzyme
methods and hormones by radioimmunoassay. Obtained data were
statistically processed. Individually nine patients (23.6%) had abnor-
mally elevated glucose tolerance curves after the oral overload,
whereas OTT curve for mild and moderate CRF patients did not differ
from the control group significantly (P > 0.05). In both experimental
groups, the increase of GH and insulin levels was evident. The increase
of insulin together with normal or relatively elevated blood sugar levels
support the presence of insulin resistance. The most evident disorders
were present in the moderate CRF group. Thus, it can be stated that
such disorders are more obvious while the deterioration of the renal
function advances.
Study of the mortality due to chronic renal failure (CRF) during
1980—1989 in CamagUey Province, Cuba. P.L. Santa Cruz, J.L. Aguiar,
N. Herrera, M.E. Ran gel, and N. Bonet, "Manuel Ascunce Do-
menech" Teaching Provincial Hospital, Camaguey, Cuba. A retro-
spective study of death certificates for persons aged over 15 years who
died from January, 1st, 1980 to December 31st, 1989 in the province of
Camaguey, Cuba were surveyed to determine the mortality rate due to
CRF. The total was 42,987 casualties. Out of the total 1233 (2.9%) were
diagnosed as having CRF among the main causes of death. Most deaths
(87.3%) occurred in hospitals and the estimated mortality rate for CRF
ranged from 114.7 to 209.3 per million inhabitants. Elderly patients
were mostly affected (72.1%), especially male subjects (62.5%), though
mortality for both sexes was significantly higher (P < 0.001) in relation
to age, especially in the age group of 60 years or over. The most
important etiologies of CRF were nephroangiosclerosis, chronic inter-
stitial nephritis, primary glomerulopathies, diabetic nephropathy and
polycystic kidneys. The results suggest the increasing importance of
CRF as a health problem in the general population.
Hyperproteic diet and renal function In rats. P.L. Santa Cruz, M. de
LeOn, G. LeOn, L. Izada, and M.E. Range!, "Manuel Ascunce Do-
menech" Teaching Provincial Hospital, Camaguey, Cuba. Seventy-
seven Sprague-Dawley female rats were studied. Each rat weighed
approximately 180 g and they were divided into 2 experimental groups.
Group 1 was made up of 37 normal rats with a normal diet. Group 2
consisted of 40 normal rats which had a normal diet plus sheep jelly
administered via gastric probe at 1.2 g/lOO g. of body wt, once a day. All
animals were given water and food (ratonine) ad libitum. Rats of the
first group were also subjected to daily gastric probing. They were
checked on days 10, 20, 30 and 40 after treatment. At the end of such
period, blood inulin clearances, paramino-hypuric acid and endogenous
creatinine were measured together with blood creatinine and total
protein levels. Data obtained in this study were automatically processed
with a 95% reliability. It was concluded that the proteins administered
in the diet significantly increased the effective renal blood flow and the
glomerular filtration rate (P < 0.05) and they also increased the blood
creatinine concentrations, findings which were present from the first
course of the study.
Ilyperproteic diet and renal function in rats with a 5/6 reduction of
nephron mass. P.L. Santa Cruz, M. de LeOn, G. LeOn, L. Izada, and
M.E. Rangel, "Manuel Ascunce Domenech" Teaching Provincial
Hospital, Camaguey, Cuba. Seventy-eight Sprague-Dawley female rats
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were studied to assess the possible damage of a proteic diet sustained
during chronic renal failure (CRF) course. The rats weight 178 4.71 g
and were divided into 2 groups. They were also partly nephrectomized
5/6. One group was supplemented with sheep jelly for proteins by
gastric probing at a rate of 1.2 g/l00 g of body wtldaily and the other
group was not administered such supplement, although the animals in
the second group were subjected to daily gastric probing. The rest of the
conditions for the animals were similar. The effective renal blood flow,
glomerular filtration rate, blood creatinine clearance, serum creatinine
and total proteins were measured in the animals on days 10, 20, 30 and
40. The results were statistically verified by computerized procedures,
a = 0.05 being established as the significance level. Both groups
developed CRF, but the protein-supplemented group showed an evi-
dent deterioration, especially when measuring the effective renal blood
flow and the glomerular filtration rate in the last two periods of
controlling the course, when results were significantly different (P <
0.01). It was demonstrated that a proteic diet-sustained worsens the
course of CRF in rats with a reduction of nephron mass.
Chronic renal failure (CRF) prevalence. Study In an open population.
Importance of primary health care. P.L. Santa Cruz, I. Pereira, M.E.
Range!, I. Collot, and P. Abril, "Manuel Ascunce Domenech" Teach-
ing Provincial Hospital, Camagfley, Cuba. Twelve thousand two
hundred thirty-eight subjects (5,711 men and 6,527 women) over 15
years of age from a Camaguey City urban area were studied to
determine the prevalence of CRF in an open population from April 1,
1987 to April 1, 1989. Serum creatinine was measured by Jaffé-Folin
method being considered as CRF two measurements of over 141
&moII1iter with a 30 day interval in the absence of etiologic factors
leading to acute renal dysfunctions after being verified at a referral
laboratory. Forty-one patients were diagnosed as having CRF (34 did
not know they actually had it). The prevalence rate per 100,000
inhabitants was estimated in 335, being significantly higher (P < 0.001)
in male patients, especially for 60 years or over. The main causes for
CRF were nephroangiosclerosis, interstitial nephritis, glomerulopa-
thies, diabetic nephropathy, and polycystic kidneys, among others. Out
of the 34 patients who did not know they were suffering from CRF, 28
had creatinine levels under 353 jsmol/liter and 2 had already died.
Another 6 cases showed creatinine levels over 354 smol/liter (4 of them
died) and three of them over 707 smol/liter. Primary health care is being
stressed in this study and the role of family doctors as well for the
adequate management of this entity. Thus, it is suggested that a care
model based on either prevention or early diagnosis of such disease
should be instituted together with a strict system of follow-up and
specialized advice from early stages of this condition.
Use of cyclo-oxygenase and lipoxygenase inhibitors in hypertension of
pregnancy. J.C. Fraire, and M.C. Famd Laino, Department of Ne-
phrology, Italian Hospital, COrdoba, Argentina. We considered that
pre-eclampsia may be produced by imbalance of the end products of
arachidonic acid metabolites by two pathways: (a) cyclo-oxygenase
(CO) PG and TxA2, (b) lipoxygenase (LO) leukotrienes (LTs). We
decided to use, preventively, AAS as CO inhibitors and lysine clonix-
mate as LO inhibitors and atenolol for the treatment of hypertension.
Material and Methods: We included 14 patients: 9 were pregnant with
chronic hypertension, and many of them had the antecedent of previous
pre-eclampsia and stillbirth; 5 had transient hypertension. Gestational
age was: 5 patients between 14th and 20th weeks; 5 between 20th and
25th weeks; 4 patients between 30th 34th weeks. Since the 14th week
we started with AAS 100 mg/day until delivery, and lysine clonixinate
250 mg/day, increasing to 375 mg/day throughout the 20th week of
pregnancy. Results: All pregnancies had an uneventful course, except
one with spontaneous onset of labor due to placental failure at 33.5
weeks. Type I-I! placentas. Newborns: Apgar score 7 to 9. No cases
required respiratory assistance or any other type of respiratory support,
except one case with placental failure, which stayed in NICU for 48
hours. Conclusion: The association of AAS plus lysine clonixinate in
pregnant patients of high risk suggests: (1) There were no side effects
for mothers and fetuses and newborns. (2) Lower doses of atenolol
were average 50 mg/day to control blood pressure.
Peritoneal kinetics in children on continuous ambulatory peritoneal
dialysis (CAPD). Marcos Ariza, Rebeca Gonzales, and Miriam Flors,
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Hospital de Ninos "J.M. de los Rios," Caracas, Venezuela. In order to
study the peritoneal kinetics in children on CAPD, we performed the
peritoneal test (PET) in 13 children, ages 7 to 14 years (mean of 11.6
years) from August 1990 until February 1992. Unlike Twardowsky, we
used Dianeal 1.5% in order to avoid hyperglycemia. On the morning of
the study, the overnight solution was drained from the peritoneal cavity
and Dianeal 1.5% was introduced (1000 cc in children over 20 kg and
500 cc in 2 children under 20 kg). After 10 minutes and 5 minutes
respectively, the peritoneal content was drained and a sample was
analyzed for glucose, urea, creatinine and electrolytes. The solution
was reintroduced into the peritoneal cavity and the procedure was
repeated 2 and 4 hours after. Simultaneously, with peritoneal content
samples, venous blood was drawn and analyzed for the same parame-
ters in order to calculate the peritoneal liquid to plasma ratios (pls) of
urea, creatinine, chloride, sodium and potassium. The hourly ratio of
peritoneal glucose to peritoneal glucose at 10 minutes (P.G/GlO) was
also calculated.
10 minutes 2 hours 4 hours
P/S urea 0.24 0.05 0.84 0.09 0.98 0.04
P/S chloride 0.93 0.08 0.95 0.04 0.968 0.03
P/S sodium 0.93 0.04 0.9 0.03 0.92 0.03
P/S potassium 0.53 0.07 0.748 0.08 0.84 0.16
G.PIG1O 1.0 0.05 0.77 0.15 0.578 0.2
P/S creatinine 0.2 0.1 0.661 0.21 0.88 0.14
Conclusion: Peritoneal kinetics may be studied in children with Dianeal
1.5% using Twardowsky's recommendations in regard to the utilization
of the values obtained at 2 and 4 hours.
Urinary concentration capacity in infants with and without perinatal
asphyxia. M. Ariza, M. Paredes, Z. Telleria, and R. Sucre, Hospital de
Niños "J.M. de los Rios," Caracas, Venezuela. Urinary concentration
capacity was evaluated in 13 infants with a previous history of perinatal
asphyxia and 18 infants with no evidence of perinatal asphyxia. On the
first day of life, urinary osmolality was determined in a random
specimen. At three months of age we performed a urinary concentration
test, which consisted in a last feeding the previous night with double
concentration formula followed by water restriction during 8—10 hours.
At the end of this period a urinary sample was obtained and analyzed
for urinary osmolality. In those infants who did not achieve 900
mOsm/kg of urinary osmolality, the test was repeated at 6 and 9 months
of age. Results: All the infants with no perinatal asphyxia achieved a
urinary osmolality of 900 mOsm/kg or more at 3 months of age (range
900—1120 mOsm/kg). Of the 13 infants with perinatal asphyxia, 5
(38.4%) reached 900 mOsm/kg at 3 months of age, 2 (15%) at 6 months
of age, and the remaining 6 (46.2%) at 9 months of age. In two infants
with perinatal asphyxia who did not achieve 900 mOsm/kg at 3 months
of age, the concentration test was repeated with the administration of 2
units of oleous Pitresin I.M. after which an adequate response was
obtained. Possible mechanisms involved in the limited urinary concen-
tration capacity of infants with previous perinatal asphyxia are dis-
cussed, and guidelines in regard to their follow-up are recommended.
Long-term longitudinal study of bone mineral density in hemodialysis
and renal transplantation. R. Alonso, X.M. Lens, E. del RIo, J.M.
Fraga, and D. Sdnchez-Guisande, Hospital Xeral de Galicia, Santiago
de Compostela. The aim of the present study, initiated in 1985, was to
investigate the usefulness of bone mineral content for diagnosis and
follow-up of osteodystrophy in end-stage renal failure. Ninety patients
(55 males, 46 14 years old and 35 females 45 15, ,t SD) and 190
healthy subjects (80 males, 44 20 and 110 females, 47 19) were
studied by means of simple photon absorptiometry (Gambro bone
mineral detector). Calculations were based on scans across the ulna
shaft. Patients with end-stage renal failure had less bone mineral density
(g/cm2) than the control group, both males (0.710 0.144 vs. 0.909
0.123, i SD, P 0.01) and females (0.623 0.140 vs. 0.786 0.101,P = 0.01). After hemodialysis for 18 4 months, bone mineral density
decreased in males from 0.764 0.160 to 0.695 0.155, P = 0.01 (0.4%
per month), and didn't change significantly in females (from 0.568
0.103 to 0.536 0.142). After renal transplantation for 29 2 months,
bone mineral density increased in males from 0.660 0.150 to 0.748 ±
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0.136, P < 0.01 (0.4% per month), and didn't change significantly in
females (from 0.657 0.106 to 0.701 0.110). Bone mineral density is
a useful parameter for non-invasive monitorization of renal osteodys-
trophy. There is a clear impairment in comparison to healthy subjects.
Bone mineral density is modified by sex and type of substitutive
treatment, so only in males do a significant increment on hemodialysis
and an amelioration on renal transplantation occur.
Deferoxanune test: Can dose be reduced? X.M. Lens, R. Alonso, C.
Martin, V. Arcocha, B. Correa, D. Arza, C. Alonso, D. Novoa, R.
Romero, and D. Sánchez-Guisande, Hospital Xeral de Galicia, San-
tiago de Compostela. Deferoxamine (DFO) test gives us information
about aluminum (A1)-reiated disease, but it can be accompanied by
serious side effects. In order to study if lower doses yield similar results
with less side effects, we have compared the Al mobilization and
auditive toxicity (normal and high frequency audiometer) of standard
(30 mg/kg) versus low-dose DFO test (10 mg/kg) administered during
the last 30 minutes of one dialysis session. We have studied 12
hemodialyzed patients (6 males), 56 15 ( SD) years old with basal
blood Al 77 38 1cg/liter. Post-DFO 10 administration, Al was 169
36, with a mean increment of 141 63% over basal values; three
patients had less hearing until 25 db between 1000 and 15000 c/s
frequencies. Post-DFO 30 administration, Al was 206 83, with a mean
increment of 210 109% over basal values; five patients had auditive
impairment until 45 db between 4000 and 15000 c/s frequencies.
Sensitivity was 80% and specificity 43%. Positive and negative predic-
tive values were 50% and 75%, respectively. There was no linear
correlation between percentual increments post-DFO 10 and post-DFO
30 administration (r = 0.0697). Low-dose deferoxamine test is a useful
method, virtually free from adverse effects, to study aluminum-related
disease. High-doses should be reserved only for patients with a positive
low-dose deferoxamine test.
Bimodal timing distribution of tuberculosis in renal transplantation. C.
Alonso, X.M. Lens, R. Alonso, V. Arcocha, D. Novoa, R. Romero, D.
Arza, and D. Sdnchez-Guisande, Hospital Xeral de Galicia, Santiago
de Compostela. Twelve of 150 patients with renal transplantation were
diagnosed with Mycobacterium tuberculosis infection. Renal transplan-
tation was made in our institution localized in a high endemic area, from
May 1982 to March 1992. All patients had at least pulmonary disease:
they were 47 years old, range 27—65 years, and 7 were males. When
timing of infection after transplantation was investigated a bimodal
distribution was observed. In group I, formed of 6 patients, tuberculosis
had an early time of appearance, 3 months, range 1—6. Their character-
istics were: good response to treatment (6), elevated rate of cavitation
(3), high immunosuppressor medication (3), use of cyclosporine (3), and
hepatitis B infection (2). In group II, consisting of 6 patients, tubercu-
losis had a late time of appearance, 5 years, range (1.5—11). Their
characteristics were: low immunosuppressor medication (exclusively
prednisone plus azathioprine (5), miliary dissemination (4), and one
case of death with no response to six months of treatment. Depending
of the grade of immunosuppression, tuberculosis can appear early or
late after renal transplantation with different clinical courses.
Two step percutaneous renal biopsy using ultrasound. Rosa M.
Campo, A. Ferndndez, R. Araujo, V. Flores, and R. Almao, Nephrol-
ogy Service, Hospital Jesds Maria Casal-Ramos, Acarigua, Venezuela.
We report our experience with a two step ultrasonic percutaneous renal
biopsy (PRB) procedure. One or two days prior to the PRB, the lower
renal pole is located with real-time ultrasound, its depth is measured,
and a cutaneous ink mark is set. One or two days after the localization
of the kidney, the PRB is carried out with tru-cut needle. From January
1986 to December 1991, our staff's nephrologists performed 100 biop-
sies. Indications for biopsy were: nephrotic syndrome 43%, systemic
lupus erythematosus 33%, acute renal failure 10%, others 14%; sex:
59% males, 41% females; average age 33 years. At the time of biopsy
43% showed renal failure (serum creatinine > 1.4 gs%). Adequate
tissue for diagnosis was obtained in 93% of the biopsies. Complications
were seen in 5 patients; of those 2 patients needed blood transfusion for
gross hematurin and retroperitoneal blood collection. With this ultra-
sonic method we can safely and effectively separate the renal localiza-
tion from the biopsy procedure itself.
The nutritional status of CAPD patients. A. Molina, I. Nebreda, A. de
Paula, A. Rodrigo, and M.E. Plagaro, "Rio Hortega" Hospital, Renal
Unit, Valladolid, Spain. The limited amount of printed material in Spain
on the nutritional status of CAPD patients led us to carry out a
descriptive study on the subject. Patients and methods: We based our
research on anthropometric measurements (AM), assessment of vis-
ceral protein (VP), and immunological measurements (IM), of 19
patients, 10 men (M) and 9 women (F). Age (X SD), M: 58.8 11.1,
F: 63.9 11.3 years. Length of time on CAPD, M: 24.7 14.4, F: 26.9
12.5 months. Occurrences of peritonitis in the previous six months,
M: 0.8 1.2, F: 1.1 1.7. Residual renal function (RRF), M: 1.6 1.9,
F: 1.9 2.1 mI/rn. Results: There were no differences between either
sex regarding age, time on CAPD, occurrences of peritonitis in the six
months previous to the study, RRF, peritoneal kinetics, PCR, UNA,
Ks/V, peritoneal Cr, total proteins in effluent peritoneal liquid, glucose
peritoneal uptake, urea, creatinine, Ca, P. CI, Na, K, hemoglobin,
ferritin, folic acid, vitamin Bl2, cholesterol, triglycerides and cortisol.
M F P
AM
Present body weight kg 68.44 9.54 68.83 12.08 NS
Height cm 165.30 7.04 150.78 3.67 <0.001
Desirable body weight 106.19 6.5 135.05 21.9 <0.01
%
Weightiheight 0.41 0.05 0.45 0.77 NS
Height/weight 2.47 0.35 2.24 0.38 NS
Weigth kg/Height m2 25.02 3.15 30.21 5.03 <0.001
Skinfold thickness
of triceps mm 14.10 5.88 26.33 7.48 <0.001
Body fat % 23.39 5.71 35.59 5.96 <0.001
Total body fat kg 16.31 5.39 24.94 7.11 <0.01
Mid-arm circumference 27.70 3.77 31.67 4.92 <0.05
cm
Mid-arm muscle
circumference cm 23.26 2.48 23.39 3.53 NS
Mid-arm muscle area 136.70 28.27 139.50 40.49 NS
cm2
VP
Total proteins g/dl 6.62 0.68 6.54 0.54 NS
Albumin g/dl 3.40 0.48 3.52 0.70 NS
Transferrin mg/dl 237.50 61.18 253.55 52.01 NS
Prealbumin mgldl 29.54 9.26 30.64 10.56 NS
IM
IgG mg/dl 1205.80 449.53 1104.11 306.77 NS
IgA mg/dl 283.50 125.54 273.11 166.91 NS
1gM mg/dl 121.85 100.05 83.60 41.61 NS
C3 ,ng/dl 109.55 23.24 119.55 23.80 NS
C4mg/dl
Lymphocytes mm3
Reaction to subcutaneous
31.40
1764.30 217.41
antigens
29.99± 5.61
2035.67 687.32
NS
NS
NS
Conclusions: The presentation of AM, assessment of VP and IM can be
used as references for future evaluations of the nutritional status of
patients undergoing CAPD, as well as for comparative studies of other
substitutionary methods of renal function.
Is there any relation between the nutritional status and the type of
peritoneal transport (TPT) of patients undergoing continuous ambulatory
peritoneal dialysis (CAPD)? A. Molina, I. Nebreda, A. de Paula, A.
Rodrigo, and M.E. Plagaro, "Rio Horlega" Hospital, Renal Unit,
Valladolid, Spain. We have always been interested in the different
peritoneal "behavior" of patients undergoing CAPD. The aim of this
study was to try to find the relation between the nutritional status of
CAPD patients with the TPT. Patients and Methods: We based our
research on anthropometric measurements (height, weight, % desirable
weight, weight/height, height/weight, body mass ratio, skinfold thick-
ness of triceps, % body fat, total body fat, mid-arm circumference,
mid-arm muscle circumference, mid-arm muscle area), immunological
measurements (IgG, IgA, 1gM, C3, C4, lymphocyte count, reaction to
cutaneous antigens), assessment of visceral protein (total proteins,
albumin, transfemn, prealbumin), peritoneal equilibration tests (PET)
according to Twardoswski, of 19 patients, 10 men and 9 women. Age (X
SD), 61.2 11.2 years. Length of time on CAPD 25.42 13.57
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months. Occurrences of peritonitis in the 6 months previous to the
study, 0.95 1.4. Residual renal function (RRF) 1.7 1.9 mI/rn. The
TPT was assessed using the ratio of dialysate/plasma (DIP) of creatinine
after 4 hours of PET and the ratio of glucose in the effluent of peritoneal
liquid after 4 hours of PET (D4) and at the beginning (DO). We classified
the patients as follows: high TPT, those with a D4/DO of glucose less
than X — 1 SD, average TPT, those with a ratio between X — 1 SD and
X + I SD, and low TPT, those with X + 1 SD. The results are as follows:
X SD Range
D4/DO glucose 0.43 0.11 0.21—0.59
D/P creatinine 0.69 0.14 0.50—0.93
RRF mi/rn 1.73 1.90 0.00-6.40
Albumin gIdi 3.46 0.60 2.60-4.80
As we expected, an inverse correlation exists (r =
—0.9253), and very
significantly (P < 0.001), between D4/D0 of glucose and D/P of
creatinine. It does not exist (r =
—0.1662) between D4/DO of glucose
and RRF. A positive correlation (r = 0.4285,P < 0.05) exists (one-way)
between D4/D0 of glucose and serum albumin. We did not discover any
correlation between the rest of the nutritional measurements and the
ratio D4IDO of glucose. Conclusions: The high TPT, those having greater
problems of ultrafiltration with the classical CAPD, have significantly
lower levels of serum albumin. By increasing the level of serum
albumin, would it be possible to avoid using dialysis techniques such as
the costly continuous cyclic peritoneal dialysis (CCPD) or the nightly
peritoneal dialysis (NPD) which requires confinement to bed during
treatment and a cycling machine? This is a question which requires
further research.
Transcranlal Doppler diagnosis of brain death. Clinical usefulness. R.
Vila, C. Gonzalez, A. Dalmau, J. Marquez, J. Jubert, and A. Diaz,
Departments of Vascular Surgery, Anesthesiology, Neurophysiology
and Transplantation, Hospital Universitari de Bellvitge, Barcelona,
Spain. The need for organs for transplantation is one of the most
pressing problems of this kind of surgery. Loss of organs may some-
times be due to a delay in brain death diagnosis. EEG is commonly used
as the only method for the diagnosis of brain death, but it has some
drawbacks, the most important one is that a negative titration of
benzodiacepine and barbiturates is needed for a suitable assessment of
brain death. We present our experience with transcranial Doppler
(TCD) as a complementary method in the diagnosis of brain death.
From May 1991 to May 1992 we performed a transcranial Doppler
exams on 16 clinically brain dead patients. Mean age was 31.7 years (r:
17—59). All had EEGs done also, although in three a consistent
diagnosis was not possible due to positive titration of depressive drugs.
TCD was consistent with brain death in 13 cases. Findings included
detection of only small spikes or a reverse diastolic flow in at least two
cerebral arteries. Brain death was confirmed in all of them by EEG.
Three patients did not meet TCD criteria of brain death, as some flow
was detected in one cerebral artery; two had absence of brain electric
activity in EEG and the other had minimal activity. TCD showed a
100% specificity, 86% sensibility an 87% accuracy in the diagnosis of
brain death. TCD diagnosed brain death in three cases of positive
titration of depressive drugs and allowed a multiorganic extraction that
would otherwise be missed due to poor hemodynamic situation of the
patient and difficulty in eliminating barbiturates. TCD is a useful and
specific tool for the diagnosis of brain death, especially when EEG
assessment is unsuitable.
Results of ten years of hemodialysis in Uruguay. E. Schwedt, F.
Gonzalez, J. Fernandez, P. Ambrosoni, and N. Mazzuchi, Registro
Uruguayo de Hemodidlisis, Sociedad Uruguaya de Nefrologia
(S.U.N.), Montevideo, Uruguay. The S.U.N. has a hemodialysis (HD)
patient registry whose data are obtained annually. We made a compar-
ative study of morbidity for all dialysis patients (pts) alive during 1984,
1986, 1988, and 1990. We alsoanalyzed the different causes of death and
actuarial survival according to age, sex, primary renal disease, year of
beginning HD and blood pressure control at entry on HD. Actuarial
survival has been calculated by the Mantel-Cox test. The Cox proper-
tional hazard model was used to estimate the relationship between the
different variables considered. The rate of patients with hepatitis B
virus has decreased from 9.8% in 1984 to 4.2% in 1990, while patients
with AcHBC(+) decreased from 30.6% to 16.5% and AcHBs(+)
increasedfrom 19% to 47.4% (12.2% due to natural immunity and 35.2%
due to vaccination, P < 0.0001). The number of complications has
decreased (3.4, 2.8, 2.4 and 2.2, respectively).
Table 1. Complications per patient
Period % Cardiov. Infec. Fistula Malnutr. GIIHEP N pts
1984 % 60.6 28.3 14.9 13.3 9.9 350
1986 % 77.1 26.5 18.2 16 21.3 511
1988 % 75.1 40.2 19.3 3.6 12.3 251
1990k % 63.1 37.4 21.3 4.6 8.6 964
a p < 0.001
The quality of life was assessed for all dialysis patients alive in the years
considered. Percentage of patients working (partial or full time) was
decreasing due to acceptance of more elderly pts and longevity of our
patients. There was an increased number of patients that were retired
and an decrease in disabled patients (table 2).
Table 2. Rehabilitation
1984 1986 1988 1990
N % N % N % N %
Work (partial or fuiltime) 216 61.7 235 46.1 171 48.7 491 47
Noworka 134 38.3 276 53.9 180 51.3 552 53
a P < 0.001
Table 3. Causes of death (%)
N Sudden
Period pts Cardiovasa Infec. Metab. death Neoplas.
1980—84 122 29.5 14.7 6.6 34.4 0.8
1985—87 83 33.7 14.5 7.2 28.9 1.2
1988—90" 171 42.1 18.7 4.5 18.1 5.8
a include stroke
bp < 0.001
Cumulative survival for all patients was 91% at 1 year, 68% at 5 years,
and 52% at 10 years. Cumulative survival according to age showed
longer survival in younger patients (P < 0.05). According to primary
renal disease diabetic patients showed the lowest survival (80% at 1
year and 32% at 5 years) and patients with polycystic kidney disease
had the best survival (80% at 5 years). Cumulative survival according to
blood pressure control at entry to treatment showed longer survival in
patients with normal blood pressure (P < 0.05). Cumulative survival
according to year of starting HD showed the longest survival between
1985—87 (P < 0.001). Cox proportional hazard model was able to
identify significant independent variables of risk [age, period of start
HD (10)) and primary renal disease (diabetes).
Evolution of nutritional status in patients undergoing maintenance
hemodlalysis. Emma Schwedt, Teresa Antoria, Mabel Bracco, Pablo
Ambrosoni, and Hena Caorsi, Centro de Nefrologia Renis, Mon-
tevideo, Uruguay. Several reports have documented a high prevalence
of malnutrition (MN) in patients (pts) undergoing hemodialysis (HD),
mainly a marked reduction in muscle mass in males. MN has also been
considered as a negative prognostic index. We made a longitudinal
assessment of nutritional status (NS) in 78 pts (42 males, 36 females,
mean age 55 13 years) with more than 6 months on HD (mean 36.3
27.3 mo) between 1/1/82 and 8/31/91. The premorbid NS was assessed
by usual body weight (UBW). Ideal (%IBW) and UBW percentage
(%UBW) and body mass index (BMI) were calculated. A nutritional
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diagnosis (ND) was made at the start of HD and every 3 months
according to anthropometric measurements: BW, height, midarm cir-
cumference (MAC) and skinfold thickness measurements (STM), and
biochemical methods (serum albumin concentration, SAC). We de-
fined: protein caloric MN (PCM) if BW was <90% IBW, BMI < 20 and
the sum of STM < 5th percentile; obesity if BW was> 120% IBW, BMI
> 25 and the sum of STM > 85th percentile. Muscle and visceral
protein stores were considered depleted if midarm area (MAA) was <
5th percentile and SAC < 3.5 gfliter. Results: We found a high
prevalence of premorbid obesity (62.9%). Weight loss during preHD
period was 14 9 k, without significant difference between sex. NS is
shown in Table 1:
incidence and prevalence of pts on HD in South America (93 and 316.6
per million population, respectively, in 1990). We analyzed patient
characteristics at entry to treatment in three periods: 1980—84, 1985—87,
1988—90. There was an increasing number of men, reaching 62.7% in
1990 (P <0.001). The mean age of women and men is 49 17 years and
51.7 17 years, respectively. The age distribution has shown a growing
tendency to accept older patients (P < 0.0001), particularly men over 60
years old. Most pts enter into treatment with severe complications of
renal failure, although its rate decreased from 62.2% to 54.4% (P <
0.0001). There was a significant change in primary renal disease in the
different periods: a decrease in glomerulonephrytis (Glom) and an
increased in hypertensive nephroesclerosis (NAE) (Table 1), due
mainly to acceptance for treatment of more elderly pts.
ND
N
pts Males Females
Age
years
 >
50 50
Year of
start of
HD
 >
1986 1986
Nephropathy
Non-
Diabetic diabetic
Obese
Normal
Depleted
14
34
30
5
17
20
9
17
10
3 11
6 28
l6 14
7 7
11 23
15 14
2
7
4
12
27
26
ap< 0.01
43% were normal, 38% depleted and 18% obese pts. Mean SAC was
3.94 0.44 g/liter without changes during the study. The anthropomet-
nc evolution is shown in Table 2:
Table 2. Anthropometric evolution
%IBW %UBW BMI STM MAC MAA
Initial 103.4
21
81.3
11.3
23.7
4.3
27.6
12.2
27.5
4.2
43.3
4.2
Final 114.9
24
89.1
8
26.2
5.3
40
15.7
30.1
5.3
48.4
15.7
There was an increase in all parameters (P < 0.05). At 1st yr, 56.5% of
depleted and normal pts reached 85% of UBW and 56.2% reached more
than 90% IBW. At the end of the study, 37.2% were normal, 28.2%
were depleted, and 34.6% were obese pts (P = 0.058). NS improved in
pts with PCM. The percentage of PCM was greater in males but actively
depleted pts improved better. Obese pts remained similar. Normal pts
developed obesity which was greater in sedentary pts. Twenty-one pts
died. At 1St year, mortality was greater in obese premorbid pts (due to
cardiovascular and sudden death). Depleted pts showed the lowest
survival. The development of obesity is perhaps due to premorbid
obesity, genetic influence, physical activity (sedentanism), dietetic
habits or psychological factors (previous corporal image). Conclusion:
We found 62.9% of premorbid obesity; 38% of depleted pts and 18% of
obese pts at start of HD; PCM was greater in pts <50 years old and in
males. Active depleted pts improved better and normal pts developed
obesity (mainly sedentary pts). Mortality was greater in depleted pts.
Ten years of hemodialysis in Uruguay. Patient characteristics on
admission and dialysis prescription. Emma Schwedi, Juan Fernández,
Francco Gonzalez, Pablo Ambrosoni, and Nelson Mazucchi, Regis-
tro Uruguayo de Hemodialisis, Sociedad Uruguaya de Nefrolog(a
(S. U.N.), Montevideo, Uruguay. Chronic maintenance hemodialysis
(HD) began in Uruguay in 1980, supported by a national program of
treatment of end-stage renal failure. Since then, the S.U.N. has a
dialysis patient registry. From 12/80 to 12/90, 1989 patients (pts) were
accepted for treatment in 25 centers. Uruguay has the highest rate of
Period % Glom NAE Tubuloint. Diabetics B virus(+)
10 % 30.8
2° % 16.5
30a % 16.8
10.9
20.5
24.8
13.6
18.9
16.4
11.5
14.1
14.2
18.1
7.1
5.7
570
256
476
ap < o.oooi
Table 2. 0ther complications per patient
10 % 72.9 67.8 18.3 8.4 23.2 3.9 11.8 578
20 % 73.7 76.7 22.9 12.7 20.5 4.9 5.4 205
30a % 76.3 64.8 31.6 8.1 7.8 9 6.9 332
All pts entered HD with serum determination of hepatitis B virus and
there are separate areas of HD according to B virus condition. In the
last period, 95.5% ofpts also had AcHBc and AcHBs determinations.
The rate of pts with B virus infection decreased significantly (P <
0.0001) (Table 1). Most pts needed hospitalization at the start of HD,
but there was a decrease in the number of days they had been
hospitalized (P < 0.0001). The prevalence of hypertension is very high
at the beginning of HD. The number of complications per patient
decreased in the 3 periods (2.4—2.3 and 1.8, respectively) (Table 2). HD
prescription and water treatment were analyzed in 1984, 1986, 1988, and
1990. In 1990, 82.1% of pts were on dialysis for 4 hours and 91.5% in
three dialysis periods weekly. Most pts use hollow-fiber dialyzers with
cuprophane fiber. The rate of pts without water treatment decreased
from 78.6% to 12.9% in the last years. The water treatment options
available in 1990 were deionization (41.5% of pts) and reverse osmosis
(45.7% of pts).
Progression of chronic renal failure—Methods of evaluation. Francisco
Lacordelle, Emma Schwedt, and Nelson Mazzuchi, Centro de Nefrol-
ogla, Hospital de ClInicas, Montevideo, Uruguay. Several methods to
assess the rate of progression of chronic renal failure (CRF) have been
described. Some of them are easy to perform, like the slope (b) of
reciprocal creatinine versus time (1/cr-t), and others are more compli-
cated with different advantages and disadvantages, like inulin clear-
ance, creatinine clearance, and isotope clearance. We applied the i/cr-t
method and the mathematical model of Jones and Molitoris (the
breakpoint test) to estimate whether the progression of CRF better fits
by a single linear regression or there are significant breakpoints (SB)
identified by the last statistical approach, describing another pattern of
progression. We retrospectively studied 65 adult patients with CRF that
were selected based on the presence of the following criteria: date of
start of hemodialysis (HD), > 6 months of follow-up, at least 4 serum
creatinine determinations before starting HD (N cr) and initial creati-
nine (icr) between 2.5 and 4 mg%. Linear regression equations were
calculated and the correlation coefficient (r) was  0.7 in 47 patients
(group A) and < 0.7 in 18 patients (group B).
Table 1. Nutritional diagnosis at the start of HD Table 1.
N
pts
N
HTA Cardiovas. Infec. Fistula Metab. GI/H Malnutr pts
ap< 0.0001
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Males Females Age years Icr
group A
group B
27
11
20
7
51.2
49.1
15.8
15.4
3 o.7
3.7 1.3
ap< 0.05
Final Cr N cr
Time
months Slope (- b)
7.6 1.7
6.8 1.7
11.4 8.4
15.4 10.6
37.2 27.3
37.8 21.4
0.0089 0.008
0.0039 0.003a
Applying the Jones and Molitons model we found significant break-
points in 13 patients: 5/45 in group A and 8/18 in group B (P < 0.0025).
They appeared at different times: 4/5 patients in group A had early SB
due to I cr values between 2.5 and 2 mg% showing an improvement
concerning the initial determinations; 6/8 patients in group B showed
late SB due to acceleration in progression rate after a stable renal
function phase. In group A we also calculated the prediction error (PE):
predicted time minus the actual time of HD start. Most patients (32/47)
started HD before predicted time, 7 at the predicted time and 18 after
the predicted time. The mean PE was 6.8 months. Conclusions: Most
patients (72.3%) had a constant rate of progression of CRF and better
fitted by a single straight line with a PE of 6.8 months. This was
confirmed by the application of the Jones and Molitoris model, that
didn't find SB in patients with a r 0.7 and I cr >3 mg%. The Jones
and Molitons model also better described the group B evolution (r <
0.7) showing a stable first phase and a late acceleration in progression
rate.
Lupus nephrltls. EvaluatIon of risk factors and treatment. Nelson
Mazzuchi, PabloAmbrosoni, Lilian Curi, Enriqueta Carbonell, Nelson
Acosta, Hena Caorsi, and Laura Rodriguez, Centro de Nefrologia,
University Hospital, Faculty of Medicine, Montevideo, Uruguay. Sur-
vival of patients, of renal function and the predictive value of renal
failure, histologic features, clinical symptoms and treatment were
analyzed in 102 patients with histological diagnosis of lupus nephritis.
The methods used for this analysis were actuarial survival rates
determined with the Kaplan-Meier method and Cox's proportional
hazards model. Survival of the patients was 81.4% at 5 years and 74.3%
at 10 years and survival of renal function, 64.1% and 47.5%, respec-
tively. Diffuse proliferative glomerulonephritis and initial serum creat-
mine values > 3 mg/dl are associated with a worse outcome, with renal
function survival at 5 years of 36% (P = 0.0001) and of 3 1.8% (P =
0.0299), respectively. Association of cytotoxic drugs to corticoid ther-
apy significantly improved the outcome of renal function. Actuarial
survival rates at 5 years were 56.2% without cytotoxics and 72.5% with
cytotoxic drugs (P = 0.0291). By multivariate analysis, the three
variables maintain their significant relationship with renal function
survival. Initial serum creatinine > 3 mg/di is shown as the most
important risk factor, with a relative risk of 5.70. Treatment with
cytotoxic drugs is shown to diminish the risk of renal failure, with a
relative risk of 0.25. The relative risk for the group at greater risk
(serum creatinine > 3 mgldl, diffuse proliferation and without cytotoxic
drug treatment) compared with the group at lower risk is 35.7. Relative
risk diminishes to 9.1 when this group of patients is treated with
cytotoxics. The treatment variable is also significant when it is added to
the model with three categories; without cytotoxics (N 56), azathio-
prime (N = 28) and cyclophosphamide (N = 18) (P = 0.0070). Prediction
of renal function survival at 3 years for the group at greater risk is 4.4%
without cytotoxics, 25.5% with azathioprine and 55.1% with cyclophos-
phamide. Treatment with cytotoxic drugs is the only variable that
shows significance in death prediction with the proportional hazards
model. It diminishes 4.02 times the relative risk of death. It is concluded
that initial serum creatinine values greater than 3 mg/dl and diffuse
proliferation histology are the most important risk factors in survival of
renal function. Also that treatment with cytotoxic drugs improves renal
function prognosis and survival of the patients and that initial treatment
with cyclophosphamide offers the best results.
Dialysis-related amyloidosls (DRA) in Uruguay. 1. Olaizola, A. Petra-
glia, H. Caorsi, P. Ambrosoni, N. Ca,npistrds, D. Pereyra, A. Sandier,
and N. Mazzuchi, Centro de NefrologIa, Hospital de ClInicas, Servicio
de Radiologia, Instituto de Reumatologia, Montevideo, Uruguay. The
DRA, especially osteoarticular, is a relatively frequent complication of
patients on long-term hemodialysis (HD). Its systemic participation has
also been noticed in recent years. One hundred fifty-three patients with
5 years or more on HD were studied over a total population of 740
patients treated coming from 15 I-ID centers, excluding patients with
amyloidosis caused nephropathy. We evaluated prevalence, clinical,
humoral and radiological (RX) features and cardiac compromise of the
DRA. We studied 82 men, 71 women, ages = 58 14 years and time(T) on HD = 85 18 months (60—140). All patients were on HD 12
hrs/week with treated water (osmosis or deionizator); 98% of them were
dialyzed with cuprophane fiber. The population was divided into Group
(G) A: symptomatic (N = 67) [symptoms suggestive of DRA: shoulder
pain, carpal tunnel syndrome (CTS)J; G B: asymptomatic (N = 86). In
both G we analyzed age on admission to HD and at the moment of the
study; T in HD; T of exposition (expo) to aluminium (Al) by water;
serum calcium (Ca), phosphorus (P), alkaline phosphatase (AP), PTH
and /32 microglobulin; bone RX; bone and sinovial histology and median
nerve motor and sensory conduction. In 5 patients, suspicious of DRA
we performed cardiac gammagraphy with Tc-pyrophosphate. The prev-
alence of DRA diagnosed by the symptoms and/or RX was 19%. Al
expo T was significantly higher in G A (P < 0.008) and patients in G A
were older on admission to HD and at the moment of the study.
Symptoms were more frequent in patients older than 40 years on
admission to HD (P < 0.02). We did not find significant differences in T
on HD, although it was longer in G A. Ca, P. AP, PTH and /32
microglobulin were similar in both groups. Twenty-two patients of G A
had CTS that was bilateral in 14 patients. The median nerve conduction
was lower than 25% in 13 of the 22 patients. In 10 patients we performed
the surgical treatment, confirming amyloid by biopsy in 6 patients. The
bone RX of 121 patients showed lesions suggestive of DRA in 38
patients (31.4%), 30 of them belonged to G A. We found a good
association between bone RX (geodes, destructive arthropathy) and
CTS (x2 = 12.1; P < 0.00001). The patients with RX lesions had been
exposed longer to Al (P <0.04) and were older on admission to HD.
Bone biopsy (31 patients) showed no significant difference in the
distribution of histological forms in both groups. In the 5 cardiac
gammagraphies we did not find alterations compatible with amyloid-
osis. Conclusions: (a) There was a high prevalence of clinical and/or RX
signs suggestive of DRA (19%) in the population we studied; (b) There
was a highly significant relation between signs and RX; (c) Age on
admission to HD is important as a risk factor for development DRA.
Metabolic disorders detected in 825 patients with nephrolithiasis by
simplified metabolic evaluation. L. Reyes, R. Mañalich, R. Fraxedas, J.
Lagomasino, P. Jimenez, I. Gonzalez, and M. Smith, Instituto de
Nefrologia, Habana, Cuba. The advent of technology in the last years
has allowed us to make reliable, accurate, and easier diagnosis of risk
factors of nephrolithiasis in order to prevent its recurrence. We have
analyzed laboratory protocols from 825 outpatients with indeterminant
metabolic activity carried out during 2 years. Protocols included a 24
hour urine collection to determine calcium, phosphorus, uric acid,
magnesium, citrate, oxalate, nitroprusside test, pH, culture, and uri-
nary volumen and blood profile including analysis of total calcium,
phosphorus, uric acid, alcaline phosphatase and PTH. A computerized
program listed risk factors and calculated urinary saturation level for
oxalate and its risk of crystal formation. We have found metabolic
and/or physicochemical disorders in 96.6% of the protocols. Of the
patients, 37.6% were hypercalciuric, 19.8% were hyperoxaluric, 14.7%
had decreased citrates, 11.1% were hyperuricemic, 8.6% were hyper-
uricosuric, 13.4% had infection stones, 0.5% had hyperparathyroidism
and 0.4% had cystinuria. Hypercalciuria was found as the single factor
in 53.3% of hypercalciuric patients. It was associated with hyperox-
aluria (14.2%) and hypocitraturia (11.3%). Isolated hypocitraturia was
detected in 50.8%. These results are essential to know single and
associated risk factors, and their treatment can prevent recurrence.
Transmission of Chagas disease (ChD) through kidney transplantation
(KT). M.C. Vázquez, C. Zala, C. Luna, M. Lauricella, M. Pattin, and
A. Rearte, Hospital Argerich MCBA, and INDIECH MSP, Buenos
Aires, Argentina. ChD is endemic in Argentina and the prevalence of
T-cruzi infection ranges from 23.7% to 30% in different provinces of the
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country. Since 1988 the C.U.C.A.I. has provided cadaveric kidneys
serologically positive for ChD. The purpose of this work was to
evaluate prospectively the infective power of ChD-positive cadaveric
donors (CD). Materials and methods: At Cosme Argerich Hospital, 72
KT were done from January 1988 to July 1992: 45 with CD and 27 with
living related donors. Five non-ChD patients received a kidney from a
ChD-positive CD. Azathioprine, prednisone, cyclosporine and antilym-
phocyte globulin were the immunosuppressive drugs utilized. Serologic
and parasitologic methods were used: three times a week the first
month, once a week the second month, and monthly after this period.
Results: Four patients were followed: two for 27 months with good renal
function did not show seroconversion for ChD. Among the other two
patients, one died suddenly and the other was nephrectomized because
of chronic rejection after 25 and 26 months respectively, without
evidence of ChD. The fifth patient became infected 45 days post-
transplantation, showing T-cruzi parasitemia and positive serology for
ChD. Nifurtimox (5 mg/kg/day) was administered during 21 days. The
parasitemia became negative after one week. The treatment was
stopped because of leukopenia. Conclusion: Up to now, there are only
two reports about ChD transmission through kidney transplantation.
ChD infection can be detected by careful follow-up of transplanted
patients. The specific prophylactic antiparasitic treatment should not be
necessary in recipients narrowly controlled. In countries with a high
prevalence of ChD, infected organs should not be rejected for KT.
Evolution of Chagasic kidney transplant patients. M.C. Vázquez, C.
Zala, F. Alvarez, A. Campanini, E.L. Segura, and A. Rearte, Hospital
Cosme Argerich MCBA, and INDIECH MSP, Buenos Aires, Argen-
tina. Chagas disease affects 6% of the Argentine population, with an
infection prevalence ranging from 23.7% to 30%, according to the areas.
The aim of this work was to evaluate the evolution of Chagasic patients
transplanted with non-Chagasic patients' kidneys (K). Materials and
methods: At Cosme Argench Hospital 72 KT were done from January
1988 to December 1991: 45 with K of cadaveric donors (CD) and 27 with
living related donors (LRD). Eight patients were Tx (7 with CD and 1
with LRD), and one non-ChD patient (Tx with non-ChD LRD) returned
afterwards to an endemic area. Antilymphocyte globulin, azathioprine,
prednisone and cyclosporine were the immunosuppressive drugs uti-
lized. All the patients were followed with serologic and parasitologic
methods (Strout and/or microhematocrite) to detect reactivation of
ChD, every three days during the first month, every week during the
second month, and monthly after this period. Specific prophylactic
antiparasitic treatment was not administered. Results: The non-ChD
patient who returned to the endemic area became infected two years
post-transplantation without clinical signs of ChD, with subpatent
parasitamia (negative Strout), positive xenodiagnostic. He did not
receive antiparasitic treatment. Only 2 patients transplanted with CD
showed parasitemia, and one of them had patent parasitemia (positive
Strout). Besnidazol (8 mg/kg/day) was administered during 21 days. The
Strout became negative after IS days and the treatment was stopped
because of leukopenia. Conclusions: Up to now, our patients did not
show reactivation of Chagas disease. Only one patient showed patent
parasitemia (positive Strout) needing antiparasitic treatment. Kidney
transplantation should not be contraindicated in Chagasic patients
controlled with a careful follow-up.
Renal artery embolism as a cause of acute renal failure: Diagnosis,
prognostic factors and treatment. J. Fort, A.J. Segarra, J. Camps, A.L.
Segarra, J. Gomez, R. Roca, A. Olmos, and L. Piera, Departments of
Nephrology, Radiology, Vascular Surgery, Hospital General Vail
d'Hebrón, Barcelona, Spain. Renal artery embolism is sometimes a
cause of acute renal failure in patients suffering from embolic valvular
cardiopathy. Diagnosis can be unnoticed in cases of unilateral embo-
lism. Although therapy remains controversial, surgical embolectomy
and fibrinolytics have been used with satisfactory results. This prospec-
tive study shows our two years experience in this pathology. We
studied nine patients (5 females and 4 males; mean age of 58.7 5.7
years) suffering from acute renal failure secondary to renal artery
embolism. Four patients were treated with surgical embolectomy and
four with intra-arterial fibrinolytics according to a protocol previously
dessigned. In all the cases we evaluated the levels of plasmatic
creatinine at six months and their relationship among the maximum
value of creatinine, LDH and LDH isoenzymes, the type of embolism
and the time elapsed since the beginning of clinical symptoms until the
treatment was started. The value of maximum creatinine, 4.6 3.1
sg/dl didn't correlate with either the maximum value of LDH, nor with
the type of treatment, nor with the elapsing time. The creatinine levels
at six months, 1.5 1.1 mg/dl, were significantly correlated (P < 0.05)
with the value of maximum creatinine and the elapsing time. No
correlation was found when we took into account the maximum value of
LDH. In our series either surgical embolectomy or fibrinolytic therapy
has been satisfactory. LDH isoenzymes (I and II) values have been
proven a useful diagnostic procedure, although they didn't have prog-
nosis value. Renal function recovery depended on early diagnosis and
treatment.
Evaluation of the clinical effect of corticosterold therapy against
Ponticelli's and factors of poor prognosis in the outcome of membranous
nephropathy (MN). J. de Rojo Bacelar, G. Rosa, R. Ibarra, B. Fongi,
M.A. Nadal, Hospital de Clinicas, Division Nefrologia and Departa-
mento Patologia Facuitad de Medicina, Universidad de Buenos Aires,
Buenos Aires, Argentina. Twenty-four patients with MN in stages I and
II, with serum creatinines 2.5 mg/dl were treated, 16 of them with
Ponticelli's schedule and 8 of them with MPS 1 mg/kg/day in 6 months.
Results N
Ponticelli
% N
MPS
%
Complete remission 5 3 1,25 2 25
Partial remission 0 0 0 0
Resistance 8 50 4 50
CRF (chronic renal failure) 1 6,25 1 12,5
Dialysis 2 12,5 1 12,5
Total 16 100 8 100
The factors of poor prognosis in the outcome of the MN were studied in
these groups, because of the influence of such variables as age, gender,
AP, serum creatininemia, serum cholesterol, quantity of proteinuria,
stage of the MN, glomerular sclerosis, tubular and vascular injuries,
and the volume of the interstitial space. Conclusions: (1) There was no
difference in the answer of the two therapeutic schedules within this
number of cases. (2) The statistic study didn't show significant differ-
ences between the risk factors of the cures and resistant patients.
Ventilatory alterations before and during hemodialysis with two differ-
ent membranes, cuprophane (CU) or polysulfone (PS), and bicarbonate
dialysate in patients with or without chronic obstructive lung disease
(COPD). Guido 0. Perez, Jesus Navarro, Carmen Serrano, and Elio
Donna, VAMC and Department of Medicine, University of Miami
School of Medicine, Miami, Florida, USA. Disordered breathing pat-
terns during maintenance hemodialysis may occur in patients with
end-stage renal disease (ESRD). Patients with COPD may be more
vulnerable to dialysis-induced respiratory abnormalities. The present
study explored breathing patterns and blood gas values during CU or PS
bicarbonate hemodialysis in six patients with COPD. Breathing patterns
were monitored by respiratory impedance plethysmography during two
consecutive 3-4 hour hemodialyses. Apneas were defined as a decrease
in tidal volume greater than 75% lasting more than ten seconds. The
number of apenic episodes during CU bicarbonate (17 6, SE) was
greater than those during PS bicarbonate (10 5; P 0.05) dialysis. The
decrement in Po2 (baseline to 60 mm) was 17 7 during CU and 4 5
mm Hg during PS dialysis (P = 0.1). Subsequently, we evaluated
respiratory function during the two hours preceding dialysis and during
dialysis in nine patients without COPD undergoing PS bicarbonate
hemodialysis. Apneic episodes in the two hours before (40 14) did not
differ from those during the two hours after beginning dialysis (56 19).
In COPD, apneic episodes are less severe during PS bicarbonate
dialysis. They appear to be related to uremia per se and not to
hemodialysis.
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Alkalosis acute adaptation is a proximal phenomenon. A. Martinez, A.
Tejedor, E. Junco, R. Perez, C. Dall'Anese, and F. Valderrabano,
Hospital General "Gregorio Marañón," Madrid, Spain. Metabolic
alkalosis is a potentially dangerous process, able to produce breathing
depression, hypercapnia and hypoxia. We show that acute defense
against alkalosis depends on proximal and thick ascending limb (TAL),
but not distal adaptation. Six isogenic minipigs were studied under
control (NaCl infusion at 0.2 mEq/kglhr for 60 mm) and alkalosis
conditions (NaHCO3 infusion at 2.5 mEqlkg/hr for 60 mm). Acid base
balance, renal hemodynamics, tubular function and substrate metabo-
lism and cortex concentration were studied during both periods. Bicar-
bonate infusion increased blood pH (7.38 to 7.50) and HC03 concen-
tration (19.3 to 32.5 mEq/liter). Despite of ventilatory assistance, PCO2
increased from 32 to 40 mm Hg, with no changes in PCO2. Renal blood
flow did not change, but GFR increased, with a 15% rise in the filtration
fraction. Fractional reabsorption of Na, however, decreased by 6%,
with a 5 times increase in distal delivery, showing an alteration of the
glomerulo-tubular balance. Ammonia synthesis dropped from 122 to 87
mEq/min 100 ml GFR. Glutamine and glutamate extraction decreased
and energetic metabolism showed a progressive lactate dependence.
TAL Na transport was also decreased as induced from the rise in the
ratio Na transported/02 consumed, and the interference with free
water clearance. At the distal level, the higher Na delivery tripled K
fractional excretion. However, no changes in T1'KG were evident.
During the alkalosis period, urine PCO2 did rise, suggesting a non-
adaptative increase in the distal H secretion rate. During the first
minutes following acute alkalosis, renal response is mainly based on
filtration increase and inhibition of Na, Cl and HC03 reabsorption
at the proximal and TAL levels. Distally, urinary HC03 initially
stimulates H secretion.
Effect of aluminum on erythropoiesls in experimental renal failure.
Graciela Garbossa, Abraham Gutnisky, Maria E. Castro, Norma
Rizzo, and Alcira Nesse, Facultad de Ciencias Exactas y Naturales,
Universidad de Buenos Aires y Centro de Estudios FarmacolOgicos y
Botdnicos (CEFYBO), CONICET, Buenos Aires, Argentina. Anemia of
chronic renal failure has been associated with aluminium (Al) accumu-
lation. The present work aimed to determine the effect of Al on
erythropoiesis in vivo. Male Wistar rats were randomly distributed into
two groups: sham operated animals with normal renal function
(SHAM), and uremic animals with surgically induced renal failure (RF).
Each group was subdivided into: control (SHAM, N = 5; RF, N = 10)
and Al overloaded (SHAM+Al, N = 5; RF+A1, N = 10). Between 25
and 200 mol Al/day or deionized water were administered through the
intragastric route during 102 days. At the end of the treatment period,
hematological parameters, urea and creatinine concentrations were
measured. Liver, bone, kidney, brain and heart were removed for Al
quantification. Clonal assays of late erythroid progenitor cells (CFU-E)
stimulated in vitro with recombinant human erythropoietin were carried
out. Hematocrit (RF: 35.4 6.94 vs. SHAM: 43.9 1.55%; RF+Al:
31.1 11.98 vs. SHAM+A1: 46.3 2.08%) and hemoglobin (RF: 123
19.7 vs. SHAM: 150 10.0 g/liter; RF+Al: lii 40.1 vs. SHAM+Al:
153 8.0 g/liter) in RF animals were significantly lower than those
found in controls. Although mean hematocrit and hemoglobin values
were diminished in RF+Al versus RF groups, no statistical differences
were found because of individual variability. Percent CFU-E in RF
group was lower than that in SHAM group (76 36% vs. 100%),
probably due to the presence of erythropoiesis circulating inhibitors.
Similar results were observed in Al-overloaded rats (RF+A1: 46 10%;
SHAM+Al: 66 + 25%). We conclude that Al action on erythroid
progenitor cells in bone marrow could be responsible for anemia
aggravation in uremic rats.
Depressed erythroid progenitor cell activity in aluminium-overloaded
mice. Graciela Garbossa, Abraham Gutnisky, Norma Rizzo, Maria E.
Castro, and Alcira Nesse, Facultad de Ciencias Exactas y Naturales,
Universidad de Buenos Aires y Centro de Estudios Farmacologicos y
Botánicos (CEFYBO), CONICET, Buenos Aires, Argentina. The aim of
the present study was to evaluate the effect of aluminium (Al) on in vivo
erythropoiesis in mice. Al citrate (10 /Lmol Al/day) was administered to
C3H mice through the intragastric route, adopting two schedules:
2-week and 6-week treatments. Controls received no treatment or
deionized water. At the end of each treatment period, in vitro clonal
assays of late erythroid progenitor cells (CFU-E) were carried out,
hematological parameters obtained, and bone and liver histological
aluminum staining performed. CFU-E growth was inhibited in over-
loaded mice, at the end of both, 2-week (% CFU-E SD: 34 14%) and
6-week (% CFU-E SD: 52 8%) Al treatment periods. Mean
hematocrit (36.6 3.52%) and hemoglobin (115 9.6 g/liter) values
after the 6-week schedule proved slightly though significantly lower (P
<0.01) than those found in control mice (42.0 3.18% and 128 6.4
g/liter, respectively), indicating some degree of anemia. However, no
differences in these values were found when comparing the 2-week
treated and control groups. Both treatment schedules failed to affect
erythropoietin levels and reticulocyte counts. No tissue Al accumula-
tion could be demonstrated by histological aluminon staining. The
2-week schedule mice, allocated in 4 experimental groups, received two
doses of either Al chloride or Al citrate (2.5 and 10 jmol Al/day). No
dose-related differences on CFU-E growth were found regardless of the
compound administered. Al chloride failed to inhibit CFU-E growth,
but Al citrate significantly depressed CFU-E growth, probably due to
the enhanced Al intestinal absorption caused by citrate anion presence.
We conclude that, even in the absence of severe anemia, Al overload
may depress hematopoiesis by decreasing red blood cell production.
Urinary obstruction after renal transplantation. Institute of Nephrol-
ogy, 1971—1992. 0. De La Concepcion, I. Cara via, R. Reyes, and L.
Alonso, Instituto de Nefrologia, La Habana, Cuba. Urinary obstruc-
tion is a serious complication after renal transplant. The clinical feature
can be acute (anuria) or slow (hydronephrosis), and it should be readily
differentiated from other causes of diuresis fall and creatinine increase
in order to avoid the impairment of renal allograft function. A descrip-
tive and retrospective study of patients with urinary obstruction was
made to find out the incidence of this complication during a period of 21
years of experience in the institution. The clinical records of 667 renal
allografts performed in the Institute of Nephrology from February 1971
to January 1992 were reviewed. Of the sum total, 626 were from
cadaveric donors and 41 were from live donors. Urinary obstruction of
different degrees was found in 35 patients with a 5.24% total incidence
and an annual rate oscillating in a range from 0 up to 20.8%. Ureter
obstruction due to lymphocele was the most frequent entity observed,
11 cases (31.4%), and ureteral torsion (6 cases), while litiasis was found
in 3 cases. The predominant presentation pattern of urinary obstruction
was the ureterohidronephrosis (68.6%). Surgical treatment was applied
in 30 patients (85.72%), performed from primary percutaneous ne-
phrostomy to ureteropielostomy as definitive treatment. Five patients
received diuretic administration and subsequent observation confirmed
that the obstruction disappeared. No organ loss or deaths occurred due
to this complication. The obstructive complications found in this series
are consistent with other transplant studies.
Urinary lIstula after renal transplantation. Institute of Nephrology.
1971—1992. 0. De La Concepcion, I. Caravia, R. Reyes, andL. Alonso,
Instituto de Nefrologia, La Habana, Cuba. Urinary fistula is a serious
complication after renal transplantation with a high morbidity caused by
the presence of urine in the allograft lodge which jeopardizes the
allograft and receptor's survival. A retrospective study of patients with
urinary fistula was made to determine the frequency of this complica-
tion during a period of 21 years of experience in the Institute of
Nephrology. The clinical records of 667 transplants performed from
February 1971 to January 1992 were reviewed (626 cadaveric donors
and 41 live donors). A descriptive analysis of the obtained data was
carried out (frequency and percentage). Urinary fistula was found in 43
patients with a total incidence of 6.4%, of which 37 were cadaveric
donors (86.04%) and 6 live donors (13.09%). Annual incidence ranged
from 0 to 18%. Ureteral fistula was the most frequent entity in this
series: 25 (58.13%). The surgical procedure most frequently performed
was the pyeloureterostomy (25%). Ureteral ischemia was the principal
cause identified. Only 7 patients lost the allograft due to urinary fistulae
(1.04%), and 2 patients died because of this complication (0.29%). The
survival of the allograft and the receptor depends greatly on the prompt
diagnosis and treatment of fistula. Even though the results of this work
are comparable to those reported by other transplantation centers, the
identification of the causes and the prevention of this complication need
further studies.
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Which are the optimal levels of intact parathyroid hormone (i-PTH) in
uremic patients? A. Torres, D. Hernandez, M.T. Concepcion, A.P.
Rodriguez, J.C. Rodriguez, M.E. Martinez, M.L. Dominguez, L.
Perez, M. Rufino, J.M. Gonzalez-Posada, E. De Bonis, and V.
Lorenzo, Nephrology Section, University Hospital of Tenerife, Tener-
ife, Spain. Bone biopsy and i-P'FH levels (IRMA) from 101 unselected
uremic patients (38 predialysis with GFR <10 mI/mm; 34 on CHD, and
29 on CAPD) were compared. Bone lesions were: 41% high bone
turnover (HBT), 50% low bone turnover (LBT), and 11% mixed
disease. Only 5 biopsies showed >10% of bone surface stained with
aluminum. Linear correlation coefficients are shown in the Table.
Ob.S/BS Fb(IV N.Oc BFR
Predialysis 0.86a 0.61a 0.68a 043b
Dialysis 0.83a 0.73a 0.76a 0.65a
Abbreviations are: Ob.S/BS, osteoblastic osteoid surface (%); Fb./
TV, volume of fibrosis (%); N.Oc, Osteoclastsxmm2; BFR, bone
formation rate (im3/m2 day). a P < 0.001; b p < 0.01.
The slope of the i-PTH versus Ob.S/OS regression was different in the
two groups (0.005 and 0.01; P <0.05). For both groups, an i-PTH <120
(normal 10—65 pg/mI) had a positive predictive value (PPV) of 89% for
LBT disease, and a value >500 a PPV of 100% for HBT or mixed
disease. The analysis of the regression lines and its 95% confidence limit
bands in dialysis patients showed that i-PTH should be >120 to obtain
an Ob.SIBS >1.5% and a BFR >0.03. To keep Fib/TV <0.5%, i-PTH
should be <200 pg/mI. Conclusions: (1) In the uremic state the relation-
ship between i-PTH levels and their bone response is shifted right-ward,
more in predialysis than in dialysis patients; (2) i-PTH values between
1.8—3 times the upper normal limit are necessary to maintain an optimal
bone histology in dialysis patients.
Comparison of three methods to measure cyclosporin A (CsA) levels in
kidney transplantation. A. Torres, A. Milena, M.L. DomInguez, A.P.
Rodriguez, L. Perez, M. Rufino, E. De Bonis, J.M. Gonzdlez-Posada,
M.T. Concepcidn, and C. Gonzalez, Nephrology and Biochemistry
Sections, University Hospital of Canary Islands, Tenerife, Spain. CsA
level monitoring is required for an optimal therapeutic control in organ
transplantation. Specific monoclonal RIA using V25 (RIA-Mo) measures
native CsA and shows an excellent correlation with HPLC. Fluores-
cence polarization using a monoclonal antibody (TDX-Mo) has the
advantage of being rapid and automated. The correlation of this method
with RIA-Mo, however, is not well-established. Whole blood trough
concentrations were measured in 58 renal transplant patients. In three
of them, an additional sample was obtained after 2, 3.5, 5, 8.5, and 12
hours after the morning CsA dose (12 hours profile). The 73 specimens
were measured by three methods: RIA-Mo, TDX-Mo, and polyclonal
TDX (TDX-Po). The TDX-Mo values were on average 1.3 times the
corresponding RIA-Mo values. The correlation between them was: y =
1.26X + 8.93, r = 0.97, P < 0.0001. If only RIA-Mo values <250 ng/ml
were selected the correlation was maintained (r = 0.90; P < 0.0001;
slope 1.2). For RIA-Mo >250 a similar slope was obtained (r = 0.95;P
< 0.0001; slope 1.22). In the 12 hours profile the relation peak-level!
basal level was similar for RIA-Mo and TDX-Mo (5.14 and 5.11
respectively). The correlation of TDX-Po with RIA-Mo was worse for
values <250 iig/ml (r = 0.80) than for those >250 nglml (r = 0.90).
Moreover, the slopes were different (2.76 and 1.45 respectively; P <
0.01). The Y intercept of the TDX-Po versus RIA-Mo regression line
was 92 ng/ml. Conclusions: (a) The TDX-Mo method has cross-reactiv-
ity with some CsA metabolites; (b) it shows, however, an excellent
correlation with RIA-Mo, providing a rapid and precise method for
measuring CsA in whole blood; (c) Polyclonal TDX is more useful to
detect high levels than to maintain therapeutic levels in the late
post-transplant period.
Cardiovascular and cerebrovascular complications after renal trans-
plantation. L. Mesa, L. Bolanos, J. Lavilla, M. Martin, V. Artolazabal,
P. Errasti, and A. Purroy, Nephrology Service, University Clinic of
Navarra, Pamplona, Spain. Acute myocardial infarction (AMI) and
cerebrovascular accidents (CVA) are one of the principal causes of
morbility and mortality after renal transplant (RT). Their incidence and
characteristics were retrospectively studied in 319 patients with RT.
Different parameters were considerated: age, sex, prevalence of hyper-
tension, interval between the RT and the vascular event, time on
hemodialysis, serum levels of cholesterol, HDL and LDL-cholesterol,
cholesterol/HDL index, HLA, and immunosuppressive treatment. Vas-
cular complications were present in 14 patients (4.4%), 9 had AMI
(2.8%), and 5 CVA (1.6%); 12 of these patients (85%) were men and 2
(15%) were women. Immunosuppressive treatment with cyclosporin A
(double or triple therapy) was employed in 64.25%, and the classic
therapy in 21.5% of these patients. Mean age for patients with AMI was
45 years old, range between 32—55 years, and 53 years old for patients
with CVA, range between 44—59 years. Besides, 93% of patients were
hypertensive receiving hypotensive treatment. Cholesterol/HDL index
in patients with AM! was 7, and 4.6 in patients with CVA. The mortality
was 67% and 60%, respectively. A curious fact was the significantly
high incidence of the HLA-A2 observed in 77% of patients with AM!,
and in 60% of patients with CVA, compared with 44% of RT patients
without vascular complications (P < 0.01). There was a direct correla-
tion between the time on hemodialysis and the cholesterol/HDL index,
being major in patients with AMI. Conclusions: Low incidence of AM!
and CVA in our group of patients is associated with a high mortality.
Between the studied parameters, cholesterol/HDL index and the
HLA-A2 were the only significant predictors of cardiovascular and
cerebrovascular complications. This suggests that HLA-A2 in RT
patients could be considered as a possible risk marker of vascular
complications (AMI or CVA).
Plasma and bone aluminum concentration in uremic patients under
aluminum hydroxide therapy. M.D. Fernandez, A.L.M. De Francisco,
M. Arias, Departments of Clinical Biochemistry and Renal Medicine,
University Hospital "Marques de Valdecilla,' Santander, Spain. Pa-
tients with chronic renal failure under dialysis treatment increased
aluminum body burden, which may induce severe toxic disorders.
Patient monitoring for aluminum load is achieved by the measurement
of aluminum in serum with controversial results. The aim of this study
was to determine serum and bone aluminum content in 37 patients on
hemodialysis (dialysis fluid <10 pg Al/liter) and aluminum hydroxide
therapy. Results were as follows:
Serum aluminum X = 55 pg/liter (14—150)
Bone aluminum X = 29.3 g/g (13—77)
Control group N = 45
Serum aluminum X = 9 (5—14), Bone aluminum 7 (2—10)
Serum aluminum did not correlate with bone aluminum, time on dialysis
and aluminum hydroxide ingestion. Bone aluminum content correlated
with dialysis time and aluminum hydroxide ingestion. Conclusions:
Bone aluminum content reflects aluminum intoxication. Serum alumi-
num does not provide a real index of the total amount of tissue
aluminum content.
Relapsing hematurla, a review of 101 cases with histopathological
study L. Garcia, A. Gimenez, J.A. Camacho, and E. Guardia, Hospi-
tal Infantil Sant Joan. de Déu, Barcelona, Spain. Relapsing hematuria is
a usual process in childhood. During 1974-1991, in a group of 472
patients with hematuria, we have separated 164 cases of relapsing
hematuria; the patients were between 2—16 years old. The previous
clinical-analytical study permitted us to classify 63 cases of hematuria +
hypercalciuria; the other 101 cases are the objective of this report. We
analyzed clinical-analytical and histopathological facts to differentiate
and group them in order of frequency: (I) Benign recurrent hematuria
(N = 41): This group is characterized by a normal histology. Clinically,
80% of these cases presented brotes of macroscopic hematuria joined
with respiratory tract processes. Proteinuria appeared in 60% of cases.
Renal function was normal in all of them. There were family anteced-
ents at 18 cases. (2) Alport's syndrome (N = 33): 18 women, 15 men,
the average age was 7 years old. The diagnosis was confirmed by
electronic microscopy. Proteinuria was important in 40% of cases; 4
cases of them were in a nephrotic rank. We detected renal failure in 5
cases, and bilateral hypacousis of perception in 11 cases. The average
time of pursuit was 7.8 years. (3) Berger's disease or IgA nephropathy
(N = 27): 20 men and 7 women; the average age was 7.3 years old. They
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were selected according to the following clinical and anatomical crite-
ria: (a) More than 3 brotes of relapsing hematuria were in a time higher
than 6 months. (b) There was absence of some kind of systemic disease.
(c) There was normal audiometry. (d) There were diffuse mesangial
proliferation with granulated deposits of IgA. There were proteinuria in
20 cases, and 5 cases of them were into a nephrotic rank. The average
time of pursuit has been ten years; the renal function was normal,
except for two cases that presented nephrotic syndrome. Conclusions:
(1) The histopathological study (optical microscope electromcal micro-
scope, direct inmunofluorescence) is the only method able to differen-
tiate and classify the different clinical entities that cause relapsing
haematuria, (2) The clinical and analytical facts are good to diagnose the
majority of cases, but only renal biopsy is the best method of diagnosis.
Hemodynamic effects of the opening and closing of the A-V fistula in
chrome hemodialysis patients. J.C. Vergottin, A.M. Sesin, A. Rivas
Jordan, and E. Kuschnir, Hospital Nacional de Clinicas, Córdoba,
Spain. Twenty patients with chronic renal insufficiency in chronic
hemodialysis with A-V fistula were studied with a radioisotopic yen-
triculogram using Tc to evaluate the hemodynamic changes. The
mean age of the patients was 40.9 (R 72—22), 12 males and 8 females.
None of the patients was on any medication for 48 hours prior to the
onset of the study; none was digitalized. Determinations were made at
rest, with an open fistula and with a closed fistula. The closing of the
A-V Fistula ARM was performed for 3 minutes with the assistance of a
blood pressure cuff which was insuflated 1 mm Hg below the maximal
systolic blood pressure, to allow a minimal flow; therefore, there was no
need to anticoagulate the patient and the pain caused by the closing was
well-tolerated. Results were as follows:
Open fistula Closed fistula
Heart rate 83.85 13.8 (NS) 83.65 16.37
Systolic blood pressure 163.94 34.5 (NS) 165.26 38.05
Diastolic blood pressure 85.84 23.81 (NS) 90.52 26.13
Cardiac output 1/mm 10.27 4.13 (P < 0.005) 8.16 2.77
Cardiac index uterI 6.49 2.60 (P < 0.005) 5.26 1.69
minim2
Systolic volume mi/s 120.9 38.73 (P < 0.001) %.2 25.3
Systolic index mi/s 77.05 25.39 (P < 0.001) 61.5 16.85
End diastolic volume 116.50 25.33 (P < 0.005) 102.8 18.76
index ml/m2
End systolic volume 40.45 18.55 (NS) 41.2 18.36
index mum2
Ventricular function 4.83 2.49 (NS) 5.15 3.28
index
Left ventricular ejection 0.67 0.15 (P < 0.04) 0.61 0.15
fraction
Right ventricular ejection 0.47 0.08 (NS) —0.46 0.10
fraction
Peak filling rate 4.11 1.74 (NS) 4.08 1.45
Many factors contribute to the cardiovascular complications in patients
with chronic hemodialysis working in combination. The knowledge of
the physiopathology and the individualized management of each of
these variables contribute to improve the prognosis of the chronic
myocardial syndrome with acute hemodynamic changes.
Continuous venovenous, pump-assisted, hemofiltration: A better alter-
native to continuous arteriovenous hemofiltration? L. Bolanos, L. Mesa,
C. Vdzquez, J. Laviila, M. Martin, V. Artolazdbal, P. Errasti, and A.
Purroy, Servicio de NefroiogIa, C/mica Universitaria, Universidad de
Navarra, Navarra, Spain. Continuous hemofiltration has actually be-
come an ordinary technique in most intensive care units (ICU), which
allows better management of critically ill patients with acute renal
failure. We report our experience with 14 critically ill patients (nine
males and five females) who underwent continuous venovenous pump—
assisted hemofiltration (CVVH) within a fifteen month period. In three
patients, we used a dialysate circuit (hemodiafiltration) to improve the
clearance of uremic toxins. The mean age (± SD) was 51.5 20 years.
The average blood flow rate was 168.2 21 mI/mm. The hourly mean
ultrafiltrate volume was 400 82 ml and the daily fluid balance attained,
with respect to hemofiltration, ranged from —1.250 to —7.300 ml (X
4.283 2.040 ml). In nine patients (64%), the hemofiltration technique
was discontinued because of death. In the remaining five (36%), the
procedure was terminated once a good diuresis rate was achieved.
Hemodynamic tolerance was very good. The suggested importance of
obtaining an adequate ultrafiltrate volume, as well as lesser complica-
tions in venovenous techniques (in our experience one case of pneu-
mothorax after central vein cannulation the venous access and one
episode of digestive bleeding attributed to heparin) compared to arte-
riovenous hemofiltration, would point to continuous venovenous hemo-
filtration as the treatment of choice in the management of critically ill
patients with oliguric acute renal failure.
Atrial natriuretic factor (ANF) in patients with CAPD. J. Mora-Macia,
T. Donate, J. Ocon, M. Roda, and G. Del Rio, Nephroiogy Service,
Fundacion Puigvert, Barcelona, Spain. Increased levels of ANF have
been reported in chronic renal failure. The aim of this study was to
confront the levels of ANF and the angiotensin-aldosterone-remn
system in patients in CAPD with patients on chronic hemodialysis
(HD). Subjects and methods: We have studied three groups. CAPD
group (CAPDg): 10 patients, aged 25—66 years. HD group: 10 patients,
aged 35—69 years, before (HDpre-) and after (HDpost-) a 4 hour HD
session with ultrafiltration. Control group (CG): 10 subjects with normal
renal function, aged 21—65 years, matched for age, height, weight and
diastolic pressure with CAPDg. Blood samples for plasma renin activity
(PRA), plasma aldosterone (PA) and ANF were taken at 08:00 hours,
and before and after the HD. At the same time we measured the blood
pressure (BP). PRA and PA were measured by RIA. For ANF we used
RIA prior to an extraction in Sep-Pack Cl8 microcolumns. Results: The
BP and levels of ANF, PRA and PA were: in CG, 121 15/75 4mm
Hg, 7.3 5.6 pmol/liter, 1.1 0.8 ngiml/hr, 0.4 0.3 nmollliter. In
CAPDg, 132 26/76 12 mm Hg (NS), 8.3 3.5 pmoliliter (NS), 5.6
4.4 ngiml/hr (P < 0.001), 4.9 4.0 nmoliliter (P < 0.001). In HDpre-,
159 25/95 12mm Hg (P < 0.001), 16.0 8.5 pmol/liter (P < 0.005),
11.9 9.0 ngiml/hr (P < 0.001), 2.6 2.3 nmol/liter (P < 0.001). In
HDpost-, 145 29/84 15 mm Hg (P < 0.05, vs. CG), 13.4 6.9
pmol/liter (P <0.05, vs. CG), 14.9 10.3 ngfmlihr (P < 0.001, vs. CG),
3.8 2.9 nmoliliter (P < 0.001, vs. CG). There is a positive correlation
between BP and ANF in HD patients before ultrafiltration (r = 0.700/r
= 0.772, P < 0.05/P < 0.01), and a negative correlation between ANF
and PA in HD after ultrafiltration (r =
—0.731, P < 0.05). Conclusions:
An increased plasma ANF was observed in HD patients, before and
after ultrafiltration, in comparison to levels of ANF in CAPD or control
groups. The correlation between BP and ANF only in HD patients
suggest not only a difference in plasma volume, if not a direct role of BP
in these patients. However, in CAPDg, the normal values of BP and
ANF indicate a better volume balance achieve in these particular
patients.
Does age influence mineral metabolism In children on continuous
ambulatory peritoneal dialysis (CAPD)? A. Aionso Meigar, E. Hernan-
dez, A. Fernández Escribano, C. Garcia Meseguer, and M. Navarro,
Division of Nephrology, Hospital Infantil "La Paz," Madrid, Spain. In
order to analyze the differences in mineral metabolism related to age,
we studied 20 children (9 boys, II girls) on CAPD during 10.9 10.25
months. In the younger group there were five infants with a mean age of
1.05 0.8 years, whereas the mean age of the fifteen children in the
older group was 9.7 4.5 years. All patients received oral calcium
carbonate (175 146 mg/kg/day) and calcitrioi (9.4 12 ng/kg/day).
Aluminum hydroxide was avoided. The dialysate calcium was 1.75
mmollliter and magnesium was 1.5 mEq/liter. Height velocity increased
significantly during the first year on CAPD, from —2.7 SD to 1.1 4
SD (P < 0.05), and height increased from —2.75 DS to —2.2 5DS (NS).
The younger patients didn't improve on mineral metabolism. Bone
disease mineral metabolism did not improve in the younger patients;
furthermore, persistence or worsening of the bone disease and second-
ary hyperparathyroidism have been observed. These patients did not
show significant differences between CRF period and CAPD period in
serum levels of calcium (9.9 I vs. 4.2 I mg/dl), ionic calcium (1.3
0.15 mmoliliter), phosphorus (4.4 1 vs. 4.2 1), and serum
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immunoreactive parathormone (iPTH) (273 320 vs. 263 305) when
the dose of calcitriol was progressively increased from 19 ng/klday to 27
ng/k/day. Results in the older group before and during CAPD are:
Before
CAPD
During
CAPD P
Hypercalcemic episodes/year 2.7 2 6.04 4 <0.05
Serum calcium mg/di 9.3 0.9 10.2 0.1 <0.05
Ionic calcium mmol/iiter 1.25 0.1 1.33 0.12 < 0.05
Phosphorus mg/dl 5.1 0.8 6.1 1.5 <0.05
i-PTH pg/mI 126 125 128 256 NS
Calcium-phosphorus product mg/di 48 16 62 15 <0.01
Conclusions: (1) 100% of the younger patients had renal osteodystrophy
and secondary hyperparathyroidism during CAPD. (2) Serum levels of
calcium, phosphorus and calcium-phosphorus product increased signif-
icantly in older patients, but hypercalcemia episodes and extraskelletal
calcifications risk, also increased. (3) Height velocity improved in both.
(4) We advocate using 1.75 mmollliter dialysate calcium in younger
patients on CAPD and low calcium dialysate on older patients.
Effect of dialysate and replacement solution buffer on organic anions in
short dialysis. J. Hdez-Jaras, A. Estrada, A. Gaidn, J. Martin, C.
Garcia-CantOn, and J.A. Traver, Hospital Fco de Borja, GandIa,
Hospital de Ia Princesa, Madrid, Spain. Acetate and bicarbonate are
generally used as dialysate buffers in hemodialysis (HD), while bicar-
bonate or lactate are the most important buffers employed in substitu-
tion fluids in hemodiafiltration (HDF). The aim of the present study was
to evaluate the influence of these anions in the main metabolic pathways
(Krebs cycle, anaerobic glucolysis, ketogenesis) during short hemodi-
alysis and HDF. Thirty-two patients, divided into four groups, were
studied. The treatment time was 3 hours, three times per week. Group
I: HD with acetate dialysate (35 mEq/liter); Group II: Biofiltration with
acetate dialysate and simultaneous infusion in postdilution mode of 3
liters (Na: 145, C03H: 100, Cl: 45 mEq/liter). Group III: Pair-
filtration-dialysis (PFD) with bicarbonate (33 mEq/liter) and acetate (4
mEq/liter) dialysate and infusion of Ringer's lactate. Group IV: HD
with bicarbonate (33 mEq/liter) and acetate (4 mEq/liter) dialysate. pH
and bicarbonate in Group I were significantly different from those in
other groups. Plasma acetate concentration rose during hemodialysis
from 0.03 and 0.07 to 7.42 and 7.11 in Groups land II, respectively, and
from 0.01 to 0.33 and 0.53 mEq/liter in Groups III and IV. Plasma
lactate fell in Groups I, II, IV and rose in Group III. Pyruvate
concentration rose in all groups during dialysis. Citrate concentration
rose significantly in groups with acetate dialysis; there was no signifi-
cant change in Group III, and it fell significantly in group IV, during
dialysis. Beta-hydroxy-butyrate rose in all groups, but the highest
values were detected in groups with acetate dialysate. Conclusions: The
use of HDF, independently of buffer dialysate, leads to better replen-
ishment of bicarbonate buffer stores, depleted by interdialytic acid
generation. During acetate dialysis, this anion is the main substrate of
Krebs cycle, increasing concentration of citrate. The capacity of Krebs
cycle is exceeded and acetate will be diverted into the production of
beta-hydroxybutyrate.
Phagocytic function of hemodialysis (lID) patients: Effect of membrane
biocompatibility. C. GOmez RoidOn, A. Rubio Vitalier, E. Gailego, M.
Calvo, A. Serrano, L. Sdnchez, E. Andrés, and E. Olivas, Genera!
Hospital, Albacete, Spain. Patients on HD have a higher rate of
infections than the normal population. Several functional alterations
have been described in leukocytes, but the effects of dialysis membrane
on phagocytosis are still under study. We present our results on
phagocytic activity of leukocytes from patients dialyzed with two
membranes with different biocompatibilities (cellulose acetate, CA;
polyacrylonitrile, PAN). Methods: We included 14 patients, 4 females
and 10 males, with a mean age of 51 15.6 years, and an average time
on HD of 67.3 45.7 months. Patients with diabetes, chronic or acute
infectious conditions were not included. Selected patients were succes-
sively dialyzed with CA and PAN, and the same dialysis scheme
(bicarbonate fluid, controlled UF). Blood was drawn at 0 and 30
minutes of HD, and immediately post-HD. Phagocytosis was estimated
by total blood incubation at 0° and 37°C with FITC labeled E. Coli and
DNA staining, and counting on a flux cytometer.
Pre-HD 30 mm HD post-HD
Total phag. cell (CA) 8713 6l8 7634 1152 8336 614
Total phag. cell (PAN) 8783 349k 8204 425 8039 617
a P < 0.01.
Conclusions: (I) HD induces a decrease in phagocytic activity that
partially recovers during the session. (2) Cellulose acetate and poly-
acrylonitrile are not different in the degree of depression-induced
phagocytosis.
Analysis of obstructive uropathy (OU) post-kidney transplant. A.
Fiabane, K. Velazquez, S. Marquez, J. Morales, J. Pefaur, A. Mocar-
quer, and J. AguilO, Servicio de Medicina, Hospital Barros Luco
Trudeau, Facultad de Medicina, Universidad de Chile, Santiago,
Chile. OU is a kidney transplant related complication, which causes
functional damage and even loss of allografts; its incidence varies from
3 to 20%. The main objective of this study was to analyze the incidence,
etiology, severity and functional prediction of allografts with OU. Three
hundred and sixty kidney transplants were retrospectively studied on
which an extravesical (antireflux) ureteral anastomosis was done. The
diagnosis of OU was based on the presence of ectasia, hydronephrosis
after the first month of transplant. Techniques such as echotomogra-
phies, intravenous pyelographyes, and surgical exploration were used.
The cases were divided into mild, moderate and severe, according to
renal functional impact. They were classified as early and late, depend-
ing on the time of development of OU (before or after the 3rd month).
The incidence of OU was 8.8% (32 patients). The etiology was ureteral
stenosis (34%), uretral stenosis (19%), ectasia (18%), extravasation
(9%), refiux (6%) and others. Nine patients presented OU mild, 12
moderate and 11 severe; 13 patients were early and 19 patients late.
Five allografts were lost, only one due to OU. Plasma creatinine was
studied before and after the corrective operation and there was no
change in the moderate group; meanwhile, in the severe form, plasma
creatinine decreased significantly (P = 0.05). The graft survival was
79% at 5 and 10 years, without any deaths in this group. Conclusions:
The incidence of OU was 8.8%, stenosis of ureter and uretra being the
most frequent cause; 34% of cases were severe and the corrective
surgery improved the renal function in this group. The graft survival
was similar to the general population of transplants done in the same
unit.
Migration of peritoneal catheter In CAPD. M. Moreiras, A.J. Perez,
J.A. Sobrado, L. Palomares, A. Gdndara, L. Glez Rguez, I. Glez Diaz,
and M. Courel, Nephrology Section, Hospital Xerai de Vigo, Pizarro,
Vigo, Spain. Between May 1986 and December 1991, 52 pentoneal
catheters were inserted into 38 CAPD patients (21 males and 17
females). Patients' ages ranged from 6—81 years. The types of the
Tenckhoff catheters were: 24 standard straight and 28 Swan-Neck (SN),
(19 straight and 9 coiled). Migration of the catheter tip causing inade-
quate fluid drainage occurred 16 times (3 1%) in II patients (29%), with
a higher frequency in the first 4 months after the insertion. The
following procedures for repositioning the catheter tip were succes-
sively attempted: (a) use of enemas and laxatives; (b) guide-wire
manipulation under fluoroscopic control; (c) surgical replacement. The
use of enemas and laxatives was only effective in 2 cases. Fluoroscop-
ically directed guide-wire manipulation was successful in 3 of 8 at-
tempts, Surgical repositioning without fixation of the catheter tip
(replacement and creation of a new tunnel) was performed in 7 cases. In
3 of them new migrations occurred and in the other 2 cases there was
not enough time of follow-up (removal of the catheters due to other
causes). Open surgical proceedings for repositioning and fixation of the
catheter tip under general anesthesia (by fixing the catheter tip to a
lateral pelvic peritoneal tunnel, or by passing the distal portion of the
catheter trough the mesosigma) were performed in 3 cases of catheter
migration and in another patient without catheter migration (placement
of a catheter with simultaneous surgical repair of an umbilical hernia-
tion) with successful and permanent results in all these 4 cases after a
follow-up of 7, 9, 10 and 29 months. One of the patients, with polycystic
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kidney disease, developed an umbilical laparocele. The migration rate
was significantly lower (P = 0.016) with the use of the SN catheters.
There were no significant differences depending on the shape of the
catheter tip (straight or coiled) nor on the number of cuffs. Conclusions:
(1) Catheter tip migration is an early and frequent complication. (2) Its
frequency is lower with the use of the Swan-Neck catheter. (3) If the
conservative management does not have effective results, the surgical
fixation (expected to be performed by laparoscopy in a near future) is
the definitive solution.
Hepatitis C virus (HCV) seroconversion. Epidemiological factors and
ways of transmission at hemodialysis (HI)). J. Garcia- Valdecasas, M.C.
Bernal, F. Garcia, M. Manjon, J.G. Hervas, and S. Cerezo, Depart-
ments of Nephrology andMicrobiology, University Hospital, Granada,
Spain. The high prevalence of anti-HCV antibodies (Ab) and the
incidence of morbidity have led us to evaluate anti-HCV evolution and
to analyze the probable transmission mechanisms. Patients and meth-
ods: We have tested anti-HCV by 2nd generation ELISA and confirmed
them by RIBA-2 in 107 HD patients. Seroconversion was evaluated
throughout an 18 month period and related to the following epidemio-
logical factors: sex, time at dialysis, transaminase elevation, and being
dialyzed at the same monitor as seropositive patients. Patients were not
blood transfused during the study period. Throughout the study, 12
patients were excluded (4 were seropositive); the remaining 95 patients
were dialyzed at three units (A, B, C) with 25, 22 and 28 patients,
respectively. Results: 27 out of 107 patients were seropositive (preva-
lence = 25.2%). During the follow-up, 6 patients lost antibodies against
at least one peptide: Ab C-22, I patient; C-33c, 2 patients; 5-1-1 and
C-lOO-3, 3 patients. Thirteen seroconversions were observed (18.0%);
no statistical relationship with sex or transaminase elevation was found.
The time spent at dialysis was found to be statistically significant (P <
0.01; 84.6% were being dialyzed for more than 5 years). At unit A, 5
seropositive patients shared monitors with 3 seronegative who serocon-
verted; no other seroconversions were observed. At unit B, 5 seropos-
itive patients shared monitors with 3 seronegatives who seroconverted;
2 more patients (unrelated) seroconverted as well. At unit C, 13
seropositive patients shared monitors with 10 seronegatives: 4 serocon-
verted and 1 more patient (unrelated) seroconverted as well. Conclu-
sions: (I) Anti-HCV prevalence at our unit has increased from 25.2% to
37.9% during 18 months. (2) Seropositive patients tended to lose certain
Ab; its significance is yet unknown. (3) Seroconversion is clearly
related with time at dialysis. (4) Our study supports a possible way of
transmission: patient-patient through the dialysis monitor.
Hepatitis C virus at predialysis: Epidemiological factors involved. J.
Garcia- Valdecasas, M.C. Bernal, E. Quiros, A. Navas-Parejo, M.J.
Garcia, and S. Cerezo, Departments of Nephrology and Microbiology,
University Hospital, Granada, Spain. Anti-HCV prevalence at dialysis
units, ranged over 20%, contrasts with the value for the normal
population (0.8—1.2%) and blood donors (1.0%). The aim of this study
was to investigate the situation of predialysis patients. Patients and
methods: 27 patients at terminal stages of renal insufficiency were
followed up during 1990—91. Anti-HCV were tested by 2nd generation
ELISA and confirmed by RIBA.2. Anti-HCV prevalence was related to
the following epidemiological factors: sex, time of illness evolution,
number of transfusions, transaminases elevation, and invasive proce-
dures (biopsies, percutaneous insertion catheters in subclavian, jugular
or femoral veins, arteriovenous fistulas, etc.). Results: 5 of the 27
patients were anti-HCV positive (pre-dialysis prevalence: 18.5%).
There was no relationship with sex. There was no relationship with
number of transfusions: 2 positive for anti-FICV out of 10 patients with
transfusions (20%), against 3 positive out of 17 without transfusions
(17.6%). Statistical significance was found (P < 0.01) when time of
illness evolution was studied: 38.2 months for anti-HCV positive
patients against 17.7 months for seronegative. Transaminase elevation
was found in 5 positive patients (80%) (P < 0.01). No relationship
between biopsy or one isolated therapeutic activity and anti-HCV
positivity was observed. However, coincidence in several therapeutic
activities was significant (P < 0.01) when more than 5 invasive acts
were performed (15 patients, 4 anti-HCV positive: 26.7%) compared to
less than 5 (12 patients, 1 anti-HCV positive: 8.3%). Conclusions: (1)
There was a high prevalence of anti-HCV among pre-dialysis patients
(18.5%). (2) There was no relationship with blood transfusions. (3)
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There was transaminase elevation among these patients. (4) There was
a high relationship with time of illness evolution, probably related to
invasive procedures.
Serological markers of uremic prurltus in 114 chronic hemodialyzed
(lID) patients. J. Tercedor, A. Navas-Parejo, M. Manjon, J. Garcia-
Valdecasas, J.M. Caridad, S. Serrano, and S. Cerezo, Department of
Nephrology, University Hospital, Granada, Spain. Pruntus is one of
the most common symptoms in HD, affecting up to 85% of all patients;
however, its etiology remains uncertain. We analyzed several serolog-
ical parameters that are altered in these patients, to evaluate their
possible associations with pruritus. Material and methods: A total of 114
patients completed an analogue visual questionnaire in which they were
asked to rate the intensity of pruritus on a scale from 0 to 10. These
results were used to establish three categories of pruritus: slight (0—4),
moderate (5—8), and severe (9—10). Predialysis blood samples were
obtained to measure serum total and ionic calcium, inorganic phospho-
rus, magnesium, alkaline phosphatase, intact and half-molecule par-
athormone, osteocalcin and aluminum using the deferoxamine test.
Results: Pruritus was present in 57 patients (50.0%). Of the parameters
studied, statistically significant associations were found between pruri-
tus and magnesemia higher than 2.7 mg/dl (P < 0.02). In addition, mean
magnesemia in patients with pruritus (2.84 mg/dl) was higher than in
patients without this symptom (2.60 mg/dl; P < 0.007). Ionic calcium
was lower in patients with pruritus (1.15 mmol/liter) than in symptom-
less patients (1.22 mmollliter), although these differences were not
statistically significant (P < 0.06). No significant relationships were
found between the presence or intensity of pruritus and any of the
remaining parameters studied. Conclusions: (1) A significant relation
was found between pruritus and elevated levels of magnesemia. (2) No
relation was found between uremic pruritus and levels of parathormone
or aluminum. (3) Hypermagnesemia appears to be involved in the
etiology of uremic pruritus.
Ferritin and iron (Fe) levels in anemic hemodialyzed (LID) patients
treated with erythropoietin (rHuEPO) and desferoxamine (DFO). M.J.
Garcia, M. Manjon, J. Garcia-Valdecasas, A. Navas-Parejo, J.G.
Hervas, and S. Cerezo, Department of Nephrology, University Hospi-
tal, Granada, Spain. Several authors have described the possible
interference between intestinal Fe absorption in uremic patients intox-
icated by aluminum. We studied the variations in the level of serum Fe
and ferritin on HD patients with anemia treated with rHuEPO and
DFO. Material and methods: We have studied 32 HD patients who
showed levels of Hb <8 g/dl. They were classified in relation to the
DFO test in two groups, and they were followed-up during 1 year with
different treatments for the anemia correction: Group I: DFO test (—);
all of then treated with 25 U/kg of rHuEPO three times a week. Group
II: DFO test (+); these patients were classified in two subgroups: Ila:
treated with rHuEPO, and LIb treated with rHuEPO and DFO (20
mg/Kg/dialysis). In all patients there were detected serum levels of Fe
and ferritin monthly during the study period (1 year). All of them took
500 mg of ferrous sulfate every day at the beginning of the study.
Results: An adequate response to red series was observed. Group I: No
variation in ferritin levels. In 64.7% of patients, the dose of ferrous
sulfate was doubled. Sera Fe dropped significantly at the beginning (P
<0.001 at 4th month). Group Ila: sera Fe levels dropped significantly
(P < 0.01 at 4th month) and ferntin also (P < 0.05 at 4th month), even
with a double dose of ferrous sulfate in 62.5% of patients. Group lIb:
There were not any significant differences in Fe and ferritin levels. Only
28.6% of patients required an increase in ferrous sulfate. Conclusions:
(I) Use of supplementary oral Fe is necessary in order to correct the
anemia in HD patients treated with rHuEPO. (2) Aluminum intoxication
might interfere with intestinal absortion of Fe, allowing the use of Fe
endogenous pools and a drop in ferritin sera levels. (3) The correction
of intoxication of aluminum with DFO provides the absortion of Fe.
Protein and caloric malnutrition in chronic hemodialysis patients
(CLII)). Validity of the determination of protein catabolic rate (PCR). V.
Lorenzo, D. Hernandez, M. Dotninguez, A. Rodriguez, L. Perez, Al.
Rufino, A. Torres, B. Maceira, M. Losada, and J. Gonzalez Posada,
Nephrology Service, Hospital Universitario de Canarias, Tenerife,
Spain. Protein and caloric malnutrition are relatively common among
CHD patients and have direct bearing on morbidity and mortality. The
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aim of the present study was to know the nutritional status of our CHD
patients, and test the validity of the determination of PCR. Twenty-nine
stable patients undergoing thrice weekly CHD (18 M, I iF, mean age 49
17 years, 68 6 months on CHD) were studied. Nutritional status
was assessed by biochemical methods (total serum protein and albumin,
transferrin, and prealbumin concentration), urea kinetic studies (PCR
was obtained according to Sargent's formula, and Watson equation was
used to calculate urea distribution volume), anthropometric measure-
ments (relative body weight, triceps skinfold thickness and arm muscle
circumference), and dietary intake was recorded during a 3 day period.
Relative body weight and anthropometric measurements were reduced
in 38% and 62% of patients, respectively. In contrast, all biochemical
data were within normal limits, indicating that these parameters have
low sensitivity and probably represent a relatively late manifestation of
malnutrition. There was a greater reduction of energy (26.8 11.9
Kcal/klday) than protein intake (1.02 0.4 g/k/day). The greater
number of patients (24/29) had a low calorie intake, and 16 out of 29
ingested less than I g of protein/kg/day. A negative relationship
between age and protein intake (r =
—0.65; P < 0.01) was established.
There was a good correlation between PCR and protein intake (r = 0.77;
P < 0.01). When PCR and BUN were plotted, a direct correlation was
found (r = 0.54; P < 0.01). A negative relationship between urea
nitrogen appearance-nitrogen intake ratio and protein (r = —0.6; P <
0.01) and caloric intake (r = —0.39; P <0.05) was found, indicating that
a negative nitrogen balance occurs more frequently in the patients with
the least caloric and protein intake. In summary, protein and caloric
undernutrition occurred more commonly in older patients, in associa-
tion with lower BUN and PCR values. These patients are at higher risk
of developing a negative nitrogen balance.
Intravenous versus oral post-dialysis bolus administration of calcitriol
(CTR). Comparison of efficiency. V. Lorenzo, A. Rodriguez, D. Her-
nandez, M. Doininguez, M. Rufino, E. de Bonis, and A. Torres,
Nephrology Service, Hospital Universitario Canarias, Tener(fe, Spain.
Numerous studies have demonstrated a direct suppressive effect of
CTR on PTH synthesis, but the patients often develop hypercalcemia
and hyperphosphatemia. To examine this question, 13 chronic hemo-
dialysis (CHD) patients (55 17 years, 6 males/7 females, >6 months
on CHD) with marked secondary hyperparathyroidism, intact PTH
levels greater than 250 pg/mI (normal 10—65 pg/mi) and/or bone histo-
morphometric criteria of osteitis fibrosa were treated for six months
with CTR. Oral (2.5 ,ug, N 7) and intravenous (1 pg. N = 6)CTR was
administered thrice weekly at the end of each dialysis session. A
constant dialysate calcium concentration of 2.5 mEq/liter was used. The
patients received CaCO3 and (OH)3A1 (when P04 > 7 mg/dl) as
phosphate binders. The doses of binders and CTR were adjusted to
maintain Ca 10.2—11.2 mg/dl, P04 < 6 and CaxPO4 < 65. Serum levels
of calcium, phosphorus, alkaline phosphatase (AP), intact PTH
(IRMA), GLA (RIA), and aluminum were monitored monthly or more
often. At the 2nd month of therapy there was a significant increase of
calcium (18%) and phosphorus (22%) levels. PTH decreased by 55%
and serum AP also was reduced by 16%. All parameters remained
constant until the end of the 6th month. GLA did not change during the
study and aluminum remained below 80 pg/liter in all patients. The
pulse therapy was successful in all except one patient. After CTR
therapy, the increase in calcium and phosphorus levels and the reduc-
tion in PTH and AP levels were similar in both groups. Episodes of
hypercalcemia and hyperphosphatemias were frequent and limited our
ability to increase or continue CTR. The requisite dose of (OH)3A1
necessary to control hyperphosphatemia was higher in the oral CTR
group and increasing doses of CO3Ca and CTR were better tolerated by
intravenous CTR group. In conclusion, whereas both oral and intrave-
nous postdialysis bolus administration of CTR is an effective therapy
for the reduction of parathyroid hormone levels, our data suggest that
the intravenous route is more efficient in terms of calcium and phos-
phorus control.
Ablation of irreversibly rejected renal allograft by embolization with
absolute ethanol: A new clinical application. V. Lorenzo, L. Perez, M.
Dominguez, M. Machado, A. Rodriguez, J. Gonzalez Posada, D.
Hernandez, A. Torres, and F. Diaz, Nephrology Service and Radiodi-
agnosis Service, Hospital Universitario de Canarias, Santa Cruz de
Tener(fe, Spain. Surgical allograft nephrectomy has been the conven-
tional therapy for removing failed kidney allografts when clinical
manifestations of graft intolerance appear. However, the surgical
removal of a transplanted kidney is an invasive technique associated
with high morbidity/mortality rates. On the other hand, transcatheter
vascular embolization (TVE) has been proven useful in ablating organs
and could be applied for renal transplant ablation. The aim of this study
was to present the results of TVE technique for the treatment of graft
intolerance syndrome (GIS) in failed allograft kidneys. TVE was
performed in 14 allograft recipients (33 13 years; 10 males and 4
females) affected by graft intolerance syndrome after irreversible kid-
ney allograft failure. Absolute ethanol (0.1 ml per kg of body wt) was
injected in the allograft artery and in 7 patients a stainless steel coil was
left in renal artery following ethanol injection. GIS was diagnosed by
fever (93%), hematuria (50%), graft pain (36%), flu-like symptoms
(29%), and increased graft size (14.3%). All patients showed clinical
disappearance of the GIS. No major complications occurred, but a
post-embolization syndrome of pain, fever, hematuria, numbness, and
paresthesia of the affected area appeared in 11 of 14 patients. After 2—56
months of follow-up, no late complications occurred, nor was transpla-
tectomy required for embolized kidneys left in situ. In conclusion, TVE
is a safe and effective method for kidney graft ablation, and it may
become an alternative treatment for GIS following irreversible rejec-
tion.
Experience of the Institute of Nephrology in renal transplant with living
donors. Since February 1970 up to December 1991,688 transplants have
been carried out, 42 of which (6.1%) were from living donors. The lack
of cadaver donors as well as the higher survival rates of the graft and the
patient have contributed to the increase of this kind of transplant. With
the aim to analyze our results in kidney transplants from living donors,
a study of the 42 patients submitted to this surgical procedure was
carried out. The average age was 29.6 11.1 years, 54.8 males and 45.2
females. The primary glomerulopathies in 45% of the cases were the
main cause of the TCRI, followed by nephroangiosclerosis (17.1%) and
interstitial nephritis with 12.5%. The donor was haploidentical in 73.8%
and identical in 26.2%. The immunosuppressive therapy used was
imuran-prednisone in 3 patients and cyclosporine-imuran-prednisone in
5 cases. The survival of the graft was 92% at the end of the year and
79% 5 years later, meaning 100 and 86% in the identical and 89 and 71%
in the haploidentical in similar periods. In 7 cases the function was lost,
2 due to arterial thrombosis, 4 due to rejection, and 1 due to relapsing
glomerulonephritis. Only 2 cases died, both due to sepsis. The best
evolution of the patients was obtained when the triple and quadruple
therapy was applied, considering that from the results obtained, trans-
plants from living donors constitute a true choice for the carriers of
TCRI in our environment.
Surgical complications of the renal transplant in six years. Due to the
developments in the last decades in the field of immunology, such as the
appearance of new surgical techniques as well as powerful immunosup-
pressor drugs, kidney transplantation has become an important element
in the treatment of the patient with ICR!. Surgical complications still
occur, being an important cause in the loss of the graft and the patients
life. In 315 transplants carried out in the last 6 years we checked the
surgical complications and their incidence in the survival of the graft
and the recipient: 277 transplants were from a cadaver donor, 10
pancreas-kidney transplants, and 38 from living donors. The glomeru-
lopathy and nephroangiosclerosis were the most frequent causes of
TCRI, and diabetes was present in 10.3% of the transplantations from
cadaver donors. Acute tubular necrosis was only present in the group
from cadaver donors (41.8% of the patients). Urinary fistula had a
greater incidence in the kidney transplant from living donors (16.6%).
Sepsis of the wound was present in 6.2% of the grafts coming from
cadaver donors. Twelve arterial thrombosis (4.1%) and 9 venous
thrombosis (3.1%) occurred in the group from cadaver donors, while in
the group from living donors a percapita (2.7%) was present. Four
arterial stenosis were detected (1.4%), all in the cases of cadaver
donors. Due to urological complications 14 losses were produced in the
graft (8.7%) and 5 losses due to vascular complications (3.1%). There
were no deaths due to urological complications and 1 due to disruption
of suture. The high incidence of surgical complications in our environ-
ment influences the loss of the grafts, as well as the lives of the patients.
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Pulmonary function changes in patients treated with erythropoietin. C.
Sanz Moreno, E. Baamonde, S. Ruiz Andrés, J. Hernandez, J.M.
Garrancho, J.L. Gallego, and J. Botella, Nephrology and Pulmonary
Function Service, Puerta de Hierro Hospital, Madrid, Spain. The
anemic state shows an increase ofthe differences between alveolar and
arterial oxygen tension which tend to be towards the normal values
post-recovery of the hemoglobin values. It has been suggested that this
change is the result of an increase in the functional residual capacity
post-correction of the anemia; this would increase the contact surface
between blood and air and make the 02 diffusion easier. We have
studied the pulmonary function in 9 patients in our HD program before
and after one year treatment with erythropoietin. Hematocrit values
increased from 21.8 1.1% to 34.2 1.6%. The plethysmographic
functional residual capacity was diminished in all patients before
treatment, mean 1.54 0.6 1 (predicted values 2.03 0.32 1). The
functional residual capacity and total lung capacity relation were also
lowered. After one year correcting the anemia, the functional residual
capacity increased significantly to 2.65 0.8 1 (P < 0.001) and the
functional residual capacity/total lung capacity increased in the same
proportion. These changes were reflected in an increase of the pCO2
from 34.2 3.05 to 37.2 3.6 mm Hg (P < 0.01), without changes of
the p02, pH and HCO3. Neither were the remaining pulmonary function
parameters changed (vital capacity, inspiratory reserve, expiratory
reserve, total lung capacity, VEMS, maximal and critical flows, aereal
tracts resistance, etc.). These data show that the correction of anemia
tends to raise the functional residual capacity allowing a decrease of the
overventilation of these patients.
Maternal and fetal complications in pregnancies with chronic renal
failure. B. Fernando and C. Miguel, Division of Nephrology, Rebagliati
Martins Hospital, IPSS, Lima, Perá. With the purpose of determining
the pregnancy complications and fetal alterations following pregnancies
with chronic renal failure (CRF), we reviewed 13 pregnancies in 8
patients with CRF. The CRF was defined when creatinine level was
more than 1.5 4% prior to when first seen during pregnancy. Five
patients had primary glomerular disease, 4 focal segmental glomerulo-
sclerosis, and I idiopathic rapidly progressive glomerulonephritis; two
pregnancies had interstitial nephritis, and a history of arterial hyperten-
sion was found in one patient (nephrosclerosis). Impairment of the renal
function was seen in 69% of the pregnancies. Five patients (36%)
required hemodialysis and the hypertension either impaired or was
present in the 70% of the pregnancies. Five (35%) fetuses were born
alive, but there was one fetal death after birth. Four of them were
premature and one was full term. Four pregnancies underwent hemo-
dialysis during gestation and one in the puerperio. Fetal death either
intrauterine or perinatal reached 65%. Inconclusion, the majority of our
pregnancies had impaired renal function or hypertension. However, the
women with viable fetuses can have successful outcomes of their
pregnancies if hypertension is controlled or hemodialysis is applied
adequately.
Determination of metallothionein (MT) in relation with the concentra-
tion of zinc (Zn) in patients on continuous ambulatory peritoneal dialysis
(CAPD). C. Garcia Ruiz, N. Serrat, A. Martinez Vea, J. Paternain, N.
Garcia, and J. Oliver Rotellar, Servicio de Nefrologia, Hospital Joan
XXIII, CIMallafré Guasch, Tarragona, Spain. MT is a low molecular
weight cytosolic protein that binds essential trace elements, such as
zinc and copper, regulating their transport and tissue metabolism. Data
on MT in patients on CAPD are not available. In order to evaluate the
role of MT in the metabolism of zinc, the content in serum and
erythrocytes of Zn and MT in 9 patients on CAPD, in 10 patients in
hemodialysis (HD), and in 15 healthy subjects was measured. Zn and
MT fluxes were studied during a single 4 hour dialysis exchange and
over a 3-day period. Basal serum Zn and MT levels were lower in
patients on CAPD in comparison to the HD group (14.7 3 vs. 18.05
3.5 &mol/liter and 38.1 17.5 vs. 113.5 32,7 ng/ml, P < 0.01) but
similar to the control group. Erythrocyte Zn and MT levels were similar
to the HD group but higher than control group (1.07 0.74 mol/g prot
vs. 0.54 0.1, P < 0.01 and 2.7 3.7 vs. 0.7 1.1 ng/g prot). After 4
hour dialysis exchange serum Zn and MT levels decreased. Mean Zn
content of predialysis solutions was 3.1 1.01 .tmoI/liter. After a 4 hour
dialysis exchange, Zn concentrations of the dialysates did not change
(2.52 0.79 pmollliter). MT could be detected in the dialysate in all
patients (32.42 20.16 sg/liter). Mean peritoneal clearances of MT
were 9.66 mI/mm. Total loss of MT in the effluent during 24 hours was
418.1 385.5 zg/liter. A significant correlation was found between the
content of Zn and MT in the effluent (P < 0.02). Conclusions: (I) CAPD
patients have lower basal serum Zn and MT levels than the HD group,
but similar to the control group; (2) CAPD leads to peritoneal loss of
MT; (3) This loss may contribute to the decreased serum Zn levels
observed during CAPD.
Additive antiproteinuric effect of converting enzyme inhibition (CE!)
and a low protein intake (Pt). C. Campo, M. Praga, M.C. Casal, J.M.
Alcázar, L. Guerrero, M.L. Ferndndez, J.L. Rodicio, and L.M. Rui-
lope, Servicio de Nefrologia, Unidad de Hipertensidn, Hospital 12 de
Octubre, Madrid, Spain. We have tested the hypothesis that CE! and
low P1 could have additive antiproteinuric effects. Seventeen non-
diabetic patients with proteinuria> 3.0 g/24 hr responsive to CE! were
submitted to a 4 week wash-out period followed by a 3 week period of
study. During the 1st and 2nd weeks P1 was 0.3 g/kg/day and in the third
week 1.0 g/kg/day and enalapril (E) (20mg OD) was administered during
the 2nd and 3rd week. Low P1 induced a significant fall of proteinuria (P
<0.01), inulin (GFR) and PAH (RPF) clearances. The addition of E
induced a further decrease of proteinuria (P < 0.01) and a fall in
filtration fraction (FF) (P < 0.05), while serum K, PEA, GFR and PRF
values increased significantly (P < 0.01). The change in protein intake
during the third week induced a significant increase in proteinuria, GFR
and RPF (P <0.01) in the absence of changes in FR, serum K and PEA.
These results indicate that low P1 and CE! have additive antiproteinuric
effects while avoiding the fall in renal hemodynamics induced by the
diet.
A double-blind comparison of the renal effects of placebo and mtren-
dipine in mild essential hypertension (MEH). C. Campo, J.M. Alcdzar,
J.L. Rodicio, and L.M. Ruilope, Servicio de Nefrologia, Unidad de
Hipertensión, Hospital 12 de Octubre, Madrid, Spain. Renal vasodila-
tory effects of calcium antagonists (CA) depend on the preexisting
vascular tone. An exaggerated renal vasodilator response to CA has
been described in the normotensive offspring of hypertensive parents.
We have investigated if such a response was also present in MEH. A
group of 24 previously untreated patients with MEH were randomly
assigned in a double-blind fashion to a 4 week period of therapy with
placebo (P) (N = 12) or nitrendipine (N) (N = 12) (20 mg o.d.). Before
and at the end of therapy, blood pressure (BP), body weight (body wt),
inulin (GFR) and PAH (RPF) clearances, PRA and aldosterone, and the
renal capacity to eliminate and iv. sodium load (2 liters isotonics
saline/4 hr) were determined while on a sodium replete state. A
significant fall of BP was observed with both therapies (P < 0.01),
meanwhile BW decreased significantly (P < 0.01) only in those patients
treated with N. GFR and RPF, PRA and aldosterone did not change in
any group. The renal capacity to excrete the i.v. sodium load increased
markedly when N was the treatment employed (P < 0.001). These
results seem to indicate that in untreated MEH renal hemodynamics be
have similarly when chronically confronted to placebo or a CA,
although the natriuretic effect of the drug is clearly present. Hence, a
functional increase of renal vascular tone reversible by CA does nor
seem to be present in MEH as in the normotensive offspring of
hypertensive parents.
Influence of protein intake on the renal effects of verapamil in patients
with nephrotlc proteinurla C. Campo, L.M. Ruilope, M. Praga, E.
Hernández, J.M. Alcdzar, and J.L. Rodicio, Servicio de Nefrologia,
Unidad de Hipertensión, Hospital 12 de Octubre, Madrid, Spain.
Calcium antagonists (CA) and protein intake (P1) can interfere with the
renal autoregulatory capacity. Our aim was to investigate whether P1
could influence the effect of CA on renal hemodynamics and proteinuria
in patients with non-diabetic nephrotic proteinuria (>3 g/day). A group
of IS patients with biopsy proven primary glomerular disease was
included in the study. After a 4 week wash-out period patients were
entered a 3 week study (1st and 2nd week was 0.3 g,'kg/day, in the 3rd
1.0 g/kg/day). Slow-releasing verapamil (SRV) (120 mg b.i.d.) was
administered during the 2nd and 3rd week. Blood pressure (BP), inulin
(GFR) and PAH (RPF) clearances, PRA and aldosterone, Na, K and in
urine 24 hour proteinuria, Na, K and urea excretion were determined at
the end of the wash-out and once weekly thereafter. The decrease in P1
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induced a significant (P < 0.01) fall in proteinuria, GFR and RPF
without changes of the remaining parameters. The addition of SRV
induced a significant fall of BP (P < 0.01) in absence of changes in renal
hemodynamics or proteinuria. The increase of P1 during the last week
induced a significant increase in GFR and RPF (P < 0.01) and in
proteinuria (P> 0.05), while BP remained stable. Urea excretion fell
significantly during the 1st and 2nd week of the study. These results
indicate that calcium channel blockade with SRV does not interfere
with renal autoregulatory capacity while Pt is low and does not change
protein excretion. The relevance of these findings during long-term
therapy remain to be elucidated.
Complications of percutaneous renal biopsy: Incidence and evolution of
arteriovenous fistulas detected by color-coded Doppler ultrasonography.
J.I. Minguela, J. Gainza, I. Lopez Vidaur, L.M. Ruiz, A. Merino, R.
Cebayos, and I. Lampreabe, Department of Nephrology, Hospital de
Cruces, Baracaldo (Vizcaya), Spain. We evaluated the clinical impor-
tance of arteriovenous fistula (AVF) and other complications of percu-
taneous renal biopsy. We studied 53 renal percutaneous biopsies
performed in 52 patients (age: 47 2 years) with a 14 Ga Tm-cut needle
under ultrasound guidance. An ultrasonography control was made at 24
hours of each puncture using real time, and color-coded Doppler. AVF
was diagnosed by saturation of color. The peak flows and resistivity
index in segmentary arteries and AVF were measured; that procedure
was repeated at 15th day if pathological findings were detected. Blood
pressure, urine tests, and biochemical and hematological tests in
peripheric blood were also recorded (data are reported in mean
standard error). The punctures were performed in 32 native kidneys
(60%) and 21 allografts. Seven AVF were detected at 24 hours after
puncture; one in a native kidney and 6 in allografts (Fisher exact test; P
= 0.011). Two of them still remained at the 15th day, one disappearing
in two months. Systolic blood pressure at the biopsy day was higher in
subjects with AVF than in those without it (162 16 vs. 139 13 mm
Hg; P = 0.033), but there was no difference in the proportion of
hypertensive patients. Hematoma appeared in two patients, but both
were solved without complications. Ninety-four percent of the patients
had postpuncture hematuria, but 77% of them had presented it previ-
ously. No one required surgical management. Percutaneous renal
biopsy under ultrasonographic guidance is a relatively safe method,
with few complications. AVF detected by color-coded Doppler was an
incidence of 14% and is more frequent in the transplanted kidney. Most
cases disappear in a short time, The higher systolic blood pressure at
the puncture time may imply a greater risk for its occurring.
Prolonged correction of miocardial morphology and function in hemo-
dialysis (HO) patients treated with erythropoietin (EPO). J. Pascual, J.L.
Teruel, F. Liaño, J.J.J. Nacher, and J. Ortuño, Department of Ne-
phrology, Hospital RamOn y Cajal, Madrid, Spain. Uremic miocardi-
opathy consists of an inadequate left ventricular hypertrophy (LVII).
We have reported normalization of cardiac index (CI) and regression of
LV mass (LVM) after 12 months of EPO treatment in hemodialysis
patients. Elevations of BP are frequent under EPO treatment and
whether these reported beneficial effects are transient or persistent is
unknown. We have prospectively studied II severely anemic HD
patients with Doppler echocardiography (after midweek HD on dry
weight) before starting EPO and after 2 months, 1 year and 2 years of
maintained correction of anemia. BP was strictly controlled with
increased drug prescription as needed. Mean hemoglobin before EPO
was 6.3 0.9, rose significantly up to 2 months and then remained
constant. After 2 months, CI had significantly decreased, while periph-
eral resistances increased. This renormalization of hyperdynamic state
was maintained after 2 years of EPO without further improvement. No
changes were seen in myocardial parameters at short follow-up. After I
year, LVM decreased concomitantly with a decrease of diastolic
diameter and both septum and posterior wall thicknesses. After 2 years,
this regression was maintained and the decrease in both septum and
posterior wall thicknesses became the most significant parameters. LV
systolic work demands and left cardiac work showed precocious and
steady improvement. Our results confirm that regression of LVH and
normalization of CI and other hemodynamic and functional parameters
typically disturbed in uremic patients not only are evident during initial
phases of anemia correction with EPO but are maintained for long
periods of time despite continuing HD treatment, providing an adequate
BP control,
Bacteremia in patients with renal failure: A retrospective analysis of
114 infectious episodes. T. Adragtio, L. Gusmao, H. Estibeiro, M.
Gonçalves, f.M. Boquinhas, J. Simoes, C. Toscano, and T. Marques,
Departments of Nephrology and Microbiology, Hospital Santa Cruz,
Lisboa, Portugal. One hundred and fourteen infectious episodes,
defined by positive blood culture, occurring in 95 patients with renal
failure (F = 46; M = 49; mean age = 57 15 years) between 1987 and
1991, were reviewed. The majority of the episodes (65%) were from
extra-hospital origin (EH); gram-positive agents predominated (75%;
Staph aureus 50%); 52% of patients had sepsis and 10.5% were in
shock. The average hospitalization time was 27 28 days. Mortality
was 14% (16 patients). The Hospital acquired (H) infectious episodes
had longer hospitalization times (46 32 days; P <0001) and a greater
incidence of associated urinary infection by the same agent isolated
from blood (25% vs. 1.6%; P < 0.01) than EH infections. They
presented identical mortality (14%). Patients with sepsis (59) were older
(62 13 vs. 51 16 years; P < 0.001), had higher leucocyte counts
(14400 6700 vs. 10700 6000/mm3; P < 0.01) and higher mortality
(22% vs. 5%; P < 0.02). Patients that were in shock had higher mortality(83%; P < 0.0001). Leukocytosis (>10000/mm3) was associated with
sepsis (75% vs. 32%; P < 0.0001) and with shock (17% vs. 3%; P <
0.02). Infections originating from A-V fistula colonization had longer
hospitalization times than catheter-related infections (18 14 days vs.
6 5 days; P < 0.02). Patients with diabetes mellitus (28) presented no
greater incidence of sepsis or shock. They had higher leukocyte counts(P < 0.05). Conclusions: In our population bacteremia was mainly
caused by gram-positive agents, especially Staph aureus. Older age,
high leukocyte counts, sepsis and shock correlated with a worse
prognosis. The nosocomial origin of the infection and the coexistence of
diabetes mellitus did not aggravate the prognosis.
PTH changes in end-stage renal failure (ESRF) patients treated with
erythropoietin. T. Adragao, H. Boquinhas, f.M. Boquinhas, L. Arez, A.
Gaspar, and J. Simoes, Hospital Santa Cruz, Lisboa, Portugal. Sixty-
three ESRF patients on hemodialysis (F = 37; M = 26; mean age = 57
14 years) treated with erythropoietin (EPO) were studied throughout
a period of more than 6 months. In 30 patients (Group I) there was a
significant increase of P1'H (P < 0.001) (526 598 to 2028 1105
pmol/liter) while in the remaining 33 patients (Group II) PTH remained
stable (1194 936 to 1269 968 pmol/liter) (NS). The average time on
hemodialysis was identical in both groups. In Group I, phosphorus (P)
increased during the 2nd month of treatment with EPO (54 1.2 mg/dl
to 6.3 1.3 mg/dl; P = 0.02). This group also presented a lower calcium
(Ca) than Group II during the 5th month of treatment with EPO (Ca1 =
8.1 0.8 mg/dl; Ca1 = 9.3 0.9mg/dl; P < 0.05). The initial dose, the
administration routes of Epo, the hemoglobin levels and the recovery
time were similar in both groups. During a period of 12 months, the
value of PTH was not different between these 63 patients treated with
EPO and a control group of 50 ESRF patients on hemodialysis not
treated with EPO. Conclusions: In this series the increase of PTH was
associated with an increase of P and decrease of Ca and was not
different from a control population not treated with EPO. PTH increase
didn't affect the speed of anemia correction.
Treatment of membranous and diffuse.prollferative forms of lupus
nephritis with intravenous cyclophosphamlde (IVCF). S. Zdrraga, L.M.
Ruiz Muñoz, R. Muñiz, B. Aurrekoetxea, R.1. Munoz, J.M. Martinez,
J. GaInza, and!. Lampreabe, Department of Nephrology, Hospital de
Cruces, Basque Country University, School of Medicine, Baracaldo
(Vizcaya), Spain. Our objective was to evaluate the effect of IVCF on
the evolution of the diffuse-proliferative (DP) and membranous (M)
forms of lupus nephritis. Design: This was a descriptive, prospective
and non-randomized study. Patients and methods: We treated 14 con-
secutive patients (M/F 3/11; age = 29 11)diagnosed by renal biopsy
of DP (Group I, N = 9) and M (Group 11, N = 5) lupus nephritis. IVCF
was administered monthly (initial dose: 0.5—0.75 g/m2 body surface
area) for a minimum of 6 months followed by trimestral pulse adminis-
tration if proteinuria decreased to a level lower than 1 g/24 hours.
Treatment was discontinued if proteinuria was lower than 0.5 g/24 hours
and microheinaturia lower than 10,000 RBC/minute. Every patient also
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received concurrent low-dose corticosteroid therapy. The follow-up
time was 36 months for Group I and 9 months for Group II. Our main
results were as follows:
Mo
Group I
Cr Up mh N
0
3
9
24
36
1.5 1.0
0.9 0.3
0.9 0.2
0.9 0.5
1.0 0.4
4.2 4.6
3.5 3.1
3.0 3.2
1.2 1.3
0.8 0.4
120000
108000
41500
7500
5375
9
9
9
6
4
Group H
1Cr U, mh N
0.9 0.2
0.9 0.2
0.8 0.1
9.5
3.7
2.2
8.6
3.0
2.0
20000
53000
13700
5
5
4
Abbreviations are: Mo, Month; Cr, Plasma creatinine; protein-
uria g/24 hours; mh, RBC/minute. Pr,. and Po in mean standard
deviation and mh only in mean.
Renal function did not change in any group during the follow-up. In
Group I a decrease in U, and mh with a complete remission was
observed in 3 cases. In Group II a tendency to a decrease in Up and an
increase in plasma albumin was detected. There were neither infectious
complications nor hemorrhagic cystitis. Leukocyte counts never de-
creased to levels lower than 2,000/mm3. Conclusion: In our experience
IVCF is a useful treatment, without important adverse effects both in M
and DF forms of lupus nephritis, with clinical remission of their
activity.
Dysplicemia in CAPD and valoration of possible pathogenic factors. A.
Otero Glez, Esteban Morcillo, E. Armada, and L. Martin, Service of
Nephrology, Cristal-Pinor Hospital, Orense, Spain. Arteriosclerosis is
the main cause of mortality in IRT and the most important risk factors
are arterial hypertension and alterations in the lipid metabolism. In
CAPD the dyslipemia can be conditioned by the absortion of glucose
from the dialysis liquid (LD). In order to assess these alterations we
have selected 9 patients, 5 men and 4 women, with an average age of 57
and 53.3, who stayed on CAPD an average of 22.5 months. In all of
them total cholesterol (CT), triglycerides (TG), CHDL, LDL, VLDL,
apoprotein A-I (Apo A), apoprotein B (Apo B), lipoprotein (a) (Lipo a)
and TC/HDL-c, Apo-Al/Apo B, and CT/HDL-C were determined, and
these values were correlated with the time they spent on CAPD
(T-CAPD), the average concentration of glucose in LD (0), and the
protein loss in (Pt LD). The statistic method used was mean calculus,
standard deviation and analysis of the multiple linear correlation.
X-STD T-CAPD PtD G P
CT 237 63 —0.1 —0.2 0.82 NS
TG 219 177 —0.4 0.6 0.82 NS
CHDL 48.2 II 0.3 —0.4 —0.3 NS
LDL 184.2 69 0.08 —0.03 0.82 NS
VLDL 43.8 35 —0.4 0.6 0.82 NS
Lipo (a) 71.4 59 0.4 —0.1 0.82 NS
Apo A-I 150.5 39 0.3 —0.17 0.93 NS
Apo B 146.3 40 0.1 0.4 0.93 NS
Apo A/Apo B 1.12 0.54 0.2 —0.4 —0.3 NS
HDL/Apo A 0.33 0.06 —0.2 —0.1 —0.2 NS
CT/HDL 3.74 2.18 —0.3
0.4
0.6
0.83
0.93
0,93
0.05
In conclusion, lipidic rate is atherogenic, but there is no relation with
the T-CAPD (r: 0.4) or with the protein loss by LD (r: 0.83), but the
glucose of the Ld is related to the atherogenic factor CT/HDL (r: 0.93).
Hemodynamlcs tolerance (HT) in short hemodialysis (HI)) with bicar-
bonate (DCBI): Effect of different profiles of osmolarity and ultrafiltra-
tion. E. Armada, J. Esteban Morcillo, and A. Otero Glez, Service of
Nephrology, Cristal-Pinor Hospital, Orense, Spain. In spite of the
advances achieved in HD biocompatibility (M.Bc) [bathing of bicarbon-
ate (B.Bi), volumetric control of the ultrafiltration (CVUF)), the hemo-
dynamics instability is still the main cause of intradialytic morbidity,
limiting a bigger time reduction of HD. By using a dialysis monitor of
programming osmolarity profiles (P) andlor UF, we have studied the Th
in 5 patients (age 53.4 + 9.1), with regular dialysis by means of DCBI
(180 minutes, M. AN-69, B.Bi, CVUF), for a total of 60 sessions,
programming 4 different profiles, although always the (Na) total mean of
the bathing was 140 mEq/liter: (I) (Na) bathing and UF were constants
during the whole session. (2) (Na) in regressive descending profile
(PDR) (152 . . . 132) and steady UF measure. (3) (Na) and UF both in
PDR. (4) (Na) cte and UF in PDR. Besides the usual parameters of
dialysis (TA., F.C, increase and loss of weight), we have determined at
the second session of each week: gasometry, adrenine, norepinephrine,
dopamine and PGE2: Hto, Prot tot., Na, K, Ca, plasma Osm at the
beginning, end and every hour of the HD. The increase and loss of
weight were similar in the 4 p., as well as the intradialytic variations of
Hto, Na, K, Ca and acidosis adjustment, however the intradialytic
morbidity was smaller in the P. 2.3 and 4 (number of hypotensions a
week: 0.4, 0.6 and 0.4 vs. 1.2 in the P.1), which was correlated with a
smaller increase of PGE2, showing the P.3 (Na and UF variables) with
the smaller tendency to the variation of the TA and the FC. The
relationships discovered between the studied hemodynamic and bio-
chemical parameters are discussed. We infer that besides the use of
B.Bi, M.Bc and CVUF, the TH can be perceptibly improved by the use
of P. variables of Osm and UF.
A study of parasites In stools of chronic hemodialysis patients. Mi.
Aladrén, P.J. Vives, and C. Aspiroz, Servicio de NefrologIa y Micro-
biologia, Hospital de Cala:ayud, Calatayud, Spain. We have studied
the presence of parasites in stools in patients on maintenance hemodi-
alysis (HD), and they have been compared to the general population
(GP) for nine months. In all patients the stools were studied in both
periods, symptomatic and asymptomatic. Patients on hemodialysis
Symptomatic Asymptomatic HD OP
Endolima.r nana 1 4 11.6% 3.4%
Entamoeba coli 2 — 4.6% 0.4%
Blastocystis hominis 4 I 11.7% 2.1%
No parasites 12 19
Number of samples 43 435
We conclude that there are significant differences in our findings
between both groups, and the patients on hemodialysis with symptoms
have more elimination of Blastocystis hominis.
Renal allograft rupture in the cyclosporine era. R. Lauzurica, J.
Bonet, A. Serra, F. Cofdn, E. Castellote, and A. Caraips, Hospital
Universitari Germans Trias i Pujo! de Badalona, Servei de Nefrologia,
Badalona, Spain. Renal allograft rupture (RAR) is a dramatic compli-
cation in renal transplantation (RT). The incidence oscillated between
0.3% to 9% before the cyclosporine era. The mechanism was obscure
and probably multifactorial, but acute rejection (AR) seemed to be the
most important factor. Introduction of cyclosporin A (CsA) has been
associated with an important reduction of AR rates. This paper ana-
lyzes the frequency, mechanism, prognosis and treatment of the RAR
seen in a group of 88 renal transplantated patients treated with the same
immunosuppressive protocol: steroids, CsA, and ATGAM (2—6 doses).
Five episodes of RAR (5.7%) were detected in 3 men and S women aged
31 years (23—47). RAR occurred early after the operation, and in all of
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them before the 10th day after transplantation. Clinical data: Fever and
sudden pain occurred over the graft. Two patients did not show changes
in their normal urinary output. Mechanism of the RAR: Three had AR
[one of them with associated renal vein thrombosis (RVT)]; one had
acute tubular necrosis, and one RVT exclusively. Clinical evolution and
treatment: In two an urgent transplant nephrectomy was performed. In
one, surgical exploration with a three dimensional corsseting; in one
surgical exploration and AR treatment; in one only AR treatment was
done. At present all 5 patients are alive. The three patients in whom the
graft was preserved have plasma creatinines of 150, 180, and 330
mol/liter. Comments: (I) Our incidence of RAR does not seem to have
decreased. (II) RAR occurs early in renal transplantation. (III) RAR is
related with AR, but an increase in the incidence of RVT possibly
related with CsA is apparent. (IV) In more than 50% of the cases,
combined medical and surgical treatment appeared to preserve the renal
allograft.
Do kidneys from the same donor have a different prognosis? R.
Lauzurica, J. Bonet, J. Bonal, A. Serra, F. Cofan, E. Caste/lot, and A.
Caraips, Servei de Nefrologia, Hospital Universitari Germans Trias i
Pujol de Badalona, Badalona, Spain. The initial outcome of two
transplanted kidneys from the same donor (paired cadaveric kidneys,
PCK) is likely to be similar except for differences in the time of cold
ischemia and intraoperative management. The present study evaluates
the differences in terms of outcome of 44 PCK, all of them removed and
transplanted in our hospital. All PCK were transplanted by the same
surgical team and consecutively (1st transplant and 2nd transplant).
Two groups were formed: Group I, 22 patients transplanted in the 1st
place and Group 11, 22 patients transplanted in the 2nd place. Patients
were treated with the same immunosuppressive drugs and received
similar penoperative management, Patients details and results
Group I(N=22) Group 11(N=22)
Match B+DR 1.5 0.6 1.5 0.6 NS
Mismatch B+DR 2.2 0.5 2.2 0.6 NS
Age 43±13 46±10 NS
HD months 21 14 33 29 P < 0.1
Clhours 19±4 26±7 P<0.00l
N.HD post-transplant 0.7 2.2 1.8 3.1 NS
CR 1st. month 218 149 276 249 NS
CR 6th month 156 5 146 43 NS
Acute rejection 7/22 8/22 NS
ATN 4/22 8/22 P < 0.1
Renal graft SR 93% 86% NS
Patient SR 100 90% P < 0.05
Abbreviations are: CI, cold ischemia; SR. survival rates; NS, not
significant.
Conclusions: There seems to he a worse survival rate in patients
transplanted in 2nd place compared to those operated in the 1st place.
ATN related to increased duration of cold ischeinia could be the cause.
Multivariate analysis showed that 6 month plasma creatinine correlates
with the presence of ATN, time on hemodialysis, and donor age.
Swan neck peritoneal catheters. A multi-center study. Multicenire
Groupof Study of ContinuousAmbulatory Peritoneal Dialysis. Servicia
de Nefrologia, Hospital Universitario, Ramón y Cajal s/n, Valladolid,
Spain. We have studied by means of a prospective questionarre the
evolution of 259 double cuffed Swan neck peritoneal catheters with skin
exit pointing downward, with intraperitoneal segment straight (180,
70%) or coiled (79, 30%), in 232 patients from 10 hospitals, from June
1988 to December 1991. Details on catheter type, insertion technique
(surgical 178, 69%, bedside by means of trocar 79, 31%) and early (first
30 days) or late complications were recorded. Patients were 123 men
and 109 women aged between 15 and 83 years (54 IS); 23% were
obese and 41% diabetics. Mean permanency of catheters was 14 10.9
months (range, I day to 43 months). Cumulative permanency was 3590
months/patient. All patients received general antibiotic prophylaxis and
local prophylaxis (cuff impregnation) was added in 16% of catheters.
Early and late complications with respect to number of catheters are
shown in table:
Early Late
Delayed catheterization 27 (11)
Poor inflow or drainage 42 (16%) 18 (8%)
Hemopentoneum 13 (5%) 27 (12%)
Dialysis solution leak 30 (12%) 12 (5%)
Cuff extrusion 5 (2%) 9 (4%)
Exit site infection 22 (9%) 80 (37%)
Tunnel infection 6 (2%) 26 (12%)
Peritonitis 24 (9%) 102 (44%)
Any complication 113 (44%) 151 (65%)
No complications 146 (56%) 81(35%)
The surgical insertion technique is slightly better than trocar, but the
external cuff must be fixed at 2 cm of skin exit site, and antibiotic
impregnation of cuffs does not protects against infection or dialysis fluid
leak. A wide exit site hole is a risk factor of local infection. Straight
intrapentoneal segments present less complications than coiled ones
and, at last, the skin exits pointing downward do not seems to reduce
the incidence of exit site infections as previously suggested.
Beta-2 microglobulin (/32m) in the lymphocyte culture supernatant and
its relationship with IL-i and TNF release. Influence of membrane and
dialysate. F. Cofdn, J. Bonal, M. Vives, E. Abad, C. Pastor, M.
Doladé, J. Bonet, E. Castellote, R. Lauzurica, A. Serra, J. Teixidó, R.
Romero, and A. Caraips, Hospital Universitari Germans Trias I Pujol,
Badalona, (Barcelona), Spain. Dialysis associated amyloidosis patho-
genesis and the influence of the different membranes used remain
controversial. We have studied 10 patients on stable chronic hemodi-
alysis (HD). They were dialyzed for two periods: first with duproam-
monium membrane (CU) and afterwards with polyacrylonitrile mem-
brane (PAN-AN69). Dialysis fluids (acetate vs. bicarbonate) were
studied. At the end of each phase, a peripheral blood mononuclear cell
culture (PBMNC) and a cytofluorometnc study were performed.
PBMNC cultures were made in basal state and after stimulation with
phytohemagglutinin (PHA), and Interferon gamma (INF7). Beta-2
microglobulin (f32m), TNF and IL-I were measured in the PBMNC
culture supernatant. IL-2 receptor alpha (lL-2Ra) and HLA class H
expression (TIDr+ and Dr+ cells) were studied by cytofluorometry.
CU PAN-AN69
TNF (B) 2039 1448 852 380 P < 0.05
TNF (INF) 4014 2722 1946 1579 P < 0.05
TNF(PHA) 2323± 1316 1170±566 P<0.05
IL-I (B) 449 114 406 121 P <0.05
IL-I (INF) 774 298 575 206 P < 0.05
IL-i (PHA) 930 590 506 165 P < 0.05
/32m (B) 101 45 102 51 NS
f32m (INF) 143 70 154 83 NS
f2m (PHA) 188 61 201 94 NS
IL-2Ra 16.1 5.2 15.8 5.5 NS
T/Dr+ 19.9 10.7 24.9 13.4 NS
Dr+ 13.5 5.24 13.7 7.5 NS
The CU membrane produced greater release (basally and post-stimula-
tion) of IL-I and TNF, but not of f3m. The dialysis fluid did not
influence p2m levels. The type of membrane did not modify lymphocyte
activation by cytometry. Nevertheless, a strong significant correlation
exists for each patient and independent of the type of membrane for:
T/Dr+ cell (r = 0.9), Dr-I- cell (r = 0.95) and IL-2Ra (r = 0.88).
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Conclusions: Greater bioincompatibility of the cuprophan membrane is
shown by greater cytokine release (TNF and IL-I), but does not
influence in vitro beta-2 microglobulin or lymphocyte activation expres-
sion.
Interleukln-2 receptor expression and class H lILA molecules in
lymphocytes of patients on peritoneal dialysis. F. Cofan, J. Bonal, I.
TeixidO, M. Vives, R. Romero, and A. Caralps, Hospital Universitari
Germans Trias i Pujol, Badalona, (Barcelona). Spain. During hemodi-
alysis (HD), the interaction between blood and the dialysis membrane
provokes activation of the inflammatory response which does not occur
in peritoneal dialysis (PD). The aim of the study was to compare
lymphocyte activation between patients on HD and those on PD. Ten
patients on periodic hemodialysis (Cuprophan membrane) and ten
patients on continuous ambulatory peritoneal dialysis (CAPD) were
studied. Lymphomononuclear cells (LMC) were obtained by peripheral
blood centrifugation in a Ficoll gradient. LMC were incubated with
monoclonal antibodies labeled with fluorescein to interleukin-2 receptor
alpha (IL-2Ra) and to class H HLA molecules (T/Dr+ cells and Dr+
cells). They were studied by cytofluorometry. Statistically significant
differences (Mann-Whitney) were observed in IL-2Ra expression and
Dr+ cell expression between patients on HD and those on CAPD
(IL-2Ra: HD 16.2 5.5 and CAPD 10.6 4.9, P < 0.05; Dr+ cells: HD
13.8 5.2 and CAPD 8.8 3.1 P < 0.05). T/Dr+ cell expression
differed, but was not statistically significant (TIDr+ cells: HD 22.4
10.4 and CAPD 16.9 5.9 NS). Conclusions: Patients on pentoneal
dialysis presented less lymphocyte activation (IL-2Ra expression and
class II HLA molecules expression) than patients on hemodialysis.
Study of a hypertensive population with adrenal masses. F. Cofán, R.
Romero, J. Bonal, I. Reverter, J. Bonet, I. TeixidO, R. Lauzurica, E.
Castellote, and A. Caralps, Hospital Universitari Germans Trias i
Pujol, Badalona, (Barcelona), Spain. The aim of the study was to
assess a group of hypertensive patients with adrenal masses. The
etiology and its possible relationship to the origin of hypertension were
studied. The group included 25 hypertensive patients with an adrenal
mass detected by echography and/or tomography (CT). Routine hor-
mone studies in blood (basal and stimulated aldosterone, basal and
stimulated renin, basal and post-rapid suppression cortisol, dehydro-
epiandrostendione) and urine (metanephnnes, total catecholamines,
aldosterone and cortisol) were conducted. Secondly, and according to
suspected diagnosis, corresponding analytic, gammagraphic and/or
pathologic studies were performed. Twenty-five hypertensive patients
(9 men, 16 women; mean age 50.8 years, 24—75 years) were studied. A
history of HTA of more than 5 years' duration was found in 96%. A
solitary nodule was observed in 84% and bilateral adrenal increase in
16%. Nodule size ranged from 1—3 cm in 56% (14/25), 3—6 cm in 20%
(5/25) and over 6 cm in 8% (2/25). Hypokalemia was present in 40%.
Etiology: non-functioning nodule 44%, aldosterone producing adenoma
20%, idiopathic hyperaldosteronism 16%, pheochromocytome 8%, and
others 12%. Conclusions: Forty percent of nodules were non-function-
ing masses and 48% hormonally-active masses. The presence of an
adrenal nodule does not necessarily imply it is the cause of hyperten-
sion. Correct hormonal and/or radiologic evaluation is required for
etiologic diagnosis of adrenal masses.
Mass transfer coefficient: Comparison between methods. J. Teixido, F.
Cofan, M. Borrds, J. Boner, J. Bonal, R. Galimany, C. Biosca, and A.
Caralps, Hospital University Germans Trias i Pujol, Badalona, Spain.
Mass transfer area coefficient (MTC) is in theory the best parameter for
solute transport evaluation in CAPD patients, but there are various
methods for its calculation. The aims of the study were to assess: (1) the
simplified MTC [according Garred (0), Krediet (K) or Lindholm (L)];
or (2) D/P 240' ratio (PET), is equivalent to complex MTC [Randerson
(MTCX)]. We performed 29 MTCX with Dianeal 2.5% in 24 stable
CAPD patients, I4MJIOF, with a mean age of 62 years (13—83), and a
mean duration on CAPD of 14.6 months. Dialysate samples were
collected at 0, 30, 60, 120, 180 and 240 minutes. Initial and final blood
samples were drawn. MTC and PET (urea and creatinine) were calcu-
lated in all tests without exclusion of poorly consistent data. Paired
1-test and Pearson's correlation coefficient were used.
Complex MTCX Simplified
Paired
t-test
Corre
r =
lation
P <
Urea x Sn
20.53 (7.06)
G: 20.19 (9.5)
K: 22.68 (10)
L: 20.85 (10.8)
DIP: 0.87 (0.08)
NS
NS
NS
—
0.78
0.76
0.72
0.73
0.001
0.001
0.001
0.001
Creatinine x Sn
9.36 (4.32)
G: 9.07 (4.35)
K: 10.48 (4.55)
L: 9.87 (4.96)
DIP: 0.66 (0.13)
NS
P < 0.05
NS
—
0.82
0.81
0.68
0.85
0.001
0.001
0.001
0.001
There were no differences between MTCX and each one of the
simplified MTC, except for K-creatinine which was different for paired
1-test but had a good correlation. Correlation between complex and
simplified methods was acceptable. Conclusions: (1) Simplified MTC for
urea and creatinine has an acceptable correlation with complex MTCX
and can be useful in clinical practice. (2) D/P ratio 240' also has a good
correlation with complex MTCX.
Decrease of infectious morbidity and mortality with cyclosporin A
(CsA). J. Lavilla, P. Errasti, L. Bolaños,L. Mesa, C. Vazquez, M.
Martin, V. Artolazabal, and A. Purroy. We performed a comparative
study of all infectious complications and causes of death due to
infection in 313 consecutive kidney transplant patients between No-
vember 1976 and February 1992. There were 269 primary grafts and 21
re-transplants (in 290 patients). One hundred eighty-seven of these
patients received classic therapy (azathioprine and prednisone), while
126 were also treated with CsA. There were no significant differences
between the two groups in age, sex and duration of previous dialysis.
There were more high risk patients (older patients, hyperimmunized or
re-transplants) in the CsA group. Thirty-one patients (9.9%) have died;
38.7% of these (twelve patients) died as a consequence of an infectious
cause. Eleven of them belonged to the group treated with classic
therapy and only one to the cyclosporine group. Comparing the
infectious complications, there was a significant decrease when the
patients were treated with cyclosponne (7 pneumonia vs. 42, 7 urinary
infections vs. 14, 2 peritonitis vs. 6). There was also a decrease in the
incidence of abcesos, salmonellosis, herpes, etc. Conclusions: Treat-
ment with CsA may decrease morbidity and mortality due to infection
in the post-kidney transplant patient. However, these results may not
only be due to CsA but also to a decreased steroid dose and an
extensive clinical experience.
Experience in cadaveric renal retransplantation. M. Martin, L. Bol-
años, L. Mesa, C. Vdzquez, J. Lavilla, P. Errasti, and A. Purroy,
Service of Nephrology, University Clinic of Navarra, Pamplona,
Spain. Between October 1976 and January 1992, 315 kidney transplants
were performed in our center. Twenty-one of these were second (20) or
third (I) retransplants, receiving both kidneys at our center (43 al-
lografts total). The average age at the time of second transplantation
was 34 years. Eight patients were male and thirteen female. Failure of
the first graft was related to chronic rejection in eleven cases, acute
rejection in nine, and a technical failure in the other one. The mean time
between the first and second graft was 71 months. Nine out of the
twenty-one patients had cytotoxic antibodies. Eighteen patients re-
ceived CsA therapy (in double or triple regimens), and three were
treated with conventional immunosuppressive therapy (azathioprine
and prednisone). Eighteen patients (85%) had acute rejection episodes(ranging between one and four crises); five of these were resistant to
steroids and were treated with monoclonal antibodies OKT3 (6 to 14
doses per patient). The patients who received monoclonal antibodies
now have functioning grafts. Now with a mean follow-up ranging
between 4 and 78 months, 17 patients out of 21 have functioning grafts
(81%), with creatinine levels of 71 to 283 iunol/liter (average ISO
&moI/liter). Four of the patients now have chronic rejection with
creatinines ranging between 257 to 283 smol/liter. Three grafts never
functioned and one was lost because of chronic rejection after 36
months. The overall patient actuarial survival rate is 100%. Conclusions:
In our experience retransplanted patients have a high incidence of acute
rejection episodes, with a good response to OKT3 in case of steroid
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resistance rejection. Overall patient and graft survival rates are similar
to those in first transplant recipients.
Blood lipids in two populations of patients on renal replacement
therapy. C. Vdzquez, A. Purroy, and B.M. Hendry, Servicio de Nefro-
logla, Cilnica (Jniversitaria, Facultad de Medicina, Pamplona, and
Renal Unit, Churchill Hospital, Oxford, England, United Kingdom.
Cardiovascular disease is an important risk factor in patients with
chronic renal failure (CRF) on replacement therapy. Abnormalities of
lipid metabolism are recognized in these patients, both those on dialysis
and after renal transplantation. The objective of this study was to
quantify the blood lipid profiles in 2 populations of patients: from
Oxford (0), UK and Pamplona (P), Spain. Here we report mean values
for total cholesterol (CT) and triglycerides (Tg) in patients on hemodi-
alysis (HD), continuous ambulatory peritoneal dialysis (CAPD), living
related renal transplants (TRL), and cadaver renal transplants (TRC).
The table and figure below show patient numbers (N) and mean CT and
Tg in mmol/liter. Differences between treatments and populations were
evaluated by Student's t-test for unpaired data. A P value of <0.05 was
considered significant.
N CT Tg
0
HD 75 5,366 2,166
CAPD 66 6,242 2,194
TRC 460 6,691 2,154
TRL 43 6,114 1,637
P
HD 27 4,790 1,681
TRC 191 6,093 1,607
Conclusions: For blood cholesterol in Oxford the TRC group exhibited
significantly higher values than the CAPD group (P = 0.015) and the HD
group (P < 0.001). The CAPD group also exhibited significantly higher
values than the HD group (P = 0.003). The TRL group cholesterol
values were lower than the TRC group (P = 0.008) but higher than the
patients on HD (P = 0.014). Similarly for blood cholesterol in Pamplona
the TRC group levels were significantly higher than HD patients (P <
0.001). Where comparison is possible, the cholesterol values in Oxford
are higher than the corresponding results for Pampiona (such as for the
TRC groups P < 0.001). The blood triglycerides in the TRC group were
significantly higher in Oxford than in Pamplona (P < 0.001). Within
each center there were no significant Tg differences comparing TRC and
the dialysis groups. The TRL triglyceride values in Oxford were
significantly lower than the TRC (P 0.011), HD (P = 0.004) and
CAPD (P = 0.013) groups.
Serum concentration of LP(a) In chronic renal failure. Relationship
with other parameters of the lipidic metabolism and post.transplant
evolution. A. Segarra, P. ChacOn, M. Martin, M. Cotrina, M. Vilardell,
R. Roca, J. Vila, C. Cantareli, L.L. Capdevila, and L.L. Piera,
Hospital Vail d'HebrOn, Barcelona, Spain. Our aim of this study was to
determine the serum concentration of Lp(a) in patients with CRF, its
relationship with other parameters of the lipid metabolism, and its
evolution after renal transplantation. Patients and methods: We deter-
mined the serum Lp(a) level (ELISA Lp(a)MACRA TERUMO), total
cholesterol, HDL, LDL, VLDL, TG, Apo Al and ApoB in 30 patients
with CRF before and 12 months after a renal graft. We studied the
relationship between Lp(a) and age, sex, BMI, immunosuppressors,
and other parameters of the lipid metabolism, and we compared the
concentration of Lp(a) with that of healthy controls. Results: The
concentration of Lp(a) was higher in CRF patients than in healthy
controls. In the CRF phase no relationship between Lp(a) and any of
the variables studied can be seen. The rate of the patients with risk
levels is higher in CRF patients. After kidney allograft, the Lp(a)
concentration decreased meaningfully, so that there was no difference
between the Lp(a) levels of the transplanted patients and that of the
healthy controls. Post-transplant no relationship between Lp(a) and the
other variables can be observed. The concentration of Lp(a) was not
related to the doses of glucocorticoids or CsA. Conclusion: The con-
centration of Lp(a) both in uremia and after renal transplantation is
independent of the other variables of the lipidic metabolism. The
increase in Lp(a) in the patients with CRF depends only on the loss of
renal function.
Evolution of the lipid and apoprotein alterations of the uremlc patients
after the renal transplant. A. Segarra, P. ChacOn, M. Martin, M.
Cotrina, J. Vila, M. Vilardell, C. Cantarell, L.L. Capdevila, and L.L.
Piera, Hospital General Vail D'Hebron, Barcelona, Spain. Our aim
was to study the changes in the lipid and apoprotein concentration
occurring after renal transplantation, and to determine the factors
leading to them. Patients and Methods: Thirty patients (18M, 12 F, aged
43 10 years), transplanted and treated only with CsA and prednisone
were studied. During the first year of evolution they didn't have any risk
factors leading to secondary dislipemia. We determined total, HDL,
LDL, VLDL cholesterol, TG, VLDLTG, Apo Al, B, CII, CIII and E,
glycemia, BMI and serum creatinine before the transplant and 12
months after it. We considered maximum value of each parameters as
the average I 5D of the value obtained in a sample of healthy controls.
Results: Before the transplant the patients suffered a decrease in
HDLcol, HyperTG, a deficit of ApoAl and an increase in CIII and CII.
After the transplant there's a meaningful increase in col, HDL, LDL,
ApoAl and Apo B and a decrease of CIII and CII. The predominant
post-transplant dislipemia is hypercholesterolemia. The cholesterol
increase is independent of BMI and the CsA dose. In previously
dislipemic patients, post-transplant dislipemia was meaningfully higher
and LDL cot was related to steroid dose. Conclusions: The post-
transplant period is a high risk factor leading to secondary dislipemia.
The change in dislipemia phenotype is closely related to the apoproteic
changes produced after the transplant.
Alterations of high density lipoproteins and very low density lipopro-
teins in patients with CRF. A. Segarra, P. Chacón, M. Martin, M.
Vilardell, R. Roca, J. Fort, J. Camps, A. Olmos, and L.L. Piera,
Hospital General Vail d'HebrOn, Barcelona, Spain. The aim of this
study was to determine the cause of the alterations of the metabolism of
HDL and VLDL in patients with CRF, and to study whether both
alterations are interrelated or not. Patients and methods: Thirty patients
(aged 45 12 years, 16 M, 14 F) with chronic renal failure treated with
HD were studied. We determined the caloric and qualitative composi-
tion of the diet, alcohol intake and pharmacological treatment. We
determined cholesterol, HDL, LDL, VLDL total TO, HDL TO, VLDL
TO, Apo Al, CII, CIII, B, Glycemia, basal insulinemia, and BMI. The
results were compared with a control group whose age, sex and BMI
were similar. Results: 83% of the patients had a decrease of HDL; 50%
suffered from hypertriglyceridemia with an increase in VLDL and HDL
TG, while 96% showed low levels of Apo Al, 73% an increase in Cli,
and 90% an increase in Clii. HDL is directly related to apoAl and
inversely related to TO. Total TG depended mainly on the Cilh/CII ratio
and secondarily on caloric content in the diet. Olycemia and basal
insulinemia were meaningfully higher in CRF patients but were not
related to total TO. No parameter was related to BMI. Conclusions:
Uremic dislipemia depended on two factors having different origins but
being interrelated: the deficit in HDL cot and Apo Al is predominant
and independent of other factors. HyperTG is mainly due to decrease in
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lipolitic activity but which may be intensified by other environmental
factors.
Clinical significance of anti-RNP, Sm and Ro antibodies measured by
ELISA in lupus nephropathy. J.M. López-Gómez, R. Jofre, F.J. Lopez-
Longo, M. Lago, M.R. Mahou, C. Albarracin, and F. Valderrabano,
Hospital General Gregorio MaranOn, Madrid, Spain, Antibodies
against soluble ribonuclear antigens RNP, Sm and Ro (anti-ENA ab.)
were measured by ELISA in the sera of 107 patients (89% females)
diagnosed with SLE by ARA criteria, and the results were compared
with the immunoblotting method. Normal values were determined
through media plus 3 SD of 90 sera of normal subjects. SLE patients
were classified into three groups: I (N = 50) without renal damage, H (N
= 36) with microscopic hematuria and/or proteinuria and/or cilindruria
but with normal renal function, and III (N = 21), patients with renal
failure (serum creatinine > 1.6 mg/dI). Thirty-one patients had at least
one kidney biopsy. Distribution of anti-ENA ab. was similar with
immunoblotting and ELISA, but sensibility was significantly higher in
the last method. Anti-RNP, Sm and Ro antibodies were found in 67,
38.3 and 49.5%, respectively. Anti-RNP and anti-Sm antibodies showed
an inverse correlation with renal damage severity. Anti-Ro antibodies
were significantly less in patients with renal failure (54.6 vs. 28.5%).
Anti-ENA ab. were higher in male than in female patients, and men
were more frequent in group III. Diffuse lupus nephropathy and male
patients had a low incidence of anti-ENA ab. In conclusion, ELISA is a
more sensitive method to investigate anti-ENA ab. SLE patients with high
risk to develop renal failure have a lesser frequency of anti-ENA ab., and
these antibodies can be used as a marker of therapeutic aggressiveness.
Subcutaneous rHuEPO in the management of anemia of chronic renal
failure in predialysls patients. R. Jofre, J.M. LOpez-GOmez, M. Lago, C.
Albarracin, F. Gomez, A. Tejedor, E. Junco, and F. Valderrabano,
Servicio de Nefrologia, Hospital Gregorio Maranon, Madrid, Spain.
We treated 13 patients (8M and 5 F), age range between 20 and 83 years,
and serum creatinine 2.6—9.7 mgldl, with subcutaneous rHuEPO with a
mean weekly dose of 62.5 24.9 U/kg/week. Six patients received
rHuEPO once a week (group I) and 7 patients three times a week (group
H) without differences in total dose. Arterial pressure, hematocnt,
hemoglobin, ferritin, and creatinine clearance were measured monthly.
The progression rate of renal failure was determined by the reciprocal
of serum creatinine over time curve during the twelve months before
and after treatment. Mean maintenance dose after three months of
treatment was 50.6 23.0 U/kg/week. Increases in hematocrit and
hemoglobin were similar in groups I and II at 3, 6 and 12 months after
treatment. The slope of the I/Cr versus time curve did not change
significantly before and after treatment (—0.0105 0.0082 vs. —0.0065
0.0031). Mean arterial pressure was unchanged, although in two
patients, it was increased the hypotensive treatment. All the patients
increased their well-feeling and exercise capacity with no side effects.
We conclude that rHuEPO is a safe and effective treatment to improve
anemia in chronic renal failure in predialysis patients. There was no
evidence that rHuEPO accelerates the progression of renal failure and
one single weekly subcutaneous administration is adequate for the
maintenance treatment of renal anemia.
Erythropoletln (EPO) treatment In cases of chronic renal failure before
Initiating dIalysIs (Pre-EDRF). R. Diaz-Tejeiro, J.E. Garc(a-DIaz, T.
Sierra, F. Ah(jado, E. Gomez-Tejada, E.T. Gonzalez, and M.A. Garcia
Rubiales, Nephrology Department, Virgen de Ia Salud Hospital, To-
ledo, Spain. Objectives: The aim of this study was the evaluation of
response to subcutaneous erythropoietin treatment (EPO) in patients
with CRF in a pre-dialysis situation (Ce. 5—15 mI/in.). Subjects and
methodology: Therapeutic protocol included either 1000 or 2000 U/3
times per week, depending on whether patient weight was above or
below 65 kg. This was then adjusted to suit hematometnc levels. Ten
patients (7 female and 3 male) were studied. Average age was 49.1 6.8
years (17—76), and follow-up lasted from 18.2 7.7 weeks (6—24).
Results: Treatment with EPO brought about an increase in levels of Hb
and Htc. This increase was significant from the fourth week on, and was
maintained to the end of the study. All patients needed iron supple-
ments during treatment, presenting functional and/or deposition ferro-
penia. No effects harmful to the maintenance of arterial pressure were
observed, nor were any detected in terms of kidney function, phospho-
calcium metabolism or levels of potassium in serum. Tolerance was
excellent, and the administration of EPO gave rise to no side effects,
except for one case of slight local pruntus at the point of injection.
Conclusions: The treatment of anemia by subcutaneous administration
of EPO in patients with chronic renal failure in pre-HD phase: (1) Was
effective at low levels of dosage (<20 U/kg/x 3 weeks) and generally
needed iron supplements. (2) Our experience is that EPO has shown
itself to be a safe technique, having no important side effects.
Hepatitis C In hemodialysls (lID): Its prevalence in our treatment unit,
and relevant factors. J.E. Garcia DIaz, R. Diaz Tejeiro, M.A. Garcia
Rubjales, E. Gonzalez, G. Fernández, F. Ahyado, E. GOmez, and T.
Sierra, Nephrology Department, Virgen de Ia Salud Hospital, Toledo,
Spain. We study the prevalence of hepatitis C seropositivity in a
population of 80 patients on HD (37 M, 43 F) using the detection of IgC
anti-HCV by second generation ELISA as the diagnostic technique.
Mean age of the group was 54.8 years (17—77) and time on HD was 58.4
months (1—287). The following potentially relevant parameters were
evaluated: (1) the number of transfusions; (2) time on HD; (3) age; (4)
sex. (5) etiology of CRF; (6) background of natural exposition to HBV;
(7) biochemical data suggesting chronic hepatitis. Results: (a) The rate
of prevalence was 32.5% (26/80). (b) It was found to be significantly
statistically related to time spent on HD (P < 0.001) and the number of
transfusions (P < 0.05). (c) It was unrelated to age, sex or etiology of
CRF. (d) Unrelated to natural exposition to HBV. (e) In those patients
with hepatic biochemistry compatible with chronic hepatitis, 75% were
seropositive for HCV, while this was the case for only 20% of those
who presented normal hepatic biochemistry (P < 0.05). (1) 54.5% of
patients seropositive for HCV presented hepatic biochemistry compat-
ible with chronic hepatitis. Conclusions: (1) A high rate of prevalence
exists in our program. (2) This is related to time spent in the HD
program and to the number of units of blood transfused. (3) The pattern
of contagion in our unit seems to differ from that of HBV. (4) An
important tendency to chronicity is found.
The probable effect of erythropoletln on the hypophislal-gonadal axis In
cases of chronic renal failure before Initiating dialysis. R. Diaz-Tejeiro,
M.A. Carrasco, i.E. GarcIa-Diaz, J.M. Gasalla, F. Ahi-jado, E.T.
Gonzalez, M.A. Garcia Rubiales, E. Gomez Tejada, and T. Sierra,
Nephrology Department, Virgen de la Salud Hospital, Toledo, Spain.
Introduction: Alterations in the hypothalamic-hypophisic-gonadal axis
have been described in cases of chronic renal failure (CRF). It is has
been shown that these alterations improve following treatment of the
anemia with erythropoietin (EPO). Nevertheless, it is not known
whether this is due to a direct effect of the EPO, or to the improvement
in overall health which follows correction of anemia. Objectives: To
analyze the effects of EPO on LH, FSH and PRL response to LHRH
stimulus in patients with CRF. Subjects: All patients were male (N = 6),
34 9 years old (X SD) with CRF prior to initiating dialysis (Car <
10 mi/mm) who had not received previous EPO treatment. Methodol-
ogy: Levels of LH (mU/ml), FSH (mU/mi) and PRL (ng/mI) are
measured over time periods of 0, 30, 60, 90 and 120 minutes in two
different types of situation: (I) Following i.v. "bolus" of 100 of
LHRH at time 0 (— EPO). (2) Following i.v. "bolus" of 100 g of
LHRH at time 0, including continuous infusion of 40 lU/kg EPO from
time — 15 minutes to + 15 minutes (+ EPO). Results: (1) Both LH (P <
0.01) and FSH (P < 0.05) increased following the infusion of LHRH in
both situations [(+EPO) (—EPO)], while PLR did not change in either.
(2) The infusion of EPO brought about a decrease in the lower area of
the LH response curve (RA) [(3390 1090 vs. 2850 877), X SD, P
<0.05)] and FSH [(899 471 vs. 760 415), X SD, P <0.05] without
changing PRL. Conclusions: (I) In pre-dialysis CRF cases LHRH brings
about an increase in the secretion of LH and FSH without changing
PRL. (2) Under the same circumstances, EPO gives rise to an acute
decrease in LH and FSH response to LHRH, without changing PRL.
This suggests that EPO has a direct effect on the hypothalamic-
hypophysial-gonadal axis in cases of CRF.
The elevation of total IgE and specific anti-ethylene oxide IgE in
patients on hemodlalysis (HD). Its relation to hypersensitivity. i.E.
Garcia D(az, R. Diaz Tejeiro, A. Garcia Rubiales, E. Gonzalez, G.
Fernández, F. Ahijado, E. GOmez, and T. Sierra, Nephrology Depart-
ment, Virgen de Ia Salud Hospital, Toledo, Spain. Allergic symptoms
which appeared in 77 patients during HD sessions were analyzed over
a six month period. Mean age of patients was 54.5 years (18—81), and
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mean stay time on HD was 52.9 months (1—186). The protocols
governing each HD session were studied, and a clinical questionnaire
with a personal interview was used. We divided results into three
groups: Group I (GI): grave symptoms. Group II (Gil): light to
moderate symptoms. Group III (Gill): asymptomatic. Total IgE (IgE1.)
was studied in all patients, while anti-ethylene oxide (IgE0), eosino-
philes in peripheral blood and IgG4 were studied in selected patients.
Results: (1) 14.2% of patients were asymptomatic (11/77; 2 from GI and
9 from GIl). (2) IgE level was elevated in 63.6% of symptomatic
patients. Of these, 71% also presented elevation of IgEQ. (3) IgE..
was raised in 16 patients (20.7%): 2/2 of GI (100%), 5/9 GIl (55.5%) and
9/66 of Gill (13.6%). (4) IgEØ was raised in 10 patients (12.9%), 2/2 of
GI (100%), 3/9 GIl (33.3%) and 5/66 of GIll (7.5%). (5) Eosinophile
recount was above 500 cells/mm3 in 13 patients (16.8%), 2/2 of GI
(100%), 1/9 GIl (11.1%) and 10/66 of GIll (15.1%). ConclusIons: (1)
Although both the sample and follow-up time are relatively small, a
greater prevalence of allergic symptoms is found than that described in
the literature. (2) A clear relation with ethylene oxide can be seen in
those cases with grave symptoms. This relation is not so clear in those
with light to moderate symptoms, and therefore other possible allergic
agents should be studied. (3) It is probable that in the absence of
symptoms in some IgE0 carriers is due to the presence of blocking
antibodies (IgG4)? (4) Light and moderate symptoms occur with suffi-
cient frequency to make dialysis an uncomfortable technique for a
significant group of patients.
Study of the level of immunoglobulin C (IgG) in the peritoneal liquid
and Its relation with the Incidence of peritonitis. J.C. Alonso, R. Lopez
Menchero, A. Miguel, R. Garcia Ramon, A. Abarca, and P. Laporta,
University Hospital, Valencia, Spain. We present a study carried out
using 32 patients who have spent more than three months in a national
health clinic undergoing a program of continuous peritoneal dialysis
(CAPD). We have measured: IgG seric IgG in the dialysis liquid,
clarification of the total IgG, and fibronectin, among other parameters,
in order to later establish a correlation between the level of IgG in the
peritoneal liquid and the incidence of peritonitis/patient year. The
results of the aforementioned calculations are the following: seric IgG:
904.4 318.04 mg/dl; IgG in dialysis liquid: 8.24 3.32 mg/dl; clarifica-
tion of IgG: 8.170.3l 1615.99 mI/mm; and an average of peritonitis of
0.82 0.96 peritonitis/patient/year. With these data we divided the
patients into two groups based on their level of IgG in dialysis liquid.
Group A was comprised of 27 patients with levels of IgG > 5 mg/dl in
all cases, with an average of 9.1 2.85 mg/dl of IgG in dialysis liquid, and
who had 0.65—0.9 episodes of peritonitis/patient/year during their stay in
the clinic. Group B was made up of five patients whose IgO levels
remained below 5 mg/dl and whose average level was 3.6 0.89 mg/dl
with an average incidence of 1.54—1.09 episodes of peritonitis/patienll
year. Based on these data we have concluded that a significant
difference exists in the levels of IgG in peritoneal liquid in both groups
(P — 0.001) which is reflected in a lower incidence of peritonitis in group
A, this group being statistically significant (P = 0.05). Given the
reduced number of patients in group B the results may be less
demonstrative but no less significant.
Lymphocyte subsets In uremia and In patients on chronic ambulatory
peritoneal dialysis (CAPD). R. LOpez-Menchero, 1. Bene:, A. Miguel,
M. Marugan, R. Garcia RamOn,J.C. Alonso, and S. Pons, Nephrology
Service, Clinical University Hospital of Valencia, and Hematokigic
Deparment, University of Medicine, Valencia, Spain. Introduction:
Chronic renal failure is accompanied by lymphocytopenia which can be
corrected in part by substitutive treatment. The relationship between
the different lymphocyte subsets is also affected in uremia, and various
alterations have been observed in patients on dialysis. Objectives: To
determine the effect of CAPD on the total numbers of lymphocytes and
I lymphocyte subsets and compare these with control subjects, uremic
subjects without dialysis, and patients on hemodialysis; also, to com-
pare the relationship between these values and the appearance of
peritonitis in CAPD. Materials and methods: 62 subjects divided into
four groups were studied: controls (N is; age: 33.3 2.8), patients
with end-stage renal disease (ESRD) preceding their inclusion in CAPD
(N = 14; age: 56.1 3.4; Cr < 10 mI/mm), patients on CAPD(N = 18;
cuprophan filters) (N = 15; age: 55 5.6; months on HD: 70.6 15.8).
The total amount of lymphocytes was counted (Technicon H-I auto-
matic counter) as were the following lymphocyte subsets: total T
lymphocytes (CD3T), T helpers (CD4) and T suppressors (CD8) (mark-
ing with monoclonal antibodies and reading by flow cytometry-FACS-
CAN). The data of the results are expressed as a mean 2 SEM,
Student's (-test was used for the analysis. Results: The values obtained
were as follows:
mm3 Lymphocytes CD3T
Controls 2049 234 1580 244
CAPD 2129 460 1436 304
vs. control NS NS
HD 1626 320 994 314
vs. control P < 0.05 P < 0.005
vs. CAPD P < 0.05 P < 0.05
ESRD 1574 430 814 206
vs. control P < 0.05 P < 0.005
vs. CAPD P < 0.05 P < 0.005
mm3 CD4 CD8 CD4/CD8
Controls 957 136 655 140 1.66 0.3
CAPD 832 196 615 130 1.4 0.2
vs. control NS NS NS
HD 619 206 410 186 2.15 0.76
vs. control P < 0.01 P < 0.05 NS
vs. CAPD NS (P = 0.07) P < 0.05 P < 0.05
ESRD 453 122 369 130 1.46 0.30
vs. control P < 0.05E-4 P < 0.005 NS
vs. CAPD NS (P = 0.09) P < 0.01 NS
It follows that the numbers of lymphocytes and T cell subsets return to
normal values after beginning treatment with CAPD, while in those
patients on HD the figures are similar to uremic patients without
treatment. The CD4/CD8 quotient remains constant in all the groups,
except in the HD group in which is greater. In the patients on CAPD no
correlation was found between values of lymphocyte and T cell subsets
and the peritonitis/year index (1.50 0.6; range 0—4.8). ConclusIons: (1)
The total numbers of lymphocytes and the number of T lymphocyte
populations diminish noticeably in uremia. (2) Treatment with CAPD
returns the figures to normal values after a year of treatment. (3) In
patients on HD, after more than five years of treatment, the numbers of
lymphocytes and T cells remain severely diminished. (4) The total
number of lymphocytes and the number of T cells do not influence the
rate of peritonitis in CAPD.
Different needs for Iron (Fe) In patients treated with recombinant
erythropoletln (rHuEPO) with two types of dialysis. R. Garcia Ramon,
J.M. Escobedo, R. Lopez Menchero, H. Alcocer, J. Villaro, E. Garri-
gos, and A. Miguel, University Hospital, and General Hospital, Va-
lencia, Spain. In the present study we compared the needs for Fe in two
groups of patients with different dialytic treatments, and different doses
and means of administration of the rHuEPO in order to obtain the same
objective: HCTO> 30% and/or HB> 10 g/dl. We divided the patients
into two groups: Group I was made up of 12 patients undergoing
continuous peritoneal dialysis in national health clinics (CAPD) for a
minimum of 3 months, aged between 35 and 78, and with an average
rHuEPO dose of 60—120 U/kg/week administered subcutaneously.
Group 2 consisted of 14 patients on HD aged between 35 and 77. The
average rHuEPO dose was 50—390 U/kg/week administered intrave-
nously after HD. The needs for Fe were indicated by 1ST < 20% and/or
ferritin (FR) <60 mg/mI. We calculated the Fe to be replenished
according to NECESSITIES = 150(10 real FIB) and the replenishment
was effected with Na, Fe gluconate was administered intravenously.
Controls for HCTO, HB, 1ST, Fe and Fr were carried out monthly. The
administration of rHuEPO produced a rise in HCTO and HB in both
groups. The variations of Fe and 1ST were not significant in either
group, whereas the reduction of the FR was significant in both. At the
end of the study the differences in HCTO and between the two groups
were insignificant, but the Fe, 1ST and FR were higher in Group 1. The
needs of Fe in Gl were 450 41 mg/p/year and in Group 2, 695 439.
Basal 21.9 2.55 31.55 7.50 338.92 152
CAPD
Final 31.5 4.66 31.50 6.65 204.00 114
Basal 27.0 4.66 25.00 1.41 513.40 455
HD
Final 29.9 4.13 17.20 10.2 97.50 152
Study of the migration of two types of peritoneal dialysis catheter:
Repercussion on the volume of drainage. J.L. Olivas, J.A. Miguel, R.
GarcIa-RamOn, R. LOpez-Menchero, J.C. Alonso, and N. Uribe,
University Hospital, Valencia, Spain. Migration of the peritoneal
catheter outside the pelvis is a common complication in patients
undergoing CAPD treatment. The present work was aimed at establish-
ing the rate of incidence of this complication in our unit, and its relation
with the type of catheter implanted and the age of the patient.
Twenty-nine patients were retrospectively reviewed: 12 men and 17
women with an average age of 61.2 years and an average period of
treatment in the program of 25.5 months. A total of 29 catheters was
implanted, of which 11 were Tenckhoff catheters and 18 were "Swan-
neck." The process of locating the catheter tip was carried out by
means of simple abdominal X-ray, the abdomen being divided into the
nine classic anatomical regions. Migration of the catheter outside of the
pelvis was considered malposition. The volumes of drainage obtained in
the control following the diagnostic of malposition were compared with
the base values. Twelve catheters underwent migration, 8 of them (27%
of the total), all Tenckhoff catheters (81% of them), moved outside of
the pelvis. Only three (16.6%) of the 18 Swan-neck catheters migrated,
doing so horizontally. Of the 11 catheters implanted in patients aged
over 65 years only two (18%) migrated to regions above the abdomen.
However, of the 18 catheters implanted in patients younger than 65, six
(33.3%) migrated to upper regions, with no significant difference be-
tween the two groups. The difference between the average drainage
volumes before (1.73—0.76 ml/min) and after malposition (1.11—0.57
mI/mm) was significant (P = 0.05) with the low drainage volumes
corresponding to those catheters in which the cause of the malposition
was the trapping of the catheter by the omentum.
Single initial bolus of low molecular weight heparin: Comparison with
standard regimen and performance in 3 different membranes. C. Bernis,
N. Gomez, I. Motellon, B. Rincon, G. Barn!, E. Gruss, P. Gomez-
Manzano, J.A. Sanchez-Tomero, J.M. Fdez-Rañada, and J.A. Traver,
Services of Nephrology and Hematology, Princesa Hospital, Madrid,
Spain. Low molecular weight heparin (LMWH) has been found to have
potential clinical advantages compared to standard unfractionated
heparin (UFH). We studied the effectiveness and safety of LMWH
(enoxaparin) in hemodialysis. Twenty-seven patients on hemodialysis
received either UFH (4960 1600 LU) or LMWH, Enoxaparin (4000 LU
aXa). Blood was sampled for APTT and plasma anti-Xa activity prior to
dialysis, at 5, 30, 60, 180 minutes and at 48 hours. Plasma anti-Xa
activity was assayed using cromogenic substrate (KABI). Paired and
unpaired Student's i-test was used for statistical analysis. Results: A
single initial bolus of enoxaparin was safe and effective. Bleeding or
thrombotic complications did not occur. APTT were significantly less
for enoxaparin than for UFH at 5 minutes (58 + II v.s. 114 + 43, P <
0.01) and at 180 minutes (36.6 + 6 v.s. 54.4 + 4 P < 0.05). Anti-Xa
activity was significantly higher for enoxapann than for UFH at 5
minutes (0.58 + 0.2 v.s. 0.39 + 0.18 P < 0.05) and 180 minutes (0.37 +
0.05 v.s. 0.22 + 0.1 P < 0.05). Anti-Xa activity at 48 hours after
enoxaparin was similar to basal levels. Performance in the 3 different
membranes (cuprophan, AN-69, and EVAL) was not significantly
different. Evaluation of dialyzers was slightly better on enoxaparin.
Conclusions; A single initial bolus of enoxaparin is safe and effective in
hemodialysis. AP'TT was less with enoxaparin and may reduce bleed-
ing. of risk Anti-Xa activity was higher with enoxaparin, but anti-Xa
activity was not detected at 48 hours. Performance was comparable in
the 3 membranes evaluated.
Risk factors for the development of acute renal failure during bone
marrow transplantation. E. Gruss, C. Garcia-Canton, J.F. Tomas, C.
Bernis, A. Figuera, M. Berberana, V. Paraiso, J. Hernandez-Jaras,
J.M. Fdz-Ranada, and J.A. Traver, Services of Nephrology and
Hematology, Princesa Hospital, Madrid, Spain. To assess the mci-
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dence, risk factors, etiology, course and outcome of acute renal failure
(ARF) following bone marrow transplantation (BMT), a retrospective
analysis of 275 patients (183 allografts and 92 autografs) was under-
taken. ARF was defined as an increase up to 2 mg/dl of serum
creatinine. Seventy-seven cases of ARF were diagnosed in 72 patients
(28%). The incidence was higher in allogenic (38.7%) than in autologous
(6.52%) grafts. The etiology was multifactorial 40.2%, nephrotoxics
34%, venoclusive disease of the liver (HVCD) 14.2%, graft versus host
disease (GVHD) 5.1%, sepsis 2.7%, hemolytic uremic syndrome 2.5%,
and hemoglobinuria 2.7%. ARF, usually non-oliguric, occurs in 69.4%
within the first month. Thirty-five patients (45.4%) died during ARF.
Seventeen cases with oliguric renal failure required dialysis mainly in
association with HVCD (70.5%). The dialyzed group had the highest
mortality (88.23%). A strong risk factor for the development of ARF
was the presence of HVCD (40% in the ARF group v.s. ll% in the
group without), age older than 20 (76.3% v.s. 23.6%). Neither GVHD,
nor underlying disease, nor previous treatments correlated with the
developement of ARF. Survival in the ARF group was worse at I month
(65.5 v.5. 93.6%), 3 months (74.6% v.s. 47.5%), and 6 months (70.2%
v.s. 37.7%). Actuarial survival at 10 years was 29.7% and 53.2%.
Conclusions: ARF is a common and early complication following BMT,
specially in allogenic grafts. Presence of HVCD and age older than 20
were risk factors for the development of ARF. The survival rate is
considerably less in the ARF group.
Arterial hypertension in the adolescent. Incidental arterial pressure
(LAP) versus continuous monitoring of ambulatory blood pressure data
(CMABP). N.S. Jabary, M.L. Bretaña, J. Ardura, G. Sanchez, and J.
Bustamante, Hospital Universitario, Valladolid, Spain. The blood
pressure (BP) obtained in the hospital can increase as a result of alert
reactivity provoked by the doctor or the nurse, causing an inaccurate
diagnosis of hypertension. The objective of this work was to check the
differences between the data and the percentage of hypertensives in
adolescence by means of lAP and CMABP. We have studied 21
adolescents considered to be hypertesives (SBP> 142 yb DBP > 92
mm Hg) in epidemiological research in a school, and we have sent them
to the HBP unit, average age 16.5 years (16—18), 20 males and I female.
Clinical histories, physical examination, basic blood chemistry, and
special tests (chest X-ray, EKG, abdominal echography, IVP, etc..)
were made when necessary. LAP and CMABP were carried out with an
automatic non-invading instrument (Spacelab 5200) each 24 hours.
Hourly readings were taken. To check them we used the average of the
daytime period between 8 a.m. and 22 p.m. Results: SBP 141.7 II
versus 130 90 (SS), DBP 78 11 vs. 74 11 (SS), HR 86.4 13 vs.
80 10 (NSS). Only 39% of cases reached the diagnosis criteria of
hypertension, and secundarism was not found in any of them. Conclu-
sion; CMABP records blood pressure significantly lower. CMABP for
the diagnosis of hypertension in adolscents is useful.
Enalapril lessens alterations induced by elevation of hematocrit in rats
with reduced renal mass. A. Torralbo, J.I. Trobo, J.A. Herrero, E.
Velasco, M. Borque, A. Gonzalez-Mate, M. Marcello, A. Fontanellas,
P. Gonzalez, A. Cruceyra, J. Blanco, and A. Barnientos, Hospital
Universitanio San Canlos and Hospital 12 de Octubre, Madrid, Spain.
Reduction of renal mass in rats above 65% leads to hyperfiltration,
hyperperfusion, and changes in glomerular hemodynamics that result in
progressive renal damage. Elevation of hematocrit (Hto) with erythro-
poietin (EPO) severely accelerates hemodynamically mediated glomer-
ular injury. It has not been studied if it is possible to ameliorate that
situation with the concomitant administration of antihypertensive pre-
and postglomerular drugs. Four groups of male Wistar rats (N = 35)
were used in these studies: 0-I, two-thirds nephrectomy (NX); 0-Il,
NX plus treatment with subcutaneus EPO (target: elevation of Hto 5
units %); 0-Ill, NX+EPO plus treatment with subcutaneous verapamil
(0.5 g/g/day); G-IV, NX+EPO plus treatment with enalapril (50
mg/liter in the drinking water). We measured Hto, plasma creatinine
(Crp), creatinine clearance (Car), 24 hour proteinuria (Prot) and Prot/
Cr at 6, 10 and 16 weeks after NX. We measured systolic blood
pressure (SBP) by the tailcuff method at 16 weeks after NX. We
observed progressive lowering of in groups 1, II and III (P < 0.05);
it was maintained in G-IV. Prot rose significantly more in groups IL and
Ill with respect to 0-tV (P < 0.05). ProtlCcr rose in all groups (P <
0.05) except in the rats that received enalapril.
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Ccr ml/min/100 g Prot mg/24 hr Prot/Ccr
G-1
6 weeks 0.34 0.09 27.1 9.3 81.9 25
10 weeks 0.36 0.08 27.8 10.5 84.0 36
16 weeks 0.21 0.05 49.7 27.5 253.0 170
G-1I
6 weeks 0.29 0.11 25.8 7.9 92.5 21
10 weeks 0.24 0.05 38.6 18.9 173.5 117
16 weeks 0.18 0.05 55.5 37.2 361.0 313
G-III
6 weeks 0.30 0.04 31.9 10.1 111.7 59
10 weeks 0.25 0.07 52.8 40.3 260.2 283
16 weeks 0.22 0.07 75.7 52.6 463.6 530
G-IV
6 weeks 0.25 0.09 20.7 4.2 91.5 36
10 weeks 0.27 0.07 39.2 5.4 135.0 32
16 weeks 0.24 0.03 29.2 3.3 124.8 22
SBP (in mm Hg) was lower in the group treated with enalapril at 16
weeks after NX (140.4 5.7 in G-IV vs. 165.6 6.7 in G-I, 183.5 15.3
in G-II and 183.4 24.2 in G-III: P < 0.01). Conclusions: (1) Our results
confirm that in rats with reduced renal mass elevation of hematocrit
with EPO is associated with progressive proteinuria. (2) Treatment with
enalapril controls systemic blood pressure and maintains glomerular
filtration and proteinuria levels.
Endothelin (ET) in chronic renal failure (CRF) and treatment with
recombinant human erythropoietin (rHuEPO). A. Torralbo, J.A. Her-
rero, J. Portoles, M. Borque, A. Gonzalez-Maté, F. Coronel, A.
Marañes, and A. Barrientos, Hospital Universitario San Car/os,
Madrid, Spain. Little information is available about the pathophysio-
logical role of ET in systemic arterial hypertension in CRF patients.
Changes in ET plasma concentration during hemodialysis (HD) ses-
sions is poorly studied. The role of ET in hypertension associated with
treatment with rHuEPO is unknown. Fifteen stable patients on regular
HD were studied. Six of them were hypertensive controlled with
antihypertensive drugs. Nine patientes received treatment with
rHuEPO. We measured blood pressure, hematological parameters, and
ET plasma concentration before the beginning of treatment and at 7, 14,
30 and 90 days after treatment. We measured plasma El concentration
before and after HD in 10 patients. In ten age-matched normal subjects
we determined ET circulating levels. ET plasma values in CRF patients
(N = 15) versus normal subjects were 1.45 0.09 pmol/liter versus 1.13
0.05 pmol/liter (P < 0.05). ET plasma conceitration in Ivrmotensive
subject was 1.37 0.08 pmol/liter (N = 9) versus 1.52 d .20 pmol/liter(N = 6) in hypertensive patients (p = NS). We found no changes in ET
plasma levels during treatment with rHuEPO: .39 0.13 pmol/liter
before treatment, versus 1.42 0.17, 1.38 0.19, 1.51 0.26, 1.45
0.12 pmollliter after 7, 14, 30, and 90 days of treatment, respectively (P
= NS). ET plasma levels before versus after HD were no different (1.62
0.14 vs. 1.63 0.07 pmol/liter, NS). Conclusions: (1) El plasma
levels are elevated in patients with CRF. (2) Circulating T was not
related to hypertension in our patients. (3) Treatment with rHuEPO is
not associated with changes in ET plasma concentration. (4) There is no
remarkable difference in the plasma El concentration before versus
after hemodialysis. (5) Further studies are needed to define the biolog-
ical activity of circulating ET in CRF patients.
Effects ofhematocrit and vasoactive substanes levels on blood pressure
of patients treated with erythropoietln (EPO). A. Torraibo, J.A. Herrero,
J. Portoles, M. Borque, A. Gonzalez-Mate, F. Coronel, A. Maranes,
and A. Barrientos, Hospital Universitario San Carlos, Madrid, Spain.
Mechanisms of arterial hypertension associated with treatment with
EPO in hemodialysis patients are not completely understood. The
increase in vascular resistance demonstrated in these patients must be
related with increment in blood viscosity arid/or vascular tone. We have
studied the evolution of blood pressure in patients treated with EPO in
relation with hematocrit (blood viscosity) and vasoactive substances
levels (vascular tone). We have measured mean blood pressure (MBP),
hemoglobin (Hb), hematocrit (Hto), plasma endothelin (El), plasma
renin activity (PRA), free norepinephrine (NE), free epinephrine (E),
and free dopamine (DE) before and at 7, 14, 30 and 90 days after
treatment with EPO. The starting dose was 40 units per kg body wt.
EPO was administered intravenously after the dialysis. MBP was not
significantly changed (basal 97.4 9.4 mm Hg vs. 98.3 10.2 mm Hg
at 90 days; P = NS). Hb and Hto increased significantly at 15 days of
treatment (Hb 7.93 0.63 vs. 8.77 0.62 g/dl, P < 0.05; Hto 23.64
1.57% vs. 25.77 2.45%, P < 0.05); after 90 days of treatment Hb
was 9.92 0.62 g/dl (range 9.0—10.6 g/dl), and Hto was 29.69 1.53%
(range27.9—32.2%). The levels of vasoactive substances are given in the
table:
Basal 7 days
ETpmo//liter
PRA ng/ml/hr
NEpmol//iter
E pmol//iter
DEpmol/liter
1.39 0.41
5.34 5.14
2715 1195
598 655
<100
1.42 0.53
3.80 4.78
3007 1314
346 199
143 112
14 days 30 days 90 days
ETpmol/liter
PRA ng/ml/hr
NE pmol/liter
E pmo//liter
DEpmo//liter
1.38 0.57 1.51 0.78
3.77 5.60 6.82 13.6
2587 749 2438 1037
240 146 265 256
132 66 328 311
1.45 0.37
4.50 3.62
3629 10210
462 199
131 57
a P < 0.01 90 days vs. basal
There was no correlation between MBP and norepinephrine levels.
Conclusions: (1) Inour patients, elevations of Hto near 30% and Hb near
10 g'il did not increase blood pressure. (2) No correlations were found
between MBP and vasoactive substances after treatment with EPO.
Erythropoietin (EPO) levels in renal transplantation. A. Maranes, J.L.
Alvarez-Sa/a, D. Prats, J.A. Herrero, A. Torra/bo, J. Portoles, and A.
Barrientos, Hospital Universitario San Carlos, Madrid, Spain. The
EPO levels in the evolution of the renal transplantation (Tx) and its
hematological correlation have received little attention until now. We
have studied the serum EPO levels (RIA Biomerieux: normal values
3—16 mU/mI) and their relationship with hemoglobin (Hb), hematocrit
(Hto), MCV, and serum Fe, ferritine, creatinine (Cr), cyclosporin A
(CsA), and intact PTH (iPTH) in 41 transplanted patients with several
base diseases, throughout a medium post-Tx period of 15.4 months
(1—67). Excluded were the patients with Cr above 1.4 mg/dl, the medium
increment of the Hb after the Tx was 3.4 2.7 g/dl (P < 0.001). We
found a large dispersion for the EPO values above all in anemic patients
(27 + 20 mU/mi when Hto < 38% vs. 5.0 4.4 mU/ml when Hto>
45%). We did no find a significant correlation between increments of
Hb-Hto and EPO levels. Considering patients with Hto < 38% and
>45% there were no differences in relation neither to the post-Tx time
(10.6 5.7 vs. 9.8 8.3 months), Fe (100 33 vs. 94 26 ng/dl),
ferritine (284 660 vs. 249 481 nglml), MCV (93.3 5.2 vs. 95.1
5.7 fi) nor IPTH (142 97 vs. 127 117pg/mI). In the group of patients
with Hto < 38% and EPO> 16 mU/mi, IPTH was 122 113 pg/mI, and
in those with EPO < 16 mU/mi iPTH was 140 93. No relationship was
foundbetween EPO and CsA. We conclude that, with reference to EPO
and its relationship with Hb and Hto, there were three different
tendencies in renal transplantation: (I) Increments of Hb and Hto to
normal values with EPO within the lower limit of the normal, which
meant a usual Hb-EPO feed-back and hematopoyetic response. (2)
Inadequate improvement of the Hb and Hto with high EPO was not
attributable to iron deficiency, P'FH, CsA, nor renal insufficiency. (3)
Inadequate improvement of Hb and Hto with low EPO was apparently
caused by renal dysfunction.
Bone densitometry In CAPD patients. F. Coronel, C. Lozano, J.A.
Herrero, M. Borque, I. de Pablos, L. Ortega, J. Portolés, and A.
Barrientos, Hospital Universitario San Car/os, Madrid, Spain. The
value of bone mineral content (BMC) using dual energy X-ray absorp-
tion method was assessed in 20 CAPD patients (12 M, 8 F, mean age 55
years, mean time on CAPD 19.4 months, 12 diabetics). Two studies
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were performed with an interval of 6 months. Measurement of trabec-
ular bone on lumbar spine (LS), and cortical and trabecular bone on
femoral neck (FN) were done. Radiological, biochemical (Ca, P, AP,
serum aluminum) and hormonal (iPTH, PTHm, 250HD3, l,250HD3)
studies were performed at the same time. Bone biopsy was performed
in 10 CAPD patients. We compared the BMC results with those
obtained in 20 HD patients. We have found no differences in BMC
between the two studies in CAPD. BMC values were similar in CAPD
and HD. In women there was inverse correlation between BMC (LS)
and age (r = —0.58, P < 0.05). No significant differences in BMC were
found between diabetic and non-diabetic patients on CAPD. There was
no correlation between BMC and biochemical or hormonal values.
Radiologically (CAPD+HD) 17 patients were normal, 17 showed os-
teopenia and 5 hyperparathyroidism (HPT). There was a significant
difference in BMC (LS) values between normal versus osteopenic X-ray
studies (P < 0.01), but there was no difference between normal versus
HPT. There was a trend to lower BMC (LS and FN) in patients with
findings of osteoporosis in bone biopsy. We can conclude that bone
densitometry could be a useful method to detect and follow osteopenia
in CAPD patients.
Treatment of leukopenia in renal transplant (RT) patients with leuko-
cyte colony-stimulating factors (CSF). A. Alonso, T.G. Fakón, M. Cao,
C.F. Rivera, F. Arrojo, J. Moncalián, J. Oliver, and F. Valdés, Servicio
de Nefrologia, Hospital Juan Canalejo, La Coruña, Spain. Leukopenia
is a frequent complication of RT. It is usually secondary to drug therapy
and/or CMV infection. Leukocyte CSF may represent an effective
therapy for this condition. Four RT recipients developed severe (<
1.000 granulocytes/mm3) and persistent (mean 16 days, range 8—21)
leukopenia after azathioprine therapy (N = 4) and/or CMV infection
treated with Gancyclovir (N = 2). Acute rejection (N = 1), ureteral
fistula (N = 1), candida albicans urinary tract infection (N = 2) and P.
carinii pneumonia (N = I)were complicating conditions. In three cases,
leukopenia was treated with granulocyte CSF (g-CSF, Neupogen,
Roche), 300 pg/day i.v. (N = 2) or subcutaneously (s.c.) (N = 1) for 7
days. The remaining patient was treated with granulocyte-macrophage
CSF (gm-CSF, Leucomax, Sandoz), 5 jsg/kg/day s.c. for 5 days.
Leukocyte counts behaved as follows:
Day 0 3
Leukocytes mm3 430—1500 2030—2600
Granulocytes mm3 340—560 1100—1620
Day 5 Final
Leukocytes mm3
Granulocytes mm3
6150—7010
1680—4626
7000—18250
4600—12775
All patients survived. No adverse reactions were observed, except for
mild arthralgias in one case. Renal function remained stable. Azathio-
prine could be later reintroduced without relapse of leukopenia. In
conclusion, g-CSF and gm-CSF are very effective for treatment of
severe and persistent leukopenia in RT patients with associated risk
factors.
The kidney retransplant: A risk factor? J. Oliver Garcia, M. Gao
Vilariño, A. Alonso Herndndez, C. Fernández Rivera, M. Adeva
Andany, T. Garcia FalcOn, F. Arrojo Alonso, and F. Valdés Caédo.
The second kidney transplant is normally considered a risk, especially
when the first transplant was lost very early, such as during the first
three months. Reviewing our files of 458 kidney transplants done
between January 1981 and December 1991, there were 46 cases of
second kidney transplant. Comparing the second kidney transplants
with the first ones, we observed that there were no significant statistical
difference in relation to age or sex between donors and recipients, basic
illness, number of blood transfusions received, immunity state, HLA
compatibility, time of cold storage, grafts not working from start time
before initial working, number of transpiantas not working, number of
days in the hospital, number of problems of acute rejection, evolution of
transplant during 3, 6 and 12 months, complications and survival of
1479
transplant and patients. There are differences with the type of immu-
nosuppressor used, having used some combinations which include
cyclosporin A in nearly all the second kidney transplants and only in
about half of the first kidney transplants. We conclude that in our series
the retranspiant is not a greater risk and we attribute it to the better
immunological compatibility (although without significant statistics) in
the retransplants and by using in these cases better immunosuppressive
therapy.
Treatment of anemia with erythropoletln (EPO) in patients on CAPD
and hemodialysis (HD). A comparative study. M. Perez Fontán, T.
Garcia FalcOn, J. MoncaliOn, A. Rodriguez-Carmona, F. Arrojo, C.
Fernández Rivera, and A. Alonso, Nephrology Service, Hospital Juan
Canalejo, La Coruña, Spain. We have studied comparatively the
results of treatment with EPO in our uremic patients treated with CAPD(N = 73) or HD (N = 68). EPO was initiated in patients with
hemoglobin (Hb) < 8 g/dl after >1 month on dialysis, in the absence of
other correctable causes of anemia. Treatment schedule was 100—150
U/kg/week in 2—3 doses, with highly predominant use of the subcuta-
neous route. The target Hb was 10—— 12 g/dl. EPO therapy was
necessary in 15 patients on CAPD (20%) [Group I, (G. 1) mean age 46,
13% hypertensives, follow-up on EPO 8 5 months) and 39 patients on
HD (57%, P < 0.01) (Group 2, (G.2) age 51, 44% hypertensives P <
0.01, follow-up on EPO 9 7 months). The higher requirement for EPO
in 0.2 was more remarkable for diabetics and patients with primary
glomerular or interstitial disease (P <0.05). The dose of EPO necessary
to attain target Hb was 148 44 U/kg/week in G.l and 186 86 in G.2
(NS), and the time to response was 10 weeks in 0.1 vs 11 in G.2 (NS).
The maintenance dose of EPO was lower in G. 1 (101 52 U/kg/week)
than in G.2 (176 110) (P < 0.025). Mean Hb at 0, 3 and 6 months was
7.3, 10.8 and 11.2 g/dlforG.l, and 7.1, 10.0 and 10.7 in G.2(NS). Sixty
percent of patients of G. I required Fe supplementation, versus 46% of
G.2(NS). No clear effect of EPO on dialysis prescription was observed.
EPO failure occurred in 2 patients of G.l (13%) and 4 of G.2 (10%) (NS),
but was irreversible in only one patient of G.2. Vascular access
thrombosis occurred in 2 patients in each group. Appearance or
worsening of hypertension was observed in 3 patients of 0.1(20%) and
14 of G.2 (36%) (NS). Three patients of 0.1 discontinued EPO due to
hypertension, versus 0 of 0.2. CAPD patients need EPO less fre-
quently, and at a lower dose, than those on HD. Moreover, hyperten-
sion complicates EPO therapy more frequently in HD patients, at least
partly due to a higher basal prevalence of hypertension in these
patients. On the other part, spontaneous vascular access thrombosis
seems to be particularly frequent in patients on CAPD treated with
EPO.
Treatment of acute rejection steroid resistance (RACR) with OKT3:
Long-term results. M. Cao, T.G. FalcOn, A. Alonso, J. Oliver, M.
Adeva, F. Arrojo, C.F. Rivera, J. Moncalián, A.R. Carmona, M.P.
Fontán, and F. Valdés, Servicio de Nefrologia, Hospital Juan
Canalejo, La Coruña, Spain. We analyzed patients treated with OKT3
between April 1989 and November 1991, with RACR, diagnosed by
means of biopsy (except in one case), and defined as those who didn't
respond to 2 cycles of 3—4 "bolus" of 500mg of 6 methyl prednisolone
(6 MP), or who after a favorable initial response presented a progressive
increase in serum "creatinine" (Cr) in relation to persistent rejection.
They formed a group of 20 patients (11 female, 9 male) aged between 16
and 51 (mean age 33) immunosuppressed with CsA + Pd(8), CsA + Pd
+ Aza(l I), or Aza + Pd(1) of which three received a second renal
transplant (RT) and 3 were highly sensitized (HI) (PRA > 85%); 10—14
doses of 5 mg of OKT3 were administered cutting in half or suspending
the baseline immunosuppression during the therapy and reintroducing it
in full doses 3 days before finalizing the cycle. The response was
considered to be favorable when the post-treatment creatinine was
lower than at the beginning. The average continuation was 17 months
(8—34 months). Results: A favorable response was obtained in 14 out of
20 patients (70%). Among the group of patients who responded and
those who didn't there were no significant differences in the age or sex
of the donor or recipient, patients' rate HI, number of DR matches or
mismatches, numbers of previous grafts, day when the rejection ap-
peared, or histological findings. Although the initial favorable response
was 70%, it was lower in the long-term, with a 50% graft survival after
12 months, dropping to 40% after 24 months and 28% after 30 months
(statistically lower than patients without RA or with RA steroid
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sensitive for any post-RT phase). The cause of graft loss was immuno-
logical (except one patient who died from sepsis). The losses were:
chronic rejection (RC), 7 (36.6%); acute cellular rejection (RCA), 2
(10.5%); acute vascular rejection (RVA), I (5.3%); and abandoning of
the medication, 1 (5.3%) whose graft was functioning. Patient survival
was 95%, similar to the rest of patients in the transplant program.
Conclusions: OKT3 constitutes a safe and efficient treatment of RACR.
Short-term results are higher than those obtained in the long run, with
a clear reduction in survival as the observation period is prolonged. The
main cause of loss was immunological in relation to chronic rejection!
uncontrolled acute rejection. The number of recurrences of RA epi-
sodes was very low, appearing in just one case (5.3%) with a favorable
response to steroid treatment. With this therapy we succeeded in
"saving" 28% of grafts after three years, which otherwise would have
been lost in the short-term.
Renal artery embolism as a cause of acute renal failure: Diagnosis,
pronostic factors and treatment. J. Fort, A.J. Segarra, J. Camps, A.L.
Segarra, J. Gomez, R. Roca, A. Olmos, and L. Piera, Nephroiogy,
Radiology, and Vascular Surgery Departments, Hospital General Vail
d'Hebrón, Barcelona, Spain. Renal artery embolism is sometimes a
cause of acute renal failure in patients suffering from embolic valvular
cardiopathy. Diagnosis can be unnoticed in cases of unilateral embo-
lism. Although therapy remains controversial, surgical embolectomy
and fibrinolytics have been used with satisfactory results. This prospec-
tive study shows our two year experience in this pathology. We studied
nine patients (5 females and 4 males) with a mean age of 58.7 5.7
years, suffering from acute renal failure secondary to renal artery
embolism. Four patients were treated with surgical embolectomy and
four with intra-arterial fibrinolytics according to a protocol previously
designed. In all the cases we evaluated the levels of plasma creatinine
at six months and its relationship among the maximum value of
creatinine, LDH and LDH isoenzymes, the type of embolism and the
time elapsed since the beginning of clinical symptoms until the treat-
ment was started. The value of maximum creatinine (4.6 3.1 g/dl)
didn't correlate with the maximum value of LDH, nor with the type of
treatment, nor with the elapsing time. The creatinine levels at six
months (1.5 1.1 mgldl) were significantly correlated (P < 0.05) with
the value of maximum creatinine and the elapsing time. No correlation
was found when we took into account the maximum value of LDH. In
our series either surgical embolectomy or fibrinolytic therapy has been
satisfactory. LDH isoenzymes (I and II) values have been proven a
useful diagnosis procedure, although they didn't have prognosis value.
Renal function recovery depended on an early diagnosis and treatment.
Kidney transplant survival (SV) In Andalusia. Results 1985-1991. M.A.
Gentil, M. Gui, F.G. Excribano, M.G. Molina, G.R. Algarra, R.P.
Calderon, M,R. Rivero, A.M. Osuna, J.J. Govantes, A. Nunez, Re-
gional Secretary of Kidney Transplantation, Andalusia, Spain. We
analyzed the outcome of 956 kidney transplants carried out in 6
transplant centers during 1985 through 1991, when cyclosporine use
became generalized in our region. In comparison with the previous
period (1978—84), we found a great increase in patient SV (95%—87% at
1st and 5th year, versus 85%—72% in 1978—84; P < 0.001), as well as in
graft SV (83%—65% at lst—Sth year, vs. 61%—42%; P < 0.001). There
were remarkable differences among transplant centers concerning pa-
tient SV (at 1st year, from 86% to 98%; P <0.01) and graft SV (1st year,
from 71% to 91%; P < 0.01). A good matching in HLA B or DR locus
was associated with better graft SV, but only when both loci were
considered together did the improvement reach statistical significance
(graft SV with 0—I lILA B+DR mismatch: 86%—70% at lst—Sth year,
vs. 80%—62% for >1 mismatch; P < 0.01). Transplant in recipients with
peak panel reactive antibodies > 50% did not show different SV
(84%—62% at lst—5th year). A multivariate analysis demonstrated
independent significant effects on graft SV of transplant center, year of
transplant, donor sex, HLA B + DR mismatching and regraft, but not
of peak panel reactive antibodies > 50%. ConclusIon: We observed a
striking recent progress in kidney transplant SV in our region. HLA
compatibility remains a significant factor determining graft survival at
present.
Organ exchange (OE) in a regional kidney transplant (KT) program.
Effects on patient access to transplant, HLA matching and survival. M.A.
Genii!, G. Escribano, M. Cabello, P. Pereira, D. Castillo, M. Alonso,
A. Monies, A. Giralt, F. Garrido, and A. Nuñez, RegionalSecretary of
Kidney Transplantation, Andalusia, Spain. During 1978 through 1991,
1415 KT were carried out in 8 transplant centers of Andalusia. On a
voluntary basis, we have been applying a common OE policy: for the
majority of the viable pairs of organs, one kidney was implanted out of
the harvesting area in another center in the region. We gave priority to
recipients under the age of 15, high peak PRA and clinical emergencies.
Otherwise, we selected the best recipient according to HLA matching.
Grafts were registered and periodically followed-up until death or
return to dialysis. An overall analysis revealed the following: (I)
Thirty-eight percent of kidneys were implanted in a transplant center
other than that in which it was removed. Local differences in organ
procurement gave rise to early imbalances in the OE among centers.
Because of this, the more active centers tended to lower, and later
abandon the OE, with a decreasing flow of kidneys with time. (2)
Self-regulated OE has not contributed to lessening the marked local
differences in patient access to KT. (3) OE improved access to KT for
children, sensitized and critical patients. For other patients, OE in-
creased HLA compatibility: 16% more cases with 0—I HLA B+DR
mismatch in the exchanged group of kidneys. (4) OE did not appear to
have an effect on graft or patient survival (multivariate analysis on 217
paired kidneys).
Importance of the administration route of erythropoletln in blood
pressure control in hemodialysis patients. J. Teruel, J. Navarro, J.
Pascual, C. Gdmez, F. Liaño, R. Marcén, and J. Ortuño, Hospital
Ramón y Cajal, Madrid, Spain. The appearance or worsening of arterial
hypertension is the most important undesirable effect of recombinant
human erythropoietin (rHuEPO) administration in uremic patients. The
aim of the present study has been to assess whether the administration
of rHuEPO by the subcutaneous (s.c.) route improves blood pressure
control in dialysis patients, hypertensive when treated with intravenous
(i.v.) rHuEPO. We selected 13 hemodialysis patients who were hyper-
tensive after more than one year of i.v, rHuEPO treatment (22 8
months, range 12—35 months). Hematocrit, rHuEPO dose, predialysis
mean arterial pressure and antihypertensive drug dosage had remained
constant during the last six months. These patients were switched to
s.c. administration of rHuEPO with reduction of rHuEPO dose by
one-third (from 149 56 to 98 53 lU/kg/week). Predialysis mean
arterial pressure significantly decreased (113.1 7.8 mm Hg during the
last month of i.v. administration vs. 107.8 9.8 mm Hg during the first
month of s.c. administration, P < 0.05, and 105.5 9.2 mm Hg at six
months, P < 0.05), without relevant changes in hematocrit. After six
months of s.c. administration, 5 patients remained normotensive with-
out drugs and 6 out the remaining 8 patients required decreased doses
of antihypertensive drugs. The use of s.c. route for rHuEPO adminis-
tration decreases dose requirements and improves blood pressure
control in patients who remained hypertensive when treated by the i.v.
route.
Hyperuricemia in kidney transplantation. Treatment with benzio-
darone. R. Marcen, L. Orofino, C. Gdmez, N. Gallego, J. Sabater, J.L.
Teruel, J. Pascual, and J. Or:uno, Hospital Ramón y Cajal, Madrid,
Spain. Hyperuricemia is a frequent finding in patients on cyclosporine
(CsA). Its pathogenic mechanism has not been clearly elucidated and its
management is difficult, mainly in patients on triple therapy. Among 102
renal transplant recipients on CsA, with serum creatinine (Sr) below
2.5 mg/dl, 62 patients (61%) presented hyperuricemia. it was associated
with higher Sr (1.4 0.3 vs. 1.2 0.2mg/dl, P < 0.05) and number of
patients on diuretics (88% vs. 11%, P < 0.01). To investigate the renal
handling of urate a combined pyrazinamide-probenecid test was per-
formed on 23 patients, 9 normouricemic and 14 hyperuricemic. The test
showed a lower fractional urate excretion (FE1) during the maximal
probenecid-induced uricosuria in the hyperuncemic patients (32 II
vs. 46 9%, P < 0.01) as well as lower urate secretion (21.5 2.3 vs.
35 9.2% of filtered load, P < 0.01), but there were no differences
either in the presecretory reabsorption or in the postsecretory reabsorp-
tion. According to these data 20 hyperuncemic patients were treated
with the uricosuric agent benziodarone (100 mg/day), 9 patients were on
CsA and 12 on triple therapy, S. was 2.1 0.7 mg/dl, and creatinine
clearance 52 17 mI/mm, and the follow-up after transplantation 39.5
23.4 months. The drug was administered between I and 21 months
(mean 8 3.1 months). At one month, serum urate decreased from 10.1
Ito 5.6 1.3 mg/dl (P < 0.001) and the FEurate increased from 7.7
2 to 23.8 7% (P < 0.001); similar findings were observed in the last
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follow-up. A light increase in serum cholesterol was observed as the
only side effect. Our results showed that CsA-induced hyperuricemia
could be due to impairment of GFR and of urate secretion by the renal
tubule. Benzodiarone seems to be effective and safe in controlling
hyperuricemia despite low creatinine clearances, but studies with
longer follow-up are needed.
Azathioprine addition to cyclosporine-treated patients with allograft
dysfunction. More than one year of follow-up. L. Orofino, R. Marcén, C.
Quereda, J. Pascual, J.J. Villafruela, J. Burgos, and J. Ortuño,
Servicio de Nefrologla, Hospital RamOn y Cajal, Madrid, Spain.
Forty-seven cyclosporine-treated patients, 30 males and 17 females,
with a progressive dysfunction from 14.1 13.7 (1—50) months after
transplant were studied. By clinical and histological (N = 36) criteria,
they were classified into 4 groups: I—Chronic rejection (N = 19);
II—CsA toxicity (N = 14); 111—Repeated acute rejection (N = 8); and
IV—Chronic rejection and CsA toxicity association (N = 6). Azathio-
prine was added to the treatment at doses of 1—2 mg/kg/day and CsA
was decreased from 4.1 1.5 to 2.9 1.2 mg/kg/day, P < 0.001. At the
beginning of the study, plasma creatinine (Cr) was similar in all groups
(2.8 I mg/dl), but proteinuria was more in group I than in groups II
and III, P < 0.01 and <0.05, respectively. After a follow-up longer than
a year in all cases (26.6 15 months), Cr was stable or decreased in 35
cases (11/19 of group I, 14/14 of patients from group II, 6/8 from group
Ill and 4/6 from group IV), and increased in other 12 patients. During
the follow-up, II grafts were lost because of immunological causes (8
from group I, I from group III and 2 from group IV). The grafts of
patients with a bad evolution, proceeded from older donors than the
rest (38.6 13.4 vs. 27.8 14.2 years), and had at the start of the study
a higher Cr and a larger proteinuria (3.1 0.74vs. 2.69 1.08mg/dl and
28.5 26 vs. 11.4 22 mg/kg/day, respectively, P < 0.05). Conclusion:
The late addition of azathioprine and the decrease of CsA dosage can be
useful in the treatment of the malfunctioning graft, even without
evidence of CsA toxicity.
Acute hemodynainic effects of Intravenous cyclosporine (CsA) infusion
in dogs. L. Orofino, R. Marcén, J.J. Villafruela, C. Quereda, P. Jorge,
L. LandIn, L. Orte, J. Sabater, andJ. Or:uño, Servicios de Nefrologla,
lnvestigación, and M. Intensiva, Hospital RamOn y Cajal, Madrid,
Spain. The study was carried out in 20 dogs of 20—39 kg body weight,
anesthetized with sodium thiopental. After right and left atrium cathe-
terization a 40 mI/kg load of saline 0.9 and glucose 5% infusion during
90 minutes, heart rate, mean arterial pressure (MAP), cardiac output
(CO), dp/dt max., systemic vascular resistance (SVR) and systolic work
index of both ventricles were registered continuously. The hemody-
namic response to acute administration during 60 minutes of CsA, 5
mg/kg, in a fat emulsion, its commercial equivalent (SAND), or the
vehicle, cremophor (C-EL), was studied. SAND infusion produced
from the 9th minute, a decrease of MAP and SVR, with a maximum
effect at 30 minutes, P < 0.05. Heart rate, dp/dt and CO decreased
sligthly (NS). C-EL had a similar effect on MAP, with a decrease of CO
and dp/dt, P < 0.01, and an increase of SVR, P < 0.05. CsA did not
modify MAP, but an increase of CO and a decrease of SVR was seen.
Maximum hemodynamic changes (%)
CsA C-EL SAND
MAP —1.9 0.8 —32.3 5.1 —26.9 7.9
CO 11.3 12 —54.6 22.5 —8.8 3
SVRI —13 8 +59.7 38.7 —20.5 6.5
dp/dt —8.2 6.7 —30.5 4.8 —13.8 9.3
ConclusIons: (I) In the dog, acute infusion of SAND and C-EL produced
a fall in MAP and changes in CO and SVR. (2) Isolated CsA infusion did
not change MAP, but decreased SVR with an increase of CO.
Ventricular arrhythmias during Insertion of percutaneous double lu-
men catheters for hemodialysis. J. Martin, A. Bernat, E. Garrigós, E.
Parra, I. Villaro, J. Sanchis, and A. Perez, Servicio de Nefrologia,
Hospital General Universitario, Valencia, Spain. Arrhythmias are
frequently observed during cardiac catheterism. Ventricular arrhyth-
mias are triggered by contact of the guidewire with the tricuspid valve
or with the wall of the right ventricle. Insertion of hemodialysis (HD)
percutaneous catheters into the superior vena cava through the subcla-
vian or the internal jugular vein has also been associated with the risk
of cardiac arrhythmias. We present the case of a 54 year-old woman
with end-stage renal disease, who died as a consequence of ventricular
fibrillation during replacement of a HD catheter placed in the internaljugular vein. After this experience, we have inserted all new HD
catheters and made all replacements under electrocardiographic moni-
toring. The results in 24 consecutive episodes areas follows: in 12 cases
(50%) we observed arrhythmias, always of ventricular origin, and
triggered simultaneously with guidewire insertion. Six patients pre-
sented isolated ventricular premature complexes, but the other 6 had
bursts of ventricular tachycardia, which ceased after wire withdrawal.
We have not observed any difference or severity of arrhythmias,
whether the catheter was introduced through the subclavian or the
internal jugular vein. Our conclusions are: (I) Ventricular arrhythmias
occur frequently during insertion or replacement of HD catheters into
the superior cava vein. (2) These arrhythmias are observed during
guidewire insertion and decline with its withdrawl. Insertion of more
than 15 cm of the wire's length must be avoided. (3) Insertion and
replacement of HD catheters into superior cava vein must be performed
under electrocardiographic monitoring and with cardiopulmonary re-
suscitation devices available.
Ambulatory blood pressure monitoring (ABPM) In the evaluation of
treatment efficacy of moderate and severe arterial hypertensIon. L.
Garcés, I. Villaro, J.M. Escobedo, M. Giménez, E. GarrigOs, E. Parra,
A. Bernat, and A. Perez, Servicio de Nefrologia, Hospital General
Universitario, Valencia, Spain. Out of 150 consecutive patients exam-
ined by ABPM, we selected a group of 30(19 male, II female, mean age
50 8.5 years) with moderate or severe hypertension (dyastolic BP>
115 mm Hg). Nine patients were receiving treatment with the associa-
tion of three or more drugs (third or fourth step of WHO treatment
protocol), and had a WHO stage 2 target organ damage, four of them
with chronic renal failure. The following mean systolic and diastolic
figures were obtained from ABPM, day and night, all patients receiving
antihypertensive therapy:
Mean day Mean night
Systolic BP 142 21 134 26
Diastolic BP 98 13 98 13
On comparing mean day figures with blood pressure readings from
before current treatment, we observed a significant improvement in the
control of the systolic as well as of the diastolic BP(P <0.001). In spite
of treatment, the difference between mean night readings and the mean
early morning rise readings did not diminish with respect to BP as well
as heart rate figures.
Anaphylactold reactions (AR) associated with AN69: Hypersensitivity
enhanced by ACE Inhibitors versus pyrogen reaction due to backfittra.
don. J. Martin, A. Bernat, E. GarrigOs, E. Parra, J.M. Escobedo, R.
Moll, and A. Perez, Servicio de Nefrologia, Hospital General, Valen-
cia, Spain. AR during hemodialysis (HD) with AN69 membranes in
patients simultaneously treated with ACE! have been reported. Some
authors consider them due to pyrogen leak into the bloodstream from a
non-sterile dialysis solution. Others consider that they are induced by
the composition of the membrane itself, not depending on its high
permeability, and enhanced by ACEI. In our HD unit, 17 patients were
using AN69 dialyzers and 6 of them were treated simultaneously with
ACE!. Thirteen patients were on acetate or bicarbonate HD and the
other 4 on acetate-free biofiltration. Before HD, the dialyzers were
washed with 2 liters of sterile saline solution. Dialysis bath was
connected several minutes after blood had been circulating through the
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extracorporeal circuit and minimal safe ultrafiltration rate was main-
tained throughout the entire HD session in order to avoid backfiltration.
There was no bacterial contamination of the dialysis solution. In 3 of
our patients dialyzed with AN69, who were also receiving ACE!, AR
were observed. These AR took place in the first minutes of the HD
sessions. All 3 patients were on bicarbonate HD. These patients did not
present further AR after replacing AN69 membranes for cellulose
acetate and after stopping ACE!, AR occurred neither in patients
undergoing dialysis with another membrane, nor in those on AN69
without ACE! treatment. These results favor a blood-membrane inter-
action and suggest that it is preferable to avoid ACE! in patients treated
with AN69 membrane.
The Influence of erythropoletin (EPO) treatment on arterial pressure
control during hemodlalysis. L. Garcés, E. Garrigós, J. Sanchis, A.
Bernat, M. Giménez, R. Mo!!, C. Kortebi, E. Parra, and A. Perez,
Servicio de Nefro!ogia, Hospita! Genera! Universitario, Va!encia,
Spain. The aim of this study was to evaluate the influence of EPO
treatment on blood pressure control in a group of 19 patients on
hemodialysis (HD) for 42.8 28 months (mean age 56 14, range 29—75
years). EPO dosage varied from 14 to 100 U/kg body wtJweek (mean 41
24), and duration of treatment was 11.8 9 months. Blood pressure
was measured in five first-of-the-week HD sessions, before and after
hematocrit reached a steady value after EPO treatment. Statistical
analysis included Student's t-test for coupled data and analysis of
variance.
Pre-EPO
SBP DBP
Pre-HD
Mid-session
Post-HD
147±16
143 26
145 26
84±8
79 13
80 11
Weight gain 1.6 0.8
Post-EPO
SBP DBP
Pre-HD
Mid-session
Post-HD
145 16
135 16
134 17
83 8
76 6
76 8
Weight gain 2.0 0.9
After EPO treatment, hematocrit rose from values of2l 3% to 28.9
4% (P < 0.001). We found no significant differences pre-HD arterial
systolic and diastolic pressure, nor in interdialysis weight gain nor in
blood pressure values in the middle and at the end of the HD session.
Blood pressure control required the introduction of antihypertensive
therapy or intensification of previous treatment in 7 patients (36%). In
2 patients, however, treatment had to be withdrawn (10.5%). We
conclude that blood pressure control during HD sessions can be
achieved with individualized EPO dosage, in order to achieve a gradual
increase in hematocrit value. However, some adjustment in antihyper-
tensive therapy may be needed.
Expression of y&TCR In patients with cadaver kidney grafts treated
with OKT3. J. Martin, A. Gascón, A. O,fao, J. San Miguel, and J.
Tabernero, Services of Nephro!ogy and Haemaw!ogy, University Hos-
pita!, Salamanea, and Insalud Hospital, A vi Ia, Spain. The effect of
immunosuppressor treatment with OKT3 monoclonal antibodies and
cyclosporine on the expression of the l5 fraction of T lymphocytes in
patients with kidney grafts was studied. In a group of 12 patients
receiving a cadaver kidney transplant the a/ and subpopulations of
T cells were analyzed by direct immunofluorescence in flow cytometry.
The iinmunosuppressor treatment of the transplanted patients was:
OKT3 (day 0 to day 5), cyclosponne (as from day 3) and corticosteroids
as from the start. The subpopulations were determined from samples of
peripheral blood with EDTA on days: pre-TX, 3, 5, 15 and 45 after TX.
On the third day of treatment OKT3 was observed to induce a
significant decrease in I lymphocytes both in percentages and in
absolute numbers; only a small proportion of them expressed the
aJI3-TCR fraction (68 10% vs. 0.7 0.7%) and 1080 276 x 109/liter
vs. 3 3x 109/liter (P < 0.001) or the &TCR (2..2 3.5% vs. 0.4
0.5 (P <0.001) and 41 .66x 109/liter vs. 2 3x 109/liter (P <0.001). On
the 5th day, a slight increase in both subpopulations was seen: aJ/3 (15
21% and 106 204x 109/liter and (ö(0.5 0.óand5 7x 109/liter).
After discontinuing treatment with OKT3, the expression of both
markers increased progressively from the 5th to the 15th day (a/a: 62
17% and 1220 571x 109/liter; &: 1.2 1.7% and 27 37x 109/liter)
and on day 45 (a/13: 65 10% and 1775 1250 x 109/liter; b: 3.4
3.1% and 102 129 x 109/liter). Modulation of both T cell receptors
was also observed in vitro after incubation with anti-CD3 monoclonal
antibodies. The expression of both receptors began to decrease after 30
minutes, completely disappearing after one hour. These data show that
OKT3 monoclonal antibodies do not only exert their modulating effect
on the lymphocyte subpopulations expressing the aJf3 TCR receptor but
also on the )f& subpopulation; until now that has not been described.
The meaning of these findings remains uncertain; however, important
immunological implications are being reported with respect to the 'S
subpopulation.
Effect of renal transplant on the formation of anti-OKT3 antibodies in
carrier patients receiving prophylactic OKT3. J. Martin, A. GascOn, A.
Orfao, L. Corbacho, J. San Miguel, B. De Leon, and I. Tabernero,
Services of Nephrology and Haematology, University Hospital Sa!a-
manca, and !nsa!ud Hospital, Avila, Spain. The levels of anti-OKT3
IgG antibodies were determined in 12 patients with ages ranging
between 24 and 68 years who received a cadaver kidney graft and
received immunosuppressor therapy with OKT3 during the first five
days together with corticosteroids and cyclosporin A as from the 3rd
day. The decrease in the number of peripheral blood lymphocytes from
the 5th day onwards was significant, both in absolute numbers and in
terms of percentage (754 484 vs. 1571 776,P <0.01, and 10.4 6.2
vs. 28.3 8.4, P <0.01). Antibody determination was performed using
an ELISA technique in sera obtained at 5, 15, 45 and 100 days after
grafting. The existence of antibodies at titers above 1:100 ng/ml was
detected in three patients (25%) after the 15th day. Only in one of these
patients was the titer higher than 1:1000, this remaining above 1:300 at
100 days post-grafting. In the other two patients the titers became
negative and were less than 1:150 at 45 days. After analyzing different
T lymphocyte subpopulations and activation markers, the expression of
CD3 on dayS was seen to be higher in the two patients with higher titers
(1:900 and >1:1000) than in the rest of the patients (62% and 45% vs.
28.7 17.7%). This difference was more pronounced on analyzing the
expression of TCR-a13 (36% and 46% vs. 0.4 0.4%). From the 15th
day onwards, there were no significant differences in the expression of
different activation markers or in the different subpopulations, with the
exception of the Tgd cell subpopulation, which was higher in these two
patients as from the 45th day post-grafting (4.4 and 9.9% vs. 2.7
2.4%). One of these patients acutely rejected the graft; this was
reversed by bolus steroids on day 24 post-transplantation. In the other
patients there was no evidence of rejection at 30 days post-grafting. It
is concluded that the incidence of the formation of OKT3 anti-idiotype
antibodies is low when corticosteroids and cyclosporin A are associated
with treatment. When they are present at high titers, their immunosup-
pressor effect is lower, which may favor the appearance of acute
rejection. This type of situation is to be suspected when an early
increase in the expression of CD3+ITCR+ occurs in T cells.
Lymphocyte subpopulations and expression of activation antigens In
patients with TCRI on hemodlalysis. A. GascOn, I. Martin, A. Orfao, J.
San Miguel, and I. Tabernero, Services of Nephrology and Haemato!-
ogy, University Hospital, Salamanca, and Insalud Hospital, Avila,
Spain. The aim of the present work was to analyze the lymphocyte
subpopulations and the expression of activation antigens in samples of
peripheral blood from patients with TCRI on HD. Twelve patients with
an age range of 24—68 years awaiting kidney grafts were included in the
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study. Different populations of 1, B and NK lymphocytes were
analyzed, together with different markers of activation using double
labeling with direct immunofluorescence and flow cytometry, employ-
ing a panel of monoclonal antibodies against the antigens CD3, CD56,
CD25, CD8, CD38, CD11b, CD4, CD45RO, HLA-DR, TCR-a/g and
TCR-g/d. As controls, 10 healthy sex- and age-matched individuals
were studied. The patients with TCRI on HD showed a decrease in
CD3+ cells with respect to the controls as regards both percentages and
absolute numbers (72.2 8.8 vs. 78.1 2.5, P <0.08) and (1168 288
vs. 1915 379, P < 0.003). This decrease was due to the presence of a
low number of T CD3+ffCR-a/+ cells, both as a percentage (63.1
8.4 vs. 67.5 10.3, P < 0.07) and absolute numbers (1075 276 vs.
1545 366, P < 0.02). Also, a slight increase in T TCR-g/d cells was
observed (41.6 59.7 vs. 19 17.6, NS). An increase in CD16+/HLA-
DR+ cells was detected in these patients, as both a percentage (2.5
1.8 vs. 0.6 0.7, P < 0.01) and absolute value (41.5 33.1 vs. 16.2
18.6, P < 0.05). No significant differences were found in the main T cell
subpopulations CD4+, CD8+ nor in the expression ofCD4/CD45RO+,
CD8/CD38+, CD8/CDllb, nor in CD56+ NK cells nor in T cells
expressing CD3/CD25+. These findings disclose an alteration in the
cellular immunity of patients on HD, apparent in a decrease in Ta//3+
lymphocytes and an increase in the number of CD16+ activated NK
cells.
Pruritus in hemodlalysis. B. LeOn, E. Fernández, A. Bondla, and M.
Yuste, Services of Nephrology and Dermatology, University Hospital,
Salamanca, Spain. To check the incidence of pruritis, its characteris-
tics, its relationship with exploratory and skin histologic data and its
correlation with several qualitative and quantitative analytic and ther-
apeutic variables, we studied 43 patients on periodic haemodialysis(HD), with a history of dialysis of 62.1 57 months. Twenty-four
patients (55.8%) referred to having (70.8%) or having had (29.1%)
pruritis, which became manifest before the 1st HD in 20.8% and after it
in 79.1%. The rhythm was paroxysmal in 79.15% and continuous in
20.8%; it was exacerbated by the HD session in 75%, with stress in
83.3% and with heat in 54.1%. Intensity was moderate (37.5% to intense
41.6%). There was no appreciable seasonal relationship and body
distribution was both global (41.6%) and local (58.3%). The following
were outstanding in the dermatological exploration: hyperpigmentation
in 41.8%, dryness in 65.1%, alteration in sweating in 46.5%, nail
alterations in 88.3% (disappearance of the crescents in 62.7), and a pale
yellowish pigmentation in 5 1.6%. Skin biopsy was performed in all the
patients; the most striking findings were as follows: (I) epidermal
alterations consisting of hyperkeratosis in 69.7%; basal hyperpigmen-
tation in 72% and atrophy in 55.8%. (2) atrophied sweat glands in
30.2%. (3) increased mast-cell numbers in 34%. None of the exploratory
or histological data had any statistically significant relationship with the
presence of pruritis. Regarding the analytic variables, residual clear-
ance, urea and creatinine pre-HD, K,V, P'FH, calcemia, phosphatemia,
calcium-phosphate, transaminases, serum lipids, ferritin, sideremia,
saturation index, serum aluminium, magnesium and zinc levels) and
type of treatment, both dialytic (type of membrane, dialysis buffer
liquid) and pharmacologic (erythropoietin, vit. D, calcium carbonate,
aluminium hydroxide), those appearing in the table have significant
correlations (Student's 1-test for independent data).
Pruritis yes
N=24
Mean SD
Pruritis no
N=19
Mean SD P
Creatinine mgldl 12.1 3 10.3 2. < 0.05
iPTH pg/ml 130.2 148 346.9 492 <0.05
Calcium Carbonate 3.4 1 2.4 0 <0.05
Doses glday
ALP lU/liter 41.6 41 20.4 15 <0.05
Iron, serum pgIdl 98.7 29 76.6 20 <0.05
Saturation I. % 41.9 15 29.7 12 <0.05
From these data, the following can be deduced: (1) The patients
showing pruritis in HD do not have dermal alterations different from
those normally found in uremia; (2) The presence of pruntis is related to
factors already reported by other authors, such as dialysis efficacy,
PTH, and the doses of calcium salts; (3) There was a significant
differences in iron levels, the saturation index and ALP between both
groups that has not been reported before; this could be related to
hepatopathy due to depositions of iron.
Study of hypophosphatemla following kidney transplantation. B. LeOn,
J.L. Lerma, J. Deira, L. Corbacho, A. Bondla, and J.M. Tabernero,
Service of Nephrology, University Hospital, Salamanca, Spain.
Different factors participating in the genesis of hypophosphatemia
following kidney transplantation are evaluated, offering our own expe-
rience on a topic where the mechanisms of production have not been
fully elucidated. Twenty-seven patients (mean age 37 24 years) were
studied at two months after receiving a cadaver kidney transplant. The
patients were divided into two groups. Group A: 15 patients with
hypophosphatemia (serum phosphate >3 mg/dl), and Group B: 12
patients with normal phosphate levels. Nine patients from Group A
were reappraised at 9 months after the first study, forming Group C. In
all patients the parameters shown in the table were studied. The data
obtained were studied statistically using the Mann-Whitney "U" test.
Group A(N = 15)
Mean SD
Group B(N = 12)
Mean SD
Group C(N = 9)
Mean SD
Phosphorus S. 2.41 0.30 3.3 0.1k 2.6 0.4
mg/dl
Calcium serum 9.1 0.3 9.2 0.3 9.6 0.4a
mg/dl
Creatinine serum 1.4 0.5 1.5 0.7 1.2 0.3
ng/dl
RTP % 66.3 20.9 64.9 12.6 68.3 22.5
Magnesium S. 0.78 0.06 0.87 0.0? 0.89 o.o4
mmol/liter
iPTH pg/mI 104.4 53.9 81.5 27.3" 62.4 22.5"
Calcium urine 142.5 93.5 152.9 17.0 184.8 135.3
mg/24 hr
Phosphorus 1000.7 380.6 996.8 320.3 913.4 245.7
U/mg/24 hr
Magnesium 32.9 9.3 36i2 4.7" 35.8 6.6
UImmol/24 hr
Prednisona 22.6 3.4 22.9 3.3 11.9 1.l
mg/24 hr
Uric acid 800.6 259 729.4 255 543.3 l60
U/mg/24 hr
a p < 0.001; b p < 0.05
From the results it may be inferred that hypophosphatemia is basically
due to a decrease in RTP and that this may be affected by PTH although
with no correlation between either parameter since, during their evo-
lution, the patients continued to show a decrease in RTP despite the
significant decrease in PTH. The presence of hyperuricosuna with
normal values of uncemia, the occurrence of glycosuria in certain cases
from Group A, and the fact that two patients from this group had
excretory hypercalciuna would be suggestive of a tubular lesion sec-
ondary to transplantation. Corticoids participate both in the inhibition
of RTP and in the intestinal absorption of phosphate. The reciprocal
effect of hypophosphatemia and serum magnesium which, in Group A,
was at the lowest limit of normality, although with no significant
correlation, should not be ruled out. The negative correlation (r =
—0.5,
P < 0.01) between serum calcium levels and the doses of prednisone
received is striking.
Influence of hemodialysis and age on the production of free radiCals.
J.L. Lerma, B. LeOn, J.M. Tabernero, J. Deira, and J.F. Maclas,
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Nephrology Service, University Hospital, Salamanca, Spain. The role
of free radicals (FR) as a possible pathogenic factor in the progression
of chronic renal impairment (CR!) has been studied in different works.
However, the few publications that have appeared show that superox-
ide dismuthase decreases in CR! and during hemodialysis (HD). It is
therefore assumed that there would be an increase in FR production,
although until now it has not been possible to measure this directly in
human subjects. There is also an increasing number of patients older
than 65 on HD who suffer greater morbidity/mortality. The aim of the
present study was to analyze by chemoluminiscence the repercussion of
HD on free radical production in two populations of patients: group 1:
<65 years, and group 2: >65 years. Samples of peripheral blood were
taken at the beginning (basal), every hour, and at the end of HD from
the arterial and venous channels. The samples were immediately
processed for the determination of the production of FR by chemolu-
miniscence on a Bio-Orbit 1251 Luminometer. Results: (expressed as
percentages of maximum increase in FR with respect to basal produc-
tion):
Group 1 (<65) Group 2 (>65) P
N 14
Mean SD
18
Mean so
EDAD 59.5 3.6 72.7 6.3
RL % 56.5 8.3 69.5 6.2 <0.012
Conclusions: (1) HD stimulated the production of FR at all ages. (2) This
effect is enhanced in patients older than 65. (3) The maximum produc-
tion of FR occurs constantly during the last hour of HD. (4) The
pathogenic role of high levels of FR in HD, especially in elderly
patients, remains to be elucidated, although it could be related, among
other factors, to the greater risk of intradialysis cardiovascular compli-
cations that this group is subject to.
Platelet function in uremia. A study of the expression of adhesive and
activation glycoprotein receptors by flow cytometry. B. LeOn, L.
Vdzquez, A. Orfao, J. Deira, f.M. Tabernero, and V. Vicente, Service
of Nephrology, Service of Haema:ology, University Hospital, Sala-
manca; and General University Hospital, Murcia, Spain. One of the
greatest complications arising in uremic patients undergoing different
invasive processes or surgery is hemorrhage. Although several mech-
anisms have been proposed to account for platelet dysfunction, which
of them is predominant remains to be elucidated. In the present work,
8 subjects with a mean age of 52 years (range 32—67) suffering from
chronic renal impairment and on hemodialysis for 4.5 hours thrice
weekly were studied. A capillary 1.3 dialyzer with an acetate bath was
used. Each patient was studied at three different times: (a) before
starting dialysis a sample was taken from the afferent branch; (b) from
the efferent branch (a single turn of the circuit) and; (c) two hours alter
starting dialysis. At the time of study half of the subjects referred to
having suffered some hemorrhagic phenomenon. Using flow cytometry
(Facs Scan, Becton-Dickinson) the expression of the glycoprotein
complexes lbfIX, JIb/lila and IlIb and platelet activation were quanti-
fied. The monoclonal antibodies employed were U-tb, U-Plo, CD36,
CD62, CD63 and CD9. For receptor quantification calibration beads of
8.5 m diameter were used (Microbeads Simply CellularTM Flow
Cytometry Corporation, USA) that have known quantities of receptors
for mouse Igs. The results obtained show that prior to HD the uremic
subjects show a decrease, although not significant, in glycoproteins lb.
lIb/Illa and Ilib with respect to the control group. Initiation of HD did
not alter the number of adhesive receptors of the platelet membrane.
However, there were clear signs of platelet activation in terms of an
increase in the expression of GMP 140 and p53. By contrast, no
significant modifications in the numbers of CD9 antigen receptors were
observed. Two hours alter starting dialysis, the parameters of cell
activation persisted and were in fact more intense. It can therefore be
concluded that the process of HD involves a stimulation for platelet
activation but does not modify the expression of adhesive glycopro-
teins. However, the state of uremia itself involves a decrease in the
number of receptors for glycoprotein lb which becomes more signifi-
cant in the patients who had suffered from hemorrhagic phenomena.
Study of the relationship between plasma zinc levels and anemia in
patients with CR1 on hemodialysls. B. LeOn, C. Gonzalez, C.M. Gonzd-
lez, J.L. Lerma, J. Deira, and f.M. Tabernero, Nephrology Service,
University Hospital, Salamanca, and Biochemistry Service, Virgen de
Ia Vega Hospital, Salamanca, Spain. Owing to the paucity of refer-
ences in the literature, a study was made of the relationship between
plasma zinc concentrations and the degree of anemia in patients with
CR1 on hemodialysis. The patients were divided into two groups. Group
A: 35 patients who did not receive erythropoietin; Group B: 24 patients
receiving erythropoietin. Both groups were again divided into sub-
groups, according to their plasma zinc levels: greater and lower than 9.9
molJliter (mean value of laboratory controls). Hb Wdl), VH (%),
serum ferritin (ng/dl) and dose of EPO Hru (U/week), were evaluated in
all cases. Plasma zinc levels were analyzed by atomic absorption
spectrophotometry with an air-acetylene flame. The recovery results
ranged between 97% and 101%. The statistical study was performed
with Student's t-test and the Mann-Whitney "U" test for independent
data. The results obtained are shown in the table.
Group A
>9.9 pmol/liter <9.9 pinol/liter P
n 15 20
VH. % 29.2 3.2 27.6 3.0 NS
Hb g/dl 9.4 1.0 9 1.0 NS
Ferritin S ng/ml 249.4 226.4 198.5 179.9 NS
Zinc pinol/liter 11.0 0.7 8.6 1.0 <0.001
EPO doses U/week
Group B
>9.9 pinol/liter <9.9 pinol/liter P
n 13 11
VH. % 29.2 4.4 29.5 3.5 NS
Hb gIdi 9.7 1.4 9.9 1.2 NS
Ferritin S ng/ml 369.4 459.0 375.6 681.8 NS
Zinc pnol/liter 11.0 0.9 8.8 0.7 <0.001
EPO doses U/week 4807 3766 5772 3770 NS
Although the differences in the plasma zinc levels in both subgroups of
both groups were significantly different, no difference was found among
the hematologic parameters studied. No correlation was found between
the plasma zinc levels and Hb (r = 0.024) or VH (r = 0.011). Neither
were there any differences in the doses of EPO between the two
subgroups receiving it. There was no correlation between EPO and
plasma zinc (r = 0.020). Our data are not consistent with the theory that
a deficit in plasma zinc would favor a worsening of anemia in these
patients nor that patients with low plasma zinc levels require higher
doses of EPO Hru.
Why do females dIalyze easier then males? F. Maduell, A. Caridad, F.
Sigüenza, F. Miralles, and E. Ochoa, Services of Nefrologla and
Bioqulmica, Hospital de Xdtiva, Xdriva, Spain. The urea kinetic model
is used to monitor the dialysis and dietary protein prescriptions. From
the usual practice we have observed that it is easier to reduce the
dialysis time in women as compared with men. The purpose of this
study was to find out the reasons for such observation and to corrob-
orate it. Forty patients, 24 males and 16 females, on thrice weekly
dialysis (3 hours/session) were studied. In all patients hemodialysis was
performed with the following characteristics: blood flow 350 mI/mm,
ultrafiltration 1.5 llhr, time 3 hours, bicarbonate buffer and 1.5 square
meter cuprophane membrane. The dialysate was collected in a gradu-
ated 120 liter tank. Urea concentration in blood and in dialysate was
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determined. Ky, dialyzer clearance (K), urea distribution volume (V)
and protein catabolic rate (PCR) were calculated.
Males
(N = 24)
Females
(N = 16) EST SIG
Ky 0.83 0.14 1.00 0.11 P <0.00!
Weight kg 65.5 11.6 61.1 8.23 NS
V liter 38.8 7.22 30.9 3.08 P < 0.001
V %weight 60.0 6.62 51.0 5.97 P < 0.001
K mI/mm 174.3 5.86 170.7 14.2 NS
PCR g/kg 1.03 0.17 1,035 0.13 NS
We can conclude that, under identical dialysis characteristics, it is
easier to dialyze females than males. The difference between V values
in both sexes seems to be the reason for this, since we have not found
differences in body weight, dialyzer clearance or protein catabolic rate
values.
Bone mass valuation by ultrasonic bone densitometry (UBD) and Its
relationship with hyperparathyroidlsm (HPT) degree. F. Siguenza, A.
Caridad, F. Maduell, and P. Muñoz, Services of Nefrologla and
Reumatologia, H. "Lluis Alcanys" Xdtiva, Spain. UBD quantifies
bone mass (BM) density by measuring the loss level of ultrasonic vawes
through the bone. End-stage renal patients (ESRP) tend toward a
multifactorial loss of BM. Objective: BM valuation of ESRP and its
relationship with HPT degree. Material and methods: 23 ESRP in
hemodialysis program (HDP), 12 males and 11 females, with a mean age
of 55.5 15.3 years old, undergoing HDP for 58.9 51.4 months. We
measured calcium (Ca), phosphate (Ph), alkaline phosphatase (AP),
intact-PTH (i-PTH), and UBD (UBA 575) was performed in left
calcaneous. Results: UBD was globally diminished (50.2 13.2).
Patients were divided into two groups depending on i-PTH level: Grave
(>200 pg/mI) and Light (<200 pg/mI).
Light Grave P
i-PTH 111 85 533 375 <0.01
UBD 58 13.3 44.4 10.5 <0.01
UBD correlates with i-P1'H. (r =
—0.5) and with AP (r = —0.46), but
not with age, sex or months in HDP. Conclusions: (I) There is globally
a tendency to BM loss. (2) The higher i-PTH and AP, the lower BM. (3)
There is no correlation with Ca, Ph, months in HDP, age or sex.
Effect on renal fUnction of subcutaneous rHuEPO administered once-
a-week. A. Caridad, F. Maduell, and F. Siguenza, H. "Lluis Alcanys,"
Xdtiva, Spain. rHuEPO administration in ESRD patients before dialy-
sis has been related to deterioration of renal function. Methods: We
have studied 22 patients, 12 males and 10 females, affected with ESRD
before dialysis. They received 4.000 I.U. of rHuEPO subcutaneously
once-a-week during six months. All of them presented Htc <27% (M:23
2.1). We tried to get Htc: 30—35%. Urea (U), creatinine (Cr) and the
inverse of creatinine percent (I/Cr) as well as other biological and
hematometric parameters were evaluated. Results: 4.000 I.U. repre-
sents for a medium weight of 56.9 9.0 kg a medium dose of 71.8
11.5 lU/kg/week. Initial values were: U:163 28, Cr:5.0 1.3, and
l/Cr:21.4 6.3. Three months later they had reached Htc:3l.6 5.7,
which was maintained stable until the sixth month. There were no
significant variations in Cr and I/Cr at three and six months. Urea
showed a significant (P < 0.01) increase which we considered was due
to a better food intake, as there was no significant deterioration of renal
function,
Htc
Pre-HD
23.2±2.1
3 months 6 months Significance
31.6±5.7 31.6±2.1 P<0.0l
Urea 163 28 160 41 198 41 P < 0.01
Cr 5.0 1.3 4.9 1.6 6.0 2.3 NS
I/Cr 21.4 6.3 22.4 7.7 19.8 8.3 NS
Discussion: Self-administered once-a-week subcutaneous rHuEPO is an
efficient, comfortable, and cheap treatment of ESRD predialysis pa-
tients with anemia, which does not deteriorate renal function.
Hepatitis C virus (HCV) antibodies in hemodlalysls patients. I. Ferre-
ras, J. Nieto, F. Mora, and G. Caparros, Alarcos Hospital, Ciudad
Real, Spain. In order to know the evolution of the specific antibodies
against HCV, we studied 148 hemodialyzed patients by 2nd generation
assays, EIA (Abbott), every 3 months and confirmatory 4-RIBA test
(Ortho) in reactive sera simples. Also SGPT values were recorded. The
follow-up period was a year. Seventy-five patients were reactive against
HCV (51%); 71 of them were confirmed by 4-RIBA, resulting as the
following reactivity: c22.3 93%, c33c 97%, cIOO.3 56%, and 5-I-I 66%.
In this patient group there was not any variability in the ELA response
in the follow-up period. In 3 patients we found more reactivity against
clOO.3 and 3 patients had late seroconversion (>9 months) against the
same protein. Seventy-seven patients were not reactive; 8 (10%)
became reactive during the study. The reactivity was earlier (< 3
months) against 2nd generation epitopes, c22.3 (N = 6) and c33c (N =
7). And only in 3 patients we found later reactivity (>6 months) against
1st generation epitopes clOO.3 (N = 3), and 5-I-I (N = 2). In 4 patients
raised SGPT values were observed before reactivity (23—72 months), 3
patients had normal SGPT values and in I patient, the raised SGPT
value was observed after reactivity sample. Conclusions: The 2nd
generation assays against VCH are faster and more sensitive than 1st
generation tests. Antibodies against HCV do not disappear rapidly in
hemodialysis patients. In our patients there are no correlations between
the HCV seroconversion and the first SGP'I' rise in value.
Hepatitis C virus (HCV) In hemodialysis (HI)) patients: Correlation
between clinical, biochemical and histological findings. J. Nieto, I.
Ferreras, F. Mora, G. CaparrOs, E. Rodriguez, R. GarralOn, F. de Ia
Rubia, and A. Calero, Alarcos Hospital, Ciudad Real, Spain. It has
been reported that HCV is a relatively benign hepatic disease in
hemodialyzed patients. Our purpose was to correlate the histological
findings with clinical and biochemical data in 12 HD patients who had
antibodies to HCV by a 2nd generation assay (4-RIBA). The liver
specimen was obtained by consent biopsy (N = II) and autopsy (N =
I). We found the following pathological patterns: (I) Cirrhosis (N = 2);
(2) Chronic active hepatitis (N = 1); (3) Chronic active hepatitis with
portal-central bridges (N = 2); (4) Chronic persistent hepatitis (N = 7).
Associated hemosiderosis was found in 8 specimens; II patients had
been transfused and only one of them had antiHBs and antiHBc
antibodies. We did not find correlations between histological patterns
and enhanced SGPT values (sustained or in peaks), nor reactivity
against the HCV peptides using 4-RIBA assay. Patients with chronic
active hepatitis had longer enhanced SGPT values (>4 years) versus
those who had chronic persistent hepatitis (<4 years). Conclusions:
There is no correlation between clinical and histopathological patterns
in our patients, but it seems that long-term biochemical disturbances
would be an expression of more hepatic damage. The shorter survival of
hemodialyzed patients would be the reason for underestimating further
severe hepatic damage.
High-dose methylprednlsolone inhibits the OKT3-lnduced first-dose
reaction. R. Peces, J.M. (Jrra, M. De La Torre, A. Sanchez-Fructuoso,
and C. López-Larrea, Services of Nephrology and Immunology, Hos-
pital Alarcos, Ciudad Real, Hospital Covadonga, Oviedo, Spain.
OKT3 antibody is the most effective immunosuppressive agent for
prophylaxis and treatment of acute rejection of solid organ grafts.
However, the first dose of OKT3 is associated with a systemic reaction.
This reaction likely results from a transient release of some cytokines,
including TNF-a. As a therapeutic procedure to decrease the severity
of the symptoms characteristic of OKT3-induced reaction, a protocol
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consisting of a single dose of methylprednisolone (MP) administered I
hour before the first OKT3 injection was introduced. Five renal
transplant recipients received 5 mg OKT3 preceded by 500 mg i.v. MP
as part of the immunosuppressive therapy. OKT3 was initiated within
1—14 post-transplantation days because of delayed graft function, and
side effects were monitored and quantitated. TNF-a was measured in
supernatants of peripheral blood mononuclear cells by using the WEHI
164 cell line assay. Blood was drawn before initiation of MP, 1 hour
after MP, immediately before OKT3, and 90 minutes after OKT3. The
results showed that the spontaneous production of TNF-a was inhibited
1 hour after MP, and OKT3 did not increase it. The fact that no patients
experienced a significant systemic reaction to OKT3 and the absence of
detectable TNF-a implicate this cytokine as a primary etiological agent
of the first-dose reaction. Thus, the use of high-dose of MP I hour
before the first OKT3 injection may provide a means for improving
anti-CD3 monoclonal antibody therapy.
TNF-a production and HLA-antigens. f.M. Urra, R. Peces, A.
Sdnchez-Fructuoso, M. De La Torre, and C. LOpez-Larrea, Services of
Nephrology and Immunology, HospitalAlarcos, Ciudad Real, Hospital
Covadonga, Oviedo, Spain. TN F-a is a cytokine implicated as mediator
in several immunological disorders and in acute rejection of renal
allograft. The gene encoding TNF-a is located in the HLA region
between the HLA-DR and HLA-B loci. Recent studies have shown an
association between certain HLA antigens and the capability to pro-
duce TNF-a. This HLA association may be due to the HLA molecules
themselves, or to linkage disequilibrium between HLA genes and
closely located genes, or it may be due to both. Because the TNF-a
genes are located closer to class I genes than to class II genes we
investigated the production of TNF-a by PMA-stimulated peripheral
mononuclear cells (PBMC) from class I HLA-typed healthy subjects.
TNF-a levels were determined after 24 hours in supernatants of PBMC
by using a specific ELISA. We studied 31 members of II different
families and we observed that the mean value of TNF-a showed
significant interfamilial differences. In addition, we studied 26 unrelated
healthy subjects and we found a group of 6 high producers of TN F-a
(5700 970 vs. 672 131 pg/mI, P < 0.01) in repeated tests. This group
showed a higher frequency of the antigen B18 (3/6) associated with the
antigen A30 (2/3). These results suggest that there is a genetic HLA-
associated influence in the secretion of TNF-a. High levels of TNF-a
could merely reflect a higher frequency of certain HLA haplotype
determining the intensity of the immune response in autoimmune
disorders and in acute rejection.
Association between HLA antigens and TNF-a production in renal
transplantation. f.M. Urra, R. Peces, A. Sdnchez-Fructuoso, M. De La
Torre, and C. LOpez-Larrea, Services of Nephrology and Immunology,
Hospital Alarcos, Ciudad Real, Hospital Covadonga, Oviedo, Spain.
TNF-a is a cytokine implicated as mediator in acute rejection of renal
allograft. The gene encoding TNF-a is located within the major histo-
compatibility complex between the HLA-DR and HLA-B loci. Recent
studies have shown that HLA DR2-positive healthy subjects secrete
low levels of TNF-a, whereas HLA-DR4-positive subjects secrete high
levels. The possibility that the HLA molecules could determine the
quantitative variation in the production of TNF-a and the intensity of
the immune response to the foreign antigen is an attractive hypothesis.
We investigated the role of class II HLA molecules in the secretion of
TN F-a, spontaneous and induced by OKT3, by peripheral blood
mononuclear cells (PBMC) from 27 renal transplant recipients during
stable transplant function. TNF-a was determined using the WEHI 164
cell line. We observed that HLA-DR2 positive subjects showed lower
TNF-aproduction, spontaneous(l2l 51 vs. 365 70pg/mI; P <0.01)
and after stimulation with OKT3 (275 34 vs. 722 107 pg/mI; P <
0.001), than HLA-DR2 negative individuals. On the contrary, HLA-
DR4 positive subjects showed higher spontaneous TN F-a secretion
than HLA-DR4 negative patients (767 130 vs. 244 51 pg/mI; P <
0.01). These results suggest that TNF-a production is associated with
class 11 HLA molecules. This quantitative variation in TNF-a induc-
ibility liLA-related may be relevant in host responsiveness against the
graft.
Blanco, M. De La Torre, R. Peces, and A. Barrientos, Service of
Nephrology, Hospital Cilnico S. Carlos, Madrid, and Service of
Nephrology, Hospital A!arcos, Ciudad Real, Oviedo, Spain. The
incidence of ARF in the elderly secondary to glomerular disease is
unknown, maybe due to the symptomatology that is attributed to
pre-existing and/or associated disease. So, quite a number of RPG could
be attributed to other causes. We reviewed renal biopsies performed in
our hospital in a 20 year period: 20 out of the 60 elderly patients
biopsied had RPG (mean age 70.4 7.4), 15 men and 5 women. In 11
cases, RPG was secondary (8 vasculitis, 2 lupus nephropathy, I
endocarditis) and was idiopathic in 9. On admission 14 patients (70%)
had hypertension, 13 (64%) showed edema, and 12 (60%) had dyspnea;
64% of the patients showed oliguria requiring dialysis, and 20% of the
patients had gross haematuria and in 25% red blood casts were
observed. Initial diagnostic errors occurred in 7 patients and its etiology
was attributed to other disease (i.e. pneumonia, chronic renal failure,
dehydratation). Time elapsed until the biopsy was performed was 34
29 days. Clinical follow-up was possible in 18 patients: 7 progressed to
ESRD in less than 6 months, 6 recovered renal function, and 5 died
during the first month. We conclude: (I) The low incidence of RPG in
the elderly could be misleading; this could be related to the low index of
suspicion. (2) RPG in the elderly had the same clinical presentation as
in younger patients. (3) There is a high frequency of secondary RPG in
the elderly. (4) RPG in the elderly had a worst clinical outcome than in
younger age groups. (5) Renal biopsy should be performed in every
elderly patient with ARF of unknown etiology.
Experimental lead nephropathy. A. Sdnchez-Fructuoso, I. Blanco,
M. Arroyo, J.L. Santos, A. Cruceyra, F. Tornero, R. Peces, and A.
Barrientos, Service of Nephrology, Hospital ClInico S. Carlos, Madrid,
and Service of Nephrology, Hospital Alarcos, Ciudad Real, Spain. The
chronic intoxication caused by lead (Pb) is characteristic among adults
who suffer from a progressive interstitial nephropathy where essential
signs are hypertension and/or gout. Some authors differ whether the
renal insufficiency is only due to the lead's toxic effect or if pre-existing
renal failure may be an important risk factor in developing nephropathy
due to Pb exposure. To clear up this aspect, an experimental study was
carried out among 112 male Wistar 6 month-old rats. They were divided
into 2 groups: GE (N = 56) chronically intoxicated by Pb acetate (500
ppm) into the drinking water for three months, and Gil (N = 56) as
control group. Blood, urine, and renal tissue samples were attained at
different times (30, 60, 90, 107, 121 and 135 days of study) for Pb
measuring and pathologic study. The most outstanding results in this
study were:
Group I Group II P
Kidney Pb concentration g/g
ALA-dehydratase
nmol/ml/min
Creatinine plasma mg/dl
Proteinuria mg/day
Uricosuria mg/day
The list's three latest parameters were not altered until 4 months of
study. The blood lead decreased progressively from 52.2 3.7 (at 30
days) to 22.8 3.36 g/dl (at 135 days). The pathologic studies proved
important tubular alterations, mainly in the proximal convoluted tu-
bules with partially lost of brush borders, intranuclear inclusion bodies,
and alterations in nuclci and nucleoli. We conclude that: (I) In the rat,
Pb per se causes a nephropathy, which is slowly progressive, and
characterized by slight proteinuria and decrease in urinary excretion of
uric acid. (2) One of the parameters more perceptible in the lead
nephropathy is the ALA-dehydratase activity's decrease. (3) The blood
lead is an untrustworthy parameter to evaluate this illness due to its
being diminished while the intoxication progresses.
Acute renal failure (ARF) In the elderly secondary to rapidly progres- Treatment of experimental lead nephropathy. A. Sdnchez-Fruciuoso,
sive glomerulonephrltls (RPG). A. Sdnchez-Fructuoso, M. MacIa, J. M. Arroyo, f. Blanco, fL. Santos, A. Cruceyra, F. Tornero, R. Peces,
16.4 2.61 2.03 0.15 <0.001
1.59 0.2 3.2 0.7 <0.01
0.7 0.02
22.7 2.2
8.3 0.6
0.54 0.01
16.6 0.7
1.3 0.2
<0.001
<0.01
<0.001
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and A. Barrientos, Service of Nephrology, Hospital ClInico S. Carlos,
Madrid, and Service of Nephrology, Hospital Alarcos, Ciudad Real,
Spain. Lead (Pb) is the origin of a progressive nephropathy which leads
to chronic renal failure. There are not clear parameters to establish a
treatment scheme, the information in the medical literature being scarce
and improbable. Classically, chelating agents have been used until the
removal of Pb into urine becomes normal, but it's thought this param-
eter may be a false healing sign. For these reasons, a study made on 42
male Wistar rats chronically intoxicated with Pb divided into 2 groups:
Group I (N = 21) that received treatment with EDTA (0.5 mg/kg/day
intraperitoneally) and Group II (N = 21) which received serum saline
0.9% the same way. We performed 3 turns of treatment during 5 days
leaving an interval of 10 days between each one. When every turn was
finished, 7 rats of each group were sacrificed for measuring lead in
tissues. Moreover, different biochemical parameters were determined
and also ALA-dehydratase, blood and urine Pb. From the renal lead
values of 72.1 7.8 uJg of dry weight a decrease was found to 8.6 0.8,
5.3 0.5, 3.66 0.8 pig in the 1st, 2nd and 3rd treatment's turn,
respectively, the results between them being statistically significant and
compared with the 2nd group (in the consecutive turns: 32.9 7.7, 22.5
2.8, 16.4 2.6 pIg). However, the Pb deposit in the bone was not
modified. When the treatment finished, there was less plasma creatinine
in the Group I with respect to Group 11(0.6 0.02 vs. 0.7 0.02 mg/dl;
P < 0.01), higher urinary excretion of uric acid (3.4 0.08 vs. 1.38
0.2 mg/day; P < 0.05) and higher ALA-dehydratase activity (2.3 0.2
vs. 1.5 0.2 nmol/ml/min; P < 0,05). With the chelating treatment Pb's
urinary eliminations were very elevated in the Group I, although with
their progressive decrease in spite of elevated blood lead (clearance's
pb's decrease along the treatment) and elevated deposits in different
tissues. Conclusions: (I) A progressive decrease in the Pb renal deposits
is obtained with EDTA treatment in intoxicated animals, together with
improvement in the renal function and in the uric acid's excretion. (2) In
our study, the EDTA has not produced nephrotoxicity. (3) The uric acid
excretion and the ALA-dehydratase's activity may be useful parame-
ters for pursuing the treatment of the nephropathy due to lead. (4) As
the treatment's time advances the effects of EDTA are less.
Distribution of lead in the experimental Intoxication in rats. A.
Sdnchez-Fructuoso, J. Blanco, M. Arroyo, A. Cruceyra, A. Torralbo,
R. Peces, and A. Barrientos, Service of Nephrology, Hospital ClInico
S. Carlos, Madrid, Service of Nephrology, Hospital Alarcos, Ciudad
Real, Spain. Lead (Pb) has been considered as an industrial hazard for
many years. However, today it is well-known that it is an important
environmental toxin and it has been described in an undepreciable
number of lead chronic nephropathies in the general population not
working in areas related to this metal. In order to study the effects of the
chronic intoxication by Pb an experimental study protocol has been
developed in 112, 6 month old, Wistar male rats that have been divided
into: 01 (N = 56) that were intoxicated with lead acetate (550 ppm) in
the drinking water during 3 months; and GIl (N = 56) drinking lead-free
water. Then, both groups drank lead-free water for 45 days. Seven rats
of each group were sacrificed after 60, 90, 107, 121 and 135 days of
study. Samples of bone, liver, lead and brain by means of Pb atomic
absorption spectrometry. The results, in pg of Pb/g of dry tissue, are
summarized in the following table:
_________ —
011 01 (60 days) 01 (90 days) 01 (135 days)
Brain Pb 0.59 0.06 3.33 0.3a 2.50 0.2k 1.05 0.9k
Liver Pb 1.14 0.26 9.09 l.09a 3.80 0.7a 0.60 0.07
Bone Pb 2.49 0.32 44.9 lO.7M 44.2 6.6a 45.07 3,7S
Kidney Pb 2.03 0.15 74.6 8.02a 72.08 7•9a 16.4 2.6r
Blood Pb 4.06 0.38 52.16 3.76 33.3 l.37a 22.8 3.36
a P < 0.001 vs. control
Our conclusions are: (I) a tricompartimental model seems to exist in the
lead intoxication between blood, bone and soft tissues. (2) The first
compartment is the blood that interchanges lead with the soft tissues.
The Pb blood decreases as the intoxication progresses and it is an
inexact pointer of the real lead corporal deposits. (3) The second
compartment is composed of soft tissues with which lead is easily
exchanged with the blood that can be eliminated in the urine. (4) The
kidney is the soft tissue where the biggest amount of lead is deposited,
possibly because it is one of the most important elimination routes of
this metal. (5) The third compartment is the bone, which contains the
highest amount of corporal lead, and it is difficult to vary in time. Bone
biopsy is one of the most trustworthy methods to diagnose the chronic
lead distribution.
Lead mobIlization during EDTA therapy In experimental intoxication
In rats. A. Sdnchez-Fructuoso, M. Arroyo, J. Blanco, M. Cano, N.
Trobo, A. Cruceyra, R. Peces, and A. Barrientos, Service of Nephrol-
ogy, Hospital ClInico S. Carlos, Madrid, Service of Nephrology,
Hospital Alarcos, Ciudad Real, Spain. EDTA is the drug most used for
diagnosis and treatment of lead nephropathy. Despite of its wide use,
there are doubts about the lead sources that are mobilized by EDTA.
Just one experiment in the area has been reported. High doses of EDTA
were applied and it was observed that a dangerous redistribution
happened. Redistribution of Pb with augmentation of this in the brain
and in the liver were detected after the treatment. So, the drug's safety
has been questioned. In order to try to clarify this point, an experiment
with 56 Wistar male rats was performed. The rats were divided into two
groups: Group I was intoxicated with lead acetate (550 ppm) during 3
months (N = 42); Group II, (N = 14) control rats, was not intoxicated.
Group I was further subdivided into two subgroups: Group Ia (N = 21),
that was treated later with EDTA (0.5 mg/kg/day intraperitoneally) and
Group lb (N = 21), that received physiologic saline serum in the same
way. Three turns of treatment during five days were made, leaving ten
days without treatment between the turns. The lead amount in bone,
brain, liver and kidney (by means of atomic spectography) was mea-
sured. After the first turn of treatment, a significant decrease was
observed in the tissular lead in Group Ia. The measured amounts in the
brain, liver and kidney were l.% 0.53, 0.98 0.14 and 8.66 0.85
pg/g of dry weight, respectively in comparison to 3.4 1.6, 1.3 0.14
and 32.9 7.7 pg/g in Group lb (P < 0.001). At the end of the
experiment, the values measured were the following (x 5EM):
Control Group Ia Group lb
Brain Pb 0.59 0.06 0.88 0.1? 1.05 O36'
Liver Pb 1.1 0.26 0.52 0.06 0.64 0.07
Kidney Pb 2.02 0.15 3.6 0.29a 16.4 26b
Bone Pb 2.49 0.32 41,3 g6b 45.1 3.7
P < 0.01 vs. control; b P < 0.001 vs. control.
Our conclusions are: (I) The lead is transitorily accumulated in the liver
and brain. It is redistributed later on to other tissues. However, normal
values were not observed during the experiment. (2) The highest lead
level is accumulated in the bones. So, this tissue is probably a fixed pooi
that is hardly accessible to the chelating treatment. (3) The EDTA
treatment induces a great and quick decrease in the content of Pb in the
tissues. (4) EDTA, in our experiment, does not produce redistribution
of lead to critical tissues as liver and brain. We think that it can be safely
used in the diagnosis and treatment of lead nephropathy.
Recurrence of focal segmental glomerulosclerosis in renal transplanta-
tion. J.J. Amenábar, A. Vallo, P. GOmez-Ullate, 1. Minguela, RI.
Muñoz, and I. Lanpreabe, Departments of Adult Ncphrology and
Pediatric Nephrology, Hospital de Cruces, Baracaldo, Bizkaia, Spain.
Objective: We report the clinical evolution after renal transplantation in
patients diagnosed with primary focal glomeruloscierosis (FSGS).
Methods: We reviewed 522 renal transplants (RT) performed in our unit
between 1979 and 1991. Thirty-two RT (6%) corresponded to 29
patients who had been diagnosed with primary FSGS as the cause of
their renal failure. These were split into two groups: a "pediatric
group" composed of 9 RT performed in 7 patients under 18, in whom
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FSGS started at 5.4 3.6 (1—9) years, end-stage renal disease devel-
oped in 4.4 2(1—7) years, their graft was given at 11.2 2.7(8—16)
years, and 6 cases were treated with cyclosporin A (C5A) from the
beginning; and an "adult group" composed of 23 RT performed in 22
patients, n whom FSGS started at 31 11(6—51) years, end-stage renal
disease developed in 7 3 (1—16) years, their graft was given at 39 10
(21—58) years, and 19 cases were treated with cyclosporin A (CsA). We
evaluated the onset of proteinuria in the early postoperative period (2
months), its evolution, the onset of nephrotic syndrome and the
occurrence of graft failure. Results: Pediatric group: 8 (89%) of RI
developed proteinuria in the early postoperative period. Three cases
lost their graft in the first 6 months because of rejection. Another 3
cases, followed-up for 16—.48 months, showed normal renal function but
have nephrotic-range proteinuria. One patient was undergoing two
transplants, both receiving CsA, developed nephrotic syndrome and
renal failure in both grafts, losing his first one at 16 months and having
advanced renal failure at 28 months of his second graft. In 2 out of 8
cases a renal biopsy was taken. Adult group: 1 (4%) of RT developed
early proteinuria and subsequent nephrotic syndrome, retaining a
normal renal function at 27 months. The other patients have not
presented any indication suggesting recidive as yet. Conclusions: FSGS
recurrence in our pediatric population was too common (89%) and with
good clinical evolution except for one case. In adults recurrence was
rare.
A randomized study with two Immunosuppressive therapies In renal
transplantation. J.J. Amendbar, P. GOmez-Ullate, R.I. Munoz, B.
Aurrekoetxea, F. Garcia LOpez, J. GaInza, and I. Lampreabe, Depart-
ment of Nephrology, Hospital de Cruces, Baracaldo, Bizkaia, Spain.
Objective: Comparison of two common immunosuppressive therapies in
renal transplantation. Methods: An open randomized trial conducted in
168 renal transplantation cases for three years (February 1989 to
February 1992). Iwo groups: double therapy (81 cases): cyclosporin A
(CsA) 10 mg/kg + prednisone (Pred) 2 mg/kg; and triple therapy (87
cases): CsA 6 mg/kg ÷ Pred 1 mg/kg + azathioprine 2 mg/kg. Patients
under IS, diagnosed of diabetes and having > 75% lymphocyte-
mediated cytotoxic antibodies against the panel were excluded. Both
groups were homogeneous in relation to donor age and recipient age,
cold ischemia time, number of retransplants, blood transfusions and B
+ DR misidentities. Statistical bivariate, survival (Kaplan-Meier) and
multivariate (Cox regression) analyses were performed. Results: Graft
survival at 3 years: 86% in the triple and 76% in the double (P = 0.26).
The relative risk (RR) of triple group versus double group is 0.65, 95%
confidence interval (CI): 0.3—1.4. Serum creatinine levels (mg/dl): at
first year 1.33 0.4 in the triple group vs 1.53 1.4 in the double group
(P = 0.13); at second year 1.2 0.08 in the triple group vs. 1.9 1.6 in
the double group (P = 0.02). Adverse reactions because of CsA: 7% in
the triple group vs. 24% in the double group (P = 0.005). Acute renal
necrosis post-transplantation: 30%, lasting 11.8 7.3 days in the triple
group vs. 26% lasting 8.8 6.3 days in the double group (P = 0.61 and
0.14). Prognostic factors for graft failure: in the multivariate analysis the
only factors found were the donor age and the recipient age. A donor
age over 55 showed a RR of 3.1 (95% CI: 1.3—7.2) compared to a donor
age under 55. A recipient age over 55 vs. under 55 showed a RR of 2.0
(95% CI: 0.9—4.3). Conclusions: The patients undergoing a triple therapy
showed fewer adverse effects produced by CsA, serum creatinine levels
slightly lower and their graft survival tended to be longer. In our study,
donor age and recipient age over 55 influenced negatively on the graft
survival.
High prevalence of urinary infections in chrome hemodiaiysls patients.
J.C. Santos, F. Aguilera, I. Garcia Posse, f.M. Cossio, P.P. Szeci, and
A.R. Mohedano, Inst ituto Medico del Riñon, San Miguel de Tucuman,
Argentina. Urinary infection (UI) in chronic hemodialysis patients is a
common finding that in spite of its high frequency it often passes
unnoticed. With the objective of studying the prevalence of UI in
chronic hemodialysis patients with diuresis, urinary sediment and
uroculture were done in 50 asymptomatic patients. The uroculture was
positive (+) in 33 patients (66%) and was negative (—) in 17 patients
(34%). Of these, 7 had alterations of the urinary sediment. The presence
of Tnchomonas in 19 of the patients studied (38%) was an attention-
calling discovery. Of these, 10 also had positive (+) uroculture and 9
had negative (—) uroculture. The microorganisms found in the urocul-
tures were as follows: E. Coli in II urocultures (33.33%); Streptococcus
in 6 urocultures (18.18%); Proteus in 5 urocultures (15.15%); Entero-
bacter in 4 urocultures (12.12%); Klebsiella in 3 urocultures; Neisseria
in 2 urocultures, and Staphylococcus in 2 urocultures. Our conclusion
was that chronic hemodialysis patients under treatment, despite not
having specific UI symptomatology, showed a high number of positive
urocultures. Therefore, we believe that in the follow-up protocol of
chronic hemodialysis patients, the periodic study of the urinary sedi-
ment should be included.
Prevalence of the antibody against Hepatitis C virus (anti-VHC) In 149
chrome hemodialysis patients. A multi-center study. J.C. Santos, F.
Aguilera, C.M, Weller, J.M. Cossio, P.P. Szecsi, A.R. Mohedano, D.
Woli, S. Tirado, and W. Contino, Instituto Medico del Riñon, San
Miguel de Tucuman, Argentina. With the objective of knowing the
prevalence of antibodies against hepatitis C in the patient population
under hemodialysis in the city of San Miguel de Tucuman, a study was
undertaken in three (3) hemodialysis service providing centers. It was
determined through ELISA the anti-VHC in 149 patients with an
average time under dialysis of 25.5 months (1—128 months). The
anti-VHC was positive (+) in 79 patients (53.02%) and was negative (—)
in 70 patients (46.98%). The average time elapsed in dialysis was greater
in patients with anti-VHC (+) (30.7 vs. 18.7 months). No differences
between male and female sexes were observed either in patients with
anti-VHC (+) (41 vs. 38) or in patients with anti-VHC (—) (32 vs. 38).
In the group with the anti-VHC (+) (75.95%, 60 patients) had received
blood transfusions. According to the time that the patients underwent
hemodialytic treatment, the percentage of positiveness of the anti-VHC
was the following: 14.7% at 6 months; 48.6% at 12 months; 73.3% at 18
months; 78.5% at 24 months; and 80% in those who had undergone
hemodialysis during 30 and 36 months. It was concluded that there
exists a high prevalence of anti-VHC (+) and despite that blood
transfusions may have played an important role in the positive anti-
VHC, we believe that the time elapsed under dialysis can be another of
the principal determining factors.
Prevalence of antibody against hepatitis C virus (antl-VHC) In chrome
hemodlalysis patients. J.C. Sanlos, F. Aguilera, C. Weller, P.P. Szeci,
J.M. Cossio, and R.A. Mohedano, Instituto Medico del Riñon, Labo-
ratorio Analisis Bioquimico, San Miguel de Tucuman, Argentina. With
the objective of knowing the prevalence of the anti-VHC in chronic
hemodialysis patients, it has been determined through ELISA the
anti-VHC in 93 patients with an average time under dialysis of 25.04
months (1—128 months). The anti-VHC was positive (+) in (47.3%) of
the cases studied and negative (—) in 52.7%. The elapsed time under
dialysis was greater in patients with anti-VHC (+) (31.4 vs. 22.02
months). No male or female sex differences were observed in patients
with anti-VHC (—) (25vs. 24) but differences did occur in anti-VHC (+)
patients (26 vs. 18). In hemodialysis patients the increase of hepatic
enzymes had no relation to the presence of the anti-VHC. The clinical
manifestations observed in patients with anti-VHC (+) were non-
specific. In this group 72.7% had received blood transfusions and 34%
evidence of positive (+) anticore, for which reason we do not consider
this antibody a substitute mark of the infection by virus C. The four
patients with PBH had evidence of persistent chronic hepatitis. It is
concluded that the infection by virus C in hemodialysis patients
demonstrates a high prevalence in correlation to the time under dialysis
and the blood transfusions received.
Lupus nephrltls patients in hemodlalysis treatment: Reversibility of
renal failure. PA. Rainoldi, F. Segovia, S. Roperto, and M.A. Nadal,
Hospital de Clinicas "José de San Martin"; Division of Nephrology,
Buenos Aires University, Buenos Aires, Argentina. Nineteen patients
with lupus nephritis (15 women and 4 men, age SD: 29 6 years)
underwent hcmodialysis (HD) for renal failure. On each patient percu-
taneous renal biopsy (PRB) was performed: 12 fulfilled the morphologic
criteria for diffuse proliferative lupus glomerulonephritis (DPLGN) and
7 patients presented lupus sclerosing glomerulonephritis (LSGN). Time(months) measured from the date PRB was performed to first HD
determined the rate of renal function decrease (PRB-HD period). The
group with PRB-HD period: 0 month recovered renal function and
discontinued dialysis. The other two groups with PRB-HD: 10.3 8.9
months and PRB-HD: 40.7 46 months, respectively did not recover
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renal function. No differences were found between high doses of
methyiprednisolone (MPS) or cyclosphosfamide (CF) pulses and plas-
mapheresis (PF) in each group who received these treatments. Duration
of systemic lupus erythematosus disease (SLE) from onset to hemodi-
alysis (SLE-HD period) was shorter in the reversible renal failure
group.
SLE- Patients who
HD Duration received
Number
of periodx SD
PRB-HD
period
of HDI SD Pulses
patients PRB month I SD month MPS CF PF
6 DLPGN 28 32 0 2 1 3 6 3
6 DLPGN 57 70 10.3 8.9 24 14 2 6 2
7 LSGN 79 56 40.7 46 45 32 — — —
We concluded that DLPGN patients with rapid deterioration of renal
function (PRB-HD period: 0) had more improved glomerular filtration
rate than those with an underlying pattern of slowly progressive renal
insufficiency (PRB-HD period: 10.3 8.9 months and PRB-HD period:
40.7 46 months).
Donor-specific Immunological hyporesponsiveness assessment In the
monitoring of kidney transplantation. E. Massip, M. Mestre, J. Bas, A.
Valls, J. Alsina, J.M. GriñO, A.M. Castelao, and E. Buendia, Immu-
nology and Nephrology Services, Ciutat Sanitària de Bellvitge, Barce-
lona, Catalonia, Spain. In order to assess the grade of immunological
hyporesponsiveness acquired along the monitoring of kidney transplan-
tation we have determined the frequencies of cytotoxic T lymphocyte
precursors (CTLp) to allo-MHC antigens in the peripheral blood of
cadaveric renal allograft recipients. Transplant patients (N 14)
received a prophylactic immunosuppressive triple therapy consisting of
anti-T cell antibodies plus CsA and steroids. Peripheral blood lympho-
cyte samples were obtained prior to transplant (fx) and at three months
post-Tx. A limiting dilution assay (LDA) measuring release of 51Cr from
labeled target cells was used to evaluate cytotoxic T lymphocyte
precursor frequencies (CTLpI). Specific in vitro cytotoxic alloresponse
to cryopreserved donor spleen cells was assessed. Thirty replicates
were set up for each responder concentration (eight dilutions ranging
from 5 x lO to 0.25 x l0 cells per well). CTLpf were calculated by
regression analysis and Chi-square minimization procedure. Ten pa-
tients evolved free of acute rejection. This group showed a statistically
significant reduction in donor specific CTLpf at three months post Tx
(1.89 x iO 1.29 x lO SD) with respect to pre Tx values (5.77 xl0 4.95 x 1O SD) (P 0.018, Wilcoxon paired data test).
However, one patient without any clinically demonstrable episode of
rejection presented an increase in CTLpf at third month (3.4 x l0—)
versus pre-Tx value (0.3 x l0—). On the other hand four patients
experienced acute rejection episodes. Three patients presented acute
rejection episodes at third month post-Tx exhibiting higher CTLpf
during rejection (10.8 x 10 9.02 x io— SD) in comparison with
pre-Tx values (1.75 x l0 3.05 X I0 SD). One patient presenting
a reversible rejection crisis at first week post-Tx exhibited a very high
CTLpf (14.5 x 10—s) at pre-Tx, but this frequency decreased to 0.26 X
lO at third month post-Tx correlating with the improvement of graft
function. These preliminary results suggest that a donor hyporespon-
siveness is achieved early during the post-Tx period (at three months) in
patients with well-functioning grafts, but this specific low alloresponse
is not observed in patients with renal allograft rejection.
Molecular characterization of endothellal nitric oxide synthase (EC-
NOS) expression in endothellal and mesangial cells S. Lamas and TM.
Michel, Brigham and Women's Hospital, Harvard Medical School,
Boston, Massachusetts, USA. EC-NOS catalyzes the reaction involved
in the generation of nitric oxide (NO), which is responsible at least in
part for the biological activity of EDRF. The molecular characterization
of this protein is of potential physiological and pathophysiological
relevance. Several clones for NO synthase were isolated and charac-
terized from a bovine aortic endothelial cell (BAEC) cDNA library and
the full-length cDNA coding region was identified. The deduced amino
acid sequence of the cDNA predicted a protein containing 1205 amino
acids with a molecular mass of 133 kDa. EC-NOS protein is 60%
identical to the rat brain constitutive isoform and 50% identical to the
inducible murine macrophage isoform. Transfection of EC-NOS cDNA
in COS-7 cells demonstrated basal enzymatic activity using a cell
reporter (RFL-6) bioassay. This activity was stimulated by calcium
ionophore and inhibited by nitro arginine in the transfected cells. A 4.6
kb mRNA transcript was specifically expressed in bovine aortic and
glomerular endotheial cells. TNF-a has been previously shown to
augment EDRF production in BAEC. Expression of EC-NOS inRNA
was not increased by treatment of BAEC with TNF-a. Northern blot
analysis performed in bovine glomerular mesangial cells, where an
inducible isoform has been described, did not demonstrate any tran-
script either in the presence or absence of TNF-a. A new isoform for
NO synthase has thus been characterized, which appears to be consti-
tutive and calcium-calmodulin dependent. The study of the molecular
regulation of this enzyme in the renal endotheium may conthbute to a
greater understanding of the physiology and pathophysiology of renal
blood flow.
Significance of antiphospholipid antibodies in lupus nepbropathy. M.
Boronat, M. Perdiguero, M.C. Prados, P. Marco, L. Jiménez, and F.
Rivera, Nephrology and Hematology Units, Alicante General Hospital
(SVS), Facultad Medicina (Dpto Internal Medicine), Alicante, Spain.
Although several clinical and morphologic changes observed in overt
systemic lupus erythematosus have been associated with the presence
of antiphospholipid antibodies (APA), the relation between these anti-
bodies and lupus nephropathy is not well-known. We have retrospec-
tively studied 23 patients (mean age 28.5 12.3 years, all females) with
biopsy proven lupus nephritis with the aim to investigate the relation-
ship between the presence of APA and clinical and immunobiological
data derived from renal damage. The mean follow-up was 55 42
months (range 5—149). All the patients were determined, at least once,
with the presence of APA (IgG and 1gM) by ELISA and/or lupus
anticoagulant (Kaolin-time). Seven patients (36.4%) were APA+, and
the remainder APA—. We did not find differences between age, period
of follow-up, antinuclear antibodies, anti-DNA antibodies, levels of
complement (C3, C4), mean blood pressure, and systemic manifesta-
tions in the subgroup of APA+ patients versus APA— patients. The
histological patterns in both series were also similar. However, 42.8%
of APA+ patients had microthrombosis in the glomerular capillaries
lumens, in contrast with APA— patients who had thrombosis in only
1.5%. In the APA+ subgroup the proteinuria was significantly higher
compared with APA— patients (P = 0.029). Furthermore, the evolution
of renal function (evaluated by the changes of the slope of Cr vs.
time) was more unfavorable in APA+ patients compared with APA—
patients. We conclude that the presence of APA in patients with lupus
nephropathy induces several characteristics of renal involvement and
may influence its evolution. However, the specific role of APA in the
pathogenesis of lupus nephropathy needs to be confirmed in large
prospective studies.
IL-4 and IL-6 in idiopathic IgA nephropathy (IgAN). F. Rivera, M.
Parera, M. Perdiguero, J. Egido, and A. Campos, Nephrology Unit,
Alicante and Elda Hospital (SVS), C. Transfusiones (SVS); Facultad
Medicina (Dpto Internal Medicine), Alicante, Spain. IL-2 is involved in
the cellular immunoregulation of IgAN. However, the participation of
other cytokines is not well-established. The aim of this study was to
investigate the role of IL-4 and IL-6 in IgAN. We studied 23 inactive
patients and 11 controls. IL-4 and IL-6 were measured by ELISA in
serum and in supernatants of PBMC cultures. IL-4 and IL-6 serum
levels did not differ among controls and patients. The stimulation of
PBMC with PHA induces an significant increase of supernatant IL-6 in
patients; this response was less pronounced in controls. The superna-
tant levels of IL-4 and IL-6 after addition of TNF or IL-2 to PBMC were
not different. IL-4 and IL-6 levels were similar in the subgroups of
patients with asymptomatic urinary findings or with macrohematuria
bouts. There were no correlations between IL-4 or IL-6 and clinical or
inununobiological data (% ofCD4+, CD8+, CD25+ cells, levels of IL-2
and serum levels of sIL-2R). We conclude that IL-6 participates in the
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immune response of IgAN, especially after antigenic exposure. The role
of IL-4 is less defined.
Left ventricular hypertrophy (LVH) and insulin resistance in essential
hypertension (EH). M.C. Prados, A. CarriOn, M. Perdiguero, M.
Mauri, P. Bordes, and F. Rivera, Nephrology and Cardiology Units,
Alicante General Hospital (SVS); Facultad Medicina (Dpto Internal
Medicine), Alicante, Spain. The insulin resistance and resulting hyper-
insulinemia could be a possible non-hemodynamic mechanism involved
in the pathogenesis of LVH observed in several forms of EH. We have
studied 42 patients (20 males and 22 females) diagnosed with EH,
without glucose intolerance or being overweight (mean of body mass
index 25.5 2.6) and normal renal function. The blood pressures were
controlled with antihypertensive drugs. The control group was com-
posed of 14 healthy persons (age, sex and BMI matched). In all cases
we measured glucose, insulin and C-peptide in blood after oral sur-
charge of 75 g of glucose, at 0, 30, 60, 90, and 120 minute intervals.
LVH was evaluated by 3 ECG approach; moreover LVH was measured
by M-module echocardiogram. The patients with EH showed an insulin
profile with levels of insulin higher than controls and its mass of LV was
also significantly higher (128 87 vs. 89.6 23.5 gIm2/sec, respec-
tively; P = 0.002). The curves of glucose, insulin and C-peptide were
similar in the subgroup of patients with LVH (measured by ECG or
echocadiography) compared with the patients without LVH. These
subgroups did not showed differences in age, sex and BMI. We
conclude that in the patients with treated EH without obesity or overt
glucose intolerance there were hyperinsulinemia and increased mass of
VI; however, the relationship between these findings is not clear.
Kidney transplantation system by microcomputer. Mi. Ndñez
Valdés, J.A. Muñoz Perez, C. Magrans, J. Alfonzo, S. Arce, and R.
Herrera, Institute of Nephrology, C. Habana, Cuba. A computer
system has been developed in order to automate the donor-recipient
optimal selection process in those patients (recipients) with chronic
renal failure, given a cadaveric donor. The system creates and main-
tains a waiting list of recipients for the whole country. There are two
input sources: Newcomers and Update. The data stored in the com-
puter have everything to accomplish the selection task adequately. The
system keeps the following-up of all the stages before and after the
transplantation. The algorithm assigns a score to every patient in the
waiting list based upon immunological and clinical criteria. The score is
able to select the optimal recipient among the pool of all recipients.
Finally the waiting list is sorted in descending order of the scores. The
system provides five reports: (1) A listing of individual patients showing
the potential recipients. (2) The clinical record of any patient (optional).
(3) A listing of the waiting list broken down by dialysis centers. (4) A
map of patients of the Terasaki plates. (5) An error listing (if any). The
programming was made using CLIPPER language, autumn's 87 version
(Richard McConnel et al). The system has been used in Cuba since
1987. More than 700 patients have been transplanted through it; 19 of
them were a kidney-pancreas combination. It has completely replaced
the hand-made selection process with the obvious advantages of the
computer.
Hemodlalysis and prescription by microcomputer. J. Munoz, M.J.
Ndnez Valdés, and C. Magrans, institute of Nephrology, C. Habana,
Cuba. It is almost impossible to adequately assess hemodialysis man-
ually because of the complexity of the steps to be solved by means of
the iterative calculus. For this reason, it was necessary to automate the
kinetic models achieved in the 1960's by Gotch and Sargent. Some
elements have been added to those models to improve the dialytic
processing. The system has two fundamental functions: (1) prescrip-
tion: Allows us to carry out the optimum hemoclialysis prediction in
patients who have never been treated before. (2) control: Allows us to
control the dialytic regimen quality (dialysis dose, protein intake,
uremic environment, dialyzer and dialysis efficiency), in an easy way
employing three quantification methods based upon urea kinetics:
direct, indirect and simple calculation method. This system allows: (1)
Dependability and accuracy of results. (2) Optimization of human
resources and dialysis center materials. (3) Offers general and specific
suggestions in the dialytic processing. (4) Controls the dialysis effi-
ciency. (5) After each trial, patient will be in better mental and physical
shape due to the reduction in the dialysis time and also to the right
selection of the dialyzer used. This system was written in CLIPPER
language and is currently running on an IBM compatible microcom-
puter.
Variations of arterial pressure (BP) in hemodlalysis patients (LID)
treated with erythropoletin (EPO). M. Romero, M. Casals, J. Gabds,
J.M. EscribO, A. MartInez-AmenOs, H. Rama, and X. Sarrias, Centre
de NefrologIa MatarO, Servicio de Medicina Preventiva y NefrologIa,
R.S. PrIncipes de Espana, Hospitalet de Llobregat, Barcelona, Spain.
One of the most frequent and important complications in the treatment
with EPO is arterial hypertension. We have studied the AP variations in
15 patients (4 m and lit), with an average age of 53 13 years, and an
average time on HD of 4.1 2.8 years, by means of a continuous
register (RACPA) for 24 hours a day, on initiating the study (Period I)
and after 10.2 2 months (Period 2) of treatment with EPO. The
statistical method of the Student's t-test has been applied to the results.
Results: The study of both periods showed a drop in the systolic APs in
the day (SDAP) and the night (SNAP) and the diastolic night AP
(DNAP), while the diastolic day AP (DDAP) increased slightly, al-
though no change was statistically significant. Within the group of
normal pressure patients, increases appeared in all the AP figures which
were not significant either. Nevertheless, the decreases of AP in the
hypertensive group were significant in the SDAP (P < 0.05), SNAP (P
<0.01) and DNAP (P < 0.03). With regard to the doses of EPO ( 120
lU/kg/week), no statistically significant differences have appeared ei-
ther. At the end of the study there are fewer hypertensive patients (3 of
7) and fewer patients with alteration of circadian rhythm of the AP (6 of
9). There has been a significant change in the hematocrit (P < 0.0001),
the hemoglobin (P < 0.0001), the urea (P < 0.05) and the total proteins(P < 0.05). ConclusIons: According to our experience: (I) The AP
variations in normotensive patients are not statistically significant. (2)
Statistically significant decreases are shown in the hypertensives. (3)
The EPO dose has not affected the AP. (4) The APis normalized in 37%
of hypertensive patients. (5) The circadian rhythm recovers the normal
standard in 33.3% of all the patients studied.
Computable nutritional evaluation. Julio Muhoz, Maria J. NOñez
Valdés, and Eusebio Delgado, Institute of Nephrology, C. Habana,
Cuba. A great interest for knowing the nutritional status of hospitalized
adult patients and/or patients with chronic disease was aroused in
recent years because of a high incidence and prevalence of malnutrition
in this population. These studies are even more important in patients
subjected to surgical operations because of the relationship between
malnutrition stages and increased sepsis and the susceptibility of
postoperatory complications. To this aim, a program system was
developed which allows the nutritional evaluation of that population,
thus freeing the assisting physician of troublesome estimates and the
constant consultations of age, sex and height tables. This system allows
us (through biochemistry, anthropometnc and immunological variables)
to evaluate each individual patient from a nutritional point of view in the
following aspects: (1) Protein visceral status (2) Fat store (3) Protein
somatic mass (4) Immunocompetence. Finally, it helps the physician to
apply an adequate nutritional therapy. This system was written in
BASIC language and is currently running on an IBM compatible
microcomputer.
Estimated probability of survival using non-parametric methods. l.A.
Muñoz, M.J. Ndñez Valdés, Arce Bustabad, and A. Guerra, Institute of
Nephrology, C. Habana, Cuba. It is important to the physician, in
many high mortality diseases, to be able to give a fairly good prognosis.
Statisticians have developed tools which calculate the probability of the
outcome of an event in a given gnoseologic entity as a function of time.
Today one of the most widespread techniques employed to the that
effect is the survival curve from non-parametric statistics. Before the
computer era, the calculations involved were time-consuming and very
error prone, so we decided to develop an automated system which is
capable of estimating the probability of survival related to time of a
group of patients, taking into account the evolutive behavior of previ-
ous cases. This was done through two traditional methods: actuarial
and Kaplan Meier methods. The system is very useful in those
institutions involved in organ transplantation, malignancies, and other
high mortality diseases. It is also advantageous in those cases where
discrimination between two different treatments or other factors could
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favorably influence the patients' survival. This system was written in
BASIC language and is currently running on a compatible IBM micro-
computer.
Datamanagement system on kidney transplanted patients. M.J. Náñez
Valdés, J. Munoz, A. Guerra, D. Moreno, and H.B. Vea, institute of
Nephrology, C. Habana, Cuba. To have an adequate data management
system of transplanted patients and their evolution after the transplan-
tation is very useful to nephrologists, urologists, immunologists, sur-
geons and many other physicians involved in organ transplantation. Our
data management system collects historical data of the patients, and its
main goal is to estimate the survival of the graft and of the patient.
There are about 1700 records in the data base, 19 of them being
pancreas-kidney combination transplants. The data management sys-
tem gathers information about the pre-dialytic stage, before and after
the surgical act, and so on. This up-to-date register of transplanted
patients covers the whole country. It allows the physicians to perform
statistical and survival studies for each transplantation center, as well
as for the whole country. The programming was made using CLIPPER
language and currently running on a compatible IBM microcomputer.
Cyclosporin monotherapy as primary iminunosuppression in renal
transplantation. Five years experience. J. Andreu, J.M. Campistol, F.
Oppenheimer, V. Torregrosa, M.J. Ricart, J. Vilardell, and P. Car-
retero, Renal Transplant Unit, Hospital Clinic, Barcelona, Spain.
Steroids (ST) are responsible for an important part of iatrogenia in renal
transplantation (Tx). From January 1986 to December 1990, 229 trans-
planted patients received CsA monotherapy (CsA-M) as primary im-
munosuppression. ST were introduced at the first rejection episode, so
Tx without any rejection crisis remained without ST. ALG or OKT3
were administered in vascular and/or ST-resistant rejections. Actuarial
patient survival was 95.9 1.5% and 89.7 2.8% at two and five years,
respectively, and graft survival was 87.2 2.3% and 80.7 2.8%at two
and five years, respectively. With CsA-M, 30% of the Tx with a
follow-up over one year were rejection-free (without ST). This percent-
age is over 50% in elderly recipients and it is only 15% in hyperimmu-
nizedlreTx. Rejection episodes in non-hyperimmunized/reTx were eas-
ily controlled: only 10% of those recipients needed OKT3/ALG because
of vascular or ST-resistant rejections, while 40% of hyperimmunized/
reTx recipients needed OKT3/ALG therapy. It seems worth avoiding
ST in a considerable percentage of Tx, in spite of a higher occurrence
of mild rejection in the remaining, than to reduce rejection at the
expense of giving ST to all Tx. CsA-M does not jeopardize survival or
graft function, at least over a five year follow-up period. CsA-M is
mainly indicated in the elderly, and it does not seem advisable in
hyperimmunized/reTx. It is debatable whether or not CsA-M is advan-
tageous in younger non-hyperimmunized/reTx, and in recipients with
acute renal failure after surgery.
Two years study of the evolution of HCV markers in two lID units.
Influence of non-blood-related transmission factors. G. Barril, M. Cas-
tro, J. Naranjo, B. Rincon, J. Schez Tomero, E. Gruss, .C. Bernis, J.
Motellon, T. Naya, R. Moreno, and J.A. Traver, Service of Nephrol-
ogy, Hepathology Unit, Hospital de Ia Princesa, Universidad Au-
tónoma, Madrid, Spain. We have studied two hemodialysis (HD) units
with 62 and 92 patients, respectively. HCV markers were performed by
ELISA 2 test over a two year period. At the begining of the study there
were 5 anti-HCV+ patients in Unit 1. In two years another seven
patients became HCV+, 6 of them anti-HCV+ by RIBA4 and one of
them anti-HCV(—) by RIBA4. One patient died and three patients were
transplanted, being anti-HCV+ at 5, 12, and 20 months after renal
transplantation. In Unit 1 all the seroconversions have happened in 2
monitors. Eight monitors have been only by anti-HCV(—) patients, and
no seroconversions have occurred. In Unit 2, 6 HD monitors have been
used only by anti-HCV(--) patients and there were no seroconversions.
In 4 monitors used by anti-HCV+ patients, the seroconversion rate for
the patients using the same monitor ranged between 40—75%. The rest
of the anti-HCV+ patients were dialyzed in other 9 monitors. Twelve
nurses were studied: two were anti-HCV+ by ELISA 2. In second
determination, one of them was anti-HCV(—), and this was confirmed
by RIBA4. The other nurse was anti-HCV+ by RIBA4. The rest of the
unit personnel staff (8 persons) were anti-HCV negative. Conclusions:
(1) Despite the reduction of the number of blood transfusions and the
serological control of them, there exists a high seroconversion rate in
our HD units. (2) The confirmation test seems necessary to exclude the
false positive cases by ELISA 2. (3) Probable time on HD and personal
individual factors play an important role in the HCV transmission. (4)
There seems to exist a high risk of seroconversion for the patients who
share monitors with anti-HCV+ patients. (5) Long-term studies should
be performed.
Are the blopolymeric prosthesis (BPM) valid alternatives to grafts in
the arteriovenous fistulae (AVF) of HI) patients? G. Barril, J. Melon, B.
Rincon, C. Bernis, I. Motellon, J.A.Sz. Tomero, E. Gruss, M.T. Naya,
C.G. Canton, P. Sanz, and J.A. Traver, Service Nefrologla y Cirugla
Cardiovascular, Hospital de La Princesa, Universidad Autónoma,
Madrid, Spain. We have validated the AVF realized from March 1985
to March 1992. From the 170 realized, 22 were grafts, 18 BPM, and 4
PTFE. Eighteen AVF were put in 16 patients, 6 males and 10 females
with an average age of 60.33 years (46—76), and an average on time on
HD of 16.23 months (0—74). In 25% of the cases the etiology was
diabetes and the other 25% was undetermined etiology. It was used as
first election in I case, 13 had Cimino as previous fistulae, and 4 cases
a graft, and BPM in 2. The time until the fistulae were punctured varied
between 3—4 weeks from their implantation, obtaining an average blood
flow of 350 mI/mm (300-400) and an average venous pressure of 150mm
Hg (100—175). Only 4 patients (22%) had antiaggregant treatment. The
average period of use of the graft during the study was 9.61 months.
There were complications in the first punctures in 2 diabetic patients
which were spontaneously resolved. There were no infections and no
aneurism formations. There were thromboses in 5 AVF: in one case
before it was used, in the other 4 cases there was obstruction with
Fogarty. In 2 cases with definitive results and in another case a new
prosthesis of BPM was needed and in the last case it was necessary to
perform PTA and insert stenotic endoprosthesis. We studied coagula-
tion time of puncture sites of without seeing any differences between
autologous AVF. The cost is similar for prosthesis P'FFE. Actuarial
survival of BPM prosthesis is 84% during 24 months. Conclusions: In
our experience the BPM prosthesis could be a good alternative when
grafts are needed for patients' AVF.
Is the autoexpanded metallic endovascular prosthesis (AMEP) a valid
alternative to surgical intervention of the arteriovenous flstulae (AVF)
stenosis? G. Barril, D. Tagarro, B. Rincon, C. Bernis, I. Motellon,
J.A.Sz. Tomero, M. Naya, C.G. Canton, E. Gruss, P. Sanz, andf.A.
Traver, Services of NefrologIa y Radiologla, Hospital de La Princesa,
Universidad Autónoma, Madrid, Spain. Due to the admission of older
patients to HD units with severe vascular pathology and longer survival
on HD, it seems necessary to use all kinds of therapeutic possibilities in
order to maintain the functioning AVF. The alternative to PTA offers
the possibility to avoid the surgical method of maintaining the vascular
access when there is a severe stenosis with the possibility, when it is
reiterative, of percutaneous implantation of AMEP that would correct
the problem. We report the first two cases of definitive resolution of
AVF stenosis with this method in patients over 68 years old. Included
was a patient 77 years old with 6 years on HD and one radiocephalic
fistula in which we can see a distal stenosis with an important decrease
of blood flow and an increase of venous pression. After PTA 3 times
during 1 year with severe stenosis before treatment, we performed in
the last PTA the percutaneous insertion of AMEP obtaining a blood
flow of 400 mI/mm and a venous pressure of 180 mm Hg, without any
complications during 8 months. There was also a patient 88 years old,
diabetic, 3 years on HD and autologous AVF with posterior thrombosis
who had a humero-axilàr biopolymeric prosthesis which after two
months was thrOmbosed. It was resolved with Fogarty but a severe
stenosis was discovered. After 2 PTA it was decided to perform the
percutaneous insertion of AMEP, obtaining a blood flow of 350 mI/mm
and venous pressure of 160 mm Hg during 9 months. Neither of the two
cases needed antiaggregant treatment. There were no post-treatment
complications and fistulae could be used immediately. Conclusions: The
use of the AMEP is a useful non-surgical treatment for the definitive
resolution of the stenosis, also in the autologous and heterologous
fistulae. It is necessary to use in more cases in order to generalize its
use.
The use of HCV markers in hemodialysis (lID) patients and kidney
donors. The Spanish HCV Multicentric Study Group, G. Barril, and
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J.A. Traver, Servicio de NefrologIa, Universidad AutOnoma, Hospital
de La Princesa, Madrid, Spain. Patients of 81 dialysis units, 54
hospitals and 27 peripheral satellite units, have been studied all over
Spain. Some 97% of the hospital units make routine screening of
patients for HCV markers with a periodicity of 5.39 3.26months. The
ELISA second generation was the most commonly used test, with a
percentage of 95% of the units. The 47% of units that make a
confirmation test, use the RIBA2. The 35% of the 54 hospital units used
isolation techniques, all of them with monitors exclusively for the
HCV+ patients inside the general unit. There have been 28 accidents
with follow-up ranging from 0.5—36 months, finding 1 seroconversion
(3.57%) in 16 units of the 54 who answered. The 81% of the hospitals
which have transplant units make a routine determination of HCV
markers in kidney donors before transplant. The 93.1% of those studied
use the ELISA2 method. In the 89.5% of those who have answered, the
kidneys of HCV+ donors are transplanted only to HCV+ receptors.
Conclusions: (1) Because of the high prevalence of antiHCV+ in the
dialysis patients, routine screening of patients for HCV markers is
performed in most of the hospitals units (97%). (2) The number of the
dialysis units which use confirmation methods is increasing every day.
(3) The 35% of the hospitals use exclusive isolation monitors for HCV+
patients. (4) In the accidents with HCV+ patients seroconversion is
possible. (5) The importance of the problem in relation with transplant
is shown by the high number of centers that use ELISA2 in the donors
before transplant.
The prevalence of HCV markers in patients and unit staff personnel.
The Spanish HCV Multicentric Study Group, G. Barn!, and J.A.
Traver, Servicio de Nefrologla, UniversidadAutónoma, Hospital de La
Princesa, Madrid, Spain. Eighty-one dialysis units, 54 hospitals and 27
peripheral satellite units have been studied with 4684 patients (41.8% of
the total HD patients in Spain). The global prevalence of anti-HCV was
29.5%. Anti-HCV prevalence in 2615 HD hospital patients was 34.8%
versus 25.4% in 1635 patients on HD in satellite units (P = 0.001).
Prevalence in 350 CAPD patients (31.3% of the total patients in CAPD
in Spain) was 10.2% with significant statistical difference versus hospi-
tal HD and satellite units HD (P = 0.001). Sixty-six patients on home
HD (28.5% of the total patients on home HD in Spain) had a prevalence
of 6.8%, lower than hospital HD, satellite units HD and CAPD (P =
0.001). The 42% of the involved hospitals made anti-HCV determina-
tions in the unit staff personnel. We found anti-HCV+ in I of 106
physicians (0.94%), 16 of 390 nurses (4.10%), 5 of 224 technicians
(2.23%), and none of the 27 other unit staff. Conclusions: (1) We found
a high prevalence of anti-HCV+ in dialysis patients—significantly
higher than in the healthy population in Spain. (2) This prevalence is
significantly higher in hospital HD than on satellite HD, or CAPD, or
home HD. (3) The unit staff are a risk population for HCV, higher in the
nurses. (4) This study shows the importance of HCV infection in
dialysis patients.
Single initial bolus of low molecular weight heparin: Comparison with
standard regimen and performance in 3 different membranes. C. Bernis,
N. Gomez, J. Motellon, B. Rincon, G. Barn!, E. Gruss, P. Gomez-
Manzano, J.A. Sanchez-Tomero, J.M. Fdez-Raflada, andf.A. Traver,
Services of Nephrology and Hematology, Princesa Hospital, Madrid,
Spain. Low molecular weight heparin (LMWH) has been found to have
potential clinical advantages compared to standard unfractionated
heparin (UFH). We studied the effectiveness and safety of LMWH
(enoxaparin) in hemodialysis. Twenty-seven patients on hemodialysis
received either 1JFH (4960 t 1600 LU) or LMWH, enoxaparin (4000 LU
aXa). Blood was sampled for AP'VF and plasma anti-Xa activity prior to
dialysis, at 5, 30, 60, 180 minutes and at 48 hours. Plasma anti-Xa
activity was assayed using cromogenic substrate (KABI). Paired and
unpaired Student's t-test was used for statistical analysis. Results:
Single initial bolus of enoxaparin was safe and effective. Bleeding or
thrombotic complications did not occur. APTT was significantly less for
enoxaparin than for UFH at 5 minutes (58 + II vs. 114 + 43, P < 0.01)
and at 180 minutes (36.6 + 6 vs. 54.4 + 4, P < 0.05). Anti-Xa activity
was significantly higher for enoxaparin than for UFH at 5 minutes (0.58
+ 0.2 vs. 0.39 + 0.18, P < 0.05) and 180 minutes (0.37 + 0.05 vs. 0.22
+ 0.1, P < 0.05). Anti-Xa activity at 48 hours after enoxaparin was
similar to basal levels. Performance in the 3 different membranes
(cuprophan, AN-69, and EVAL) was not significantly different. Evalu-
ation of dialyzers was slightly better on enoxaparin. Conclusions: Single
initial bolus of enoxaparin is safe and effective in hemodialysis. APTF
was less with enoxaparin and may reduce bleeding risk. Anti-Xa
activity was higher with enoxaparin, but anti-Xa activity was not
detected at 48 hours. Performance was comparable in the 3 membranes
evaluated.
Risk factors for the development of acute renal failure during bone
marrow transplantation. E. Grass, C. Garcia-Canton, J.F. Tomas, C.
Bernis, A. Figuera, M. Berberana, V. Paraiso, J. Hernandez-Jaras,
J.M. Fdz-Ranada, and J.A. Traver, Services of Nephrology and
Hematology, Pnincesa Hospital, Madrid, Spain. To assess the inci-
dence, risk factors, etiology, course and outcome of acute renal failure
(ARF) following bone marrow transplantation (BMT), a retrospective
analysis of 275 patients, 183 allografts and 92 autografts was under-
taken. ARF was defined as an increase up to 2 mg/dl of serum
creatinine, and 77 cases of ARF were diagnosed in 72 patients (28%).
The incidence was higher in allogenic (38.7%) than in autologous
(6.52%) grafts. The etiology was multifactorial 40.2%, nephrotoxics
34%, venoclusive disease of the liver (HVCD) 14.2%, graft versus host
disease (GVHD) 5.1%, sepsis 2.7%, hemolytic uremic syndrome 2.5%,
hemoglobinuria 2.7%. ARF, usually non-oliguric, occurs in 69.4%
within the first month. Thirty-five patients (45.4%) died during ARF,
and 17 cases with oliguric renal failure required dialysis mainly in
association with HVCD (70.5%). The dialyzed group had the highest
mortality (88.23%). A strong risk factor for the development of ARF
was the presence of HVCD (40% in the ARF group vs. 11% in the group
without), and age older than 20 (76.3% vs. 23.6%). Neither GVHD, nor
underlying disease, nor previous treatments correlated with the devel-
opment of ARF. Survival in the ARF group was worse at 1 month (65.5
vs. 93.6%), 3 months (74.6% vs. 47.5%) and 6 months (70.2% vs.
37.7%). Actuarial survival at 10 years was 29.7% and 53.2%. Conclu-
sions: ARF is a common and early complication following BMT,
especially in allogenic grafts. Presence of HVCD and age older than 20
were risk factors for the development of ARF. Survival is considerably
less in the ARF group.
Results of percutaneous transluminal angioplasty (PTA) in hemodialy-
sis fistula stenosis. J. Motellén, G. Barnil, S. Herndndez, D. Tagarro, B.
Rincdn, E. Gruss, J.A. Sz-Tomero, C. Bernis, P. Sanz, M. Naya, and
J.A. Traver, Departments of Nephrology and Radiology, Hospital de Ia
Pnincesa, (Jniversidad AutOnoma, Madrid, Spain. From June 1990 to
February 1992, 29 PTA of stenoses in HD fistulas were performed in 19
patients. There were 10 men and 9 women whose mean age was 58.3
15.5 years. The etiology of ESRD was diabetes in 4 cases, 3 nephro-
sclerosis, 1 amyloidosis, 4 glomerulonephritis, 4 intersticial nephritis,
and 1 polycystic kidney disease. Angioplasty balloons 4F-7F were used
for venous dilation, with pressures of 8—10 atmospheres. The stenotic
fistula was the first one created in the patient in 10 cases (35%), in 14
(48%) it was the second one, and in 5 cases 3 or more fistulas had been
performed; 23 (79%) were autogenous fistulas and 6 (21%) grafts (3
PTFE and 3 bovine carotid grafts), and 79% were located in the forearm
and 21% in the upper arm. Pre-PTA, angiography alone was performed
in 5 cases (17%) and angiography plus Doppler in 24 (73%). Clinical
signs of fistula insufficiency were increased venous line pressure (9),
decreasing blood flow rates (15), and mixed arterial and venous blood in
the extracorporeal circulation (5). In 7 patients, anti-aggregation was
needed. The stenotic lesion was wider than 70% of fistula diameter in 18
cases and between 50—70% in 10 cases. Results: Primary post-PTA
results: total success (post-PTA stenotic lesion diameter less than 10%
of fistula diameter) 46%, partial success (remaining stenotic lesion
diameter lO%—50%) 50%, and failure 4%. Post-PTA there were in-
creased blood flow rates in 34% of fistulas and decreased venous
pressures in 52%. The mean patency rate was 6.61 6.94months until
the end of the study. Using Kaplan test, the possibility for a fistula to
remain patent 21 months after I PTA is 67% and performing as many
PTA as necessary for recurrent restenosis, the possibility is 80% after
21 months. The fistula can be used for lID immediately after PTA.
Conclusion: PTA is a successful technique to preserve the function of
HD fistulas, making longer their patency rates and avoiding new
surgical reconstructions.
Treatment of the diffuse proliferative lupus glomerulonephritis with
intravenous cyclophosphamide. Experience in 11 patients. F. Santacruz,
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D. Cuevas, S. Barreto, M. Mayor, and N. Breuer, Nephrology Depart-
ment, Clinic's Hospital, AsunciOn, Paraguay. The objective of the
present study was to evaluate the response of 11 patients with systemic
lupus erythematosus (LES) and diffuse proliferative lupus glomerulo-
nephritis (GNPLD) to the treatment with intravenous cyclophospha-
mide (i.v.). The drug was administered at doses of 0.5 g/m2 the first
month, 0.7 g/m2 the second month, and I g/m2 the third month.
Afterwards, we administered doses of 1 g/m2 every three months. A
satisfactory response was considered when the urinary sediment was
normalized, the renal function was stabilized, and the proteinuria was
inferior to I g/day during a period of one year. In four patients the
response was considered satisfactory during the first year. Another five
patients had satisfactory response but they did not finish the follow-up
period. During the study, one patient presented a terminal chronic renal
failure, and another continues with mild alterations of the renal func-
tion. All patients had normal blood pressure with or without medical
treatment. The main secondary effects of the cyclophosphamide were:
nausea and/or vomiting, major infections, alopecia herpes zoster and
amenorrhea. Nevertheless, hemorrhagic cystitis or secondary neopla-
sias were not observed. In conclusion, the cyclophosphamide i.v. is
effective for the treatment of patients who suffer from the diffuse
proliferative lupus glomerulonephritis. Such treatment is easy to ad-
minister which facilitates its acceptance and compliance. The second-
ary effects of the drugs are acceptable.
Ventilatory alterations before and during hemodialysis with two differ-
ent membranes [cuprophane (CU) or polysulfone (PS)] and bicarbonate
dialysate in patients with or without chronic obstructive lung disease
(COPD). Guido 0. Perez, Jesus Navarro, Carmen Serrano, and Elio
Donna, VAMC and Department of Medicine, University of Miami
School of Medicine, Miami, Florida, USA. Disordered breathing pat-
terns during maintenance hemodialysis may occur in patients with
end-stage renal disease (ESRD). Patients with COPD may be more
vulnerable to dialysis-induced respiratory abnormalities. The present
study explored breathing patterns and blood gas values during CU or
PS-bicarbonate hemodialysis in six patients with COPD. Breathing
patterns were monitored by respiratory impedance plethysmography
during two consecutive 3—4 hour hemodialyses. Apneas were defined as
a decrease in tidal volume greater than 75% lasting more than ten
seconds. The number of apenic episodes during CU-bicarbonate (17
6 SE) was greater than those during PS-bicarbonate (10 5; P = 0.05)
dialysis. The decrement in Po2 (baseline to 60 mm) was 17 7 during
CU and 4 5 mm Hg during PS dialysis (P = 0.1). Subsequently, we
evaluated respiratory function during the two hours preceding dialysis
and during dialysis in nine patients without COPD undergoing PS-
bicarbonate hemodialysis. Apneic episodes in the two hours before (40
14) did not differ from those during the two hours after beginning
dialysis (56 19). In COPD, apneic episodes are less severe during
PS-bicarbonate dialysis. They appear to be related to uremia per se and
not to hemodialysis.
Sixteen years experience of treatment of acute renal failure (ARF) in the
Institute of nephrology of Cuba. R. Rivas, A. Martinez, I. Martinez, and
R. Bohorques. Acute renal failure is a serious and frequent complica-
tion in the clinical course of gynecological, medical, traumatic, septical,
surgical, and other conditions. The persistently high mortality rate of
ARE, despite technical improvements and proper management of
uremia, today remains a challenge to medical work. The purpose of this
paper is report the results of the treatment of 420 patients with ARF
admitted to the Intensive Therapy Unit of the Institute of Nephrology of
Cuba during the period 1976—1991. Twelve patients presented with
prerenal and 61 (death rate 6.5%) with postrenal ARF; 347 cases (death
rate 52.2%) had parenchymatous ARF, and the etiology of this group
was classified as obstetric, medical, toxic, surgical, and traumatic. The
overall mortality was 44%. Patients with parenchymatous ARF due to
surgical and traumatic causes had the worst death rates (66 and 60%,
respectively). The age classification showed that patients older than 50
(46%) had the higher death rates (69%). The prognosis in the studied
group depended on the etiology of ARF and accompanying risk factors
such as infection, electrolyte disturbances, encephalopathy, failure of
other end organs, etc. It was also found that patients presenting with
anuria or oliguria had a worse prognosis when compared with patients
who had normal urine output. We conclude that a proper protein and
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caloric intake to revert catabolic stress together with early and adequate
dialysis treatment play the major roles in the management of patients
with severe acute renal failure.
Urinary obstruction after renal transplantation. Institute of Nephrol-
ogy. 1971—1992. 0. De La Concepcion, I. Caravia, R. Reyes, and L.
Alonso, Instituto de Nefrologia, La Habana, Cuba. Urinary obstruc-
tion is a serious complication after renal transplant. The clinical feature
can be acute (anuria) or slow (hydronefrosis) and it should be readily
differentiated from other causes of diuresis fall and creatinine increase
in order to avoid the impairment of renal allograft function. A descrip-
tive and retrospective study of patients with urinary obstruction was
made to find out the incidence of this complication during a period of 21
years of experience in the institution. The clinical records of 667 renal
allografts performed in the Institute of Nephrology from February 1971
to January 1992 were reviewed. Of the sum total, 626 were from
cadaveric donors and 41 were from live donors. Urinary obstruction of
different degrees was found in 35 patients with a 5.24% total incidence
and an annual rate oscillating in a range from 0—20.8%. Ureter obstruc-
tion due to lymphocele was the most frequent entity observed: 11 cases
(31.4%), and ureteral torsion (6 cases), while lithiasis was found in 3
cases. The predominant presentation pattern of urinary obstruction was
the ureterohidronephrosis (68.6%). Surgical treatment was applied in 30
patients (85.72%), performing from primary percutaneous nephrostomy
to ureteropielostomy as definitive treatment. Five patients received
diuretic administration and subsequent observation confirmed that the
obstruction disappeared. No organ loss or deaths occurred due to this
complication. The obstructive complications found in this series are
consistent with other transplant studies.
Renal function quantification. A current problem In clinical nephrol.
ogy. R. Manalich, R. Fraxedas, L. Reyes, F. Zayas, P. Jiménez, I.
Gonzalez, and M. Smith, Institute of Nephrology, Havana, Cuba.
During the present decade many centers have diagnosed chronic renal
failure and its progression by plasma creatinine concentrations. In this
work we evaluated creatinine as a biochemical tracer of renal function,
as well as other alternative determinations to measure the degree and
the course of chronic renal failure. We obtained linear of mean
creatinine excretion per kg of body weight (OrV) against mean age for
each sex for a total of 1125 patients. The large variation of OcrV was
demonstrated independently of age and sex. A large coefficient varia-
tion (CV%) was observed for each group of patients and sex. In men for
plasma creatinine (Pr,.) 17%, for OcrV 20%, for creatinine clearance
(Ccr) 20% and for inulin clearance (C1,,) 23%. While in women for Pc
13%, for OcrV 16%, and for C. 16%. The CV% in different days for the
same male subjects were 4.39% for 1Cr, 14.37% for OcrV and 15.17%
for Car. 'ICr' 0Cr' and Ccr modify their values after protein intake.
Creatinine tubular secretion ranged between 15 and 38% of excreted
creatinine. A water load overestimates Ccr. The clearance of iodothala-
mate 1-125 (Ciodot) is similar to C1,,. Low correlation between I/Cr and
glomerular filtration rate is observed. Cr is non-sensitive to diagnose
the degree of renal function, but very precise for individual follow-up.
We propose to determine the level of renal function with Ciodot,
compare it to Cr and follow the course with 'Cr
Analysis of 148 hypercalcluric patients studied by a calcium depletion
and overload test. R. Mañalich, R. Fraxedas, and L. Reyes, Institute of
Nephrology, Habana, Cuba. Hypercalciuria is the most common
finding in stone former patients. A group of 148 hypercalciuric patients
was studied by a short-term calcium depletion (12 hours fasting) and
overload (I g calcium by oral route) test. In blood and urine were
determined calcium, phosphorus, parathohormone (PTH) and in urine
only creatimne and cyclic AMP. A classification algorythm is proposed
for the analysis of results. Most of the studied cases were of the
absorptive type (50%), while renal cause patients were very rare (2%).
AMP determinations showed great variations and did not correlate
adequately with plasma PTH. Different from Pak's report, we found
many patients with elevated fasting hypercalciuria and normal PTH,
which denotes possible bone resorption. This group must be studied by
other techniques.
Effect of GGmTc-MAG3 impurities on its pharmacokinetics. F. Zayas,
R. Fraxedas, M. Ddz, R. Mañalich, L. Aragon, A. Castell-Florit, A.M.
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Mattas, L. Abdala, F. Ponce, and A. Peix, Institute of Nephrology,
Institute of Cardiology, CEADEN, La Habana, Cuba. MAG3 prepara-
tions are routinely purified by HPLC before or after kit preparation,
prior to administration. Even though its use is widespread, there is no
common opinion about the relation between the level of impurities in
the preparation and its effect on renal excretion and on gammagraphic
images. The aim of this work is to demonstrate the variations of
pharmacokinetics of MAG3 in the presence of radiocolloids. Twenty-
nine normal volunteers were studied using two preparations of different
purity. Plasma clearance and renal excretion were determined and
simultaneously gammacamera images were obtained. No significant
difference was detected in the volume of distribution, the plasma
clearance or plasma T50. On the contrary, significant differences were
noted in the urinary excretion. A significant effect on images was
visualized only when the level of impurities was higher than 40%. We
conclude that the most significant effect of impurities is on urinary
excretion. In renal images it is shown as a delay in excretion and in
extreme cases there is liver visualization.
Metabolic disorders detected in 825 patients with nephrollthlasis by a
simplified metabolic evaluation. L. Reyes, R. Manalich, R. Fraxedas, I.
Lagomasino, P. Jimenez, I. Gonzalez, and M. Smith, Institute of
Nephrology, Havana, Cuba. The advent of technology in the last years
has allowed us to make reliable, accurate and easier diagnoses of risk
factors of nephrolithiasis in order to prevent its recurrence. We have
analyzed laboratory protocols from 825 outpatients with indeterminant
metabolic activity carried out during 2 years. Protocols included a 24
hours urine collection to determine: calcium, phosphorus, uric acid,
magnesium, citrate, oxalate, nitroprusside test, pH, culture, urinary
volume, and blood profile including analysis of total calcium, phospho-
rus, uric acid, alkaline, phosphatase, and PTH. A computerized pro-
gram listed risk factors and calculated urinary saturation level for
oxalate and its risk of crystal formation. We have found metabolic
and/or physicochemical disorders in 96.6% of the protocols. Of the
patients, 37.6% were hypercalciuric, 19.8% were hyperoxaluric, 14.7%
had decreased citrates, 11.1% were hyperuricemic, 8.6% were hyper-
uricosuric, 13.4% had infection stones, 0.5% had hyperparathyroidism,
and 0.4% had cystinuna. Hypercalciuna was found as the single factor
in 53.3% of hypercalciuric patients; it was associated with hyperox-
aluria (14.2%) and hypocitraturia (11.3%). Isolated hypocitraturia was
detected in 50.8%. These results are essential to know single and
associated risk factors and their treatment which can prevent recur-
rence.
Urinary fistula after renal transplantation. Institute of Nephrology,
1971—1992. 0. De La Concepcion, I. Caravia, R. Reyes, and L. Alonso,
Instituto de Nefrologia, La Habana, Cuba. Urinary fistula is a serious
complication after renal transplantation, with a high morbidity caused
by the presence of urine in the allograft lodge which jeopardizes the
allograft and receptor survival. A retrospective study of patients with
unnary fistula was made to determine the frequency of this complica-
tion during a period of 21 years of experience in the Institute of
Nephrology. The clinical records of 667 transplants performed from
February 1971 to January 1992 were reviewed (626 cadaveric donors
and 41 live donors). A descriptive analysis of the obtained data was
carried out (frequency and percentage). Urinary fistula was found in 43
patients with a total incidence of 6.4%, of which 37 were cadaveric
donors (86.04%) and 6 were live donors (13.09%). Annual incidence
ranged from 0 to 18%. Ureteral fistula was the most frequent entity in
this series: 25 (58.13%). The surgical procedure most frequently per-
formed was the pyeloureterostomy (25%). Ureteral ischemia was the
principal cause identified. Only 7 patients lost the allograft due to
urinary fistulae (1.04%), and 2 patients died because of this complica-
tion (0.29%). The survival of the allograft and the receptor depends
greatly on the prompt diagnosis and treatment of fistula. Even though
the results of this work are comparable to those reported by other
transplantation centers, the identification of the causes and the preven-
tion of this complication need further studies.
A multicenter study on cellulose triacetate dialyzer. A multihospital
study. Eighty stable patients were included, over 18 years old, using
cuprophane membrane for at least 3 months. The study covered 30
weeks, 4 with cuprophane (Cu) membrane and 26 weeks with cellulose
triacetate (CT). The following were studied: biochemical, hematological
and intradialysis parameters, drug modifications, adverse events and
dialyzer failure, during 1st, 3rd, 6th, 14th, 22nd and 30th weeks. This
paper presents the partial results of 40 patients, 24 of whom have
finished the 14th week of treatment. The 3rd week in which Cu was used
has been compared with the 14th week using CT, and the following
results were obtained: an increase in K1N (1.1 0.2 vs. 1.3 0.3; P <
0.01), and PCR, (1.01 0.2 vs. 1.13 0.2; P < 0.05); a decrease in
phosphate (6.1 1.8 vs. 5.4 1.6; P < 0.05), and /32 microglobulin
(54.8 14.5 vs. 36.09 9.1; P < 0.001); an increase in total CO2 (20.8
2.6 vs. 21.8 2.2; P < 0.05), with a decrease in the "anion gap"
(20.01 5.8 vs. 18.2 5.2; P < 0.05). The phosphate binder did not
decrease significantly. During the 1st and 3rd weeks (cuprophane
period) four adverse events (10%) were observed, together with one
dialyzer failure (2.5%) and nine cases of dialyzer clotting of different
degrees (23.7%). During the 6th and 14th weeks (tnacetate period)
neither adverse events nor dialyzer failure occurred, and dialyzer
clotting was observed in only one case (4.2%). A drop out happened on
the 6th week due to an anaphylactic reaction occurring after 3 minutes
of the beginning of the dialysis. With these results we can conclude that
CT has good results with a low incidence of adverse events.
Kidney function measurement in renal transplant recipients (Tx) In
treatment with and without cyclosporin A (CsA). C. Albarracln, M.L.
Martinez, J.M. Lopez GOmez, R. Perez Garcia, M.S. Garcia Vinuesa,
F. Anaya, M. Lago, and F. Valderrdbano, Servicio Nefrologia, Hos-
pital "Gregorio MarañOn," Madrid, Spain. Since the recognition of
CsA nephrotoxicity, accurate monitoring of renal function has been
imperative. In order to establish the best routine procedure to measure
kidney function, we studied different techniques of glomerular filtration
rate (GFR) estimation in 41 Tx with more than 6 months of evolution:
28 with treatment of CsA (age 43 13 years; 16 M and 9 F with a mean
follow-up of 29.6 24.1 months) and 13 without CsA (age: 37 10
years; 10 M and 3 F with a mean follow-up of 92.3 32.8 months). We
determined in all of them: serum creatinine (Se,.), 24 hour endogenous
creatinine clearance (Ce,), creatinine clearance estimated from the
Cockroft and Gault equation (CE), and clearance of 99m Tc-DTPA
(CTcDTPA). Renal plasma flow (RPF) by 131 I hippuran and filtration
fraction (FF) were also calculated. Results (mean SD) are expressed
in the table:
CTcDTPA Cr CarE RPF FF Scr
41±22 51±2445±18200±92 20±7 1.9±0.6With
CsA
Without 63±29 75±39 64±19 332±161 19±5 1.6±0.7
CsA
P <0.05 NS NS <0.05 NS NS
Ce,. and CTcDTPA in patients having treatment with CsA are lower
than in patients without CsA, Cr overestimates CTcDTPA by a mean
value of 25%, but the difference is not significant in patients without
CsA. When groups of patients with similar renal function are compared
there is no significant overestimation of Ccr by CTcDTPA between the
groups with and without CsA. In the relationship between GFR and Se,.,
the last one is to become elevated overtly until GFR has fallen by at
least 50% below normal values. We concluded that the group of Tx with
CsA has a GFR and RPF significantly lower than patients without CsA.
Neither C. nor Sr is ideal for the long-term monitoring of renal
function in renal transplant recipients, because they overestimate GFR
by a phenomenon of tubular creatinine secretion. Apparently, it's not a
direct effect of CsA in favor of tubular creatinine secretion.
Carnitine losses in hemodlalysls: Influence of different membrane-
dlalyzers and relationship with nutritional status. R. Perez-Garcia, F.
Anaya, J. Arenas, M.S. Garcia- Vinuesa, C. Albarracin, E. Junco, and
F. Valderrabano, Servicio Nefrologia, Hospital Gregorio Marañon,
Madrid, Spain. In patients undergoing maintenance hemodialysis (HD),
free carnitine (CAR) is frequently low in plasma and skeletal muscle,
but acylcarnitines may be elevated. These CAR abnormalities have
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been related with some disorders in HD patients, such as lipid metab-
olism, skeletal and myocardial muscle function, post-HD asthenia, and
cramps. The effect of intravenous L-CAR supplementation in HD
patients is controversial. The aim of this study was determine the losses
of CAR during HD sessions, with different membranes, and their
relationship with malnutrition. Forty patients (p), aged between 28 and
64 years, 21 males and 19 females, stable on HD for a period between
6 months and 12 years, were studied. Free CAR and acylcarnitines were
determined in plasma, and their clearances (CL) measured during HD,
and compared to creatinine and urea CL, with different membranes:
cellulosic 12p; AN69 13p; Polysulfone (PSF) 8p and Cellulose triacetate
(CTA) 7p. Dialysis tolerance and nutritional status, biochemical, an-
thropometric, and urea kinetic, were studied. Mean total carnitine
(CAR) level in plasma was normal, 55.9 2 nM/mi, mean + SEM, but
free-CAR was decreased, 31.9 1.5 nM/mI, 60%p. Short-chain acyl-
carnitines were elevated in plasma, 19.5 1.3 nM/mi. Carnitine
clearances with high-permeability membranes (HP) were significantly
higher than cellulosic ones, about > 30%. CAR losses per HD with HP
dialyzers were calculated in 888 microM and with Cellulosic in 685
microM. They represent a high proportion of normal daily metabolism
of CAR. Nine out of 40 p show severe malnutrition. The best predictors
of malnutrition were: MAMC, serum albumin, PCR. Free-CAR corre-
lates significantly with: PCRJKV, PCR, serum albumin. Free-CAR was
decreased in all patients with a poor nutritional status. High losses of
CAR and low protein supply may lead to chronic negative CAR
balance, and may be associated with malnutrition.
Plasma tumor necrosis factor-alpha (TNF) and lnterleukin-6 (IL-6) in
patients on hemodialysis (LID). R. Perez-Garcia, F. Anaya, M.S. Garcia
Vinuesa, C. Albarracin, A. Tejedor, J. Chisvert, and F. Valderrabano,
Servicio Nefrologia, Hospital Gregorio Marañon, Madrid, Spain. TNF
and IL-6 are two cytokines that may be of pathogenetic relevance in at
least some of the collateral effects observed in HD patients, and are
actually considered as markers of biocompatibility. The aim of this
study was to observe changes in these cytokines in relation with
different membrane-dialyzers combined with either presence or ab-
sence of endotoxins. In 37 adult patients on maintenance HD during a
period between 1 and 15 years, plasma levels of TNF and IL-6 (RIA,
Amerlex) were measured: before, and at 15, 120, and 180 minutes of the
HD session. Patients were successively dialyzed using Polyacrylonitrile
AN69, Polysulfone (PSF), Cellulosic triacetate (CTA) or Cuprophan
membranes on hemodialysis with bicarbonate dialysate and in acetate-
free hemodiaffitration with AN69. Presence or absence of bacterial and
pyrogen contamination was studied in dialysate. There are great vari-
ations of basal levels of these cytokines between different patients,
without any clinical evidence of active inflammatory disease, Mean
plasma IL-6 and TNF levels were elevated in HD patients, 43 18
pg/mi and 425 192 pg/ml, mean + SD, respectively. No statistically
significant differences in plasma TNF and IL-6 were found during HD
when analyzing all determinations together. TNF increased signifi-
cantly during HD with cuprophan membrane, but it did not with AN69
or PSF. When there was evidence of dialysate contamination, plasma
IL-6 increased during HD with PSF, AN69 and CTA, but not with
Cuprophan. Patients on chronic HD with AN69, PSF and CTA and
contaminated dialysate had higher pre-HD plasma TNF and IL-6 levels
than who those were on Cuprophan or with sterile dialysate. We
concluded that at least in some patients, TNF and IL-6 may be induced
systemically during HD, depending on dialysis-related factors. Results
suggest that the permeability of dialyzers and water contaminants may
be of greater importance for systemic cytokine induction.
Epidemiology of glomerulonephritis (GN) in Spain, 1991 Data. Spanish
Registry of Glornerulonephritis (REGN). The REGN was established in
1987 by implementation of the Cooperative Study Group of Glomeru-
lonephritis (ECGN) and the Spanish Society of Nephrology (SEN). The
REGN presented in October 1992 the epidemiological study of GN in
Spain for the year 1991. Data reported to REGN included: Cases of ON
diagnosed by biopsy, clinical features that conditioned renal biopsy,
and ON diagnosed only in clinical basis. Patients were considered as
"adults" when they were 15 years old and older, and "children" if they
were younger than 15 years. Patients with a functioning kidney allograft
were excluded from the study. Patients were classified according to
their kidney pathology into 9 categories of primary GN (PGN) and 4 of
secondary GN (SGN). Two new categories were considered for the first
time this year: amyloidosis and 1gM Nephropathy (1gM) with idiopathic
nephrotic syndrome (NS). Sixty-five referring hospitals reported adult
cases and 20 hospitals reported ON in children, 75% of response.
Adults' results: the number of biopsy patients registered during 1991
was 1169. Clinical data were reported in 775 out of 1169 patients
biopsied. The percentage PGN/all GN was 69%. Annual ratio of
membranoproliferative GN/PGN during 1991 was 7.5%; this ratio kept
decreasing according to the expected behavior proposed by REGN and
ECON using the data of 1970—1990. IgA ON frequency remained
without significant variation, 22.2% of PGN, being the most frequent
ON in Spain. Clinical syndromes of IgA ON at time of renal biopsy have
changed, macroscopic hematuria is decreasing, and persistent urinary
abnormalities (proteinuria and microscopic hematuria) are increasing.
Extracapillary ON (EON) is more frequent in the northern region than
in the rest of Spain. Rapidly progressive ON (12%) was due to EGN and
vasculitis (VAS) in 70% of cases, 8.7% to lupus nephritis (LES), and
3.4% to IgA ON. Patients with nephrotic syndrome (39.2%) presented:
18.4% membranous GN (MGN); 15.8% focal glomerulosclerosis (FOS);
13.6% minimal change ON (MC); 12% LES. LES, 144 cases reported in
1991, represents 39.6% of SON. Systemic VAS, with 21,7%, is the
second most frequent cause of SON. Amyloid nephropathy was found
in 15.4% of SON. Children's results: the report included 651 children
diagnosed with ON on a clinical basis and 279 of them were biopsied
(1989—91). Fifty-six percent of NS were biopsied with only 21% being
acute nephritic syndromes. NS represents 66% of indications of biopsy
in children. In 1991, MC, with 28%, was the PGN most frequently
biopsied in children, IgA ON 20%, FGS 15.1%, endocapillary prolifer-
ative 8.1%, EGN 7%, and 1gM 7%. VAS and LES were the first causes
of SON, 50%. An overall annual incidence of 41.2 new ON biopsied per
million of adult inhabitants was found, of whom 30 belonged to PGN,
similar to 43 and 32, respectively, reported in 1987 and 1988.
Renal transplantation (RT) of patients with antibodies anti-hepatitis C
(HCV) who received kidneys from anti-HCV positive donors. A prospec-
tive study. f.M. Morales, G. Castellano, F. Colina, M.A. Muñoz, A.
Fuertes, A. Andres, R. Sanchez, and J.L. Rodicio, Hospital 12 de
Octubre, Madrid, Spain. The use of organs from anti-HCV positive
donors is controversial. Due to lack of organs, our policy is to
transplant anti-HCV positive kidneys in seropositive recipients, with
good DR matching and after informed consent has been obtained.
Prospectively we analyzed the clinical course after RI of 8 anti-HCV
positive recipients, Group I [6 with chronic hypertransaminasemia (CH)
and 2 with normal liver values] who received a kidney from a seropos-
itive HCV donor. Results were compared with those of 15 seropositive
patients (11 with CH) who received a kidney from a seroaegative donor.
HCV antibodies were determined by ELISA second generation and
RIBA-4. All were on steroids and cyclosporine. In the first post-RI
month liver biopsies were performed: 6 in Group I [5 minimal change
(MC)], I persistent chronic hepatitis (PCH), and 11 in the control group
(5 MC, 2 PCH, 2 active CH 1, siderosis). During the follow-up (10.3
5 months, range 6—25) the most remarkable finding was the good
evolution of patients of Group I: Only one exhibited ALT > 2.5 normal
values 6. Of the patients with PCH, at the 5th month, 3 showed mild
liver abnormalities and the remaining 4 with normal liver values. There
were no differences with the control group: 10 showed CH and 2 of
them with ALT > 2.5 HCV serology remained positive in all. In
summary, our results suggest that seropositive HCV kidneys could be
transplanted in positive HCV recipients without an important risk of
developing severe chronic liver disease.
Usefulness (SDCS) of single dose captopril scintigraphy In the diagnosis
of transplant renal artery stenosis (TRAS). A. Mazuecos, A. Manrique,
V. Nuñez, B. Gomez, G. Hidalgo, A. Andrês, E. Hernandez, J.L.
Rodicio, and f.M. Morales, Hospital 12 de Octubre, Madrid, Spain.
TRAS is a well-known cause of arterial hypertension (AH) after renal
transplantation (RI). The role of (SDCS) in the TRAS diagnosis is not
well-established. The aim of the present work was to study if SDCS
could be useful in the diagnosis of TRAS. Thirteen renal transplant
patients (serum creatinine <2.5 mg/day, treated with steroids and C5A)
with suggestive clinical findings (AH difficult to control, murmur in the
graft area and/or mild worsening of renal function) and duplex doppler
ultrasound indicative of TRAS (flow velocity >7.5 kH2 in the stenosis)
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were studied. Scintigraphy basal and post-captopril (50 mg v.o.) with
MAG-TCm 99, (irrespective of the results) and a digital angiography
(AD) were performed in each one. Four of them (30.7%) showed TRAS
lumen vascular reduction < 70% (Group I). In the remaining 9 there was
no evidence of TRAS, although in 6 cases severe kinking in the artery
was observed (Group II). In Group I, SDCS was positive in all (typical
modification in the captation, elimination or scintigraphy morphology,
sensibility 100%). In Group II, in 6 cases SDCS was negative and in 3
positive (23% of false positives). Remarkably no patient with negative
SDCS presented TRAS in the DA. In three patients with TRAS, after a
successful angioplasty, SDCS was normalized. In summary, our results
suggest that SDCS is a safe, useful and sensitive method in the
diagnosis of TRJtS and in the post-AD follow-up. Therefore, we
propose that it should be included in the TRAS screening before AD.
Gancyclovir therapy for cytomegalovirus infection in renal transplant
patients. G. Rojo, G. Fernandez, C. Garcia, M.A. Muñoz, S. Sancho,
C. Campo, A. Mazuecos, A. Andrés, J.M. Aguado, f.M. Morales, and
J.L. Rodicio, Hospital 12 Octubre, Madrid, Spain. Gancyclovir (GAN)
is the elective antiviral agent against CMV infection. We present our
preliminary experience in 8 first renal transplant (RT5) patients (6M, 2F,
aged x 48 12 years) with CMV infection who received GAN treatment
among 164 RTs performed in the last two years under CsA and steroids.
CMV infection was diagnosed by BAL and/or liver biopsy and/or blood
and urine culture and/or serology. Six of them presented an episode of
acute rejection immediately before, and in 4 it was necessary to
administer an OKT3 rescue therapy (5 mg i.v. during 14 days). GAN
was used i.v. in doses adjusted to renal function (2.5—3.2 g total doses
during 14—28 days). Hyperimmune gammaglobulin was administered
combined with GAN in 2 cases. The therapeutic response was excellent
in 6 cases and the remaining exhibited residual pulmonary fibrosis and
the other liver CMV infection. Leukopenia was observed in 2 patients,
and reversible nephrotoxicity was evident in 3 patients with CsA
treatment. In summary, the treatment of CMV infection with gancyclo-
vir in RI patients was effective with scarce side effects.
Renal transplantation (RT) in patients more than 50 years with double
therapy with an optional change to cyclosporin A (CsA) monotherapy(M). Long-term results. f.M. Morales, A. Andres, C. Campo, M.
Praga, T. Ortuno, E. Hernandez, f.M. Alcazar, J.L. Rodicio, Hospital
12 de Octubre, Madrid, Spain. Immunosuppressive protocols with low
steroids (S) and CsA monotherapy are indicated in low renal transplant
patients, especially in older people. The aim of the study was to analyze
the long-term evolution after RT of patients > 50 years with a protocol
of steroids (S and CsA with optional change to CsAM. In our Hospital
between October 1988 and September 1991, 27 renal transplants were
performed: 98 (23%) were > 50 years (x56.7 4.9) (58 > 55 and 15>
6 years). They received S and CsA (10—14 mg/kg/day). In 18 selected
patients [>1 year of graft functioning, x20.9 11.6 months, not
hyperimmunized, first transplants, without recurrent acute rejection
(AR) and with good tolerance to CsA]; S were withdrawn maintaining
low CsA doses. Results were compared with those of a comparable
group of 20 patients, who were maintained on the initial immunosup-
pression. Actuarial global graft survival rate % (Kaplan-Meier with
Mantel test) was: 90.6, 80.2 and 68.7 without differences with patients
< 50 years: 90.9, 83.2 and 70.6 at one, three and five years, respec-
tively. Actuarial patient survival rate was similar (91.4% vs. 95% ours)
at 5 years. Post-transplant acute tabular necrosis, CsA nephrotoxicity
and AR incidence was similar, although there was a tendency toward
lower AR in older patients. Four patients died (3 sepsis, 1 cancer), and
14 lost their grafts, mainly by chronic rejection. From M CsA patients
only 3 presented AR [one was uncontrollable and in the remaining 5
(83%) the clinical course was excellent, maintaining stable renal func-
tion at 2 years (Sr 1.15 0.18 mg/dl)] with CsA doses of 2.79 0.87
mg/kg/day, without differences from the control group in the incidence
of AR, CsA nephrotoxicity, or in the association of azathioprine, In
conclusion, our results demonstrate that in older patients, a protocol
with low S and CsA doses with optional change to M CsA is a useful
treatment with comparable results to young people and with low
morbidity and mortality.
Corynebacterium Urealyticum: A new pathogen In renal transplant
(RT) patients. f.M. Morales, f.M. Aguado, A. Andrès, R. Diaz Gonza-
lez, M.A. Martinez, E. Salto, M. Praga, E. Hernandez, and J.L.
Rodicio, Hospital "12 de Octubre," Madrid, Spain. Corynebacterium
Urealyticum is a slow-growing, urea-splitting, multiantibiotic-resistant
microorganism that may produce urinary tract infections (UTI5) and
deposits of struvits on the vesical wall or on the renal pelvis, leading to
the development of incrusted cystitis (IC) or incrusted pyelitis (IP).
During a 2 year period, Corynebacterium Urealyticum (10 cfu/ml) was
isolated from the urine of 16 RT patients (10 males, 6 females),
representing 10 percent of all RTs performed during this period. Only 4
patients had concurrent UTIs by bacteria other than Corynebactenum
Urealyticum. The time elapsed from the RT to the first culture of
Corynebacterium Urealyticum from urine oscillated from 5 to 24
months (mean 10 months). Alkaline urines with struvite crystals,
microscopic hematuria, and sterile conventional urine cultures were
present in all our cases. The infection was symptomatic in 6 cases (IP 4
pts, IC 1 pt, UTI 1 pt) and non-symptomatic in the remaining 10 cases.
The predisposing factors for the development of UT! by Corynebacte-
rium Urealyticum were: urologic procedures [nephrostomy, prolonged
vesical catheterization (70%), previous use of antibiotics (75 percent),
and previous UTIs (50%)]. Prolonged ureteral catheterization with a
"pig-tail" catheter was performed in the 4 patients with IP, but in none
of the other patients (P < 0.05). All patients with IP developed
obstructive uropathy with deterioration of the renal function and
pyelonephritis or renal abscesses. Chronic urinary discomfort and
macroscopic hematuria were present in the patient with IC. The most
effective antibiotics in vitro were vancomycin (100%), rifampin (60%),
and ciprofloxacin (40%), but Corynebacterium urealyticum showed
resistance to the majority of the conventionally used antibiotics for the
treatment of UTIs. Vancomycin (14-2 1 days) was used in all the
symptomatic patients. A asymptomatic patient who had a ureteral
catheter in place was prophylactically treated with vancomycin i.v. for
14 days, and he did not develop symptoms. Despite the antibiotic
treatment, all patients with IP required a derivative procedure and a
cystoscopic resection of the incrustations was necessary in the patient
with IC. We conclude that Corynebacterium Urealyticum could have a
pathogenic role in the development of serious complications in RT
patients, and it should be investigated in RI patients with negative
routine urine cultures who develop an obstructive uropathy or chronic
urinary symptoms.
Liver pathological lesions in patients with dialysis-acquired hepatitis C
(HCV) who receive a renal transplant. J.M. Morales, G. Castellano, F.
Colina, A. Andres, A. Blanco, M.A. Munoz, E. Hernandez, and J.L.
Rodicio, Nephrology Department, Hospital 12 de Octubre, Madrid,
Spain. Dialysis-acquired HCV can represent a serious complication
after renal transplantation (RI). The scarce histological information
derived from high risk of complications after biopsy this a problem in
dialysis and mainly after RT. We have started a prospective clinical and
pathological follow-up study in HCV patients after RT and the initial
point is the liver biopsy performed early after surgery. In our hospital
between October 1990 and April 1992, 12 renal transplants had been
performed. Thirty-five of them (29%), 15 with normal liver values and
20 with chronic hypertransaminasemia (CH), exhibited antibodies anti-
HCV positive (immunoenzyme assay ELISA 2nd generation and RIBA-
4). In 27 of them (77%), 10 with normal liver values and 17 with CH, a
liver biopsy was performed between the 15th and 30th post-RT days
(when renal function and Ivy test were normal). There were no
complications post-biopsy. The most frequent histological picture was
minimal change (62%), that was the only diagnosis observed in patients
with normal liver enzymes, in two cases associated with Siderosis.
chronic hepatitis (CH) was evident in 8, 4 persistent CH, and 4 active
CH (with a Knodell index between S and 12), and the remaining 2,
Siderosis alone. In summary, liver pathological study of patients with
dialysis-acquired HCV showed a pattern almost normal in 62% of
selected patients who received a renal transplant. The incidence of
severe diagnosis as ACH is relatively low and it was only present in
patients with chronic hypertransaminasemia.
Influence of calcium antagonists (CA) on short-term function after
renal transplantation (RT) in adults from pediatric donors (PD) under
cyclosporine (CsA) therapy. f.M. Morales, A. Andres, E. Hernández,
M.A. Munoz, T. Ortuflo, M. Praga, R. Diaz-Gonzalez, and J.L.
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Rodicio, Hospital 12 de Octubre, Madrid, Spain. There is no experi-
mental or clinical information about the action of CA in the growth and
function of the kidney under CsA therapy. This clinical model can be
represented by renal transplantation (RT) in adult from PD. Prospec-
tively we study the clinical course in the first six months after RT of 5
patients (ps) (aged 43 13.3 years, range 28—57) who received a
cadaveric kidney from PD < 6 years of age (X 39.8 20 months, range
12—72). In order to avoid CsA nephrotoxicity (CsAN) they were treated
with Nifedipine, a CA, 40—80 mg/day. Immunosuppressive treatment
was steroids (S) and CsA; in two of them CsA was added 14 days alter
RT. Delayed graft function (DGF) was seen in 2, acute rejection (AR) in
2 (both controlled, one with S and the other with OKT3), and only one
suffered early CsAN with low FENa and CsA blood levels elevated in
the early postransplant period. Renal function was improving during the
follow-up, exhibiting at 6 months. S. 1.44 0.47 mg/dl (range 1—2) and
70.9 20.7 ml/m/l.73 m2 (range 40—95) with a CsA dose of 3.6
1.23 mg/kg/day. Remarkably, nobody present had transitory acute
episodes of CsAN during the follow-up. The size of the kidney
measured by ecography was normal in all (11.2—12 cm longitudinal
diameter) except for one patient who presented DGF and AR. Slight
proteinuria was only evident in 3 (0.10—0.20 g/day), and the other
presented microalbuminuria. In summary, our results suggest that CA
could improve the short-term clinical course of RT from PD when a
protocol of low CsA doses is used.
Simvastatin (SIM) therapy of hypercholesterolemia associated with
chronic rejection (CR) after renal transplantation (RT). A prospective
study. M.A. Munoz, J.M. Morales, A. Andrès, S. Larumbe, M.T.
Gomez, A. Araque, M. Delgado, J.R. Mosquera, and J.L. Rodicio,
Hospital "12 de Octubre," Madrid, Spain. HMG-CoA inhibitors are
useful drugs in the treatment of hypercholesterolemia (HC). Until now
there has been no information about the use in patients with CR after
RT. The aim of the study was to treat HC associated in CR with SIM
and to know their possible influence on renal function, proteinuna and
CsA blood levels (TDx monoclonal). We selected 12 patients (9 males
and 3 females aged 48 15 years) diagnosed with chronic rejection
(clinical and histological data) maintaining stable renal function and
with HC >250 mg/dl in three determinations in spite of a hypocaloric
diet. Eight received steroids, CsA and azathioprine, and the remaining
were on conventional therapy. All received SIM 10 M/day during two 3
months.
Basal I month 2 months
TOTAL 292.25 32.03 225.3 38.2a 221.2 21.6a
CH
HDL 67.5 19.5 63.21 17.9 64.2 19.2
CH
LDL 168.63 31.9 143.9 3785b 134.2 33.5
CH
CH/ 5.11 1.79 4.09 0.82 1 0.95
HDL
TG 166.8 78.8 133.8 63.3 169.5 78.39
CLCR 43 17.5 41.6 14.4 45.8 23.11
a P < 0.001; b p < 0.05. Abbreviation is TG, Triglicerides.
After SIM therapy a good control of total HC and LDL-HC was
observed, without change in renal function and proteinuna. Interaction
between SIM and CsA, using low CsA doses (1.92 0.6 basal and 1.67
0.35 mg/kg/day at 2 months), there were no observed rabdomiolisis or
elevations in liver enzyme values in any case. In conclusion, our
preliminary data suggest that low dose of SIM could be useful in order to
control HC in patients with R, with good clinical tolerance that permits
concomitant therapy with CsA. In this short-time of follow-up, SIM
therapy was not associated with changes in renal function and proteinuria.
Aluminium (Al) removal: Effect of different forms of desferroxamine
(DFO) administration. W. Dout hat, J.L. Fernández MartIn, R. Mouzo,
and J.B. Cannata, Bone and Mineral Research Unit, Hospital Central
de Asturias, and Renal Unit, Hospital Camino de Santiago, Ponfer-
rada, Spain. Recent results from a group of patients in whom we
sequentially evaluated the Al removal with or without the use of DFO
(15 mg/kg/week), demonstrated the amount of Al collected in the
dialysate was always between 10—15% of the total serum Al. These
findings suggest the increment in Al removal using 15 mg/kg of DFO 44
hours before dialysis was mainly achieved due to the increment in
serum Al, rather than due to an increment in the percentage of
ultralllterable Al. The aim of this study was to compare, in hemodialysis
patients, the effects of different forms of DFO administration (15
mg/kg), (a) 44 hours before dialysis (classic scheme), and (b) 1 hour
before dialysis (new scheme). The study was divided into: Phase 1: we
measured Al removed only in one dialysis session after DFO adminis-
tration in 23 patients on HD; and Phase 2: we measured Al removed
throughout the three dialysis sessions following the DFO administration
in 10 patients on HD. In both phases we investigated the Al removed
measuring the amount of Al excreted to the dialysis fluid, moreover
measuring the serum Al and the dialysis solution. Results in phase I
(one dialysis): when the DFO was given 44 hours before dialysis, we
observed a higher Al removal compared with the results obtained when
the DFO was given immediately before dialysis (Al removed: DFO 44
hrs: 9.5 5.1 sgfliter; DFO I hr: 5.0 3.0 tg/l, P < 0.01). However,
with the new scheme, the Al removed according to the serum Al level
achieved with DFO (ratio Al removed/serum Al) was similar in both
schemes (DFO 44 hrs: 4.99 2.04%;DFO 1 hr: 5.62 2.98% NS). Due
to these preliminary results, the study was completed with a second
phase aimed at knowing the amount of Al removed in three dialysis
sessions (one week of dialysis) using both schemes. Results in phase 2
(one week): throughout one week of study using the classic scheme of
DFO administration, we observed the highest serum Al peak (128.9
62.7 pg/liter) 44 hours after DFO administration. With the new scheme,
the serum Al peak was lower (97.0 37.7 tg/liter), but it was also
achieved later (48 hrs after DFO administration) despite with this
scheme part of the DFO and the DFO-Al complex should have been
mobilized in the previous dialysis. The total amount of Al removed in
one week (three dialyses) was similar using both schemes (DFO 44 hrs:
6.12 2.97 zg/liter DFO 1 hr: 6.32 2.35 pg/liter). We concluded that
these results demonstrated 15 mg/kg of DFO given before dialysis (new
scheme) was as effective as the same dose administered 44 hours before
dialysis (classic scheme). With the new scheme, this amount of Al
removal was achieved with significantly lower increments in serum Al
(more safe for patients). The new scheme had the best performance
(similar removal of Al with lower serum Al increments) and as demon-
strated with this new strategy, we are mainly removing Al thanks to an
increase in the amount of ultrafilterable Al, with little changes in the
total amount of serum Al, a goal to be achieved with the use of any
chelating agent.
Effect of desferroxamine (DFO) on osteoblast proliferation. C. Tzanno-
Martins, R. Elorriaga, P. Menendez, M. Naves, S. McGregor, V.
Jorgetti, and J.B. Cannata, Hospital Central de Asturias, Oviedo,
Spain, and Universidad de San Pablo, Brasil. In the last few years DFO
has been used to treat patients with chronic renal failure and aluminium-
induced bone disease. In addition, recently it has been suggested that
DFO could influence the metabolism of bone cells. Therefore, in this
study our aim was to analyze the effect of DFO on the proliferation of
the osteoblasts and to evaluate the likely effect of iron in this process.
MG63 cell line was used and two consecutive studies were carried out.
In the first, different concentrations of DFO were added (1, 2, 5, 10, 20,
40 and 100 /LM) and the cells were incubated for 24 and 48 hours. In the
second study, DFO was used at 50, 100 and 200 M adding iron citrate
at a concentration of 100 M. When the cells were incubated with DFO
without iron a decrease in proliferation was observed with all concen-
trations of DFO (P < 0.01). In the second study in which iron was
added, when the concentration of DFO and iron was the same, or, when
iron was in excess, there was no decrease in proliferation. Neverthe-
less, when the concentration of DFO was higher (at least twice the iron
concentration) the proliferation decreased compared with the control of
this experiment, but was still higher compared with the results obtained
when there was no iron in the medium (P < 0.01). These preliminary
results demonstrate that DFO may inhibit osteoblast proliferation, and
its effect appears to be at least partially related to iron depletion. This
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interference should be kept in mind when we use DFO in patients with
iron deficiency because the effect on bone cells may be different from
what one might expect.
The effect of aluminum on bone cells: An effect modulated by cytokines.
S.J. McGregor, M.J. Fernández Menéndez, P. Menéndez Fraga, J.H.
Brock, and J.B. Cannata, Unidad de Investigacion, Bone and Mineral
Research, Hospital General de Asturias, Oviedo, Spain, and Depart-
ment of Immunology, Western Infirmary, Glasgow, Scotland, United
Kingdom. Aluminum is found deposited in high concentrations in more
than 3 out of every 5 classic bone lesions in renal osteoporosis.
Independent of the route of entry, the Al is deposited in the highest
proportion in the bone tissue. This predisposition to localize in the
bones may be mediated by cytokines such as interleukins 1 and 6 (IL-i,
IL-6) and tumor necrosis factor (TNF), factors which are increased in
renal patients as a consequence of dialysis and renal failure and which
may favor uptake of Al through binding to transfemn (TO receptors in
a similar way as iron (Fe). The object of this work was to evaluate the
effect of (a) IL-i and TNF, and (b) IL-6 on the incorporation of
thymidine, the synthesis of DNA and the cellular uptake of Al in the
human osteobiast "like" cells MG-63. The cells were incubated for 24
or 48 hours in MEM-Earle Medium with the addition of: 0.2% fetal calf
serum, 0.2% human albumin and 100 og/ml AlTf to which were added
concentrations of IL-i or TNF (1, 10, 50 and 100 U/mi) or IL-6 (0.001,
0.01, 0.1, 1 and 10 units/mI). The experiments were each carried out six
times, and within each experiment 4 replicates per assay. The results
with IL-i and TNF were consistent but the action of IL-6 although
evident was more variable. We observed that IL-i like TNF increased
the uptake of AITf by the osteoblasts reaching significance at 50 U/mi (P
< 0.05), especially at 48 hours. Also, TNF and IL-i decreased the
incorporation of thymidine (Figure) and synthesis of DNA by the bone
cells, although IL-I always to a lesser extent than TNF. The results of
incorporation, synthesis and uptake of Al were more evident at 48 hours.
significant differences in Al in bone (101.6 13.4 vs. 1.04 0.2 g/g Al
in tibia in the experimental and control groups, respectively); (B) in the
experimental group, a gain in bone mass compared with basal values
and with the control group (in lumbar bone 242.9 24 vs. 226.2 13 and
231.9 24 mg/cm2, respectively; P < 0.02); (C) an increase in trabecular
bone volume with a moderate increment of the surface trabecular with
osteoid; (D) no differences in calcium, phosphorous, VFH or pH between
groups. We found, however, a negative correlation between serum Al and
osteocalcin in the experimental group. In conclusion, in the presence of
NRF Al was able to augment bone mass stimulating the synthesis of bone
matrix. However, in both NRF and chronic renal failure we found a small
negative effect on bone mineralization.
Different techniques in the diagnosis of aluminum stores in bone in
chronic renal failure. J.L. Fernández Martin, P. Menéndez Rodriguez,
P. Menéndez Fraga, B. DIaz Lopez, and J.B. Cannata, Bone and
Mineral Research Unit, Hospital Central de Asturias, Oviedo, Spain.
Bone disorders caused by aluminum stores in bone are still very
important in chronic renal failure. We therefore needed a reliable
method for the diagnosis of aluminum stores in the bone. The aim of this
study was to compare the sensitivity and specificity of Aluminon and
Solochrome Azurine stain and their correlation with bone aluminium
content. The study was performed on 30 biopsies of iliac crest from
patients on chronic hemodialysis. Aluminum content was determined by
graphite furnace atomic absorption spectrometry. The range of aluminum
levels were from 2.36 sg/g to 228.6 sg/g and all samples were stained with
both Aluminon and Solochrome Azurine. Microscopic examination was
considered negative (—), positive (+) and double positive (+ +). It was
correlated with aluminum content. All biopsies with Al content below 20
zg/g (N — 7) were Aluminon negative. There were 7 biopsies in which the
Al content was above 20 sg/g but the Aluminon results were negative
(range 22.1—119.2 g/g). These samples showed hyperparathyroidism with
very high bone activity. The other biopsies (N = 16) were either Aluminon
positive (+) or double positive (+ +). Solochrome Azurine stain was
negative when the aluminum was under 20 g/g except for one biopsy.
This last sample was also Perls positive (Iron stain). The biopsies with
aluminum above 20 g/g were all positive.
These results suggest that the release of cytokines produced as
consequence of dialysis could augment the toxic effect of Al and at a
level of bone metabolism, not only increase intracellular concentrations
but also interfere with the multiplication and growth of the bone cells.
Aiummnum (Al) effect on bone metabolism in the presence of normal
renal function (NRF). C. GOmez Alonso, P. Menéndez Rodriguez, M.J.
VirgOs, M. Serrano, M.A. Gonzalez Carcedo, J.B. Cannata, Bone
Mineral Research Unit, Hospital Central de Asturias, Oviedo, Spain.
In the presence of chronic renal failure (CRF) the Al toxic effect on
bone is a very well-known fact. Nevertheless, bone effects with normal
renal function still are not well-understood. The aim of this work, done
in two phases, has been to evaluate the effect of "toxic" Al concen-
trations in bone metabolism on NRF animals. Phase 1: Histological
assessment and Al tissue quantifying in rats with NRF and chronic
AIC13 intoxication (i.p., 2 mg/day, 5 days per week for twelve months,
N = 6) compared with a control group without Al exposure (N = 5).
Phase 2: Histological and density values (DEXA) assessment of AlCl3
effect (i.p., 10 mg/kg/day, 5 days per week for 4 months, N = 8) on
lumbar and caudal vertebraes and tibia, as well as biochemical param-
eters of bone turnover in osteopenia rats (who were given oral NH4CI
during 6 months) compared with results from a control group. In Phase
I we observed significant differences in bone Al concentration (63.7
16.5 .og/g) in the Al intoxication group; 1.13 0.29 rg/g in the control
group; also, we observed normal trabecular bone mass in tibia of Al
group and decrease in the control group. In Phase 2 we observed: (A)
Solochrome Azurine was more sensitive than Aluminon (always posi-
tive with Al > 20 mg/g), but does not appear to be more specific.
Aluminon was not sensitive enough and we were not able to detect
aluminum stores when there was a high bone activity. Iron appears to
interfere with aluminum detection in both histochemical techniques.
We must measure aluminum if we want to avoid these restrictions.
New perspectives in the treatment of aluminium intoxication. R.
Elorriaga, fL. Fernández Mart(n, P. Menéndez Fraga, P. Menéndez
Rodriguez, ML. Naves, andJ.B. Cannata, Unidad de InvestigaciOn de
Metabolismo Oseo y Mineral, Hospital Central de Asturias, Oviedo,
Spain. Desferroxamine (DFO) has been shown to be effective in
removing iron (Fe) and aluminium (Al) from the stores. However, it is
inactive when given orally and there is some evidences about its toxic
effect. Recent papers have claimed that LI (I ,2-dimethyl-3-hydroxipy-
rid-4-one) is effective, via oral, in removing Fe. Preliminary results
show that on a short-term basis, LI is able to remove Al from
Al-intoxicated animals with chronic renal failure (CRF). The purpose of
this study was to evaluate: "in vitro" the LI effect on ultrafiltrable-Al,
and "in vivo" the long term effect of LI on Al removal from tissues
stores of chronically Al-overloaded rats with CRF. In vitro: we mea-
sured the ultrafiltrable-Al with different concentrations of DFO and LI
(0, 2, 4, 6 and 8 mg/l). In vivo: 22 rats with CRF, by 5/6 nephrectomy
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(NFX), received ip injections of AICI3 (2.5 mg/Kg of Al) 5 days/week for
9 weeks, as show in the scheme:
--1W 9 weeks 1W 6 weeks 1W--
NFX Intoxication
I I I I
Treatment (Gil, III y IV)
After the period of Al intoxication the rats were divided in four groups:
Group I: (N 6) was sacrificed and the other three groups received
different treatments during another 6 weeks. Group II: (N = 5) received
30 mg/kg/day of i.p. DFO. Group III: (N = 5), Placebo, received by a
gastrointestinal tube, saline solution 0.9% (pH = 2.7). Group IV: (N
6) received also by a gastrointestinal tube 50 mg/kg/day of Li. Before
and after the treatment period, Al in bone and liver was quantified by
atomic absorption spectrometry (AAS) and histological evaluation of
undecalcified bone was performed. In vitro both Ll and DFO were
similar increasing the ultrafiltrable-Al (—30%). In vivo both Ll and DFO
were effective at reducing the Al concentration in bone (P < 0.05)
quantified by AAS. Moreover, LI showed a more clear histological
improvement than DFO and placebo, suggesting a more specific effect
of drug in bone.
Acute renal failure in patients who have undergone hepatic transplant.
C. Sanz-Moreno, f.M. Garrancho, V. Cuervas-Mons, E. Baamonde, J.
Hernandez, J. Fernandez, J. Botella, Department of Nephrology and
Liver Transplantation, Hospital Puerta de Hierro, Madrid, Spain. One
of the complications of liver transplant is the development of acute
renal failure (ARF), which makes treatment more difficult and the
prognosis more pesimistic. We studied the evolution of the hepatic
transplant carried out in our hospital from January 1990 to September
1991 (N = 59). Of these 16 (25.4%) developed ARF, which required
treatment with blood purification techniques. The following factors are
possible causes of the ARF: (a) greater incidence of hypotension during
surgery (P < 0.05); (b) higher number of blood transfusions (P < 0.05);
(c) higher bilirubin figures during post-op (P < 0.05); (d) use of
nephrotoxic antibiotics (P < 0.05) and (e) higher number of repeated
surgical interventions (P < 0.05). Blood purification with the continu-
ous arterio-venous ultrafiltration technique was used on 4 patients,
continuous hemodiafiltration on 6, conventional hemodialysis on 2, and
4 patients required a few or all of these techniques. A total of 43.8% of
the patients recovered from the ARF; the rest died from causes not
related to the ARF. It was not possible to prove the influence, either on
survival or death, of the different blood purification techniques used.
The long-term survival rate of patients who do not suffer ARF is 100%
and only 18.8 in those who do.
Analysis of systolic and diastolic cardiac function in patients on regular
dialysis treatment. E. Baamonde, C. Sanz-Moreno, M.A. Cavero, J.
Hernandez, f.M. Garrancho, D. Sanz-Guajardo, J. Botella, Hospital
Puerta de Hieero, Madrid, Spain. Patients with Chronic Renal Insuffi-
ciency suffer numerous irregularities in the cardiac function. These
irregularities have been attributed to an increase in the blood levels of
the parathyroid hormone and the catecholamines. This paper analyses
the systolic and diastolic cardiac function in 19 patients on Regular
Dialysis Treatment. The study was carried out using and Echo-Doppler
and simultaneous levels of iPTH and catecholamines. Only 4 patients
(21.05%) had a reduction in the ejection fraction (0.5 0.04) and 19
(100%) had diastolic malfunction of the left ventricle, i.e., the "Passive
diastolic filling velocity/Active diastolic filling velocity" ratio was
below 1.0 (0.7 0.11 cm/seg.). Eleven patients (57.8%) had high levels
of iPTH (691.01 178.27 pg/nil) the remaining 8 had normal levels
(57.11 29.45 pg/nil). There were no significant differences between
these groups (high iPTH and normal iPTH), neither in the ejection nor
in the diastolic filling velocity. No difference in the levels of adrenaline
or noradrenaline were found either. In conclusion: patients on Regular
Dialysis Treatment often have diastolic malfunction of the left ventricle.
This irregularity seems to be independent of the degree of hyperpara-
thyroidism and the levels of catecholamines in the blood.
